arsenic has been researched along with arsenic trioxide in 2620 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 80 (3.05) | 18.7374 |
| 1990's | 130 (4.96) | 18.2507 |
| 2000's | 1155 (44.08) | 29.6817 |
| 2010's | 1167 (44.54) | 24.3611 |
| 2020's | 88 (3.36) | 2.80 |
| Authors | Studies |
|---|---|
| Bolliger, CT; Louw, JA; van Zijl, P | 1 |
| Gill, BS; Sandhu, SS | 1 |
| Chen, TD; Kim, TW; Ma, TH; Peng, Y; Sandhu, SS | 1 |
| Lacalle, H; Luburich, P; Munné, P; Nogué, S; Reig, R; Sanz-Gallén, P | 1 |
| Boeckx, M; Buchet, JP; Lauwerys, R; Offergelt, JA; Roels, H | 1 |
| Forth, W; Kreppel, H; Reichl, FX | 1 |
| Fichtl, B; Forth, W; Kreppel, H; Reichl, FX; Schäfer, B | 1 |
| Fichtl, B; Forth, W; Kreppel, H; Reichl, FX; Szinicz, L | 4 |
| Commissionat, Y | 1 |
| Kim, E; Na, KJ | 1 |
| Agarwal, R; Attri, A; Gupta, S; Raza, SS; Saksena, M; Saxena, PN | 1 |
| Chinombo, D; Edelsten, M; Norman, TL; Soldan, AW | 1 |
| Currier, M; Park, MJ | 1 |
| Budd, AJ; Gwilt, DJ; Jolliffe, DM | 1 |
| Dong, J | 1 |
| Mashiko, M; Takahashi, K; Yamamura, Y; Yamauchi, H | 1 |
| Sigg, H; Tamborini, P; Zbinden, G | 1 |
| Abe, E; Itoh, T; Miyate, H; Murai, S; Nagahama, H; Saito, H; Saito, Y; Zhang, YF | 1 |
| Fichtl, B; Forth, W; Kreppel, H; Muckter, H; Reichl, FX; Schumann, K; Szinicz, L | 1 |
| Edelman, P | 1 |
| Corbella, J; Munné, P; Nogué, S; Rodriguez-Pazos, M; Sanz, P | 1 |
| Ma, TH; Peng, Y; Sandhu, SS; Zhou, XD | 1 |
| Chang, EC; Kosman, DJ; Willsky, GR | 1 |
| Baker, DH; Lowry, KR | 1 |
| Aoyama, H; Harada, M; Hotta, N; Kurumatani, N; Nagira, T; Tsuda, T; Yamamoto, M | 1 |
| Bekemeier, H; Hirschelmann, R | 1 |
| Forth, W; Kreppel, H; Reichl, FX; Szinicz, L | 1 |
| Yuan, ST | 1 |
| Balme, R; Bertaux, L; Chouraki, L; Conso, F; Dally, S; Danan, M | 1 |
| Forth, W; Szinicz, L | 1 |
| Mossop, RT | 1 |
| Wang, GQ; Yao, H | 1 |
| Dahlgren, E; Eriksson, A; Gerhardsson, L; Lagerkvist, BE; Lundström, J; Nordberg, GF | 1 |
| Ishii, Y | 1 |
| Shimotsuura, S | 1 |
| Garabedian, C; Levin-Scherz, JK; Patrick, JD; Weber, FH | 1 |
| Aoyama, H; Kume, Y; Nagira, T; Tsuda, T; Yamamoto, M | 1 |
| Lee-Feldstein, A | 1 |
| Akbarov, AA; Kamil'dzhanov, AKh; Ubaĭdullaev, RU | 1 |
| Azumi, T; Kawasaki, T; Nakajima, T; Yakata, H | 1 |
| Rhoads, K; Sanders, CL | 1 |
| Aranyi, C; Bradof, JN; Graham, JA; Miller, FJ; O'Shea, WJ | 1 |
| Kamil'dzhanov, AKh; Ubaĭdullaev, RU | 1 |
| Carter, DE; Webb, DR; Wilson, SE | 1 |
| Yamamura, Y; Yamauchi, H | 2 |
| Arcangeli, A; Cavaliere, F; de Francisci, G; De Giacomo, M; Magalini, SI | 1 |
| Farmer, JG; Lovell, MA | 1 |
| Nevill, EM | 1 |
| Björklund, NE; Nordberg, G; Pershagen, G | 1 |
| Fuentes, N; Rosenmann, M; Zambrano, F | 1 |
| Kawaguchi, M; Tsutsumi, S | 1 |
| Shimomura, H | 1 |
| Hosokawa, T; Kitagawa, H; Saito, H; Sakamoto, K; Sugimoto, T; Yanaura, S | 1 |
| Low-Beer, TS; Robertson, DA | 1 |
| Deng, Q | 2 |
| Tamura, H | 1 |
| Ogino, J; Tabuchi, Y; Takahashi, K; Tanabe, H; Yazima, K | 1 |
| Kozachenko, VI; Pashin, IuV; Toroptsev, SN | 1 |
| Carter, DE; Sipes, IG; Webb, DR | 1 |
| Harms, WE; Ketterer, PJ; Robertson, ID | 1 |
| Brunet, C; Cazin, M; Luyckx, M | 2 |
| Hisanaga, A; Inamasu, T; Ishinishi, N; Yamamoto, A | 1 |
| Ishinihsi, N; Yamamoto, A | 1 |
| Buratti, M; Calzaferri, G; Colombi, A; Foà, V; Maroni, M | 1 |
| Futaki, S | 1 |
| Albou, JP | 1 |
| Tamura, A | 1 |
| Kamkin, AB | 1 |
| Hisanaga, A; Inamasu, T; Ishinishi, N | 1 |
| Buchet, JP; Croquet, F; Lauwerys, R; Roels, H; Truc, J | 1 |
| Kamil'dzhanov, AKh | 1 |
| Costello, RJ; Landrigan, PJ; Stringer, WT | 1 |
| Di Sacco, I | 1 |
| Buchet, JP; Lauwerys, R; Mahieu, P; Roels, HA | 1 |
| Kawaguchi, I | 1 |
| Dissanaike, DS; Harrington, JM; Lenihan, JM; Renwick, JH; Waldron, HA | 1 |
| Smith, SB; Venkatesan, R; Wombolt, DG | 1 |
| Eichner, D; Gottschalk, D; Gottschalk, I; Norpoth, K; Schmidt, EH; Thomas, H; Witting, U | 1 |
| Jones, MM; Kreppel, H; Paepcke, U; Reichl, FX; Singh, PK; Szinicz, L; Thiermann, H | 1 |
| Lagerkvist, BJ; Zetterlund, B | 1 |
| Scheindlin, S | 2 |
| Dittmann, J; Harisch, G | 1 |
| Fichtl, B; Forth, W; Kreppel, H; Mückter, H; Reichl, FX; Szinicz, L | 1 |
| Jones, MM; Kleine, A; Kreppel, H; Reichl, FX; Singh, PK; Szinicz, L | 1 |
| Calbi, G; Calbi, P; Marcovigi, P; Valtancoli, E | 1 |
| Boudene, C; Cluet, J; de Ceaurriz, J; Javelaud, B; Telolahy, P | 1 |
| Fichtl, B; Hunder, G; Nguyen, PT; Schümann, K | 1 |
| Fichtl, B; Forth, W; Hunder, G; Liebl, B; Reichl, FX | 1 |
| Delos, M; Lardot, C; Lasfargues, G; Lauwerys, R; Lison, D | 1 |
| Billings, R; Bogdanffy, M; Carlson, TJ; Costa, M; Finley, B; Gargas, M; Kuykendall, J; Patierno, S; Paustenbach, D; Wetterhahn, K; Xu, J; Zhitkovich, A | 1 |
| Mervis, J | 1 |
| Chen, GQ; Chen, SJ; Chen, Z; Gazin, C; Jin, XL; Li, XS; Ma, J; Naoe, T; Ni, JH; Shen, ZX; Shi, XG; Si, GY; Sun, GL; Tang, W; Wang, ZY; Xong, SM; Zhang, P; Zhang, TD; Zhong, HJ; Zhu, J | 1 |
| Kołaciński, Z; Kruszewska, S; Mielczarska, J; Wiese, M | 1 |
| Gotoh, K; Hirata, M; Inoue, N; Ishinishi, N; Makita, Y; Omura, M; Tanaka, A; Zhao, M | 1 |
| Allen, TM; Bezabeh, DZ; Chang, DP; Jones, AD; Kelly, PB; Kennedy, IM; McCauley, EM; Smith, CH | 1 |
| Andre, C; Chelbi-Alix, MK; Chen, Z; de The, H; Degos, L; Dhumeaux, D; Guillemin, MC; Herve, L; Koken, MH; Quignon, F; Wang, ZY; Zhu, J | 1 |
| Cai, X; Chen, GQ; Chen, SJ; Chen, Z; de The, H; Han, ZG; He, KL; Jia, PM; Kitamura, K; Liu, MM; Ma, J; Miller, W; Naoe, T; Ni, JH; Niu, C; Paul, P; Shi, GY; Shi, XG; Tang, W; Wang, ZY; Waxman, S; Xiong, SM; Zhang, P; Zhang, TD; Zhu, J | 1 |
| Chen, GQ; Chen, SJ; Chen, Y; Chen, Z; Fang, ZW; Li, XS; Ma, J; Ni, JH; Qiu, QY; Shen, ZX; Sun, GL; Tang, W; Wang, YT; Wang, ZY; Xiong, SM; Yang, KQ; Zhang, P; Zhang, TD; Zhou, L; Zhu, J | 1 |
| Kwong, YL; Todd, D | 1 |
| Lancashire, RJ; Sorahan, T | 1 |
| Gabrilove, JL; Jakubowski, A; König, A; Pandolfi, PP; Rivi, R; Warrell, RP; Wrazel, L | 1 |
| Kitamura, K; Kiyoi, H; Naoe, T; Ohno, R; Takeshita, A; Tobita, T; Yoshida, H | 1 |
| Dejean, A; Matunis, MJ; Müller, S | 1 |
| Look, AT | 1 |
| Avvisati, G; Davison, K; Fanelli, M; Ferrara, FF; Gambacorti-Passerini, C; Lamph, WW; Lo Coco, F; Miller, WH; Nervi, C; Pelicci, PG; Peschle, C; Riccioni, R; Rosenauer, A; Shao, W; Testa, U; Waxman, S | 1 |
| Asari, Y; Kamijo, Y; Ohwada, T; Soma, K | 1 |
| Benoit, G; Chelbi-Alix, MK; Chen, Z; de Thé, H; Giannì, M; Koken, MH; Lanotte, M | 1 |
| Gebel, T | 1 |
| Delva, L; Gabrilove, JL; Gambacorti-Passerini, C; König, A; Pandolfi, PP; Rivi, R; Scheinberg, DA; Wang, ZG; Warrell, RP | 1 |
| Akao, Y; Kojima, S; Mizoguchi, H; Naoe, T; Ohishi, N; Yagi, K | 1 |
| Fujisawa, S; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Shigeno, K; Takeshita, A; Takeshita, K; Zhang, W | 1 |
| Chen, G; Shi, G; Tang, W | 1 |
| Zhang, Z | 1 |
| Calleja, E; Corso, D; Dardashti, LJ; DeBlasio, A; Gabrilove, J; Jhanwar, S; Maslak, P; Pandolfi, PP; Scheinberg, DA; Soignet, SL; Wang, ZG; Warrell, RP | 1 |
| Gallagher, RE | 2 |
| Avvisati, G; Lo Coco, F; Mandelli, F; Nervi, C | 1 |
| Arima, T; Chyuman, Y; Hanada, S; Ishitsuka, K; Makino, T; Shimotakahara, S; Suzuki, S; Takeshita, T; Takeuchi, S; Uozumi, K; Utsunomiya, A | 1 |
| Miller, M | 1 |
| Ikeda, Y; Kinjo, K; Kizaki, M; Muto, A; Ueno, H | 1 |
| Dai, J; Jing, Y; Waxman, S; Weinberg, RS | 1 |
| Awaraji, C; Bazarbachi, A; de Thé, H; Dianoux, L; El-Sabban, ME; Haidar, JH; Hermine, O; Kersual, J; Nasr, R; Quignon, F; Zermati, Y | 1 |
| Chang, CS; Chen, YC; Chou, WC; Chung, CY; Huang, SF; Huang, SY; Kuo, TL; Shen, MC; Tang, JL; Tien, HF; Wang, CH; Yao, YT | 1 |
| Accominotti, M; Benramdane, L; Fanton, L; Malicier, D; Vallon, JJ | 1 |
| Buzyn, A; Daniel, MT; de Thé, H; Degos, L; Gianni, M; Koken, MH; Licht, J; Minard, P; Varet, B; Zelent, A | 1 |
| Brouet, JC; Fermand, JP; Labaume, S; Larghero, J; Marolleau, JP; Noguera, MH; Rousselot, P | 1 |
| Paternostro, G; Tamm, I; Zapata, JM | 1 |
| Conrad, ME | 1 |
| Li, Y; Pan, Y; Zhu, H | 1 |
| Ling, B; Yao, H; Zhang, C | 1 |
| Ling, B; Liu, J; Yao, H; Zhang, C | 1 |
| de Thé, H; Kroemer, G | 1 |
| Cai, X; Chen, GQ; Chen, SJ; Chen, Z; Dai, J; Huang, Y; Jia, PM; Jing, YK; Shen, YL; Shi, GY; Sun, YP; Tang, W; Wang, ZY; Waxman, S; Zhang, TD; Zhu, XH | 1 |
| Alemany, M; Caen, JP; Han, ZC; Levin, J; Lu, M; Sequeira-Le Grand, A; Sulpice, E | 1 |
| Hoelzer, D; Jensen, K; Ottmann, OG; Puccetti, E; Ruthardt, M; Sternsdorf, T; Will, H | 1 |
| Cai, WJ; Chen, C; Shen, J; Shen, ZY; Tan, LJ; Tang, XM; Zheng, MH | 1 |
| de Thé, H; Giannì, M | 1 |
| Gallagher, RE; Huang, XJ; Klein, RS; Wiernik, PH | 1 |
| Bau, DT; Gurr, JR; Jan, KY; Liu, F; Lynn, S | 1 |
| Deng, YP; Fu, M; Lin, C; Wu, M; Xiao, PG; Zheng, J | 1 |
| Chen, WJ; Chen, YC; Huang, CH; Lee, YT; Wu, CC | 1 |
| Vincent, PC | 1 |
| Caen, J; Cai, X; Chen, GQ; Chen, SJ; Chen, Z; Guo, WM; Ju, B; Pan, L; Sun, GL; Wang, HL; Wang, ZY; Yao, YY; Zhao, WL; Zhu, J | 1 |
| Akao, Y; Akiyama, K; Nakagawa, Y | 1 |
| Bukhsh, AR; Datta, S; Mallick, P | 2 |
| Barchowsky, A; Dudek, EJ; Ganju, N; James, PE; Klei, LR; Roussel, RR; Smith, KR | 1 |
| Carmignani, A; Fazzi, R; Galimberti, S; Papineschi, F; Petrini, M; Testi, R | 1 |
| Agis, H; Edelhäuser, M; Fonatsch, C; Geissler, K; Lechner, K; Mitterbauer, G; Seewann, HL; Thalhammer, R; Valent, P; Weltermann, A | 1 |
| Chalmers-Redman, RM; Dai, J; Jing, Y; Tatton, WG; Waxman, S | 1 |
| Haanen, C; Vermes, I | 1 |
| Farr, CH; Holson, JF; Stump, DG; Ulrich, CE | 1 |
| Chan, P; Huff, J; Nyska, A; Waalkes, M | 1 |
| Farr, CH; Fleeman, TL; Holson, JF; Nemec, MD; Stump, DG | 1 |
| Egan, DA; Evans, RA; Reed, JC; Torii, S | 1 |
| Cao, Q; Chen, GQ; Chen, SJ; Chen, Y; Chen, Z; Gu, BW; Gu, FY; Hu, J; Li, JM; Li, XS; Liu, JX; Niu, C; Ren, MY; Shen, ZX; Su, XY; Sun, HP; Wang, ZY; Waxman, S; Wu, W; Xiong, SM; Yan, H; Yang, RR; Yu, T; Yuan, MM; Zeng, XY; Zhang, FQ; Zhang, TD; Zhou, L | 1 |
| Donelli, A; Galimberti, S; Leonardi, G; Luppi, M; Marasca, R; Petrini, M; Torelli, G; Vaccari, P; Zucchini, P | 1 |
| Chen, JC; Chen, YC; Kuo, ML; Yang, CH | 1 |
| Duperret, S; Fanton, L; Guillaumée, F; Malicier, D; Miras, A; Vallon, JJ | 1 |
| Hyun, JM; Jung, CW; Kim, BK; Kim, ES; Lee, YY; Park, WH; Seol, JG | 2 |
| Cao, EH; Li, JF; Ma, W; Qin, JF; Zhang, TC | 1 |
| Brown, SL; Griffin, RJ; Kim, JH; Lew, YS; Song, CW | 1 |
| Cai, WJ; Hong, C; Shen, J; Shen, ZY; Zheng, MH | 1 |
| Chen, SJ; Chen, Z; Hu, J; Shen, ZX; Sun, GL; Wang, ZY | 1 |
| Bhalla, KN; Fang, G; Kim, CN; Perkins, C | 1 |
| Alessio, L; Apostoli, P; Bartoli, D; Buchet, JP | 1 |
| Cai, X; Chen, GQ; Chen, SJ; Chen, Z; Huang, Y; Jia, PM; Shen, YL; Wang, ZY; Xiong, SM; Yu, Y; Zhang, JW; Zhou, L; Zhu, Q | 1 |
| Fabry, U; Galm, O; Osieka, R | 1 |
| Annunziata, M; Boccuni, P; Cimino, R; Copia, C; Costantini, S; Del Vecchio, L; Dello Russo, A; Di Noto, R; Ferrara, F; Lo Pardo, C | 1 |
| Chen, H; Pan, Q; Qin, S | 1 |
| Gotoh, K; Hirata, M; Inoue, N; Makita, Y; Omura, M; Tanaka, A; Yamazaki, K; Zhao, M | 1 |
| Fukuchi, Y; Hata, J; Ikeda, Y; Ito, M; Kinjo, K; Kizaki, M; Muto, A; Nishihara, T; Ueyama, Y; Umezawa, A; Yamato, K | 1 |
| Akao, Y; Nakagawa, Y; Yamada, H | 1 |
| Cheson, BD; McBee, WL; Murgo, AJ | 1 |
| Clevidence, KJ; Farr, CH; Holson, JF; Knapp, JF; Stump, DG | 1 |
| Kizaki, M | 1 |
| Hoshi, S; Kitamura, K; Kiyoi, H; Koike, M; Naoe, T; Saito, H | 1 |
| Cao, EH; Li, JF; Zhang, T | 1 |
| Hirosawa, S; Kamei, S; Koyama, T; Ohsawa, M; Shibakura, M | 1 |
| Alemany, M; Levin, J | 1 |
| Chang, IY; Huang, MJ; Lin, CP; Lin, WY | 1 |
| Chang, IY; Huang, MJ; Lin, WY; Sheu, YT | 1 |
| Alet, P; Do, B; Guilley-Gaillot, M; Guyon, F; Poupon, J; Pradeau, D | 1 |
| Betti, L; Brizzi, M; Nani, D; Peruzzi, M | 1 |
| Chen, YC; Huan, SY; Yang, CH | 1 |
| Hayashi, T; Imanaka, T; Ishii, K; Komatsu, H; Nakamura, F; Ono, Y; Sawada, H; Tanaka, Y | 1 |
| Bächli, E; Betts, DR; Calandra, T; Fehr, J; Hossle, JP; Joller-Jemelka, HI; Schaffner, A; Schoedon, G; Walter, R | 1 |
| Hyun, JM; Jung, CW; Kim, BK; Kim, ES; Lee, CC; Lee, YY; Park, WH; Seol, JG | 1 |
| Bukhsh, AR; Kundu, SN; Mitra, K | 1 |
| Firkin, F; Spencer, A | 1 |
| Camacho, LH; Chanel, S; Ellison, R; Heller, G; Ho, R; Scheinberg, DA; Soignet, SL; Warrell, RP | 1 |
| Warrell, RP | 2 |
| Brüggenolte, N; Güller, S; Hoelzer, D; Orleth, A; Ottmann, OG; Puccetti, E; Ruthardt, M | 1 |
| Dias, S; Lam, G; Lane, WJ; Rafii, S; Roboz, GJ; Soignet, SL; Warrell, RP | 1 |
| He, LZ; Pandolfi, PP; Rego, EM; Wang, ZG; Warrell, RP | 1 |
| Chiodino, C; Donelli, A; Panissidi, T; Roncaglia, R; Torelli, G | 1 |
| Buchet, JP; Bulpa, P; Dive, A; Haufroid, V; Installé, E; Mahieu, P; Michaux, I | 1 |
| Hess, JL; Westervelt, P; Zhang, T | 1 |
| Au, WY; Kwong, YL; Liang, R; Ma, SK; Ooi, C | 1 |
| Akao, Y; Kitamura, K; Kiyoi, H; Minami, Y; Naoe, T; Saito, H; Yamamoto, K | 1 |
| Abboushi, N; Ameisen, JC; Bazarbachi, A; Bex, F; Dbaibo, G; de Thé, H; El-Sabban, ME; Hermine, O; Nasr, R; Quignon, F | 1 |
| Bondesson, L; Garwicz, S; Jönsson, C; Ljungberg, J; Ora, I; Pâhlman, S; Pörn-Ares, I | 1 |
| Han, Y; Li, F; Li, L | 1 |
| Arima, T; Hanada, S; Ishitsuka, K; Uozumi, K; Utsunomiya, A | 1 |
| Novick, SC; Warrell, RP | 1 |
| Henney, JE | 1 |
| Cotter, FE; Fennell, DA | 1 |
| Miller, JL | 1 |
| Fujisawa, S; Fujita, Y; Matsui, H; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Satoh, H; Shigeno, K; Shinjo, K; Sugiyama, S; Takeshita, A; Terada, H; Yoshida, H | 1 |
| Scheinberg, DA | 1 |
| Calleja, EM; Warrell, RP | 1 |
| Chen, GQ; Chen, Z; Jing, Y; Miller, WH; Wang, L; Waxman, S; Xia, L | 1 |
| Chen, H; Liu, L; Liu, W; Ma, J; Qin, S; Wang, J | 1 |
| Cho, CH; Chun-Yu Wong, B; Jiang, SH; Jiang, XH; Kung, HF; Lai, KC; Lam, SK; Lin, MC; Wong, BC; Yuen, ST | 1 |
| Powell, BL | 2 |
| Goker, E; Karabulut, B; Omay, SB; Sanli, UA; Sezgin, C; Terzioglu, E; Uslu, R | 1 |
| Burkham, J; Coen, DM; Hwang, CB; Weller, SK | 1 |
| Cohen, MH; Flamm Honig, S; Hirschfeld, S; Ibrahim, A; Johnson, JR; O'Leary, JJ; Pazdur, R; White, RM; Williams, GA | 1 |
| Cobcroft, R; Gill, D; Kennedy, GA; Marlton, P | 1 |
| Chen, GQ; Chen, SJ; Chen, Z; Shen, ZX; Wang, ZY | 1 |
| Miller, KB; Relias, V; Roberts, TF; Schenkein, D; Sprague, K | 1 |
| Guo, W; Wang, H; Zhao, W | 2 |
| Bai, Y; Huang, S | 1 |
| Cai, X; Jia, P; Shi, X | 1 |
| Api, M; Chiaramida, S; Dutcher, JP; Garl, S; Lucariello, R; Unnikrishnan, D; Varshneya, N; Wiernik, PH | 1 |
| Arnulfo, A; Baj, G; Canella, D; Deaglio, S; Malavasi, F; Waxman, S | 1 |
| Sun, G; Wu, W; Xiao, D | 1 |
| Dejean, A; Lehembre, F; Müller, S; Pandolfi, PP | 1 |
| Bachleitner-Hofmann, T; Gisslinger, B; Gisslinger, H; Grumbeck, E | 1 |
| Chen, G; Chen, S; Chen, Z; Fang, Z; Huang, Y; Li, X; Liu, H; Ni, J; Shen, Z; Wang, Z | 1 |
| Au, WY; Chim, CS; Kwong, YL; Liang, R; Pang, A; Suen, C | 1 |
| Blythe, D; Joyce, DA | 1 |
| Lewitt, MS | 1 |
| Aiuchi, T; Iwama, K; Nakajo, S; Nakaya, K | 1 |
| Falnoga, I; Jacimovic, R; Mazej, D; Scancar, J; Slejkovec, Z; Stibilj, E; Tusek-Znidaric, M | 1 |
| Buchwald, AL | 1 |
| Allain, N; Anger, JP; Fardel, O; Guillouzo, A; Payen, L; Vernhet, L | 1 |
| Antman, KH | 1 |
| Soignet, SL | 1 |
| Munshi, NC | 1 |
| Murgo, AJ | 1 |
| Rust, DM; Soignet, SL | 1 |
| Balasubramanian, P; Chandy, M; George, B; Mathews, V; Shaji, RV; Srivastava, A | 2 |
| Chen, J; Chen, SJ; Chen, Z; Li, JM; Li, XS; Liu, YF; Niu, C; Shen, Y; Shen, ZX; Tang, W; Wang, ZY; Wu, F; Wu, W; Xiong, SM; Yan, H; Zeng, XY; Zhao, WL | 1 |
| Bhalla, KN; Nguyen, D; Nimmanapalli, R; Perkins, C; Porosnicu, M; Worthington, E | 1 |
| Ahuja, YR; Danadevi, K; Ishaq, M; Jamil, K; Saleha Banu, B; Visweswara Rao, K | 1 |
| Guo, W; Qu, B; Shen, Z; Wang, H; Wang, X; Wang, Z; Wu, F; Zhao, W | 1 |
| Zelent, A | 1 |
| Altucci, L; Chomienne, C; Gronemeyer, H; Raffelsberger, W; Reitmair, A; Rossin, A | 1 |
| Bruey, JM; Corcos, L; Garrido, C; Leroy, I; Lizard, G; Miguet, C; Plenchette, S; Rébé, C; Solary, E; Sordet, O | 1 |
| de Thé, H; Doubeikovsky, A; Duprez, E; Freemont, P; Honoré, N; Koken, M; Lallemand-Breitenbach, V; Pandolfi, PP; Puvion, E; Puvion, F; Zhu, J | 1 |
| Al-Hashimi, S; Bazarbachi, A; Bazzi, R; Darwiche, N; de Thé, H; El-Sabban, M; Hermine, O; Nasr, R | 1 |
| Adkins, DR; Brown, RA; Curtin, P; DiPersio, JF; Hurd, D; Khoury, H; Ley, TJ; Luger, SM; Ma, MK; Westervelt, P | 1 |
| Hori, S; Ichijo, H; Kakehi, Y; Kakizuka, A; Maeda, H; Nishitoh, H; Ogawa, O | 1 |
| Du, YH; Ho, PC | 1 |
| Bahlis, NJ; Boise, LH; Dalton, WS; Grad, JM; Oshiro, MM; Reis, I | 1 |
| Fukuchi, Y; Hata, J; Hozumi, N; Ikeda, Y; Ito, M; Kawamura, C; Kizaki, M; Matsushita, H; Muto, A; Ueyama, Y; Umezawa, A; Yamada, T; Yamato, K | 1 |
| Bengtzen, S; Christensson, B; Lehmann, S; Paul, A; Paul, C | 1 |
| Acar, V; Bénazeth, S; Chaumeil, JC; Corriol, O; Curis, E; Deschamps, P; Guyon, F; Nicolis, I; Zerrouk, N | 1 |
| Baek, SH; Choi, YJ; Jang, MA; Kwon, TK; Lim, JH; Park, JW; Passaniti, T | 1 |
| Bazarbachi, A; Hermine, O | 1 |
| Barbey, JT | 1 |
| Singer, JW | 1 |
| Calleja, E; Coutré, S; Dahlberg, S; Douer, D; Ellison, R; Frankel, SR; Kalaycio, M; Kantarjian, H; Scheinberg, DA; Sievers, EL; Soignet, SL; Steinherz, P; Stone, RM; Tallman, MS; Warrell, RP | 1 |
| Au, WY; Chan, GC; Chim, CS; Ho, WK; Kwong, YL; Ooi, GC; Shek, TW | 1 |
| Hong, SH; Privalsky, ML; Yang, Z | 1 |
| Pandolfi, PP | 1 |
| Nie, L; Zhang, Y | 1 |
| Huang, X | 3 |
| Ishaque, AB; Schneider, J; Tchounwou, PB; Wilson, BA | 1 |
| Barbey, JT; Soignet, S | 1 |
| Chelbi-Alix, MK; de Thé, H | 1 |
| Chen, GQ; Chen, SJ; Chen, Z; Wang, ZG; Wang, ZY; Zhang, TD | 1 |
| de Thé, H; Lallemand-Breitenbach, V; Zhu, J | 1 |
| Lanotte, M; Roussel, MJ | 1 |
| Cai, X; Chen, G; Jia, P | 1 |
| Su, H; Sun, G; Xiao, D | 1 |
| Guo, W; Wang, H; Zhu, J | 1 |
| De Santis, S; Diverio, D; Lo Coco, F; Mandelli, F; Meloni, G; Petrucci, MT; Petti, MC; Pinazzi, MB; Romano, A; Tafuri, A | 1 |
| Tallman, MS | 8 |
| Brady, JN; Gessain, A; Mahieux, R; Misteli, T; Nicot, C; Olivier, R; Perret, E; Pise-Masison, C | 1 |
| Bai, H; Lu, JH; Ou, YX; Wei, YM; Zheng, RL | 1 |
| Hirayama, Y; Ishikawa, K; Ishitani, K; Kondo, A; Koyama, R; Matsunaga, T; Nagai, T; Niitsu, Y; Ohta, H; Sakamaki, S | 1 |
| Chen, J; Deng, Y; Fu, M; Liang, X; Lin, C; Wu, M; Xiao, P; Zheng, J | 1 |
| Chen, Z; Guo, W; Qu, B; Shen, Z; Wang, H; Wang, X; Wang, Z; Zhao, W | 1 |
| Hu, J; Li, X; Shen, Z; Sun, G; Sun, H; Wang, Z; Wu, W | 1 |
| Bi, K; Jiang, G; Tang, T | 1 |
| Cai, X; Chen, G; Shen, Y | 1 |
| Chen, G; Huang, Y; Zhu, Q | 1 |
| Cai, X; Chen, G; Chen, S; Huang, X; Jia, P; Shen, Y; Wang, L; Wang, Z; Yang, J; Yu, Y; Zhang, X; Zhou, L; Zhou, Y | 1 |
| Guo, W; Ju, B; Wang, H; Wang, X; Zhao, W; Zhu, J | 1 |
| Lu, G; Tong, Q; Zeng, F; Zhao, J; Zheng, L | 1 |
| Cai, X; Huang, X; Zhou, Y | 1 |
| Hu, N; Hu, X; Ma, L | 1 |
| Zhang, T | 1 |
| Hussein, MA; Juturi, JV; Lieberman, I | 1 |
| Shen, Z; Wang, H; Wang, X; Wu, F; Zhao, W | 1 |
| Qiao, Z; Yang, L; Zhang, X | 1 |
| Chen, G; Pan, L; Zhou, L | 1 |
| Liang, X; Lin, C; Xu, M | 1 |
| Feusner, JH; Nabhan, C; Rowe, JM; Tallman, MS | 1 |
| Cai, X; Chen, SJ; Chen, Z; Flexor, M; Jia, PM; Lanotte, M; Shen, YL; Tong, JH; Waxman, S; Yu, Y; Zhang, JW; Zhu, HQ; Zhu, Q | 1 |
| Kuriyama, K | 1 |
| Senior, K | 1 |
| Douer, D | 1 |
| Chen, BA; Chen, HY; Qin, SK; Wang, W | 1 |
| Chen, CY; Chen, JY; Li, QS; Shen, J; Shen, ZY; Yi, Z | 1 |
| Gao, F; Li, H; Shi, GY; Shi, XG; Tang, XM; Yi, J | 1 |
| Cai, WJ; Chen, MH; Shen, J; Shen, WY; Shen, ZY; Yi, Z | 1 |
| Cao, EH; Qin, JF; Zhang, TC | 1 |
| Antimisiaris, SG; Gortzi, O; Ioannou, PV; Kontoyannis, CG; Papadimitriou, E | 1 |
| Buyukececi, F; Omay, SB; Sanli, UA; Saydam, G; Terzioglu, E; Uslu, R; Yuksel, S | 1 |
| Gartenhaus, RB; Gordon, LI; Li, Y; Paniaqua, M; Prachand, SN | 1 |
| Akiyama, H; Fukuhara, O; Hiruma, K; Maeda, Y; Mikoshiba, M; Ohashi, K; Okuyama, Y; Sakamaki, H; Takei, N; Takeshita, A | 1 |
| Baldus, C; Knauf, W; Rojewski, MT; Schrezenmeier, H; Thiel, E | 1 |
| Chen, Y; He, Z; Liu, X; Qian, J; Qin, S; Shao, Z; Wang, L | 1 |
| He, Z; Qian, J; Qin, S | 1 |
| Gu, W; Ling, B; Liu, J; Song, X; Wang, G; Zhang, C | 1 |
| Dai, J; Gu, S; Huang, Y; Liu, J; Lou, Y; Wang, G; Xie, Y; Yin, M; Ying, K | 1 |
| Akao, Y; Kito, M; Nozawa, Y; Ohishi, N; Yagi, K | 1 |
| Chen, M; Hong, C; Li, Q; Shen, J; Shen, Z | 1 |
| Han, X; Hu, L; Li, X; Liu, P; Qiu, F; Wang, S; Xiao, Y; Yang, H; Zhang, P; Zhou, J | 1 |
| Chu, H; Guo, W; Pan, L; Qu, B; Wang, H; Wang, X; Zhao, W; Zhu, J | 1 |
| Chen, F; Li, Y; Xu, G; Zhang, M | 1 |
| Jin, H; Lou, F; Yu, L | 1 |
| Cai, WJ; Chen, MH; Shen, J; Shen, WY; Shen, ZY; Zeng, Y | 1 |
| Hussein, MA | 2 |
| Au, WY; Chim, CS; Kwong, YL; Liang, R; Lie, AK | 1 |
| Bai, H; Ding, F; Liu, Z; Ou, Y; Wang, X; Wu, M; Xie, D; Yin, S; Zhou, C | 1 |
| Fujisawa, S; Fujita, Y; Matsui, H; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Sahara, N; Satoh, H; Shigeno, K; Shinjo, K; Takeshita, A; Terada, H; Yoshida, H | 1 |
| Bloomfield, CD; Slack, JL; Tallman, MS; Tricot, G; Waxman, S | 1 |
| Miller, WH | 1 |
| O'Dwyer, M | 1 |
| List, AF | 1 |
| Chopin, M; Dombret, H; Pierron, G; Poupon, J; Raffoux, E; Récher, C; Sigaux, F; Stern, MH | 1 |
| Chen, J; Guan, JY; Hour, TC; Huang, CY; Lu, SH; Pu, YS | 2 |
| Gao, F; Li, H; Shi, G; Shi, X; Tang, X; Wang, Z; Yi, J | 2 |
| Akao, Y; Hirata, I; Katsu, K; Morikawa, H; Nakagawa, Y; Naoe, T; Ohishi, N; Yagi, K | 1 |
| Lo Coco, F | 1 |
| Annunziata, M; Ciolli, S; Fanci, R; Ferrara, F; Gianfaldoni, G; Leoni, F; Nozzoli, C | 1 |
| Davison, K; Mann, KK; Miller, WH | 1 |
| Dombret, H; Fenaux, P; Soignet, SL; Tallman, MS | 1 |
| Bhalla, KN; Druker, BJ; La Rosée, P; Nimmanapalli, R; O'Dwyer, ME | 1 |
| Chen, GQ; Chen, SJ; Chen, Z; Shen, ZX; Sun, GL; Tong, JH; Wang, ZY | 1 |
| Garnier-Suillerot, A; Petroutsa, M; Salerno, M | 1 |
| Chun, YJ; Chung, HY; Hong, SI; Kim, TH; Lee, SJ; Lee, YS; Park, IC; Park, MJ; Rhee, CH; Woo, SH | 1 |
| Miller, WH; Waxman, S | 1 |
| Chan, JY; Fung, KP; Siu, KP | 2 |
| André, N; Braguer, D; Briand, C; Carles, G; Carré, M; Ciccolini, J; Douillard, S | 1 |
| Liao, J; Wang, Z; Xu, Y | 1 |
| Kawakami, K; Kawamoto, K; Shi, C; Tsuchida, T; Zhao, S | 1 |
| Chun, YJ; Hong, SI; Lee, HC; Lee, SH; Lee, SJ; Park, IC; Park, MJ; Rhee, CH; Woo, SH | 1 |
| Arima, T; Ishibashi, K; Ishitsuka, K; Kohara, K; Komorizono, Y; Oketani, M; Tuvdendorj, D | 1 |
| DiPersio, JF; Ley, TJ; Ma, MK; Oldfather, KM; Pollock, JL; Walter, MJ; Westervelt, P; Williams, A | 1 |
| Arnulfo, A; Baj, G; De Cesaris, MG; Deaglio, S; Ferrero, E; Malavasi, F; Mallone, R; Surico, N; Vigone, A | 1 |
| Begum, RA; Farah, IO; Ishaque, AB | 1 |
| Lee, JS; Miller, WH; Schipper, HM; Singer, J; Waxman, S | 1 |
| Huang, S; Jiang, S; Kong, B; Ma, Y | 1 |
| Jing, Y; Waxman, S; Xia, L | 1 |
| Gao, F; Li, H; Shi, G; Shi, X; Tang, X; Yi, J | 1 |
| Cai, X; Chen, G; Huang, Y; Jia, P; Yu, Y | 1 |
| Druker, BJ; Johnson, K; La Rosée, P; O'Dwyer, ME | 1 |
| Arima, T; Hanada, S; Ikeda, R; Ishitsuka, K; Ohno, N; Suzuki, S; Takatsuka, Y; Takeshita, T; Takeuchi, S; Uozumi, K; Utsunomiya, A | 1 |
| Lopez-Berestein, G; Ozpolat, B | 1 |
| Higashi, Y; Pallis, M; Russell, N; Turzanski, J | 1 |
| Brown, SL; Kim, JH; Kolozsvary, A; Lew, YS | 1 |
| Nabhan, C; Tallman, MS | 1 |
| Anderson, KC; Cole, CE; Ryoo, JJ | 1 |
| Guo, P; Hu, Y; Qiao, Z; Shen, G; Song, S; Wang, J; Yang, L; Zhang, X; Zhou, H | 1 |
| Bae, JH; Choi, YJ; Kim, SP; Kwon, TK; Mun, KC; Park, JW; Song, DK; Suh, SI | 1 |
| Holland, JF; Jiang, JD; Ling, YH; Perez-Soler, R | 1 |
| Kang, YJ; Li, Y; Sun, X; Wang, L; Zhou, Z | 1 |
| Chiang, CE; Ding, PY; Luk, HN; Wang, TM | 1 |
| Anaissie, E; Badros, A; Barlogie, B; Desikan, R; Morris, C; Munshi, NC; Toor, A; Tricot, G; Zangari, M | 1 |
| Motzer, RJ; Schwartz, L; Vuky, J; Yu, R | 1 |
| Chim, CS; Kam, S; Kwong, YL; Lam, CC; Man, C; Wong, KF | 1 |
| Chen, Z; de Thé, H; Lallemand-Breitenbach, V; Zhu, J | 2 |
| Deb, DK; Kalvakolanu, DV; Kambhampati, S; Minucci, S; Mohindru, M; Platanias, LC; Ravandi, F; Sassano, A; Verma, A | 1 |
| Fung, M; Leung, KN; Mak, NK; Wong, RN | 1 |
| Choi, HI; Kim, HJ; Kim, T; Lee, IS; Shim, MJ; Yang, SJ | 1 |
| Feng, CQ; Guo, QY; Li, L; Ma, WL; Shi, R; Song, YB; Wu, QH; Zheng, WL; Zhu, J | 1 |
| Au, WY; Chim, CS; Kwong, YL; Pang, A; Wai Lie, AK | 1 |
| Auffray, C; Candeil, L; Copois, V; Crabbé, L; Del Rio, M; Gourdier, I; Martineau, P; Mechti, N; Pau, B; Pommier, Y; Ychou, M | 1 |
| Barnes, J; Chen, P; Chrest, FJ; Gorospe, M; Li, J; Liu, Y; Sinogeeva, N; Wersto, RP | 1 |
| Feng, CQ; Guo, QY; Ma, WL; Song, YB; Wu, QH; Zheng, WL | 1 |
| Bachleitner-Hofmann, T; Gisslinger, H; Kees, M | 1 |
| Chaudhary, PM; Matta, H; Sun, Q | 1 |
| Kong, L; Wang, X; Yang, P; Zhao, J | 1 |
| Kim, EJ; Lee, SY; Myoung, J; Namkoong, SE; Park, JS; Um, SJ | 1 |
| Anderson, KC; Chauhan, D; Hideshima, T; Munshi, NC; Richardson, P | 1 |
| Amiot, L; Bernard, M; Drenou, B; Fardel, O; Fauchet, R; Lamy, T; Le Meur, A; Le Thiec, A; Lecureur, V | 1 |
| Daniel, MT; De Thé, H; Degos, L; Dombret, H; Gourmel, B; Guillemin, MC; Janin, A; Kogan, S; Lallemand-Breitenbach, V; Lanotte, M; Raffoux, E; Soilihi, H; Vitoux, D; Zhu, J | 1 |
| Au, WY; Kou, M; Kumana, CR; Kwong, YL; Lam, CW; Lee, NS; Mak, RW | 1 |
| Chen, GQ; Chen, SJ; Chen, Z; Jia, PM; Tong, JH; Wang, ZY; Yu, Y; Zhu, Q | 1 |
| Chen, CX; Huang, FL; Wang, HN; Wang, YL | 1 |
| Huang, SG; Jiang, S; Kong, BH; Yang, RF | 1 |
| Au, WY; Chim, CS; Chung, LP; Kwong, YL; Ma, SK | 1 |
| Cairoli, R; Di Bona, E; Marenco, P; Montillo, M; Morra, E; Nosari, A; Tedeschi, A; Tresoldi, E | 1 |
| Dalton, WS | 1 |
| Bahlis, NJ; Boise, LH; Eckman, J; Fernandez, HF; Goodman, M; Jordan-McMurry, I; Kharfan-Dabaja, M; Lee, KP; McCafferty-Grad, J; Neil, J; Reis, I | 1 |
| Huang, SG; Jiang, S; Kong, BH; Ma, YY | 1 |
| Hee Cho, Y; Hyuck Im, Y; Hyun Park, W; Ki Kang, W; Kim, K; Lee, MH; Oh Park, J; Park, K; Won Jung, C | 1 |
| Gao, G; Huo, J; Liu, Y; Shi, Y | 1 |
| Allain, N; Fardel, O; Guillouzo, A; Le Vée, M; Morel, F; Vernhet, L | 1 |
| Akiyama, M; Anderson, KC; Chauhan, D; Hayashi, T; Hideshima, T; Munshi, NC; Richardson, P; Schlossman, RL; Waxman, S | 1 |
| Anderson, KC; Hayashi, T; Hideshima, T | 1 |
| Liu, JW; Shen, Y; Tang, Y; Zhong, XY | 1 |
| Akiharu, W; Jing, HM; Ke, XY; Yoshiro, K; Yukihiro, S | 1 |
| Li, J; Shen, T; Zhang, ZN; Zuo, L | 1 |
| Li, B; Lou, FD; Wang, YZ; Yao, SQ; Yu, L; Zhu, HL | 1 |
| Chen, SY; Li, XM; Liu, SX | 1 |
| Feng, CQ; Ma, WL; Zheng, WL | 1 |
| Ravandi, F; van Besien, K | 1 |
| Gazitt, Y; Hilsenbeck, S; Liu, Q | 1 |
| Chang, IY; Hsieh, RK; Huang, MJ; Lin, CP; Liu, HJ | 1 |
| Alwayn, IP; Basker, M; Cooper, DK; Correa, L; Gollackner, B; Harper, D; Knosalla, C; Mauiyyedi, S; Ryan, D; Salomon, G; Thall, A | 1 |
| Arnulf, B; Bazarbachi, A; Bex, F; de Thé, H; El-Sabban, ME; Hermine, O; Lepelletier, Y; Nasr, R; Rosenwald, A; Staudt, L; Zalloua, P | 1 |
| Du, CW; Li, DR; Lin, YC; Wu, MY | 1 |
| Fang, JZ; Li, KH; Xiao, T | 1 |
| Berthoux, L; Gurer, C; Luban, J; Pandolfi, PP; Salomoni, P; Towers, GJ | 1 |
| Yin, KS; Zhou, LF | 1 |
| Angerer, J; Heinrich-Ramm, R; Horn, J; Schaller, H | 1 |
| Ann, DK; Lai, MZ; Lin, DY; Shih, HM | 1 |
| Huang, C; Jiang, H; Li, J; Wang, J; Wang, X; Zhao, Z | 1 |
| Bachleitner-Hofmann, T; Baumgartner, M; Roth, E; Sturlan, S | 1 |
| Chen, MH; Shen, J; Shen, WY; Shen, ZY; Zeng, Y | 1 |
| Chen, CH; Chen, TC; Jan, KY; Lin, SY; Samikkannu, T; Wang, AS; Yih, LH | 1 |
| Shan, Y | 1 |
| Horii, T; Kitamura, K; Maekawa, M; Matsui, H; Naito, K; Nakamura, S; Naoe, T; Ohnishi, K; Ohno, R; Shigeno, K; Shinjo, K; Takeshita, A | 1 |
| Hirano, T; Hu, XM; Oka, K | 2 |
| Lin, M; Tong, H | 1 |
| Chew, EC; Wang, Z; Yu, D; Zhu, L | 1 |
| Hirayama, Y; Matsunaga, T; Niitsu, Y; Sagawa, T; Sakamaki, S; Takayanagi, N; Tsuji, Y | 1 |
| Aybar, B; Haznedaroğlu, F; Yalçin, S; Yücel, E | 1 |
| Bommert, K; Dorken, B; Hinz, M; Janz, M; Jundt, F; Lietz, A; Mathas, S; Scheidereit, C | 1 |
| Cai, X; Chen, SJ; Chen, Z; Jia, PM; Tong, JH; Wang, ZY; Yu, Y; Zhu, Q | 1 |
| Cao, Q; Chen, SJ; Chen, X; Chen, Z; Liu, YF; Shen, ZX; Wang, AH; Wang, ZY; Zhu, YM | 1 |
| Bai, DC; Li, YN; Ma, LF; Peng, X; Wang, P; Wei, HL; Yao, XJ; Zhao, HS | 1 |
| Li, DP; Li, HQ; Li, R; Qi, JY; Qian, LS; Wan, CC; Wang, ZQ; Zhao, YZ; Zhou, CL | 1 |
| Baccarani, M; Malagola, M; Martinelli, G; Piccaluga, PP; Rossi, M; Visani, G | 1 |
| DiPersio, J; Douer, D; Giralt, S; Hu, W; Lill, M | 1 |
| Au, WY; Chan, CH; Chan, JC; Chen, YT; Chim, CS; Kwong, YL; Liang, R; Lie, AK; Liu, SY; Ma, SK; Mak, YK; So, CC; Wong, LG; Yeung, YM; Yip, SF | 1 |
| Chen, GQ; Chen, Z; Jing, Y; Styblo, M; Walton, F; Waxman, S; Weinberg, R; Zhou, L | 1 |
| Cortes, J; Estey, E; Kantarjian, H; Lazo, G; O'Brien, S; Thomas, D | 1 |
| Hong, L; Qi, QH; Wang, SS; Wang, XL; Zhang, T | 2 |
| Ling, B; Liu, J; Wang, G; Zhang, C | 1 |
| Germano, I; Ito, H; Kanzawa, T; Kondo, S; Kondo, Y | 1 |
| Bellon, L; Bergé-Lefranc, JL; Bideau, C; Botta, A; Burnichon, V; Gérolami, V; Jean, S; Maraninchi, M; Margotat, A; Orsière, T | 1 |
| Côté, S; Davison, K; Mader, S; Miller, WH | 1 |
| Kang, HK; Kang, HW; Kang, JH; Kang, SH; Kim, SJ; Lee, YK; Park, DB; Song, JH | 1 |
| Guo, J; Zhang, ZY | 1 |
| Jia, CR; Jia, JS; Ma, J; Wang, Y; Xu, SR; Yao, YR | 1 |
| Chen, CL; Cheng, AL; Lin, CJ; Su, MJ; Sun, SS; Wu, MH | 1 |
| Wang, ZH; Yu, D; Zhu, LY | 1 |
| Buzyn, A; Cassinat, B; Chomienne, C; Cimerman, P; Daniel, MT; de Thé, H; Degos, L; Delarue, R; Dombret, H; Fermand, JP; Hermine, O; Lebbé, G; Poupon, J; Raffoux, E; Réa, D; Rousselot, P; Taksin, AL; Tibi, A | 1 |
| Au, WY; Chan, GC; Kou, M; Kumana, CR; Kwong, YL; Lam, CW; Mak, R | 1 |
| Stull, DM | 1 |
| Cai, X; Chen, GQ; Chen, Z; Dai, W; Huang, Y; Jia, PM; Tong, JH; Yu, Y; Zhang, L; Zhao, Q | 1 |
| Keung, YK; Lyerly, ES; Powell, BL | 1 |
| Li, L; Zhang, R; Zhu, ZL | 1 |
| Lu, G; Tong, Q; Zeng, F; Zhu, Z | 1 |
| Liu, SX; Wang, HY; Zhang, M | 1 |
| Carew, JS; Feng, L; Hileman, EO; Huang, P; Keating, MJ; Pelicano, H; Plunkett, W; Zhou, Y | 1 |
| Chen, YZ; Huang, MJ; Lu, LH; Wu, Y | 1 |
| Chen, YB; Ding, SQ; Fu, WJ; Hou, J; Kong, XT; Wang, DX; Yuan, ZG | 2 |
| Brannon, J; Dent, P; Fisher, PB; Gopalkrishnan, RV; Grant, S; Lebedeva, IV; Linehan, WM; McKinstry, R; Mitchell, C; Qiao, L; Rosenberg, E; Sarkar, D; Su, ZS; Valerie, K; Yacoub, A | 1 |
| Adrian, TE; Ding, X; Li, X | 2 |
| Chen, MH; Li, EM; Li, JT; Shen, J; Shen, ZY; Xu, LY; Zeng, Y | 1 |
| Beran, M; DiPersio, J; Greenberg, P; List, A; Rosenfeld, CS; Slack, J; Vey, N | 1 |
| Han, ZC; Liu, P | 1 |
| Huang, YL; Luan, TZ; Mei, Y; Qu, XF; Xu, DX | 1 |
| Chen, D; Deng, Y; Lin, C; Wu, M; Xiao, P; Zhang, X | 1 |
| Chen, JP; Deng, Y; Fu, M; Lin, C; Wu, M; Xiao, P; Zheng, J | 1 |
| Kurki, S; Laiho, M; Latonen, L | 1 |
| Akira, S; Kawai, T; Reed, JC | 1 |
| Cao, EH; Liang, XQ; Qin, JF; Zhang, Y | 2 |
| Akhand, AA; Emi, N; Hossain, K; Kajiguchi, T; Nakashima, I; Naoe, T; Saito, H; Yamamoto, K | 1 |
| Corbin, AS; Deininger, MW; Druker, BJ; Johnson, K; La Rosée, P; Mauro, MM; Melo, JV; Moseson, EM; Stoffregen, EP; Willis, S | 1 |
| Chiplunkar, S; Gollapudi, S; Gupta, S; Kim, C; Kim, D; Yel, L | 1 |
| Li, XQ; Sun, HY; Wang, QL; Wang, YF | 1 |
| An, S; Bae, IJ; Gwak, HS; Hong, SI; Lee, HC; Lee, SH; Park, IC; Park, MJ; Rhee, CH; Seo, KM; Woo, SH | 1 |
| Grigg, A; Kimber, R; Szer, J | 1 |
| Lin, C; Xing, S; Zhu, Z | 1 |
| Nakamura, S; Nakao, S; Ohtake, S; Okumura, H; Zhu, J | 1 |
| MCGILL, CM; PINTO, SS | 1 |
| Cheng, LC; Liang, YC; Ou, BR; Yeh, JY | 1 |
| MEYER, FO | 1 |
| SEDIVEC, V | 1 |
| FALLANI, M | 1 |
| ABBOTT, DD; HARRISSON, JW; PACKMAN, EW | 1 |
| LASCH, F | 1 |
| MORETTO, G | 1 |
| CH'EN, W; CHOU, Y | 1 |
| Gisslinger, H; Kees, M | 1 |
| HUKOVIC, S; STERN, P | 1 |
| BENNETT, BM; PINTO, SS | 1 |
| MASCHINSKI, G | 1 |
| MARRAS, G | 1 |
| Song, J; Zhang, DS | 1 |
| Mehta, J; Pichardo, D; Rosen, S; Singhal, S | 1 |
| Barbey, JT; Pezzullo, JC; Soignet, SL | 1 |
| Bai, XC; Gui, L; Han, XQ; Li, M; Lu, D; Luo, SQ; Zheng, WS | 1 |
| Udvardy, M | 1 |
| Betti, L; Borghini, F; Brizzi, M; Calzoni, GL; Lazzarato, L; Nani, D; Trebbi, G | 1 |
| Chang, HH; Chang, KH; Chen, HW; Chen, YJ; Chung, CH; Huang, MJ; Lai, YL; Lin, LH; Su, WH; Wang, WY | 1 |
| Aller, P; Amrán, D; de Blas, E; Fernández, C; Ramos, AM; Sancho, P | 2 |
| Akao, Y; Futatsugawa, S; Kito, M; Matsumoto, K; Naoe, T; Nozawa, Y; Sera, K; Wada, N | 1 |
| Aguilar, TM; Bahlis, NJ; Boise, LH; Krett, N; Lee, KP; McCafferty-Grad, J; Reis, I | 1 |
| Peng, L; Xu, X | 1 |
| Bachelez, H; Degos, L; Dombret, H; Dubertret, L; Dupuy, A; Jean-Louis, F; Michel, L; Musette, P; Poupon, J; Sors, A; Viguier, M | 1 |
| Bali, P; Bhalla, K; Fuino, L; Guo, F; Houghton, P; Nimmanapalli, R; O'Bryan, E; Wu, J | 1 |
| Lü, CF; Meng, R; Wang, W; Yang, BF; Zhou, J | 1 |
| Bi, K; Guo, G; Jiang, F; Jiang, G; Liu, C; Liu, X; Peng, J; Ren, H; Ren, Q; Tang, T; Tian, Z; Zhang, Y; Zhen, G | 1 |
| Bai, D; Ge, J; Ma, L; Su, H; Wang, B; Wei, H; Yao, X; Zhao, H | 1 |
| Fan, S; Li, X; Lu, C; Meng, R; Yang, B; Zhou, J | 1 |
| Shen, WL; Zhang, Y | 1 |
| Almasan, A; Chen, J; Chen, Q; Jiang, C; Jin, H; Shi, Y; Tang, H; Tian, C; Zheng, Y | 1 |
| Chen, JY; Chen, MH; Luo, WH; Shen, J; Shen, ZY; Zeng, Y; Zhang, Y | 1 |
| Benoit, G; Bobé, P; Canova, A; Chelbi-alix, MK; Pine, R | 1 |
| Hayashi, H; Kamikawa, T; Katoh, H; Maekawa, M; Naito, K; Ohnishi, K; Ohno, R; Sahara, N; Shinjo, K; Takeshita, A; Uehara, A; Yamazaki, K | 1 |
| Aposhian, HV; Carter, DE; Gandolfi, AJ | 1 |
| Dorsey, WC; Tchounwou, PB; Yedjou, CG | 1 |
| Körper, S; Nolte, F; Rojewski, MT; Schrezenmeier, H; Thiel, E | 1 |
| Brown, SL; Kim, JH; Kolozsvary, A; Lew, YS; Ryu, S | 1 |
| Drolet, B; Roden, DM; Simard, C | 1 |
| Davison, K; Mann, KK; Miller, WH; Waxman, S | 1 |
| Huang, C; Jiang, SJ; Lei, ML; Li, HC; Mu, XY; Wang, CX; Wang, LF | 1 |
| Chen, XH; Cheng, J; Liu, KT; Liu, Y; Wang, G; Wang, GQ; Zhang, YX | 1 |
| Li, JT; Ou, QJ; Wu, YC | 1 |
| Körper, S; Rojewski, MT; Schrezenmeier, H; Thiel, E | 2 |
| Chen, JL; Li, Q; Li, RS; Song, XZ; Xu, M | 1 |
| Jin, HF; Li, H; Shi, GY; Tang, XM; Yang, J; Yi, J; Zhu, P | 1 |
| Akay, C; Gazitt, Y; Thomas, C | 1 |
| Gong, Z; Le, XC; Lu, X; Wang, Z; Zhou, J | 1 |
| Gao, F; He, R; Sang, H; Tang, X; Yang, J; Ye, RD; Yi, J | 1 |
| Ji, L; Li, X; Wang, Z | 1 |
| LAMANNA, A; PASQUINELLI, F | 1 |
| Dutcher, JP; Garl, S; Lucariello, R; Unnikrishnan, D; Varshneya, N; Wiernik, PH | 1 |
| Brouet, JC; Chopin, M; Dosquet, C; Fermand, JP; Janin, A; Labaume, S; Larghero, J; Marolleau, JP; Poupon, J; Rousselot, P | 1 |
| Boles, E; Liu, Z; Rosen, BP | 1 |
| Cai, Z; Lin, MF; Tong, HY; Xiong, H | 1 |
| Cohen, FJ; Gui, D; Ikezoe, T; Koeffler, HP; Kumagai, T; O'Kelly, J; Said, JW; Tong, XJ | 1 |
| Takeshita, A | 1 |
| Li, BX; Liu, Y; Meng, R; Wang, W; Yang, BF; Zhou, J | 1 |
| Aisa, Y; Iguchi, T; Ikeda, Y; Miyamoto, K; Mori, T; Okamoto, S; Shimizu, T; Yokoyama, K | 1 |
| Hori, S; Kakehi, Y; Kakizuka, A; Maeda, H; Ogawa, O; Ohizumi, H; Segawa, T | 1 |
| Jing, Y; Lu, M; Luo, D; Waxman, S; Xia, L | 1 |
| Vey, N | 1 |
| Ahmed, M; Gazelle, GS; Goldberg, SN; Horkan, C; Kruskal, JB; Liu, Z; Solazzo, SA | 1 |
| Bonati, A; Costanzo, A; Levrero, M; Lunghi, P | 1 |
| Lanska, DJ | 1 |
| Colomer, D; Montserrat, E; Villamor, N | 1 |
| Gao, F; Shi, GY; Tang, XM; Yi, J; Yuan, JQ | 1 |
| Agre, P; Carbrey, JM; Liu, Z; Rosen, BP | 1 |
| Chen, SJ; Chen, Y; Chen, Z; De Thé, H; Fang, J; Gu, BW; Li, JM; Liu, YF; Shen, Y; Shen, ZX; Shi, JY; Shi, ZZ; Tang, W; Wang, ZY; Waxman, S; Wu, W; Yan, H; Zheng, PZ; Zhu, YM | 1 |
| Arnulf, B; Bazarbachi, A; Brouet, JC; Damaj, G; de Thé, H; Degos, L; Delarue, R; Dombret, H; Fermand, JP; Hermine, O; Lefrère, F; Poupon, J; Rousselot, P; Varet, B | 1 |
| Allen, T; Rana, SV; Singhal, R | 1 |
| Chen, SL | 1 |
| Meng, R; Wang, Y; Yang, BF; Zhou, J | 1 |
| Nand, S; Tanvetyanon, T | 1 |
| Bradley, D | 1 |
| Lin, MF; Wei, GQ; Zhang, SL; Zou, DB | 1 |
| Gibson, AD; Klem, J; Price, N; Reddy, GK | 1 |
| Afarideh, H; Jalilian, AR; Kyoumarsi, M; Raisali, GR; Rowshanfarzad, P; Sabet, M; Shafiee, A | 1 |
| Hong, WD; Li, J; Li, QH; Luo, SK; Peng, AH; Tan, EX; Tong, XZ; Zhang, GC; Zheng, D | 1 |
| Hara, S; Ishitsuka, K; Iwao, Y; Shirahashi, A; Shishime, M; Suzumiya, J; Takamatsu, Y; Takatsuka, Y; Tamura, K; Utsunomiya, A | 1 |
| Bai, XC; Cheng, BL; Deng, F; Li, M; Li, XM; Liu, B; Lu, D; Luo, SQ | 1 |
| Mann, KK; Miller, WH | 1 |
| Hayakawa, F; Privalsky, ML | 1 |
| Holcman, A; Kovac, M; Stibilj, V; Vadnjal, R | 1 |
| Cannizzaro, L; Ding, W; Gallagher, RE; Guidez, F; Kim, SH; Paietta, E; Ramesh, KH; Sun, Y; Warrell, RP; Zelent, A; Zhou, DC | 1 |
| Kaufman, J; Lonial, S | 1 |
| Karlsson, J; Påhlman, S; Pörn-Ares, I; Øra, I | 1 |
| Avvisati, G; Breccia, M; Carmosino, I; Finolezzi, E; Latagliata, R; Lo Coco, F; Petti, MC | 1 |
| Kakehi, Y; Ogawa, O; Wu, XX | 1 |
| Ellison, R; Hussein, MA; Mason, J; Ravandi, F; Rifkin, RM; Saleh, M | 1 |
| Bai, XC; Cheng, BL; Deng, F; Gui, L; Li, XM; Liu, B; Lu, D; Luo, SQ; Su, YC; Zeng, WS | 1 |
| Faires, MC | 1 |
| Jing, Y | 1 |
| Antony, S; Fu, H; Kohlhagen, G; Liao, Z; Liu, H; Pommier, Y; Sordet, O; Stevens, EV | 1 |
| Li, JQ; Li, Y; Shi, YJ; Wu, SL | 1 |
| Chen, LM; Ding, Y; Fu, LW; Huang, M; Li, YF; Liang, YJ; Wang, XD | 1 |
| Chen, YY; Hu, QS; Jing, YW; Li, H; Shi, GY; Tang, XM; Yi, J | 1 |
| Alvi, MI; Buonamici, S; Candoni, A; Chaudary, NI; Galili, N; Gallegos, JA; Gezer, S; Imran, M; Li, D; Lisak, L; Mumtaz, M; Nucifora, G; Pervaiz, H; Raza, A; Reddy, P; Singer, J; Tahir, S; Venugopal, P | 1 |
| Brown, AM; Dennis, AT; Ficker, E; Hawryluk, P; Kuryshev, YA; Obejero-Paz, C; Wang, L; Wible, BA | 1 |
| Fang, MY; Jiang, F; Peng, HJ; Wang, Y | 1 |
| Guo, ZX; Jin, J | 1 |
| Bertola, A; Boccadoro, M; Bruno, B; Giaccone, L; Massaia, M; Palumbo, A; Rotta, M | 1 |
| Evens, AM; Gartenhaus, RB; Tallman, MS | 1 |
| Boehlke, L; Frater, JL; Nabhan, C; Parmar, S; Raji, A; Riley, M; Rundhaugen, LM; Tallman, MS | 1 |
| Dryden, MJ; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, HM; Pierce, S; Ratnam, S; Tsimberidou, AM; Whitman, GJ | 1 |
| Keckesova, Z; Towers, GJ; Ylinen, LM | 1 |
| Meng, R; Yang, BF; Zhao, DY; Zhou, J | 1 |
| Allen, T; Rana, SV | 3 |
| Ravandi, F | 5 |
| Arnulf, B; Chevret, S; Cimerman, P; Claude Brouet, J; Dombret, H; Hermine, O; Larghero, J; Madelaine-Chambrin, I; Paul Fermand, J; Poupon, J; Rousselot, P; Royer, B; Tibi, A | 1 |
| Alvarez, RH; Cortes, JE; Giles, F; Kantarjian, HM; O'Brien, SM; Talpaz, M | 1 |
| Chiou, JM; Ho, CH; Hsu, JT; Huang, KK; Hwang, DR; Lee, JC; Lin, RK; Lin, YT; Tsai, YC; Yeh, CT | 1 |
| Aminaka, Y; Pi, J; Sun, G; Waalkes, MP; Yamauchi, H; Yoshida, K | 1 |
| Chan, JY; Chow, SK; Fung, KP | 2 |
| Khan, MA; Oubrahim, H; Stadtman, ER | 1 |
| Bertol, E; Fineschi, V; Karch, SB; Mari, F | 1 |
| Ahn, WS; Bae, SM; Kim, CK; Kim, YW; Lee, IP; Lee, JM; Lee, KH; Namkoong, SE; Seo, JS; Sin, JI | 1 |
| Hayash, H; Horii, T; Kitamura, K; Kobayashi, M; Maekawa, M; Naito, K; Nakamura, S; Naoe, T; Ohnishi, K; Ohno, R; Sahara, N; Shigeno, K; Shinjo, K; Takeshita, A | 1 |
| Ishaque, AB; Tchounwou, PB; Washington, T; Wilson, BA | 1 |
| Dubey, RS; Jha, AB | 1 |
| Dawson, AH; Isbister, GK; Whyte, IM | 1 |
| Billi, AM; Cappellini, A; Cocco, L; Falà, F; Manzoli, L; Martelli, AM; Tabellini, G; Tazzari, PL | 1 |
| Cheng, AL; Hsueh, YM; Lin, CJ; Sun, SS; Wu, MH | 1 |
| Bhattacharjee, H; Carbrey, J; Mukhopadhyay, R; Rosen, BP | 1 |
| Knox, SJ; Ning, S | 2 |
| Pan, B; Xu, L; Yang, X | 1 |
| Brown, SL; Jiang, TT; Kim, JH | 1 |
| Chandy, M; George, B; Mathews, V; Poonkuzhali, B; Shaji, RV; Srivastava, A | 1 |
| Feusner, J; Gregory, J; Ravindranath, Y | 1 |
| Ma, H; Wang, C; Wang, XF; Wang, Y | 1 |
| Jiang, H; Jiang, T; Wang, Y | 1 |
| Wang, G; Xiao, B; Zhang, C | 1 |
| Hahm, ER; Han, SS; Jung, CW; Kim, K; Kim, WS; Kimler, BF; Lee, JH; Lee, MH; Lee, SJ; Park, CH; Park, HK; Park, K; Park, S; Riordan, HD; Riordan, NH; Surh, YJ; Yang, JH; Yoon, SS | 1 |
| Meng, R; Yang, BF; Zhou, J | 2 |
| An, S; Cho, H; Gwak, HS; Hong, SI; Hong, YJ; Jin, HO; Lee, HC; Lee, SJ; Park, IC; Park, MJ; Park, SA; Rhee, CH; Woo, SH | 1 |
| Bachleitner-Hofmann, T; Baumgartner, M; Roth, E; Sturlan, S; Wessner, B | 1 |
| Garip, H; Garip, Y; Göker, K; Salih, IM; Sener, BC | 1 |
| Berenson, JR; Ferretti, D; Purner, MB; Swift, RA | 1 |
| Antimisiaris, SG; Fatouros, D; Kallinteri, P; Klepetsanis, P | 1 |
| Cai, L; Cui, J; Gao, S; Jiang, Z; Li, W; Liu, Z; Song, Y; Wang, G; Yang, Y; Yao, C; Yuan, CJ | 1 |
| Bae, IJ; Jeong, MB; Jeong, SM; Kim, JT; Nam, TC; Park, MJ; Rhee, CH; Seo, KM; Yi, NY; Yoo, MH | 1 |
| Liang, Y; Lu, QH; Su, LD; Zhang, XH; Zhao, XY | 1 |
| Balasubramanian, P; Chandy, M; George, B; Mathews, L; Shaji, RV; Srivastava, A | 1 |
| Luban, J; Sayah, DM | 1 |
| Li, J; Shen, T; Wang, X; Xu, CM; Yang, Y; Zhang, ZN; Zuo, L | 1 |
| Han, K; Kang, CS; Kim, M; Kim, Y; Lee, EJ; Lim, J; Moon, Y; Pai, SH; Park, G | 1 |
| Chen, J; Guan, JY; Hour, TC; Huang, CY; Lee, JM; Lin, CC; Pu, YS | 1 |
| Berenson, JR; Borad, MJ; Swift, R | 1 |
| Wang, W; Zhang, R; Zhang, XH; Zhu, ZL | 1 |
| Kwong, YL | 2 |
| Chen, CA; Cheng, CH; Chou, CH; Hsieh, CY; Huang, YJ; Kuo, ML; Lai, KP; Wei, LH | 1 |
| Buchet, JP; Haufroid, V; Heilier, JF; Meulemans, A; Michels, A; Sabbe, M; Vanderschueren, S; Vantroyen, B | 1 |
| Bi, L; Chen, SX; Liu, SM; Xu, HY; Yang, YL | 1 |
| Bonati, A; Lo-Coco, F; Lunghi, P; Pelicci, P; Pelicci, PG; Tabilio, A | 1 |
| Chen, YY; Guo, QS; Hu, QS; Kang, XL; Li, H; Lu, Y; Shi, GY; Tang, XM; Wang, XJ; Yang, J; Yi, J | 1 |
| Beck, BD; Lewandowski, TA | 1 |
| Byrd, DM; Kruse, MB; Lai, S; Lamm, SH; Tucker, SB | 1 |
| Hahm, ER; Han, SS; Jung, CW; Kim, J; Kim, K; Kim, WS; Kimler, BF; Lee, JH; Lee, SH; Lee, SJ; Park, CH; Park, K; Park, S; Yoon, SS | 1 |
| Chen, H; Hua, HQ; Qin, SK; Wang, JH | 1 |
| Chen, L; Fei, XH; Gao, L; Huang, ZX; Lou, JW; Wang, JM; Xu, XP | 1 |
| Baldus, C; Hofmann, WK; Thiel, E; Uharek, L | 1 |
| Hirose, Y; Kinoshita, H; Tanaka, T; Yamazaki, Y | 1 |
| Fink, RH; Friedrich, O; Körper, S; Nolte, F; Rojewski, M; Schrezenmeier, H | 1 |
| Chen, Z; Li, W; Liu, Z; Wu, X; You, Y; Zhou, H; Zou, P | 1 |
| Chang, YF; Chern, YT; Chi, CW; Wang, JJ | 1 |
| Germano, IM; Kanzawa, T; Kondo, S; Kondo, Y; Xiao, L; Zhang, L | 1 |
| Chandy, M; George, B; Poonkuzhali, B; Srivastava, A; Srivastava, VM | 1 |
| Wang, XW; Wei, L; Zuo, WS | 1 |
| Chou, WC; Dang, CV | 1 |
| Sekeres, MA | 3 |
| Körper, S; Rojewski, MT; Schrezenmeier, H | 1 |
| Civallero, M; Cosenza, M; Marcheselli, R; Pozzi, S; Sacchi, S | 1 |
| Hermine, O; Mahieux, R | 1 |
| Chen, G; Chen, L; Chen, S; Claude, G; Jin, X; Li, X; Liu, W; Ma, J; Ni, J; Shen, Z; Shi, X; Tang, W; Wang, Z; Xiong, S; Zhang, P; Zhang, T; Zhong, H; Zhu, J | 1 |
| Chen, G; Chen, L; Chen, S; Li, X; Ni, J; Shen, Z; Tang, W; Wang, Z; Xiong, S; Zhong, H; Zhu, J | 1 |
| Chen, G; Chen, L; Chen, S; Fang, Z; Huang, Y; Li, X; Liu, H; Ni, J; Shen, Z; Wang, Z | 1 |
| Chen, G; Chen, L; Chen, S; Jia, P; Ni, J; Shen, Z; Shi, G; Shi, X; Tang, W; Wang, Z | 1 |
| Du, J; Liu, BR; Qian, XP; Wang, LF; Yin, HT; Zou, ZY | 1 |
| Lu, M; Meng, R; Sui, XH; Wang, DS; Yang, BF; Zhou, J | 1 |
| Deeg, HJ; Li, X; Pu, Q; Shen, WM; Tohyama, K | 1 |
| Benecke, A; Cayre, YE; Denis, FM; Di Gioia, Y; Lutz, PG; Touw, IP | 1 |
| Gao, X; Li, C; Tong, QS; Xie, SS; Yu, LZ; Zeng, FQ; Zhou, J | 1 |
| Cardinale, G; Gervasi, F; Pagnucco, G | 1 |
| Chen, Y; Hao, JZ; Wang, ZH; Yu, D | 1 |
| Meng, R; Sui, XH; Yang, BF; Zhou, J | 1 |
| Daniel, PT; Dörken, B; Essmann, F; Scholz, C; Schulze-Osthoff, K; Stärck, L; Wieder, T | 1 |
| Jena, RK; Sahu, GR | 1 |
| Bastien, J; Bauer, A; Bruck, N; Gianni, M; Rochette-Egly, C; Tarrade, A | 1 |
| Milton, AG; Ratnaike, RN; Zalewski, PD | 1 |
| Emi, N; Kajiguchi, T; Naoe, T; Sawa, M; Yamamoto, K | 1 |
| Fung, Y; Lin, B; Liu, D; Ma, X; Qin, J; Wang, W; Ye, N; Yu, L | 1 |
| An, S; Gwak, HS; Hong, SI; Jin, HO; Lee, HC; Lee, SJ; Park, IC; Park, MJ; Rhee, CH; Woo, SH | 1 |
| Comenzo, RL; Kalakonda, N; Zhou, P | 1 |
| Kaplow, R | 1 |
| Chen, Q; Lee, MW; Tang, H; Tian, C; Wang, HG; Yamaguchi, H; Zheng, Y | 1 |
| Ikeda, T; Kimura, F; Kufe, D; Motoyoshi, K; Nakata, Y; Ogura, K; Sato, K; Sporn, M | 1 |
| Chen, ZC; Li, WM; Liu, ZP; Wu, XF; You, Y; Zou, P | 1 |
| Beal, N; Diehl, LF; Huff, CA; Jones, RJ; Matsui, W; Smith, BD; Vala, M | 1 |
| Giri, U; Kala, SV; Lieberman, MW; Story, MD; Terry, NH | 1 |
| Li, H; Luo, WH; Shen, ZY; Zhang, Y | 1 |
| Chen, W; Guo, HX; Jiang, HC; Liu, LX; Liu, ZH; Wang, XQ; Wu, M; Zhang, TD; Zhu, AL | 1 |
| Desmond, JC; Hewison, M; Hughes, SV; Koeffler, HP; Kumagai, T; O'Kelly, J; Shih, LY | 1 |
| Douer, D; Tallman, MS | 1 |
| Amadori, S; Fenaux, P; Ludwig, H; O'dwyer, M; Sanz, M | 1 |
| Griffin, RJ; Park, HJ; Song, CW; Williams, BW | 1 |
| Chen, Y; Wang, ZH; Yu, D; Zheng, J | 1 |
| Han, B; Kakudo, K; Tang, W; Wang, X; Zhang, J; Zhang, Q; Zhou, G | 1 |
| Gogvadze, V; McConkey, DJ; Mirnikjoo, B; Nutt, LK; Orrenius, S; Uthaisang, W | 1 |
| Bazarbachi, A; de Thé, H; Hermine, O; Kfoury, Y; Nasr, R | 1 |
| Gao, WR; Hou, J | 1 |
| Chen, SJ; Zhao, WW | 1 |
| Chng, WJ; Lau, LG; Mow, BM; Yusof, N | 1 |
| Huang, Q | 1 |
| Au, WY; Cheung, GT; Kumana, CR; Kwong, YL; Yuen, TW | 1 |
| Auffray, C; Chen, SJ; Chen, YL; Chen, Z; Du, YZ; Eveno, E; Fan, HY; Huang, QH; Imbeaud, S; Jin, G; Shen, SH; Wang, KK; Waxman, S; Xiao, DK; Zhang, J; Zhang, QH; Zhang, QY; Zhao, CJ; Zheng, PZ | 1 |
| Brown, SL; Kim, JH; Kolozsvary, A | 1 |
| Cao, EH; Qin, JF; Zhang, Y | 1 |
| Chen, Q; Jiang, CS; Jin, HJ; Liu, L; Wang, XH; Wang, ZX; Wu, Q | 1 |
| Horii, T; Maekawa, M; Matsui, H; Naito, K; Naoe, T; Ohnishi, K; Ohno, R; Sahara, N; Shigeno, K; Shinjo, K; Shirai, N; Takeshita, A | 1 |
| Ke, JJ; Ling, ZQ; Shao, QS; Ye, ZY | 1 |
| Chen, QB; Gao, WR; Hou, J; Xiong, H | 1 |
| Chen, SL; Chen, WM; Li, CL; Liu, JZ; Xiao, B; Zhang, HB | 1 |
| Chen, L; Chen, SY; Li, QY; Xu, XP; Xu, XW; Yi, K; Zhou, F | 2 |
| Huang, HS; Liu, ZM | 3 |
| An, S; Chung, HY; Han, CJ; Hong, SI; Jin, HO; Kwak, HJ; Lee, HC; Lee, JY; Lee, SH; Park, CM; Park, IC; Park, MJ; Rhee, CH; Woo, SH | 1 |
| Han, ST; Kim, YH; Kwon, TK; Park, EJ; Park, JW | 1 |
| Fukumoto, JS; Greenberg, PL | 1 |
| Hao, CY; Liu, JM; Min, ZH; Wang, DH; Wei, HL; Zhao, HS | 1 |
| Arai, A; Kitano, A; Kurosu, T; Miki, T; Miura, O; Murakami, N; Yamamoto, K | 1 |
| Lu, XN; Zheng, J | 1 |
| Daniel, PT; Dörken, B; Lehmann, M; Richter, A; Scholz, C; Schulze-Osthoff, K | 1 |
| Fu, HY; Shen, JZ | 1 |
| Chik, KW; Chuen, CK; Fok, TF; Lam, HK; Li, CK; Li, K; Liu, VC; Ng, PC; Shing, MM; Yang, M; Yuen, PM | 1 |
| Balk, RA; Hassaballa, HA; Lateef, OB; Silver, MR | 1 |
| Anderson, KC; Catley, L; Chauhan, D; Tai, YT | 1 |
| Akay, C; Gazitt, Y | 1 |
| Edsjö, A; Karlsson, J; Påhlman, S; Pettersson, HM | 1 |
| Cui, JW; Gao, SJ; Jiang, ZY; Li, W; Liu, ZL; Song, YQ; Wang, GJ; Yang, Y; Yao, C; Yuan, CJ | 1 |
| Song, XR; Wang, XW; Wei, L; Zuo, WS | 1 |
| Cang, H; Wang, XJ; Yang, J; Yi, J; Zou, YQ | 1 |
| Bai, SZ; Chen, GQ; Fu, GH; Guo, ZW; Liu, XB; Wang, Y; Xi, YH; Yang, BF | 1 |
| Dierickx, PJ | 1 |
| Islam, N; Misbahuddin, M; Siddique, MA | 1 |
| Tajima, M | 1 |
| Hao, LC; Wang, H; Zhang, LZ | 1 |
| Huang, JF; Ni, RZ; Tan, B; Wei, Q; Zhang, H | 2 |
| Novák, L; Půza, V | 1 |
| Abbasi, N; Deeg, HJ; Kerbauy, DM; Lesnikov, V; Scott, B; Seal, S | 1 |
| Aradi, J; Dudognon, C; Hillion, J; Lanotte, M; Pendino, F; Ségal-Bendirdjian, E; Tarkanyi, I | 1 |
| Baccarani, M; Billi, AM; Bortul, R; Evangelisti, C; Grafone, T; Martelli, AM; Martinelli, G; Tabellini, G; Tazzari, PL | 1 |
| Ikeda, Y; Ito, K; Kizaki, M; Nakazato, T | 1 |
| Jin, J; Lin, MF; Qian, WB; Tong, HY; Xu, WL | 1 |
| Bedikian, AY; Camacho, LH; Kim, KB; McCullough, C; Papadopoulos, NE | 1 |
| Huang, X; Ma, A; Ma, X; Qiao, D; Tian, X; Yan, F | 1 |
| Engel, RH; Evens, AM | 1 |
| Bhattacharya, S; Roy, S | 1 |
| Fenaux, P; Lo Coco, F; Sanz, MA | 1 |
| Jia, J; Meng, L; Meng, R; Sui, X; Yang, B; Zhou, J | 1 |
| Asou, N | 1 |
| Kobayashi, M; Maekawa, M; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Sahara, N; Shigeno, K; Shinjo, K; Takeshita, A | 1 |
| Asaka, M; Ehira, N; Imamura, M; Kanamori, H; Kawamura, T; Masauzi, N; Obara, S; Tanaka, J; Tsutsumi, Y; Yamato, H | 1 |
| Estey, E; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Kantarjian, H; Patel, SP; Verstovek, S | 1 |
| Fardel, O; Lemarie, A; Mérino, D; Micheau, O; Morzadec, C; Vernhet, L | 1 |
| Colosimo, AL; Guo, Q; Kurie, JM; Lee, HY; Mann, KK; Miller, WH; Padovani, AM | 1 |
| Chen, SJ; Chen, Z; Zhou, GB | 1 |
| Dong, DL; Song, WH; Yang, BF | 1 |
| Wei, S; Xiang, G; Xie, S; Zeng, F; Zhou, J | 1 |
| Hu, Y; Qiao, Z; Song, S; Yang, L; Zhang, X; Zhou, H | 1 |
| Fujisawa, S; Kobayashi, M; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Sahara, N; Shigeno, K; Shinjo, K; Takeshita, A | 1 |
| Patlolla, AK; Tchounwou, PB | 2 |
| Dong, X; Jiang, H; Kanwar, JR; Krissansen, GW; Luo, L; Meng, F; Qiao, H; Sun, X; Zhou, B | 1 |
| Alimoghaddam, K; Ghavamzadeh, A; Nafisi, S; Sobhanmanesh, A; Tajmir-Riahi, HA | 1 |
| Aghdami, N; Alimoghaddam, K; Bahar, B; Baybordi, E; Ghaffari, SH; Ghavamzadeh, A; Hosseini, R; Iravani, M; Jahani, M; Khodabadeh, A; Mortazavi, Y; Mossavi, A; Rostami, S; Totonchi, M | 1 |
| Cheng, F; Hiraku, Y; Kawanishi, S; Ma, N; Murata, M; Oikawa, S; Piao, F; Yamauchi, T; Yokoyama, K; Zhong, L | 1 |
| Betti, L; Borghini, F; Brizzi, M; Lazzarato, L; Nani, D; Peruzzi, M | 1 |
| Baumgartner, S; Binder, M; Thurneysen, A | 1 |
| Büchner, T; Hehlmann, R; Lengfelder, E; Saussele, S; Weisser, A | 1 |
| Li, BX; Lin, DH; Lin, LM; Xiao, JB; Yang, BF | 1 |
| Au, WY; Kwong, YL | 2 |
| Bornstein, J; Fares, F; Haj, A; Harroch, J; Sagi, S | 1 |
| Auffray, C; Chen, S; Chen, Y; Chen, Z; Du, Y; Eveno, E; Fan, H; Fang, H; Graudens, E; Imbeaud, S; Li, J; Pan, X; Wang, K; Xiao, D; Zhang, J; Zhang, Q; Zhao, C; Zheng, P | 1 |
| Fujita, N; Haga, N; Tsuruo, T | 1 |
| Li, B; Li, WH; Sun, YL; Wang, CF; Xu, YL; Zhang, HY | 1 |
| Ebert, SN; Katchman, AN; Koerner, J; Tosaka, T; Woosley, RL | 1 |
| Chang, WC; Chi, CC; Chuang, CH; Ding, L; Hsu, PY; Huang, HS; Liu, ZM; Wang, SH | 1 |
| Fan, J; Wang, HM; Wu, QL; Yao, H | 1 |
| Alimoghaddam, K; Ghavamzadeh, A; Jahani, M; Rostami, S; Sanaat, Z; Shariftabrizi, A; Tavangar, M; Tavangar, SM | 1 |
| Chang, LW; Cheng, Y; Tsou, TC | 1 |
| Tamm, I | 1 |
| Chen, GQ; Huang, Y; Jiang, Y; Peng, ZG; Wu, YL; Yan, H; Yu, Y; Zhao, Q; Zhu, YS | 1 |
| Au, WY; Chan, CH; Chim, CS; Fung, AT; Kwong, YL; Liang, RH; Ma, ES; Wong, KF | 1 |
| Bajel, A; Balasubramanian, P; Chandy, M; George, B; Lakshmi, KM; Mathews, V; Shaji, RV; Srivastava, A; Srivastava, VM; Viswabandya, A | 1 |
| Estey, E; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Jones, D; Kantarjian, H; Verstovsek, S | 1 |
| Saunders, G | 1 |
| Antimisiaris, SG; Frederik, P; Ioannou, PV; Piperoudi, S | 1 |
| Chow, J; Huang, M; Lee, C; Lin, C; Lin, Y; Liu, C; Liu, HE | 1 |
| Frankfurt, O; Tallman, MS | 1 |
| Chen, JY; Chen, L; Du, CW; Li, DR; Lin, W; Lin, YC; Wen, BG; Wu, MY; Zheng, YW | 1 |
| Ma, AD; Ma, XD; Qiao, DF; Tian, XM; Yan, F | 1 |
| Benedusi, M; Bertagnolo, V; Bovolenta, M; Brugnoli, F; Capitani, S; Miscia, S | 1 |
| Binet, F; Cavalli, H; Girard, D; Moisan, E | 1 |
| Bhattacharya, A; Bhattacharya, S | 1 |
| Cahill, S; Meyer, M; O'Dwyer, M; Samali, A; Szegezdi, E | 1 |
| Luban, J; Sebastian, S; Sokolskaja, E | 1 |
| Fukuda, M | 1 |
| Li, A; Liu, Q; Wang, X; Ye, J; Zhou, J | 1 |
| Murakami, H | 1 |
| Boehrer, S; Chow, KU; Hoelzer, D; Mitrou, PS; Nowak, D | 1 |
| Bonati, A; Costanzo, A; Levrero, M; Lo-Coco, F; Lunghi, P; Mazzera, L; Noguera, N; Salvatore, L; Tabilio, A | 1 |
| Li, DM; Liang, B; Xie, JX | 1 |
| Akioka, T; Hanafusa, T; Hara, S; Oka, T; Tsuji, M; Yamano, T; Yokote, T | 1 |
| Andreeff, M; Carew, JS; Huang, P; Keating, MJ; McQueen, TJ; Pelicano, H; Plunkett, W | 1 |
| Ahn, E; Bach, A; Bouzari, N; Chen, H; Nouri, K; Ricotti, CA | 1 |
| Chen, GQ; Huang, Y; Jiang, Y; Liu, W; Peng, ZG; Song, LP; Zhao, Q | 1 |
| Anderson, KC; Hideshima, T; Richardson, PG; Schlossman, R | 1 |
| Au, WY; Kumana, CR; Kwong, YL; Lau, CP; Siu, CW; Tse, HF; Yung, C | 1 |
| Bajel, A; Chandy, M; Desire, S; George, B; Lakshmi, KM; Mathews, V; Rao, JG; Srivastava, A; Srivastava, VM; Viswabandya, A | 1 |
| Liu, PB; Liu, SX; Wang, MC | 1 |
| Bazarbachi, A; Contamin, H; de Thé, H; Gessain, A; Heraud, JM; Hermine, O; Kazanji, M; Mahieux, R; Merien, F; Mortreux, F; Pouliquen, JF; Wattel, E | 1 |
| Ades, L; Bordessoule, D; Castaigne, S; Chevret, S; de Botton, S; Degos, L; Dombret, H; Fegueux, N; Fenaux, P; Guerci, A; Kelaidi, C; Link, H; Meyer-Monard, S; Raffoux, E; Rayon, C; Rigal-Huguet, F; Sanz, M; Stoppa, A; Thomas, X; Vekhoff, A | 1 |
| Au, WY; Fong, BM; Kwong, YL; Tam, S | 4 |
| Ammatuna, E; Lo Coco, F; Noguera, N | 1 |
| Cheung, WM; Chu, PW; Kwong, YL | 1 |
| De la Rosa, G; Gardea-Torresdey, JL; Martinez-Martinez, A; Parsons, JG; Peralta-Videa, JR | 1 |
| Jing, Y; Waxman, S; Wurmbach, E; Xia, L | 1 |
| Chang, WH; Chen, RJ; Guo, HR; Ho, SY; Huang, PC; Tai, C; Wang, YJ; Wei, BL; Wu, WJ | 1 |
| Alkharfy, KM; Arafah, MM; Saad, SY | 1 |
| Cui, X; Hatakeyama, K; Hirano, S; Shirai, Y; Wakai, T; Yokoyama, N | 1 |
| Bai, YL; Chu, WF; Dong, DL; Liu, Y; Sun, HL; Wang, XH; Yang, BF; Zhou, J | 1 |
| Jin, J; Lu, J; Xu, WL | 1 |
| Wang, B; Zhang, J | 1 |
| An, Y; Ge, JB; Huang, YL; Li, WM; Liu, HL; Liu, XB; Qu, XF; Tian, Y; Yang, W | 1 |
| Liu, T; Meng, WT; Tan, J; Yu, J; Zhu, HL | 1 |
| Cheng, JH; Liu, F; Wu, YH; Zhang, M; Zou, P | 1 |
| Besançon, F; Mathieu, J | 2 |
| Chen, JY; Du, CW; Hong, CQ; Hong, X; Li, DR; Lin, YC; Lin, ZZ; Peng, X; Wen, BG; Wu, MY; Xie, LX; Zhang, H | 1 |
| Stone, RM | 1 |
| Bosly, A; Bowen, D; Burnett, A; Casadevall, N; Dennis, M; Dombret, H; Dreyfus, F; Fenaux, P; Feremans, W; Guerci, A; Legros, L; Ribrag, V; Vey, N | 1 |
| Douer, D; Hainsworth, JD; List, AF; Mason, J; Rizzieri, D; Saleh, M; Schiller, GJ; Slack, J | 1 |
| Fukai, Y; Hirata, M; Ichikawa, N; Kaise, T; Kinoshita, K; Kobayashi, H; Ohta, S; Saitoh, H; Sakurai, T; Ueno, M | 1 |
| Jeong, ET; Kim, EJ; Kim, HR; Kim, SJ; Park, C; Park, R; So, HS; Yang, SH; Youn, MJ | 1 |
| Beer, TM; Crawford, ED; Dreicer, R; Margolin, KA; Nichols, CR; Quinn, DI; Raghavan, D; Stephenson, WT; Tangen, CM | 1 |
| Hess, U | 1 |
| Cohly, HH; Graham-Evans, B; Tchounwou, PB; Yu, H | 1 |
| He, W; Hu, Y; Sun, C; Wang, Y; Zhang, X | 1 |
| Goldberg, SN; Hines-Peralta, A; Liu, ZJ; Regan, M; Signoretti, S; Sukhatme, V | 1 |
| Abou-Jawde, RM; Andresen, S; Baz, R; Hussein, M; Karam, MA; Kelly, M; Reed, J; Walker, E | 1 |
| Au, WY; Chan, EY; Cheng, VC; Kumana, CR; Kwong, YL; Lam, CW; Liu, R; Shek, TW | 1 |
| Bellincampi, L; Bernardini, S; Bonati, A; Federici, G; Lo Coco, F; Lunghi, P; Mann, K; Miller, WH; Noguera, NI; Nuccetelli, M | 1 |
| Emi, N; Iida, S; Kajiguchi, T; Naoe, T; Ueda, R; Yamamoto, K | 1 |
| Caillot, D; Fenaux, P; Huguet, F; Pigneux, A; Raffoux, E; Thomas, X | 1 |
| Kobayashi, M; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Sahara, N; Shigeno, K; Shinjo, K; Takeshita, A; Tobita, T | 1 |
| Kai, T; Kimura, H; Maruyama, Y; Ogawa, K; Sato, H; Shiga, Y | 1 |
| Arthur, JS; Kannan-Thulasiraman, P; Katsoulidis, E; Platanias, LC; Tallman, MS | 1 |
| Gomolka, M; Hornhardt, S; Jung, T; Walsh, L | 1 |
| Bhattacharya, S; Ghosh, D; Mazumder, S | 1 |
| Fan, SJ; Han, XY; Hu, LH; Wang, Y; Wu, N; Zhou, J | 1 |
| Pu, Q | 1 |
| Ji, XM; Jia, JP; Li, LM; Meng, R; Yang, BF; Zhou, J | 1 |
| Beran, M; Freireich, E; Giles, F; Kantarjian, H; Perez, N; Quintás-Cardama, A; Ravandi-Kashani, F; Verstovsek, S | 1 |
| Chen, Y; Hu, Q; Jing, Y; Li, H; Shi, G; Tang, X; Wang, Y; Yang, J; Yi, J | 1 |
| Brdiczka, D; Israelson, A; Sheu, SS; Shoshan-Barmatz, V | 1 |
| Deng, SH; Han, MZ; Li, QC; Li, X; Li, Y; Li, YT; Li, ZJ; Qiu, LG; Wan, CC; Yang, RC; Zhao, YZ | 1 |
| Alimoghaddam, K; Ghavamzadeh, A; Jahani, M | 1 |
| Hussein, MA; Kalmadi, SR | 1 |
| Davis, RJ; Giafis, N; Higgins, LS; Katsoulidis, E; Nebreda, AR; Platanias, LC; Sassano, A; Tallman, MS | 1 |
| Moore, P; Tchounwou, PB; Yedjou, CG | 1 |
| Dong, X; Jiang, H; Krissansen, GW; Liu, B; Pan, S; Qiao, H; Sun, X | 1 |
| Alimoghaddam, K; Bashash, D; Ghaffari, SH; Ghavamzadeh, A; Rostami, S | 1 |
| Carter, DE; Hays, AM; Lantz, RC; Srinivasan, D; Witten, ML | 1 |
| Meng, L; Meng, R; Sui, XH; Yang, BF; Zhou, J | 1 |
| Ma, AD; Qiao, DF; Wang, HJ; Yan, F | 1 |
| Fu, Q; Hu, BR; Li, JJ; Li, Y; Ming, ZY; Qian, JQ; Tang, Q; Xiang, JZ | 1 |
| Bennett, JM; Dewald, GW; Gallagher, RE; Jain, V; Lee, S; Litzow, MR; Mazza, JJ; Paietta, EM; Racevskis, J; Rousey, SR; Tallman, MS | 1 |
| Ehninger, G; Helwig, A; Illmer, T; Klemm, M; Röllig, C; Schüttig, R; Wassilew, N | 1 |
| Jin, J; Liu, J; Ni, W; Qian, W; Xu, W | 1 |
| Guo, W; Tang, S; Tang, XD; Yang, Y | 1 |
| Huilgol, NG | 1 |
| Chung, JH; Jeong, JH; Joe, Y; Kang, H; Kim, MK; Motoyama, N; Pandolfi, PP; Yang, S | 1 |
| Bagic, A; Kessler, CM; Lupu, V; Tornatore, C | 1 |
| Ai, Z; Lu, W; Qin, X | 1 |
| Aleskog, A; Barbany, G; Bengtsson, M; Björnberg, A; Höglund, M; Larsson, R; Lindhagen, E; Olsson-Strömberg, U; Simonsson, B | 1 |
| Duan, LN; Guo, ZK; Ji, SQ; Wang, HX | 1 |
| Benihoud, K; Bobé, P; Bonardelle, D; Chelbi-Alix, MK; Opolon, P | 1 |
| Duan, Y; Li, HM; Liu, H; Yu, MJ; Zhang, XM | 1 |
| Ahn, HS; Jang, JJ; Jung, HS; Kim, CJ; Kim, HS; Lee, MJ; Ryu, KH; Seoh, JY; Shin, HY | 1 |
| Cheng, AL; Hsu, C; Hsu, CH; Hsu, WL; Lin, CC; Yang, CH | 1 |
| Fujisawa, S; Hashimoto, H; Kaise, T; Kinoshita, K; Kobayashi, M; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Sahara, N; Shigeno, K; Shimoya, M; Shinjo, K; Suzuki, Y; Takeshita, A | 1 |
| Niki, E; Piga, R; Saito, Y; Yoshida, Y | 1 |
| An, S; Choe, TB; Hong, SI; Jin, HO; Kim, JI; Kwon, TJ; Lee, HC; Lee, SJ; Park, IC; Park, MJ; Rhee, CH; Seo, SK; Woo, SH; Yoo, DH; Yoon, SI | 1 |
| Gokhalé, P; Morrison, MJ; Patel, T; Vissers, MC | 1 |
| Bauer, N; Bergmann, L; Chow, KU; Glienke, W | 1 |
| Kwong, YL; Leung, J; Pang, A; Tse, EW; Yuen, WH | 1 |
| Aller, P; Amrán, D; de Blas, E; Esteban, D; Fernandez, C; Palacios, MA; Ramos, AM | 1 |
| Ohnishi, K | 2 |
| Chen, X; Liu, SX; Ren, LF; Wu, DD; Xiao, YF | 3 |
| Chang-chun, W; Jian-xiang, W; Lu-gui, Q; Ming-zhe, H; Qiao-chuan, L; Ren-chi, Y; Wan-jun, S; Xin, L; Yan, L; Yao-zhong, Z; Yun-tao, L; Zeng-jun, L | 1 |
| Berenson, JR; Bessudo, A; Boccia, R; Bozdech, M; Ferretti, D; Flam, M; Jilani, S; Louie, R; Lutzky, J; Moss, R; Patel, R; Russell, K; Siegel, D; Stadtmauer, E; Steis, R; Swift, RA; Talisman Pomeroy, J; Volk, J; Wong, SF; Yeh, HS | 1 |
| Buscemi, S; Cai, L; Chen, GQ; Fu, GH; Pan, XY | 1 |
| Ewer, MS; Jones, RL | 1 |
| Ge, J; Huang, Y; Li, W; Liu, H; Liu, X; Qu, X; Sun, A; Yang, W; Zhao, K; Zou, Y | 1 |
| Caldas, C; Chin, SF; Cowell, JK; Kasyapa, CS; Kunapuli, P | 1 |
| Chen, H; Krett, NL; Li, S; MacDonald, RC; O'Halloran, TV; Rosen, ST | 1 |
| Abe, S; Harigae, H; Imaizumi, M; Ishikawa, I; Kaku, M; Sasaki, T; Takahashi, S; Yokoyama, H | 1 |
| Hayashi, H; Katoh, H; Naito, K; Ohnishi, K; Satoh, H; Takeshita, A; Terada, H; Uehara, A; Yamazaki, K | 1 |
| He, XE; Lei, JH; Liang, J; Luo, HY; Wang, WL; Yang, X | 1 |
| Boles, E; Jiang, X; Landfear, SM; Liu, Z; Rosen, BP; Sanchez, MA | 1 |
| Agrawal, N; Kumar, A; Kumar, R; Mahapatra, M; Naithani, R | 1 |
| Bellon, M; Brown, M; Nicot, C | 1 |
| Avivi, I; Gesundheit, B; Ofran, Y; Or, R; Rowe, JM; Zuckerman, T | 1 |
| Chang, CC; Chang, KS; Chao, TT; Chen, YC; Fang, HI; Ho, CC; Huang, YS; Hung, CC; Hwang, MJ; Jeng, JC; Kuo, HY; Lin, DY; Lin, TP; Maul, GG; Shih, HM; Suen, CS | 1 |
| Emi, N; Kajiguchi, T; Kinoshita, T; Naoe, T; Ninomiya, M; Yamamoto, K | 1 |
| Hou, KZ; Jin, B; Liu, YP; Yu, P | 1 |
| Sanz, MA | 2 |
| Gurr, JR; Jan, KY; Pu, YS; Wang, AS; Wang, TC | 1 |
| Estey, E; Kantarjian, H; Keating, MJ; Tsimberidou, AM | 1 |
| Baer, MR; Baumann, H; Brady, MT; Cheng, Y; Cowell, JK; Donohue, KA; Kunapuli, P; Li, ZR; McDonald, AA; Mortazavi, A; O'Loughlin, KL; Tracy, E; Wallace, PK; Wetzler, M | 1 |
| Altman, J; Giafis, N; Katsoulidis, E; Mears, H; Platanias, LC; Redig, AJ; Sassano, A; Smith, J; Tallman, MS; Yoon, P | 1 |
| Ackerstein, A; Bitan, M; Gesundheit, B; Or, R; Resnik, IB; Shapira, MY | 1 |
| Avvisati, G; Breccia, M; Buffolino, S; Cimino, G; De Angelis, G; Lo-Coco, F; Mariella, M; Martini, V; Minotti, C | 1 |
| Amadori, S; Beksac, M; Sonneveld, P; van Droogenbroeck, J; Wu, KL; Zweegman, S | 1 |
| Blusztajn, A; Kenific, C; Ren, R; Shackelford, D; Waxman, S | 1 |
| Chan, R; Chen, D; Jing, Y; Waxman, S | 1 |
| Bonati, A; Lunghi, P; Rizzoli, V | 1 |
| Cui, XF; Hu, AH; Xie, WP; Yin, KS; Zhou, LF; Zhu, Y | 1 |
| Bertoglio, J; Bréard, J; Potin, S | 1 |
| Martins, J; OlivaTeles, L; Saker, ML; Soares, ML; Vasconcelos, VM | 1 |
| Baysan, A; Gollapudi, S; Gupta, S; Su, H; Yel, L | 1 |
| Fang, MY; Wang, Y | 1 |
| Tchounwou, PB; Yedjou, CG | 2 |
| Chen, SJ; Chen, Z; de Thé, H; Guillemin, MC; Lallemand-Breittenbach, V; Li, JM; Shen, ZX; Vitoux, D; Zhao, WL; Zhou, J; Zhu, J | 1 |
| Jing, Y; Waxman, S | 1 |
| Berenson, JR; Yeh, HS | 1 |
| Jin, J; Lu, J | 1 |
| Chung, HY; Kang, YH; Kim, CH; Lee, SJ; Lee, YS; Park, IC; Park, MT | 1 |
| Bi, KH; Jiang, GS | 1 |
| Fujimura, A; Oshima, Y; Sasaki, A | 1 |
| Akar, U; Berestein, GL; Colburn, N; Danilenko, M; Kornblau, S; Ozpolat, B; Steiner, M; Tirado-Gomez, M; Zorrilla-Calancha, I | 1 |
| Seo, T; Ueda, T; Urasaki, Y | 1 |
| Bae-Jump, V; Boggess, JF; Gehrig, PA; Zhou, C | 1 |
| Büchner, T; Hehlmann, R; Lengfelder, E; Schultheis, B | 1 |
| Cui, X; Liu, T; Meng, WT; Xi, YM; Ye, XS | 1 |
| Dumlu, A; Güvercin, M; Olgac, V; Yalcinkaya, S | 1 |
| Chen, RJ; Cheng, TJ; Ho, YS; Kao, WW; Wang, YJ | 1 |
| Li, W; Meng, R; Sui, X; Yang, B; Zhou, J | 1 |
| Chen, SJ; Chen, Z; Wang, ZY; Zhang, J; Zhou, GB | 1 |
| Aribi, A; Cortes, JE; Estey, EH; Faderl, SH; Garcia-Manero, G; Kantarjian, HM; Koller, CA; Kornblau, SM; Laddie, NM; Thomas, DA | 1 |
| Aoki, M; Arai, A; Ichijo, H; Miura, O; Yan, W | 1 |
| Akay, C; Gazitt, Y; Kircelli, F | 1 |
| Bai, J; Chen, H; Chen, R; Li, A; Liu, Z; Mao, W; Ye, J; Zhou, J | 1 |
| Ammatuna, E; Lo Coco, F; Sanz, MA | 1 |
| Beissert, T; Bug, G; Henschler, R; Hoelzer, D; Puccetti, E; Rüster, B; Ruthardt, M; Seshire, A; Zheng, X | 1 |
| Lin, SX; Xia, XR; Zhou, Y | 1 |
| Berenson, JR; Mapes, R; Matous, J; Morrison, B; Swift, RA; Yeh, HS | 1 |
| Fu, M; Li, Y; Liang, X; Lin, C; Qian, H; Wang, Y; Yu, J; Zhang, X | 2 |
| Büsselberg, D; Florea, AM; Splettstoesser, F | 1 |
| Ahn, WS; Bae, IJ; Bae, SM; Chang, HS; Kim, CK; Kim, YW; Kwak, SY; Lee, YJ; Min, HJ; Shin, JC | 1 |
| Leikin, J; Mahajan, N; Wang, EE; Wills, B | 1 |
| Brady, MT; Earp, JC; Jusko, WJ; Keng, MK; Wetzler, M | 1 |
| Beckman, S; Karlsson, J; Larsson, C; Påhlman, S; Pettersson, HM; Pietras, A | 1 |
| Gattermann, N; Germing, U; Käferstein, H; Knipp, S; Schapira, M | 1 |
| Liang, B; Liu, JL; Qin, DY; Wu, T | 1 |
| Chen, JY; Du, CW; Hong, CQ; Li, DR; Lin, XH; Xie, LX | 1 |
| Jin, W; Sun, BG; Wen, QZ; Xue, JX; Zhang, JJ; Zhao, JL; Zhuang, WY | 2 |
| de The, H; Nasr, R; Vitoux, D | 1 |
| Hede, K | 1 |
| Emi, N | 2 |
| Cai, B; Liu, J; Liu, Y; Wang, G | 1 |
| Avani, G; Rao, MV | 1 |
| Aoki, M; Hara, S; Ishitsuka, K; Ogata, K; Suzumiya, J; Tamura, K | 1 |
| Fu, HY; Sheng, JZ; Sheng, SF; Zhou, HR | 1 |
| Guo, T; Hong, M; Hu, Y; Shen, GX; Song, SJ; Wei, WN; Xia, LH; Zhang, XH | 1 |
| Chen, GQ; Li, D; Liu, W; Wang, Y; Wang, YC; Wu, YL; Yan, H | 1 |
| Ardalan, B; Lima, M; Subbarayan, PR | 1 |
| Han, YH; Kim, SH; Kim, SZ; Park, WH | 7 |
| Shi, XY; Song, C; Wang, HY; Xue, DB; Yun, XG; Zhang, WH; Zheng, B | 1 |
| Dong, X; Sun, X; Zhang, J; Zhang, X; Zhao, S | 1 |
| Bonapace, L; Bornhauser, BC; Bourquin, JP; Cario, G; Lindholm, D; Martinez, R; Niggli, FK; Schäfer, BW; Schrappe, M | 1 |
| Fung, KP; Kong, SK; Kwok, TT; Lui, JC; Suen, YK; Wong, JW | 1 |
| Karlsson, J; Påhlman, S; Pettersson, HM; Pietras, A; Øra, I | 1 |
| Abdallah, M; Bazarbachi, A; Darwiche, N; Dbaibo, GS; de Thé, H; El-Sabban, M; Hermine, O; Kfoury, Y; Kozhaya, L; Nasr, R; Panjarian, S | 1 |
| Härtel, N; Hehlmann, R; Hochhaus, A; Konig, H; La Rosée, P; Lorentz, C; Melo, JV; Schatz, M; Schultheis, B | 1 |
| Chen, SC; Chou, Y; Tian, TY; Tsai, CH; Ueng, KC; Yeh, HI | 1 |
| Emi, N; Kajiguchi, T; Naoe, T; Ono, Y; Yamamori, S; Yamamoto, K | 1 |
| Abou-Merhi, R; Arnoult, D; Bazarbachi, A; Dbouk, H; de Thé, H; El Hajj, H; El-Sabban, ME; Gessain, A; Hermine, O; Khoriaty, R; Mahieux, R; Munier, S | 1 |
| Au, WY; Fong, BM; Hui, CK; Kwong, YL; Liu, CL; Shek, TW; Tam, S | 1 |
| Jiang, L; Wu, L; Yi, H | 1 |
| Berridge, MV; Herst, PM; Hesketh, EL; Ritchie, DS | 1 |
| Liu, M; Wang, XX; Wei, FC; Zhang, J | 1 |
| Berman, JN; Look, AT | 1 |
| Baritaki, S; Berenson, JR; Bonavida, B; Campbell, RA; Chen, H; Gordon, M; Pang, S; Said, J; Sanchez, E; Shalitin, D; Steinberg, JA; Wang, C | 1 |
| Czyz, M; Duechler, M; Stańczyk, M; Stepnik, M | 1 |
| Chandy, M; George, B; Mathews, V; Srivastava, A; Srivastava, VM; Thomas, M | 1 |
| Farhat, M; Venugopal, P | 1 |
| Hu, YH; Huang, XR; Qi, MX; Wu, ZZ; Yan, J | 1 |
| Ma, J | 1 |
| Ai, Z; Liu, H; Lu, W; Qin, X; Shen, Z; Sou, T; Ton, S | 1 |
| Horváth, V; Ondrousková, E; Smarda, J; Soucek, K | 1 |
| Falnoga, I; Podgornik, H; Pucer, A; Slejkovec, Z; Tusek-Znidaric, M | 1 |
| Ahn, HS; Kang, HJ; Park, JA; Shin, HY; Yun, JH | 1 |
| Chen, JP; Cong, YW; Dong, B; Fu, YL; Huang, R; Liang, YG; Liu, ZY; Mao, BZ; Shan, YJ; Wang, SQ; Xiao, H; Yu, ZY; Zhao, QS; Zhao, ZH | 1 |
| Chew, EH; Holmgren, A; Lu, J | 1 |
| Meng, H; Qian, W; Shao, K; Yang, C; Yang, X; Ye, X; Zhou, Y | 1 |
| Jiao, Y; Jin, J; Liu, J; Ni, W; Qian, W; Xu, W; Zhang, W | 1 |
| Chen, H; Gu, J; Ma, L; Shen, WG; Wang, XL; Zhang, JD; Zhang, Y | 1 |
| Hampton, T | 1 |
| Cohn-Cedermark, G; Kälkner, KM; Ullén, A; Wersäll, P | 1 |
| Au, WY; Kwong, YL; Tam, S | 1 |
| Fu, YB; Li, L; Meng, FY; Sun, QX; Tian, S | 1 |
| Aller, P; Amrán, D; Bréard, J; Calle, C; de Blas, E; Fernández, C; Ramos, AM; Sánchez, Y | 1 |
| Bismar, TA; Diaz, Z; Laurenzana, A; Mann, KK; Miller, WH; Schipper, HM | 1 |
| Feng, TM; Tan, LJ; Wang, W; Wei, QF; Yang, BF; Zhou, J | 1 |
| Albihn, A; Henriksson, M; Jiang, G; Tang, T; Tian, Z | 1 |
| Campbell, LJ; Catalano, A; Dawson, MA; Iland, H; Opat, S; Schwarer, A; Somana, K | 1 |
| Banerjee, P; Belon, P; Biswas, SJ; Khuda-Bukhsh, AR | 1 |
| Chen, GQ; Wang, LS; Wu, YL; Yu, Y | 1 |
| Chen, SJ; Chen, Z; Li, G; Zhou, GB | 1 |
| Dyś, P; Magdalan, J; Porebska, B; Smolarek, M; Zawadzki, M | 1 |
| Correa, R; Mangeat, B; Piguet, V; Pion, M; Stalder, R; Towers, GJ | 1 |
| Jin, Z; Man, Z; Ran, M | 1 |
| Cang, H; Li, L; Shi, G; Wang, J; Yi, J | 1 |
| Chen, SY; Dong, Y; Guo, WJ; Ma, LH; Wang, ZY | 1 |
| An, L; Cheng, B; Han, Z; Liu, S; Yang, X | 1 |
| Augustyniak, C; Evens, AM; Gordon, LI; Gupta, R; Mehta, J; Ziegler, SL | 1 |
| Li, DR; Lin, W; Lin, YC | 1 |
| Dai, CW; Pei, MF; Shen, JK; Xu, YX; Zhang, GS; Zheng, WL | 1 |
| Au, WY; Fong, BM; Ho, KL; Kwong, YL; Tam, PC; Tam, S | 1 |
| Huang, HB; Yu, QH; Zhan, R | 1 |
| Jonas, JB; Li, B; Li, W; Shi, G; Wang, C; Zhang, H | 1 |
| Guan, JM; Hu, LH; Jiang, HC; Liu, BR; Liu, D | 1 |
| Cai, YX; Fu, YB; Li, L; Meng, FY; Sun, QX | 2 |
| Adamson, PC; Balis, FM; Blaney, SM; Fox, E; Goodspeed, W; Murgo, AJ; O'Brien, M; Razzouk, BI; Reaman, GH; Widemann, BC; Xiao, S | 1 |
| Cui, H; Duncan, G; Liu, P; Reddan, JR; Wang, L; Wormstone, IM; Yang, BF; Zhang, H | 1 |
| Betti, L; Brizzi, M; Lazzarato, L; Nani, D | 1 |
| Dong, XS; Fu, SB; Geng, JS; Liu, M; Wang, GY; Wang, K; Wang, XS; Xu, HT; Zhang, QF; Zhao, JH | 1 |
| Bischof, JC; Griffin, RJ; Johnson, GL; Lee, BW; Olin, M; Williams, BW | 1 |
| Gu, J; Liang, H; Ma, L; Shen, WG; Wang, XL; Zhang, JD; Zhang, Y | 1 |
| Cao, WJ; Li, Q; Wang, Y | 1 |
| Kumar, R; Mukhopadhyay, AK; Paul, MK | 1 |
| Fu, YB; Li, CY; Li, L; Meng, FY; Song, LL; Sun, QX; Yi, ZS | 1 |
| Altman, JK; Glaser, H; Hay, N; Jordan, A; Katsoulidis, E; Kroczynska, B; Platanias, LC; Redig, AJ; Sassano, A; Tallman, MS; Yoon, P | 1 |
| Han, JG; Li, BX; Xue, YW; Yang, BF | 1 |
| Cunha De Santis, G; Cunha, FQ; Faccioli, LH; Falcão, RP; Garcia, AB; Lima, AS; Moreno, SE; Rego, EM; Secco, D; Sousa, RB; Tamarozzi, MB | 1 |
| Takatoku, M | 1 |
| Ma, LM; Qiao, ZH; Wang, HW; Wang, T; Yang, LH; Zhang, HP | 2 |
| Cui, XP; Li, P; Lu, MD; Shen, AG; Wang, Y | 1 |
| Barberá, R; Farré, R; Laparra, JM; Montoro, R; Vélez, D | 1 |
| Binet, F; Chiasson, S; Girard, D | 4 |
| Benson, DM; Denlinger, N; Farag, SS; Hofmeister, CC; Jansak, B; Kraut, EH | 1 |
| Antonioli, E; Cas, LD; D'Aloia, A; Raddino, R; Vizzardi, E; Zanini, G | 1 |
| Hu, Y; Shen, GX; Song, SJ; Wei, WN; Zhang, XH | 1 |
| Fei, XM; Ge, Z; Li, JY; Lin, RF; Liu, P; Lu, H; Shen, WY; Wang, YR; Wu, YJ; Zhang, JF | 1 |
| Li, HM; Li, LH | 1 |
| HANSE, F; MØLLER, KO | 1 |
| Cernelc, P; Falnoga, I; Goessler, W; Podgornik, H; Raml, R; Slejkovec, Z; van Elteren, JT | 1 |
| Chen, Q; Gao, P; Jin, H; Tian, C; Wang, X; Yue, W; Zheng, Y | 1 |
| Li, WQ; Li, XS; Wang, WB | 1 |
| Gao, B; Jia, YL; Liang, ZQ; Qin, ZH; Yang, YP | 1 |
| Dawes, IW; Dilda, PJ; Hogg, PJ; Lock, RB; Perrone, GG; Philp, A | 1 |
| He, XE; Lei, JH; Lian, J; Luo, HY; Wang, WL; Yang, X; Zhang, M | 1 |
| Choi, KS; Kim, EH; Kim, SU; Kwon, TK; Sohn, S; Yoon, MJ | 1 |
| Ballon, DJ; Chang, CC; Cheng, HY; Feng, Y; Huang, J; Liu, S; Mo, A; Rice, L; Wen, J; Zu, Y | 1 |
| Jardin, F; Massy, J; Massy, N; Stamatoullas, A; Thery, JC; Tilly, H | 1 |
| Abe, Y; Muta, K; Nakashima, Y; Ohtsuka, R; Sada, E; Tachikawa, Y; Takayanagi, R | 1 |
| Aoki, S; Asai, T; Chiba, S; Hangaishi, A; Kanda, Y; Kurokawa, M; Motokura, T; Nagai, S; Ohtomo, K; Oshima, K; Watanabe, T | 1 |
| Bareau, B; Corolleur, M; Fardel, O; Fest, T; Morzadec, C; van Grevenynghe, J; Vernhet, L | 1 |
| Cai, J; Chen, Y; Hu, Q; Niu, X; Shi, G; Wang, J; Wu, H; Yi, J | 1 |
| Liu, P; Liu, S; Wang, M | 1 |
| Alkalay-Snir, I; Alsheich-Bartok, O; Appella, E; Haupt, S; Haupt, Y; Saito, S | 1 |
| Aldape, K; Aoki, H; Bogler, O; Conrad, C; Hess, K; Hollingsworth, EF; Iwado, E; Kobayashi, R; Kondo, S; Kondo, Y; Mills, G; Sawaya, R; Shingu, T; Shinojima, N; Tamada, Y; Yamamoto, A; Yokoyama, T; Zhang, L | 1 |
| An, S; Choe, TB; Hong, SI; Jin, HO; Kim, ES; Kim, JI; Lee, HC; Lee, SJ; Park, IC; Rhee, CH; Seo, SK; Woo, SH; Yoo, DH | 1 |
| Li, D; Wei, F; Zhang, W; Zhang, X | 1 |
| Agarwala, SS; Gooding, WE; Islam, MF; Kirkwood, JM; Tarhini, AA; Tawbi, H | 1 |
| Estey, E; Kopp, L; Quezada, G; Wells, RJ | 1 |
| Chou, FP; Kuo, HC; Lin, TH; Lu, FJ | 1 |
| Asslaber, D; Greil, R; Hamacher, F; Heyder, C; Holler, C; Merkel, O; Papak, C; Prokesch, A; Scheideler, M; Stöcher, M; Tinhofer, I; Trajanoski, Z | 1 |
| Bowling, BD; Doudican, N; Manga, P; Orlow, SJ | 1 |
| Altman, JK; Carayol, N; Dolniak, B; Fukunaga, R; Katsoulidis, E; Platanias, LC; Redig, AJ; Tallman, MS; Ueda, T; Watanabe-Fukunaga, R | 1 |
| Chen, Z; Wang, ZY | 1 |
| Levy, M; McLean, TW; Powell, BL; Wofford, MM | 1 |
| Fu, WJ; Hou, J; Wang, DX; Yuan, ZG; Zhou, LL | 1 |
| Chai, LM; Chen, JX; Du, ZM; Li, GY; Liu, Y; Lu, YJ; Yang, BF; Zhang, Y; Zhao, XY | 1 |
| Li, B; Qu, GP; Shen, J; Xiu, QY | 1 |
| Bael, TE; Gollob, JA; Peterson, BL | 1 |
| Chen, H; Feng, T; Lu, Y; Shan, H; Yang, B; Zhang, Y; Zhao, X | 1 |
| Döbbeling, U; Dummer, R; Hassel, JC; Navarini, AA; Oberholzer, PA; Qin, JZ; Tun-Kyi, A | 1 |
| Boise, LH; Gutman, D; Lee, KP; Morales, AA | 1 |
| Bazarbachi, A; de Thé, H; Habib, A; Hamade, E; Mahfouz, R; Nasrallah, MS | 1 |
| Huang, R; Qin, DY; Wu, T | 1 |
| Aller, P; Ramos, AM | 1 |
| Isobe, Y; Oshimi, K; Sasaki, M; Sugimoto, K | 1 |
| Li, A; Ye, J; Zhao, X; Zhou, J | 1 |
| Kang, YH; Lee, SJ | 2 |
| Ann, DK; Cao, X; Chen, Y; Clavijo, C; Li, X; Lin, HH; Shih, HM | 1 |
| Bourdonnay, E; Fardel, O; Lemarie, A; Morzadec, C; Vernhet, L | 1 |
| Chen, X; Chen, Y; Zhang, L; Zhao, H; Zhu, X; Zou, Y | 1 |
| Craig, CM; Schiller, GJ | 1 |
| Chen, H; Ge, Y; Gu, J; Jiang, J; Liu, D; Wei, Y; Xu, J; Yun, X; Zhou, F | 1 |
| Che, CT; Cheng, CH; Lin, ZX; Tse, WP | 1 |
| Goyer, RA; Liu, J; Lu, Y; Waalkes, MP; Wu, Q | 1 |
| Burry, L; Cashin, R; Peckham, K; Reynolds, S; Seki, JT | 1 |
| Bae, JH; Chung, BS; Kang, CD; Kim, JY; Kim, SH; Lee, EY; Lee, SH | 1 |
| Dong, X; Liu, Y; Sun, X; Zhang, J; Zhang, X; Zhao, S; Zou, H | 1 |
| Avigan, DE; Bernardi, R; Ikeda, Y; Ito, K; Matsuoka, S; Morotti, A; Pandolfi, PP; Rosenblatt, J; Saglio, G; Teruya-Feldstein, J | 1 |
| Hu, J; Shu, C; Xu, W; Ye, Y | 1 |
| Aras, MH; Kaya, GS; Yalçin, E; Yavuz, MS | 1 |
| Hazaka, Y; Kondo, T; Minami, Y; Onishi, N; Tanaka, Y; Toyoshima, K; Tsukada, J; Tsukuda, Y; Watanabe, Y; Yoda, A | 1 |
| Fu, W; Hou, J; Jiang, H; Wang, D; Yuan, Z; Zhou, L | 1 |
| Büsselberg, D; Florea, AM | 1 |
| Acevedo-Alvarez, M; Akar, U; Lopez-Berestein, G; Ozpolat, B; Vivas-Mejia, P; Zorrilla-Calancha, I | 1 |
| Au, WY; Fong, BM; Kwong, YL; Tam, S; Wan, TS; Yip, SF | 1 |
| Cui, YZ; Luo, RC; Wu, J; Zhang, H | 1 |
| Dong, J; Jing, Y; Wang, R; Xu, L; Yu, Z | 1 |
| Aller, P; Amrán, D; de Blas, E; Fernández, C; Sánchez, Y | 1 |
| Banerjee, P; Belon, P; Bhattacharyya, SS; Khuda-Bukhsh, AR; Naoual, B; Pathak, S | 1 |
| Akiyama, H; Hiruma, K; Jinta, M; Ohashi, K; Okuyama, Y; Sakamaki, H; Ueki, T | 1 |
| Colombo, M; Mann, KK; Miller, WH | 1 |
| Alimoghaddam, K; Ghaffari, SH; Ghavamzadeh, A; Jamialahmadi, AH; Shayan-Asl, N | 1 |
| Schiffer, CA; Srinivasan, S | 1 |
| Litzow, MR | 1 |
| Baker, RT; Blackburn, AC; Board, PG; Brew, J; Cappello, J; Cavanaugh, JA; Coggan, M; Eyre, HJ; Schmuck, E; Sutherland, GR | 1 |
| Cheong, HJ; Kim, SJ; Lee, HR; Lee, NS; Park, HS; Won, JH | 1 |
| Cen, J; Chen, Z; Gu, M; Liu, D; Qi, X | 1 |
| Bonati, A; Cantoni, AM; Corradi, A; Costanzo, A; Giuliani, N; Levrero, M; Lombardi, G; Lunghi, P; Mazzera, L; Ricca, M; Riccioni, R; Rizzoli, V; Salvatore, L; Testa, U | 1 |
| Nelson, R; Self, WT; Talbot, S | 1 |
| Li, Y; Shen, HW; Tang, LS | 1 |
| Dong, D; Fu, S; Wang, G; Wang, X; Yang, B | 1 |
| Agarwal, S; Bhattacharya, S; Mazumder, S; Ray, A; Roy, S | 1 |
| Peng, J; Yang, M; Yang, Z | 1 |
| Chiou, TJ; Chu, ST; Huang, YC; Liao, CJ; Tzeng, WF | 1 |
| Colombo, M; Diaz, Z; Komarnitsky, PB; Kourelis, M; Mann, KK; Marcoux, S; Miller, WH | 1 |
| Jang, HY; Jeong, ET; Jo, HJ; Kim, EJ; Kim, HJ; Kim, HR; Lee, KK; Park, JH; Shim, H; Yang, SH | 1 |
| Jin, H; Li, L; Shi, G; Tang, X; Wang, J; Ye, RD; Yi, J | 1 |
| Gao, Q; Krebsbach, PH; Kumar, P; Ning, Y; Polverini, PJ; Wang, Z | 1 |
| Shi, JJ | 1 |
| Borghi, M; Castellani, P; Ceccarelli, J; Delfino, L; Ferrini, S; Rubartelli, A; Tosetti, F; Zappia, E | 1 |
| Chen, T; Fu, YL | 1 |
| Wu, YC; Yen, WY; Yih, LH | 1 |
| Ahuja, HG; Bailey, HH; Chang, JE; Kahl, BS; Kim, K; Kolesar, JM; Rodriguez, GA; Sanchez, FA; Voorhees, PM; Werndli, J | 1 |
| Berenson, JR; Yellin, O | 1 |
| Jansen, KP; Palazzolo, DL | 1 |
| Frisk, P; Ilbäck, NG; Molin, Y | 2 |
| Ammatuna, E; Lo-Coco, F; Montesinos, P; Sanz, MA | 1 |
| Dohmen, RJ; Göttsche, K; Horst, C; Keusekotten, K; Krause, A; Praefcke, GJ; Springer, HM; Weisshaar, SR | 1 |
| He, Y; Hu, XX; Lü, SQ; Wang, JM; Yang, JM; Zhou, H | 1 |
| Binet, F; Girard, D | 1 |
| Roboz, GJ | 1 |
| Caravati, EM; Crouch, BI; Horowitz, BZ; Mckeown, NJ; Stromness, JR; Yarris, JP | 1 |
| Chen, KS; Chou, MC; Chu, SC; Hsiao, YC; Hsieh, YS; Kuo, DY; Lin, TH | 1 |
| Cheng, LC; Cheng, YH; Lu, JH; Ou, BR; Yeh, JY | 1 |
| Grzanka, A; Izdebska, M; Litwiniec, A; Szczepański, MA | 1 |
| Creus, A; Marcos, R; Soriano, C | 1 |
| Allen-Bard, S; Carlin, R; Christos, PJ; Curcio, T; Feldman, EJ; Mathew, S; Mazumdar, M; Provenzano, J; Ritchie, EK; Roboz, GJ; Samuel, M; Wittenberg, B | 1 |
| Das, AS; Karmakar, S; Maiti, A; Majumdar, S; Mitra, C; Mukherjee, M; Mukherjee, S; Nanda, A | 1 |
| LAMBIE, DA | 1 |
| Rigas, B; Sun, Y | 1 |
| Chen, JH; Ouyang, J; Xie, PH; Xu, XH | 1 |
| Wang, FX; Wang, YR; Wen, L; Wen, SP; Yang, BY; Yang, JC; Yang, SF; Zhang, XJ | 1 |
| Dou, HJ; Hu, JP; Ren, ZH; Wang, MM; Zhu, Q; Zou, LF | 2 |
| Cheng, C; Cui, X; Fei, M; Gao, S; He, S; Ke, Q; Li, P; Liu, Y; Lu, M; Shen, A; Wang, Y; Zhao, Y | 1 |
| Matta, ME; Mielli, AC; Nersesyan, A; Saldiva, PH; Umbuzeiro, GA | 1 |
| Carney, DA | 1 |
| Coe, E; Schimmer, AD | 1 |
| Hisaeda, Y; Nakamura, K; Pan, L; Yamauchi, H | 1 |
| Dahdaleh, FS; Musallam, KM; Shamseddine, AI; Taher, AT | 1 |
| Dalley, CD; Ezaydi, Y; Goepel, JR; Kirkbride, P; Krishna, R; Smith, DJ; Snowden, JA; Sorour, Y | 1 |
| Horikoshi, A; Iriyama, N; Kaise, T; Miyashita, SI; Shikino, O; Toyoda, H; Yoshino, Y; Yuan, B | 1 |
| Abreu e Lima, RS; Falcão, RP; Freitas, RA; Garcia, AB; Gimenes Teixeira, HL; Jordão, AA; Lima, AS; Lucena-Araujo, AR; Rego, EM; Scheucher, PS; Silva dos Santos, GA; Vannucchi, H | 1 |
| Brossart, P; Czarnocka, B; Fröhlich, E; Wahl, R | 1 |
| Cheng, YF; Liu, CF; Liu, GL; Lu, AD; Wang, B; Zhang, LP | 1 |
| Arai, S; Hangaishi, A; Koike, Y; Kurokawa, M; Masamoto, Y; Nannya, Y; Yatomi, Y | 1 |
| Bobé, P; Chelbi-Alix, MK | 1 |
| Maiso, P; Mateos, MV; Ocio, EM; Pandiella, A; San-Miguel, JF | 1 |
| Alousi, A; Anderlini, P; Champlin, RE; Giralt, S; Hosing, C; Jones, RB; Khan, FB; Mendoza, F; Nieto, Y; Parikh, G; Pelosini, M; Popat, U; Qazilbash, MH; Saliba, RM; Wang, M; Weber, DM | 1 |
| Kim, CJ; Kim, DH; Kim, JH; Kim, KW; Yu, YS | 1 |
| Aklilu, M; Kindler, HL; Nattam, S; Vokes, EE | 1 |
| Huang, ZS; Qi, TW; Wu, XJ; Xia, ZB | 1 |
| Altman, JK; Tallman, MS | 2 |
| Haferlach, T | 1 |
| Chuah, C; Melo, JV | 1 |
| Blamble, D; Cortes, J; Estey, E; Estrov, Z; Faderl, S; Ferrajoli, A; Fiorentino, J; Garcia-Manero, G; Jones, D; Kantarjian, H; O'Brien, S; Pierce, S; Ravandi, F; Verstovsek, S; Wierda, W | 1 |
| Fang, H; Wang, K; Zhang, J | 1 |
| Chang, H; Chen, G; Feng, Y; Huang, H; Lin, F; Sun, A; Wang, Y; Wu, D | 1 |
| Dai, SL; He, HY; Huang, M; Sun, PL; Yang, Y; Yao, X; Yin, KS | 1 |
| Bae-Jump, VL; Boggess, JF; Gehrig, PA; Zhou, C | 1 |
| Dou, AX; Jia, PM; Lou, YJ; Pan, XR; Tong, JH; Zhang, CL | 1 |
| Fan, LP; Lin, CM; Lin, FA; Shen, JZ; Ye, BG | 1 |
| Li, HM; Long, Y; Qing, C; Yu, MJ; Zhang, YL | 1 |
| Chang, EE; Miao, ZF; Tsai, FY; Tsou, TC; Wang, CJ; Wu, CF; Wu, KY; Yeh, SC | 1 |
| Bae, S; Lee, YS; Seo, HR | 1 |
| Brossart, P; Fröhlich, E; Wahl, R | 1 |
| Ariumi, Y; Dansako, H; Ikeda, M; Kato, N; Kuroki, M; Wakita, T | 1 |
| Kogan, SC | 2 |
| Büsselberg, D; Florea, AM; Günes, DA; Splettstoesser, F | 1 |
| Bourdonnay, E; Fardel, O; Galibert, MD; Jouneau, S; Martin-Chouly, C; Morzadec, C; Sparfel, L; Vernhet, L | 1 |
| Burnstein, KL; Rosenblatt, AE | 1 |
| Cuypers, F; De Dobbelaere, C; Hardy, A; Helsen, L; Van Bael, MK | 1 |
| Johansson, L; Karlsson, J; Munksgaard Persson, M; Påhlman, S; Pettersson, HM; Pietras, A; Shoshan, MC | 1 |
| Agarwal, S; Bhattacharya, S; Ray, A; Roy, S | 1 |
| Dölken, G; Greinacher, A; Jedlitschky, G; Kiefer, T; Köck, K; Kroemer, HK; Niessen, J; Oevermann, L; Ritter, CA; Scheitz, J; Siegmund, W; Starke, K; Zygmunt, M | 1 |
| Ahn, KJ; Bae, IJ; Choi, IH; Choi, IW; Eun, CK; Jung, JJ; Kang, MS; Lee, SW; Lew, YS; Park, CW; Park, SG; Seo, SK; Won, HJ | 1 |
| Chen, WC; Chiu, HW; Guo, HR; Ho, SY; Lai, CS; Wang, YJ | 1 |
| Liu, P; Song, Z; Yu, XH; Zhang, H | 1 |
| Kabayama, M; Kakehi, K; Kawasaki, N; Ogata, F | 1 |
| Cherian, OL; Raghu, KG | 1 |
| Bairey, O; Shpilberg, O; Vanichkin, A | 1 |
| Chen, B; Chen, QS; Chen, SJ; Chen, Z; Hu, J; Li, JM; Liu, YF; Shen, ZX; Sun, HP; Tang, W; Wang, ZY; Waxman, S; Wu, CF; Wu, W; Xu, F; Zelent, A; Zhao, WL; Zhou, GB; Zhu, YM | 1 |
| Li, X; Li, Y; Liang, Y; Wang, BX; Wang, PP; Wang, Y | 1 |
| Chiu, HW; Guo, HR; Ho, SY; Wang, YJ | 1 |
| Cao, YX; Dai, CW; Li, RJ; Pei, MF; Peng, HL; Shen, JK; Xu, YX; Yang, JJ; Yi, Y; Zhang, GS; Zheng, WL; Zhong, HY | 1 |
| Chen, W; Li, JR; Lu, X; Shu, XL | 1 |
| Antoine, F; Binet, F; Girard, D | 1 |
| Boise, LH; Cejas, PJ; Gutman, D; Lee, KP; Morales, AA | 1 |
| Abel, SJ; Kim, LH | 1 |
| Corti, A; Favini, E; Giommarelli, C; Paolicchi, A; Pompella, A; Supino, R; Zunino, F | 1 |
| Kneifel, C; Lösler, S; Rojewski, MT; Schlief, S; Schrezenmeier, H; Thiel, E | 1 |
| An, R; Dong, X; Duan, G; Pan, S; Sun, X; Wang, Y | 1 |
| Sorahan, T | 1 |
| Cao, EH; Liang, XQ; Liu, XM; Song, Y; Tang, RJ; Xiong, XF | 1 |
| Ma, R; Xu, S | 1 |
| Adachi, M; Wang, W; Zhang, R; Zhou, J; Zhu, D | 1 |
| Bourdonnay, E; Fardel, O; Morzadec, C; Vernhet, L | 2 |
| Platanias, LC | 1 |
| Ge, F; He, QY; Jin, L; Lu, XP; Xiong, S; Zeng, HL | 1 |
| Ali, MS; Chowdhury, AK; Marni, F; Nahar, L; Rabbani, GH; Raihan, SZ; Sarker, SD | 1 |
| Lee, TC; Wu, YC; Yen, WY; Yih, LH | 1 |
| Li, Y; Lu, XL; Wang, BX; Wang, L; Wang, PP | 1 |
| Aubry, M; Chelbi-Alix, MK; Dianoux, L; Estephan, P; Galisson, F; Germain-Desprez, D; Mascle, XH; Percherancier, Y | 1 |
| Tang, DZ; Tao, S; Zhou, K | 1 |
| Dong, S; Liu, C; Sun, T; Xu, X | 1 |
| Dai, W; Duan, Q; Komissarova, E | 1 |
| Chen, X; Lopez-Berestein, G; Ozpolat, B; Vivas-Mejía, PE | 1 |
| Alkis, N; Armagan, E; Dolar, E; Esen, M; Olmez, O; Yilmaz, Y | 1 |
| Bazarbachi, A; de Thé, H; El Hajj, H; Farid, R; Hatoum, H; Hermine, O; Kchour, G; Kooshyar, MM; Mahmoudi, M; Maleki, M; Rafatpanah, H; Rahimi, H; Rezaee, SA; Shirdel, A; Tarhini, M; Wattel, E; Yazdi, MT | 1 |
| Boise, LH; Cai, Y; Croutch, C; Gutman, D; Lee, KP; Matulis, SM; Morales, AA; Yehiayan, L | 1 |
| Hong, Y; Li, S; Liu, P; Piao, F; Wang, Y; Zhao, Y | 1 |
| Chung, WH; Kim, SS; Kuh, HJ; Rhim, H; Sung, BH | 1 |
| Lin, TH; Lu, FJ; Tseng, TH; Yin, YF | 1 |
| Bai, X; Cai, BZ; Li, JX; Li, XQ; Lu, YJ; Shen, YQ; Zhao, J | 1 |
| Hou, K; Hu, X; Li, Y; Liu, J; Liu, Y; Qu, J; Qu, X; Teng, Y; Zhang, Y | 1 |
| Di, C; Gu, S; Tan, X; Wu, Q; Xian, L; Yang, L | 1 |
| Illmer, T; Röllig, C | 1 |
| Petrie, K; Waxman, S; Zelent, A | 1 |
| Duzkale, H; Freireich, EJ; Golemovic, M; Johansen, M; Kantarjian, H; Manshouri, T; Orsolic, N; Quintás-Cardama, A; Verstovsek, S; Zingaro, RA | 1 |
| Ammatuna, E; Ardiri, D; Centonze, D; Divona, M; Lo-Coco, F; Montefusco, E; Pacilli, M | 1 |
| Lu, DP; Zhang, M; Zhao, XH; Zhu, HJ | 1 |
| Fu, SB; Huang, YL; Li, WM; Luan, TZ; Zhou, LJ | 1 |
| Angell, R; Aslett, H; Batson, E; Burnett, AK; Clark, RE; Diverio, D; Flora, R; Grimwade, D; Hills, RK; Jones, K; Jovanovic, JV; Lo-Coco, F; Nugent, EA; Patel, Y; Rennie, K; Solomon, E; Wheatley, K | 1 |
| Chen, X; Liu, LX; Zhang, M | 1 |
| Duggan, J; Siderov, J | 1 |
| Bowling, B; Doudican, NA; Orlow, SJ | 1 |
| Amadori, S; Ammatuna, E; Cavaliere, A; Divona, M; Lo-Coco, F; Scambia, G | 1 |
| Trivedi, SP; Yadav, KK | 2 |
| Chen, H; Wang, Y; Xue, L; Yan, S; Zhang, QY; Zheng, SS; Zhou, B | 1 |
| Chen, Y; He, PC; Lu, R; Lü, XH; Ni, ZF; Wang, HY; Zhang, M | 1 |
| Li, B; Li, HM; Li, XJ; Li, ZH | 1 |
| Bu, Q; Cai, QQ; Gao, Y; Huang, HQ; Li, S; Liao, H; Zhou, Y | 1 |
| Song, J; Wang, ZY; Zhang, DS | 1 |
| Chen, LJ; Li, XF; Lu, RZ; Ma, J; Qiu, L; Wang, XD; Wang, XL; Zhang, BL | 1 |
| Ahn, R; Chen, H; O'Halloran, TV; Thompson, DH; Van den Bossche, J | 1 |
| Abe, Y; Itoh, N; Kamada, H; Minowa, K; Nabeshi, H; Nagano, K; Nomura, T; Shibata, H; Sugita, T; Tsunoda, S; Tsutsumi, Y; Yamashita, T; Yoshikawa, T; Yoshioka, Y | 1 |
| An, L; Cheng, B; Gao, B; Liu, X; Yang, X | 1 |
| Huang, R; Huang, X; Li, W; Li, X; Yang, X | 1 |
| Ballon, DJ; Chang, CC; Chen, H; Feng, Y; Huang, W; Kamble, RT; Liao, B; Preti, HA; Rice, L; Wen, J; Zu, Y | 1 |
| Du, XY; Li, Y; Liu, XJ; Luo, JM; Wen, SP; Yang, L | 1 |
| Ahn, RW; Lee, MH; O'Halloran, TV; Odom, TW; Raja, MR; You, EA | 1 |
| Dai, L; Liu, YH; Ruan, CG; Shen, WH; Wang, ZY; Zhang, W | 1 |
| Chen, H; Li, H; Xiang, J; Zhang, Y; Zhu, X | 1 |
| Liu, H; Qiu, J; Wu, YP | 1 |
| Li, Z; Liu, S; Piao, F; Qu, S; Wang, Y | 1 |
| Bartlett, DL; Gorry, MC; Guo, ZS; Li, Q; O'Malley, ME | 1 |
| Chen, PC; Chen, YW; Chiu, YC; Huang, CF; Tang, CH | 1 |
| Guo, W; Ji, T; Lu, X; Peng, C; Zhao, H | 1 |
| Kurokawa, M; Nagai, S; Takahashi, T | 2 |
| Au, WY; Fong, BM; Hon, C; Kwong, YL; Lai, WW; Tam, S; Yau, K | 1 |
| Aller, P; Calle, C; de Blas, E; Sánchez, Y | 1 |
| Liang, T; Sun, B; Sun, D; Xue, D; Zhang, W; Zhao, S | 1 |
| Akahane, D; Gotoh, M; Kaise, T; Kiguchi, T; Kitahara, T; Ohyashiki, K; Toyoda, H; Yoshino, Y; Yoshizawa, S; Yuan, B | 1 |
| Chen, JP; Liu, JP; Xia, Y; Xu, SN | 2 |
| Hangaishi, A; Ichikawa, M; Kaise, T; Kumano, K; Kurokawa, M; Miyashita, SI; Nagai, S; Nannya, Y; Ueda, K | 1 |
| Abdolazimi, Y; Alimoghaddam, K; Dehpour, AR; Ghaffari, SH; Ghasemi, R; Ghavamzadeh, A; Momeny, M; Rahimi-Balaei, M; Zakidizaji, M | 1 |
| Di, W; Ding, CW; Hong, ZB; McGowan, E; Shi, J; Wu, ZM; Xia, P; Zhang, N | 1 |
| Chang, YC; Chen, YH; Lu, GL; Tsai, CL; Tsai, MC | 1 |
| Gotlib, J; Greenberg, PL | 1 |
| Cortes, J; Giles, F | 1 |
| Bao, L; Guo, T; Hong, M; Hu, Y; Jiang, Q; Lu, XJ; Shen, GX; Song, SJ; Xia, LH; Yang, LH; Zhang, XH; Zhao, T; Zhu, HH | 1 |
| Chen, GQ; Duan, XF; Wang, XD; Wu, YL; Xu, HZ; Yan, H; Zhao, M; Zhuang, HY | 1 |
| Bacquart, T; Devès, G; Ortega, R | 1 |
| Burchiel, SW; Hudson, LG; Lauer, FT; Liu, KJ; McDonald, JD; Mitchell, LA; Sun, X | 1 |
| Du, Y; Lai, R; Liu, H; Zhang, D | 1 |
| Ajana, I; Astier, A; Gibaud, S | 1 |
| Bajorin, DF; Halabi, S; Small, E | 1 |
| Bornhäuser, M; Platzbecker, U; Röllig, C; Stölzel, F; Thiede, C; Wermke, M | 1 |
| Oshimi, K; Sasaki, M; Sugimoto, K; Yamamoto, Y | 1 |
| Balasubramanian, P; Chandy, M; Chendamarai, E; George, B; Lakshmi, KM; Mathews, V; Srivastava, A; Thirugnanam, R; Viswabandya, A | 1 |
| Jiang, HC; Liu, TF; Song, PL; Sun, B; Zhao, XS | 1 |
| Li, B; Liu, YA; Qu, GP; Xiu, QY; Zhang, LZ | 1 |
| de Witte, TJ; Jansen, JH; Linssen, PC; Luesink, M; Muus, P; Pennings, JL; Pfundt, R; van der Reijden, BA; Wissink, WM | 1 |
| Feusner, J; Gregory, J | 1 |
| Han, YH; Kim, SH; Kim, SZ; Moon, HJ; Park, WH; You, BR | 2 |
| Leu, L; Mohassel, L | 1 |
| Berthoux, L; Bérubé, J; Nepveu-Traversy, ME | 1 |
| Bhadauria, S; Prathapan, A; Raghu, KG; Sharma, S; Singh, R; Yadav, GK | 1 |
| D'Andrea, DM; Darwish, M; Porter, JM; Remick, SC; Sweeney, CJ; Takimoto, C; Tracewell, WG; Wood, L | 1 |
| Antoine, F; Ennaciri, J; Girard, D | 1 |
| Chen, B; Guo, D; Jiang, H; Song, W; Wang, X; Wu, C | 1 |
| Baumgartner, S; Betti, L; Binder, M; Frei-Erb, M; Heusser, P; Lahnstein, L; Peruzzi, M; Thurneysen, A | 1 |
| Dong, ZR; Du, XY; Li, Y; Liu, XJ; Luo, JM; Wen, SP; Yang, JC; Yang, L; Yao, L | 1 |
| Li, L; Zhang, ZH; Zhao, WD | 1 |
| Du, ZH; Li, L; Li, W; Ma, KW; Yang, GZ | 1 |
| Liang, Y; Xu, RZ; Zhang, L; Zhao, XY | 1 |
| Li, XH; Wang, WB; Yang, GF; Zhao, Z | 2 |
| Kawamoto, K; Li, Q; Li, Y; Zhao, S; Zhen, Y | 1 |
| Sun, YK; Wang, SJ; Zhao, YQ | 1 |
| Duan, MH; Han, B; Jiao, L; Shen, T; Wang, SJ; Xu, Y; Zhang, W; Zhao, YQ; Zhou, DB; Zhu, TN; Zhuang, JL; Zou, N | 1 |
| Chan, GC; Sze, DM | 1 |
| Shao, C; Wu, X; Yang, J; Zhang, S; Zhong, F | 1 |
| Chhabra, S; Kaufman, KR; Levitt, M; Sood, R | 1 |
| Bi, X; Gu, J; Guo, Z; Mi, Q; Tang, L; Tao, S; Wang, Y; Wu, J | 1 |
| Chen, XJ; Chen, YM; Wang, JX; Wang, SC; Yang, WY; Zhang, L; Zhu, XF; Zou, Y | 1 |
| Fan, S; Han, X; Hou, J; Hu, L; Li, J; Li, L; Li, X; Liu, X; Lv, C; Wang, S; Zhang, Y; Zhao, Y; Zhou, J; Zhu, L | 1 |
| Hatta, Y; Hirabayashi, Y; Ishizuka, H; Kobayashi, Y; Takei, K; Takeuchi, J; Tanaka, T | 1 |
| Earp, JC; Ghoshal, S; Jusko, WJ; Rao, I; Wetzler, M | 1 |
| Fukushima, N; Hisatomi, T; Ide, M; Itamura, H; Kimura, S; Sueoka, E; Tanaka, M; Tomimasu, R; Urata, C; Yokoo, M | 1 |
| Jiang, J; Liu, XS; Peng, CY; Zheng, HT | 1 |
| Asghari, F; Mozdarani, H | 1 |
| Hao, G; Xia, Y; Yang, Y | 1 |
| Bachleitner-Hofmann, T; Roth, E; Sturlan, S; Wessner, B; Wirtitsch, M | 1 |
| Hong, DY; Huang, HS; Liu, ZM | 1 |
| Hu, JL; Liang, HH; Qiu, ZD; Zhang, YF | 1 |
| Ai, J; Cai, BZ; Chen, N; Li, ZY; Liu, CJ; Liu, JQ; Lu, YJ; Meng, FY; Yang, BF; Ye, ML; Zhao, J; Zhu, SL | 1 |
| Arceci, R; Dauses, T; Devetten, M; Gallagher, RE; Gojo, I; Gore, SD; Jamieson, K; Morris, L; Owoeye, I; Redner, RL; Schachter-Tokarz, E; Sekeres, MA | 1 |
| Cao, F; Gilbert, GE; Heegaard, CW; Hou, J; Rasmussen, JT; Shi, J; Zhang, Y; Zhou, J | 1 |
| Chai, L; Cheng, M; Ren, Y; Wang, S; Xie, Y | 1 |
| Anand, S; Bajaj, P; Saxena, N; Saxena, PN | 1 |
| Chang, YF; Chou, DS; Fan, CY; Hsiao, G; Jayakumar, T; Lee, JJ; Lin, KH; Sheu, JR | 1 |
| Berthou, C; Charles, F; Eveillard, JR; Ianotto, JC; Tempescul, A | 1 |
| Jiang, F; Liu, ZG | 1 |
| Dong, D; Fei, J; Gu, J; Hu, H; Huang, K; Li, Y; Lin, C; Yao, J; Zhu, X | 1 |
| Dong, D; Fei, J; Gu, J; Huang, K; Li, Y; Lin, C; Yao, J; Zhu, X | 1 |
| Efferth, T; Hoheisel, JD; Youns, M | 1 |
| Altman, JK; Dolniak, B; Glaser, H; Goussetis, DJ; Kroczynska, B; McNeer, JL; Platanias, LC; Sassano, A | 1 |
| Ferrara, F | 1 |
| Grzanka, A; Grzanka, D; Izdebska, M; Ostrowski, M; Zuryń, A | 1 |
| Alimoghaddam, K; Ghaffari, SH; Ghahremani, MH; Ghavamzadeh, A; Hosseini, R; Mandegary, A; Rostami, S | 1 |
| Rao, MV; Tiwari, H | 1 |
| Biswas, S; Byrd, JC; Jarjoura, D; Mo, X; Mone, AP; Muthusamy, N; Vargo, M; Zhao, X | 1 |
| Essers, M; Trumpp, A; Wilson, A | 1 |
| Brûlé, AO; Coser, PL; Coser, VM; Lafayette, TC; Pereira, WV | 1 |
| Cao, L; Dunlevy, JR; Garrett, SH; Sens, DA; Sens, MA; Somji, S; Zheng, Y; Zhou, XD | 1 |
| Aram, L; Arbel, N; Geula, S; Shoshan-Barmatz, V | 1 |
| Kumagai, Y; Shinkai, Y; Sumi, D | 1 |
| Chen, YA; Chiu, HW; Ho, SY; Lin, JH; Wang, YJ | 1 |
| Chen, X; Jiang, H; Krissansen, GW; Ma, Y; Pan, S; Sun, B; Sun, X | 1 |
| Baek, JH; Cha, SJ; Kim, H; Min, YJ; Noh, EK; Park, JH; Park, MJ; Won, JH | 1 |
| STAUFFER, VD | 1 |
| Kashimura, M; Ohyashiki, K | 1 |
| Chen, YW; Huang, CF; Liu, SH; Tsai, KS; Yang, RS; Yen, YP | 2 |
| Castino, R; Falnoga, I; Isidoro, C; Lah, TT; Mirković, B; Pucer, A; Slejkovec, Z | 1 |
| Grimwade, D; Guidez, F; Mistry, AR; Solomon, E | 1 |
| Mann, KK; Molina, MF; Padovani, AM | 1 |
| Arora, N; Das, R; Malhotra, P; Nath, A; Patel, FD; Varma, N; Varma, S | 1 |
| Rana, SV; Singh, S | 1 |
| Geng, Y; Hou, J; Wu, DD; Xiao, YF | 1 |
| Meng, WT; Yang, YM; Zhang, G; Zhou, J | 1 |
| Cao, Z; Cui, L; Hu, Z; Li, T; Zhang, S; Zhang, W | 1 |
| Chen, SJ; Chen, Z; de Thé, H; Hu, HY; Huang, QH; Jeanne, M; Lallemand-Breitenbach, V; Liang, WX; Song, AX; Sun, HB; Tong, JH; Wu, JH; Wu, ZY; Yan, XJ; Yang, FF; Yang, HY; Zhang, QY; Zhang, XW; Zhang, Y; Zhou, GB; Zhou, ZR | 1 |
| Crocker, IR; Curran, WJ; McDonald, MW; Shu, HK | 1 |
| Bai, Y; Li, Q; Ye, A; Zhang, Q; Zheng, Y; Zhou, M | 1 |
| Lee, TC; Lee, YJ; Liu, SY; Wen, CY | 1 |
| Chen, Y; Gao, J; Gu, L; Jia, C; Li, Q; Ma, Z; Wu, X; Zhou, C; Zhu, Y | 1 |
| Bhalla, S; David, K; Evens, AM; Gordon, LI; Guo, D; O'Halloran, T; Platanias, LC; Prachand, S; Singh, AT; Winter, JN; Yang, S | 1 |
| Fan, LP; Fu, HY; Shen, JZ; Shen, SF; Zhou, HR | 1 |
| Gessain, A; Mahieux, R | 1 |
| Gotlib, J; Oh, ST | 1 |
| Barhoumi, R; Burghardt, R; Chadalapaka, G; Jutooru, I; Lei, P; Safe, S; Sreevalsan, S | 1 |
| Kakadiya, R; Lee, PC; Lee, TC; Su, TL | 1 |
| de Thé, H; Nasr, R | 1 |
| Gao, P; Han, Y; He, T; Lin, F; Long, M; Ren, JH; Wang, X; Wei, JX; Yan, L; Zhang, HZ | 1 |
| Bian, S; Hao, L; Li, J; Wang, H; Wang, X; Wu, Q | 1 |
| Gu, JY; Li, YM; Zhu, XJ | 1 |
| Gui-Nan, L; Guo-Bao, W; Jie, L; Qi-Rong, G; Xiao-Qin, C; Yue, L | 1 |
| Canestraro, M; Cine, N; Galimberti, S; Guerrini, F; Metelli, MR; Nagy, B; Palumbo, GA; Petrini, M; Piaggi, S; Savli, H; Tibullo, D | 1 |
| Murphy, RK; O'Halloran, TV; Schatz, GC; Winter, ND | 1 |
| Hirao, A; Hoshii, T; Naka, K | 1 |
| Cai, BC; Chiang, BL; Chu, KH; Hsin, SC; Lee, CC; Wang, JH | 1 |
| Ardalan, B; Duncan, R; Fernandez, A; Ganjei-Azar, P; Gonzalez, M; Lee, K; Lima, M; Mezentsev, D; Podolsky, L; Ramos, Y; Reis, I; Subbarayan, PR | 1 |
| Haller, E; Mills, GB; Nanjundan, M; Patel, S; Raffoul, F; Smith, DM | 1 |
| Liu, D | 1 |
| Ahn, RW; Chen, F; Chen, H; Clogston, JD; Cryns, VL; O'Halloran, TV; Parimi, V; Patri, AK; Raja, MR; Stern, ST; Swindell, EP | 1 |
| Blinder, R; Chang, P; Galinsky, I; Ho, VT; Housman, E; Kesari, S; Lane, SW; Mullally, A; Stone, RM | 1 |
| Ardalan, B; Lee, K; Subbarayan, PR | 1 |
| Escobar-Díaz, E; García-Marco, JA; García-Pardo, A; Hernández Del Cerro, M; Pandiella, A; Redondo-Muñoz, J; Terol, MJ | 1 |
| Da Sacco, L; Masotti, A | 1 |
| Bjørås, M; Bøe, SO; Isakson, P; Simonsen, A | 1 |
| Changliang, P; Tingting, R; Wei, G; Xinchang, L; Yi, Y | 1 |
| Fan, LP; Fu, HY; Shen, JZ; Shen, SF; Wu, Y; Zhou, HR | 1 |
| Feng, G; Li, Z; Meng, R; Sui, M; Yang, B; Zhou, J | 1 |
| Essers, MA; Trumpp, A | 1 |
| García Salido, A; Lassaletta Atienza, A; Madero López, L; Moreno Tejero, ML; Sevilla Navarro, J | 1 |
| Aller, P; Calviño, E; de Blas, E; Sánchez, Y; Simón, GP | 1 |
| Berthier, C; de Thé, H; Duffort, S; Ferhi, O; Jeanne, M; Koken, M; Lallemand-Breitenbach, V; Le Bras, M; Peres, L; Raught, B; Soilihi, H | 1 |
| Bloom, SE; Bunaciu, RP; Nayak, S; Shen, M; Varner, JD; Yen, A | 1 |
| Berthoux, L; Létourneau-Hogan, A; Malbec, M; Nepveu-Traversy, ME; Pham, QT; Plourde, MB | 1 |
| Goussetis, DJ; Platanias, LC | 1 |
| Graham, B; Rogers, C; Stevens, JJ; Tchounwou, PB; Walker, AM | 1 |
| Beachy, PA; Gardner, D; Kim, J; Lee, JJ | 1 |
| Ndebele, K; Stevens, JJ; Tchounwou, PB; Walker, AM | 1 |
| Hu, NR; Liu, W; Mu, HB; Xu, XG; Zhang, B | 1 |
| Blomberg, J; Friman, G; Frisk, P; Hjelm, E; Ilbäck, NG; Molin, Y | 1 |
| Abraham, A; Balasubramanian, P; Chandy, M; Chendamarai, E; Desire, S; George, B; Lakshmi, KM; Mathews, V; Shaji, RV; Srivastava, A; Thirugnanam, R; Viswabandya, A | 1 |
| Fu, ZC; Fu, ZJ; Zhang, B | 1 |
| Altman, JK; Glaser, H; Goussetis, DJ; McNeer, JL; Platanias, LC; Tallman, MS | 1 |
| Lin, F; Long, M; Ren, JH; Wang, X; Wei, JX; Yan, L; Zhang, HZ | 1 |
| Boeke, JD; Douglas, NR; Frydman, J; Huang, Z; McCaffery, JM; Pan, X; Reissman, S; Wang, X; Yuan, DS | 1 |
| Ahmed, HA; Ahn, MH; Cha, GH; Hwang, IY; Lee, YH; Quan, JH; Shin, DW | 1 |
| Chen, J; Kang, X; Lan, T; Li, Z; Qi, Z; Wang, F; Xing, J; Xu, S | 1 |
| Chelbi-Alix, MK; Singer, M; Trugnan, G | 1 |
| Hu, XM; Liu, F; Ma, R | 1 |
| Campla, C; Nanjundan, M; Raffoul, F | 1 |
| Ferrarese, C; Riva, MA; Tremolizzo, L | 1 |
| Appelbaum, FR; Couban, S; Coutre, S; Feusner, JH; Gallagher, RE; Gregory, J; Larson, RA; Moser, B; Powell, BL; Rowe, JM; Stock, W; Stone, RM; Tallman, MS; Willman, CL | 1 |
| Fry, RC; Jaspers, I; Kesic, M; Liu, Q; Pi, J; Smeester, L; Zhang, H; Zou, F | 1 |
| Ambaglio, I; Bernasconi, P; Castagnola, C; Corso, A; Lazzarino, M; Rossi, M; Zappasodi, P | 1 |
| Chen, NY; Wang, J; Wang, XM; Wang, YM; Yan, B; Yan, ZY; Zhang, HX; Zhang, S | 1 |
| Li, Y; Meng, YL; Yu, JX | 1 |
| Fei, AM; Liu, JJ; Mao, CM; Mi, JQ; Zhu, J | 1 |
| Chen, Z; Song, X; Wu, C; Zhao, S | 1 |
| Bøe, SO; Simonsen, A | 1 |
| Chang, JW; Li, YY; Wang, CH; Wang, HM; Yeh, KY | 1 |
| Jenkins, J; McMurray, R; Tchounwou, P; Yedjou, C | 1 |
| Eguchi, R; Fujimori, Y; Fukuoka, K; Kuribayashi, K; Nakano, T; Ohta, T; Tabata, C; Takeda, H | 1 |
| Cortes, J; Dayyani, F; Faderl, S; Garcia-Manero, G; Jones, D; Kantarjian, H; O'Brien, S; Pierce, S; Ravandi, F | 1 |
| Kawanishi, S; Ma, N; Piao, F; Sasoh, M; Sugiura, H | 1 |
| Blanchet, F; Mangeat, B; Piguet, V; Stalder, R | 1 |
| Chen, L; Dong, Z; Meng, Q; Peng, Z; Si, J; Xia, Y | 1 |
| Takahashi, S | 1 |
| Chen, QK; Chen, YT; Huang, KH; Lin, P; Liu, JH; Xu, LS | 1 |
| Sun, BG; Wen, QZ; Zhao, JL | 1 |
| Gibson, SB | 1 |
| Baĭdil'dina, DD; Dubrovina, ME; Maschan, AA; Maschan, MA; Rumiantsev, AG; Rumiantseva, IuV; Samochatova, EV; Skorobogatova, EV | 1 |
| An, RH; Cao, Y; Ding, Q; Guo, GY; Wang, Y; Yu, SL | 1 |
| Cox, AJ; Davis, BH; Davis, KT; Fang, G; Hock, JM; Li, X; Liu, Y; Sullivan, C | 1 |
| Chung, JG; Huang, WW; Kuo, SC; Lai, IC; Lai, TY; Lin, CC; Lin, JJ; Wen, YF; Yang, JS | 1 |
| Gao, J; Liu, D; Mei, Y; Wang, H; Zhang, Z; Zhao, Y; Zheng, Y | 1 |
| Huang, Y; Li, Y; Lin, X; Liu, R; Liu, W; Ma, L; Tian, Y; Wang, D; Wu, M | 1 |
| Shen, Q; Tang, YH | 1 |
| Liu, ZJ; Lu, N; Wang, N; Yan, Z | 1 |
| Bau, DT; Chang, NW; Hsu, CM; Lin, SS; Sun, SS; Tsai, CW; Tsai, MH; Tsai, RY; Wang, RF; Wu, CN | 1 |
| Ardalan, B; Francheschi, D; Livingstone, A; Oh, M; Podolsky, L; Subbarayan, PR | 1 |
| Cheng, IC; Lee, TC; Shue, JJ; Wang, TC | 1 |
| Han, Y; Hou, J; Hu, X; Jiang, W; Meng, X; Shi, J; Tang, S; Tao, Y; Tricot, G; Wu, X; Wu, Y; Zangari, M; Zhan, F | 1 |
| Allen-Bard, S; Christos, PJ; Curcio, T; Feldman, EJ; Mathew, S; Provenzano, J; Ritchie, EK; Roboz, GJ; Samuel, M; Segovia, J | 1 |
| Advani, A; Afable, M; Chan, J; Englehaupt, R; Erba, HP; Kalaycio, ME; Maciejewski, JP; Seel, S; Sekeres, MA; Sobecks, R | 1 |
| Abeltino, M; Agnelli, L; Bolzoni, M; Bonomini, S; Colla, S; Giuliani, N; Neri, A; Rizzoli, V; Storti, P; Todoerti, K | 1 |
| Abe, Y; Kamada, H; Minowa, K; Nabeshi, H; Nagano, K; Nomura, T; Shibata, H; Sugita, T; Tsunoda, S; Tsutsumi, Y; Yoshikawa, T | 1 |
| Battastini, AM; Braganhol, E; Dalmolin, RJ; de Souza, LH; Gelain, DP; Moreira, JC; Pasquali, MA; Schröder, R; Zanotto-Filho, A | 1 |
| Chen, C; Gao, SM; Jiang, L; Tan, Y; Wu, J; Xing, CY; Ye, A; Yin, L; Yu, K | 1 |
| Chen, MF; Chen, MJ; Hu, DN; Yang, PY; Ye, YZ | 1 |
| Fu, CC; Jin, ZM; Liang, JY; Liu, YJ; Ma, X; Qiu, HY; Tang, XW; Wu, DP | 1 |
| Huang, QF; Li, P; Liang, YH; Liu, X; Zhao, JX | 1 |
| Chen, X; Jiang, H; Liu, L; Ma, Y; Pan, S; Sun, X; Wang, J; Zhu, H | 1 |
| Kavitha, C; Lavanya, S; Malarvizhi, A; Ramesh, M | 1 |
| Dennis, AT; Ficker, E; Heredia-Moya, J; Kirk, KL; Obejero-Paz, C; Overholt, JL; Wan, X | 1 |
| Douer, D; Gore, S; Powell, BL; Ranganathan, A; Ravandi, F; Rowe, J; Sanz, MA; Tallman, M | 1 |
| Hasan, SK; Lo-Coco, F | 2 |
| Allegood, J; Cruickshanks, N; Curiel, DT; Dash, R; Dent, P; Dmitriev, IP; Fisher, PB; Grant, S; Hamed, HA; Mitchell, C; Ogretmen, B; Park, MA; Spiegel, S; Tye, G; Yacoub, A | 1 |
| Ablain, J; Bazarbachi, A; de Thé, H; El Hajj, H; El-Sabban, M; Hall, W; Hasegawa, H; Hermine, O; Janin, A; Kfoury, Y; Mahfouz, R; Nasr, R; Nicot, C; Saab, ST; Zaatari, G | 1 |
| Dai, L; Jiang, M; Liu, Y; Ruan, C; Wang, Z; Wu, D; Zhang, W | 1 |
| Betti, L; Brizzi, M; Nani, D; Peruzzi, M; Trebbi, G; Zurla, M | 1 |
| Chen, X; Jiang, HC; Liu, LX; Meng, XZ; Pan, SH; Wang, JB; Zhang, WH; Zheng, TS | 1 |
| Fu, HY; Shen, JZ; Shen, SF; Wu, DS; Xu, CB; Zhu, YF | 1 |
| Jing, L; Jinglei, Q; Kezuo, H; Xiujuan, Q; Xuejun, H; Ye, Z; Yingchun, L; Yuee, T; Yunpeng, L | 1 |
| Chang, YJ; Cheng, YW; Chiou, JF; Hsieh, PY; Hsu, CH; Ko, HL; Liu, TZ; Ting, LL; Tung, JN; Wu, AT | 1 |
| Raju, GP | 1 |
| Albanese, C; Beauchamp, EM; Bulut, G; Hall, MD; Lee, YC; Macdonald, TJ; Ozdemirli, M; Peaceman, D; Ringer, L; Rodriguez, O; Sajwan, KP; Toretsky, JA; Uren, A | 1 |
| Gao, WQ; Liu, P; Wang, LX; Yu, XH; Zhang, H | 1 |
| Printz, C | 1 |
| Lo-Coco, F; Sanz, MA | 1 |
| Bai, Y; Chen, X; Du, Z; Hong, Y; Pan, Z; Shan, H; Sun, I; Yang, B; Zhang, Y; Zhao, J | 1 |
| Manji, GA; Tallman, MS | 1 |
| Cheng, H; Cheng, M; Lei, L; Li, W; Liu, K; Ma, J; Qiu, L; Zhang, H; Zhao, X | 1 |
| Gong, YP; Luo, S; Yang, L; Yang, YM | 1 |
| Chen, R; Huang, S; Li, G; Liang, Y; Liu, L; Liu, Q; Wu, Y; Yin, D; Zhang, B | 1 |
| Fu, Y; Hou, J; Li, H; Liu, X; Shi, J; Song, P; Zhang, Y; Zhou, J | 1 |
| Cheng, YL; Huang, HS; Liu, ZM | 1 |
| Ando, H; Fujimura, A; Hosohata, K; Koshimizu, TA; Kumazaki, M; Oshima, Y; Sasaki, A; Ushijima, K | 1 |
| Chen, X; Chen, Y; Zhang, L; Zhu, X; Zou, Y | 1 |
| Li, R; Li, Y; Shi, Y; Wang, Y; Wei, Y; Zhang, H | 1 |
| Wang, L; Wang, YJ; Weng, CY; Wu, MJ | 1 |
| Liang, Y; Liu, Y; Shi, C; Sun, Z; Yang, G; Zhang, X; Zhao, S; Zheng, T | 1 |
| Aller, P; Castellanos, E; Fernández de la Pradilla, R; Gallardo-Vara, E; Guisado, A; Mar González-Barroso, M; Redondo-Horcajo, M; Rial, E; Rodríguez-Sánchez, L; Viso, A | 1 |
| Ebinger, M; Feuchtinger, T; Gessler, P; Handgretinger, R; Hildenbrand, S; Lang, P; Scheel-Walter, HG; Schwarze, CP | 1 |
| Ahsan, J; Kumari, B | 1 |
| Rogers, JE; Yang, D | 1 |
| Chiu, HW; Ho, SY; Lin, W; Wang, YJ | 1 |
| Gore, SD; Prebet, T | 1 |
| Han, H; Jiang, T; Lu, H; Luo, R; Shen, P | 1 |
| An, Z; Huang, D; Liu, Y; Qi, Y; Zhang, W; Zhang, Y | 1 |
| Chen, Z; Jin, J; Li, K; Mei, C; Tong, H; Wang, H | 1 |
| Chen, BA; Liu, L; Qin, SK | 1 |
| Gu, N; Li, GZ; Lu, Q; Niu, HZ; Teng, GJ; Wang, ZY; Xu, RZ; Yu, H; Zhang, DS; Zhu, GY | 1 |
| Chen, X; Cho, SJ; Liu, S; Yan, W; Zhang, J; Zhang, Y | 1 |
| Chan, SY; Ho, PC; Ong, PS | 2 |
| Andrews, C; Baer, MR; Barcos, M; Baumann, H; Block, AW; Ford, LA; Nowak, NJ; Sait, SN; Tighe, S; Wang, ES; Wetzler, M | 1 |
| Chen, YJ; Li, HM; Li, XJ; Li, ZH; Liang, Y; Long, Y; Qing, C; Yu, M; Zhang, XM; Zhang, YL | 1 |
| Bowen, D; Burnett, AK; Cahalin, P; Craig, J; Hills, RK; Hunter, A; Kell, J; McMullin, MF; Milligan, D; Russell, N; Wheatley, K; Yin, J | 1 |
| Anderson, LD; Collins, RH; Kirk, A; Levitt, D; Naina, HV; Scaglioni, PP; Vusirikala, M | 1 |
| Chen, G; Ho, PC; Liu, J; Shao, Y; Wu, J | 1 |
| Chen, C; Huang, D; Qi, Y; Wang, Y; Xi, Y; Zhang, Y | 1 |
| Arkusz, J; Ferlińska, M; Gradecka-Meesters, D; Smok-Pieniążek, A; Stańczyk, M; Stępnik, M | 2 |
| Hua, H; Li, J; Qin, S; Rui, J | 1 |
| Chen, XW; Xia, HL; Xia, RX | 2 |
| Alimoghaddam, K; Ghaffari, H; Ghavamzadeh, A; Hosseini, R; Iravani, M; Jahani, M; Jalili, M; Mousavi, A; Rostami, S | 1 |
| Castellani, P; Ciriolo, MR; Delfino, L; Lucibello, M; Rubartelli, A; Venè, R | 1 |
| Chang, CF; Chen, YW; Cheng, PW; Ho, TJ; Huang, CF; Jinn, TR; Liu, SH; Lu, TH; Su, CC; Su, YC; Wu, CC; Yen, CC | 1 |
| Huang, D; Liu, Y; Qi, Y; Zhang, W; Zhang, X; Zhang, Y | 1 |
| Alimoghaddam, K; Ghaffari, SH; Ghavamzadeh, A; Hajhashemi, M; Mozdarani, H; Yaghmaie, M | 1 |
| Chung, JY; Han, SH; Joo, BS; Kim, JM; Kim, JY; Kim, WR; Kim, YJ; Lee, SG; Park, JE; Yoo, KS; Yoo, YH | 1 |
| Bao, Y; Duan, Y; Kong, J; Liu, Z; Ma, X; Shan, B; Wang, Y; Wu, X | 1 |
| Geng, XX; Ma, R; Quan, LN; Tang, LP | 1 |
| Chiu, HW; Ho, YS; Wang, YJ | 1 |
| Block, GJ; Esteves, KC; Flemington, EK; Lasky, JA; Lin, Z; Shan, B; Sides, MD | 1 |
| Atsumi, A; Goto, E; Hayakawa, F; Kiyoi, H; Naoe, T; Tomita, A | 1 |
| Estey, EH; Hutchinson, F | 1 |
| Alimoghaddam, K; Bahar, B; Ghaffari, SH; Ghavamzadeh, A; Iravani, M; Jahani, M; Jalili, M; Mousavi, SA; Rostami, S | 1 |
| Hong, DY; Huang, HS; Liu, ZM; Tseng, JT | 1 |
| Nie, C; Qiu, J; Wang, F; Wei, Y; Yuan, Z; Zhao, X; Zhao, Z | 1 |
| Jeong, KH; Park, TS; Yoon, HS | 1 |
| Breccia, M; Cicconi, L; Giannì, L; Latagliata, R; Lo-Coco, F; Minotti, C | 1 |
| Bazarbachi, A; Fields, P; Hermine, O; Suarez, F | 1 |
| Ducas, J; Ducas, RA; Seftel, MD; Seifer, C | 1 |
| Fan, Q; Lu, SH; Ma, Z; Wang, F; Wang, L; Wang, R; Wu, X; Yang, J; Zhang, W | 1 |
| Sun, H; Zhang, S | 1 |
| Dimov, IK; Ducrée, J; Kang, T; Kijanka, G; Lee, LP; Park, Y | 1 |
| Li, YT; Wang, L; Wang, ZY; Zhang, DS; Zhang, J | 1 |
| Acalovschi, M; Aldea, M; Fischer-Fodor, E; Irimie, A; Kacso, G; Mosteanu, O; Petrushev, B; Pop, T; Soritau, O; Susman, S; Tomuleasa, C | 1 |
| Jia, B; Li, JH; Li, XF; Liu, QJ; Ma, J; Qiu, L; Wang, CH; Wang, XL; Xu, W | 1 |
| Chen, JP; Qin, DB; Wang, SQ | 1 |
| An, Y; Li, Y; Liu, J; Wang, L; Wang, Z; Zhang, D; Zhang, J | 1 |
| Burnett, AK; Hills, RK | 1 |
| Bechelli, J; Ifthikharuddin, JJ; Jordan, CT; Liesveld, JL; Lu, C; Messina, P; Mulford, D; Phillips Ii, GL; Rosell, KE | 1 |
| Chen, YA; Chiu, HW; Guo, HR; Ho, SY; Ho, YS; Wang, YJ; Wu, WJ | 1 |
| Beezhold, K; Castranova, V; Chen, F; Kan, H; Liu, J; Meighan, T; Shi, X | 1 |
| Bian, J; Guo, J; Wang, Y; Wu, H; Wu, X; Zhang, C; Zhang, S; Zhou, J | 1 |
| Chen, HZ; Chen, XY; Qi, H; Rong, ZX; Wang, BS; Wang, H | 1 |
| Dong, X; Han, Q; Jiang, Y; Liu, Z; Ma, N; Qu, B; Zhang, Y; Zhao, D | 1 |
| Kim, SH; Park, WH | 1 |
| Liu, YF; Yu, RH; Zeng, L | 1 |
| Tang, X; Wang, C; Xiao, G; Yao, C | 1 |
| Ai, Z; Liu, H; Lv, C; Pan, H; Suo, T; Tong, S; Wang, Y | 1 |
| Balayssac, S; Ballot, C; Briand, G; Dammak, A; Dauphin, V; Formstecher, P; Idziorek, T; Jendoubi, M; Joha, S; Jonneaux, A; Kluza, J; Maboudou, P; Malet-Martino, M; Marchetti, P; Quesnel, B | 1 |
| Akashi, K; Harada, M; Kamimura, T; Miyamoto, T | 1 |
| Duru, N; Guo, Q; He, G; Kong, X; Li, JJ; Sui, L; Wan, B; Wang, L; Wang, Q; Wu, X; Yu, L; Zhang, P; Zhou, Y | 1 |
| Gambacurta, A; Garaci, E; Lucibello, M; Pierimarchi, P; Rasi, G; Rubartelli, A; Serafino, A; Zonfrillo, M | 1 |
| Abboud, CN; Cashen, AF; DiPersio, JF; Gao, F; Hassan, A; Klco, JM; Procknow, E; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Welch, JS; Westervelt, P | 1 |
| Shinagawa, K | 1 |
| Falnoga, I; Slejkovec, Z; van Elteren, JT; Zelenik Pevec, A | 1 |
| Chen, C; Edin, ML; Gong, W; Li, Y; Liu, L; Wang, DW; Zeldin, DC | 1 |
| Li, A; Shen, L; Xu, W; Ye, J; Zhou, J | 1 |
| Chen, J; Dai, H; Ekberg, H; Lin, Y; Qi, Z; Su, J; Xi, Y; Yan, G | 1 |
| Hariganesh, MR; Jeevan, RG; Radhakrishnan, G; Subramanian, NH | 1 |
| Sun, ZQ; Tan, DW | 1 |
| Abreu e Lima, RS; Curti, C; de Thé, H; dos Santos, GA; Falcão, RP; Gimenes-Teixeira, HL; Lima, AS; Lucena-Araujo, AR; Nasr, R; Pandolfi, PP; Pestana, CR; Rego, EM; Rodrigues, FP; Santana-Lemos, BA; Scheucher, PS; Thomé, CH; Uyemura, SA | 1 |
| Falnoga, I; Slejkovec, Z; van Elteren, JT | 1 |
| Park, JH; Tallman, MS | 1 |
| Bashir, Q; Bassett, RL; Champlin, RE; Giralt, SA; Hosing, CM; Khan, H; Orlowski, RZ; Parmar, S; Popat, UR; Qazilbash, MH; Shah, JJ; Shah, N; Sharma, M; Thall, PF; Wang, M | 1 |
| Chen, YJ; Chow, LP; Lee, TC; Lin, YP | 1 |
| Aller, P; Boyano-Adánez, Mdel C; Bréard, J; Calviño, E; de Blas, E; Estañ, MC; Sancho, P; Simón, GP | 1 |
| Chang, SY; Chien, CW; Lee, PC; Lee, TC; Yao, JH | 1 |
| Au, WY; Chan, GC; Ha, SY; Kwong, YL; Lee, V; Li, CK; Yau, J; Yuen, HL | 1 |
| Hofmann, WK; Lengfelder, E; Nowak, D | 2 |
| Guo, W; Lu, XC; Ren, TT; Tang, GQ; Zhang, S; Zhao, FL | 1 |
| Chen, G; Chen, JX; Hua, ZC; Tang, B; Wang, K; Yang, BY | 1 |
| Goel, A; Spitz, DR; Weiner, GJ | 1 |
| Alimoghaddam, K; Dizaji, MZ; Ghaffari, SH; Ghavamzadeh, A; Malehmir, M | 1 |
| Cao, L; Liu, L; Wang, Z; Xie, M; Yang, L; Yang, M; Yu, Y; Zhang, H; Zhao, M | 1 |
| Block, GJ; Chadwick, RW; Flemington, EK; Lasky, JA; Shan, B; Sides, MD | 1 |
| Au, WY; Kumana, CR; Kwong, YL; Lau, JS; Lee, HK; Lin, SY; Liu, H; Yeung, DY | 1 |
| Aguayo, A; Armillas-Canseco, FM; Martínez-Baños, D | 1 |
| Eid, JI; El-Ghor, AA; Noshy, MM | 1 |
| Chang, JY; Chen, KL; Chen, LT; Chen, SN; Cheng, YT; Kuo, CC; Liu, JF; Liu, TW; Pan, WY; Shiah, HS; Wu, CM; Yang, YN | 1 |
| Esfahani, A; Gharamaleki, JV; Rezazadeh, M; Sanaat, Z; Ziae, JE | 1 |
| Dudel, EG; Mkandawire, M | 1 |
| Gurung, A; Huang, BT; Li, BS; Xiao, Z; Zeng, QC; Zhao, WH | 1 |
| Flomenberg, N; Goldberg, A; Howell, A; Ko, YH; Lin, Z; Lisanti, MP; Martinez-Outschoorn, UE; Pavlides, S; Pestell, RG; Sotgia, F; Wang, C | 1 |
| Alimoghaddam, K; Bashash, D; Dizaji, MZ; Ghaffari, SH; Ghavamzadeh, A | 1 |
| Blackburn, AC; Board, PG; Sun, RC | 1 |
| Shi, Y; Xia, J; Yang, TH | 1 |
| Liu, JH; Wan, YB; Wang, QH; Zhou, J | 1 |
| Calderon, PB; Dauguet, N; Diepart, C; Feron, O; Gallez, B; Grégoire, V; Jordan, BF; Karroum, O; Leveque, P; Magat, J; Stockis, J; Verrax, J | 1 |
| An, R; He, C; Su, Y; Wang, X; Xu, W; Xue, L; Yang, D | 1 |
| Su, Y; Sun, Z; Zhang, M; Zhang, X | 1 |
| Advani, A; Bejanyan, N; Chan, J; Jankowska, A; Kalaycio, M; Maciejewski, JP; Mooney, L; Raza, A; Saunthararajah, Y; Sekeres, MA; Tiu, RV | 1 |
| Cheng, Z; Li, L; Liang, W; Pan, L; Yan, X; Yang, N | 1 |
| Mi, J | 1 |
| Brenneman, MA; Chen, JD; Denissova, NG; Hakhverdyan, Z; Nasello, C; Yeung, PL | 1 |
| Gibbons, J; Kanwar, JR; Kanwar, RK; Verma, AK | 1 |
| Ghali, L; Iles, RK; Li, D; Liu, S; Wen, X; Zhang, Y | 1 |
| Hatta, Y; Hirabayashi, Y; Horikoshi, A; Iriyama, N; Takeuchi, J; Toyoda, H; Yoshino, Y; Yuan, B | 1 |
| Guo, L; Hou, J; Shi, H; Wei, W; Zhang, Y; Zhou, F | 1 |
| Inoue, A; Kawakami, C; Takitani, K; Tamai, H | 1 |
| Park, WH | 1 |
| Basak, P; Chaklader, M; Chatterjee, S; Chaudhuri, S; Das, P; Law, S; Pereira, JA | 1 |
| Alexander, D; Billups, CA; Houghton, PJ; Kang, MH; Kurmasheva, RT; Reynolds, CP; Smith, MA; Toretsky, JA | 1 |
| Batár, P; Kiss, A; Rejto, L; Reményi, G; Szász, R; Telek, B; Udvardy, M; Ujj, ZÁ | 1 |
| Guo, LP; Li, LW; Li, XY; Lu, SX; Yu, XY; Zhou, Y | 1 |
| Christos, PJ; Feldman, EJ; Gergis, U; Mayer, S; Ritchie, EK; Roboz, GJ; Scandura, JM; Wissa, U | 1 |
| Fei, J; Li, Y; Luo, X; Zhu, X | 1 |
| Guo, G; Hu, T; Shen, Y; Wang, C; Wu, Y; Xu, Y | 1 |
| Li, XF; Wang, CH; Wang, XL | 1 |
| Chen, Q; Hao, XZ; Liu, JW; Qin, SK; Qu, FL; Qu, T; Sui, GJ; Sun, Y; Zhang, HP | 1 |
| Amano, S; Gao, Y; Gu, C; Koizumi, S; Namba, H; Tokuyama, T; Yokota, N | 1 |
| Chen, YA; Chiu, HW; Ho, SY; Wang, YJ | 1 |
| Chen, X; Easteal, AJ; Jiang, H; Ma, Y; Pan, S; Sun, X; Zhang, C | 1 |
| Abraham, A; Ahmed, R; Alex, AA; Balasubramanian, P; Chandy, M; Chendamarai, E; Ganesan, S; George, B; Janet, NB; Lakshmi, KM; Mathews, V; Nair, SC; Sitaram, U; Srivastava, A; Srivastava, VM; Viswabandya, A | 1 |
| Du, J; Fu, W; Hou, J; Qu, X; Xi, H; Zhang, C; Zou, J | 1 |
| Chen, Y; Li, Z; Lu, Q | 1 |
| Chen, P; Chen, YZ; Huang, HF; Lin, ZX; Lu, R; Wu, Y | 1 |
| Hu, K; Ren, JJ; Song, YP; Xie, J; Zhang, M; Zhang, YJ | 1 |
| Chen, Y; Ge, QF; Lu, Y; Mu, QT; Ouyang, GF; Zhang, Y | 1 |
| Beauchamp, EM; Uren, A | 1 |
| Byers, LA; Carter, B; Chiang, CM; Girard, L; Heymach, JV; Konstantinidou, G; Rabellino, A; Rimessi, A; Scaglioni, PP; Teruya-Feldstein, J; Wu, SY | 1 |
| Cao, Z; Li, Q; Ruan, M; Wang, J; Zhang, L; Zhu, X; Zou, Y | 1 |
| Liu, J; Wang, L; Wang, Z; Zhang, D; Zhang, J | 1 |
| Chen, SJ; Chen, Z; Li, JM; Mi, JQ; Shen, ZX | 1 |
| Benoilid, A; Broly, F; Echaniz-Laguna, A; Fornecker, LM; Goullé, JP; Lannes, B; Mousson de Camaret, B; Vinzio, S | 1 |
| Cools, F; Gallacher, DJ; Lu, HR; Vlaminckx, E | 1 |
| Bagel, B; Gujral, S; Gupta, S; Khattry, N; Menon, H; Nair, R; Subramanian, PG | 1 |
| Chang, KL; Cheng, HL; Hsieh, BS; Hu, YC; Huang, LW; Huang, TC | 1 |
| Breccia, M; Lo-Coco, F | 1 |
| Couchman, IMS; Ive, EC; Reddy, L | 1 |
| Batteux, F; Chéreau, C; Kavian, N; Laude, H; Marut, W; Nicco, C; Servettaz, A; Weill, B | 1 |
| Hsu, NC; Kuo, HH; Wu, YC; Yih, LH | 2 |
| Chen, J; Cheng, J; Wei, HL; Xie, B | 1 |
| Barnett, JB; Davis, ME; Holaskova, I; Jiang, BH; Lu, Y; Rojanasakul, Y; Schafer, R; Stueckle, TA; Wang, L | 1 |
| Stein, EM; Tallman, MS | 2 |
| Huang, HS; Liu, ZM; Tseng, HY | 1 |
| Huang, H; Liu, H; Qin, Y; Teng, R; Xu, M; Xu, R; Yang, L; You, X | 1 |
| Knox, SJ; Li, X; Nolley, R; Peehl, DM; Reese, SW; Tian, J; Young, SR; Zhao, H | 1 |
| Guo, WW; Liu, WJ | 1 |
| Choudhry, A; DeLoughery, TG | 1 |
| Falnoga, I; Marc, J; Mlakar, SJ; Šlejkovec, Z; Zajc, I; Zelenik Pevec, A; Žnidarič, MT | 1 |
| Du, J; Hu, C; Jiang, F; Li, Z; Liu, H; Qi, H; Wang, X; Wang, Y; Zhong, C; Zhou, N | 1 |
| Batteux, F; Borderie, D; Chéreau, C; Dupin, N; Kavian, N; Lemaréchal, H; Marut, W; Nicco, C; Servettaz, A; Weill, B | 1 |
| Bauer, J; Briehl, MM; Efferth, T; Hock, K; Plinkert, PK; Sertel, S; Tome, M | 1 |
| Ding, Y; Fei, J; Li, Y; Zhang, Y; Zhu, X | 1 |
| Angaran, P; Gula, LJ; Kathirgamanathan, K; Lazo-Langner, A | 1 |
| Andersen, ME; Chen, Y; Dong, J; Fu, J; Hou, Y; Pi, J; Qu, W; Tokar, EJ; Waalkes, MP; Wang, A; Woods, CG; Xu, Y; Xue, P; Yarborough, K; Zhan, L; Zhang, H; Zhang, Q | 1 |
| Park, WH; You, BR | 1 |
| Arcese, W; Aversa, F; Bacigalupo, A; Breccia, M; Camboni, A; Cupelli, L; Di Veroli, A; Iori, AP; Lo-Coco, F; Papayannidis, C; Ramadan, SM | 1 |
| Bjerkvig, R; Bjørås, M; Bruserud, O; Bøe, SO; Grudic, A; Lång, E; Pankiv, S; Simonsen, A | 1 |
| Guo, Y; Hu, B; Shi, Y; Wang, H; Xia, J | 1 |
| Canet, MJ; Cherrington, NJ; Gandolfi, AJ; Hardwick, RN; Klimecki, WT; Kopplin, MJ; Lake, AD; Scheffer, GL | 1 |
| Chen, Y; Cortes, J; Kantarjian, H; Ravandi, F; Wang, H | 1 |
| Chen, SJ; Zhou, GB | 1 |
| Bashford, J; Bradstock, K; Browett, P; Catalano, A; Collins, M; Di Iulio, J; Filshie, R; Firkin, F; Grigg, A; Hertzberg, M; Hugman, A; Iland, HJ; Moore, J; Reynolds, J; Seldon, M; Seymour, JF; Supple, SG; Szer, J; Taper, J; Taylor, K; Tiley, C | 1 |
| Ahn, WS; Bae, SM; Bang, HJ; Battogtokh, G; Kim, YW | 1 |
| Dashdorj, A; Ha, J; Jang, M; K R, J; Kim, SS; Kim, SY; Kim, Y; Lim, S; Min, YH; Shokat, KM; Won, H | 1 |
| Jia, S; Yang, S; Yang, T; Yang, Y; Zhang, X | 1 |
| Gabrilove, J; Jing, Y; Wang, R; Waxman, S; Xia, L | 1 |
| Andreeff, M; Cheng, X; Freireich, EJ; Gao, MZ; Golemovic, M; Kantarjian, HM; Quintás-Cardama, A; Verstovsek, S; Zingaro, R | 1 |
| Doñate, F; Fruehauf, JP; Lee, K; Mazar, AP; Trapp, V | 1 |
| Bing Ma, L; Chen, P; Gong, SB; Ji, XY; Li, K; Liu, SK; Liu, Y; Ouyang, RY; Wang, GY; Xiang, XD; Xu, L; Zhang, L | 1 |
| Cao, FL; Gao, CY; Hou, JX; Li, JM; Li, JN; Liu, SC; Liu, Y; Ma, RS; Shi, JL; Tan, XY; Wang, J; Yang, X; Zhou, J | 1 |
| Chun, HJ; Chung, BH; Kim, JI; Kim, SJ; Min, WS; Moon, IS; Sun, IO; Yang, CW | 1 |
| Cui, YH; Gu, JF; Hua, QL; Huo, XQ; Li, SQ; Li, WW; Li, XR; Liang, HJ; Lu, P; Miao, ZH; Yang, QH; Zhang, QQ | 1 |
| Li, X; Niu, Q; Yuan, FS; Zhang, HM | 1 |
| Bode, AM; Dong, Z; Kim, DJ; Kim, HG; Lee, KY; Li, S; Li, X | 1 |
| Cai, F; Chu, W; Dong, D; Du, Z; Li, B; Li, C; Liang, H; Lu, Y; Qiao, G; Qu, X; Wang, X; Yang, B; Yu, X; Zhang, Y; Zhao, D; Zhao, X | 1 |
| Chandler, JP; Grimm, SA; Jovanovic, B; Levy, RM; Marymont, M; McCarthy, K; Muro, K; Newman, SB; Raizer, JJ | 1 |
| Liu, J; Liu, Y; Qu, J; Qu, X; Xu, L; Zhang, G; Zhang, Y; Zheng, H | 1 |
| Cai, B; Chen, X; Du, Z; Fan, Y; Liang, H; Lu, Y; Shan, H; Song, X; Xu, C; Yang, B; Yang, L; Zhang, Y | 1 |
| Chang, MC; Chang, YF; Chen, CG; Chiang, YH; Hsieh, RK; Lim, KH; Lin, HC; Lin, J | 1 |
| Altman, JK; Bogyo, M; Gounaris, E; Goussetis, DJ; Platanias, LC; Sharma, B; Vakana, E; Wu, EJ | 1 |
| Firkin, F | 2 |
| Park, JH | 1 |
| Bhuta, S; Ding, B; Huang, J; Liu, N; Sun, Y; Tai, S; Thor, RK | 1 |
| Doudican, NA; Mazumder, A; Orlow, SJ; Wen, SY | 1 |
| Liu, H; Ma, F; Qiu, J; Tao, X; Wang, M; Wu, C | 1 |
| Fan, S; Han, L; Han, X; Hu, L; Li, J; Li, L; Li, X; Li, Y; Lv, C; Su, Y; Wang, S; Zhang, X; Zhang, Y; Zhang, Z; Zhao, H; Zhao, Y; Zhou, J | 1 |
| Aizawa, S; Hatta, Y; Horikoshi, A; Iriyama, N; Takeuchi, J; Toyoda, H; Yoshino, Y; Yuan, B | 2 |
| Alimoghaddam, K; Bashash, D; Ghaffari, SH; Ghavamzadeh, A; Mirzaei, R; Momeny, M | 1 |
| Ahmad, A; Bao, B; Chen, Z; Li, Y; Mei, C; Miele, L; Sarkar, FH; Wang, Z; Xia, J; Yang, Q | 1 |
| Chen, J; Cheng, J; Wang, B; Wei, H; Xie, B | 1 |
| Allensworth, JL; Devi, GR; Diehl, AM; Lyerly, HK; Morse, MA; Rangwala, F; Smith, GR; Thomas, Z; Williams, KP | 1 |
| Cilloni, D; Galimberti, S; Gioia, D; Guerrini, F; Levis, A; Messa, E; Palumbo, GA; Petrini, I; Petrini, M; Salvi, F | 1 |
| Chen, Z; Jung, HJ; McCarty, N | 1 |
| Chen, YZ; Li, XF; Liao, XY; Wu, Y; Yang, JH | 1 |
| He, C; Jiang, H; Jiang, X; Qiao, H; Sun, X; Sun, XP; Zhang, X | 1 |
| Li, YJ; Xia, J; Zhao, R | 1 |
| Gong, Y; Jiang, G; Li, H; Liu, H; Liu, W; Wu, Y; Zhan, S | 1 |
| Chin, A; Ciancaglini, P; de Oliveira, KT; dos Santos, GA; Faça, VM; Falcão, RP; Ferreira, GA; Greene, LJ; Hanash, SM; Izumi, C; Leopoldino, AM; Rego, EM; Scheucher, PS; Simão, AM; Thomé, CH | 1 |
| Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Tong, H; Tong, Y | 2 |
| Ge, M; Liu, L; Xue, J; Yu, M; Zhang, W; Zhang, Z | 1 |
| Murray, E; Selvaraj, V; Yeager-Armstead, M | 1 |
| Aubry, M; Chelbi-Alix, MK; Dianoux, L; El Asmi, F; Kheddache-Atmane, S; Maroui, MA | 1 |
| Alhasan, MK; Lewis, MA; Liu, L; Magnusson, J; Mason, RP | 1 |
| Chen, J; Hu, W; Lanza, GM; Shen, B; Wang, K; Zhang, B; Zhang, L; Zhao, F | 1 |
| Aller, P; Boyano-Adánez, Mdel C; Calviño, E; de Blas, E; Estañ, MC; Gómez-Gómez, M; Mena, ML; Rial, E | 1 |
| Fang, B; Li, N; Song, Y; Zhou, J | 1 |
| Zhou, J | 1 |
| Gounaris, E; Goussetis, DJ; Platanias, LC | 1 |
| Fang, B; Lin, Q; Song, Y | 1 |
| Abhilash, M; Abhilash, S; Manju, A; Mathews, VV; Nair, RH; Paul, MS | 1 |
| Gabrilove, J; Jing, Y; Liu, C; Wang, R; Waxman, S; Xia, L; Zhao, G | 1 |
| Aul, C; Berdel, WE; Braess, J; Büchner, T; Erben, P; Haferlach, C; Haferlach, T; Hanfstein, B; Hehlmann, R; Heinecke, A; Hiddemann, W; Hofmann, WK; Horst, HA; Kreuzer, KA; Krug, U; Lengfelder, E; Müller-Tidow, C; Sauerland, C; Schneider, S; Schnittger, S; Schultheis, B; Serve, H; Spiekermann, K; Wörmann, B | 1 |
| Chen, P; Chen, YZ; Huang, HF; Lu, R; Wu, Y | 1 |
| Auberger, P | 1 |
| Dong, Z; Fu, J; Gong, Y; Jin, L; Li, B; Sun, M; Yang, B; Zhang, K; Zhang, Y; Zhao, X | 1 |
| Alexandre, J; Annereau, M; Batteux, F; Chéreau, C; Dauphin, A; Goldwasser, F; Lemare, F; Mongaret, C; Nicco, C; Thomas-Schoemann, A; Weill, B | 1 |
| Damdindorj, L; Hosokawa, Y; Hossain, E; Karnan, S; Konishi, H; Konishi, Y; Nitta, M; Ota, A; Takahashi, M; Yokochi, T | 1 |
| Fang, B; Li, N; Liu, Y; Song, Y | 1 |
| Armistead, MY; Cohenford, M; Murray, E; Selvaraj, V | 1 |
| Fan, QX; Wang, F; Wang, LX; Wang, R; Wu, XA; Xu, DF; Zhang, WJ | 1 |
| Prathapan, A; Raghu, KG; Soumya, RS; Vineetha, VP | 1 |
| Cao, J; Chen, D; Chen, L; Du, X; Fan, Z; Li, S; Lin, L; Liu, X; Ma, J; Pei, R; Sha, K; Tang, S; Wu, J; Ye, P; Zhang, B; Zhang, P | 1 |
| Hirano, T; Onda, K; Sugiyama, K; Tanaka, S; Tohyama, N | 1 |
| Bauckman, KA; Dutta, PS; Kodigepalli, KM; Nanjundan, M | 1 |
| Luo, Y; Meng, XB; Qin, M; Sun, GB; Sun, J; Sun, X; Sun, XB; Wang, HW; Wang, M | 1 |
| Shih, HM; Yang, WC | 1 |
| Huo, JM; Kang, J; Li, X; Sang, YL; Xu, ZP | 1 |
| Hu, S; Piao, F; Wang, X; Zhang, J; Zhao, L | 1 |
| Cao, LM; Li, HY | 1 |
| Aravena, C; Beltrán, AR; Cornejo, M; Díaz, ES; Guzmán-Gutiérrez, E; Leiva, A; Pardo, F; Ramírez, MA; Sobrevia, L; Torres, V | 1 |
| Chen, XL; Cong, WH; Guo, G; Li, H; Li, XX; Wang, R; Yu, XN | 1 |
| Dai, MK; Huang, QF; Li, P; Liang, YH; Zhao, JX | 1 |
| Hock, JM; Li, X; Liu, Y; Van Beneden, RJ | 1 |
| Chen, MH; Liu, M; Liu, TB; Xle, JM; Yang, AQ; Yang, P | 1 |
| Hao, LM; Huang, JQ; Li, XM; Wang, SM; Wei, LY; Wu, HY | 1 |
| Attarbaschi, A; Boztug, H; Chen, HY; Cooper, BW; Dworzak, MN; König, M; Strehl, S; Suzukawa, K; Zhang, SJ | 1 |
| Chen, X; Jung, YS; Yan, W; Zhang, J; Zhang, Y | 1 |
| Boise, LH; Cai, Y; Lee, KP; Matulis, SM; Morales, AA; Yehiayan, L | 1 |
| Aftab, BT; Beachy, PA; Borodovsky, A; Chen, B; Epstein, EH; Kim, D; Kim, J; King, EM; Lee, AH; Rezaee, M; Riggins, GJ; Rudin, CM; Tang, JY | 1 |
| Alimoghaddam, K; Bashash, D; Ghaffari, SH; Ghavamzadeh, A; Hassani, S; Hezave, K; Kazerani, M; Rostami, M; Zaker, F | 1 |
| Chen, H; Liu, J; Liu, L; Liu, M; Shi, B; Ye, L; Yu, L; Zhang, Y | 1 |
| Gagat, M; Grzanka, A; Grzanka, D; Izdebska, M | 1 |
| Cao, F; Chen, B; Le, XC; Lu, X; Shen, S; Yuan, C; Zhou, J | 1 |
| Iland, HJ; Seymour, JF | 1 |
| Cheng, HT; Guo, CY; Hu, HT; Li, HL; Luo, JP; Meng, YL; Xiao, JC; Yao, QJ | 1 |
| Chang, KL; Cheng, HL; Hsieh, BS; Hu, YC; Huang, IY; Huang, LW; Huang, TC | 1 |
| Byun, JM; Jeong, DH; Kang, MS; Kim, JR; Kim, KT; Kim, YN; Lee, DS; Lee, KB; Park, SG; Sung, MS | 1 |
| Chen, Y; Han, L; Meng, H; Shi, C; Sui, M; Wang, H; Zhang, Z; Zhou, J; Zhou, Q | 1 |
| Hsu, NC; Kuo, HH; Wu, YC; Yen, WY; Yih, LH | 1 |
| Li, H; Wang, X; Wang, Z; Xu, Z; Yue, X; Zhang, X | 1 |
| Du, Z; Fan, Y; Hang, P; Liu, Y; Pan, Z; Wang, C; Wang, N; Zhang, Y | 1 |
| Chen, XL; Gu, RD; Han, F; He, B; Huang, JM; Shi, SY; Wu, JH; Zhang, Y | 1 |
| Altman, JK; Galvin, JP; Goussetis, DJ; Platanias, LC; Sassano, A; Szilard, A; Vakana, E | 1 |
| Cui, X; Gao, H; Han, S; Jia, Y; Liu, D; Ma, X; Sun, S; Wang, Y; Xiao, D; Zhang, M; Zheng, Y | 1 |
| Chen, F; Jiang, M; Mo, BW; Wang, CM; Wang, JY; Zhao, XQ | 1 |
| Chao, NJ; de Castro, CM; Diehl, LF; Gasparetto, C; Gockerman, JP; Held, LA; Horwitz, ME; Long, GD; Moore, JO; Rizzieri, D | 1 |
| Li, C; Mitchell, AM; Samulski, RJ | 1 |
| Atsuta, Y; Emi, N; Fujimaki, K; Fujisawa, S; Fujita, H; Kobayashi, Y; Maeda, A; Miyazaki, Y; Naoe, T; Ohtake, S; Ohwada, A; Sunami, K; Takeshita, A; Taniwaki, M; Tsuboi, K; Tsuzuki, M; Yanada, M | 1 |
| Hao, L; Wang, H; Wang, X; Xu, G; Zhao, J | 1 |
| Althuri, A; Banerjee, R; Binod, P; Mathew, J; Pandey, A; Sindhu, R | 1 |
| Han, LN; Hu, LH; Kong, DS; Liu, JJ; Liu, SX; Qin, F; Zhang, Z; Zhao, YH; Zhou, J | 1 |
| del Rincon, SV; Diaz, Z; Garnier, N; Gupta, A; Kourelis, M; Kwan, S; Mann, KK; Miller, WH; Molina, MF; Petruccelli, LA; Schipper, HM | 1 |
| Chuang, YT; Huang, YW; Jiang, ST; Kuo, WC; Lai, MZ; Lin, YC; Lo, YH; Mo, ST; Shih, HM; Tsai, CS; Wu, YH | 1 |
| Beneytout, JL; Bertrand, J; Ghezali, L; Leger, DY; Liagre, B | 1 |
| Abhilash, M; Abhilash, S; Manju, A; Mathews, VV; Nair, RH; Paul, MV | 1 |
| Assuncao, A; Cavenee, WK; Cloughesy, TF; Dang, J; Furnari, FB; Gini, B; Iwanami, A; Kitabayashi, I; Kohyama, J; Matsutani, T; Mischel, PS; Nael, A; Nakamura, M; Okano, H; Toyama, Y; Yang, H; Zanca, C; Zhu, S | 1 |
| Gong, J; Jiang, X; Li, H; Shao, H | 1 |
| Cohen, KJ; Fisher, PG; Gibbs, IC; Gore, L; Hayashi, RJ; Macy, ME | 1 |
| Baek, SY; Kim, EY; Kim, SH; Lee, SS; Shin, DH; Shin, JH | 1 |
| Chen, L; Han, F; Qu, H; Ren, L; Yan, H; Yang, S | 1 |
| Li, Y; Liu, L; Ma, D; Xue, J; Yu, M; Zhang, W; Zhang, Z | 1 |
| Fernández-Bringas, L; Núñez-Nogueira, G; Valentino-Álvarez, JA | 1 |
| Ando, H; Fujimura, A; Kakei, M; Koshimizu, TA; Kumazaki, M; Taniguchi, Y; Ushijima, K; Washino, S; Yamato, S; Yoshida, M | 1 |
| Bradley, TP; Budman, DR; Kritharis, A | 1 |
| Chen, P; Gong, S; Ji, X; Li, J; Li, K; Liu, S; Liu, Y; Ma, L; Wang, G; Xiang, X; Xu, L; Zeng, H; Zhang, L | 1 |
| Ge, J; Gong, F; Li, W; Qian, J; Shen, L; Sun, A; Tian, W; Yang, W; Zhang, F; Zou, Y | 1 |
| Ahn, RW; Avram, MJ; Bally, MB; Barrett, SL; Chen, H; Gordon, LI; Jozefik, JK; Mazar, AP; O'Halloran, TV; Raja, MR; Shea, LD; Spaho, L; Winter, JN; Woodruff, TK | 1 |
| Chen, Z; Liu, P; Naranmandura, H; Rehman, K; Wang, WW; Xu, S; Zhang, M; Zhang, YF | 1 |
| Aki, T; Bessho, M; Funakoshi, T; Kato, C; Noritake, K; Uemura, K; Unuma, K | 1 |
| Bi, Y; Chen, X; Han, D; Ji, Z; Li, H; Liu, H; Liu, Y; Shen, C; Shi, C; Wang, C; Wu, J; Yang, G; Zhang, D; Zhao, S | 1 |
| Chu, W; Li, C; Liu, Y; Liu, Z; Lu, Y; Mei, L; Nie, D; Qu, N; Qu, X; Wang, X; Xu, W; Yan, J; Yang, B; Yu, X | 1 |
| Ge, M; Liu, J; Liu, Y; Ma, D; Xue, J; Yao, C; Zhang, W; Zhang, Z | 1 |
| Berger, W; Ferk, F; Heffeter, P; Hoda, MA; Jungwirth, U; Karnthaler-Benbakka, C; Knasmüller, S; Kowol, CR; Kryeziu, K | 1 |
| Firkin, F; Iland, H | 1 |
| Andersson, LC; Bironaite, D; Venalis, A; Westberg, JA | 1 |
| An, L; Bai, B; Chen, J; Li, X; Yang, X | 1 |
| Liu, Z; Sun, G; Wang, F; Wang, H; Wang, Y; Xi, S; Xu, Y; Yang, Y; Zheng, Q; Zheng, Y | 1 |
| Cheng, Y; Gao, L; Liu, Y; Ma, D; Xue, J; Yao, C; Zhang, Z | 1 |
| Cao, JJ; Chen, D; Chen, LG; Du, XH; Fan, Z; Li, SY; Lin, L; Liu, XH; Ma, JX; Pei, RZ; Sha, KY; Shi, XW; Tang, SH; Wu, JY; Ye, PP; Zhang, BB; Zhang, PS; Zhuang, XX | 1 |
| Wang, Y; Zhu, CS; Zhu, XX | 1 |
| Belin, E; Chesnut, G; Taylor, S | 1 |
| Anur, P; Kodigepalli, KM; Nanjundan, M; Sims, PJ; Spellman, P | 1 |
| Cavenee, WK; Cloughesy, TF; Iwanami, A; Mischel, PS | 1 |
| Dworzak, M; Lackner, H; Müller, E; Seidel, MG; Urban, C | 1 |
| Baumann, H; Brady, MT; Ford, LA; Lee, KP; Miller, A; Minderman, H; Sait, SN; Wang, ES; Wetzler, M | 1 |
| Li, R; Rao, Y; Zhang, D | 1 |
| Alimoghaddam, K; Bashash, D; Ghaffari, SH; Ghavamzadeh, A; Hassani, S; Mardani, H; Mirzaee, R; Yousefi, M; Zaghal, A; Zaker, F; Zekri, A | 1 |
| Wang, J; Wang, Q; Wu, L | 1 |
| Bae, JY; Kim, I; Kim, JW | 1 |
| Cai, L; Li, W; Liu, Q; Miao, L; Miao, X; Su, G; Sun, W; Tan, Y; Tang, Z; Wang, Y; Wei, W | 1 |
| Kiyoi, H; Naoe, T; Tomita, A | 1 |
| Hofmann, TG; Vennemann, A | 1 |
| Flemington, EK; Lasky, JA; Lin, Z; Luo, F; Sides, MD; Sosulski, ML | 1 |
| Fan, RH; Mi, RH; Song, YP; Wei, XD; Xu, JX; Yin, QS | 1 |
| Hofmann, WK; Lengfelder, E; Nolte, F | 2 |
| Chen, B; Qian, W; Ye, B; Yu, Q; Zhang, X; Zhou, Y | 1 |
| Fan, H; Li, S; Lin, J; Lu, X; Zhu, H | 1 |
| Cernelc, P; Podgornik, H; Rebersek, K | 1 |
| Cen, JN; Fu, CM; Hu, SY; Jiao, Y; Li, Z; Qi, XF; Qiu, HY; Wu, DP; Zhu, MQ | 1 |
| Nakamura, Y; Taguchi, A; Tanaka, M; Tanaka, Y; Tanizawa, Y; Yujiri, T | 1 |
| Arnold, LL; Cohen, SM; Dodmane, PR; Hoyt, R; Lele, SM; Maness-Harris, L; Muirhead, DE; Wedel, WR | 1 |
| Chakraborty, S; Pradhan, AK; Singh, S | 1 |
| Jia, XH; Liu, JQ; Wang, KK; Wang, P; Xi, WD; Yang, XW; Zhang, H | 1 |
| He, Y; Huang, S; Mao, C; Qin, X; Sun, X; Zhu, L | 1 |
| Chen, J; Dai, H; Li, C; Li, Q; Li, Z; Lin, Y; Qi, Z; Xi, Y; Xia, J; Xu, S; Yan, G | 1 |
| Guo, SQ; Li, YH; Liu, X; Luo, JM; Meng, Z; Wang, DM | 1 |
| Chen, M; Liu, T; Niu, T; Wang, L; Xie, LP; Zeng, K; Zou, XL | 1 |
| Aniceto, N; Astier, A; Becherirat, S; Gibaud, S; Lanhers, MC; Loboda, C; Socha, M; Yemloul, M | 1 |
| Chan, TC; Chang, WR; Chiou, SH; Fang, KM; Lin, TC; Liu, JJ; Ma, SZ; Tzeng, SF; Tzou, BC; Yang, CS | 1 |
| Au, WY; Han, L; Ho, JC; Ip, MS; Kwong, YL | 1 |
| Asou, N; Fujita, H; Hyo, R; Inaguma, Y; Ishigatsubo, Y; Iwanaga, M; Izumi, T; Kiyoi, H; Matsuda, M; Miyawaki, S; Miyazaki, Y; Nakaseko, C; Naoe, T; Nomura, S; Ohnishi, K; Ohtake, S; Okada, M; Shinagawa, K; Takeshita, A; Yamauchi, T | 1 |
| Amadori, S; Avvisati, G; Brandts, CH; Breccia, M; Carella, AM; Cazzola, M; Cerqui, E; Cicconi, L; Ciceri, F; Di Bona, E; Divona, M; Döhner, H; Döhner, K; Ehninger, G; Fabbiano, F; Fazi, P; Ferrara, F; Fiedler, W; Finizio, O; Fioritoni, G; Ganser, A; Hänel, M; Hertenstein, B; Iacobelli, S; Kropp, MG; La Nasa, G; Levis, A; Link, H; Lo-Coco, F; Lübbert, M; Luppi, M; Mandelli, F; Melillo, L; Morra, E; Orlando, SM; Platzbecker, U; Rambaldi, A; Salih, HR; Sauer, M; Schlenk, RF; Schmitz, N; Sica, S; Specchia, G; Thiede, C; Venditti, A; Vignetti, M; von Lilienfeld-Toal, M; Wattad, M | 1 |
| Chen, SJ; Chen, Z | 2 |
| Gao, H; Jiang, Y; Liu, Z; Wang, L; Yao, L | 1 |
| Alimoghaddam, K; Ghaffari, SH; Ghanizadeh-Vesali, S; Ghavamzadeh, A; Mojarrad, M; Yousefi, M; Zekri, A | 1 |
| Chaudhuri, K; Kabir, SN; Kumar Mukhopadhyay, P; Mondal, S; Mukherjee, S | 1 |
| Abematsu, M; Ishidou, Y; Komiya, S; Nagano, S; Nagao, H; Nakamura, S; Setoguchi, T; Yamamoto, T; Yokouchi, M | 1 |
| Cao, F; Li, Y; Liu, X; Shi, C; Wang, H; Yang, D; Ye, X; Zhao, H; Zhou, J | 1 |
| Chen, X; Shao, J; Yan, J | 1 |
| Kuo, TC; Tian, TF; Tseng, YJ | 1 |
| Chan, SM; Feng, W; Huang, M; Li, MX; Majeti, R; Mitchell, BS; Thomas, D | 1 |
| An, L; Li, X; Yang, X | 1 |
| Du, Y; Fang, H; Xia, Y; Zhang, J | 1 |
| Chiou, SY; Kou, MC; Wang, L; Wang, YJ; Weng, CY; Wu, MJ | 1 |
| de Thé, H; Lallemand-Breitenbach, V | 1 |
| Hu, J; Huang, X; Wang, X; Zhang, Y; Zhou, H; Zhou, K | 1 |
| Feng, L; Jiang, W; Li, Y; Shan, N; Wang, X | 1 |
| Mehta, SV; Shukla, SN; Vora, HH | 1 |
| Nocuń, M; Roszak, J; Smok-Pieniążek, A; Stępnik, M | 1 |
| An, R; Gong, M; Gu, X; Guo, G; Han, K; Xu, Y | 1 |
| Jiang, T; Li, QL; Peng, JQ; Su, XM; Sun, DC; Zhang, ZW; Zheng, L | 1 |
| Fung, TK; So, CW | 1 |
| Ayoubi, HR; Bazarbachi, AA; Bitar, NM; De Thé, HB; El Eit, RM; Iskandarani, AN; Jabbour, MN; Mahfouz, RA; Mahon, FX; Nasr, RR; Saliba, JL; Zaatari, GS | 1 |
| Kwong, YL; Lo, RK | 1 |
| Dey, A; Mukherjee, S; Mukhopadhyay, PK; Pradhan, NK | 1 |
| Afaq, F; Athar, M; Ballestas, ME; Bickers, DR; Chaudhary, SC; Deshane, JS; Elmets, CA; Li, C; Matalon, S; Robbins, DJ; Srivastava, RK | 1 |
| Chen, Z; Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Suo, S; Tong, H; Tong, Y; Wang, Y; Ye, X | 1 |
| Bazarbachi, A; Berry, F; Dassouki, Z; de Thé, H; El Hajj, H; Ezzedine, M; Farid, R; Ghantous, A; Ghavamzadeh, A; Hermine, O; Kchour, G; Kooshyar, MM; Mahmoudi, M; Mortada, M; Nasser, R; Rafatpanah, H; Rahimi, H; Rezaee, R; Shirdel, A; Tarhini, M | 1 |
| Chen, X; Fu, C; Gao, C; Han, D; Ji, Z; Li, H; Li, X; Liu, H; Liu, Y; Liu, Z; Shi, H; Wang, C; Wang, L; Wu, J; Yang, G; Yin, F; Zhang, D; Zhao, S | 1 |
| Au, WY; Fong, BM; Lang, BH; Mao, KJ; Tam, S | 1 |
| Chang, HC; Chung, YT; Ho, IL; Hsieh, JT; Huang, KH; Kuo, KL; Lee, PY; Lin, WC; Pu, YS; Shi, CS | 1 |
| Bjerkvig, R; Huszthy, PC; Lah Turnšek, T; Motaln, H; Primon, M; Talasila, KM; Torkar, A | 1 |
| Ji, S; Li, W; Wang, L; Wang, M; Zhang, C; Zhang, J | 1 |
| Chen, XH; Qian, WB; Zhou, XJ; Zhou, YH | 1 |
| Banfield, L; Driedger, SM; Furgal, CM; Jardine, CG | 1 |
| Iacoboni, G; Montesinos, P; Sanz, MA | 2 |
| Cong, J; Ding, X; Jiang, M; Su, Q; Wang, L; Xie, H | 1 |
| Delaune, A; Dubus, I; Falluel-Morel, A; Goullé, JP; Petit, A; Vannier, JP; Vasse, M | 1 |
| Chen, C; Jiang, X; Zhang, Z; Zhao, W | 1 |
| Hoffman, E; Mielicki, WP | 1 |
| Betti, L; Borghini, F; Borghini, G; Brizzi, M; Trebbi, G; Zurla, M | 1 |
| Cheng, Y; Liu, G; Lu, A; Wang, B; Wu, J; Zhang, L | 1 |
| Fong, BM; Ho, JC; Lam, SK; Li, YY; Mak, JC; Zheng, CY | 1 |
| Mayor, S | 1 |
| Chen, C; Jiang, X; Ren, Y; Zhang, Z | 1 |
| Chen, L; Hu, X; Wang, J; Xu, X | 1 |
| Hasan, SK; Lo-Coco, F; Montesinos, P; Sanz, MA | 1 |
| Matsue, K; Nisihida, Y; Sugihara, H; Takeuchi, M; Tsuda, K; Ugai, T; Yamakura, M | 1 |
| García-Barrera, T; García-Sevillano, MA; Gómez-Ariza, JL; Navarro, F | 1 |
| Nguyen, DM; Robbins, DJ; Savaraj, N; Singh, S; Varona-Santos, J; You, M | 1 |
| Dong, Y; Liang, AB; Liu, SF; Wu, HX; Zhang, LQ; Zhang, WJ; Zhang, XL | 1 |
| Cheng, Y; Gao, L; Jiang, H; Ma, D; Wang, M; Xue, J; Zhang, Z | 1 |
| Brandt-Rauf, P; Cassai, N; Dinnen, RD; Fine, RL; Mao, Y; Nichols, G; Qiu, W; Slavkovich, VN; Su, GH | 1 |
| Chen, SJ; Huang, XJ; Jiang, H; Jin, J; Li, JY; Ma, J; Wang, JX; Wu, DP; Zhu, HH | 1 |
| Fei, J; Feng, M; Li, Y; Luo, X; Zhang, Y; Zhu, X | 1 |
| Chen, H; Hankins, PL; Miodragović, DU; O'Halloran, TV; Swindell, EP | 1 |
| Appelbaum, FR; Bloomfield, CD; Gallagher, RE; Gulati, K; Holowka, N; Koval, G; Larson, RA; Laumann, K; Moser, BK; Paietta, E; Poiré, X; Powell, BL; Sher, D; Stock, W; Tallman, MS; Willman, C | 1 |
| Alimoghaddam, K; Ghaffari, SH; Ghanizadeh-Vesali, S; Ghavamzadeh, A; Hassani, S; Hosseini, E; Rostami, M; Yousefi, M; Zekri, A | 1 |
| Naranmandura, H; Rehman, K | 1 |
| Černelč, P; Podgornik, H; Reberšek, K; Žontar, DM | 1 |
| Bao, JL; Feng, R; Huang, XJ; Jiang, Q; Lv, M; Qing, YZ; Zhang, XH; Zheng, XL; Zhu, HH | 1 |
| Foley, SB; Hildenbrand, ZL; Mgbemena, VE; Oravecz-Wilson, KI; Philips, ST; Ross, TS | 1 |
| Cui, J; Lin, S; Yang, H | 1 |
| Chen, L; Kang, K; Qu, H; Ren, L; Tong, D; Zhang, Y | 1 |
| Albrecht, J; Alonso, FJ; Campos-Sandoval, JA; Cardona, C; Cheng, T; Colquhoun, A; Crisma, AR; Curi, R; Deberardinis, RJ; Gómez-García, MC; Higuero, A; Lobo, C; Márquez, J; Martín-Rufián, M; Matés, JM; Nascimento-Gomes, R; Segura, JA; Szeliga, M | 1 |
| Amirheidari, B; Ghahremani, MH; Mandegary, A; Seyedabadi, M; Sharif, E; Torshabi, M | 1 |
| Dillon, R; Grimwade, D | 1 |
| Douer, D; Ganzel, C; Tallman, MS | 1 |
| Cai, D; Dong, WW; Gao, F; Liu, J; Sun, K; Wang, W; Wang, Y; Zheng, Z | 1 |
| Crown, D; Leppla, SH; Liu, J; Maier, NK; Moayeri, M | 1 |
| Dos Santos, GA; Kats, L; Pandolfi, PP | 1 |
| Arrighetti, N; Carenini, N; Cominetti, D; Cossa, G; De Cesare, M; Gatti, L; Pennati, M; Perego, P; Tinelli, S; Zaffaroni, N; Zunino, F | 1 |
| Cui, H; Gu, Y; Guo, R; Hu, M; Li, T; Li, X; Liang, H; Liu, X; Lu, Y; Pan, Z; Shan, H; Wang, L; Xu, C; Xu, Z; Yang, B; Yu, S; Zhang, Y | 1 |
| Chen, YJ; Li, HM; Lu, W; Qing, C | 1 |
| Cui, JW; Elmahi, AY; Hao, SS; Li, D; Li, W; Niu, C; Wang, GJ | 1 |
| Macheta, A; Podhorecka, M | 1 |
| Annis, MG; Dong, Z; Guilbert, C; Mann, KK; Miller, WH; Siegel, PM | 1 |
| Albert, L; Jhanwar-Uniyal, M; Karsy, M; Murali, R | 1 |
| Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Suo, S; Tong, H; Tong, Y; Yu, W | 1 |
| Ablain, J; de Reynies, A; de Thé, H; Minucci, S; Rice, K; Soilihi, H | 1 |
| Liu, L; Qu, X; Wang, P; Wang, X; Zeng, H; Zhu, H; Zhu, X | 1 |
| Ahlfeld, J; Bartelheim, K; Frühwald, MC; Handgretinger, R; Holsten, T; Hotfilder, M; Kerl, K; Kool, M; Meisterernst, M; Mertins, J; Moreno, N; Schleicher, S; Schüller, U | 1 |
| Fujii, Y; Komatsu, T; Shigemi, H; Tanaka, Y; Yamauchi, T | 1 |
| Bohle, DS; Conklin, DS; Dahabieh, MS; del Rincon, SV; Garnier, N; Gu, Y; Mann, KK; Miller, WH; Nichol, JN; Redstone, GG; Sun, Y | 1 |
| Mische, SE; Seigneres, B; Zhu, G | 1 |
| Breccia, M; Cicconi, L; Lo-Coco, F | 2 |
| Girija, S; Raghu, KG; Soumya, RS; Vineetha, VP | 1 |
| Chang, WT; Hsiao, PJ; Jao, JC; Jeng, KS; Kuo, KK; Tsai, JL | 1 |
| Contreras-Acuña, M; García-Barrera, T; García-Sevillano, MA; Gómez-Ariza, JL; Navarro, F | 1 |
| Dai, J; Dai, K; Ruan, C; Wu, Y; Yan, R; Zhang, W; Zhang, Y | 1 |
| Cai, Y; Chen, C; Chen, S; Huang, J; Lu, X; Wang, Z; Wu, Q; Yang, Q; Zhu, L | 1 |
| Gao, YH; Ma, YY; Yang, SM; Yang, Y; Yang, YM; Zhang, HP; Zhang, XY | 1 |
| Ito, K; Nakahara, F; Weiss, CN | 1 |
| Altman, JK; Beauchamp, E; Eklund, EA; Goussetis, DJ; Kosciuczuk, EM; Platanias, LC; Wu, EJ | 1 |
| Ansari, M; Bourquin, JP; Gumy-Pause, F; Huezo-Diaz, P; Judas, C; Mattiello, V; Rock, N | 1 |
| Altman, JK; Appelbaum, FR; Attar, EC; Coutre, SE; Gore, SD; Kopecky, KJ; Larson, RA; Levitan, D; Maher, T; Othus, M; Paietta, E; Powell, B; Stock, W; Tallman, MS; Wetzler, M; Willman, CL | 1 |
| Chan, DC; Liu, SH; Lu, TY; Tsai, KS; Wu, CT; Yang, RS | 1 |
| SOLINAS, AC | 1 |
| Chen, Y; Li, P; Tong, N; Yang, S; Zhang, J; Zhao, X | 1 |
| Chen, L; Gao, L; Hu, X; Lü, S; Song, X; Wang, J; Yang, J; Zhang, W | 1 |
| Furuhashi, A; Hosokawa, Y; Karnan, S; Kazaoka, Y; Konishi, H; Nakaoka, T; Ohmura, Y; Ono, T; Ota, A; Yamada, Y | 1 |
| Burchiel, SW; Gandolfi, AJ; Hudson, LG; Liu, KJ; Mobarak, C; Sun, X; Zhou, X | 1 |
| Chen, YJ; Chow, LP; Kuo, HH; Lai, KC; Lee, TC; Yih, LH | 1 |
| Montesinos, P; Sanz, MA | 1 |
| Chen, G; Sung, PT | 1 |
| Gülden, M; Klauser, E; Maser, E; Seibert, H; Seibert, S | 1 |
| Bhattacharya, S; Chatterjee, S; Mukherjee, S; Ray, A | 1 |
| de Thé, H; Rice, KL | 1 |
| Chan, L; Li, X; Niu, Q; Zhang, H | 1 |
| Altman, JK; Cull, EH | 1 |
| Bi, K; Dong, L; Dong, X; Li, H; Wang, Y; Xu, W; Zhu, C | 1 |
| Guan, X; Liu, J; Lu, R; Ma, J; Shao, X; Shao, Z; Zhan, Z; Zhao, J | 1 |
| Bai, J; Gu, J; Li, R; Li, W; Li, X; Mu, Y; Wang, X; Wang, Y; Yue, Z; Zhang, H; Zhong, L | 1 |
| Ao, JY; Bu, Y; Chai, ZT; Kong, LQ; Lu, L; Sun, HC; Tang, ZY; Zhang, KZ; Zhang, QB; Zhang, YY; Zhu, XD | 1 |
| Jiang, F; Li, Y; Li, Z; Mu, J; Ning, S; Si, L; Wang, X; Ye, X | 1 |
| Ding, D; Eberhart, CG; Lim, KS | 1 |
| Ho, JC; Kwong, YL; Lam, SK; Li, YY; Mak, JC; Zheng, CY | 1 |
| Au, WY; Cheung, WW; Gill, H; Kwong, YL; Lee, EY | 1 |
| Cicconi, L; Lo-Coco, F | 2 |
| Hu, C; Jiang, F; Li, Y; Li, Z; Mu, J; Ning, S; Si, L; Wang, X; Ye, X | 1 |
| Betti, L; Borghini, F; Bregola, V; Dinelli, G; Kokornaczyk, MO; Marotti, I; Nani, D; Trebbi, G | 1 |
| Bochtler, T; Egerer, G; Hohmann, N; Mikus, G; Siller, N | 1 |
| Bao, W; Cai, X; Chen, B; Chen, Y; He, Z; Hua, W; Shen, F; Shi, Y; Wang, C; Wang, X; Xia, G; Yu, L; Zhang, Y | 1 |
| Fang, ZT; Li, S; Liu, R; Qian, S; Qu, XD; Wang, GZ; Wang, JH; Wang, LL; Yang, GW; Yang, MJ; Zhang, W; Zhang, WS; Zhu, L | 1 |
| Lasky, JA; Luo, F; Sanchez, CG; Shan, B; Sides, MD; White, ES; Zhuang, Y | 1 |
| Luo, JM; Sun, J; Zhang, XK | 1 |
| Chen, P; Chen, YZ; Huang, HF; Wu, JY | 1 |
| Guan, X; Li, C; Li, M; Shu, X; Sun, Y | 1 |
| Aki, T; Funakoshi, T; Uemura, K; Unuma, K; Watanabe, M | 1 |
| Huang, XJ; Qin, YZ; Zhu, HH | 1 |
| Mousavizadeh, K; Noori, S; Pourfathollah, A; Safa, M; Zand, H | 1 |
| Ahmadian, S; Alimoghaddam, K; Ghaffari, SH; Ghavamzadeh, A; Khaleghian, A | 1 |
| Ardalan, B; Subbarayan, PR | 1 |
| Dong, W; Guan, H; Li, S; Liu, S; Piao, F; Piao, Y; Sun, Y; Yu, S; Zhang, C | 1 |
| Jiang, M; Li, YH; Liu, LX; Ma, ZB; Xu, HY; Yang, YL | 1 |
| de Faria, GP; Dos Santos Ferreira, AC; Kwee, JK; Pereira, DL | 1 |
| Lavasanifar, A; Le, XC; Li, XF; Vakili, MR; Zhang, Q | 1 |
| Choe, TB; Choi, HN; Hong, SI; Hwang, SG; Kim, JH; Lee, HG; Lee, YH; Park, IC; Seo, SK; Yi, JY | 1 |
| Fan, Z; Huaqun, F; Kai, W; Kaiyang, W; Linquan, W; Mingwen, H; Xiangbao, Y; Xin, Y | 1 |
| Beachy, PA; Biscocho, J; Gong, X; Jones, CD; Koyota, S; Kwei, KA; McClary, AC; Myers, BR; Neahring, L; Ng, T; Odegaard, JI; Pelham, RJ; Pollack, JR; Qu, K; Rubin, BP; Sugiyama, T; Sweeney, RT; Troxell, ML; Varma, S; West, RB; Zehnder, JL | 1 |
| Chen, C; Hu, Y; Jiang, X; Zhang, Z; Zhao, W | 1 |
| Fu, YJ; Naranmandura, H; Rehman, K; Sun, TF; Sun, WH; Wang, QQ; Wu, B; Wu, Y; Zhang, YF; Zhou, XY | 1 |
| Chen, X; Jiang, H; Li, Y; Liang, Y; Liu, J; Liu, L; Lu, Z; Meng, X; Pan, S; Qi, S; Song, X; Sun, B; Wang, J; Xie, C; Yin, D; Zheng, T | 1 |
| Kumar, S; Tchounwou, PB; Yedjou, CG | 1 |
| Chen, YR; Dou, MM; Li, PC; Yang, S; Zhang, J; Zhao, XY | 1 |
| Bhattacharya, S; Chattopadhyay, A; Mukherjee, S; Sarkar, S | 1 |
| Aldoss, I; Douer, D; Mark, L; Mohrbacher, AM; Ramezani, L; Vrona, J; Weitz, I | 1 |
| Cull, EH; Kwaan, HC | 1 |
| Garnier, N; Miller, WH; Nichol, JN | 1 |
| Iland, HJ; Seymour, JF; Wei, A | 1 |
| Grimwade, D; Hills, RK; Jovanovic, JV | 1 |
| Douer, D; Ganzel, C | 1 |
| Feusner, JH; Gregory, J; Kutny, MA | 1 |
| Liu, Y; Ren, X; Wang, D; Yu, R; Zeng, L | 1 |
| Komatsu, N | 1 |
| Boyko-Fabian, M; Budach, V; Distel, L; Niehr, F; Tinhofer, I | 1 |
| Chen, S; Chen, Z; Hu, J; Li, J; Mi, J; Wang, Z; Zhu, H | 1 |
| Wei, W; Wu, C; Wu, Y; Xu, W; Yan, H; Ye, C; Yu, Q | 1 |
| Behera, SK; Dass, RS; Garg, AK; Mohanta, RK | 1 |
| Cheong, HJ; Jung, YS; Kim, KH; Kim, SJ; Lee, N; Park, HS; Won, JH | 1 |
| Aguilera-Montilla, N; Amigo-Jiménez, I; Bailón, E; García-Marco, JA; García-Pardo, A; Ugarte-Berzal, E | 1 |
| Breccia, M; Efficace, F; Foà, R; Latagliata, R; Lo Coco, F; Minotti, C; Molica, M | 1 |
| Akrami, SM; Habibi, L; Karimi, A; Madjd, Z | 1 |
| Cao, F; Lan, W; Li, D; Li, J; Li, L; Li, Y; Liu, X; Meng, R; Shi, C; Wang, H; Yang, B; Zhang, Y; Zhang, Z; Zhao, H; Zhou, J | 1 |
| Wang, J; Yang, Y; Yu, Y | 1 |
| Fan, R; Mi, R; Wei, X; Xu, J; Yin, Q; Yuan, F | 1 |
| Bi, K; Dong, L; Guo, Y; Li, H; Wang, Y; Xu, W; Zhu, C | 1 |
| Buc Calderon, P; Felipe, KB; Glorieux, C; Kviecinski, MR; Sandoval, JM; Sid, B; Stockis, J; Valenzuela, M; Verrax, J | 1 |
| Chang, YW; Chen, CA; Chen, MW; Cheng, CC; Chiu, CF; Hong, CC; Hsiao, M; Su, JL; Wei, LH | 1 |
| Ekunwe, S; Graham, B; Leggett, SS; Ndebele, K; Rogers, C; Sims, J; Stevens, J; Wells, P | 1 |
| Fu, HQ; Huang, MW; Wang, K; Wang, KY; Wu, LQ; Yin, XB; Yu, X; Zhou, F | 1 |
| Diamantidis, MD; Papaioannou, M | 1 |
| Liu, F; Wang, W; Wei, J; Ye, C | 1 |
| Gill, H; Hai, JJ; Kumana, CR; Kwong, YL; Siu, CW; Tse, HF | 1 |
| Chen, J; Fan, LL; Li, CL; Li, LJ; Wang, B; Wei, HL; Xie, B | 2 |
| Abematsu, M; Fujimoto, Y; Ishidou, Y; Kitajima, S; Kitamoto, S; Komiya, S; Maeda, S; Nagano, S; Nagao-Kitamoto, H; Nagata, M; Nakamura, S; Setoguchi, T; Tsuru, A; Yamamoto, T; Yokouchi, M; Yonezawa, S; Yoshioka, T | 1 |
| Chen, K; Huang, H; Li, B; Sun, GY; Yang, MH; Zang, YS; Zhao, XW | 1 |
| Hernández, A; Marcos, R; Peremartí, J; Ramos, F | 1 |
| Guo, FF; Huang, T; Li, BX; Liu, C; Liu, LR; Yan, CC; Zhang, KP; Zhao, X; Zhu, QL | 1 |
| Lei, H; Ma, CM; Song, LL; Tu, YY; Wang, WW; Wei, W; Wen, DH; Wu, YL; Xia, L; Xu, HZ | 1 |
| Chen, X; Jung, YS; Yan, W; Zhang, Y | 1 |
| Gao, P; Wang, H; Zheng, J | 1 |
| Cortes, J; Daver, N; Eghtedar, A; Ferrajoli, A; Garcia-Manero, G; Kadia, T; Kantarjian, H; O'Brien, S; Pierce, S; Ravandi, F; Rodriguez, I | 1 |
| Fang, ZG; He, Y; Hu, Y; Huang, RW; Li, XD; Lin, DJ; Liu, JJ; Liu, Q; Long, ZJ; Wang, DN; Xiao, RZ; Yan, JS | 1 |
| Gao, SY; Li, YJ; Liu, WL; Lv, CJ; Pang, M; Wang, PY; Xie, SY; Zhou, X | 1 |
| Liu, SZ; Liu, Y; Qiao, GF; Xu, WX; Yan, J; Zhang, Y | 1 |
| Fan, RH; Mi, RH; Wei, XD; Yin, QS; Yuan, FF; Zhang, XH | 1 |
| Wang, XN; Zhang, M | 1 |
| Chen, M; Fan, Y; Fang, K; Meng, J; Tu, Y; Wan, L; Yu, L; Zhu, W | 1 |
| Chen, Y; Cheng, B; Cheng, Y; Gao, L; Jiang, H; Jiang, J; Shan, A; Yu, H; Zhang, Z | 1 |
| Balaz, P; Bujnakova, Z; Cholujova, D; Duraj, J; Gronesova, P; Hunakova, L; Lee, TC; Pastorek, M; Sedlak, J | 1 |
| Ho, JC; Lam, SK; Leung, LL; Li, YY; Zheng, CY | 2 |
| Fang, B; Song, Y; Wang, C; Zhao, J | 1 |
| Jiang, F; Li, Y; Li, Z; Liu, Q; Shen, J; Wang, X; Zhang, J | 1 |
| Bi, L; Jiang, L; Lin, F; Ni, W; Tan, Y; Wang, F; Wu, J; Zhang, P | 1 |
| Chen, RL; Huang, BT; Li, BS; Zeng, QC; Zhao, WH | 1 |
| He, Y; Hu, Y; Huang, R; Li, X; Wang, D; Wang, W; Xiao, R; Zhang, E | 1 |
| Bally, C; de Thé, H; Lehmann-Che, J | 1 |
| Bourouba, M; Chelbi-Alix, MK; Dutrieux, J; Maroui, MA; Nisole, S; Touil-Boukoffa, C; Zebboudj, A | 1 |
| Ai, WZ; Andreadis, C; Caballero, L; Damon, LE; Emi, N; Gaensler, KM; Greene, CC; Gupta, NK; Hwang, J; Kaplan, LD; Leavitt, AD; Logan, AC; Mahindra, A; Mannis, GN; Martin, TG; Miyazaki, Y; Naoe, T; Ohtake, S; Olin, RL; Sayre, PH; Smith, CC; Venstrom, JM; Wolf, JL; Yanada, M | 1 |
| Asou, N; Dobashi, N; Emi, N; Fujimaki, K; Gomyo, H; Hatta, Y; Kobayashi, Y; Kojima, M; Matsuo, K; Miyatake, J; Miyazaki, Y; Naoe, T; Ohnishi, K; Ohtake, S; Sakura, T; Sawa, M; Shinagawa, K; Tamaki, S; Ueda, Y; Yamazaki, E; Yanada, M | 1 |
| Lancet, JE | 1 |
| Amadori, S; Avvisati, G; Breccia, M; Cerqui, E; Cottone, F; Di Bona, E; Efficace, F; Ferrara, F; Finizio, O; Fioritoni, G; Kropp, MG; Levis, A; Lo-Coco, F; Mandelli, F; Platzbecker, U; Schlenk, RF; Sica, S; Specchia, G; Vignetti, M | 1 |
| Carlin, RF; Curcio, TJ; Feldman, EJ; Gale, L; Kligfield, PD; Provenzano-Gober, JL; Ritchie, EK; Roboz, GJ; Samuel, M | 1 |
| Arteaga, MF; Fung, TK; Mikesch, JH; So, CW | 1 |
| Chen, G; Duan, C; Gu, H; Gu, X; Liang, X; Liu, C; Luo, M; Wang, D; Zhang, H; Zhao, X; Zhao, Z | 1 |
| Chen, X; Liu, Y; Wang, C; Zhao, S; Zou, H | 1 |
| Drzewucka, J; Gackowska, L; Gagat, M; Grzanka, A; Litwiniec, A; Zuryń, A | 1 |
| Chen, HP; Chiu, YJ; King, YA; Kuo, DH; Lu, CC; Yang, JS | 1 |
| Ablain, J; de Reynies, A; de Thé, H; Halftermeyer, J; Le Bras, M; Metzger, D; Peres, L; Vitaliano-Prunier, A | 1 |
| Chen, XF; Han, DY; Sun, QX; Zhao, HB; Zhao, SG | 1 |
| Sui, M; Zhang, Z; Zhou, J | 1 |
| Bhattacharya, S; Das, A; Das, R; Haldar, PK; Haldar, S; Roy, A | 1 |
| Gore, SD; Zeidan, AM | 1 |
| Ji, H; Jiang, F; Li, Y; Shen, J; Wang, X; Yang, X; Zhang, J | 1 |
| Fujita, H | 1 |
| Gwak, HS; Jin, HO; Jung, HW; Park, IC; Park, MJ; Rhee, CH; Woo, SH | 1 |
| Jiang, F; Li, Y; Li, Z; Liu, Q; Lu, X; Shen, J; Wang, X; Zhang, J | 1 |
| Feng, L; Feng, T; Huang, Y; Qi, W; Qiao, G; Shen, Z; Yao, Y | 1 |
| Anderlini, P; Borthakur, G; Brandt, M; Cortes, J; Daver, N; Dinardo, C; Ferrajoli, A; Garcia-Manero, G; Hosing, C; Kadia, T; Kantarjian, H; Marcucci, G; O'Brien, S; Pemmaraju, N; Pierce, S; Popat, U; Ravandi, F; Verstovsek, S | 1 |
| Guo, L; Li, R; Li, W; Li, X; Mu, Y; Su, X; Wang, X; Wang, Z; Yue, Z; Zhang, H; Zhong, L | 1 |
| Nitto, T; Sawaki, K | 1 |
| Hu, J; Huang, X; Wang, X; Zhang, Y; Zhou, H | 1 |
| Ho, JC; Lam, SK; Li, YY; Zheng, CY | 2 |
| Fan, JX; Guo, KY; Li, YM; Li, ZQ; Weng, GY; Wu, JW; Zeng, YJ; Zheng, R | 1 |
| Chen, C; Jiang, X; Lai, Y; Liu, Y; Zhang, Z | 1 |
| Chen, CZ; Hu, YN; Jiang, XJ; Zhang, ZZ; Zhao, W | 1 |
| Chen, C; Jiang, X; Liu, Y; Zhang, P; Zhang, Z | 1 |
| Altman, JK; Beauchamp, EM; Kosciuczuk, EM; Nanavati, D; O'Halloran, TV; Platanias, LC; Serrano, R; Swindell, EP; Viollet, B | 1 |
| Barakat, S; Couban, S; Lachaine, J; Mathurin, K | 1 |
| Jiang, C; Li, Y; Wang, J | 1 |
| Gescher, J; Kögler, F; Küsel, K; Majzlan, J; Mangold, S; Neu, TR; Plášil, J; Rothe, J; Rusznyak, A; Škoda, R | 1 |
| Feng, PF; Li, BX; Shi, YQ; Wang, X; Yan, CC; Zhang, R; Zhang, X; Zhao, X | 1 |
| Honma, Y; Kasukabe, T; Kato, N; Kumakura, S; Okabe-Kado, J | 1 |
| Benbijja, M; Bobé, P; Mellouk, A | 1 |
| Chen, K; Huang, H; Li, B; Xie, SL; Yang, MH; Zang, YS; Zhao, XW | 1 |
| Jin, J; Qian, W; Tong, H; Wang, Y; Xu, W | 1 |
| He, C; Jiang, H; Jiang, X; Ma, L; Sun, X; Xu, L; Zhai, B; Zhao, D | 1 |
| Barakat, S; Lachaine, J; Mathurin, K; Schuh, AC | 1 |
| Chen, C; Gu, S; Jiang, X; Zhang, Z | 3 |
| Chen, C; Shi, W; Sun, M; Wang, Z; Yang, Q; Zhang, Y; Zhou, X | 1 |
| Bandi, S; Dogra, S; Gupta, S; Viswanathan, P | 1 |
| Alvarez, EM; Blanco, GA; Cavaliere, V; Costantino, SN; Kornblihtt, L; Lombardo, T | 1 |
| Chen, L; Guo, M; Guo, Y; Li, Q; Muhammad, F; Wang, A; Wang, N; Zhao, J; Zhu, G | 1 |
| Chiu, HW; Foo, NP; Guo, HR; Hsu, YH; Lin, YF; Tseng, YC; Wang, YJ | 1 |
| Bi, C; Cai, B; Chen, H; Feng, D; Li, X; Liang, J; Ma, W; Wang, Y; Yang, F; Yin, K; Zhao, L | 1 |
| Gartel, AL; Halasi, M; Pandit, B | 1 |
| Ling, S; Sun, D; Tian, Y; Wang, L; Yang, X | 1 |
| Hatakeyama, N; Hori, T; Igarashi, K; Inazawa, N; Noguchi, H; Sasaki, M; Somekawa, Y; Suzuki, N; Tsutsumi, H; Yamamoto, M | 1 |
| Deng, J; Li, Y; Luo, Q; Zhang, Z | 1 |
| Chen, X; Dong, K; He, T; Li, J; Lin, F; Long, M; Ouyang, Y; Wang, X; Wei, J; Weng, Y; Zhang, H | 1 |
| Bashey, A; Carraway, HE; Gore, SD; Holland, K; Leech, M; Morris, L; Pratz, K; Smith, BD; Solomon, S; Stewart, M; Zeidan, AM; Zhang, X | 1 |
| Aksakal, O; Esim, N | 1 |
| He, X; Hu, BS; Huang, JW; Li, Y; Liu, B; Lu, LG; Zhao, W; Zheng, YB | 1 |
| Aller, P; Boyano-Adánez, Mdel C; Calviño, E; Calvo, S; de Blas, E; Estañ, MC; Guillén-Guío, B; Rial, E | 1 |
| Gagat, M; Grzanka, A; Izdebska, M; Klimaszewska-Wiśniewska, A; Lewandowski, D; Marcin Nowak, J | 1 |
| Fu, H; Shen, J; Wu, D | 1 |
| Huang, HS; Liu, ZM; Tseng, HY; Wu, WJ; Yeh, BW | 1 |
| Bhattacharya, S; Das, A; Das, R; Haldar, PK; Kumari, U; Roy, A | 1 |
| Fang, BJ; Lin, QD; Liu, Y; Song, YP; Wang, C; Zhang, YL; Zhao, JM; Zhou, J | 1 |
| Chen, TY; Chen, ZG; Gao, X; Huang, CW; Huang, XC; Li, ZB; Maimaiti, XY; Zhang, L | 1 |
| Boobis, AR; Dabrowska, A; Hajji, N; Housein, Z; Mayán, MD; Rahman, S | 1 |
| Guo, W; Jiao, G; Ren, C; Ren, T; Yang, K | 1 |
| Ely, EA; Palazzolo, DL | 1 |
| Firkin, F; Ho, WK; Roncolato, F | 1 |
| Ades, L; Breccia, M; Cassinat, B; Di Bona, E; Fenaux, P; González-Sanmiguel, JD; Görlich, D; Grimwade, D; Hofmann, WK; Huerta, AJ; Kishore, B; Lambert, JF; Lehmann, S; Lengfelder, E; Lo-Coco, F; Montesinos, P; Nloga, AM; Pagoni, M; Ramadan, SM; Sanz, M; Sauerland, MC; Schmidt, A | 1 |
| Lin, LS; Niu, G; Wu, Y; Xie, FP | 1 |
| Cifuentes, F; Nwokocha, CR; Palacios, J | 1 |
| Du, Y; Li, NN; Lyu, FF; Wang, W | 1 |
| Chi, X; Gao, J; Li, H; Liu, H; Wang, X; Yin, Z; Zhang, H; Zhang, Z; Zhao, Z; Zhu, X | 1 |
| Hong, L; Kong, D; Qiao, Z; Shi, W; Sun, G; Zhang, Y; Zhao, H; Zhao, M | 1 |
| Bi, Y; Chen, X; Cho, K; Hou, X; Li, C; Liu, H; Liu, Y; Peng, F; Shen, C; Wang, K; Wang, X; Yang, Z; Zhang, J; Zhang, W; Zhang, X; Zhao, S; Zheng, Z; Zhong, C; Zou, H | 1 |
| Dai, L; Li, P; Liu, Y; Song, T; Wang, L; Wang, Z; Zhang, H | 1 |
| Chang, HR; Lu, FJ; Ting, HC; Tsai, ML; Yen, CC | 1 |
| Jan, SU; Khan, H; Khan, MF; Mukhtiar, M; Rehman, AU; Ullah, N | 1 |
| Bai, X; Guo, K; Guo, Z; He, H; He, X; Qiu, D; Wang, J; Weng, G; Xu, X; Ye, Y; Yi, W; Zhang, M; Zhou, R | 1 |
| Raghu, KG; Soumya, RS; Vineetha, VP | 1 |
| Banfic, H; Dembitz, V; Lalic, H; Ostojic, A; Visnjic, D; Vrhovac, R | 1 |
| Ge, JB; Liu, XB; Qian, JY; Shen, L; Sun, AJ; Wu, YZ; Yang, W; Yin, JS | 1 |
| Chai, H; Guo, G; Guo, Y; He, Y; Tian, L; Xing, M; Zhang, K; Zhang, W; Zhao, P | 1 |
| Cheng, YL; Huang, HS; Liu, ZM; Tseng, HY; Wu, WJ; Yeh, BW | 1 |
| Brunetti, L; Di Raimondo, F; Falini, B; Gionfriddo, I; Martelli, MP; Mezzasoma, F; Milano, F; Mulas, F; Pacini, R; Pettirossi, V; Pierangeli, S; Rossi, R; Sportoletti, P; Tabarrini, A; Tiacci, E; Vetro, C | 1 |
| Ades, L; Bazarbachi, A; Berthier, C; Darwiche, N; Dassouki, Z; de Thé, H; Dombret, H; El Hajj, H; Fenaux, P; Hleihel, R; Legrand, O; Mohty, M; Raffoux, E; Sahin, U; Salameh, A; Tawil, N; Zibara, K | 1 |
| Ding, Y; Feng, G; Guo, S; Jing, M; Li, F; Li, S; Ma, R; Ma, X; Niu, Q; Pang, L; Tang, JX; Wang, HX; Wei, M; Xu, S; Yan, Y; Zhang, J; Zhang, Q | 1 |
| Wang, X; Zhang, M | 1 |
| Abraham, A; Aiyaz, M; Alex, AA; Balasubramanian, P; Chandy, M; Chendamarai, E; Chomienne, C; Ganesan, S; George, B; Janet, NB; Kamath, V; Lakshmi, KM; Mathews, V; Mugasimangalam, R; Mullapudi, N; Nair, SC; Nellickal, AJ; Padua, RA; Srivastava, A; Srivastava, V; Viswabandya, A | 1 |
| An, B; Hao, Y; Li, L; Song, G; Wang, L; Wang, Y; Wei, T; Yin, C | 1 |
| Inomata, T; Sunami, K | 1 |
| Chang, SH; Ha, WS; Hong, SC; Jung, JM; Kim, DC; Kim, G; Kim, HJ; Lee, JH; Lee, WS; Lu, JN; Nagappan, A; Park, HS; Yun, JW | 1 |
| Guo, QL; Jiang, NJ; Liu, WJ; Xu, Q | 1 |
| Behtash, S; Nafisi, S; Shooshtary, S | 1 |
| Amigo-Jiménez, I; García-Marco, JA; García-Pardo, A; Lozano-Santos, C; Nova-Gurumeta, S; Pérez-Sanz, N | 1 |
| Clewell, HJ; Efremenko, AY; Gentry, PR; Seagrave, J; Van Landingham, C; Yager, JW | 1 |
| Coombs, CC; Tallman, MS; Tavakkoli, M | 1 |
| Chen, CM; Du, JK; Lu, PC; Wu, JH | 1 |
| Bhattacharya, S; Chakraborty, A; Chattopadhyay, A; Srivastava, R | 1 |
| Canesastraro, M; Di Raimondo, F; Galimberti, S; Nagy, B; Palumbo, G; Petrini, M; Savlı, H; Sünnetçi, D | 1 |
| Li, Q; Li, Y; Liu, H; Liu, R; Shen, X; Wang, W; Yu, G | 1 |
| Du, J; Fan, J; Fu, W; He, J; Hou, J; Li, R; Liu, S; Liu, X; Qu, Y; Xi, H; Yan, W; Yang, J; Zhang, C | 1 |
| Cheng, P; Gao, C; Jiang, J; Jin, N; Leng, Y; Li, C; Li, J; Li, Q; Lian, Y; Lin, Y; Ma, P; Peng, Y; Qi, Z; Wang, F; Wang, L; Xia, J; Zhao, B | 1 |
| Deng, JJ; Li, Y; Luo, QY; Zhang, ZZ | 1 |
| Ma, H; Yang, J | 1 |
| Bernardi, R; Coltella, N; Ponente, M; Ponzoni, M; Valsecchi, R | 1 |
| Chan, TS; Chau, D; Cheng, YY; Fong, B; Kwong, YL; Ng, K; Tam, S; Tse, E | 1 |
| Mason, RP; Sarkaria, JN; Zhang, L; Zhang, Z; Zhao, D | 1 |
| Guo, G; Guo, Y; Hu, Z; Tian, L; Xing, M; Zhang, K; Zhang, W; Zhao, P | 1 |
| Lai, Y; Li, Y; Luo, Q; Zhang, Z | 1 |
| Eyler, R; Moeller, J; Patel, K; Perreault, S; Pham, T; Podoltsev, N; Russell, K | 1 |
| Bhatnagar, V; Carter-Cooper, B; Emadi, A; Lapidus, RG; Levis, MJ; Sadowska, M; Sausville, EA; van der Merwe, I | 1 |
| Gao, JK; Long, B; Su, JN; Wang, LX; Wang, ZW; Ye, XT; Yin, XY; Zhou, XX | 1 |
| Jin, J; Li, F; Lu, Y; Mai, W; Meng, H; Mu, Q; Pei, R; Qian, W; Tong, H; Yu, M; Zhao, X | 1 |
| Jin, G; Liu, D; Liu, Y; Sun, Z; Wang, C; Wang, H; Wang, X; Yu, S; Zhang, B | 1 |
| Fukami, T; Fukuda, M; Hojo, M; Inubushi, T; Miyamoto, S; Muraki, K; Nozaki, K; Onishi, N; Saiki, M; Satow, T; Saya, H; Shiino, A; Tanigaki, K; Yamada, S; Yoshimura, Y | 1 |
| Gao, C; Guan, T; Li, C; Lin, Y; Lv, C; Qi, Z; Xia, J; Yan, G; Zhu, M | 1 |
| Gao, B; Lu, M; Meng, X; Miao, Z; Qiao, X; Wu, L; Xue, D; Zhang, W | 1 |
| Guo, G; Guo, Y; Hu, Z; Sun, Y; Tian, L; Xing, M; Zhang, K; Zhang, W; Zhang, X; Zhao, P | 1 |
| Chen, X; Guo, S; Qin, N; Zhang, X | 1 |
| Chen, SJ; Chen, Z; Mi, JQ; Yan, XJ; Zhou, GB | 1 |
| Anania, VG; Fasci, D; Lill, JR; Salvesen, GS | 1 |
| Chen, P; Huang, H; Jiang, X; Wu, J; Yuan, Q | 1 |
| Jiang, Z; Tang, J; Wang, C | 1 |
| Dong, S; Liu, C; Liu, L; Yong, D; Yu, D; Zhai, J; Zhu, C | 1 |
| Geng, Z; Ouyang, J; Wang, S; Wang, Z; Zhou, M | 1 |
| Cui, LY; Ren, JH; Zhang, J; Zhang, YL | 1 |
| Alimoghaddam, K; Ghaffari, SH; Ghavamzadeh, A; Hosseini, E; Shidfar, F; Tavoosidana, G | 1 |
| Cao, Y; Fan, J; He, YF; Hu, B; Huang, XW; Qiu, SJ; Sun, C; Sun, YF; Wang, Z; Yang, XR; Zeng, HY; Zhang, X; Zhou, J | 1 |
| Sun, B; Xing, M | 1 |
| Chen, Z; Chen, ZZ; Jiang, JP; Li, J; Lin, SY; Qian, WB; Shen, YY; Wang, B; Wu, LQ | 1 |
| Huang, J; Jin, J; Lou, Y; Ma, Y; Mai, W; Mao, L; Meng, H; Ni, W; Pan, H; Qian, W; Suo, S; Tong, H; Wang, Y; Wei, J; Yu, W | 1 |
| Hao, J; He, X; Li, J; Li, X; Peng, Y; Si, W | 1 |
| Ding, YS; Feng, GL; Jing, MX; Li, F; Li, SG; Liu, JM; Ma, RL; Ma, XM; Niu, Q; Pang, LJ; Wang, K; Xiang, HL; Xu, SZ; Zhang, XF | 1 |
| de Thé, H | 1 |
| Bao, N; Gu, H; Li, W; Li, Y; Liu, S; Wang, Q; Yu, C | 1 |
| Allen, SL; Altman, JK; Cortes, JE; Coutre, S; Di Bona, E; Kantarjian, H; Lo-Coco, F; Ravandi, F; Sanford, D; Sanz, MA; Wetzler, M | 1 |
| Bu, N; Cao, FL; Naranmandura, H; Wang, QQ; Zhang, YF; Zhou, J; Zhou, XY | 1 |
| Cheng, HC; Cheng, M; Li, W; Liu, SW; Ma, J; Qiu, L; Zhao, X; Zhao, XF | 1 |
| Armat, M; Bakhshaiesh, TO; Baradaran, B; Hejazi, MS; Samadi, N; Shanehbandi, D; Sharifi, S | 1 |
| Chai, H; Guo, G; Sun, X; Xing, M; Zhang, K; Zhang, W; Zhao, P | 1 |
| Barnes, G; Kruse, M; Lo-Coco, F; Martin, M; Mueller, U; Pathak, A; Wildner, R | 1 |
| Bi, Y; Ge, HY; Han, ZJ; Liu, P; Sun, WJ; Tian, P; Xue, DX; Yang, ZH | 1 |
| Chai, H; Guo, G; Guo, Y; He, Y; Li, S; Sun, X; Sun, Y; Tian, L; Xing, M; Zhang, K; Zhang, W; Zhao, P | 1 |
| Chan, R; Feddock, JM; Jyoti, A; Langner, UW; Nagarajan, R; O'Halloran, TV; Sethi, P; Swindell, EP; Upreti, M | 1 |
| Li, R; Mou, Y; Wang, X; Wang, Y; Wang, Z; Xia, J; Yue, Z; Zhang, H; Zhong, L | 1 |
| Chen, B; Chen, C; Chen, L; Chen, SJ; Chen, Z; Fu, YK; Gu, ZH; Hu, J; Jin, J; Li, JM; Lou, YJ; Mi, JQ; Shen, Y; Shen, ZX; Shi, JY; Wang, ZY; Zhao, WL; Zhu, HH; Zhu, HM; Zhu, YM | 1 |
| Clarke, KM; Mills, KI; Young, CS | 1 |
| He, J; Jin, J; Lou, Y; Ma, Y; Mai, W; Meng, H; Pan, H; Qian, W; Sun, J; Tong, H; Wang, Y; Ye, X | 1 |
| Kong, P; Ma, Y; Shen, Z; Yang, S; Zeng, D; Zhang, X; Zou, Z | 1 |
| Aznab, M; Rezaei, M | 1 |
| Chen, SJ; Cui, W; Fei, AM; Gressin, R; Hermine, O; Khochbin, S; Liu, YF; Mi, JQ; Miao, SC; Peng, LJ; Wang, J; Zhao, LL | 1 |
| He, XW; Yan, W; Yang, W | 1 |
| Jiang, Y; Li, F; Lv, H; Peng, X; Wang, B; Wang, Z; Xing, G; Zhang, S | 1 |
| Chai, H; Guo, G; Guo, Y; He, Y; Li, S; Sun, X; Xing, M; Zhang, K; Zhang, W; Zhao, P | 1 |
| Chiu, CY; Lan, KC; Liu, SH; Tsai, KS; Yang, RS; Yen, YP | 1 |
| Barnes, G; Kruse, M; Lo-Coco, F; Martin, M; Mueller, U; Tallman, M; Tang, B; Wildner, R | 1 |
| Bowen, D; Burnett, AK; Clark, RE; Friis, L; Grech, A; Grimwade, D; Hills, RK; Hunter, A; Jones, G; Kell, J; Khwaja, A; Knapper, S; Lok, J; McMullin, MF; Morgan, YG; Russell, NH | 1 |
| Agar, G; Arslan, E; Aydin, M; Erturk, FA; Sigmaz, B; Taspinar, MS; Yagci, S | 1 |
| Han, S; Huang, XJ; Jiang, H; Jiang, Q; Liang, GW; Shi, LW; Zhu, HH | 1 |
| Cui, YX; Liu, KY; Liu, Y; Tan, XJ; Wang, YC; Zhou, H | 1 |
| Chang, JP; Liu, C; Sun, SB; Tao, XC; Yang, SM; Yang, TY; Yang, Y; Yang, YM; Zhang, HP; Zhang, XY | 1 |
| Alberto Redi, C; Cebral, E; Fassina, L; Garagna, S; Rebuzzini, P; Zuccotti, M | 1 |
| Cottone, F; Efficace, F; Lo Coco, F; Mandelli, F; Platzbecker, U | 1 |
| Chen, Z; Ma, X; Shen, L; Yu, Y; Zhang, G; Zhou, L; Zhu, F; Zou, J | 1 |
| He, XJ; Liu, BL; Yu, L; Zhang, BY; Zhao, YY | 1 |
| Jiang, C; Su, Y; Wang, F; Zhang, L | 1 |
| Aviram, A; Klein, A; Muchtar, E; Oniashvili, N; Parnes, D; Raanani, P; Rabizadeh, E; Shepshelovich, D; Yeshaya, J | 1 |
| Cai, Y; Ding, J; Dong, L; Hu, L; Jin, J; Liu, D; Wang, F; Wu, D; Yang, Y; Zhao, L; Zhao, X | 1 |
| Bau, DT; Chang, WS; Chung, JG; Hsia, TC; Hsieh, YH; Hsu, CM; Tsai, CW; Yang, MD | 1 |
| Cantú-Rodríguez, OG; Gómez-Almaguer, D; Gómez-De León, A; González-Leal, XJ; Gutiérrez-Aguirre, H; Jaime-Pérez, JC; Pinzón-Uresti, MA | 1 |
| Chen, T; Chen, W; Deng, H; Jian, Y; Li, J; Shan, Z; Zeng, H; Zhang, J; Zhou, H | 1 |
| Bao, S; Bian, XW; Cheng, L; Chu, CW; Fang, X; Huang, Z; Ke, SQ; Rich, JN; Shi, Y; Xie, Q; Zhou, W | 1 |
| Liu, SZ; Qiao, GF; Wu, D; Xu, WX; Yan, J | 1 |
| Ren, YQ; Wang, LL | 1 |
| Cai, XH; Chen, BA; Cheng, J; He, ZM; Sheng, F; Wang, CL; Zhang, LJ; Zhang, Y | 1 |
| Matsushita, H | 1 |
| Huang, XJ; Jiang, H; Jiang, Q; Liu, J; Zhu, HH | 1 |
| Aguilera-Montilla, N; Amigo-Jiménez, I; Bailón, E; García-Marco, JA; García-Pardo, A; Terol, MJ | 1 |
| Furukawa, T; Ishidou, Y; Komiya, S; Maeda, S; Nagano, S; Nagao-Kitamoto, H; Nagata, M; Nakamura, S; Saitoh, Y; Setoguchi, T; Tanimoto, A; Tsuru, A; Yokouchi, M | 1 |
| Chen, Z; Hu, R; Li, W; Lu, H; Zhang, T | 1 |
| Choi, JH; Chung, HJ; Hwang, DW; Kim, ES; Kim, JS; Kim, S; Lee, SK; Lee, YY; Park, BB; Uhm, J; Won, YW; Yi, JH; Yoon, JS | 1 |
| Gu, H; Li, L; Ren, Y; Zhang, H; Zhang, L | 1 |
| Chen, J; Cheng, L; Fang, B; Hong, H; Ma, C; Ma, J; Pang, H; Shi, Y; Wang, Z; Xia, J; Zeng, F; Zhang, S | 1 |
| Chen, Z; Czajkowsky, DM; Ge, F; Guo, SJ; Le, HY; Ling, JY; Liu, B; Tao, SC; Wang, JF; Wu, SF; Xiong, Q; Yan, W; Yang, L; Yang, MK; Zhang, HN; Zhang, XW; Zhou, YM; Zhu, H | 1 |
| Choe, TB; Hong, SE; Jin, HO; Kim, EK; Kim, HA; Lee, JK; Lee, YH; Noh, WC; Oh, ST; Park, IC; Seong, MK; Woo, SH; Ye, SK; Yun, SM | 1 |
| Bolduc, DL; Ghaffari, MA; Javadipour, M; Keshtzar, E; Khodayar, MJ; Rezaei, M | 1 |
| Ablain, J; de Thé, H; Esnault, C; Lehmann-Che, J; Poirot, B | 1 |
| Kolb, EA; Meshinchi, S | 1 |
| Adès, L; Alex, AA; Chomienne, C; Fenaux, P; Ganesan, S; Gorombei, P; Guerenne, L; Krief, P; Mathews, V; Omidvar, N; Padua, RA; Patel, S; Pla, M; Schlageter, MH; West, R | 1 |
| Černelč, P; Falnoga, I; Podgornik, H; Šlejkovec, Z | 1 |
| Grzanka, A; Klimaszewska-Wiśniewska, A; Krajewski, A; Litwiniec, A; Żuryń, A | 1 |
| Boehme, KA; Handgretinger, R; Hopp, U; Kluba, T; Riester, R; Schleicher, SB; Schweiss, SK; Traub, F; Zaborski, JJ | 1 |
| Bashford, J; Bradstock, K; Browett, P; Campbell, LJ; Catalano, A; Collins, M; Di Iulio, J; Filshie, R; Firkin, F; Grigg, A; Hertzberg, M; Hugman, A; Iland, HJ; Moore, J; Reynolds, J; Seldon, M; Seymour, JF; Supple, SG; Szer, J; Taper, J; Taylor, K; Tiley, C | 1 |
| Al Ustwani, O; Griffiths, EA; Torka, P; Wang, ES; Wetzler, M | 1 |
| Guo, CG; Peng, ZY; Sun, JH; Xu, SL; Zou, Y | 1 |
| Falchi, L; Kantarjian, HM; Ravandi-Kashani, F; Verstovsek, S | 1 |
| Cairoli, R; Cicconi, L; Divona, M; Iaccarino, L; Lo-Coco, F; Ottone, T; Voso, MT | 1 |
| Carrasquillo, JA; Cheung, NK; Kramer, K; Kushner, BH; Larson, SM; Modak, S; Pandit-Taskar, N; Zanzonico, P | 1 |
| Degos, L | 1 |
| Ally, MS; Atwood, SX; Bailey-Healy, I; Beachy, PA; Chang, AL; Colevas, AD; Kim, J; Oro, A; Ransohoff, K; Rezaee, M; Sarin, K; Tang, JY | 1 |
| Bai, J; Chen, M; Jiang, L; Kong, Y; Liu, S; Liu, X; Qi, B; Qiu, T; Sun, X; Yang, G; Yao, X; Zheng, Y | 1 |
| Cao, Z; Chen, X; Cui, L; Gao, B; Zhang, S; Zhang, W | 1 |
| Khadwal, A; Malhotra, P; Saikia, UN; Yanamandra, U | 1 |
| Adachi, K; Honma, Y; Kawakami, K; Miyake, T; Suzumiya, J; Takahashi, T | 1 |
| Gerber, JM; Grunwald, MR; Lipford, EH; McDonnell, MH; Smith, ET | 1 |
| Li, D; Luo, D; Wu, S; Zhang, Y; Zhou, J | 1 |
| Amini-Khoei, H; Amiri, S; Dehpour, AR; Haj-Mirzaian, A; Hosseini, MJ; Jahanabadi, S; Khedri, M; Mehr, SE; Mohammadi-Asl, A; Momeny, M; Rahimi-Balaei, M | 1 |
| Hu, L; Huang, L; Li, C; Meng, F; Tang, Y; Wan, K; Wang, Y; Xu, D; Zhou, J | 1 |
| Altman, JK; Norsworthy, KJ | 1 |
| Anselmo-Franci, JA; Barbosa Junior, F; Borges, Cdos S; da Silva, RF; Kempinas, Wde G; Kiguti, LR; Missassi, G; Pupo, AS; Villela E Silva, P | 1 |
| Chi, X; Gao, J; Liu, H; Shan, H; Zhang, Z; Zhao, Z; Zhou, H; Zhu, X | 1 |
| Chen, Y; Cheng, Y; Li, H; Li, Y; Ma, C; Mu, Q; Song, Y; Xu, H; Xu, S; Yu, H; Zhao, G | 1 |
| Cao, F; Ge, F; Hou, J; Li, H; Li, J; Li, L; Li, X; Liu, S; Lv, C; Su, Y; Wang, P; Wang, S; Xu, M; Zhang, Y; Zhou, J | 1 |
| Bhatt, P; Jadhav, V; Ray, P; Sachdeva, G | 1 |
| Chen, C; Hu, H; Li, H | 1 |
| Li, Y; Liu, J; Ma, X; Ye, BC; Zhang, B; Zuo, P | 1 |
| Himeno, S; Sumi, D; Suzukawa, K | 1 |
| Lo-Coco, F; Testa, U | 1 |
| Chen, FY; Gu, ZJ; Kulkarni, P; Li, JQ; Li, L; Liu, L; Mason, RP; Tang, BB; Tang, Q; Yi, JW | 1 |
| Bott, AJ; Catanzaro, JM; Chen, JS; Diaz-Meco, MT; Ding, WX; Dou, Z; Du, C; Jaber, N; Jiang, YP; Lin, RZ; Moscat, J; Ozato, K; Pan, JA; Sun, Y; Yang, B; Zong, WX | 1 |
| Hao, L; Lu-Qun, W; Ran, W; Xiang-Xin, L; Xiao-Ning, Y | 1 |
| Assaf, C; Beyer, M; Cosagarea, I; Möbs, M; Touba, R; Vandersee, S | 1 |
| Di Donato, L; Lo-Coco, F; Schlenk, RF | 1 |
| Li, L; Liu, Y; Pan, C; Wang, D; Zen, K; Zhang, CY; Zhu, D; Zhuo, J | 1 |
| Blondeau, S; Bouyer, S; Colin, O; Houeto, JL; Julian, A; Meurin, E; Neau, JP; Puyade, M | 1 |
| Falck, H; Galloway, JM; Macumber, AL; Nasser, NA; Neville, LA; Palmer, MJ; Patterson, RT; Roe, HM; Sanei, H; Spence, C | 1 |
| Chung, H; Jo, S; Kim, S; Lee, H; Lee, YL | 1 |
| Berger, W; Cichna-Markl, M; Englinger, B; Grillari, J; Heffeter, P; Körner, W; Kryeziu, K; Mohr, T; Pirker, C; Spitzwieser, M; Tav, K; van Schoonhoven, S; Weinmüllner, R | 1 |
| Alimoghaddam, K; Bashash, D; Dizaji, MZ; Ghaffari, SH; Ghavamzadeh, A; Momeny, M; Yousefi, M; Zekri, A | 1 |
| Chen, Z; Guo, S; Jiang, H; Li, Y; Tao, S; Yang, L; Zhang, H | 1 |
| Fei, W; Guo, M; Li, F; Liu, Y; Wei, Y; Xiao, X; Zhang, R; Zhang, Y; Zheng, G; Zheng, H | 1 |
| Alimoghaddam, K; Devlin, S; Douer, D; Esteve, J; Ganzel, C; Ghavamzadeh, A; Kuk, D; Mathews, V; Mohty, M; Nagler, A; Polge, E; Rowe, JM; Tallman, MS; Wang, H; Weisdorf, D; Zhang, MJ | 1 |
| Javadipour, M; Keshtzar, E; Khodayar, MJ; Rezaei, M | 1 |
| Albano, F; Alfonso, V; Amadori, S; Avvisati, G; Breccia, M; Cerqui, E; Ciardi, C; Cicconi, L; Di Bona, E; Divona, M; Ferrantini, A; Ferrara, F; Kropp, MG; Lavorgna, S; Levis, A; Lo-Coco, F; Mandelli, F; Ottone, T; Paoloni, F; Piciocchi, A; Santoro, A; Sborgia, M; Sica, S; Voso, MT | 1 |
| Bechara, R; Chen, Z; Deng, X; Khuri, FR; Kim, HS; Owonikoko, TK; Pakkala, S; Pillai, R; Ramalingam, SS; Rossi, MR; Saba, NF; Sica, GL; Stinson, RM; Sun, SY; Zhang, C; Zhang, G | 1 |
| Chen, YX; Zhang, PY; Zhang, WG; Zhang, WJ; Zhao, X | 1 |
| Chen, Y; Hao, JX; Ren, J; Wang, XN; Zhang, M | 1 |
| Chen, G; Hu, Q; Jiang, S; Li, T; Mao, J; Nie, X; Wang, C; Wang, X; Xu, L; Yang, J; Zhang, Y | 1 |
| Cheng, LN; Fu, JZ; Jiao, ZX; Jin, N; Leng, Y; Ni, SB; Qi, ZQ; Wang, JH; Wu, HQ; Xia, JJ | 1 |
| Chen, Y; Guan, X; Li, F; Li, N; Li, X | 1 |
| Dong, J; Hao, J; Huang, C; Lan, C; Lang, M; Li, X; Ren, H; Wang, H; Wang, X; Yang, S; Yang, Y; Yu, M | 1 |
| Afroze, D; Azad, NA; Aziz, SA; Baba, SM; Dar, FA; Jan, A; Pandith, AA; Shah, ZA | 1 |
| Chan, R; Evers, BM; Feddock, JM; Johnson, SE; Jyoti, A; Napier, D; O'Halloran, TV; Sethi, P; Swindell, EP; Upreti, M; Weiss, HL | 1 |
| Markman, TM; Nazarian, S | 1 |
| Gu, SY; Hu, YN; Zhang, ZZ | 1 |
| Bai, J; Gao, N; Guan, H; Jiang, L; Liu, S; Qiu, T; Sun, X; Wu, W; Yang, G; Yang, L; Yao, X; Zhang, Q | 1 |
| Koike, S; Nishimoto, S; Ogasawara, Y; Suzuki, T; Takagi, N; Yuan, B | 1 |
| Gu, X; Niu, Z; Qi, Y; Zhang, W; Zhang, X; Zhang, Y | 1 |
| Atashrazm, F; Dickinson, JL; Holloway, AF; Lowenthal, RM; Woods, GM | 1 |
| Han, H; Hu, S; Jiang, L; Lu, C; Su, S; Wang, Y; Xiang, J | 1 |
| Jin, J; Liu, L; Lou, Y; Ma, Y | 1 |
| Albano, F; Amadori, S; Avvisati, G; Borlenghi, E; Brandts, CH; Breccia, M; Brossart, P; Cairoli, R; Cicconi, L; Cortelezzi, A; D'Arco, AM; Di Bona, E; Di Renzo, N; Divona, M; Döhner, H; Döhner, K; Efficace, F; Ehninger, G; Fabbiano, F; Fazi, P; Ferrara, F; Fiedler, W; Fozza, C; Frairia, C; Ganser, A; Hänel, M; Hertenstein, B; La Nasa, G; Link, H; Lo-Coco, F; Lübbert, M; Mandelli, F; Melillo, L; Paoloni, F; Platzbecker, U; Pogliani, EM; Rambaldi, A; Röllig, C; Salih, HR; Sborgia, M; Schlenk, RF; Schmitz, N; Thiede, C; Vignetti, M; Wattad, M | 1 |
| Chen, L; Chen, Q; Chen, S; Chen, Y; Chen, Z; Hu, J; Li, J; Li, X; Mi, J; Shen, Z; Sun, H; Wang, A; Wang, L; Wang, Z; Zhang, Y; Zhao, H; Zhao, W; Zhao, X; Zhou, W; Zhu, H | 1 |
| Akbari, ME; Bashash, D; Bayati, S; Ghaffari, SH; Nooshinfar, E; Rezaei-Tavirani, M; Safaroghli-Azar, A | 1 |
| Fan, J; Guo, K; Li, Y; Li, Z; Weng, G; Wu, J; Xia, P; Zeng, Y; Zheng, R | 1 |
| Chen, XY; Fan, XY; Jiang, FL; Liu, Y; Liu, YJ; Zhong, HM | 1 |
| Athar, M; Deshane, JS; Elmets, CA; Harrod, KS; Li, C; Srivastava, RK; Wang, Y; Weng, Z | 1 |
| Béné, MC; Bonnet, A; Chevallier, P; Garandeau, C; Garnier, A; Guillaume, T; Houreau-Langlard, D; Hourmant, M; Le Gouill, S; Moreau, P; Peterlin, P; Tissot, A; Vantyghem, S | 1 |
| Fan, RF; Fang, ZG; Lin, DJ; Liu, XF; Lu, Y; Pan, GZ; Zhai, FX | 1 |
| Boedicker, C; Fulda, S; Graab, U; Hahn, H; Hugle, M; Klingebiel, T; Meister, MT | 1 |
| Bonora, M; Gafà, R; Giorgi, C; Kroemer, G; Lanza, G; Magri, E; Missiroli, S; Pandolfi, PP; Patergnani, S; Perrone, M; Pinton, P; Poletti, F; Raimondi, A; Tacchetti, C | 1 |
| Aldaz, P; Anguita, J; Aransay, AM; Arreal, L; Arruabarrena-Aristorena, A; Barrio, R; Baselga, J; Caldas, C; Caro-Maldonado, A; Carracedo, A; Cortazar, AR; Domenici, G; Fernández-Ruiz, S; Garcia, S; Gomis, RR; Guiu, M; Ibrahim, YH; Iovanna, JL; Lawrie, CH; Macías, I; Martín-Martín, N; Martínez-Chantar, ML; Matheu, A; Piva, M; Planet, E; Radosevic-Robin, N; Rueda, OM; Salvador, F; Sánchez-Mosquera, P; Scaltriti, M; Serra, V; Sutherland, JD; Torrano, V; Urosevic, J; Valcárcel-Jiménez, L; Varela-Rey, M; Vivanco, Md; Zabala-Letona, A; Zúñiga-García, P | 1 |
| Abraham, A; Aiyaz, M; Alex, AA; Balasubramanian, P; Balasundaram, N; Chendamarai, E; Chomienne, C; David, S; Ganesan, S; George, B; Korula, A; Kulkarni, U; Mathews, V; Mugasimangalam, R; Padua, RA; Palani, HK; Srivastava, A | 1 |
| Bao, X; Guo, W; Huang, Y; Liu, K; Ren, T; Wang, S; Zhang, F; Zheng, B | 1 |
| Chang, KL; Cheng, HL; Chiu, PR; Hsieh, BS; Hu, YC; Huang, LW; Huang, TC | 1 |
| Diemer, F; Marty, M; Noirrit-Esclassan, E | 1 |
| Chen, CW; Cheng, TJ; Guo, HR; Lin, SW; Wang, YJ | 1 |
| Chen, M; Cheng, X; Fan, X; Ji, J; Song, J; Wu, F; Ying, X; Zhang, D; Zhao, Z | 1 |
| Cen, JN; Gao, HQ; Hua, HY; Sun, AN; Wu, LL | 1 |
| Boehme, KA; Handgretinger, R; Kluba, T; Nitsch, J; Riester, R; Schleicher, SB; Traub, F | 1 |
| Ren, D; Zhu, J | 1 |
| Chai, H; Guo, Y; Xing, H; Xing, M; Zhang, W; Zhao, P | 1 |
| Atsuta, Y; Emi, N; Gotoh, M; Hashimoto, H; Henzan, H; Ichinohe, T; Kanamori, H; Kanda, Y; Kohno, A; Kurokawa, M; Mori, T; Murata, M; Nishikawa, A; Sawa, M; Takami, A; Tomita, N; Watakabe, K; Yanada, M; Yano, S | 1 |
| Alvarez-Guaita, A; Buechler, C; Eisinger, K; Enrich, C; Grewal, T; Haberl, EM; Krautbauer, S; Neumeier, M; Pohl, R; Rein-Fischboeck, L; Rentero, C | 1 |
| Cai, Y; Chen, W; Du, X; Huang, J; Lou, J; Sun, M; Wang, Z; Zhang, Q | 1 |
| Fan, L; Feng, H; Jia, B; Lan, F; Li, L; Liu, Q; Wang, T; Wang, Y; Xiao, W; Xing, G; Ye, W; Yue, X; Zhao, L; Zhou, C | 1 |
| Chang, Y; Jiang, M; Zhou, Q; Zhou, R; Zhu, C | 1 |
| Ai, Z; Chen, J; Cheng, J; Lin, L; Liu, Z; Wang, B; Wei, H; Xie, B; Yang, Y; Yi, J; Zhao, H | 1 |
| Cheng, L; Cheng, P; Huang, A; Liao, D; Ma, J; Tong, A; Wei, Y; Yue, D | 1 |
| Ma, Y; Ma, Z; Wang, J; Yan, X; Yin, S | 1 |
| Alimoghaddam, K; Eyvani, H; Ghaffari, SH; Ghavamzadeh, A; Kabuli, M; Moghaddaskho, F; Momeny, M; Tavakkoly-Bazzaz, J; Zekri, A | 1 |
| Alimoghaddam, K; Alizadeh, N; Ghaffari, SH; Ghavamzadeh, A; Hosseini, E; Momeny, M; Rostami, S; Zaki Dizaji, M | 1 |
| Che, FF; Cheng, J; Huang, XB; Shi, Y; Wang, CS; Wang, XD | 1 |
| Bardsley, MR; Burgoyne, AM; Chan, JC; Chmielecki, J; Gao, F; Harismendy, O; Kendrick, ML; Lee, TE; Leonard, SY; Mao, J; Morosini, D; Ordog, T; Ross, JS; Shi, E; Sicklick, JK; Siena, M; Syed, SA; Tang, CM; Wang, K | 1 |
| Chau, D; Kwong, YL; Piao, W; Tse, E; Yue, LM | 1 |
| Chen, Z; Dai, Y; Gao, F; Guan, G; Liu, L; Ye, Y; Zhao, M; Zhao, P | 1 |
| Chou, YT; Pu, YS; Wang, AS | 1 |
| El Malki, K; Faber, J; Gerhold-Ay, A; Kron, B; Lehmann, N; Neu, MA; Paret, C; Pietsch, T; Russo, A; Seidmann, L; Sommer, C; Theruvath, J; Wagner, W; Wingerter, A | 1 |
| Aguilera-Montilla, N; Amigo-Jiménez, I; Bailón, E; García-Marco, JA; García-Pardo, A | 1 |
| Fang, J; Guo, H; Li, Y; Liu, L; Qi, K; Xiong, X; Zhang, C | 1 |
| Abedin, S; Altman, JK | 1 |
| Angelopoulou, MK; Asimakopoulos, JV; Kelepesis, G; Konstantopoulos, K; Koutsi, C; Meletis, J; Papageorgiou, L; Petevi, K; Plata, E; Tsaftaridis, P; Vassilakopoulos, TP | 1 |
| Fan, L; Liang, K; Liang, W; Peng, G; Wang, L; Wang, R; Xu, Y; Ye, Q | 1 |
| Du, G; Du, Z; Geng, S; Guo, Z; Han, G; Li, Z; Lin, H; Meng, M; Yao, J; Zheng, Y | 1 |
| He, X; Huang, H; Liu, W; Wang, J; Wei, Z; Yang, Z; Zhang, J; Zhang, Y | 1 |
| Chen, LL; Fang, LM; Li, JP; Wang, FP; Wang, MY; Zhang, JJ; Zhang, YL; Zhang, YY | 1 |
| Liang, C; Tai, S; Xu, L; Xu, M; Zhang, K; Zhang, L; Zhang, Y | 1 |
| Bai, H; Li, Z; Liu, R; Liu, W; Ning, Y; Shu, Z; Wang, Z; Yu, X; Yun, K | 1 |
| Damiano, B; De Bondt, A; Gallacher, DJ; Goeminne, N; Kopljar, I; Lu, HR; Teisman, A; Van den Wyngaert, I; Vinken, P | 1 |
| Fei, W; Han, S; Li, F; Tao, J; Wang, X; Wei, Y; Zhang, Y; Zheng, H; Zhu, J | 1 |
| Bochennek, K; Creutzig, U; Dworzak, MN; Faber, J; Flotho, C; Graf, N; Kontny, U; Mueller, JE; Reinhardt, D; Rossig, C; Schmid, I; von Neuhoff, C; von Neuhoff, N; von Stackelberg, A | 1 |
| Gnadler, M; Hecht, A; Lengfelder, E; Mezger, J | 1 |
| Gao, F; Liu, Y; Song, W | 1 |
| Huang, F; Ling, X; Ren, G; Su, Y; Xie, P; Xu, L; Zeng, Z; Zhang, W; Zhang, XK; Zhou, H | 1 |
| Chu, WF; Ding, XQ; Dong, CJ; Li, YY; Liu, MT; Liu, SK; Liu, Y; Liu, YX; Qiu, F; Shao, XQ; Wang, JX; Wu, D; Yang, BF; Zhang, LL; Zhao, D | 1 |
| Pan, J; Zhang, X | 1 |
| Lou, Z; Shen, L; Xu, G; Zhang, G | 1 |
| Andrade, AF; Delsin, LE; Klinger, PH; Queiroz, RG; Scrideli, CA; Tone, LG; Valera, ET | 1 |
| Li, H; Sun, H; Zhou, Y | 1 |
| Gao, N; Li, XZ; Sun, JR; Wang, XX; Yu, WZ | 1 |
| Abudoureyimu, A; Muhemaitibake, A | 1 |
| Dai, H; Ling, S; Shan, Q; Song, P; Wei, X; Xie, H; Xu, X; Yang, F; Zheng, S; Zhou, L; Zhuo, J | 1 |
| Bashash, D; Dadashi, M; Ghaffari, SH; Momeny, M; Safa, M; Safaroghli-Azar, A | 1 |
| Chen, H; Dai, H; Gu, S; Li, X; Zhang, Z | 1 |
| Goux, D; Guillamin, M; Hamza-Chaffai, A; Khlifi, R; Sichel, F; Trabelsi, F | 1 |
| DiRisio, AC; Field, MS; Kamynina, E; Lachenauer, ER; Liebenthal, RP; Stover, PJ | 1 |
| Ashton, JM; Becker, MW; Gasparetto, M; Humphries, KR; Jordan, CT; Khan, N; Minhajuddin, M; Myers, JR; Pei, S; Pollyea, DA; Smith, CA; Vasiliou, V | 1 |
| Lv, XH; Wang, CH; Xie, Y | 1 |
| Baer, MR; Benner, A; Burnett, AK; Ehninger, G; Elliott, MA; Estey, EH; Gonzales, P; Görner, M; Grimwade, D; Hills, RK; Ho, AD; Kayser, S; Krämer, A; Krzykalla, J; Levis, MJ; Mayer, J; Norsworthy, K; Novak, J; Platzbecker, U; Ráčil, Z; Röllig, C; Russell, NH; Schlenk, RF; Smith, BD; Szotkowski, T; Tallman, MS; Thiede, C; Walter, RB; Westermann, J; Žák, P | 1 |
| Bellavite, P; Betti, L; Brizzi, M; Dinelli, G; Kokornaczyk, MO; Nani, D; Peruzzi, M; Trebbi, G | 1 |
| Chavda, SJ; Koh, M; Lindsay, S; Willis, F | 1 |
| Dunoyer-Geindre, S; Kruithof, EKO; Lecompte, T; Rivier-Cordey, AS; Tsopra, O | 1 |
| Chang, SH; Hong, SC; Jeong, JH; Jung, JM; Kim, GS; Lee, WS; Lu, JN; Nagappan, A; Yun, JW | 1 |
| Bazarbachi, A; Hermine, O; Marçais, A; Nasr, R | 1 |
| Du, YY; Luo, Y; Sun, GB; Sun, XB; Wang, M; Wang, W; Yu, YL; Zhang, JY | 1 |
| An, R; Fu, W; He, H; Hou, J | 1 |
| Angelini, DF; Battistini, L; Berardi, A; Castelli, G; Catalano, G; Cicconi, L; D'Angiò, A; Fioritoni, G; Graziani, G; Guerrera, G; Lo-Coco, F; Massai, L; Mastrangelo, D; Noguera, NI; Pasquini, L; Pelosi, E; Piras, E; Piredda, ML; Testa, U; Voso, MT | 1 |
| He, Y; Hou, Z; Li, S; Shao, Y; Sun, X; Wang, Y; Xing, M; Zhao, H | 1 |
| Appel, D; Gülden, M; Seibert, H; Syska, M; Uecker, S; Wages, F | 1 |
| Bai, Y; Guo, Q; Liu, W; Wang, L | 1 |
| Cai, NL; Dai, LJ; Jin, DY; Lau, ATY; Ok Kim, M; Wu, DD; Xu, YM; Yu, FY | 1 |
| Chen, J; Dai, J; Guo, H; Liu, X; Yan, L; Yu, S; Zhang, W; Zhu, J | 1 |
| Gao, L; Liu, KJ; Wang, JZ; Wang, Q; Wang, XY; Xiang, B; Zhang, FY | 1 |
| Chandler, J; Fountas, L; Grimm, S; Helenowski, I; Kumthekar, P; Levy, R; Marymont, M; McCarthy, K; Mehta, M; Muro, K; Raizer, J | 1 |
| Feng, L; Li, B; Li, F; Liu, Y; Shi, Y; Wang, J; Yan, M | 1 |
| Chu, WF; Dong, CJ; Li, D; Li, JT; Li, YY; Liu, MT; Liu, SK; Liu, Y; Liu, YX; Mu, W; Nie, D; Qiu, F; Tian, W; Wang, JX; Wang, XF; Wu, D; Yang, BF; Yang, J; Zhao, D | 1 |
| Chen, CH; Chen, CK; Lu, PH; Tseng, JC | 1 |
| Boehme, KA; Handgretinger, R; Kluba, T; Riester, R; Schleicher, SB; Traub, F; Zaborski, JJ; Zenkner, N | 1 |
| Gu, SY; Li, Y; Zhang, ZZ | 1 |
| Flemington, EK; Lasky, JA; Parsons, CH; Sides, M; Yin, Q | 1 |
| Soloway, AH; Warner, VD | 1 |
| Alonzo, TA; Feusner, JH; Fu, CH; Gamis, AS; Gerbing, RB; Gregory, JJ; Hirsch, BA; Kutny, MA; Meshinchi, S; Raimondi, SC; Wang, YC | 1 |
| Dong, Z; Fang, L; Feng, L; Hai, X; Li, B; Shen, Z; Shi, Y; Zheng, S | 1 |
| Grillari, J; Groza, D; Grusch, M; Heffeter, P; Kryeziu, K; Mildner, M; Nagelreiter, F; Rösinger, S; Schoenhacker-Alte, B; Schosserer, M; Tav, K; Tschachler, E; Weinmuellner, R; Wimmer, L; Zbiral, B | 1 |
| Geng, X; Liu, L; Liu, Z; Lundgren, J; McDermott, J; Shen, J; Tsai, KJ | 1 |
| Das, M | 1 |
| Chaudhary, A; Haque, R; Sadaf, N | 1 |
| Du, P; Lu, W; Yang, C; Zhang, JC; Zhang, JL | 1 |
| Bianchi, E; Bockstaller, M; Chan, JA; Chavez, L; Dorostkar, MM; Glass, R; Kool, M; Korshunov, A; Lambo, S; Meister, V; Merk, DJ; Neumann, JE; Neumann, P; Nowak, J; Renner-Müller, I; Schindler, P; Schneider, MR; Schüller, U; Shakarami, M; Sharma, T; Taketo, MM; von Hoff, K; Warmuth-Metz, M; Wefers, AK | 1 |
| Feng, L; Li, XY; Li, Y; Liu, X; Wang, X; Zhang, L | 1 |
| Fan, D; Fu, J; Ge, F; Hou, J; Hou, W; Li, H; Li, X; Sun, J; Wang, P; Wang, S; Yang, K; Yang, Y; Zhang, Y; Zhao, H; Zhou, J | 1 |
| Chen, S; Lv, X; Yu, J; Zhang, L | 1 |
| Li, JL; Li, SW; Shao, YZ; Wang, Y; Xing, MW; Zhao, HJ | 1 |
| Federzoni, EA; Humbert, M; Tschan, MP | 1 |
| Li, S; Shao, Y; Wang, B; Wang, Y; Xing, M; Zhao, H | 1 |
| Ferrari, M; Hu, Z; Nizzero, S; Ramirez, MR; Shen, H; Shi, C; Wu, X; Zhang, G; Zhou, J | 1 |
| Anderson, KC; Balaz, P; Bujnakova, Z; Cholujova, D; Dorfman, DM; Dutkova, E; Groen, RW; Hideshima, T; Jakubikova, J; Mitsiades, CS; Richardson, PG | 1 |
| Freeborn, RA; Kennedy, RC; Liu, S; Rockwell, CE; VanDenBerg, KR; Zagorski, JW | 1 |
| Chen, Y; He, A; Lei, B; Zhang, P; Zhang, W; Zhao, X | 1 |
| Chang, JS; Kim, KW; Yoon, IH | 1 |
| Chen, K; Feng, T; Ling, S; Liu, J; Liu, P; Shan, Q; Song, P; Xiang, P; Xie, H; Xu, X; Zhang, X; Zheng, S; Zhou, L | 1 |
| Brossart, P; Gembruch, U; Giovannini, G; Janzen, V; Mayer, K; Merz, WM; Nellessen, CM | 1 |
| Bai, J; Chen, M; Gao, N; Jiang, L; Liu, X; Qiu, T; Sun, X; Wu, W; Yang, G; Yang, L; Yao, X; Zhang, Q | 1 |
| Chen, S; Dai, H; Drexler, HG; Geffers, R; Kaufmann, M; Li, J; MacLeod, RAF; Meyer, C; Nagel, S; Pommerenke, C; Quentmeier, H; Schneider, B; Thress, KS | 1 |
| Fu, Y; Guo, BB; Jiang, HY; Li, S; Liu, LY; Wang, KK; Wu, CJ; Zhang, CM; Zhang, F; Zhang, Y | 1 |
| Madhyastha, H; Madhyastha, R; Maruyama, M; Nakajima, Y | 1 |
| Ahmadian, S; Alimoghaddam, K; Alizadeh, S; Ghaffari, SH; Ghavamzadeh, A; Hassani, S; Khaleghian, A | 1 |
| Chen, E; Hu, H; Li, Y; Zhang, T; Zhu, X | 1 |
| Hu, J; Liu, JH; Wang, GB; Xue, K | 1 |
| Du, X; Huang, Q; Liu, L; Shen, H; Tian, M; Wang, X; Zhang, J | 1 |
| Jamieson, HE; Palmer, MJ; Van Den Berghe, MD | 1 |
| Chen, HY; Dai, HM; Gu, SY; Li, XY; Zhang, ZZ | 1 |
| Chen, C; Huang, JB; Liu, ZL; Wang, J; Xu, HG; Xue, HM; Zhang, BH | 1 |
| Chen, L; Chen, SJ; Chen, Z; Cui, W; Gao, MQ; Hu, J; Li, JM; Mi, JQ; Nie, RM; Shen, ZX; Wang, J; Wang, KK; Wang, ZY; Xi, XD; Zhao, LL; Zhu, HM | 1 |
| Ahmadian, S; Alimoghaddam, K; Ghaffari, SH; Ghavamzadeh, A; Mesbahi, Y; Zekri, A | 1 |
| Arathi, P; Binu, P; Nair, RH; Vineetha, RC | 1 |
| Cai, W; He, P; Tan, M; Wang, B; Wu, B; Zhang, X | 1 |
| Asik, A; Balcı Okcanoglu, T; Biray Avci, C; Dogan Sigva, ZO; Gunduz, C; Kayabasi, C; Ozmen Yelken, B; Saydam, G; Yılmaz Susluer, S | 1 |
| Afzal, M; Anis, E; Firdaus, F; Hossain, MM; Waseem, M; Zafeer, MF | 1 |
| Dutta, S; Mahalanobish, S; Sadhukhan, P; Saha, S; Sil, PC | 1 |
| Bai, Y; Chai, L; Chu, Q; Du, W; Jiang, Y; Li, A; Li, G; Li, Y; Pavlov, V; Qin, Y; Sun, X; Tuguzbaeva, G; Wang, H; Wang, Z; Yang, B; Yue, E | 1 |
| Chiocchetti, GM; Devesa, V; Vélez, D | 1 |
| Abhilash, S; Arathi, P; Binu, P; Gifty, K; Nair, RH; Vineetha, RC | 1 |
| Akasaka, T; Honjo, G; Minoda, S; Nakagawa, M; Ohno, H; Okanoue, Y | 1 |
| Bak, YT; Chun, HJ; Joo, MK; Kim, SH; Kim, T; Lee, BJ; Lee, SW; Park, JJ; Yoo, HS | 1 |
| Roszak, J; Smok-Pieniążek, A; Stępnik, M | 1 |
| Balme, B; Carlioz, V; Collinge, E; Gerland, LM; Paubelle, E; Salles, G; Sujobert, P; Thomas, X; Tigaud, I | 1 |
| Chen, CF; Chern, CL; Ho, CT; Lin, LC; Liu, JJ; Liu, TZ | 1 |
| Ángeles Esteban, M; Chaves-Pozo, E; Cordero, H; Cuesta, A; Martínez, S; Martínez-Sanchez, MJ; Meseguer, J; Morcillo, P; Pérez-Sirvent, C | 1 |
| Alikarami, F; Kazemi, A; Teremmahi Ardestanii, M; Toosi, B; Zaker, F | 1 |
| Bøe, SO; Eriksson, J; Lång, A; Lång, E; Rowe, AD; Øye, A | 1 |
| Akhtar, A; Bell, C; Ghali, L; Wang, SX; Wen, X | 1 |
| Li, C; Wang, W; Zhang, J; Zhang, Y; Zhang, Z | 1 |
| Cao, F; Chen, B; Le, XC; Lu, X; Shen, S; Zhou, J | 1 |
| Watts, G | 1 |
| Jiang, Y; Li, J; Lv, H; Ma, B; Ma, R; Qin, W; Tang, G; Wei, J; Yang, R | 1 |
| Chahardouli, B; Ghavamzadeh, A; Mohammadi Kian, M; Mohammadi, S; Nikbakht, M; Rostami, S; Tavallaei, M; Zahedpanah, M | 1 |
| Li, J; Liu, J; Luo, L; Shao, Y; Wang, Y; Xing, M; Zhao, H | 1 |
| Hai, Y; Li, H; Li, Y; Ma, W; Song, P; Wang, X; Wu, Z; Xie, Q; Zhao, L | 1 |
| Hou, J; Hou, W; Jin, B; Li, H; Wang, P; Yang, H; Zhang, Y; Zhao, H; Zhou, J | 1 |
| Balasubramanian, P; Goni, D; Malhotra, P; Nampoothiri, RV | 1 |
| Ali, M; Ali, V; Bimal, S; Haque, R; Kumar, N; Sadaf, N | 1 |
| Li, JL; Liu, JJ; Luo, LY; Shao, YZ; Wang, Y; Xing, MW; Zhao, HJ | 1 |
| Chen, YJ; Islam, K; Maimaitiyiming, Y; Naranmandura, H; Wang, C; Wang, QQ; Xu, S; Yang, C | 1 |
| He, T; Yu, H; Yu, HQ; Yue, QX | 1 |
| Chiu, JF; Huang, N; Li, G; Lin, W; Pei, X; Tao, T | 1 |
| Chen, G; Hu, Q; Wang, X; Wei, H; Wu, J; Xing, F; Xu, L; Yao, C; Yu, S; Zhao, X | 1 |
| Chen, LM; Gong, S; Liu, X; Liu, Y; Wang, HY; Wang, MC; Xi, JY; Zhang, HY; Zhang, XX | 1 |
| Ding, SM; Kan, JY; Wang, Y; Xu, RR | 1 |
| Fang, BJ; Sony, YP; Yang, SW; Yuan, XL; Zhang, F; Zhao, JJ; Zhu, ZM | 1 |
| Alfonso, V; Breccia, M; Cicconi, L; Diverio, D; Divona, M; Foa, R; Franceschini, L; Iaccarino, L; Latagliata, R; Lo-Coco, F; Molica, M; Ottone, T; Rizzo, M; Voso, MT | 1 |
| Chen, M; Gan, LG; Li, LW; Liu, BZ; Liu, L; Shan, ZL; Xiao, CL; Xu, T; Yao, SF; Zhao, Y; Zhong, L | 1 |
| Han, S; Li, F; Lu, Y; Ma, R; Ping, Y; Tang, H; Xu, X; Zhang, Y; Zheng, H; Zou, J | 1 |
| Li, S; Liu, J; Shao, Y; Wang, Y; Xing, M; Zhao, H | 1 |
| Dou, G; Gan, H; Gu, R; Ju, M; Meng, Z; Shi, Q; Wu, Z; Zhu, X | 1 |
| Guo, W; Li, F; Lu, P; Ma, JQ; Xu, GH; Zhou, HM | 1 |
| Fan, S; Gao, C; Guo, M; Hai, X; Hu, S; Liu, S; Wang, B; Wang, W; Zhou, J | 1 |
| Bhakat, K; Chakraborty, A; Islam, E | 1 |
| Hu, J; Jin, J; Lo-Coco, F; Zhu, HH | 1 |
| Jin, J; Lou, Y; Mao, L; Tong, H; Wei, J; Xu, W; Yu, W | 1 |
| Li, B; Li, F; Li, M; Li, Y; Wang, F; Yan, C; Zhang, G; Zhang, Y; Zhao, X | 1 |
| Cai, Z; Hoffmann, PR; Huang, Z; Li, S; Ling, Q; Miao, X; Yang, H; Zhang, Y | 1 |
| Hu, YH; Li, SG; Niu, Q; Ren, QX; Wang, HX; Xu, MC | 1 |
| Eskazan, AE; Yilmaz, U | 1 |
| Li, D; Que, Y; Sun, Y; Wang, L; Yang, X; Zhu, H | 1 |
| Gong, BF; Gong, XY; Li, Y; Lin, D; Liu, BC; Liu, KQ; Liu, YT; Mi, YC; Wang, JX; Wang, Y; Wei, H; Wei, SN; Zhang, GJ; Zhou, CL | 1 |
| Amuno, S; Bedos, L; Grahn, B; Kodzhahinchev, V; Niyogi, S; Shekh, K | 1 |
| Lamoliatte, F; McManus, FP; Rinfret Robert, C; Thibault, P | 1 |
| Gao, Y; Ma, ZC; Nie, Y; Sun, YT; Tan, HL; Wang, YG; Xu, HH; Zhou, W | 1 |
| Hirano, S | 1 |
| He, Z; Pan, X; Wang, Y; Wei, Z; Xu, X; Zhang, D; Zhu, Y | 1 |
| Ji, L; Jiang, Y | 1 |
| Baron, J; Freyer, CW; Luger, SM; Man, Y; Peterson, CE; Przespolewski, A | 1 |
| Yokoyama, Y | 1 |
| Breccia, M | 1 |
| Dong, ZP; Fan, ZM; Liu, WW; Shao, HY | 1 |
| De, SK; Maiti, S; Medda, N | 1 |
| Gang, EJ; Le, J; Li, SY; Liu, HC; Lu, Y; Pei, RZ; Qian, SY; Si, T; Tang, SH | 1 |
| Loh, SN | 1 |
| Bae, IJ; Bunch, H; Calderwood, SK; Cho, DH; Kang, K; Kim, D; Park, NY | 1 |
| Chen, H; Fan, S; Gao, Y; Guo, M; Hai, X; Lin, L; Wu, Z; Zhao, Q | 1 |
| Chen, H; Gao, C; Gao, Y; Guo, M; Guo, S; Hai, X; Lin, L; Wang, X; Wu, Z | 1 |
| Pemmaraju, N | 1 |
| Kumar, S; Tchounwou, PB | 1 |
| Levis, M | 1 |
| Baer, MR; DeZern, A; Duong, VH; Emadi, A; Gehrie, E; Ghiaur, G; Gojo, I; Hambley, B; Hickey, E; Kashanian, S; Levis, MJ; Li, A; Newman, MJ; Smith, BD; Varadhan, R; Zacholski, K | 1 |
| de Thé, H; Rérolle, D; Wu, HC | 1 |
| Kalalinia, F; Khaleghian, A; Mirjalili, S | 1 |
| Chen, G; Hosoi, K; Huang, C; Liu, Y; Tang, J; Wei, H; Wu, L; Yao, C; Yu, S; Yuan, J | 1 |
| Costa, LJ; Dhir, A; Jamy, OH; Xavier, AC | 1 |
| Alex, AA; Balasubramanian, P; Balasundaram, N; Chendamarai, E; David, S; Ganesan, S; Janet, NB; Korula, A; Krishna, S; Kulkarni, U; Kumar, SP; Mathews, V; Palani, HK; Radhakrishnan, NR; Venkatraman, A; Yasar, M | 1 |
| Dhar, P; Kaler, S; Kaur, B; Mehta, K; Pandey, KK | 1 |
| Allen, S; Budman, D; Calabro, A; Devoe, C; Dhingra, R; Ghiuzeli, CM; Saunders, J; Stýblo, M | 1 |
| He, Y; Liu, M; Ni, G; Ping, N; Tan, J; Wang, M | 1 |
| Ammatuna, E; Diepstra, A; Hazenberg, CLE; Huls, GA; Santing, M | 1 |
| Guo, M; Huang, J; Peng, X; Qi, Z; Wang, J; Wang, Y; Xu, X; Yang, D; Yin, F; Zhan, L | 1 |
| Kalo, MB; Rezaei, M | 1 |
| Chang, KJ; Li, B; Yang, MH | 1 |
| Wang, H; Wang, X; Xu, L; Zhang, J | 1 |
| Hayakawa, A; Horibe, K; Iijima-Yamashita, Y; Kato, M; Kiyotani, C; Matsumoto, K; Osumi, T; Shioda, Y; Terashima, K; Tomizawa, D; Yamada, Y | 1 |
| Dhingra, S; Murti, K; Ramalingam, P; Ravichandiran, V; Singh, A | 1 |
| Jin, J; Naranmandura, H; Wang, HF; Wang, QQ; Zhao, JZ; Zhu, HH | 1 |
| Agrawal, Y; Gupta, NA; Manne, RK; Nadkarni, KS; Santra, MK | 1 |
| Hu, L; Hu, T; Huang, R; Rao, G; Tan, J; Tang, Z; Wu, S; Zhang, X; Zhong, G | 1 |
| Hu, L; Huang, R; Jiang, X; Lan, J; Pang, Q; Tang, L; Tang, Z; Wan, F; Wu, S; Zhong, G | 1 |
| Chu, X; Guan, S; Han, X; Jia, Q; Qi, J; Sun, S; Xue, Y; Yang, Y; Zhang, M | 1 |
| Buettner, R; Burnett, J; Ghoda, L; Hoang, DH; Kuo, YH; Marcucci, G; Nguyen, LXT; Pullarkat, V; Rosen, ST; Valerio, M; Zhang, B | 1 |
| Chen, YQ; Huang, DP; Huang, LB; Li, Y; Liang, C; Liao, LH; Luo, JS; Luo, XQ; Mai, HR; Tang, YL; Wang, LN; Yang, LH; Ye, ZL; Zhang, XL | 1 |
| Liu, Y; Liu, YJ | 1 |
| Golizadeh, M; Goudarzi, S; Iranshahi, M; Mahdifar, M; Rafatpanah, H; Rassouli, FB | 1 |
| Yanada, M | 1 |
| Bhattacharya, A; Ghosh, A; Ghosh, D; Khan, AN; Kumar, S; Nag, D; Ravichandiran, V; Singh, R | 1 |
| Chen, H; Deng, Y; Guo, M; Ke, H; Liu, M; Luo, J; Shen, J; Song, X; Sun, P; Wei, C; Yang, T; Zhai, Y | 1 |
| Bardania, H; Hosseini, E; Khosravani, F; Kobarfard, F; Mir, H; Mirzaei, A | 1 |
| Korsos, V; Miller, WH | 1 |
| Dong, S; Feng, J; Huang, L; Lu, G; Qin, W; Tian, R; Wang, Z; Zhai, Z | 1 |
| Chen, K; Chen, W; Clode, P; Guagliardo, P; Huang, S; Jiang, H; Leung, JK; Song, W; Xu, J; Young, SG | 1 |
| Ali, M; Bhardwaj, SK; Chaudhary, A; Haque, R; Khan, A; Sinha, KK; Srivastava, A | 1 |
| Bunce, CM; Drayson, MT; Khanim, FL | 1 |
| Chen, SN; Huang, J; Jin, J; Li, L; Li, ZY; Lou, LJ; Lou, YJ; Lu, Y; Ma, YF; Mao, LP; Meng, HT; Qian, JJ; Sun, CH; Wang, HY; Wei, JY; Wu, Q; Xu, GX; Xu, JY; Yan, XY; Yang, M; Yu, WJ; Zhu, HH; Zhu, XL | 1 |
| Wiernik, PH | 1 |
| Fan, K; Gao, Z; Jiang, W; Kong, X; Li, S; Xu, B; Yang, B; Yi, J | 1 |
| Li, WD; Mao, S; Yang, HB; Yuan, W | 1 |
| Chen, LM; Gong, S; He, PC; Li, GH; Liu, HB; Liu, L; Lu, XH; Qin, WW; Wald, DN; Wang, HY; Wang, MC; Wei, SH; Xi, JY; Yao, YZ; Zhang, CS; Zhang, HY; Zhang, M; Zhang, XX; Zheng, YS; Zhu, HH | 1 |
| Hollow, SE; Johnstone, TC | 1 |
| Chen, J; Jin, Z; Li, P; Ma, Y; Yang, H; Zhang, S; Zhang, X | 1 |
| Das, C; Das, R; Jain, A; Jandial, A; Jindal, N; Karunakaran, P; Khadwal, A; Kumar, SR; Lad, D; Malhotra, P; Naseem, S; Prakash, G; Saini, N; Singh, C; Varma, N; Varma, S; Yanamandra, U | 1 |
| He, J; Li, W; Lu, D; Lu, P; Shi, Y; Su, Y; Wu, S; Yang, J; Zhang, G; Zhang, M; Zhang, X | 1 |
| Gavali, S; Linkermann, A; Tonnus, W | 1 |
| Chen, J; Gu, J; Guo, J; Hu, X; Li, D; Li, X; Liu, J; Mei, C; Peng, C; Xiao, Y; Zhang, K; Zhang, X; Zhou, B | 1 |
| Duan, X; Liu, B; Yang, M | 1 |
| Kepp, O; Kroemer, G; Liu, P; Pan, H | 1 |
| Cheng, M; Li, B; Li, F; Piao, JG; Sun, J; Wei, Y; Ye, T; Zheng, H; Zhou, M | 1 |
| Aki, T; Funakoshi, T; Kukita, M; Takata, M; Uemura, K; Unuma, K | 1 |
| Dai, B; Gao, W; Hu, J; Li, J; Li, K; Li, Y; Wang, F; Wang, L; Wang, Y; Zhang, T; Zhao, L; Zhu, H; Zhu, J | 1 |
| Balajthy, Z; Botó, P; Czimmerer, Z; Fésüs, L; Jambrovics, K; Kolostyák, Z; Pap, A; Sarang, Z; Szatmari, I; Uray, IP | 1 |
| Gao, C; Hai, X; Li, J; Lin, L; Lv, J; Tian, S; Wu, M | 1 |
| Chen, C; Hu, J; Liu, YM; Wang, J | 1 |
| Hai, X; Hostetter, TH; Lu, S; Pang, C; Wu, M | 1 |
| Duan, R; Hai, X; Lv, J; Pang, C; Tian, S; Wu, M; Yang, H; Zhang, H | 1 |
| Bakhtari, A; Jamil, M; Mohammadi-Bardbori, A; Mokhtarinejad, M; Nikpoor, AR; Omidi, M; Safa, O; Shadboorestan, A; Zadeh, SN | 1 |
| Bau, DT; Chang, WS; Chen, CC; Chen, CH; Chen, KY; Hong, KT; Hsu, SW; Hsu, WL; Lee, HT; Pei, JS; Tsai, CW | 1 |
| Li, B; Shi, XQ; Wang, YS; Yang, MH; Yin, JZ; Zhao, XW | 1 |
| Bajel, A; Blombery, PA; Chan, KL; Dun, K; Nedumannil, R; Ng Liet Hing, M; Nguyen, T; Ninkovic, S; Ryland, GL; Tiong, IS; Westerman, DA | 1 |
| Dong, XX; Fu, TT; Huang, HT; Liu, J; Ni, J; Peng, HL; Qu, CH; Sun, MY; Wu, HM; Yin, XB | 1 |
| Abraham, A; Balasubramanian, P; Fouzia, NA; George, B; Kulkarni, UP; Lionel, S; Mani, T; Mathews, V; Nair, SC; Selvarajan, S | 1 |
| Balajthy, Z; Jambrovics, K; Póliska, S; Scholtz, B; Uray, IP | 1 |
| Bachiashvili, K; Bathini, S; Bhatia, R; Choi, JK; Dunn-Valadez, S; Godby, K; Goyal, G; Jamy, O; Mehta, A; Mikhail, FM; Morlote, D; Oliver, JD; Purdy, KE; Rangaraju, S; Reddy, VB; Vachhani, P; Worth, S | 1 |
| Fan, S; Fu, Y; Guo, D; Hou, J; Lei, R; Li, H; Liu, J; Tang, L; Wu, Y; Zhao, Y | 1 |
| Huang, X; Liu, R; Liu, Y; Yang, H; Zou, X | 1 |
| Chen, GH; Chen, HQ; Chen, YQ; Fan, Z; Feng, XQ; Guo, BY; Huang, DP; Huang, LB; Lan, HK; Li, B; Li, WL; Li, Y; Liang, C; Liu, RY; Luo, JS; Luo, XQ; Mai, HR; Tang, YL; Wan, WQ; Wang, LN; Yang, LC; Yang, LH; Zhang, XL; Zhen, ZJ; Zhou, DH | 1 |
270 review(s) available for arsenic and arsenic trioxide
| Article | Year |
|---|---|
[Effects of some antidotes on injuries induced by arsenic in rat mucous membrane (author's transl)].
Topics: Animals; Antidotes; Arsenic; Arsenic Trioxide; Arsenicals; Glutathione; Mouth Mucosa; Oxides; Rats; Thioctic Acid | 1982 |
Survival after massive arsenic poisoning self-treated by high fluid intake.
Topics: Adult; Antidotes; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Dimercaprol; Fluid Therapy; Humans; Male; Oxides; Self Care | 1998 |
[Progresses in the study of hematology in China, 1997].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Oxides; Thrombophlebitis | 1997 |
[Arsenic trioxide, a new drug for the treatment of acute promyelocytic leukemia resistant to tretinoine].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 1999 |
Arsenic-induced apoptosis in malignant cells in vitro.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Down-Regulation; Glutathione; Growth Inhibitors; Hematopoietic Stem Cells; Humans; Leukemia; Leukemia, B-Cell; Leukemia, Promyelocytic, Acute; Leukocytes, Mononuclear; Neuroblastoma; Oxides; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2000 |
[Recent advances of differentiation-inducing therapy for leukemia].
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Differentiation; Histone Deacetylase Inhibitors; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Transcription, Genetic; Tretinoin | 2000 |
The effects of arsenic trioxide (As2O3) on human megakaryocytic leukemia cell lines. With a comparison of its effects on other cell lineages.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Lineage; Humans; Leukemia, Megakaryoblastic, Acute; Megakaryocytes; Oxides; Thrombocytosis | 2000 |
Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
Topics: Acute Kidney Injury; Antineoplastic Agents; Apoptosis; Arrhythmias, Cardiac; Arsenic Trioxide; Arsenicals; Cell Differentiation; Chemical and Drug Induced Liver Injury; Drug Evaluation; Drug Screening Assays, Antitumor; Gastrointestinal Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Life Tables; Medicine, Chinese Traditional; Mitochondria; Models, Biological; Neoplasm Proteins; Neoplastic Stem Cells; Neuromuscular Diseases; Oncogene Proteins, Fusion; Oxides; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2000 |
Arsenicals and inhibitors of histone deacetylase as anticancer therapy.
Topics: Acetylation; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; China; Chromatin; Drug Evaluation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gastrointestinal Diseases; Histone Deacetylase Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Melarsoprol; Neoplasm Proteins; Neoplasms; Nervous System Diseases; Oxides; Phenylbutyrates; Protein Processing, Post-Translational; Salvage Therapy; Tretinoin | 1999 |
Arsenicals in hematologic cancers.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Drug Evaluation, Preclinical; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tumor Cells, Cultured | 2000 |
Controlling the mitochondrial gatekeeper for effective chemotherapy.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; GABA-A Receptor Antagonists; Gene Expression Regulation; Genes, bcl-2; Humans; Intracellular Membranes; Isoquinolines; Mitochondria; Neoplasms; Oligonucleotides, Antisense; Oxides; Protoporphyrins | 2000 |
Old, new drugs and new, new drugs for the new millennium.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Clinical Trials as Topic; Female; Forecasting; Humans; Imatinib Mesylate; Leukemia, Promyelocytic, Acute; Male; Oxides; Piperazines; Prognosis; Pyrimidines; Sensitivity and Specificity; Treatment Outcome | 2000 |
Differentiating agents in pediatric malignancies: all-trans-retinoic acid and arsenic in acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Child; Disease Models, Animal; Drug Therapy, Combination; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2000 |
Acute progranulocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Clinical Trials as Topic; Cytarabine; Humans; Leukemia, Promyelocytic, Acute; Neoplasm, Residual; Oxides; Prognosis; Salvage Therapy; Survival Analysis; Tretinoin | 2001 |
Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides | 2001 |
Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Oxides | 2001 |
Arsenic trioxide: an emerging therapy for multiple myeloma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Multiple Myeloma; Oxides; Prognosis | 2001 |
Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Hematologic Neoplasms; Humans; National Institutes of Health (U.S.); Oxides; United States | 2001 |
Risk/benefit profile of arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Oxides; Risk Assessment | 2001 |
Treatment of adult T-cell leukaemia/lymphoma: current strategy and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Combined Modality Therapy; Drug Therapy, Combination; Humans; Interferon-alpha; Leukemia-Lymphoma, Adult T-Cell; Oxides; Retinoids; Tumor Virus Infections; Zidovudine | 2001 |
Cardiac toxicity of arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Artifacts; Electrocardiography; Electrolytes; Humans; Leukemia; Long QT Syndrome; Oxides; Torsades de Pointes | 2001 |
Histone deacetylases and transcriptional therapy with their inhibitors.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Histone Deacetylase Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Mice; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transcription, Genetic; Tretinoin | 2001 |
APL, a model disease for cancer therapies?
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Nucleus; Cellular Senescence; Humans; Inclusion Bodies; Leukemia, Promyelocytic, Acute; Multigene Family; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Tretinoin | 2001 |
Arsenic trioxide, a therapeutic agent for APL.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Disease Models, Animal; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Mice; Mitochondria; Neoplasm Proteins; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Remission Induction; Survival Rate; Transcription Factors; Tretinoin; Tumor Suppressor Proteins | 2001 |
Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission.
Topics: Animals; Arsenic Trioxide; Arsenicals; Binding Sites; Caspases; Cell Differentiation; Cysteine Endopeptidases; Humans; Leukemia, Promyelocytic, Acute; Multienzyme Complexes; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Proteasome Endopeptidase Complex; Protein Structure, Tertiary; Remission Induction; Tretinoin | 2001 |
Maturation sensitive and resistant t(15;17) NB4 cell lines as tools for APL physiopathology: nomenclature of cells and repertory of their known genetic alterations and phenotypes.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Oxides; Phenotype; Retinoids; Terminology as Topic; Transgenes; Tumor Cells, Cultured | 2001 |
Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides; Survival Analysis | 2001 |
Multiple myeloma: present and future.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Oxides; Pamidronate; Thalidomide; Zoledronic Acid | 2002 |
Acute promyelocytic leukemia: evolving therapeutic strategies.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Remission Induction; Tretinoin | 2002 |
Advances in the treatment of relapsed acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Combined Modality Therapy; Humans; Leukemia, Promyelocytic, Acute; Neoplasm, Residual; Oxides; Recurrence; Tretinoin | 2002 |
Arsenic trioxide: a new immunomodulatory agent in the management of multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Humans; Immunologic Factors; Multiple Myeloma; Oxides | 2001 |
Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Oxides; Recurrence; Remission Induction; Survival Analysis; Treatment Outcome; Tretinoin | 2002 |
Molecular targets of arsenic trioxide in malignant cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Glutathione; Growth Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Oxides | 2002 |
Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Adhesion Molecules; Cytokines; Humans; Multiple Myeloma; Neovascularization, Pathologic; Oxides; Pyrazines; Thalidomide; Treatment Outcome | 2002 |
Multifaceted approach to the treatment of bcr-abl-positive leukemias.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Enzyme Inhibitors; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Survival Analysis; Treatment Outcome | 2002 |
New approaches to the treatment of myelodysplasia.
Topics: Amifostine; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Enzyme Inhibitors; Humans; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Prognosis; Proto-Oncogene Mas; Risk Factors; Severity of Illness Index; Thalidomide; Topotecan; Treatment Outcome | 2002 |
Introduction.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Tretinoin | 2002 |
Arsenic trioxide: mechanisms of action.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Division; Glutathione; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neovascularization, Pathologic; Oncogene Proteins, Fusion; Oxides; Recurrence | 2002 |
Established practice in the treatment of patients with acute promyleocytic leukemia and the introduction of arsenic trioxide as a novel therapy.
Topics: Antineoplastic Agents; Antineoplastic Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis; Randomized Controlled Trials as Topic; Recurrence | 2002 |
Recent advances in Philadelphia chromosome-positive malignancies: the potential role of arsenic trioxide.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Enzyme Inhibitors; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2002 |
Expanding the use of arsenic trioxide: leukemias and beyond.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Neoplasms; Oxides | 2002 |
Mechanisms of action of arsenic trioxide.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2002 |
Liposomal-all-trans-retinoic acid in treatment of acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Clinical Trials as Topic; Drug Carriers; Histone Deacetylase Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Liposomes; Oxides; Tretinoin | 2002 |
P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype.
Topics: Acute Disease; Adult; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Division; Ceramides; Child; Cyclosporine; Cyclosporins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Leukemia, Myeloid; Lovastatin; Multicenter Studies as Topic; Neoplasm Proteins; Oxides; Phenotype; Protein Kinase C; Randomized Controlled Trials as Topic; Signal Transduction; Tumor Cells, Cultured | 2002 |
Management of acute promyelocytic leukemia.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Daunorubicin; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Tretinoin | 2002 |
Novel therapies for multiple myeloma.
Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cysteine Endopeptidases; Enzyme Inhibitors; Estradiol; Humans; Multienzyme Complexes; Multiple Myeloma; Oxides; Proteasome Endopeptidase Complex; Thalidomide; Tissue Extracts | 2002 |
How acute promyelocytic leukaemia revived arsenic.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Differentiation; China; Europe; Gene Expression Regulation, Neoplastic; History, 15th Century; History, 16th Century; History, 18th Century; History, 20th Century; History, 21st Century; History, Ancient; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Transcription Factors; Tumor Suppressor Proteins | 2002 |
Arsenic trioxide: acute promyelocytic leukemia and beyond.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species | 2002 |
Novel biologically based therapies for multiple myeloma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Multiple Myeloma; Oxides; Protease Inhibitors | 2002 |
Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: N. J. Bahlis et al., Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of re
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Clinical Trials as Topic; Drug Combinations; Glutathione; Humans; Mitochondria; Multiple Myeloma; Oxides; Reactive Oxygen Species | 2002 |
Novel therapies for multiple myeloma.
Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Enzyme Inhibitors; Estradiol; Heterocyclic Compounds, 3-Ring; Humans; Multiple Myeloma; NF-kappa B; Oxides; Phthalazines; Protease Inhibitors; Protein-Tyrosine Kinases; Pyridines; Thalidomide | 2003 |
[A review of the research on malignant hemopathies treated with arsenium-containing Chinese drugs].
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia; Leukemia, Promyelocytic, Acute; Materia Medica; Oxides; Sulfides; Tumor Cells, Cultured | 2000 |
[Research advances on effect of arsenic trioxide on tumor].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Gene Expression; Gene Expression Profiling; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2002 |
Arsenic trioxide (trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Combined Modality Therapy; Europe; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Regression, Spontaneous; Oxides; Practice Guidelines as Topic; Risk Factors; Tretinoin; United States | 2003 |
Targeted therapies for the treatment of leukemia.
Topics: Alemtuzumab; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Dose-Response Relationship, Drug; Drug Interactions; Gemtuzumab; Humans; Imatinib Mesylate; Leukemia; Nurse-Patient Relations; Nurse's Role; Oncology Nursing; Oxides; Patient Education as Topic; Piperazines; Prognosis; Pyrimidines; Randomized Controlled Trials as Topic; Tretinoin | 2003 |
Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Physiological Phenomena; Clinical Trials as Topic; Humans; Myelodysplastic Syndromes; Oxides; Treatment Outcome | 2003 |
Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2003 |
Therapy strategies for multiple myeloma: current status.
Topics: Adjuvants, Immunologic; Aged; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Diphosphonates; Drug Therapy, Combination; Erythropoietin; Glucocorticoids; Growth Inhibitors; Humans; Immunosuppressive Agents; Middle Aged; Multiple Myeloma; Oxides; Peripheral Blood Stem Cell Transplantation; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Transplantation, Homologous | 2003 |
[Relationship of arsenic trioxide and tumor cell apoptosis].
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; HeLa Cells; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2003 |
Recent developments and future directions in the treatment of multiple myeloma.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Clinical Trials as Topic; Cysteine Endopeptidases; Diphosphonates; Doxorubicin; Erythropoietin; Etoposide; Forecasting; Humans; Interferons; Multienzyme Complexes; Multiple Myeloma; Organometallic Compounds; Organophosphorus Compounds; Oxides; Peripheral Blood Stem Cell Transplantation; Proteasome Endopeptidase Complex; Thalidomide; Tissue Extracts | 2003 |
[Expanding possibilities, strategic considerations, and novel methods in the diagnosis and chemotherapy of adult acute myeloid leukemia].
Topics: Adult; Anthracyclines; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Oligonucleotide Array Sequence Analysis; Oxides; Palliative Care; Prognosis; Remission Induction; Tretinoin | 2003 |
The metabolism of inorganic arsenic oxides, gallium arsenide, and arsine: a toxicochemical review.
Topics: Animals; Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Gallium; Humans; No-Observed-Adverse-Effect Level; Occupational Exposure; Oxides; Water Pollutants, Chemical | 2003 |
[Advances in the study on the effects of Chinese herbal drugs on apoptosis].
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Drugs, Chinese Herbal; Humans; Materia Medica; Oxides; Paclitaxel; Plants, Medicinal; Quercetin; Sesquiterpenes; Tumor Cells, Cultured | 2002 |
[Recent advances in the treatment of acute myelogenous leukemia: a view of the new agents].
Topics: Alkyl and Aryl Transferases; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Cyclosporine; Cytarabine; Daunorubicin; Drug Design; Farnesyltranstransferase; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Nucleosides; Oxides; Prognosis; Radioisotopes; Remission Induction; Tetrahydronaphthalenes; Topoisomerase Inhibitors; Tretinoin; Verapamil | 2003 |
Arsenic trioxide for the treatment of myelodysplastic syndromes.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials, Phase II as Topic; Humans; Myelodysplastic Syndromes; Oxides; Treatment Outcome | 2004 |
Cytotoxic effects of B lymphocytes mediated by reactive oxygen species.
Topics: 2-Methoxyestradiol; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; B-Lymphocytes; Benzodiazepines; Cell Death; Estradiol; Hexanones; Humans; Lymphoproliferative Disorders; Oxidative Stress; Oxides; Reactive Oxygen Species; Rituximab; Signal Transduction | 2004 |
Multiple myeloma: the role of transplant and novel treatment strategies.
Topics: Adjuvants, Immunologic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Oxides; Pyrazines; Stem Cell Transplantation; Thalidomide; Transplantation, Homologous | 2004 |
The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Drug Delivery Systems; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Tretinoin | 2004 |
Acute promyelocytic leukemia as a paradigm for targeted therapy.
Topics: Arsenic Trioxide; Arsenicals; Drug Delivery Systems; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2004 |
New drugs for treatment of multiple myeloma.
Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Diphosphonates; Enzyme Inhibitors; Estradiol; Humans; Multiple Myeloma; Neovascularization, Pathologic; Oxides; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Thalidomide | 2004 |
The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Hematologic Neoplasms; Humans; Oxidation-Reduction; Oxides | 2004 |
Investigational strategies in chronic myelogenous leukemia.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Cancer Vaccines; DNA Methylation; Enzyme Inhibitors; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines; Research; Treatment Outcome | 2004 |
[Advances in the study on antineoplastic action of realgar].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; K562 Cells; Leukemia; Leukemia, Promyelocytic, Acute; Materia Medica; Oxides; Tumor Cells, Cultured | 2004 |
[Progress on the study of reproduction toxicity of arsenic].
Topics: Animals; Arsenic; Arsenic Trioxide; Arsenicals; Humans; Male; Oxides; Reproduction; Spermatozoa | 2000 |
An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Remission Induction; Treatment Outcome; Tretinoin | 2004 |
Arsenic trioxide in the treatment of haematological malignancies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Drug Resistance, Neoplasm; Hematologic Neoplasms; Humans; Oxides; Remission Induction; Salvage Therapy; Tretinoin | 2004 |
Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Models, Biological; Oncogene Proteins, Fusion; Oxides; Reactive Oxygen Species | 2005 |
Arsenic trioxide as a treatment for myelodysplastic syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cell Division; Clinical Trials as Topic; Dexamethasone; DNA-Binding Proteins; Drug Therapy, Combination; Glutathione; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; MDS1 and EVI1 Complex Locus Protein; Multicenter Studies as Topic; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Proto-Oncogenes; Transcription Factors | 2005 |
Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2004 |
In vivo and in vitro treatment of HTLV-1 and HTLV-2 infected cells with arsenic trioxide and interferon-alpha.
Topics: Anti-Retroviral Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Proliferation; Clinical Trials, Phase II as Topic; Drug Synergism; Human T-lymphotropic virus 1; Human T-lymphotropic virus 2; Humans; Interferon-alpha; Leukemia-Lymphoma, Adult T-Cell; NF-kappa B; Oxides; Tumor Virus Infections | 2005 |
Targeting multiple myeloma cells and their bone marrow microenvironment.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion; Cytokines; Disease Progression; Disease-Free Survival; Humans; Ligands; Multiple Myeloma; Neovascularization, Pathologic; Oxides; Protease Inhibitors; Pyrazines; Signal Transduction; Thalidomide | 2004 |
Innovations in antineoplastic therapy.
Topics: Adjuvants, Immunologic; Alemtuzumab; Aminoglycosides; Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Bile; Boronic Acids; Bortezomib; Capecitabine; Cetuximab; Decanoic Acids; Deoxycytidine; Docetaxel; Drug Approval; Estradiol; Fluorouracil; Fulvestrant; Gefitinib; Gemtuzumab; Humans; Imatinib Mesylate; Letrozole; Leuprolide; Nitriles; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Oxides; Piperazines; Polyesters; Pyrazines; Pyrimidines; Quinazolines; Taxoids; Thionucleotides; Tissue Extracts; Triazoles; United States; United States Food and Drug Administration; Vidarabine Phosphate | 2005 |
Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Oxides | 2005 |
Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Drug Design; Hematologic Neoplasms; Humans; Mitochondria; Oxides; Polymerase Chain Reaction; Prognosis | 2005 |
The duplicitous nature of inorganic arsenic.
Topics: Antineoplastic Agents; Arsenic; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Chemistry, Inorganic; Environmental Exposure; History, 19th Century; History, 20th Century; Humans; Models, Chemical; Oxides | 2005 |
Proapoptotic regimes for HTLV-I-transformed cells: targeting Tax and the NF-kappaB pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Drug Delivery Systems; Gene Expression Regulation; Gene Products, tax; Human T-lymphotropic virus 1; Humans; Leukemia-Lymphoma, Adult T-Cell; NF-kappa B; Nitriles; Oxides; Proteasome Inhibitors; Sulfones; T-Lymphocytes | 2005 |
Targeted therapy in multiple myeloma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; DNA, Antisense; Drug Delivery Systems; Farnesyltranstransferase; Humans; Immunosuppressive Agents; Lovastatin; Multiple Myeloma; Oxides; Protease Inhibitors; Pyrazines; Thalidomide | 2005 |
Management of patients with higher risk myelodysplastic syndromes.
Topics: Age Factors; Antimetabolites, Antineoplastic; Arsenic Trioxide; Arsenicals; Azacitidine; Combined Modality Therapy; Disease-Free Survival; Farnesyltranstransferase; Hematopoietic Stem Cell Transplantation; Humans; Myelodysplastic Syndromes; Oxides; Prognosis; Risk Factors; Treatment Outcome | 2005 |
Perspectives for combination therapy to overcome drug-resistant multiple myeloma.
Topics: 2-Methoxyestradiol; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estradiol; Histone Deacetylase Inhibitors; Humans; Multiple Myeloma; Oxides; p38 Mitogen-Activated Protein Kinases; Proteasome Inhibitors; Receptor Protein-Tyrosine Kinases; Thalidomide | 2005 |
Arsenic trioxide: an anti cancer missile with multiple warheads.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; Arsenic Trioxide; Arsenicals; Chromatin Assembly and Disassembly; DNA Fragmentation; Flavoproteins; Humans; Leukemia, Promyelocytic, Acute; Membrane Proteins; Mitosis; Oxides; Tumor Suppressor Protein p53 | 2005 |
[Pharmacological and clinical properties of arsenic trioxide (Trisenox) for relapse or refractory acute promyelocytic leukemia therapy].
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Mice; Oxides | 2005 |
Oxidative stress and apoptosis: a new treatment paradigm in cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Buthionine Sulfoximine; Cell Death; Dose-Response Relationship, Drug; Glutathione; Hexanones; Humans; Metalloporphyrins; Models, Biological; Models, Chemical; Neoplasms; Oxidation-Reduction; Oxidative Stress; Oxides; Reactive Oxygen Species | 2006 |
Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence.
Topics: Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2005 |
Acute promyelocytic leukemia: a model of molecular target based therapy.
Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Drug Delivery Systems; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2005 |
Treatment concepts of acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Prognosis; Recurrence; Risk Factors; Stem Cell Transplantation; Thrombosis; Translocation, Genetic; Transplantation, Homologous; Tretinoin | 2005 |
Overview of drug therapy for multiple myeloma.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Multiple Myeloma; Myeloma Proteins; Oxides; Pyrazines; Thalidomide | 2005 |
Strategies for the treatment of acute promyelocytic leukemia.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2006 |
[New strategy for the treatment of multiple myeloma].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Dexamethasone; Drug Design; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Oxides; Prognosis; Protease Inhibitors; Purines; Pyrazines; Roscovitine; Thalidomide; Transplantation Conditioning | 2005 |
Novel agents aiming at specific molecular targets increase chemosensitivity and overcome chemoresistance in hematopoietic malignancies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Drug Resistance, Neoplasm; Enzyme Inhibitors; Hematologic Neoplasms; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; Oligonucleotides, Antisense; Oxides; Piperazines; Proteasome Endopeptidase Complex; Pyrimidines; Rituximab; Thalidomide | 2006 |
Hypoxia inducible factor-1alpha and leukemic cell differentiation.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Transformation, Neoplastic; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Leukemia; Leukemia, Promyelocytic, Acute; Oxides | 2006 |
New treatments for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Oxides; Pyrazines; Thalidomide | 2005 |
Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides | 2006 |
[The plasma cell myeloma--molecular pathogenesis and target therapies].
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Communication; Chromosome Aberrations; Gene Expression; Glycoproteins; Growth Inhibitors; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Osteoporosis; Osteoprotegerin; Oxides; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Thalidomide; Time Factors | 2006 |
Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
Topics: Administration, Oral; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Treatment Outcome | 2006 |
The voltage-dependent anion channel (VDAC): function in intracellular signalling, cell life and cell death.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Calcium; Cytochromes c; Humans; Ion Channel Gating; Mitochondria; Mitochondrial Membranes; Models, Molecular; Neoplasms; Oxides; Permeability; Protein Conformation; Protein Folding; Protein Isoforms; Proto-Oncogene Proteins c-bcl-2; Ruthenium Red; Signal Transduction; Voltage-Dependent Anion Channels | 2006 |
The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; History, 18th Century; History, 20th Century; History, 21st Century; History, Ancient; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide | 2006 |
[Therapeutic strategies for patients with relapsed acute promyelocytic leukemia].
Topics: Aminoglycosides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoates; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Hydroxamic Acids; Leukemia, Promyelocytic, Acute; Oxides; Practice Guidelines as Topic; Recurrence; Remission Induction; Tetrahydronaphthalenes; Tretinoin | 2006 |
Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs.
Topics: Anthracyclines; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cardiovascular Diseases; Heart Diseases; Humans; Interferons; Interleukin-2; Neoplasms; Oxides; Stilbenes; Tretinoin | 2006 |
Recent advances in the treatment of APL.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Diagnosis, Differential; History, 20th Century; History, 21st Century; Humans; Leukemia, Promyelocytic, Acute; Oxides; Translocation, Genetic | 2006 |
Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide?
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Therapy, Combination; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis; Tretinoin | 2006 |
Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Multiple Myeloma; Oxides; Practice Patterns, Physicians'; Treatment Outcome | 2006 |
Arsenic trioxide and acute promyelocytic leukemia: clinical and biological.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome | 2007 |
The design of selective and non-selective combination therapy for acute promyelocytic leukemia.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Administration Schedule; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2007 |
Arsenic compounds in the treatment of multiple myeloma: a new role for a historical remedy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Screening Assays, Antitumor; History, 18th Century; Humans; Medical Oncology; Models, Biological; Multiple Myeloma; Oxides | 2006 |
Relationship between cytokines and leukocytosis in patients with APL induced by all-trans retinoic acid or arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cytokines; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides; Tretinoin | 2006 |
[Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Risk Factors; Time Factors | 2007 |
Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2007 |
Treatment of relapsed or refractory acute promyelocytic leukemia.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Oxides; Transplantation, Autologous; Transplantation, Homologous | 2007 |
Acute promyelocytic leukemia: new issues on pathogenesis and treatment response.
Topics: Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Models, Biological; Oncogene Proteins, Fusion; Oxides; Tretinoin | 2007 |
[Arsenic trioxide as a therapeutic agent in APL].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2007 |
Arsenic trioxide and neuroblastoma cytotoxicity.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Brain Neoplasms; Cell Death; Cell Differentiation; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Neuroblastoma; Oxides | 2007 |
Targeting transcription factors in acute leukemia in children.
Topics: Acute Disease; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; DNA Methylation; Drug Delivery Systems; Histone Deacetylase Inhibitors; Humans; Leukemia; Oxides; Transcription Factors; Tretinoin | 2007 |
Long-term remission of extramedullary relapse from acute promyelocytic leukemia after treatment with arsenic trioxide, intrathecal chemotherapy, and brain irradiation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cranial Irradiation; Daunorubicin; Ear Neoplasms; Humans; Injections, Spinal; Leukemia, Myelomonocytic, Acute; Male; Oxides; Radiography; Remission Induction; Sarcoma, Myeloid; Tretinoin | 2007 |
Leukemia, an effective model for chemical biology and target therapy.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Dasatinib; Growth Inhibitors; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Oxides; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Tretinoin | 2007 |
From dissection of disease pathogenesis to elucidation of mechanisms of targeted therapies: leukemia research in the genomic era.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Disease Models, Animal; Humans; Imatinib Mesylate; Leukemia; Oxides; Piperazines; Pyrimidines; Tretinoin | 2007 |
PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoates; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Tetrahydronaphthalenes; Tretinoin | 2007 |
[Research advance of nanometric traditional Chinese herbal drugs for cancer treatment].
Topics: Arsenic Trioxide; Arsenicals; Camptothecin; Drug Carriers; Drugs, Chinese Herbal; Humans; Nanoparticles; Nanotechnology; Neoplasms; Oxides | 2007 |
[Molecular targeting therapy for multiple myeloma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bevacizumab; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Oxides; Protease Inhibitors; Pyrazines; Thalidomide; TNF-Related Apoptosis-Inducing Ligand; Vascular Endothelial Growth Factor A | 2007 |
[Progression of foundational and clinical studies on use of arsenic trioxide in treatment of lymphoma--review].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Lymphoma; Oxides | 2007 |
New data with arsenic trioxide in leukemias and myelodysplastic syndromes.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Myelodysplastic Syndromes; Oxides | 2007 |
Arsenic trioxide: safety issues and their management.
Topics: Administration, Oral; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Humans; Lethal Dose 50; Oxides; Prodrugs | 2008 |
Acute promyelocytic leukemia: from highly fatal to highly curable.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; History, 20th Century; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2008 |
Acute myeloid leukemia in the elderly: conventional and novel treatment approaches.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Azacitidine; Clofarabine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Oxides; Recurrence; Sulfonamides | 2008 |
Current treatment options and strategies for myelodysplastic syndromes.
Topics: Age Factors; Antimetabolites, Antineoplastic; Arsenic Trioxide; Arsenicals; Blood Transfusion; Clinical Trials as Topic; Comorbidity; Disease Progression; Erythropoietin; Farnesyltranstransferase; Hematinics; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Myelodysplastic Syndromes; Oxides; Recombinant Proteins; Social Class; Stem Cell Transplantation | 2008 |
Arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence | 2008 |
[Research of traditional Chinese medicine in the treatment of leukemia: current status].
Topics: Arsenic Trioxide; Arsenicals; Diagnosis, Differential; Drug Resistance, Neoplasm; Drugs, Chinese Herbal; Humans; Leukemia; Medicine, Chinese Traditional; Oxides; Phytotherapy | 2008 |
New drugs in multiple myeloma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Humans; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide | 2008 |
Arsenic and old lace: novel approaches in elderly patients with acute myeloid leukemia.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Oxides; Treatment Outcome | 2008 |
The expanding role of arsenic in acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Cytarabine; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2008 |
[Selected mechanisms of the therapeutic effect of arsenic trioxide in cancer treatment].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Caspases; Drug Therapy, Combination; Glutathione; Humans; Intercellular Signaling Peptides and Proteins; MAP Kinase Kinase 4; Neoplasms; NF-kappa B; Oxides; Tretinoin | 2008 |
Arsenic trioxide mechanisms of action--looking beyond acute promyelocytic leukemia.
Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Proliferation; Humans; Leukemia, Promyelocytic, Acute; Oxides; Reactive Oxygen Species | 2008 |
Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.
Topics: Arsenic Trioxide; Arsenicals; Aspirin; Boronic Acids; Bortezomib; Heparin, Low-Molecular-Weight; Humans; Incidence; Lenalidomide; Multiple Myeloma; Oxides; Pyrazines; Thalidomide; Venous Thromboembolism | 2009 |
New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings.
Topics: Antibodies, Monoclonal; Antigens, Surface; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cysteine Proteinase Inhibitors; Depsipeptides; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Farnesyl-Diphosphate Farnesyltransferase; Heat-Shock Proteins; Histone Deacetylase Inhibitors; Humans; Mitogen-Activated Protein Kinase Kinases; Multiple Myeloma; NF-kappa B; Oligopeptides; Oxides; Peptides, Cyclic; Phosphoinositide-3 Kinase Inhibitors; Protein Kinases; Receptor Protein-Tyrosine Kinases; Receptors, Cell Surface; Signal Transduction; TOR Serine-Threonine Kinases | 2008 |
What is the role of arsenic in newly diagnosed APL?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2008 |
Molecular genetic pathways as therapeutic targets in acute myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Division; Chromosome Aberrations; Genetic Markers; Humans; Karyotyping; Leukemia, Myeloid, Acute; Models, Genetic; Mutation; Oxides; Proto-Oncogene Proteins c-kit; Transcription, Genetic; Tretinoin | 2008 |
Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.
Topics: Aniline Compounds; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Amplification; Harringtonines; Histone Deacetylase Inhibitors; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2008 |
Transcriptome and proteome analyses of drug interactions with natural products.
Topics: Animals; Arsenic Trioxide; Arsenicals; Benzamides; Drug Discovery; Drug Synergism; Gene Expression Profiling; Herb-Drug Interactions; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Oxides; Piperazines; Proteome; Pyrimidines; Tretinoin | 2008 |
Interaction between arsenic trioxide and human primary cells: emphasis on human cells of myeloid origin.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Degranulation; Cell Differentiation; Gene Expression Regulation; Humans; Inflammation; Leukemia, Promyelocytic, Acute; MAP Kinase Signaling System; Myeloid Cells; NADPH Oxidases; Oxidative Stress; Oxides; Reactive Oxygen Species | 2009 |
[Progress of arsenic trioxide in treating myelodysplastic syndromes].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Myelodysplastic Syndromes; Oxides | 2009 |
Biological responses to arsenic compounds.
Topics: Antineoplastic Agents; Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Models, Biological; Models, Chemical; Neoplasms; Oxides; Signal Transduction | 2009 |
The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: a systematic review.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Oxides; Treatment Outcome | 2009 |
Differentiation therapy of acute myeloid leukemia: past, present and future.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Myeloid, Acute; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Sensitivity and Specificity; Tretinoin | 2009 |
Beneficial and adverse effects of molecularly targeted therapies for acute promyelocytic leukemia in central nervous system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Central Nervous System Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin | 2009 |
[Efficacy of arsenic trioxide for acute promyelocytic leukemia: a systematic review and meta-analysis].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2009 |
Novel biospecific agents for the treatment of myelodysplastic syndromes.
Topics: Arsenic Trioxide; Arsenicals; Azacitidine; Decitabine; Etanercept; Farnesyltranstransferase; Humans; Immunoglobulin G; Lenalidomide; Myelodysplastic Syndromes; Oxides; Receptors, Tumor Necrosis Factor; Thalidomide | 2003 |
New agents in chronic myelogenous leukemia.
Topics: Angiogenesis Inhibitors; Arsenic Trioxide; Arsenicals; Cytosine; Dioxolanes; Farnesyltranstransferase; Harringtonines; Histone Deacetylase Inhibitors; Homoharringtonine; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Vaccination | 2003 |
Acute promyelocytic leukemia in childhood.
Topics: Anthracyclines; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis; Translocation, Genetic; Tretinoin | 2009 |
[Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Tretinoin | 2009 |
Supplements for immune enhancement in hematologic malignancies.
Topics: Adult; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; beta-Glucans; Child; Clinical Trials as Topic; Dietary Supplements; Digestive System Neoplasms; Drug Screening Assays, Antitumor; Drug Synergism; Drugs, Chinese Herbal; Ganoderma; Hematologic Neoplasms; Herb-Drug Interactions; Humans; Immunologic Factors; Mice; Oxides; Phytotherapy; Plant Preparations; Polyporus; Thalidomide | 2009 |
Traditional Chinese medicines (TCMs) for molecular targeted therapies of tumours.
Topics: Animals; Antineoplastic Agents, Phytogenic; Arsenic Trioxide; Arsenicals; Artemisinins; Artesunate; Berberine; Biological Products; Cantharidin; Complementary Therapies; Curcumin; Drug Delivery Systems; Drug Screening Assays, Antitumor; Drugs, Chinese Herbal; Humans; Medicine, Chinese Traditional; Models, Biological; Neoplasms; Oxides | 2010 |
Acute promyelocytic leukemia: what are the treatment options?
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Secondary Prevention; Tretinoin | 2010 |
Signal transduction pathways and transcription factors triggered by arsenic trioxide in leukemia cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Reactive Oxygen Species; Signal Transduction; Transcription Factors | 2010 |
Acute promyelocytic leukemia: a paradigm for differentiation therapy.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Dyspnea; Fever; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Models, Biological; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Transcription, Genetic; Treatment Outcome; Tretinoin | 2010 |
Arsenic trioxide as a treatment for myelodysplastic syndrome.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; DNA-Binding Proteins; Drug Therapy, Combination; Humans; Leukemia, Promyelocytic, Acute; MDS1 and EVI1 Complex Locus Protein; Multicenter Studies as Topic; Myelodysplastic Syndromes; Oxides; Proto-Oncogenes; Salvage Therapy; Thalidomide; Transcription Factors | 2006 |
Adult T-cell leukemia/lymphoma and HTLV-1.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; CD4-Positive T-Lymphocytes; Clinical Trials as Topic; Daclizumab; Drug Resistance, Neoplasm; Endemic Diseases; Female; Gene Products, tax; Genes, pX; Human T-lymphotropic virus 1; Humans; Immunoglobulin G; Immunophenotyping; Immunotherapy; Infant, Newborn; Infectious Disease Transmission, Vertical; Interferon-alpha; Leukemia-Lymphoma, Adult T-Cell; Male; Oxides; Paraparesis, Tropical Spastic; Pregnancy; Pregnancy Complications, Infectious; Zidovudine | 2007 |
Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells.
Topics: Animals; Arsenic Trioxide; Arsenicals; beta Catenin; Bone Marrow; Cell Cycle; Cytarabine; Drug Resistance, Neoplasm; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Oxides; Protein Kinase Inhibitors; Protein-Tyrosine Kinases | 2010 |
The impact of molecularly targeted therapies upon the understanding of leukemogenesis and the role of hematopoietic stem cell transplantation in acute promyelocytic leukemia.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Survival; Cell Transformation, Neoplastic; Glutamates; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Myeloid Progenitor Cells; Neoplastic Stem Cells; Nuclear Proteins; Oxides; Prodrugs; Promyelocytic Leukemia Protein; Transcription Factors; Tretinoin; Tumor Suppressor Proteins | 2010 |
Chitin and chitosan as multipurpose natural polymers for groundwater arsenic removal and AS2O3 delivery in tumor therapy.
Topics: Arsenates; Arsenic; Arsenic Trioxide; Arsenicals; Arsenites; Chitin; Chitosan; Drug Carriers; Humans; Nanotechnology; Neoplasms; Oxides; Polymers; Water Pollutants, Chemical; Water Purification | 2010 |
Targeting leukemic stem cells by breaking their dormancy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Granulocyte Colony-Stimulating Factor; Humans; Interferon-alpha; Leukemia; Neoplastic Stem Cells; Oxides | 2010 |
Combination therapy with arsenic trioxide for hematological malignancies.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Hematologic Neoplasms; Humans; Oxides | 2010 |
[Molecular mechanism of malignant hematological tumor cell apoptosis induction by active components of traditional Chinese herbs].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Diterpenes; Drugs, Chinese Herbal; Epoxy Compounds; Hematologic Neoplasms; Humans; Oxides; Phenanthrenes; Quercetin; Tumor Cells, Cultured | 2010 |
Modern approaches to treating acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin | 2011 |
Differentiation syndrome in patients with acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Glucocorticoids; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Oxides; Risk Factors; Syndrome; Time Factors; Tretinoin | 2012 |
The medicinal use of realgar (As₄S₄) and its recent development as an anticancer agent.
Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; History, 16th Century; History, 19th Century; History, 20th Century; History, 21st Century; History, Ancient; History, Medieval; Humans; Leukemia; Medicine, Traditional; Oxides; Sulfides | 2011 |
The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis.
Topics: Adolescent; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Clinical Trials as Topic; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Tretinoin; Young Adult | 2011 |
Advances in therapies for acute promyelocytic leukemia.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Differentiation; Clinical Trials as Topic; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Multicenter Studies as Topic; Oncogene Proteins, Fusion; Oxides; Risk; Salvage Therapy; Tretinoin | 2011 |
[All-trans retinoic acid and arsenic trioxide: their molecular mechanisms of action and updated clinical progress in APL therapy].
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Tretinoin | 2011 |
Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2011 |
Acute promyelocytic leukemia can be treated successfully without cytotoxic chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2011 |
Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Treatment Outcome | 2012 |
Arsenic trioxide in acute promyelocytic leukemia: potion not poison.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2011 |
Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lymphoma, B-Cell; Multiple Myeloma; Oxidation-Reduction; Oxidative Stress; Oxides; Pyrazines; Radiotherapy | 2012 |
Antiangiogenesis in myelodysplastic syndrome.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; Bevacizumab; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Lenalidomide; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Receptors, Vascular Endothelial Growth Factor; Thalidomide | 2011 |
Curing APL through PML/RARA degradation by As2O3.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Sumoylation; Treatment Outcome | 2012 |
Current treatment strategy of acute promyelocytic leukemia.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis; Secondary Prevention; Survival Rate; Tretinoin | 2011 |
Cell-penetrating properties of the transactivator of transcription and polyarginine (R9) peptides, their conjugative effect on nanoparticles and the prospect of conjugation with arsenic trioxide.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Cell-Penetrating Peptides; Drug Carriers; Drug Delivery Systems; Humans; Nanoparticles; Oxides; Peptide Fragments; Peptides; tat Gene Products, Human Immunodeficiency Virus; Trans-Activators | 2012 |
Pathogenesis and treatment of leukemia: an Asian perspective.
Topics: Arsenic Trioxide; Arsenicals; Asian People; Cell Proliferation; Humans; Leukemia; Leukemia, Large Granular Lymphocytic; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin | 2012 |
[Current treatment of acute myeloid leukaemia in adults].
Topics: Age Factors; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mitoxantrone; Molecular Targeted Therapy; Oxides; Prognosis; Pyrazines; Recurrence; Transplantation, Homologous; Treatment Outcome; Tretinoin | 2012 |
A new era for an ancient drug: arsenic trioxide and Hedgehog signaling.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Neoplasms; Cerebellar Neoplasms; Hedgehog Proteins; Humans; Leukemia, Promyelocytic, Acute; Medulloblastoma; Oncogene Proteins; Oxides; Sarcoma, Ewing | 2012 |
How to manage acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Transformation, Neoplastic; Central Nervous System Neoplasms; Consolidation Chemotherapy; Drug Synergism; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Oxides; Recurrence; Tretinoin | 2012 |
Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease.
Topics: Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin | 2012 |
Bleeding and thrombosis in acute promyelocytic leukemia.
Topics: Antifibrinolytic Agents; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation Tests; Clinical Trials as Topic; Combined Modality Therapy; Cysteine Endopeptidases; Disseminated Intravascular Coagulation; Factor VIIa; Factor VIII; Fibrinogen; Fibrinolysis; Hemorrhage; Heparin; Humans; Leukemia, Promyelocytic, Acute; Multicenter Studies as Topic; Neoplasm Proteins; Oxides; Plasma; Platelet Count; Platelet Transfusion; Recombinant Proteins; Thromboplastin; Thrombosis; Treatment Failure; Tretinoin | 2012 |
Targeted therapy: The new lease on life for acute promyelocytic leukemia, and beyond.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Core Binding Factor Alpha 2 Subunit; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oncogene Proteins, Fusion; Oxides; RUNX1 Translocation Partner 1 Protein; Translocation, Genetic; Tretinoin; Tumor Cells, Cultured | 2012 |
Provocative pearls in diagnosing and treating acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Arsenic Trioxide; Arsenicals; Biopsy, Fine-Needle; Bone Marrow; Clinical Trials as Topic; Dexamethasone; Granulocyte Precursor Cells; Humans; Leukemia, Promyelocytic, Acute; Oxides; Practice Guidelines as Topic; Prognosis; Pulmonary Edema; Remission Induction; Respiratory Insufficiency; Tretinoin | 2012 |
Arsenic trioxide: an ancient drug revived.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Oxides; Reactive Oxygen Species | 2012 |
The evolving use of arsenic in pharmacotherapy of malignant disease.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Biotransformation; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Gastrointestinal Diseases; Gene Expression Regulation; Heart Diseases; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Metabolic Networks and Pathways; Methyltransferases; Neoplasms; Oxides; Reactive Oxygen Species; Signal Transduction; Treatment Outcome | 2013 |
A drug from poison: how the therapeutic effect of arsenic trioxide on acute promyelocytic leukemia was discovered.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Asian People; China; Drug Discovery; Humans; Leukemia, Promyelocytic, Acute; Medicine, Chinese Traditional; Oxides; Remission Induction; Treatment Outcome | 2013 |
Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Tretinoin | 2013 |
Management of elderly patients with acute promyelocytic leukemia: progress and problems.
Topics: Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Disease Management; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2013 |
Acute promyelocytic leukemia: do we have a new front-line standard of treatment?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Remission Induction; Tretinoin | 2013 |
[Arsenic trioxide: impact on the growth and differentiation of cancer cells and possible use in cancer therapy].
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Caspases; Cell Differentiation; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; MAP Kinase Kinase 4; Mitochondria; Neoplasms; NF-kappa B; Oxides | 2013 |
Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical results and open questions.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Oxides; Remission Induction | 2013 |
Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Treatment Outcome; Tretinoin | 2014 |
Biology and management of therapy-related acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Early Diagnosis; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Second Primary; Oxides; Retrospective Studies; Risk Factors; Tretinoin | 2013 |
Anticancer activity of small-molecule and nanoparticulate arsenic(III) complexes.
Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Drug Carriers; Humans; Inactivation, Metabolic; Leukemia, Promyelocytic, Acute; Nanoparticles; Oxides; Sulfhydryl Compounds; Thermodynamics | 2013 |
Double-edged effects of arsenic compounds: anticancer and carcinogenic effects.
Topics: Animals; Antineoplastic Agents; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Carcinogens; Dose-Response Relationship, Drug; Humans; Oxides | 2013 |
Postconsolidation maintenance and monitoring in patients with acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Consolidation Chemotherapy; Humans; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Monitoring, Physiologic; Oncogene Proteins, Fusion; Oxides; Polymerase Chain Reaction; Tretinoin | 2013 |
Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cell Transformation, Neoplastic; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Mice; Oncogene Proteins, Fusion; Oxides; Remission Induction; Signal Transduction; Transcriptional Activation; Tretinoin | 2013 |
[Acute promyelocytic leukemia--modern approach to disease pathogenesis and differentiation treatment].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Secondary Prevention; Survival Rate; Tretinoin | 2013 |
Novel treatment of acute promyelocytic leukemia: As₂O₃, retinoic acid and retinoid pharmacology.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Retinoids; Transcription Factors; Tumor Suppressor Proteins | 2013 |
ATRA + ATO: has a new standard of care been established in low-risk acute promyelocytic leukaemia?
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Randomized Controlled Trials as Topic; Standard of Care; Treatment Outcome; Tretinoin | 2014 |
The role of PML in hematopoietic and leukemic stem cell maintenance.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Fatty Acids; Hematopoietic Stem Cells; Humans; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Signal Transduction; Transcription Factors; Tumor Suppressor Proteins | 2014 |
How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia.
Topics: Adult; Arsenic Trioxide; Arsenicals; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Premedication; Syndrome; Tretinoin | 2014 |
Contemporary treatment of APL.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin | 2014 |
What is the standard regimen for patients with acute promyelocytic leukemia?
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Oxides; Practice Guidelines as Topic; Tretinoin | 2014 |
Advanced progress on the relationship between RA and its receptors and malignant tumors.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Proliferation; Drug Resistance, Neoplasm; Drug Therapy, Combination; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Neoplastic Cells, Circulating; Oxides; Receptors, Retinoic Acid; Signal Transduction; Tretinoin | 2014 |
In the war against solid tumors arsenic trioxide needs partners.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Brain Diseases; Clinical Trials as Topic; Combined Modality Therapy; Drug Approval; Drug Synergism; Hedgehog Proteins; Hematologic Diseases; Humans; Medicine, Chinese Traditional; Neoplasm Proteins; Neoplasms; Oncogene Proteins, Fusion; Oxides; Radiotherapy, Adjuvant; Signal Transduction; Thymidylate Synthase; Transcription Factors; Treatment Outcome; United States; United States Food and Drug Administration; Zinc Finger Protein GLI1 | 2014 |
Understanding the molecular pathogenesis of acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Transformation, Neoplastic; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Clinical Trials as Topic; Disease Models, Animal; DNA End-Joining Repair; Drug Synergism; Granulocyte Precursor Cells; Humans; Leukemia, Promyelocytic, Acute; Mice; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms, Second Primary; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Oxides; Signal Transduction; Topoisomerase II Inhibitors; Translocation, Genetic; Tretinoin | 2014 |
The coagulopathy in acute promyelocytic leukaemia--what have we learned in the past twenty years.
Topics: Annexin A2; Anticoagulants; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation Disorders; Blood Coagulation Tests; Carboxypeptidase B2; Disseminated Intravascular Coagulation; Fibrinolysis; Forecasting; Granulocyte Precursor Cells; Hemorrhagic Disorders; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recombinant Proteins; Risk Factors; S100 Proteins; Thrombomodulin; Thrombophilia; Thromboplastin; Tretinoin; Urokinase-Type Plasminogen Activator | 2014 |
Triple A therapy: the molecular underpinnings of the unique sensitivity of leukemic promyelocytes to anthracyclines, all-trans-retinoic acid and arsenic trioxide.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Granulocyte Precursor Cells; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Topoisomerase II Inhibitors; Transcription, Genetic; Tretinoin | 2014 |
Conventional induction and post-remission therapy in APL: have we arrived?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Consolidation Chemotherapy; Daunorubicin; Harringtonines; Homoharringtonine; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mercaptopurine; Methotrexate; Mitoxantrone; Multicenter Studies as Topic; Oxides; Remission Induction; Tretinoin | 2014 |
Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care.
Topics: Adult; Age Factors; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blood Coagulation Factors; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Hydroxyurea; Idarubicin; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Oxides; Platelet Transfusion; Practice Guidelines as Topic; Remission Induction; Risk Assessment; Thioguanine; Treatment Outcome; Tretinoin | 2014 |
Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Cell Differentiation; Clinical Trials as Topic; Disease Management; Drug Monitoring; Drug Resistance, Neoplasm; Historically Controlled Study; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Leukocytosis; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Real-Time Polymerase Chain Reaction; Remission Induction; Salvage Therapy; Tretinoin | 2014 |
Extramedullary disease in APL: a real phenomenon to contend with or not?
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Cerebral Hemorrhage; Humans; Incidence; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Models, Biological; Multicenter Studies as Topic; Organ Specificity; Oxides; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Risk Factors; Tetrahydronaphthalenes; Tretinoin | 2014 |
Treatment of paediatric APL: how does the therapeutic approach differ from adults?
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Age of Onset; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Blood Coagulation Disorders; Bone Marrow Examination; Cell Differentiation; Child; Child, Preschool; Heart Diseases; Humans; Infant; Leukemia, Promyelocytic, Acute; Multicenter Studies as Topic; Neoplasm, Residual; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Oxides; Prognosis; Pseudotumor Cerebri; Randomized Controlled Trials as Topic; Remission Induction; Risk Factors; Salvage Therapy; Tretinoin | 2014 |
Progress in the treatment of acute promyelocytic leukemia: optimization and obstruction.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Oxides; Salvage Therapy; Tretinoin | 2014 |
Epigenetics in acute promyelocytic leukaemia pathogenesis and treatment response: a TRAnsition to targeted therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; DNA Methylation; Epigenesis, Genetic; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Treatment Outcome; Tretinoin | 2015 |
Inhibition factors of arsenic trioxide therapeutic effects in patients with acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Mutation; Oxides | 2014 |
New strategies in acute promyelocytic leukemia: moving to an entirely oral, chemotherapy-free upfront management approach.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease Management; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Neoplasm, Residual; Oxides; Tretinoin | 2014 |
[Treatment for acute promyelocytic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Clinical Trials, Phase III as Topic; Consolidation Chemotherapy; Disseminated Intravascular Coagulation; Gene Fusion; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Molecular Targeted Therapy; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Recurrence; Remission Induction; Retinoic Acid Receptor alpha; Tetrahydronaphthalenes; Transcription Factors; Tretinoin; Tumor Suppressor Proteins | 2014 |
Molecular mechanisms of the antileukemia activities of retinoid and arsenic.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Drug Synergism; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Treatment Outcome; Tretinoin | 2014 |
Arsenic trioxide preferentially induces nonapoptotic cell deaths as well as actin cytoskeleton rearrangement in the CHO AA8 cell line.
Topics: Actin Cytoskeleton; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Cell Death; Cell Survival; CHO Cells; Cricetinae; Cricetulus; Oxides | 2014 |
Acute promyelocytic leukemia: where did we start, where are we now, and the future.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug-Related Side Effects and Adverse Reactions; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Failure; Tretinoin | 2015 |
Insights into the All-trans-Retinoic Acid and Arsenic Trioxide Combination Treatment for Acute Promyelocytic Leukemia: A Meta-Analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Chemical and Drug Induced Liver Injury; Controlled Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Randomized Controlled Trials as Topic; Remission Induction; Risk; Tretinoin | 2015 |
Synergistic targeted therapy for acute promyelocytic leukaemia: a model of translational research in human cancer.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oncogene Proteins, Fusion; Oxides; Translational Research, Biomedical; Tretinoin | 2015 |
[Pathogenesis of Acute Promyelocytic Leukemia].
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease Models, Animal; Epigenomics; Humans; Leukemia, Promyelocytic, Acute; Medicine, Chinese Traditional; Mice; Molecular Targeted Therapy; Oncogene Proteins, Fusion; Oxides; Transcription, Genetic; Tretinoin | 2015 |
p53 as an Effector or Inhibitor of Therapy Response.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Female; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oncogene Proteins, Fusion; Oxides; Treatment Outcome; Tretinoin; Tumor Suppressor Protein p53 | 2015 |
Acute myeloid leukemia in children and adolescents: identification of new molecular targets brings promise of new therapies.
Topics: Adolescent; Adult; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Clinical Trials as Topic; Down Syndrome; Epigenesis, Genetic; GATA1 Transcription Factor; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Medical Oncology; Molecular Medicine; Mutation; Oxides; ras Proteins; Receptor Protein-Tyrosine Kinases; Treatment Outcome; Tretinoin | 2015 |
Current standard treatment of adult acute promyelocytic leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Early Diagnosis; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Stem Cell Transplantation; Tretinoin | 2016 |
Swallowing a bitter pill-oral arsenic trioxide for acute promyelocytic leukemia.
Topics: Administration, Intravenous; Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Treatment Outcome | 2016 |
The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials, Phase III as Topic; Female; Follow-Up Studies; Forecasting; Hematologic Neoplasms; Humans; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Male; Oxides; Randomized Controlled Trials as Topic; Risk Assessment; Treatment Outcome | 2016 |
Acute promyelocytic leukemia with cryptic t(15;17) on isochromosome 17: a case report and review of literature.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Examination; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Disease Progression; Fatal Outcome; Genetic Predisposition to Disease; Humans; In Situ Hybridization, Fluorescence; Isochromosomes; Karyotype; Leukemia, Promyelocytic, Acute; Male; Molecular Diagnostic Techniques; Mutation; Oncogene Proteins, Fusion; Oxides; Phenotype; Predictive Value of Tests; Time Factors; Translocation, Genetic; Treatment Outcome; Tretinoin; Young Adult | 2015 |
Optimal treatment strategies for high-risk acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blood Coagulation Disorders; Disease Management; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Treatment Outcome; Tretinoin | 2016 |
Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.
Topics: Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Chromosome Aberrations; Disseminated Intravascular Coagulation; DNA-Binding Proteins; fms-Like Tyrosine Kinase 3; Hemorrhagic Disorders; Humans; Immunophenotyping; Leukemia, Promyelocytic, Acute; Leukocyte Count; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Prognosis; Risk Factors; Tandem Repeat Sequences; Treatment Outcome; Tretinoin; Tumor Protein p73; Tumor Suppressor Proteins | 2016 |
Current management of newly diagnosed acute promyelocytic leukemia.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug-Related Side Effects and Adverse Reactions; Humans; Leukemia, Promyelocytic, Acute; Oxides; Randomized Controlled Trials as Topic; Tretinoin | 2016 |
Arrhythmia and Electrophysiological Effects of Chemotherapy: A Review.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Arrhythmias, Cardiac; Arsenic Trioxide; Arsenicals; Cardiotoxicity; Humans; Oxides; Protein Kinase Inhibitors; Risk Assessment; Taxoids | 2016 |
All-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2016 |
Arsenic trioxide-induced osteo-necrosis treatment in a child: mini-review and case report.
Topics: Adolescent; Arsenic Trioxide; Arsenicals; Dental Materials; Dental Pulp Devitalization; Dental Pulp Necrosis; Female; France; Gingival Diseases; Humans; Mandibular Diseases; Necrosis; Osteonecrosis; Oxides; Pulpectomy | 2016 |
Acute promyelocytic leukemia: preventing early complications and late toxicities.
Topics: Adult; Age Factors; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Humans; Leukemia, Promyelocytic, Acute; Oxides; Survival Rate | 2016 |
Inhibition of SHH pathway mechanisms by arsenic trioxide in pediatric medulloblastomas: a comprehensive literature review.
Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cerebellar Neoplasms; Child; Child, Preschool; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Infant; Medulloblastoma; Oxides; Signal Transduction | 2017 |
Arsenic trioxide combined with transarterial chemoembolization for primary liver cancer: A meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Cholangiocarcinoma; Databases, Bibliographic; Female; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Oxides; Randomized Controlled Trials as Topic; Treatment Outcome; Young Adult | 2017 |
Overview of Targeted Therapies for Adult T-Cell Leukemia/Lymphoma.
Topics: Adult; Antineoplastic Agents, Immunological; Arsenic Trioxide; Arsenicals; Female; Human T-lymphotropic virus 1; Humans; Interferon-alpha; Leukemia-Lymphoma, Adult T-Cell; Male; Oxides; Receptors, CXCR4; Zidovudine | 2017 |
Immunomodulatory Role of Arsenic in Regulatory T Cells.
Topics: Animals; Apoptosis; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Cytokines; Environmental Pollutants; Humans; Immunocompromised Host; Immunologic Factors; Oxidative Stress; Oxides; Signal Transduction; T-Lymphocytes, Regulatory | 2017 |
Successful treatment of acute promyelocytic leukemia in pregnancy with single-agent all-trans retinoic acid.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Gestational Age; Humans; Leukemia, Promyelocytic, Acute; Neoadjuvant Therapy; Pregnancy; Pregnancy Complications, Neoplastic; Treatment Outcome; Tretinoin | 2018 |
Deciphering the molecular events during arsenic induced transcription signal cascade activation in cellular milieu.
Topics: Arsanilic Acid; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Ataxia Telangiectasia Mutated Proteins; Forkhead Box Protein O1; Humans; Oxidative Stress; Oxides; Protein Isoforms; Proto-Oncogene Proteins pp60(c-src); Signal Transduction; Skin; Transcriptional Activation | 2018 |
Double-Sided Personality: Effects of Arsenic Trioxide on Inflammation.
Topics: Arsenic Trioxide; Arsenicals; Humans; Immune System; Inflammation; Oxides | 2018 |
Arsenic trioxide combined with transarterial chemoembolization for unresectable primary hepatic carcinoma: A systematic review and meta-analysis.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Oxides; Quality of Life; Survival Rate; Treatment Outcome | 2018 |
[Research progress on anti-cancer mechanisms of arsenic trioxide and artemisinin].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Artemisinins; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasms; Oxides; Signal Transduction | 2016 |
The simpler, the better: oral arsenic for acute promyelocytic leukemia.
Topics: Administration, Oral; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Chemical and Drug Induced Liver Injury; China; Diarrhea; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis | 2019 |
Biotransformation of arsenic and toxicological implication of arsenic metabolites.
Topics: Animals; Antineoplastic Agents; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Biotransformation; Humans; Leukemia, Promyelocytic, Acute; Risk Assessment; Toxicity Tests | 2020 |
Different mechanisms of arsenic related signaling in cellular proliferation, apoptosis and neo-plastic transformation.
Topics: Antineoplastic Agents; Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Cell Proliferation; Humans; Mitochondria; Mitogen-Activated Protein Kinases; Neoplasms; Oxides; Plastics; Signal Transduction | 2021 |
Arsenic: a Culpable Element and a Possible Menace for HIV/AIDS Patients.
Topics: Animals; Arsenic; Arsenic Poisoning; Arsenic Trioxide; Carcinogens; Drinking Water; Environmental Pollutants; HIV Infections; Humans | 2022 |
Treatment for relapsed acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Treatment Outcome; Tretinoin | 2022 |
How retinoic acid and arsenic transformed acute promyelocytic leukemia therapy.
Topics: Arsenic; Arsenic Trioxide; Humans; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transcription Factors; Translocation, Genetic; Tretinoin; Tumor Suppressor Proteins | 2022 |
Does the pursuit of scientific excellence serve or hamper translational medical research: an historical perspective from hematological malignancies.
Topics: Arsenic Trioxide; Arsenicals; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Oxides; Thalidomide; Translational Research, Biomedical; Tretinoin | 2022 |
Realgar and arsenene nanomaterials as arsenic-based anticancer agents.
Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Nanoparticles; Oxides | 2023 |
Refractory acute promyelocytic leukemia with PLZF/RARa rearrangement: a case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2023 |
Nanocarrier-based delivery of arsenic trioxide for hepatocellular carcinoma therapy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms; Oxides | 2022 |
Potential of natural products in combination with arsenic trioxide: Investigating cardioprotective effects and mechanisms.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biological Products; Cardiotonic Agents; Heart; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2023 |
The efficacy and adverse events of arsenic trioxide for the patients with myelodysplastic syndrome: a systematic review and component network meta-analysis.
Topics: Arsenic Trioxide; Arsenicals; Humans; Myelodysplastic Syndromes; Network Meta-Analysis; Oxides; Treatment Outcome | 2023 |
137 trial(s) available for arsenic and arsenic trioxide
| Article | Year |
|---|---|
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Metabolic Clearance Rate; Middle Aged; Neutrophils; Oxides; Receptors, Retinoic Acid; Recurrence; Remission Induction; Retinoic Acid Receptor alpha; Survival Rate; Time Factors | 1997 |
New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoates; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Retinoids; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured | 1997 |
Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation; Daunorubicin; Drug Screening Assays, Antitumor; Endothelium, Vascular; Female; Fibrinolysis; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Thromboplastin; Tretinoin | 1999 |
Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Disease-Free Survival; Drug Monitoring; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Oxides; Recurrence; Remission Induction; Translocation, Genetic | 1999 |
Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Survival Rate; Tretinoin | 1999 |
On-line reversed-phase liquid chromatography hydride generation emission spectrometry: speciation of arsenic in urine of patients intravenously treated with As2O3.
Topics: Arsenic; Arsenic Trioxide; Arsenicals; Calibration; Chromatography, High Pressure Liquid; Cysteine; Humans; Indicators and Reagents; Injections, Intravenous; Oxides; Reproducibility of Results; Solutions; Spectrophotometry, Atomic | 2000 |
Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Death, Sudden; Female; Humans; Kinetics; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence | 2001 |
United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Electrocardiography; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Nervous System Diseases; Oxides; Pilot Projects; Platelet Count; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Syndrome | 2001 |
[An analysis of the therapeutic effects and reactions in treating acute promyelocytic leukemia with intravenous arsenic trioxide or all-trans retinoic acid].
Topics: Adolescent; Adult; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Child; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Tretinoin | 1999 |
[Arsenic trioxide for the treatment of medium and advanced primary liver cancer].
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Chemical and Drug Induced Liver Injury; Female; Humans; Liver Neoplasms; Male; Middle Aged; Oxides; Remission Induction; Treatment Outcome; Vomiting | 2002 |
Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; Oxides; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Therapeutic Equivalency; Treatment Outcome | 2002 |
Clinical activity of arsenic trioxide for the treatment of multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Evaluation; Humans; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neutropenia; Oxides; Salvage Therapy; Treatment Outcome | 2002 |
Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Karnofsky Performance Status; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Oxides; Tomography, X-Ray Computed | 2002 |
Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cause of Death; Child; Disease-Free Survival; Drug Monitoring; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Oxides; Remission Induction; Treatment Outcome | 2002 |
Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Drug Resistance, Neoplasm; Feasibility Studies; Female; Glutathione; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oxides; Salvage Therapy; Treatment Outcome | 2002 |
Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Oncogene Proteins, Fusion; Oxides; Polymerase Chain Reaction; Remission Induction; Safety; Salvage Therapy; Survival Rate; Treatment Outcome | 2003 |
Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Statistics, Nonparametric; Survival Rate; Treatment Outcome; Tretinoin | 2003 |
Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Salvage Therapy; Treatment Outcome; Tretinoin | 2003 |
Combined effect of topical arsenic trioxide and radiation therapy on skin-infiltrating lesions of breast cancer-a pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Combined Modality Therapy; Female; Gels; Humans; Middle Aged; Oxides; Pilot Projects; Skin Neoplasms | 2003 |
Arsenic trioxide induces apoptosis of cutaneous T cell lymphoma cells: evidence for a partially caspase-independent pathway and potentiation by ascorbic acid (vitamin C).
Topics: Aged; Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Caspases; Cell Division; Cell Line, Tumor; Clone Cells; Drug Synergism; Humans; Leukocytes, Mononuclear; Lymphoma, T-Cell, Cutaneous; Middle Aged; Mitochondria; Oxides; Skin Neoplasms | 2003 |
Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Topics: Adult; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Arsenites; Cacodylic Acid; Chromatography, High Pressure Liquid; Humans; Injections, Intravenous; Leukemia, Promyelocytic, Acute; Male; Methylation; Middle Aged; Oxidation-Reduction; Oxides | 2004 |
Cardiac monitoring of patients receiving arsenic trioxide therapy.
Topics: Adult; Aged; Antineoplastic Agents; Arrhythmias, Cardiac; Arsenic Trioxide; Arsenicals; Edema; Electrocardiography, Ambulatory; Female; Hematologic Neoplasms; Humans; Male; Middle Aged; Oxides; Prospective Studies | 2004 |
All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; In Situ Nick-End Labeling; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Prospective Studies; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Tretinoin; Tumor Cells, Cultured | 2004 |
Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma.
Topics: Adult; Anti-HIV Agents; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Human T-lymphotropic virus 1; Humans; Injections, Intravenous; Interferon-alpha; Leukemia-Lymphoma, Adult T-Cell; Middle Aged; Oxides; Prognosis; Recurrence; Treatment Outcome; Zidovudine | 2004 |
[Clinical observation and following up of two administration methods of arsenic trioxide in treatment of acute promyelocytic leukemia].
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Case-Control Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Male; Oxides; Remission Induction; Treatment Outcome | 2004 |
Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Oxides; Salvage Therapy; Treatment Outcome | 2004 |
Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old.
Topics: Acute Disease; Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B; Bone Marrow Examination; Disease Progression; Drug Resistance, Multiple; Female; Glycoproteins; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasms, Second Primary; Oxides; Salvage Therapy; Treatment Outcome | 2004 |
Comparing two arsenic trioxide administration methods in APL therapy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides | 2004 |
A prospective, open-label safety and efficacy study of combination treatment with melphalan, arsenic trioxide, and ascorbic acid in patients with relapsed or refractory multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Disease Progression; Drug Resistance, Neoplasm; Humans; Melphalan; Middle Aged; Multiple Myeloma; Oxides; Prospective Studies; Recurrence; Time Factors; Treatment Outcome | 2004 |
[Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia].
Topics: Adolescent; Adult; Arsenic Trioxide; Arsenicals; Female; Hair; Humans; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Nails; Oxides; Treatment Outcome; Young Adult | 1997 |
Increased erythropoietin level and reticulocyte count during arsenic trioxide therapy.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Erythropoietin; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Reticulocyte Count | 2005 |
A phase II trial of arsenic trioxide in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Choroid Neoplasms; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Oxides; Skin Neoplasms; Survival Rate; Treatment Outcome | 2005 |
Effects of administration styles of arsenic trioxide on intracellular arsenic concentration, cell differentiation and apoptosis.
Topics: Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line; Drug Administration Schedule; Humans; Intracellular Fluid; Leukemia, Promyelocytic, Acute; Oxides | 2005 |
Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Female; Humans; Japan; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Treatment Outcome | 2005 |
Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Disease Progression; Female; Follow-Up Studies; Humans; Immunohistochemistry; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Neovascularization, Pathologic; Oxides; Recurrence; Remission Induction; Survival Rate; Time Factors; Treatment Outcome | 2006 |
Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Partial Thromboplastin Time; Platelet Count; Remission Induction; Survival Analysis; Treatment Outcome | 2006 |
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.
Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Polymerase Chain Reaction; Remission Induction; Tretinoin | 2006 |
Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety.
Topics: Administration, Oral; Adult; Aged; Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Electrocardiography; Electrocardiography, Ambulatory; Female; Heart Conduction System; Heart Rate; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Treatment Outcome | 2006 |
Hepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity.
Topics: Adult; Arsenic Trioxide; Arsenicals; Chemical and Drug Induced Liver Injury; Cohort Studies; Disease-Free Survival; Female; Follow-Up Studies; Genetic Predisposition to Disease; Humans; Incidence; Leukemia, Promyelocytic, Acute; Liver; Liver Function Tests; Male; Methylenetetrahydrofolate Reductase (NADPH2); Oxides; Polymorphism, Genetic; Remission Induction; Risk Factors; Survival Rate; Treatment Outcome | 2006 |
Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline- based chemotherapy: the European APL group experience (APL 91 and APL 93 trials).
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Europe; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prognosis; Recurrence; Risk Factors; Treatment Outcome; Tretinoin | 2006 |
Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Myelodysplastic Syndromes; Oxides; Prognosis; Prospective Studies; Risk Assessment; Risk Factors; Survival Analysis; Treatment Outcome | 2006 |
Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Myelodysplastic Syndromes; Oxides; Prognosis; Prospective Studies; Risk Assessment; Risk Factors; Survival Analysis; Treatment Outcome | 2006 |
Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies.
Topics: Adult; Antineoplastic Agents; Arrhythmias, Cardiac; Arsenic Trioxide; Arsenicals; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Oxides; Pneumonia; Respiratory Distress Syndrome; Survival Rate; Testicular Neoplasms; Treatment Outcome | 2006 |
Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oxides; Recurrence; Vitamins | 2006 |
Effects of arsenic trioxide administration styles on leukocytosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Humans; Infusions, Intravenous; K562 Cells; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides | 2006 |
A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Oxides; Patient Selection; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Treatment Outcome | 2006 |
A phase I study to study arsenic trioxide with radiation and hyperthermia in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Hyperthermia, Induced; Male; Middle Aged; Oxides; Radiation-Sensitizing Agents; Treatment Outcome | 2006 |
Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Drug Administration Schedule; Fatigue; Female; Humans; Injections, Intravenous; Leukopenia; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxides; Survival Analysis; Treatment Outcome | 2007 |
Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Creatinine; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Oxides; Prospective Studies; Recurrence; Survival Analysis; Treatment Outcome | 2006 |
Synergistic effect of arsenic trioxide and flt3 inhibition on cells with flt3 internal tandem duplication.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mitogen-Activated Protein Kinase Kinases; Mutation; Oxides; Signal Transduction; Tumor Cells, Cultured; Tyrphostins | 2006 |
Arrhythmogenic effects of arsenic trioxide in patients with acute promyelocytic leukemia and an electrophysiological study in isolated guinea pig papillary muscles.
Topics: Action Potentials; Animals; Antineoplastic Agents; Antioxidants; Arrhythmias, Cardiac; Arsenic Trioxide; Arsenicals; Butylated Hydroxytoluene; Electrocardiography; Electrophysiology; Guinea Pigs; Humans; Leukemia, Promyelocytic, Acute; Lipid Peroxidation; Long QT Syndrome; Myocardial Contraction; Oxides; Papillary Muscles; Poisons; Reactive Oxygen Species; Tetrodotoxin | 2006 |
Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Dexamethasone; Drug Therapy, Combination; Follow-Up Studies; Humans; Middle Aged; Multiple Myeloma; Oxides; Recurrence | 2006 |
A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oxides; Pyrazines; Recurrence; Survival Analysis; Treatment Failure; Treatment Outcome | 2007 |
Therapeutic potential of arsenic trioxide with or without interferon-alpha for relapsed/refractory adult T-cell leukemia/lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Disease Progression; Female; Humans; Interferon-alpha; Leukemia-Lymphoma, Adult T-Cell; Male; Oxides; Recurrence; Salvage Therapy; Thrombocytopenia | 2007 |
Arsenic trioxide/ascorbic acid therapy in patients with refractory metastatic colorectal carcinoma: a clinical experience.
Topics: Adult; Aged; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Colorectal Neoplasms; DNA Primers; Gene Expression Regulation; Humans; Middle Aged; Neoplasm Metastasis; Oxides; Thymidylate Synthase; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
[Relationship between radiotherapy enhancing effect of arsenic trioxide and the proliferation and apoptosis of related protein in nasopharyngeal carcinoma patients].
Topics: Adult; Aged; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Carcinoma, Squamous Cell; Cell Proliferation; Combined Modality Therapy; Female; Humans; Immunohistochemistry; Male; Middle Aged; Nasopharyngeal Neoplasms; Oxides; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins c-bcl-2; Radiation-Sensitizing Agents; Young Adult | 2007 |
Arsenic trioxide, thalidomide and retinoid acid combination therapy in higher risk myelodysplastic syndrome patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Oxides; Risk Factors; Thalidomide; Treatment Outcome; Tretinoin | 2008 |
Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.
Topics: Abdominal Pain; Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Constipation; Dermatitis; Dose-Response Relationship, Drug; Female; Headache; Humans; Hyperglycemia; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Lymphoma; Male; Nausea; Oxides; Pancreatitis; Pneumonia; Recurrence; Time Factors; Vomiting; Water-Electrolyte Balance | 2008 |
Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Dexamethasone; Doxorubicin; Drug Evaluation; Humans; Middle Aged; Multiple Myeloma; Oxides; Treatment Outcome; Vincristine | 2008 |
Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Choroid Neoplasms; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Oxides; Skin Neoplasms | 2008 |
Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Oxides; Skin Neoplasms; Temozolomide | 2008 |
Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study.
Topics: Adult; Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Female; Glutathione; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Oxides; Safety | 2009 |
Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prognosis; Remission Induction; Survival Rate | 2008 |
Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial.
Topics: Adult; Aged; Antineoplastic Agents; Antioxidants; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Oxides; Survival Rate; Time Factors; Transplantation Conditioning; Transplantation, Autologous | 2008 |
Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Pancreatic Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome | 2008 |
Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Survival Rate; Time Factors; Tretinoin | 2009 |
Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Chemical and Drug Induced Liver Injury; Drug Eruptions; Drug Synergism; Female; Gastrointestinal Diseases; Hematologic Diseases; Human T-lymphotropic virus 1; Humans; Interferon-alpha; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Oxides; Proviruses; Remission Induction; Viral Load; Zidovudine | 2009 |
Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium | 2009 |
Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia.
Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Disease-Free Survival; Female; Humans; Karyotyping; Leukemia, Promyelocytic, Acute; Male; Neutropenia; Oxides; Remission Induction; Time Factors | 2010 |
Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxides; Prognosis; Remission Induction; Survival Rate; Treatment Outcome; Tretinoin; Young Adult | 2010 |
A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Colorectal Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Oxides; Thymidylate Synthase | 2010 |
Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Follow-Up Studies; Hair; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Nails; Oxides; Recurrence; Remission Induction; Time Factors; Treatment Outcome | 2010 |
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; North America; Oxides; Survival Analysis; Treatment Outcome; Tretinoin; Young Adult | 2010 |
[Recurrences of acute promyelocytic leukemia in children: experience with arsenic trioxide therapy and autologous hematopoietic cell transplantation].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Combined Modality Therapy; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Secondary Prevention; Transplantation Conditioning; Transplantation, Autologous | 2010 |
Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Diarrhea; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Karyotyping; Male; Middle Aged; Myelodysplastic Syndromes; Nausea; Oxides; Risk Factors; Survival Analysis; Survival Rate; Time Factors; Treatment Outcome | 2011 |
A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Administration Schedule; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Oxides; Salvage Therapy; Treatment Outcome | 2011 |
Effect of arsenic trioxide on the treatment of children with newly diagnosed acute promyelocytic leukemia in China.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; China; Cohort Studies; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Remission Induction; Survival Analysis; Tretinoin | 2011 |
Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Down-Regulation; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Oxides; STAT3 Transcription Factor | 2011 |
The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Chemical and Drug Induced Liver Injury; Comorbidity; Cytarabine; Disease-Free Survival; Early Termination of Clinical Trials; Female; Gastrointestinal Diseases; Heart Diseases; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Treatment Outcome | 2011 |
Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Disease-Free Survival; Female; Follow-Up Studies; Humans; Iran; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Survival Analysis | 2011 |
Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cytarabine; Cytokines; Farnesyltranstransferase; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Niacinamide; Oxides; Phenylurea Compounds; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyridines; Sorafenib | 2011 |
Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Azacitidine; Bone Marrow; Bone Marrow Cells; Cohort Studies; Decitabine; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Young Adult | 2011 |
A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Blood Transfusion, Autologous; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Oxides; Prognosis; Pyrazines; Transplantation Conditioning | 2012 |
Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cytarabine; Daunorubicin; Disease-Free Survival; Dyspepsia; Female; Follow-Up Studies; Headache; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Remission Induction; Time Factors; Treatment Outcome; Tretinoin | 2011 |
Arsenic trioxide in patients with refractory multiple myeloma: a prospective, phase II, single-arm study.
Topics: Adult; Aged; Arsenic Trioxide; Arsenicals; Female; Humans; Interleukin-6; Male; Middle Aged; Multiple Myeloma; Oxides; Prospective Studies; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
The early addition of arsenic trioxide versus high-dose arabinoside is more effective and safe as consolidation chemotherapy for risk-tailored patients with acute promyelocytic leukemia: multicenter experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Tretinoin; Young Adult | 2012 |
A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Myelodysplastic-Myeloproliferative Diseases; Oxides; Primary Myelofibrosis; Thalidomide | 2012 |
A combination of thalidomide and arsenic trioxide is effective and well tolerated in patients with myelodysplastic syndromes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Oxides; Pilot Projects; Survival Analysis; Thalidomide; Treatment Outcome | 2012 |
[Multicenter phase II clinical trial of arsenic trioxide injection in the treatment of primary hepatocarcinoma].
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Half-Life; Humans; Injections; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Staging; Oxides; Quality of Life; Remission Induction; Survival Rate; Vomiting | 2011 |
Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia in the ATRA and ATO era.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation, Homologous; Tretinoin | 2012 |
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Treatment Outcome; Tretinoin; Young Adult | 2012 |
Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dose Fractionation, Radiation; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Oxides; Prognosis; Radiotherapy Dosage; Survival Rate; Temozolomide | 2012 |
Improved outcome of adults with aplastic anaemia treated with arsenic trioxide plus ciclosporin.
Topics: Adipogenesis; Adult; Anemia, Aplastic; Arsenic Trioxide; Arsenicals; Blood Cell Count; Blood Transfusion; Bone Marrow; Combined Modality Therapy; Cyclosporine; Drug Therapy, Combination; Female; Humans; Male; Mesenchymal Stem Cells; Oxides; Remission Induction; Treatment Outcome; Young Adult | 2013 |
[The clinical therapeutic effects of arsenic trioxide combined with transcatheter arterial chemoembolization in treating primary liver cancer with pulmonary metastases].
Topics: Adult; Aged; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Oxides; Treatment Outcome | 2012 |
A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oxides; Pyrazines; Recurrence | 2013 |
Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Oncogene Proteins, Fusion; Oxides; Remission Induction; Transcription, Genetic; Transplantation, Autologous; Young Adult | 2013 |
PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Mice; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Signal Transduction; TOR Serine-Threonine Kinases; Transcription Factors; Tumor Suppressor Proteins | 2013 |
A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Astrocytoma; Brain Stem Neoplasms; Chemoradiotherapy; Child; Child, Preschool; Dose Fractionation, Radiation; Female; Follow-Up Studies; Humans; Male; Neoplasm Grading; Oxides; Prognosis; Survival Rate; Young Adult | 2013 |
Resveratrol ameliorates the oxidative damage induced by arsenic trioxide in the feline lung.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Analysis of Variance; Animals; Arsenic Trioxide; Arsenicals; Cat Diseases; Cats; Deoxyguanosine; Female; Gene Expression Regulation, Enzymologic; Lung Diseases; Male; Oxidative Stress; Oxides; Reactive Oxygen Species; Resveratrol; Stilbenes | 2013 |
[Clinical investigation of homoharringtonine in combination with all-transretinoic acid and arsenic trioxide for acute promyelocytic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Harringtonines; Homoharringtonine; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Retrospective Studies; Treatment Outcome; Tretinoin | 2013 |
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Middle Aged; Neutropenia; Oxides; Thrombocytopenia; Tretinoin; Young Adult | 2013 |
Arsenic trioxide suppressed mantle cell lymphoma by downregulation of cyclin D1.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Line, Tumor; Cyclin D1; Dose-Response Relationship, Drug; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Lymphoma, Mantle-Cell; Male; Oxides; Phosphorylation; Proteasome Endopeptidase Complex; Proteolysis; Retinoblastoma Protein; Transcription, Genetic; Ubiquitination | 2014 |
Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Chromosome Aberrations; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxides; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Translocation, Genetic; Tretinoin; Young Adult | 2013 |
Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Drugs, Chinese Herbal; Female; Fever; Follow-Up Studies; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Liver; Maintenance Chemotherapy; Male; Middle Aged; Oxides; Remission Induction; Sulfides; Treatment Outcome; Tretinoin; Young Adult | 2013 |
Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Female; fms-Like Tyrosine Kinase 3; Humans; Karyotype; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mutation; Oncogene Proteins, Fusion; Oxides; Prognosis; Treatment Outcome; Young Adult | 2014 |
Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy.
Topics: Adult; Aged; Aminoglycosides; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Dogs; Female; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Mercaptopurine; Methotrexate; Middle Aged; Oncogene Proteins, Fusion; Oxides; Platelet Count; Remission Induction; Risk; Treatment Outcome; Tretinoin; Young Adult | 2014 |
[Effects of arsenic trioxide on Id4 methylation status in bone marrow mononuclear cells and its clinical efficacy for myelodysplastic syndrome].
Topics: Adult; Aged; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; DNA Methylation; Female; Humans; Inhibitor of Differentiation Proteins; Male; Middle Aged; Myelodysplastic Syndromes; Oxides; Treatment Outcome; Young Adult | 2014 |
Adding ascorbic acid to arsenic trioxide produces limited benefit in patients with acute myeloid leukemia excluding acute promyelocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Oxides; Treatment Outcome | 2014 |
Arsenic trioxide and mannitol for the treatment of acute promyelocytic leukemia relapse in the central nervous system.
Topics: Adolescent; Adult; Arsenic Trioxide; Arsenicals; Blood-Brain Barrier; Central Nervous System Neoplasms; Child; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Male; Mannitol; Middle Aged; Oxides; Recurrence; Remission Induction; Young Adult | 2014 |
Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autografts; Female; Graft Survival; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Peripheral Blood Stem Cell Transplantation | 2015 |
Tamibarotene as maintenance therapy for acute promyelocytic leukemia: results from a randomized controlled trial.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Electrocardiography; Female; Humans; Male; Oxides | 2014 |
Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prospective Studies; Quality of Life; Tretinoin | 2014 |
Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukapheresis; Leukemia, Promyelocytic, Acute; Leukocyte Count; Leukocytosis; Male; Middle Aged; Oxides; Retrospective Studies; Survival Rate; Tretinoin | 2015 |
Arsenic trioxide transarterial chemoembolization with and without additional intravenous administration of arsenic trioxide in unresectable hepatocellular carcinoma with lung metastasis: a single-blind, randomized trial.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; China; Combined Modality Therapy; Drug Administration Schedule; Female; Hepatic Artery; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Oxides; Single-Blind Method; Treatment Outcome; Tumor Burden | 2015 |
A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lymphoma; Male; Middle Aged; Oxides; Recurrence; Treatment Outcome | 2015 |
Nine-month angiographic and two-year clinical follow-up of novel biodegradable-polymer arsenic trioxide-eluting stent versus durable-polymer sirolimus-eluting stent for coronary artery disease.
Topics: Aged; Arsenic Trioxide; Arsenicals; Coronary Angiography; Coronary Artery Disease; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Oxides; Percutaneous Coronary Intervention; Polymers; Sirolimus | 2015 |
Randomized clinical control study of locoregional therapy combined with arsenic trioxide for the treatment of hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Oxides; Proportional Hazards Models; Treatment Outcome | 2015 |
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Biomarkers, Tumor; Cardiovascular Diseases; Cell Differentiation; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; Drug Resistance, Neoplasm; Febrile Neutropenia; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Salvage Therapy; Tetrahydronaphthalenes; Tretinoin | 2015 |
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Denmark; Female; Humans; Idarubicin; Intention to Treat Analysis; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; New Zealand; Oncogene Proteins, Fusion; Oxides; Quality of Life; Real-Time Polymerase Chain Reaction; Time Factors; Treatment Outcome; Tretinoin; United Kingdom; Young Adult | 2015 |
[Efficacy Analysis of Arsenic Trioxide Combined with All Trans Retinoic Acid for Acute Promyelocytic Leukemia].
Topics: Arsenic Trioxide; Arsenicals; Drug Therapy, Combination; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Tretinoin | 2015 |
Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Australia; Consolidation Chemotherapy; Female; Humans; Leukemia, Promyelocytic, Acute; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Remission Induction; Treatment Outcome; Young Adult | 2015 |
Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.
Topics: 3-Iodobenzylguanidine; Adolescent; Adrenal Gland Neoplasms; Adult; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Humans; Male; Neuroblastoma; Oxides; Paraganglioma; Pheochromocytoma; Radiation-Sensitizing Agents; Radiopharmaceuticals; Survival Analysis; Treatment Outcome | 2016 |
Arsenic trioxide-based therapy is suitable for patients with psoriasis-associated acute promyelocytic leukemia - A retrospective clinical study.
Topics: Adolescent; Adult; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Psoriasis; Retrospective Studies; Survival Rate | 2016 |
PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.
Topics: Adolescent; Adult; Aged; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Humans; Induction Chemotherapy; Italy; Kinetics; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mutation; Oncogene Proteins, Fusion; Oxides; Prognosis; Tretinoin; Young Adult | 2016 |
Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cisplatin; Electrophoresis; Female; Humans; Lung Neoplasms; Male; Mice, SCID; Middle Aged; Neoplasm Recurrence, Local; Oxides; Small Cell Lung Carcinoma; Subcutaneous Tissue; Treatment Outcome; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2016 |
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prospective Studies; Risk Factors; Treatment Outcome; Tretinoin; Young Adult | 2017 |
A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Drug Therapy, Combination; Female; Glioma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Oxides; Temozolomide; Treatment Outcome; Young Adult | 2017 |
Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631.
Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Female; Historically Controlled Study; Humans; Leukemia, Promyelocytic, Acute; Male; Mercaptopurine; Methotrexate; Oxides; Young Adult | 2017 |
Effects of arsenic trioxide on the expression of ezrin in hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cytoskeletal Proteins; Female; Humans; Immunohistochemistry; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Oxides | 2017 |
Causes and prognostic factors for early death in patients with acute promyelocytic leukemia treated with single-agent arsenic trioxide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Child; Creatinine; Female; Fibrin Fibrinogen Degradation Products; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides | 2017 |
Characteristics of fibrinolytic disorders in acute promyelocytic leukemia.
Topics: Adult; Aged; Arsenic Trioxide; Arsenicals; Blood Coagulation Disorders; Blood Proteins; Female; Fibrinolysis; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Oxides | 2018 |
Efficacy and safety of early switching to an outpatient therapy model using oral arsenic plus retinoic acid based-regimen in newly diagnosed acute promyelocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic; Arsenic Trioxide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Models, Biological; Survival Rate; Tretinoin | 2019 |
[Therapies for newly diagnosed acute promyelocytic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Japan; Leukemia, Promyelocytic, Acute; Oxides; Prospective Studies; Treatment Outcome; Tretinoin | 2020 |
Curcumin antagonizes inflammation and autophagy induced by arsenic trioxide through immune protection in duck spleen.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Arsenic; Arsenic Trioxide; Autophagy; Beclin-1; Curcumin; Cytokines; Ducks; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Inflammation; Interleukin-18; Interleukin-2; Metals, Heavy; NF-kappa B; Spleen; Tumor Necrosis Factor-alpha | 2022 |
The comparison of plasma arsenic concentration and urinary arsenic excretion during treatment with Realgar-Indigo naturalis formula and arsenic trioxide in children with acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Child; Drugs, Chinese Herbal; Humans; Leukemia, Promyelocytic, Acute; Tretinoin | 2022 |
An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial).
Topics: Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2022 |
Long-term outcome of children with acute promyelocytic leukemia: a randomized study of oral versus intravenous arsenic by SCCLG-APL group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic; Arsenic Trioxide; Arsenicals; Child; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2023 |
2213 other study(ies) available for arsenic and arsenic trioxide
| Article | Year |
|---|---|
Multiple organ failure with the adult respiratory distress syndrome in homicidal arsenic poisoning.
Topics: Adult; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Female; Fetal Death; Homicide; Humans; Intubation, Intratracheal; Male; Multiple Organ Failure; Oxides; Peripheral Nervous System Diseases; Positive-Pressure Respiration; Pregnancy; Respiratory Distress Syndrome | 1992 |
Application of the Tradescantia micronucleus assay for the genetic evaluation of chemical mixtures in soil and aqueous media.
Topics: Arsenic; Arsenic Trioxide; Arsenicals; Dieldrin; Micronucleus Tests; Mutagens; Organometallic Compounds; Oxides; Plants; Soil Pollutants; Water Pollutants, Chemical | 1992 |
Synergistic and antagonistic effects on genotoxicity of chemicals commonly found in hazardous waste sites.
Topics: Arsenic; Arsenic Trioxide; Arsenicals; Dieldrin; Drug Interactions; Micronucleus Tests; Mutagens; Organometallic Compounds; Oxides; Plants; Tetrachloroethylene; Waste Disposal, Fluid; Water Pollutants, Chemical | 1992 |
[The radiological findings in poisonings by metals].
Topics: Adult; Antacids; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Bismuth; Emergencies; Female; Humans; Lead Poisoning; Male; Mercury Poisoning; Middle Aged; Oxides; Poisoning; Radiography; Suicide; Suicide, Attempted | 1992 |
Relation between airborne arsenic trioxide and urinary excretion of inorganic arsenic and its methylated metabolites.
Topics: Adult; Air Pollutants, Occupational; Arsenic; Arsenic Trioxide; Arsenicals; Chemical Industry; Humans; Male; Methylation; Oxides | 1992 |
Pyruvate and lactate metabolism in livers of guinea pigs perfused with chelating agents after repeated treatment with As2O3.
Topics: Animals; Antidotes; Arsenic; Arsenic Trioxide; Arsenicals; Chelating Agents; Dimercaprol; Guinea Pigs; In Vitro Techniques; Lactates; Lactic Acid; Liver; Male; Oxides; Oxygen Consumption; Perfusion; Pyruvates; Pyruvic Acid; Succimer | 1991 |
Effect of oral treatment with Bal, DMPS or DMSA arsenic in organs of mice injected with arsenic trioxide.
Topics: Administration, Oral; Animals; Arsenic; Arsenic Trioxide; Arsenicals; Dimercaprol; Male; Mice; Oxides; Succimer; Tissue Distribution; Unithiol | 1991 |
Reduction of arsenic trioxide toxicity in mice by repeated treatment with glucose.
Topics: Animals; Arsenic; Arsenic Trioxide; Arsenicals; Brain Chemistry; Glucose; Glycogen; Male; Mice; Muscles; Oxides | 1991 |
Effect of glucose treatment on carbohydrate content in various organs in mice after acute As2O3 poisoning.
Topics: Administration, Cutaneous; Animals; Arsenic; Arsenic Trioxide; Arsenicals; Brain Chemistry; Glucose; Glycogen; Kidney; Liver Glycogen; Male; Mice; Muscles; Oxides | 1991 |
[Arsenical necrosis still exists... I have seen it].
Topics: Adult; Alveolar Process; Arsenic; Arsenic Trioxide; Arsenicals; Dental Pulp Devitalization; Female; Humans; Mandibular Nerve; Mouth Mucosa; Osteonecrosis; Oxides; Paresthesia | 1991 |
Effect of sodium dichromate on carbohydrate metabolism.
Topics: Animals; Arsenic; Arsenic Trioxide; Arsenicals; Blood Glucose; Blood Urea Nitrogen; Chromates; Creatinine; Dose-Response Relationship, Drug; Insulin; Insulin Secretion; Lactates; Male; Oxides; Potassium Cyanide; Pyruvates; Rats; Rats, Inbred Strains; Reference Values; Time Factors | 1991 |
Central hyperthermic effect of arsenic in rabbits.
Topics: Animals; Arsenic; Arsenic Trioxide; Arsenicals; Aspirin; Body Temperature; Cerebral Ventricles; Dimercaprol; Dose-Response Relationship, Drug; Fever; Injections, Intraventricular; Male; Oxides; Phenoxybenzamine; Rabbits | 1991 |
Eradication of East Coast fever.
Topics: Animals; Arsenic; Arsenic Trioxide; Arsenicals; Cattle; Cost-Benefit Analysis; Malawi; Oxides; Theileriasis; Tick Control; Time Factors | 1991 |
Arsenic exposures in Mississippi: a review of cases.
Topics: Accidents, Home; Adolescent; Adult; Arsenic; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Child, Preschool; Environmental Exposure; Evaluation Studies as Topic; Female; Homicide; Humans; Male; Mississippi; Oxides; Poisoning; Retrospective Studies; Rodenticides; Suicide, Attempted | 1991 |
Massive acute arsenic poisoning.
Topics: Acute Disease; Adult; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Charcoal; Dimercaprol; Fluid Therapy; Humans; Male; Oxides; Poisoning; Suicide | 1991 |
[Effects of As2O3, MNNG and B(a)P on epithelia of human fetal tracheae and rat tracheae in organ culture].
Topics: Animals; Arsenic; Arsenic Trioxide; Arsenicals; Benzo(a)pyrene; Carcinogens; Epithelium; Fetus; Humans; Metaplasia; Methylnitronitrosoguanidine; Organ Culture Techniques; Oxides; Precancerous Conditions; Rats; Trachea; Tracheal Neoplasms | 1990 |
Efficacy of various dithiol compounds in acute As2O3 poisoning in mice.
Topics: Animals; Arsenic; Arsenic Trioxide; Arsenicals; Dimercaprol; Guinea Pigs; Male; Mice; Oxides; Succimer; Sulfhydryl Compounds; Unithiol | 1990 |
Effect of glucose in mice after acute experimental poisoning with arsenic trioxide (As2O3).
Topics: Animals; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Death; Diarrhea; Glucose; Insulin; Male; Mice; Oxides; Sodium Chloride | 1990 |
[Effect of S-adenosylmethionine on methylation of inorganic arsenic].
Topics: Animals; Arsenic; Arsenic Trioxide; Arsenicals; Cricetinae; Liver; Male; Mesocricetus; Methylation; Oxides; S-Adenosylmethionine | 1990 |
Acute toxicity testing in the nonlethal dose range: a new approach.
Topics: Acetanilides; Administration, Oral; Aniline Compounds; Animals; Arsenic; Arsenic Trioxide; Arsenicals; Cadmium; Cadmium Chloride; Dose-Response Relationship, Drug; Female; Methods; Oxides; Paraquat; Phenylmercuric Acetate; Poisoning; Pyrogallol; Rats; Rats, Inbred Strains; Sodium Salicylate; Thallium; Toxicology | 1990 |
The effect of arsenic trioxide on brain monoamine metabolism and locomotor activity of mice.
Topics: Administration, Oral; Animals; Arsenic; Arsenic Trioxide; Arsenicals; Brain; Brain Chemistry; Male; Mice; Motor Activity; Oxides | 1990 |
Effect of chelating agents on biliary excretion of arsenic in perfused livers of guinea pigs pretreated with As2O3.
Topics: Animals; Arsenic; Arsenic Trioxide; Arsenicals; Bile; Chelating Agents; Dose-Response Relationship, Drug; Guinea Pigs; Liver; Male; Metabolic Clearance Rate; Oxides; Perfusion; Toluene | 1990 |
Environmental and workplace contamination in the semiconductor industry: implications for future health of the workforce and community.
Topics: Arsenic; Arsenic Trioxide; Arsenicals; Environmental Health; Environmental Monitoring; Forecasting; Gallium; Hazardous Substances; Humans; Industry; Oxides; Semiconductors | 1990 |
Rhabdomyolysis in fatal arsenic trioxide poisoning.
Topics: Acute Kidney Injury; Adult; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Humans; Male; Oxides; Rhabdomyolysis | 1989 |
Clastogenicity evaluation of seven chemicals commonly found at hazardous industrial waste sites.
Topics: Aldrin; Arsenic; Arsenic Trioxide; Arsenicals; Benz(a)Anthracenes; Biological Assay; Dieldrin; Dose-Response Relationship, Drug; Heptachlor; Industrial Waste; Micronucleus Tests; Mutagens; Organometallic Compounds; Oxides; Plants; Soil Pollutants; Tetrachloroethylene; Water Pollutants; Water Pollutants, Chemical | 1989 |
Arsenic oxide-induced thermotolerance in Saccharomyces cerevisiae.
Topics: Arsenates; Arsenic; Arsenic Trioxide; Arsenicals; Arsenites; Heat-Shock Proteins; Hot Temperature; Kinetics; Methionine; Oxides; Saccharomyces cerevisiae | 1989 |
Amelioration of selenium toxicity by arsenicals and cysteine.
Topics: Animal Feed; Animals; Arsenic; Arsenic Trioxide; Arsenicals; Chickens; Cysteine; Liver; Male; Oxides; Poultry Diseases; Selenium; Weight Gain | 1989 |
Malignant neoplasms among residents who drank well water contaminated by arsenic from a king's yellow factory.
Topics: Adult; Aged; Arsenic; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Chemical Industry; Child; Cohort Studies; Drinking; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neoplasms, Multiple Primary; Oxides; Retrospective Studies; Smoking; Sulfides; Water Pollution, Chemical; Water Supply | 1989 |
Reactivity of resistance blood vessels ex vivo after administration of toxic chemicals to laboratory animals: arteriolotoxicity.
Topics: Animals; Arsenic; Arsenic Trioxide; Arsenicals; Arteries; Arterioles; Blood Pressure; Blood Vessels; Cadmium; Cadmium Chloride; Female; Hindlimb; Norepinephrine; Organometallic Compounds; Oxides; Perfusion; Rats; Rats, Inbred Strains; Vascular Resistance | 1989 |
Effects on mitochondrial metabolism in livers of guinea pigs after a single or repeated injection of As2O3.
Topics: Animals; Arsenic; Arsenic Trioxide; Arsenicals; Guinea Pigs; In Vitro Techniques; Male; Mitochondria, Liver; Oxides | 1989 |
[Research on the traditional process of preparing realgar].
Topics: Arsenic; Arsenic Trioxide; Arsenicals; Hot Temperature; Materia Medica; Oxides; Technology, Pharmaceutical; Temperature | 1987 |
[Arsenous anhydride poisoning. Peripheral neuropathy and changes in cognitive functions].
Topics: Adult; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Brain Diseases; Cognition Disorders; Female; Humans; Oxides; Peripheral Nervous System Diseases; Suicide, Attempted | 1985 |
Effect of As2O3 on gluconeogenesis.
Topics: Acetoacetates; Acetyl Coenzyme A; Animals; Arsenic; Arsenic Trioxide; Arsenicals; Fasting; Gluconeogenesis; Glutathione; Hydroxybutyrates; Kidney Tubules; L-Lactate Dehydrogenase; Liver; Male; Oxides; Rats; Rats, Inbred Strains | 1988 |
On living in a arsenical atmosphere. Part I: Hair arsenic.
Topics: Adolescent; Adult; Air Pollutants, Occupational; Arsenic; Arsenic Trioxide; Arsenicals; Child; Female; Food Analysis; Gold; Hair; Humans; Male; Middle Aged; Mining; Oxides; Zimbabwe | 1988 |
[Experimental studies on the acute and chronic combined action of arsenic and fluoride].
Topics: Animals; Arsenic; Arsenic Trioxide; Arsenicals; Drug Antagonism; Female; Lethal Dose 50; Male; Oxides; Rabbits; Sodium Fluoride | 1988 |
Fatal arsenic poisoning--a case report.
Topics: Accidents, Occupational; Arsenic; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Autopsy; Humans; Male; Metallurgy; Oxides; Tissue Distribution | 1988 |
[The relation of As2O3-induced analgesia and monoamine levels in the brain of mice].
Topics: Amines; Aminopyrine; Analgesics; Animals; Arsenic; Arsenic Trioxide; Arsenicals; Brain Chemistry; Male; Mice; Mice, Inbred Strains; Norepinephrine; Oxides; Serotonin | 1986 |
[Antineoplastic action of As2O3].
Topics: Animals; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Female; Mice; Mice, Inbred Strains; Oxides | 1986 |
Acute arsenic ingestion.
Topics: Acute Kidney Injury; Adult; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Blood Gas Analysis; Critical Care; Hemodynamics; Humans; Male; Oxides; Renal Dialysis; Suicide | 1987 |
[A case of lung cancer associated with chronic arsenic poisoning caused by neighborhood exposure of As2O3 from Toroku mine].
Topics: Aged; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Carcinoma, Squamous Cell; Chronic Disease; Female; Humans; Lung Neoplasms; Mining; Occupational Diseases; Oxides | 1987 |
Cumulative exposure to arsenic and its relationship to respiratory cancer among copper smelter employees.
Topics: Air Pollutants, Occupational; Arsenic; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Copper; Follow-Up Studies; Humans; Male; Metallurgy; Montana; Occupational Diseases; Oxides; Respiratory Tract Neoplasms; Time Factors | 1986 |
[Combined effects of arsenous anhydride and germanium dioxide after their hygienic regulation in atmospheric air].
Topics: Air Pollutants; Animals; Arsenic; Arsenic Trioxide; Arsenicals; Drug Synergism; Germanium; Male; Maximum Allowable Concentration; Oxides; Rats; Sperm Motility; Sulfhydryl Compounds | 1986 |
Extensive osteolysis of the mandible following devitalization of a tooth by arsenic trioxide.
Topics: Adult; Arsenic; Arsenic Trioxide; Arsenicals; Bone Resorption; Dental Pulp Devitalization; Diagnosis, Differential; Humans; Male; Mandibular Diseases; Osteolysis; Oxides | 1985 |
Lung clearance, translocation, and acute toxicity of arsenic, beryllium, cadmium, cobalt, lead, selenium, vanadium, and ytterbium oxides following deposition in rat lung.
Topics: Animals; Arsenic; Arsenic Trioxide; Arsenicals; Beryllium; Biological Transport; Cadmium; Cadmium Compounds; Cobalt; Environmental Exposure; Female; Lead; Lung; Metabolic Clearance Rate; Metals; Oxides; Rats; Rats, Inbred Strains; Selenium; Solubility; Tissue Distribution; Vanadium; Ytterbium | 1985 |
Effects of arsenic trioxide inhalation exposure on pulmonary antibacterial defenses in mice.
Topics: Aerosols; Animals; Arsenic; Arsenic Trioxide; Arsenicals; Atmosphere Exposure Chambers; Female; Klebsiella pneumoniae; Lung; Mice; Oxides; Pneumococcal Infections; Sulfur Radioisotopes | 1985 |
[Experimental research to study the combined action of arsenous anhydride and lead acetate in their hygienic regulation in the atmosphere].
Topics: Air Pollutants; Animals; Arsenic; Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Drug Synergism; Lead; Male; Maximum Allowable Concentration; Organometallic Compounds; Oxides; Sperm Motility; Sulfhydryl Compounds; Time Factors | 1986 |
Comparative pulmonary toxicity of gallium arsenide, gallium(III) oxide, or arsenic(III) oxide intratracheally instilled into rats.
Topics: Analysis of Variance; Animals; Arsenic; Arsenic Trioxide; Arsenicals; Gallium; Intubation, Intratracheal; Lung; Male; Organ Size; Oxides; Rats; Rats, Inbred F344 | 1986 |
Metabolism and excretion of orally administrated arsenic trioxide in the hamster.
Topics: Animals; Arsenic; Arsenic Trioxide; Arsenicals; Cacodylic Acid; Cricetinae; Erythrocytes; Kinetics; Male; Mesocricetus; Methylation; Oxides; Plasma; Tissue Distribution | 1985 |
[Acute poisoning with arsenous anhydride].
Topics: Acute Disease; Adult; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Humans; Male; Oxides | 1985 |
Arsenic speciation in urine from humans intoxicated by inorganic arsenic compounds.
Topics: Adult; Arsenates; Arsenic; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Cacodylic Acid; Female; Humans; Male; Methylation; Oxides; Time Factors | 1985 |
The effect of arsenical dips on Parafilaria bovicola in artificially infected cattle in South Africa.
Topics: Animals; Arsenic; Arsenic Trioxide; Arsenicals; Cattle; Cattle Diseases; Chlorfenvinphos; Filariasis; Insecticides; Male; Organothiophosphorus Compounds; Oxides | 1985 |
Carcinomas of the respiratory tract in hamsters given arsenic trioxide and/or benzo[a]pyrene by the pulmonary route.
Topics: Animals; Arsenic; Arsenic Trioxide; Arsenicals; Benzo(a)pyrene; Benzopyrenes; Carcinogens; Charcoal; Cricetinae; Drug Synergism; Dust; Lung Neoplasms; Male; Mesocricetus; Neoplasms, Experimental; Oxides | 1984 |
Arsenic contamination: metabolic effects and localization in rats.
Topics: Animals; Arsenic; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Energy Metabolism; Female; In Vitro Techniques; Kinetics; Oxides; Oxygen Consumption; Rats; Rats, Inbred Strains; Tissue Distribution | 1981 |
[Relationship between arsenic-induced hypothermia and brain monoamines. (2). The roles of noradrenaline and dopamine].
Topics: Adrenergic alpha-Antagonists; Animals; Arsenic; Arsenic Trioxide; Arsenicals; Body Temperature; Brain; Dopamine; Dopamine beta-Hydroxylase; Haloperidol; Male; Norepinephrine; Oxides; Rabbits | 1982 |
[Effect of As203 on monoamine levels in the rat brain and sleep duration induced by barbiturates].
Topics: Animals; Arsenic; Arsenic Trioxide; Arsenicals; Brain; Brain Chemistry; Dopamine; Neurotransmitter Agents; Norepinephrine; Oxides; Rats; Rats, Inbred Strains; Serotonin; Sleep; Thiopental | 1982 |
Effects of diiospropyl-1,3-dithiol-2-ylidene malonate (NKK-105) on acute toxicity of various drugs and heavy metals.
Topics: Animals; Antidotes; Arsenic; Arsenic Trioxide; Arsenicals; Atropine; Cadmium; Chloral Hydrate; Lead; Lethal Dose 50; Liver; Male; Malonates; Mercuric Chloride; Mercury; Metals; Oxides; Potassium Cyanide; Rats; Rats, Inbred Strains; Strychnine; Tetrodotoxin | 1982 |
Long term consequences of arsenical treatment for multiple sclerosis.
Topics: Adult; Arsenic; Arsenic Trioxide; Arsenicals; Carcinoma, Transitional Cell; Humans; Hypertension, Portal; Male; Multiple Sclerosis; Oxides; Urinary Bladder Neoplasms | 1983 |
[Detection of arsenic-trioxide in the Niuhuang Jiedu tablet].
Topics: Arsenic; Arsenic Trioxide; Arsenicals; Medicine, Chinese Traditional; Medicine, East Asian Traditional; Oxides; Tablets | 1983 |
[Detection of arsenic trioxide in Niuhuang Jiedu tablet].
Topics: Arsenic; Arsenic Trioxide; Arsenicals; Medicine, Chinese Traditional; Medicine, East Asian Traditional; Oxides; Tablets | 1983 |
[The mechanisms of antagonistic action of prostaglandin E1 against As2O3-induced hypothermia].
Topics: alpha-Methyltyrosine; Alprostadil; Animals; Arsenic; Arsenic Trioxide; Arsenicals; Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; Catecholamines; Dopamine Antagonists; Fenclonine; Hypothermia; Indoles; Male; Methyltyrosines; Methysergide; Oxides; Prostaglandins E; Rabbits; Tyrosine | 1984 |
[Arsenical polyneuropathy. Report of two cases (author's transl)].
Topics: Adult; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Arsphenamine; Female; Humans; Male; Middle Aged; Oxides; Peripheral Nervous System Diseases; Syphilis | 1981 |
[Arsenic trioxide inhibition of the thiophosphamide induction of mutations in mouse germ and somatic cells].
Topics: Animals; Arsenic; Arsenic Trioxide; Arsenicals; Bone Marrow; Erythrocytes; Genes, Dominant; Genes, Lethal; Male; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mutation; Oxides; Spermatozoa; Thiotepa | 1984 |
In vitro solubility and in vivo toxicity of gallium arsenide.
Topics: Animals; Arsenic; Arsenic Trioxide; Arsenicals; Body Weight; Dose-Response Relationship, Drug; Feces; Gallium; Lung; Male; Organ Size; Oxides; Porphyrins; Rats; Rats, Inbred F344; Solubility | 1984 |
Accidental arsenical toxicity of cattle.
Topics: Administration, Topical; Animals; Arsenic; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Australia; Cattle; Cattle Diseases; Female; Lice Infestations; Oxides | 1984 |
[Topographic distribution of arsenous anhydride in pregnant mice using macroscopic autoradiography].
Topics: Animals; Arsenic; Arsenic Trioxide; Arsenicals; Autoradiography; Female; Fetus; Maternal-Fetal Exchange; Mice; Oxides; Pregnancy; Pregnancy, Animal; Radioisotopes; Time Factors | 1983 |
Tumorigenicity of arsenic trioxide to the lung in Syrian golden hamsters by intermittent instillations.
Topics: Adenoma; Animals; Arsenic; Arsenic Trioxide; Arsenicals; Cricetinae; Female; Lung Neoplasms; Mesocricetus; Oxides; Probability; Trachea | 1983 |
Discrepancy between epidemiological evidence and animal experimental result.
Topics: Adenoma; Animals; Arsenic; Arsenic Trioxide; Arsenicals; Carcinogens; Cricetinae; Female; Lung Neoplasms; Mesocricetus; Occupational Diseases; Oxides | 1983 |
The speciation of the chemical forms of arsenic in the biological monitoring of exposure to inorganic arsenic.
Topics: Arsenic; Arsenic Trioxide; Arsenicals; Arsenites; Cacodylic Acid; Chromatography, Ion Exchange; Environmental Exposure; Food Analysis; Humans; Male; Oxides; Spectrophotometry, Atomic | 1984 |
[In the form of a "necrologie": As2O3].
Topics: Arsenic; Arsenic Trioxide; Arsenicals; Dental Pulp Diseases; Humans; Oxides; Root Canal Therapy | 1981 |
[Studies on anti-inflammatory effect of arsenic, especially on anti-edematous effect (author's transl)].
Topics: Adenosine Triphosphate; Animals; Anti-Inflammatory Agents; Arsenic; Arsenic Trioxide; Arsenicals; Edema; Granulation Tissue; Male; Oxides; Rats | 1981 |
[Review of the maximum permissible concentration of arsenic trioxide in the atmosphere of populated places].
Topics: Air Pollutants; Animals; Arsenic; Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Embryo, Mammalian; Environmental Exposure; Female; Maximum Allowable Concentration; Mutagens; Oxides; Pregnancy; Rats | 1982 |
Comparison of arsenic trioxide and calcium arsenate retention in the rat lung after intratracheal instillation.
Topics: Animals; Arsenates; Arsenic; Arsenic Trioxide; Arsenicals; Lung; Lung Neoplasms; Male; Neoplasms, Experimental; Oxides; Rats; Rats, Inbred Strains | 1982 |
The possible role of direct ingestion on the overall absorption of cadmium or arsenic in workers exposed to CdO or As2O3 dust.
Topics: Air; Air Pollutants; Air Pollutants, Occupational; Arsenic; Arsenic Trioxide; Arsenicals; Cadmium; Cadmium Compounds; Dust; Environmental Exposure; Feces; Female; Hand; Humans; Male; Mouth; Occupational Medicine; Oxides | 1982 |
[Hygienic establishment of the maximum permissible concentration of arsenous anhydride in the atmosphere].
Topics: Air Pollutants; Animals; Arsenic; Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Environmental Exposure; Maximum Allowable Concentration; Oxides; Rats; Time Factors | 1982 |
Occupational exposure to arsine. An epidemiologic reappraisal of current standards.
Topics: Air Pollutants; Air Pollutants, Occupational; Arsenic; Arsenic Trioxide; Arsenicals; Humans; Maximum Allowable Concentration; Occupational Medicine; Oxides | 1982 |
[Pharmacokinetics of arsenic trioxide in the mouse].
Topics: Animals; Arsenic; Arsenic Trioxide; Arsenicals; Female; Intestinal Absorption; Kinetics; Mice; Oxides | 1982 |
[A case of fetal arsenous anhydride poisoning].
Topics: Adolescent; Arsenic; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Female; Humans; Oxides | 1980 |
Arsenic metabolites in hair, blood and urine in workers exposed to arsenic trioxide.
Topics: Adult; Aged; Air Pollutants, Occupational; Arsenic; Arsenic Trioxide; Arsenicals; Environmental Exposure; Hair; Humans; Middle Aged; Oxides | 1980 |
The metabolism of arsenic in humans acutely intoxicated by As2O3. Its significance for the duration of BAL therapy.
Topics: Adult; Arsenic; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Child; Dimercaprol; Female; Humans; Male; Oxides; Time Factors | 1981 |
[Studies on As2O3-induced hyperglycemia (author's transl)].
Topics: Administration, Oral; Adrenal Glands; Adrenal Medulla; Adrenalectomy; Animals; Arsenic; Arsenic Trioxide; Arsenicals; Blood Glucose; Catecholamines; Hyperglycemia; Liver Glycogen; Male; Oxides; Rats; Rats, Inbred Strains; Splanchnic Nerves; Vagotomy | 1981 |
Long-term effects of acute arsenical poisoning.
Topics: Adult; Aged; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Food Contamination; Humans; Male; Middle Aged; Oxides; Skin Ulcer; Surveys and Questionnaires; Time Factors; Ultraviolet Rays | 1981 |
Results of hemodialysis & hemoperfusion in the treatment of acute arsenic ingestion.
Topics: Adult; Arsenic; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Hemoperfusion; Humans; Male; Oxides; Renal Dialysis | 1981 |
Influence of vinyl chloride monomer (VCM) and As2O3 on rat liver cell proliferation after partial hepatectomy.
Topics: Alkaline Phosphatase; Animals; Arsenic; Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Hepatectomy; Liver; Liver Neoplasms; Liver Regeneration; Male; Mitosis; Oxides; Rats; Vinyl Chloride; Vinyl Compounds | 1980 |
Therapeutic efficacy of new dimercaptosuccinic acid (DMSA) analogues in acute arsenic trioxide poisoning in mice.
Topics: Animals; Antidotes; Arsenic; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Injections, Intraperitoneal; Injections, Subcutaneous; Intubation, Gastrointestinal; Male; Mice; Oxides; Poisoning; Succimer | 1993 |
Assessment of exposure to arsenic among smelter workers: a five-year follow-up.
Topics: Adult; Aged; Air Pollutants, Occupational; Arsenic; Arsenic Trioxide; Arsenicals; Electromyography; Follow-Up Studies; Humans; Male; Middle Aged; Motor Neurons; Occupational Diseases; Occupational Exposure; Oxides; Peripheral Nerves; Peripheral Nervous System Diseases; Reaction Time; Risk Factors; Sensory Receptor Cells; Synaptic Transmission | 1994 |
More poison from Agatha Christie.
Topics: Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Oxides; Solubility | 1994 |
Temperature dependent influence of As2O3, HgHPO4 and KCl on lysosomal acid phosphatase isolated from rat liver.
Topics: Acid Phosphatase; Animals; Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Liver; Lysosomes; Male; Mercury Compounds; Oxides; Phosphates; Potassium Chloride; Rats; Rats, Wistar; Thermodynamics | 1994 |
Effect of various antidotes on the biliary and intestinal excretion of arsenic in situ and into the feces in vivo in guinea-pigs after injection of As2O3.
Topics: Animals; Antidotes; Arsenic; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Bile; Colon; Dimercaprol; Feces; Guinea Pigs; Injections, Intravenous; Jejunum; Male; Oxides; Perfusion; Poisoning; Succimer; Sulfonamides; Unithiol | 1994 |
Antidotal efficacy of newly synthesized dimercaptosuccinic acid (DMSA) monoesters in experimental arsenic poisoning in mice.
Topics: Animals; Antidotes; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Brain; Esters; Intestine, Large; Intestine, Small; Kidney; Male; Mice; Mice, Inbred Strains; Oxides; Succimer | 1995 |
[Acute poisoning from arsenous anhydride ingestion. A clinical case].
Topics: Acute Disease; Adolescent; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Feces; Female; Humans; Oxides; Poisoning; Suicide, Attempted; Time Factors | 1993 |
Urinary excretion of porphyrins by smelter workers chronically exposed to arsenic dust.
Topics: Adult; Arsenic; Arsenic Trioxide; Arsenicals; Coproporphyrins; Dust; Humans; Male; Middle Aged; Occupational Exposure; Oxides; Porphyrins; Uroporphyrins | 1993 |
Influence of inorganic and organic arsenicals on intestinal transfer of nutrients.
Topics: Animals; Arsenic; Arsenic Trioxide; Arsenicals; Body Water; Dose-Response Relationship, Drug; Glucose; Intestinal Mucosa; Jejunum; Leucine; Male; Oxides; Rats; Rats, Sprague-Dawley; Sodium | 1993 |
Effect of DMPS and various adsorbents on the arsenic excretion in guinea-pigs after injection with As2O3.
Topics: Animals; Anion Exchange Resins; Antidotes; Arsenic; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Bentonite; Charcoal; Cholestyramine Resin; Feces; Guinea Pigs; Injections, Subcutaneous; Male; Oxides; Unithiol | 1995 |
The delayed lung responses to single and repeated intratracheal administration of pure cobalt and hard metal powder in the rat.
Topics: Acetylglucosaminidase; Albumins; Animals; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Bronchoalveolar Lavage Fluid; Cobalt; Disease Models, Animal; Female; Fibronectins; Hyaluronic Acid; L-Lactate Dehydrogenase; Lung; Oxides; Powders; Proteins; Pulmonary Fibrosis; Rats; Rats, Sprague-Dawley; Silicon Dioxide; Staining and Labeling; Trachea; Tungsten Compounds | 1995 |
Interlaboratory validation of a new assay for DNA-protein crosslinks.
Topics: Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Biological Assay; Cadmium; Cadmium Chloride; Cell Line, Transformed; Cells, Cultured; Chlorides; Chromates; Cisplatin; Copper; Copper Sulfate; Cross-Linking Reagents; DNA; DNA Damage; DNA-Binding Proteins; Humans; Laboratories; Lead; Metals; Mutagens; Nitrates; Oxides; Potassium Compounds; Reproducibility of Results | 1996 |
Ancient remedy performs new tricks.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Medicine, Chinese Traditional; Oxides; Remission Induction | 1996 |
In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Lymphoma, Large B-Cell, Diffuse; Medicine, Chinese Traditional; Monocytes; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured | 1996 |
The use of haemodialysis and 2,3 propanesulphonate (DMPS) to manage acute oral poisoning by lethal dose of arsenic trioxide.
Topics: Adult; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Chelating Agents; Female; Humans; Oxides; Poisoning; Renal Dialysis; Toothpastes; Unithiol | 1996 |
Testicular toxicity of gallium arsenide, indium arsenide, and arsenic oxide in rats by repetitive intratracheal instillation.
Topics: Animals; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Gallium; Indium; Male; Organ Size; Oxides; Rats; Rats, Wistar; Sperm Count; Spermatozoa; Testis | 1996 |
Speciation of arsenic oxides using laser desorption/ionization time-of-flight mass spectrometry.
Topics: Arsenic Trioxide; Arsenicals; Oxidation-Reduction; Oxides; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Spectrophotometry, Ultraviolet | 1996 |
The PML and PML/RARalpha domains: from autoimmunity to molecular oncology and from retinoic acid to arsenic.
Topics: Animals; Antibodies, Antinuclear; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autoantigens; Autoimmune Diseases; Cell Differentiation; CHO Cells; Cricetinae; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Transcription Factors; Transfection; Tretinoin; Tumor Suppressor Proteins | 1996 |
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Cell Adhesion; Cell Division; Cell Survival; DNA, Neoplasm; Drug Resistance, Neoplasm; Humans; Immunophenotyping; Kinetics; Leukemia, Promyelocytic, Acute; Oxides; Phagocytosis; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Subcellular Fractions; Time Factors; Tretinoin; Tumor Cells, Cultured | 1997 |
Delicious poison: arsenic trioxide for the treatment of leukemia.
Topics: Adult; Antineoplastic Agents; Apoptosis; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Cell Differentiation; Fatal Outcome; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Male; Oxides; Splenomegaly | 1997 |
Lung cancer mortality in a cohort of workers employed at a cadmium recovery plant in the United States: an analysis with detailed job histories.
Topics: Arsenic Trioxide; Arsenicals; Cadmium Compounds; Cohort Studies; Follow-Up Studies; Humans; Lung Neoplasms; Male; Metallurgy; Occupational Exposure; Oxides; Poisson Distribution; Risk Assessment; United States | 1997 |
Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Cell Division; Cell Line, Transformed; Cell Survival; DNA Damage; DNA Fragmentation; Drug Screening Assays, Antitumor; Herpesvirus 4, Human; Humans; Kinetics; Leukemia, Lymphocytic, Chronic, B-Cell; Melarsoprol; Oxides; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Time Factors; Transcription, Genetic; Tumor Cells, Cultured | 1997 |
Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus.
Topics: Arsenic Trioxide; Arsenicals; Cell Nucleus; HeLa Cells; Humans; Molecular Weight; Neoplasm Proteins; Nuclear Proteins; Oxides; Phosphorylation; Promyelocytic Leukemia Protein; SUMO-1 Protein; Transcription Factors; Tumor Suppressor Proteins; Ubiquitins | 1998 |
Arsenic and apoptosis in the treatment of acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Tretinoin | 1998 |
Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Northern; Blotting, Western; Down-Regulation; Electrophoresis, Polyacrylamide Gel; Flow Cytometry; Humans; Leukemia, Promyelocytic, Acute; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transglutaminases; Tretinoin; Tumor Cells, Cultured | 1998 |
Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Microscopy, Confocal; Oxides; Tretinoin; Tumor Cells, Cultured | 1998 |
Suppression of arsenic-induced chromosome mutagenicity by antimony.
Topics: Animals; Antimony; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Cell Line; Cell Survival; Chlorides; Chromosome Aberrations; Chromosomes; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Micronucleus Tests; Mutagenesis; Mutagenicity Tests; Mutagens; Oxides | 1998 |
Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Cell Division; Embryo, Mammalian; Fibroblasts; Gene Expression Regulation; Humans; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Melarsoprol; Mice; Neoplasm Proteins; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Proto-Oncogene Proteins c-bcl-2; Receptors, Retinoic Acid; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins | 1998 |
Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: activation of caspases and down-regulation of Bcl-2 protein.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; DNA Fragmentation; Down-Regulation; Electrophoresis, Agar Gel; Humans; Leukemia, B-Cell; Neoplasm Proteins; Oxides; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 1998 |
The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Division; Cell Survival; DNA Fragmentation; DNA, Neoplasm; Humans; Interphase; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Oxides; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 1998 |
[Double effects of arsenic trioxide (As2O3) on acute promyelocytic leukemic cell line].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Transformation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Tumor Cells, Cultured | 1997 |
Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.
Topics: Adolescent; Adult; Aged; Antigens, CD; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Caspases; Cell Differentiation; Child; Humans; Immunophenotyping; Leukemia, Promyelocytic, Acute; Leukocytes, Mononuclear; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction | 1998 |
Arsenic--new life for an old potion.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Remission Induction | 1998 |
Acute promyelocytic leukemia: a curable disease.
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Drug Resistance; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Karyotyping; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neoplasm, Residual; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Recurrence; Research; Rome; Transcription Factors; Tretinoin; Tumor Suppressor Proteins | 1998 |
Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Division; HTLV-I Infections; Human T-lymphotropic virus 1; Humans; Oxides; T-Lymphocytes; Tretinoin; Tumor Cells, Cultured | 1998 |
Scientists explore use of arsenic in therapy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Neoplasms; Oxides | 1998 |
Application of heavy metal and cytokine for differentiation-inducing therapy in acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Transformation, Neoplastic; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin; Tumor Cells, Cultured | 1998 |
Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system.
Topics: Acetylcysteine; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cells, Cultured; Drug Synergism; Glutathione; Growth Inhibitors; Hematopoietic Stem Cells; HL-60 Cells; Humans; Lymphoma; Mice; Mice, Inbred Strains; Oxidation-Reduction; Oxides; Tumor Cells, Cultured | 1999 |
Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Division; Cell Line, Transformed; Cell Transformation, Viral; Cells, Cultured; Drug Synergism; Human T-lymphotropic virus 1; Humans; Interferon-alpha; Jurkat Cells; Leukocytes, Mononuclear; Oxides; T-Lymphocytes; Tumor Cells, Cultured; Viral Proteins | 1999 |
Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia.
Topics: Acute Disease; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Chronic Disease; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence | 1998 |
Arsenic speciation in human organs following fatal arsenic trioxide poisoning--a case report.
Topics: Adult; Arsenic; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Fatal Outcome; Humans; Male; Oxides; Spectrophotometry, Atomic; Tissue Distribution | 1999 |
Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Differentiation; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; DNA-Binding Proteins; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Humans; Kruppel-Like Transcription Factors; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Zinc Finger Protein; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transcription Factors; Translocation, Genetic; Tretinoin; Tumor Cells, Cultured | 1999 |
Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Cell Division; Cell Line; Cell Survival; Flow Cytometry; Fluorescent Antibody Technique, Indirect; Humans; Kinetics; Lymphocyte Activation; Melarsoprol; Multiple Myeloma; Neoplasm Proteins; Nuclear Proteins; Oxides; Plasma Cells; Promyelocytic Leukemia Protein; Transcription Factors; Tumor Suppressor Proteins | 1999 |
Treatment of acute promyelocytic leukemia with arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Marrow; Caspases; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction | 1999 |
Treatment of acute promyelocytic leukemia with arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; History, 16th Century; History, 18th Century; History, 19th Century; History, 20th Century; Humans; Leukemia; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction | 1999 |
[Teratogenic effects of arsenic on rats].
Topics: Animals; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Embryonic and Fetal Development; Female; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Oxides; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Sprague-Dawley; Teratogens | 1998 |
[Accumulative arsenic level in viscera in offsprings of exposed parent rats].
Topics: Animals; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Female; Male; Oxides; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Wistar; Spleen; Tissue Distribution; Viscera | 1998 |
[The effect of arsenic on reproduction and offspring development of rats].
Topics: Animals; Animals, Newborn; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Embryonic and Fetal Development; Female; Fertility; Male; Oxides; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Wistar | 1997 |
Arsenic trioxide, a novel mitochondriotoxic anticancer agent?
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Mitochondria; Oxides; Permeability | 1999 |
Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations.
Topics: Adenosine Triphosphate; Annexin A5; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Caspase 3; Caspases; Cell Division; Down-Regulation; Enzyme Activation; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Lymphocytes; Lymphoma; Mitochondria; Neoplasm Proteins; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins | 1999 |
Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Cell Division; Cell Survival; Gene Expression Regulation, Neoplastic; Genes, bcl-2; HL-60 Cells; Humans; In Situ Nick-End Labeling; Leukemia, Megakaryoblastic, Acute; Oxides; Tumor Cells, Cultured | 1999 |
PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspase Inhibitors; Caspases; Cell Nucleus; DNA; Humans; Leukemia, Promyelocytic, Acute; Molecular Weight; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Rabbits; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Staining and Labeling; SUMO-1 Protein; U937 Cells; Ubiquitins | 1999 |
Arsenic trioxide induces apoptosis of oesophageal carcinoma in vitro.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Esophageal Neoplasms; Flow Cytometry; Humans; Microscopy, Electron; Oxides; Tumor Cells, Cultured | 1999 |
In acute promyelocytic leukemia NB4 cells, the synthetic retinoid CD437 induces contemporaneously apoptosis, a caspase-3-mediated degradation of PML/RARalpha protein and the PML retargeting on PML-nuclear bodies.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Cell Line; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Retinoids; Transcription Factors; Tumor Suppressor Proteins | 1999 |
Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase Inhibitors; Caspases; Enzyme Activation; Etoposide; Humans; Leukemia, Myeloid; Oxides; Signal Transduction; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1999 |
Dithiothreitol enhances arsenic trioxide-induced apoptosis in NB4 cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cells, Cultured; Dithiothreitol; DNA Fragmentation; Drug Synergism; Growth Inhibitors; Humans; Oxides; Reactive Oxygen Species | 1999 |
Arsenic trioxide induces apoptosis of HPV16 DNA-immortalized human cervical epithelial cells and selectively inhibits viral gene expression.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Transformed; Cell Transformation, Viral; Cervix Uteri; DNA Damage; DNA Fragmentation; DNA, Viral; Epithelial Cells; Female; G1 Phase; Gene Expression Regulation, Viral; Genes, Tumor Suppressor; Humans; Medicine, Chinese Traditional; Oncogene Proteins, Viral; Oxides; Papillomaviridae; Papillomavirus E7 Proteins | 1999 |
Complete atrioventricular block after arsenic trioxide treatment in an acute promyelocytic leukemic patient.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Electrocardiography; Female; Heart Block; Humans; Leukemia, Promyelocytic, Acute; Oxides | 1999 |
Arsenic: a new place?
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 1999 |
Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Enzyme Activation; Glutathione; Humans; Neuroblastoma; Oxides; Tumor Cells, Cultured | 1999 |
Efficacy of a potentized homoeopathic drug (Arsenicum Album-30) in reducing genotoxic effects produced by arsenic trioxide in mice: comparative studies of pre-, post- and combined pre- and post-oral administration and comparative efficacy of two microdose
Topics: Administration, Oral; Analysis of Variance; Animals; Antidotes; Antineoplastic Agents; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Chromosome Aberrations; Disease Models, Animal; Dose-Response Relationship, Drug; Homeopathy; Mice; Mitotic Index; Mutagenicity Tests; Oxides; Poisoning; Reference Values | 1999 |
Low levels of arsenic trioxide stimulate proliferative signals in primary vascular cells without activating stress effector pathways.
Topics: Animals; Antibodies; Antineoplastic Agents; Aorta; Arsenic Trioxide; Arsenicals; Calcium-Calmodulin-Dependent Protein Kinases; Cell Death; Cell Division; Cells, Cultured; Endothelium, Vascular; Hydrogen Peroxide; Immunoblotting; Oxidative Stress; Oxides; Phosphoric Monoester Hydrolases; Phosphorylation; Recombinant Proteins; Spin Trapping; Swine; Transfection; Tyrosine | 1999 |
Arsenic and all-trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Humans; Leukemia, Promyelocytic, Acute; Male; Neoplasms, Second Primary; Oxides; Recurrence; Transplantation, Autologous; Tretinoin | 1999 |
Successful treatment with arsenic trioxide of a patient with ATRA-resistant relapse of acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Chromosome Banding; Colony-Forming Units Assay; Drug Resistance, Neoplasm; Feeding and Eating Disorders; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Metaphase; Middle Aged; Musculoskeletal Diseases; Oxides; Pain; Polymerase Chain Reaction; Recurrence; Tretinoin | 1999 |
Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway.
Topics: Amitrole; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Catalase; Cytochrome c Group; Cytosol; Flow Cytometry; Glutathione Peroxidase; HL-60 Cells; Humans; Hydrogen Peroxide; Intracellular Membranes; K562 Cells; Kinetics; Leukemia, Promyelocytic, Acute; Membrane Potentials; Mitochondria; Oxides; Thiomalates; Tumor Cells, Cultured; U937 Cells | 1999 |
Absence of prenatal developmental toxicity from inhaled arsenic trioxide in rats.
Topics: Abnormalities, Drug-Induced; Administration, Inhalation; Animals; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Atmosphere Exposure Chambers; Body Weight; Bone and Bones; Eating; Environmental Exposure; Female; Fetus; Male; No-Observed-Adverse-Effect Level; Oxides; Pilot Projects; Pregnancy; Rats; Rats, Sprague-Dawley; Reproduction; Respiratory Sounds; Risk Assessment; Toxicity Tests | 1999 |
Re: Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Growth Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Lymphocytes; Neoplasms, Second Primary; Oxides | 1999 |
Comparative effects of single intraperitoneal or oral doses of sodium arsenate or arsenic trioxide during in utero development.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Arsenates; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Craniofacial Abnormalities; Cricetinae; Female; Humans; Injections, Intraperitoneal; Male; Maternal-Fetal Exchange; Mice; Neural Tube Defects; No-Observed-Adverse-Effect Level; Oxides; Pregnancy; Rats; Teratogens | 1999 |
Human Daxx regulates Fas-induced apoptosis from nuclear PML oncogenic domains (PODs).
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Arsenic Trioxide; Arsenicals; Carrier Proteins; Cell Line; Cell Nucleus; Cloning, Molecular; Co-Repressor Proteins; Enzyme Activation; fas Receptor; Fluorescent Antibody Technique; Gene Expression Regulation; Humans; Intracellular Signaling Peptides and Proteins; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinases; Molecular Chaperones; Neoplasm Proteins; Nuclear Proteins; Oxides; Precipitin Tests; Promyelocytic Leukemia Protein; Protein Binding; Transcription Factors; Transfection; Tumor Suppressor Proteins; Yeasts | 1999 |
Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Binding Sites; Bone Marrow; Carrier Proteins; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Ligands; Male; Middle Aged; Mutation, Missense; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Point Mutation; Protein Structure, Tertiary; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tretinoin | 1999 |
Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; DNA-Binding Proteins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Glutathione; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Isoenzymes; Multidrug Resistance-Associated Proteins; MutS Homolog 3 Protein; Oxides; Tumor Cells, Cultured | 1999 |
Fatal rhabdomyolysis in arsenic trioxide poisoning.
Topics: Adult; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Fatal Outcome; Humans; Male; Oxides; Rhabdomyolysis | 1999 |
Effect of arsenic trioxide on cell cycle arrest in head and neck cancer cell line PCI-1.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; CDC2 Protein Kinase; Cell Cycle; Cell Division; Cyclin B; Cyclin B1; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; G2 Phase; Growth Inhibitors; Head and Neck Neoplasms; Humans; Mitosis; Oxides; Tumor Cells, Cultured | 1999 |
Efficacy of a potentized homoeopathic drug (Arsenicum Album-30) in reducing genotoxic effects produced by arsenic trioxide in mice: II. Comparative efficacy of an antibiotic, actinomycin D alone and in combination with either of two microdoses.
Topics: Animals; Anti-Bacterial Agents; Arsenic Trioxide; Arsenicals; Chromosome Aberrations; Dactinomycin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Homeopathy; Male; Mice; Micronucleus Tests; Mitotic Index; Oxides; Random Allocation; Spermatozoa; Transcription, Genetic | 1999 |
Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Calcium; Cell Division; DNA, Neoplasm; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; Oxides; Stomach Neoplasms; Tumor Cells, Cultured | 1999 |
Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biological Transport; Disease Models, Animal; Fibrosarcoma; Male; Metabolic Clearance Rate; Methylcholanthrene; Mice; Mice, Inbred BALB C; Necrosis; Oxides; Perfusion | 1999 |
The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Esophageal Neoplasms; Flow Cytometry; Humans; Microscopy, Electron; Mitochondria; Oxides; Tumor Cells, Cultured | 2000 |
Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L).
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Apoptotic Protease-Activating Factor 1; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; bcl-2-Associated X Protein; bcl-X Protein; Caspases; Cytochrome c Group; Cytosol; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fas Ligand Protein; fas Receptor; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Genes, bcl-2; Histones; HL-60 Cells; Humans; Immunophenotyping; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Macrophage-1 Antigen; Membrane Glycoproteins; Mitochondria; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Oxides; Protein Biosynthesis; Protein Processing, Post-Translational; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2 | 2000 |
Biological monitoring of occupational exposure to inorganic arsenic.
Topics: Adult; Arsenic Trioxide; Arsenicals; Chromatography, High Pressure Liquid; Environmental Monitoring; Glass; Humans; Male; Occupational Exposure; Oxides | 1999 |
Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Cell Differentiation; DNA, Neoplasm; Electrophoresis, Agar Gel; Enzyme Precursors; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Membrane Potentials; Microscopy, Electron; Mitochondria; Mutation; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tretinoin; Tumor Cells, Cultured | 2000 |
Pseudotumor cerebri after treatment of relapsed acute promyelocytic leukemia with arsenic trioxide.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Neoplasms; Diplopia; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Papilledema; Pseudotumor Cerebri | 2000 |
In vitro exposure of acute promyelocytic leukemia cells to arsenic trioxide (As2O3) induces the solitary expression of CD66c (NCA-50/90), a member of the CEA family.
Topics: Antigens, CD; Antigens, Differentiation; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Adhesion Molecules; Cell Membrane; Epitopes; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tumor Cells, Cultured | 1999 |
[Antitumor effect of arsenic trioxide on mice experimental liver cancer].
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Female; Flow Cytometry; Liver Neoplasms, Experimental; Male; Mice; Oxides; Proto-Oncogene Proteins c-bcl-2 | 2000 |
Comparative study of the toxic effects of gallium arsenide, indium arsenide and arsenic trioxide following intratracheal instillations to the lung of Syrian golden hamsters.
Topics: Animals; Arsenic Trioxide; Arsenicals; Body Weight; Cricetinae; Gallium; Indium; Instillation, Drug; Kidney Tubules; Lung; Male; Mesocricetus; Organ Size; Oxides; Trachea | 2000 |
Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; bcl-Associated Death Protein; bcl-X Protein; Carrier Proteins; Cell Cycle; Cell Differentiation; Cell Division; Drug Resistance, Neoplasm; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, SCID; Mice, Transgenic; Neoplasm Proteins; Neoplasm Transplantation; Oxides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Recombinant Fusion Proteins; Transplantation, Heterologous; Tretinoin; Tumor Cells, Cultured | 2000 |
Clinical trials referral resource. Clinical trials with arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Female; Humans; Leukemia; Lymphoma; Multiple Myeloma; Neoplasms; Oxides; Urogenital Neoplasms; Uterine Cervical Neoplasms | 2000 |
Evaluation of the prenatal developmental toxicity of orally administered arsenic trioxide in rats.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Body Weight; Eating; Embryonic and Fetal Development; Female; Fetus; No-Observed-Adverse-Effect Level; Organ Size; Oxides; Pregnancy; Rats; Reproduction; Risk Assessment | 2000 |
Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Drug Therapy, Combination; Enzyme Inhibitors; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Promyelocytic, Acute; Male; Oxides; Translocation, Genetic; Tretinoin; Tumor Cells, Cultured | 2000 |
A laser scanning confocal microscopy method. Simultaneous detection of intracellular Ca2+ and apoptosis using Fluo-3 and Hoechst 33342.
Topics: Aniline Compounds; Apoptosis; Arsenic Trioxide; Arsenicals; Benzimidazoles; Calcium; DNA, Neoplasm; Electrophoresis, Agar Gel; Fluorescent Dyes; Humans; Intracellular Fluid; Microscopy, Confocal; Oxides; Reproducibility of Results; Stomach Neoplasms; Tumor Cells, Cultured; Xanthenes | 2000 |
Arsenic trioxide (As2O3) gradually downregulates tissue factor expression without affecting thrombomodulin expression in acute promyelocytic leukemia cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Reverse Transcriptase Polymerase Chain Reaction; Thrombomodulin; Thromboplastin; Transcription, Genetic; Tretinoin; Tumor Cells, Cultured | 2000 |
Successful treatment of all-trans retinoic acid resistant and chemotherapy naïve acute promyelocytic patients with arsenic trioxide--two case reports.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Pregnancy; Tretinoin | 2000 |
Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin | 2000 |
Statistical analysis of the effect of high dilutions of arsenic in a large dataset from a wheat germination model.
Topics: Arsenic Trioxide; Arsenicals; Chi-Square Distribution; Germination; Growth Inhibitors; Homeopathy; Humans; Models, Biological; Odds Ratio; Oxides; Phytotherapy; Poisson Distribution; Reproducibility of Results; Triticum | 2000 |
[Successful treatment of relapsed and refractory acute promyelocytic leukemia with arsenic trioxide (As2O3)].
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Neoplasm Recurrence, Local; Oxides; Pleural Effusion; Remission Induction; Treatment Outcome; Tretinoin | 2000 |
Establishment and characterization of an arsenic-sensitive monoblastic leukaemia cell line (SigM5).
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Culture Techniques; Cell Differentiation; Cell Line; Chromosomes, Human, Pair 8; Humans; Karyotyping; Leukemia, Monocytic, Acute; Leukocytes, Mononuclear; Microscopy, Electron; Oxides; Polyploidy | 2000 |
Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Northern; Blotting, Western; Caspase 3; Caspases; Cell Cycle; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Inhibitory Concentration 50; Multiple Myeloma; Oxides; Precipitin Tests; Time Factors; Tumor Cells, Cultured | 2000 |
Efficacy of a potentized homoeopathic drug (Arsenicum-album-30) in reducing cytotoxic effects produced by arsenic trioxide in mice: III. Enzymatic changes and recovery of tissue damage in liver.
Topics: Animals; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Chemical and Drug Induced Liver Injury; Liver Diseases; Materia Medica; Mice; Oxides | 2000 |
Arsenic trioxide treatment of relapsed acute promyelocytic leukaemia: initial Australian experience.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Australia; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides | 1999 |
Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Dyspnea; Fever; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides; Pleural Effusion; Syndrome; Tretinoin | 2000 |
BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity.
Topics: Antigens, CD34; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blast Crisis; Cells, Cultured; Colony-Forming Units Assay; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Jurkat Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Philadelphia Chromosome; Proto-Oncogene Proteins c-abl; Tumor Cells, Cultured; U937 Cells | 2000 |
Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cells, Cultured; Dose-Response Relationship, Drug; Endothelium, Vascular; Humans; Leukemia; Neovascularization, Pathologic; Oxides; Time Factors | 2000 |
Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, Nude; Mice, Transgenic; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Translocation, Genetic; Transplantation, Heterologous; Tretinoin | 2000 |
Might arsenic trioxide be useful in the treatment of advanced myelodysplastic syndromes?
Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Cell Culture Techniques; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Inhibitors; Humans; Leukemia, Myeloid; Leukocytes, Mononuclear; Myelodysplastic Syndromes; Oxides | 2000 |
Repetitive endoscopy and continuous alkaline gastric irrigation in a case of arsenic poisoning.
Topics: Adult; Arsenic; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Female; Gastric Juice; Gastric Lavage; Gastric Mucosa; Gastroscopy; Humans; Hydrogen-Ion Concentration; Oxides; Radiography; Sodium Bicarbonate; Stomach | 2000 |
Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3).
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cytogenetics; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin | 2000 |
Unusual manifestations of acute leukemia. Case 1. CNS extramedullary relapse of acute promyelocytic leukemia after arsenic trioxide-induced remission.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Central Nervous System; Humans; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Male; Oxides; Remission Induction | 2000 |
Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 8; Caspase 9; Caspases; Enzyme Activation; fas Receptor; Glutathione; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tumor Cells, Cultured | 2000 |
Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Cycle; Cell Line, Transformed; Cell Transformation, Viral; DNA; DNA-Binding Proteins; Drug Synergism; Enzyme Activation; Gene Expression Regulation, Leukemic; Gene Expression Regulation, Viral; Gene Products, tax; Human T-lymphotropic virus 1; Humans; I-kappa B Proteins; Interferon-alpha; Leukemia-Lymphoma, Adult T-Cell; Ligases; Macromolecular Substances; Neoplasm Proteins; NF-kappa B; NF-KappaB Inhibitor alpha; Oxides; T-Lymphocytes; Transcriptional Activation; Tumor Cells, Cultured | 2000 |
Arsenic trioxide inhibits neuroblastoma growth in vivo and promotes apoptotic cell death in vitro.
Topics: Antigens, Differentiation; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspase Inhibitors; Caspases; Cell Differentiation; Cell Division; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Neoplasm Transplantation; Neuroblastoma; Oxides; RNA, Messenger; Tetrazolium Salts; Thiazoles; Transplantation, Heterologous; Tretinoin; Tumor Cells, Cultured | 2000 |
[Identification of realgar and arsenopyrite and their sublimates].
Topics: Arsenic Trioxide; Arsenicals; Drug Contamination; Materia Medica; Oxides; Quality Control; Sulfides; Trace Elements | 1997 |
Arsenic trioxide and the growth of human T-cell leukemia virus type I infected T-cell lines.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2 Homologous Antagonist-Killer Protein; Cell Cycle Proteins; Cell Line; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Cysteine Proteinase Inhibitors; Drug Screening Assays, Antitumor; G1 Phase; Gene Expression Regulation, Leukemic; Genes, bcl-2; Genes, p53; Human T-lymphotropic virus 1; Humans; Leukemia-Lymphoma, Adult T-Cell; Membrane Proteins; Neoplasm Proteins; Oxides; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-bcl-2; Retinoblastoma Protein; T-Lymphocytes; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2000 |
From the Food and Drug Administration.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Buprenorphine; Child; Drug and Narcotic Control; Drug Combinations; Drugs, Investigational; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Leukemia, Promyelocytic, Acute; Lopinavir; Opioid-Related Disorders; Oxides; Pyrimidinones; Receptors, Opioid; Ritonavir; United States; United States Food and Drug Administration | 2000 |
Arsenic compound approved as cancer chemotherapy agent.
Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome | 2000 |
Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Electrocardiography, Ambulatory; Female; Humans; Leukemia, Promyelocytic, Acute; Long QT Syndrome; Male; Middle Aged; Oxides; Prospective Studies; Recurrence; Remission Induction; Tachycardia, Ventricular | 2000 |
Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Northern; Blotting, Western; Cell Culture Techniques; Cell Differentiation; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance; Female; Humans; Leukemia, Experimental; Leukemia, Promyelocytic, Acute; Mice; Mice, SCID; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Survival Rate; Tretinoin | 2001 |
[An experimental study on arsenic trioxide-selectively induced human hepatocarcinoma cell lines apoptosis and its related genes].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; fas Receptor; Genes, bcl-2; Humans; In Situ Nick-End Labeling; Liver Neoplasms; Oxides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; S Phase; Tumor Cells, Cultured | 2000 |
Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3.
Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspase Inhibitors; Caspases; Cell Cycle; Cell Division; DNA Damage; Enzyme Activation; Humans; Oligonucleotides, Antisense; Oxides; Poly(ADP-ribose) Polymerases; Stomach Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Up-Regulation | 2001 |
Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Butylated Hydroxyanisole; Carcinogens; Cisplatin; DNA Fragmentation; Dose-Response Relationship, Drug; Doxorubicin; Enzyme-Linked Immunosorbent Assay; Etoposide; Female; Flow Cytometry; Humans; Male; Ovarian Neoplasms; Oxides; Prostatic Neoplasms; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 2000 |
Interactions of herpes simplex virus type 1 with ND10 and recruitment of PML to replication compartments.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Line; Cell Nucleus Structures; DNA, Complementary; Gene Products, pol; Herpes Simplex; Herpesvirus 1, Human; Humans; Mutation; Neoplasm Proteins; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Protein Isoforms; Transcription Factors; Tumor Suppressor Proteins; Virulence; Virus Replication | 2001 |
Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.
Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Arsenic Trioxide; Arsenicals; Bexarotene; Breast Neoplasms; Drug Approval; Female; Humans; Leukemia, Promyelocytic, Acute; Lymphoma, T-Cell, Cutaneous; Nitriles; Oxides; Paclitaxel; Tamoxifen; Tetrahydronaphthalenes; Triazoles; United States; United States Food and Drug Administration | 2001 |
Molecular remission without blood product support using all-trans retinoic acid (ATRA) induction and combined arsenic trioxide/ATRA consolidation in a Jehovah's Witness with de novo acute promyelocytic leukaemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Christianity; Cytogenetic Analysis; Drug Therapy, Combination; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Middle Aged; Oxides; Platelet Count; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin | 2000 |
Potential role of caspase-3 and -9 in arsenic trioxide-mediated apoptosis in PCI-1 head and neck cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptotic Protease-Activating Factor 1; Arsenic Trioxide; Arsenicals; Carcinoma, Squamous Cell; Caspase 3; Caspase 9; Caspases; Head and Neck Neoplasms; Humans; Membrane Potentials; Mice; Mitochondria; Oxides; Proteins; Tumor Cells, Cultured | 2001 |
Hyperleukocytosis during induction therapy with arsenic trioxide for relapsed acute promyelocytic leukemia associated with central nervous system infarction.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Infarction; Fatal Outcome; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides; Recurrence; Remission Induction | 2000 |
[Tissue factor expression during all-trans retinoic acid or arsenic trioxide treatment in acute promyelocytic leukemia].
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Hemostatics; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; RNA, Messenger; Thromboplastin; Tretinoin | 1998 |
[Studies on red orpiment induction of NB4 and HL-60 cell apoptosis].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Materia Medica; Oxides; Tumor Cells, Cultured | 1998 |
[In vitro study on arsenic trioxide-induced apoptosis of retinoic acid resistant acute promyelocytic leukemia cell line(MR-2)].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin; Tumor Cells, Cultured | 1998 |
Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Monitoring; Electrocardiography; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Torsades de Pointes | 2001 |
Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide (As(2)O(3)) on myeloma cells.
Topics: ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Antigens, CD; Antigens, Differentiation; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cytotoxicity, Immunologic; Dose-Response Relationship, Drug; Growth Inhibitors; Humans; Immunophenotyping; Intercellular Adhesion Molecule-1; Killer Cells, Lymphokine-Activated; Membrane Glycoproteins; Multiple Myeloma; NAD+ Nucleosidase; Oxides; Tumor Cells, Cultured | 2001 |
Co-biomodulation with arsenic trioxide in multiple myeloma.
Topics: Adjuvants, Immunologic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Humans; Killer Cells, Lymphokine-Activated; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Oxides | 2001 |
[Protein tyrosine kinase (PTK) activities during the induction of apoptosis by arsenic trioxide (As2O3)].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Fusion Proteins, bcr-abl; Humans; K562 Cells; Oncogene Proteins v-abl; Oxides; Protein-Tyrosine Kinases | 1998 |
Regulation of Pax3 transcriptional activity by SUMO-1-modified PML.
Topics: 3T3 Cells; Animals; Arsenic Trioxide; Arsenicals; Carrier Proteins; Cell Nucleus; Cells, Cultured; Co-Repressor Proteins; DNA-Binding Proteins; Embryo, Mammalian; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Leukemia, Promyelocytic, Acute; Mice; Molecular Chaperones; Neoplasm Proteins; Nuclear Proteins; Oxides; Paired Box Transcription Factors; PAX3 Transcription Factor; Promyelocytic Leukemia Protein; Repressor Proteins; SUMO-1 Protein; Transcription Factors; Transcription, Genetic; Tumor Suppressor Proteins; Ubiquitins | 2001 |
Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia?
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Drug Synergism; Drug Therapy, Combination; Humans; In Situ Nick-End Labeling; Leukemia, Myeloid; Middle Aged; Oxides; Tumor Cells, Cultured | 2001 |
Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia.
Topics: Adolescent; Adult; Arsenic Trioxide; Arsenicals; Female; Humans; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence | 1998 |
Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Drug Evaluation; Drug Synergism; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Pilot Projects; Prospective Studies; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Salvage Therapy; Treatment Outcome | 2001 |
Clearance of arsenic by haemodialysis after acute poisoning with arsenic trioxide.
Topics: Adult; Arsenic Trioxide; Arsenicals; Female; Growth Inhibitors; Humans; Male; Middle Aged; Oxides; Poisoning; Renal Dialysis | 2001 |
Stimulation of IGF-binding protein-1 secretion by AMP-activated protein kinase.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Culture Media, Conditioned; Dexamethasone; Dose-Response Relationship, Drug; Drug Antagonism; Glucocorticoids; Insulin; Insulin Antagonists; Insulin-Like Growth Factor Binding Protein 1; Multienzyme Complexes; Oxides; Protein Serine-Threonine Kinases; Rats; Ribonucleotides; Signal Transduction; Tumor Cells, Cultured | 2001 |
Apoptosis induced by arsenic trioxide in leukemia U937 cells is dependent on activation of p38, inactivation of ERK and the Ca2+-dependent production of superoxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Calcium; Caspase 3; Caspases; Cell Membrane; Cytochrome c Group; DNA Fragmentation; Dose-Response Relationship, Drug; Enzyme Activation; Genes, Dominant; Glutathione; Humans; Hydrogen-Ion Concentration; MAP Kinase Kinase 4; Mitochondria; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Oxides; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-jun; Reactive Oxygen Species; Superoxides; Time Factors; Transfection; U937 Cells | 2001 |
Effect of arsenic trioxide on metallothionein and its conversion to different arsenic metabolites in hen liver.
Topics: Animals; Arsenic; Arsenic Trioxide; Arsenicals; Biochemistry; Cadmium; Chickens; Copper; Female; Growth Inhibitors; Inactivation, Metabolic; Liver; Metallothionein; Methanol; Oxides; Selenium; Tissue Extracts; Zinc | 2000 |
Intentional overdose of dimercaptosuccinic acid in the course of treatment for arsenic poisoning.
Topics: Adult; Animals; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Chelating Agents; Drug Overdose; Humans; Male; Mice; Oxides; Rats; Succimer; Suicide, Attempted | 2001 |
Resistance of human multidrug resistance-associated protein 1-overexpressing lung tumor cells to the anticancer drug arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; ATP-Binding Cassette Transporters; Cell Survival; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Multidrug Resistance-Associated Proteins; Oxides; Tumor Cells, Cultured | 2001 |
Introduction: the history of arsenic trioxide in cancer therapy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; History, 18th Century; History, 19th Century; History, 20th Century; Humans; Neoplasms; Oxides | 2001 |
Central nervous system relapse in a patient with acute promyelocytic leukaemia treated with arsenic tri-oxide.
Topics: Adult; Animals; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Central Nervous System Diseases; Choroid Plexus; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Recurrence | 2001 |
Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence | 2001 |
Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Benzamides; Drug Synergism; Fusion Proteins, bcr-abl; Hemoglobins; Humans; Imatinib Mesylate; Leukemia; Macrophage-1 Antigen; Oxides; Piperazines; Protein Serine-Threonine Kinases; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein | 2001 |
In vivo genotoxic effect of arsenic trioxide in mice using comet assay.
Topics: Analysis of Variance; Animals; Arsenic Trioxide; Arsenicals; Blood Chemical Analysis; Comet Assay; DNA; DNA Damage; DNA Repair; Dose-Response Relationship, Drug; Leukocytes; Male; Mice; Oxides; Time Factors | 2001 |
Effects of all-trans-retinoic acid and arsenic trioxide on the hemostatic disturbance associated with acute promyelocytic leukemia.
Topics: Adolescent; Adult; Arsenic Trioxide; Arsenicals; Case-Control Studies; Female; Hemorrhage; Hemostasis; Hemostatics; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Thromboplastin; Tretinoin | 2001 |
Hot on the TRAIL of acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Caspases; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Ligands; Membrane Glycoproteins; Neoplasm Proteins; NF-kappa B; Oncogene Proteins, Fusion; Oxides; Receptors, Tumor Necrosis Factor; TNF-Related Apoptosis-Inducing Ligand; Tretinoin; Tumor Necrosis Factor-alpha | 2001 |
Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Caspases; Cell Differentiation; Coculture Techniques; Humans; Immunoblotting; Inhibitor of Apoptosis Proteins; Leukemia, Promyelocytic, Acute; Membrane Glycoproteins; Neoplasm Proteins; NF-kappa B; Oncogene Proteins, Fusion; Oxides; Paracrine Communication; Proteins; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Signal Transduction; TNF Receptor-Associated Factor 1; TNF-Related Apoptosis-Inducing Ligand; Tretinoin; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2001 |
Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Differentiation; Cell-Free System; Drug Resistance; Etoposide; Humans; Indazoles; Leukemia; Mitochondria; Oxides; Proto-Oncogene Proteins c-bcl-2; Tetradecanoylphorbol Acetate; U937 Cells | 2001 |
Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation.
Topics: Adenosine Triphosphatases; Amino Acid Motifs; Animals; Arsenic Trioxide; Arsenicals; Cell Line; Cell Nucleus; Cells, Cultured; CHO Cells; Cricetinae; Endopeptidases; Mice; Models, Biological; Mutation; Neoplasm Proteins; Nuclear Matrix; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Proteasome Endopeptidase Complex; Protein Isoforms; Protein Transport; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; SUMO-1 Protein; Transcription Factors; Tumor Suppressor Proteins; Ubiquitins | 2001 |
Retinoic acid dramatically enhances the arsenic trioxide-induced cell cycle arrest and apoptosis in retinoic acid receptor alpha-positive human T-cell lymphotropic virus type-I-transformed cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Transformed; Human T-lymphotropic virus 1; Humans; Leukemia-Lymphoma, Adult T-Cell; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; T-Lymphocytes; Tretinoin | 2001 |
Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer.
Topics: Androgens; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Death; Cell Division; Dose-Response Relationship, Drug; Enzyme Activation; Humans; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Kinase 4; Mice; Mice, Inbred BALB C; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Stem Cells; Oxides; p38 Mitogen-Activated Protein Kinases; Prostatic Neoplasms; Reactive Oxygen Species; Transplantation, Heterologous; Tumor Cells, Cultured; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2001 |
Arsenic compounds induce cytotoxicity and apoptosis in cisplatin-sensitive and -resistant gynecological cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Size; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; HeLa Cells; Humans; Ovarian Neoplasms; Oxides; Sulfides; Time Factors; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2001 |
Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells.
Topics: Acetylcysteine; Antineoplastic Agents; Antioxidants; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cell Death; Drug Synergism; Glutathione; Humans; Hydrogen Peroxide; Multiple Myeloma; Oxides; Plasma Cells; Superoxides; Tumor Cells, Cultured | 2001 |
A novel differentiation-inducing therapy for acute promyelocytic leukemia with a combination of arsenic trioxide and GM-CSF.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Drug Therapy, Combination; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, SCID; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Tumor Cells, Cultured | 2001 |
Effects of arsenic trioxide (As2O3) on leukemic cells from patients with non-M3 acute myelogenous leukemia: studies of cytotoxicity, apoptosis and the pattern of resistance.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance; Drug Resistance, Multiple; Female; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid, Acute; Male; Middle Aged; Oxides; Transfection; Tumor Cells, Cultured | 2001 |
XAS applied to pharmaceuticals: drug administration and bioavailability.
Topics: Arsenic Trioxide; Arsenicals; Biological Availability; Chemistry, Pharmaceutical; Hair; Histidine; Humans; Leukemia, Promyelocytic, Acute; Menkes Kinky Hair Syndrome; Organometallic Compounds; Oxides; Parenteral Nutrition; Spectrometry, X-Ray Emission; Synchrotrons; Zinc | 2001 |
Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937 cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Cell Division; Cycloheximide; Enzyme Activation; G2 Phase; Growth Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Mitosis; Monocytes; Myeloid Progenitor Cells; Oxides; Phosphorylation; Protein Synthesis Inhibitors; Proto-Oncogene Proteins c-bcl-2; U937 Cells | 2001 |
Cardiac toxicity of arsenic trioxide.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Approval; Drug Industry; Drug Labeling; Electrocardiography; Electrolytes; Humans; Leukemia; Long QT Syndrome; Oxides; Practice Guidelines as Topic; Safety; Torsades de Pointes; United States; United States Food and Drug Administration | 2001 |
Unusual sites of involvement by hematologic malignancies. Case 3. External auditory canal tumor: a rare chloroma in acute promyelocytic leukemia with a complete response to arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Ear Canal; Ear Neoplasms; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Tretinoin | 2001 |
Arsenic trioxide is a potent inhibitor of the interaction of SMRT corepressor with Its transcription factor partners, including the PML-retinoic acid receptor alpha oncoprotein found in human acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Nucleus; DNA-Binding Proteins; Enzyme Activation; Humans; Leukemia, Promyelocytic, Acute; MAP Kinase Signaling System; Microscopy, Confocal; Nuclear Receptor Co-Repressor 2; Oxides; Phosphorylation; Plasmids; Precipitin Tests; Protein Binding; Receptors, Retinoic Acid; Repressor Proteins; Retinoic Acid Receptor alpha; Signal Transduction; Time Factors; Transfection; Two-Hybrid System Techniques | 2001 |
Studies of apoptosis of malignant lymphoma cells induced by arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Division; DNA, Neoplasm; Dose-Response Relationship, Drug; Flow Cytometry; Humans; In Situ Nick-End Labeling; Jurkat Cells; Lymphoma; Oxides; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |
[Regulation of arsenic trioxide-inducing apoptosis].
Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase Inhibitors; HL-60 Cells; Humans; Leukemia, Myeloid; Oligopeptides; Oxides; Tretinoin; Tumor Cells, Cultured | 1999 |
Atrazine potentiation of arsenic trioxide-induced cytotoxicity and gene expression in human liver carcinoma cells (HepG2).
Topics: Arsenic Trioxide; Arsenicals; Atrazine; Cell Line, Transformed; Cell Survival; Cyclic AMP Response Element-Binding Protein; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Gene Expression; Gene Expression Profiling; Hepatocytes; HSP70 Heat-Shock Proteins; Humans; Liver Neoplasms; Metallothionein; Oxides; Proto-Oncogene Proteins c-fos | 2001 |
Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Electrocardiography; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tachycardia, Ventricular | 2001 |
[The mechanisms of arsenic trioxide-induced apoptosis in hematopoietic malignant cells].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tumor Cells, Cultured; U937 Cells | 1999 |
[Effects of As2O3 on the BCR/ABL protein tyrosine phosphorylation in K562 cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Fusion Proteins, bcr-abl; Humans; Janus Kinase 2; K562 Cells; Oxides; Phosphorylation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Signal Transduction; Tyrosine | 1999 |
[Effects of all-trans retinoic acid, arsenic trioxide and daunorubicin on tissue factor expression in NB4 cells].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Daunorubicin; Factor VIII; Humans; Leukemia, Promyelocytic, Acute; Oxides; RNA, Messenger; Thromboplastin; Tretinoin; Tumor Cells, Cultured | 1999 |
Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676).
Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Arsenic Trioxide; Arsenicals; Central Nervous System; Combined Modality Therapy; Female; Gemtuzumab; Gene Rearrangement; Genes, MDR; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Oxides; Sialic Acid Binding Ig-like Lectin 3; Translocation, Genetic; Tretinoin | 2001 |
Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; bcl-X Protein; Caspase 3; Caspases; Cell Line, Transformed; Cell Nucleus; Cytochrome c Group; DNA-Binding Proteins; Flow Cytometry; Human T-lymphotropic virus 1; Human T-lymphotropic virus 2; Humans; I-kappa B Proteins; Interferon-alpha; Leukemia-Lymphoma, Adult T-Cell; Membrane Potentials; Microscopy, Fluorescence; Mitochondria; NF-kappa B; NF-KappaB Inhibitor alpha; Oxides; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53 | 2001 |
Down-regulation of four arsenic antagonists on apoptosis and telomerase activity induced by arsenic trioxide in three myelocytic leukemia cell lines.
Topics: Acetylcysteine; Aminoquinolines; Antineoplastic Agents; Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Catalase; Down-Regulation; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid; Oxides; Telomerase | 2001 |
Successful treatment of a case of relapsed acute promyelocytic leukemia with arsenic trioxide.
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Treatment Outcome | 2001 |
Overexpression of Bcl-2 partly inhibits apoptosis of human cervical cancer SiHa cells induced by arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Cell Cycle; Cell Survival; DNA, Neoplasm; Female; Humans; Oxides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53; Uterine Cervical Neoplasms | 2000 |
Hemostatic abnormalities associated with acute promyelocytic leukemia and corrective effects of all-trans-retinoic acid or arsenic trioxide treatment.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation Factors; Female; Hemostasis; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Thromboplastin; Tretinoin | 2000 |
Long-term survey of outcome in acute promyelocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Prognosis; Remission Induction; Time Factors; Treatment Outcome; Tretinoin | 2000 |
[Potentiation of arsenic trioxide-induced apoptosis by retinoic acid in retinoic acid sensitive and resistant HL-60 myeloid leukemia cells].
Topics: Alitretinoin; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Division; Drug Resistance, Neoplasm; Drug Synergism; HL-60 Cells; Humans; Oxides; Tretinoin | 2000 |
[Drug resistance of acute promyelocytic leukemia (APL) to all-trans retinoic acid (ATRA) and its reversion].
Topics: Alprostadil; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Arsenic Trioxide; Arsenicals; Cell Survival; Drug Interactions; Drug Resistance; Harringtonines; HL-60 Cells; Homoharringtonine; Humans; Interferon alpha-2; Interferon-alpha; Leukemia, Promyelocytic, Acute; Oxides; Recombinant Proteins; Tretinoin | 2000 |
[Glutathione synthesis inhibitor enhances arsenic trioxide-induced apoptosis].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Glutathione; Humans; Leukemia; Lymphoma; Oxides; Tumor Cells, Cultured | 1999 |
[The relationship between sensitivity to arsenic trioxide and antioxidative capacity of malignant hematopoietic cells].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Survival; Glutathione Peroxidase; Glutathione Transferase; Hematologic Neoplasms; HL-60 Cells; Humans; K562 Cells; Oxides; Superoxide Dismutase; Tumor Cells, Cultured; U937 Cells | 2000 |
Arsenic trioxide induces multiple myeloma cell apoptosis via disruption of mitochondrial transmembrane potentials and activation of caspase-3.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Caspase 3; Caspases; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Membrane Potentials; Mitochondria; Multiple Myeloma; Oxides; Tretinoin; Tumor Cells, Cultured | 2001 |
Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; RNA, Messenger; Thromboplastin; Tretinoin; Tumor Cells, Cultured | 2001 |
Apoptosis inducing effects of arsenic trioxide on human bladder cancer cell line BIU-87.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Division; DNA; Humans; Immunohistochemistry; Oxides; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2001 |
[Mechanisms of arsenic trioxide-induced apoptosis in myeloma cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Division; Dithiothreitol; Drug Interactions; Humans; Interferon-alpha; Multiple Myeloma; Oxides; Tretinoin; Tumor Cells, Cultured | 2001 |
[Ailing No. I in treating 62 cases of acute promyelocytic leukemia].
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Drugs, Chinese Herbal; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides | 1999 |
[Cell differentiation and apoptosis of tumor cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Transformation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Oxides | 1999 |
[A study of tissue factor expression and hemostatic molecular markers in patients with acute promyelocytic leukemia].
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Hemostasis; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; RNA, Messenger; Thromboplastin; Tretinoin | 2001 |
[Effects of arsenic trioxide on K562 cells stably expressing two promyelocytic leukemia-specific fusion proteins].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Differentiation; Cell Division; Gene Expression; Growth Inhibitors; Humans; K562 Cells; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Tretinoin | 2000 |
[Effects of all-trans retinoic acid and arsenic trioxide on tissue factor expression of acute promyelocytic leukemia cells].
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation; Cells, Cultured; Female; Gene Expression; Humans; Leukemia, Promyelocytic, Acute; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; RNA, Messenger; Thromboplastin; Transcription, Genetic; Tretinoin; Tumor Cells, Cultured; U937 Cells | 2000 |
[Experimental study on combination of Ad-p53 with CDDP or As(2)O(3) in human lung adenocarcinoma cell line GLC-82].
Topics: Adenocarcinoma; Adenoviridae; Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cisplatin; Combined Modality Therapy; Disease Models, Animal; Genetic Therapy; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Oxides; Transfection; Transplants; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2000 |
Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Division; Cyclic AMP; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Receptor Cross-Talk; Signal Transduction; Thionucleotides; Tumor Cells, Cultured | 2002 |
Arsenic trioxide newly joins treatment strategies for acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Treatment Outcome | 2001 |
Arsenic: carcinogen or cancer therapy?
Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Carcinogens; Humans; Oxides; Poisons; Telomerase | 2002 |
Experimental study on antitumor effect of arsenic trioxide in combination with cisplatin or doxorubicin on hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; Female; Humans; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Oxides; Tumor Cells, Cultured | 2001 |
Morphological and functional changes of mitochondria in apoptotic esophageal carcinoma cells induced by arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Esophageal Neoplasms; Flow Cytometry; Humans; Membrane Potentials; Microscopy, Electron; Mitochondria; Oxides; Tumor Cells, Cultured | 2002 |
The sensitivity of digestive tract tumor cells to As2O3 is associated with the inherent cellular level of reactive oxygen species.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Esophageal Neoplasms; Flow Cytometry; Humans; Oxides; Reactive Oxygen Species; Stomach Neoplasms; Tumor Cells, Cultured | 2002 |
Nitric oxide and calcium ions in apoptotic esophageal carcinoma cells induced by arsenite.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Arsenites; Calcium; Esophageal Neoplasms; Humans; Microscopy, Electron; Nitric Oxide; Oxides; Teratogens; Tumor Cells, Cultured | 2002 |
Opposite biological effects of arsenic trioxide and arsacetin involve a different regulation of signaling in human gastric cancer MGC-803 cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; DNA Fragmentation; Enzyme Activation; Enzyme Inhibitors; Humans; Oxides; Phosphorylation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Stomach Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
Arsonoliposomes, a novel class of arsenic-containing liposomes: effect of palmitoyl-arsonolipid-containing liposomes on the viability of cancer and normal cells in culture.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Line; Cell Survival; Humans; Inhibitory Concentration 50; Lipids; Liposomes; Oxides; Palmitic Acid; Tumor Cells, Cultured | 2002 |
Arsenic trioxide and methylprednisolone use different signal transduction pathways in leukemic differentiation.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Dose-Response Relationship, Drug; HL-60 Cells; Humans; K562 Cells; Leukemia; Methylprednisolone; Oxides; Phosphoprotein Phosphatases; Signal Transduction | 2002 |
Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspase 8; Caspase 9; Caspases; Cell Division; Dexamethasone; Drug Resistance, Neoplasm; Glutathione; Glutathione Transferase; Multiple Myeloma; Oxidation-Reduction; Oxides; Steroids; Time Factors; Tumor Cells, Cultured | 2002 |
Successful unrelated bone marrow transplantation after arsenic trioxide treatment in a patient with relapsed acute promyelocytic leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Bone Marrow Transplantation; Combined Modality Therapy; Drug Resistance; Female; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Tretinoin | 2002 |
Dual effects of arsenic trioxide (As2O3) on non-acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Division; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid; Oxides; Tumor Cells, Cultured | 2002 |
[Arsenic trioxide in the treatment of advanced primary liver and gallbladder cancer].
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Gallbladder Neoplasms; Humans; Injections, Intravenous; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxides; Quality of Life; Treatment Outcome | 2001 |
[The effect of fluoride-arsenic exposure on the lipid peroxidation and antioxidation of the offspring of rats].
Topics: Animals; Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Female; Glutathione Peroxidase; Lipid Peroxidation; Lipid Peroxides; Male; Oxides; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Wistar; Sodium Fluoride; Superoxide Dismutase | 2000 |
[Inhibitory effects of recombinant human neurotrophin-4/5 protein on neurotoxicity caused by arsenic trioxide].
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Survival; Cells, Cultured; Chick Embryo; Coculture Techniques; Environmental Exposure; Nerve Growth Factors; Neurons; Neuroprotective Agents; Oxides; PC12 Cells; Prosencephalon; Rats; Recombinant Proteins | 1999 |
Arsenic trioxide-induced apoptosis and its enhancement by buthionine sulfoximine in hepatocellular carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Carcinoma, Hepatocellular; Caspases; Cell Division; Cell Nucleus; DNA Fragmentation; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Synergism; Glutathione; Humans; Kinetics; Liver Neoplasms; Oxides; Reactive Oxygen Species; Tumor Cells, Cultured | 2002 |
[Morphological changes of mitochondria in apoptosis of esophageal carcinoma cells induced by As(2)O(3)].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Cell Line, Tumor; Esophageal Neoplasms; Humans; Mitochondria; Mitochondrial Swelling; Oxides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2 | 2000 |
[Seven years' summary report on the treatment of acute promyelocytic leukemia with arsenic trioxide--an analysis of 242 cases].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Survival Rate | 2000 |
[Mechanism of tissue factor expression on NB4 cells down-regulated by all-trans retinoic acid and arsenic trioxide].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cycloheximide; Dactinomycin; Down-Regulation; Gene Expression Regulation; Humans; Leukemia, Promyelocytic, Acute; Oxides; Thromboplastin; Tretinoin; Tumor Cells, Cultured | 2000 |
[Regulation of telomerase activity in HL-60 and NB4 cells by arsenic trioxide].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Size; HL-60 Cells; Humans; Oxides; Proto-Oncogene Proteins c-bcl-2; Telomerase; Time Factors; Tretinoin; Tumor Cells, Cultured | 2000 |
[p15 gene expression in acute lymphoblastic leukemia cell line Molt4 induced by arsenic trioxide].
Topics: Acute Disease; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p15; DNA Methylation; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphoid; Oxides | 2001 |
Mitochondria, calcium and nitric oxide in the apoptotic pathway of esophageal carcinoma cells induced by As2O3.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Calcium; Esophageal Neoplasms; Humans; Membrane Potentials; Mitochondria; Nitric Oxide; Oxides | 2002 |
Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Recurrence; Remission Induction; Tretinoin | 2002 |
Arsenic trioxide (As(2)O(3)) induced apoptosis and its mechanisms in a human esophageal squamous carcinoma cell line.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Squamous Cell; Cell Adhesion; Cell Division; DNA Fragmentation; Dose-Response Relationship, Drug; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Microscopy, Electron; Oxides; Tumor Cells, Cultured | 2002 |
Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Drug Monitoring; Electrocardiography; Female; Heart; Heart Diseases; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prospective Studies; Remission Induction; Tretinoin | 2002 |
In vitro and in vivo effectiveness of arsenic trioxide against murine T-cell prolymphocytic leukaemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Leukemia, Prolymphocytic; Leukemia, T-Cell; Male; Mice; Mice, Transgenic; Models, Animal; Oxides; Proto-Oncogene Proteins; Survival Rate; Tumor Cells, Cultured | 2002 |
Arsenic trioxide as a novel anticancer agent against human transitional carcinoma--characterizing its apoptotic pathway.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Carcinoma, Transitional Cell; Caspase 3; Caspases; Cisplatin; DNA, Neoplasm; Drug Resistance, Neoplasm; Enzyme Activation; G1 Phase; Humans; Membrane Potentials; Mitochondria; Oxides; Reactive Oxygen Species; Signal Transduction; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2002 |
The inherent cellular level of reactive oxygen species: one of the mechanisms determining apoptotic susceptibility of leukemic cells to arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Separation; Dose-Response Relationship, Drug; Flow Cytometry; Humans; In Situ Nick-End Labeling; Leukemia, Myeloid; Naphthoquinones; Oxides; Reactive Oxygen Species; Tumor Cells, Cultured | 2002 |
Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Colonic Neoplasms; Glutathione; Humans; Oxidative Stress; Oxides; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2002 |
Clinical usefulness of arsenic trioxide in the treatment of acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Salvage Therapy | 2002 |
[Ascorbic acid enhances the apoptosis of U937 cells induced by arsenic trioxide in combination with DMNQ and its mechanism].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Drug Synergism; Flow Cytometry; Humans; Naphthoquinones; Oxides; U937 Cells | 2002 |
The MRP1-mediated effluxes of arsenic and antimony do not require arsenic-glutathione and antimony-glutathione complex formation.
Topics: Antimony; Antimony Potassium Tartrate; Arsenic; Arsenic Trioxide; Arsenicals; Biological Transport, Active; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Glutathione; Humans; K562 Cells; Kinetics; Leukemia, Promyelocytic, Acute; Multidrug Resistance-Associated Proteins; Oxides; Spectrophotometry, Atomic; Tumor Cells, Cultured | 2002 |
Enhancement of radiation response in human cervical cancer cells in vitro and in vivo by arsenic trioxide (As2O3).
Topics: Animals; Arsenic Trioxide; Arsenicals; Carcinoma; Cell Survival; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Evaluation, Preclinical; Female; HeLa Cells; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Oxides; Radiation-Sensitizing Agents; Treatment Outcome; Tumor Stem Cell Assay; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2002 |
Differentiation induction as a treatment for hematologic malignancies.
Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Hematologic Neoplasms; Leukemia, Promyelocytic, Acute; Models, Biological; Oncogene Proteins, Fusion; Oxides; Signal Transduction; Transcription, Genetic | 2002 |
Effect of arsenic trioxide on human hepatocellular carcinoma HepG2 cells: inhibition of proliferation and induction of apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Caspase 3; Caspases; Cell Cycle; Cell Division; Enzyme Activation; Humans; Liver Neoplasms; Mitochondria; Oxides; Tumor Cells, Cultured | 2002 |
Involvement of microtubules and mitochondria in the antagonism of arsenic trioxide on paclitaxel-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Division; Drug Antagonism; Humans; Microtubules; Mitochondria; Oxides; Paclitaxel; Tumor Cells, Cultured | 2002 |
Experimental study on apoptosis of HL-60 cell induced by arsenic trioxide.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; HL-60 Cells; Humans; Oxides; Telomerase | 2000 |
Effect of As2O3 on cell cycle progression and cyclins D1 and B1 expression in two glioblastoma cell lines differing in p53 status.
Topics: Arsenic Trioxide; Arsenicals; Blotting, Western; Brain Neoplasms; Cell Cycle; Cell Division; Cyclin B; Cyclin B1; Cyclin D1; Dose-Response Relationship, Drug; Flow Cytometry; Glioblastoma; Humans; Oxides; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
Arsenic trioxide induces apoptosis through a reactive oxygen species-dependent pathway and loss of mitochondrial membrane potential in HeLa cells.
Topics: Acetylcysteine; Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Catalase; Dose-Response Relationship, Drug; Enzyme Activation; HeLa Cells; Humans; Hydrogen Peroxide; Membrane Potentials; Mitochondria; Oxides; Reactive Oxygen Species; Signal Transduction | 2002 |
Inhibition by arsenic trioxide of human hepatoma cell growth.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Cycle; Cell Division; Coloring Agents; Dose-Response Relationship, Drug; Flow Cytometry; Glutathione; Humans; Oxides; Tetrazolium Salts; Thiazoles; Time Factors; Tumor Cells, Cultured | 2002 |
Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Immunocompetence; Leukemia, Promyelocytic, Acute; Liposomes; Mice; Mice, Inbred C3H; Mice, SCID; Mice, Transgenic; Neoplasm Proteins; Neoplasm Transplantation; Oncogene Proteins, Fusion; Oxides; Tretinoin | 2002 |
Arsenic trioxide and breast cancer: analysis of the apoptotic, differentiative and immunomodulatory effects.
Topics: Adjuvants, Immunologic; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Breast Neoplasms; Cell Differentiation; Cell Division; Drug Resistance, Neoplasm; Flow Cytometry; Fluorescent Antibody Technique; Genes, bcl-2; Glutathione; Humans; In Vitro Techniques; Intercellular Adhesion Molecule-1; Killer Cells, Lymphokine-Activated; Lymphocyte Function-Associated Antigen-1; Oxides; Sulfhydryl Compounds; Tumor Cells, Cultured | 2002 |
Pifithrin-alpha (PFT-alpha) caused differential protection of rat liver cells and HepG2 cell line in response to the selective cytotoxicity of arsenic and cadmium.
Topics: Animals; Arsenic Trioxide; Arsenicals; Benzothiazoles; Cadmium Chloride; Cell Line; Cytoprotection; Dose-Response Relationship, Drug; Liver; Oxides; Rats; Rats, Wistar; Regression Analysis; Thiazoles; Toluene | 2002 |
[Apoptosis of drug-resistant human ovarian carcinoma cell line 3AO/cDDP induced by arsenic trioxide and its mechanism].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Drug Resistance, Neoplasm; Fas Ligand Protein; fas Receptor; Female; Humans; Membrane Glycoproteins; Ovarian Neoplasms; Oxides; Tumor Cells, Cultured | 2002 |
Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia.
Topics: Acetamides; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Butyrates; Cell Differentiation; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Tretinoin; Tumor Cells, Cultured | 2002 |
Apoptosis susceptibility of tumor cells to arsenic trioxide and the inherent cellular level of reactive oxygen species.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; DNA, Neoplasm; Flow Cytometry; Fluorescent Dyes; Humans; Oxides; Reactive Oxygen Species; Rhodamine 123; Tumor Cells, Cultured | 2002 |
[Diamide and cyclosporin A enhanced arsenic trioxide-induced apoptosis in NB4 cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cyclosporine; Diamide; Drug Synergism; Enzyme Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Membrane Potentials; Mitochondria; Oxides; Sulfhydryl Reagents; Tumor Cells, Cultured | 2002 |
In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Biomarkers, Tumor; Caspase 3; Caspases; Cell Division; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2002 |
Cytotoxicity of arsenic trioxide to transitional carcinoma cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Carcinoma, Transitional Cell; Cisplatin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Glutathione; Humans; Oxides; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2002 |
Arsenic trioxide induces apoptosis in HTLV-I infected T-cell lines and fresh adult T-cell leukemia cells through CD95 or tumor necrosis factor alpha receptor independent caspase activation.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Line; Enzyme Activation; fas Receptor; G1 Phase; Humans; Leukemia-Lymphoma, Adult T-Cell; Membrane Potentials; Oxides; Poly(ADP-ribose) Polymerases; Receptors, Tumor Necrosis Factor; T-Lymphocytes; Tumor Necrosis Factor-alpha | 2002 |
Synergistic interaction with arsenic trioxide and fractionated radiation in locally advanced murine tumor.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Dose Fractionation, Radiation; Male; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Oxides; Radiation-Sensitizing Agents; Tumor Necrosis Factor-alpha | 2002 |
Arsenic trioxide, retinoic acid and Ara-c regulated the expression of annexin II on the surface of APL cells, a novel co-receptor for plasminogen/tissue plasminogen activator.
Topics: Adolescent; Adult; Annexin A2; Antineoplastic Agents; AraC Transcription Factor; Arsenic Trioxide; Arsenicals; Bacterial Proteins; Female; Fibrinolysin; Gene Expression Regulation; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Plasminogen Activators; Repressor Proteins; RNA, Messenger; Tissue Plasminogen Activator; Transcription Factors; Transfection; Tretinoin; Tumor Cells, Cultured | 2002 |
Arsenic trioxide-induced apoptosis in U937 cells involve generation of reactive oxygen species and inhibition of Akt.
Topics: Acetylcysteine; Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspase Inhibitors; Caspases; Cytochrome c Group; Enzyme Activation; Humans; Oxides; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; U937 Cells | 2002 |
Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; CDC2 Protein Kinase; Cell Cycle; Cell Division; Cyclin B; Drug Resistance, Neoplasm; Humans; Microtubules; Mitosis; Oxides; Paclitaxel; Phosphorylation; Polymers; Proto-Oncogene Proteins c-bcl-2; Tubulin; Tumor Cells, Cultured | 2002 |
Myocardial toxicity of arsenic trioxide in a mouse model.
Topics: Adrenergic beta-Agonists; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Body Weight; Caspase 3; Caspases; Heart Diseases; Immunoenzyme Techniques; Isoproterenol; Mice; Mice, Inbred Strains; Microscopy, Electron; Myocardium; Organ Size; Oxides; Signal Transduction; Ventricular Function, Left | 2002 |
Prolongation of cardiac repolarization by arsenic trioxide.
Topics: Action Potentials; Administration, Oral; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Contraindications; Dose-Response Relationship, Drug; Electrocardiography; Guinea Pigs; Heart; Infusions, Intravenous; Membrane Potentials; Oxides | 2002 |
Atypical blasts and bone marrow necrosis associated with near-triploid relapse of acute promyelocytic leukemia after arsenic trioxide treatment.
Topics: Adult; Arsenic Trioxide; Arsenicals; Biopsy; Bone Marrow; Chromosome Aberrations; Fatal Outcome; Female; Humans; Karyotyping; Leukemia, Promyelocytic, Acute; Necrosis; Oxides; Ploidies; Recurrence | 2002 |
Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide.
Topics: Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Bone Marrow Cells; Enzyme Activation; Enzyme Inhibitors; Growth Inhibitors; Humans; Imidazoles; Isoenzymes; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Oxides; p38 Mitogen-Activated Protein Kinases; Pyridines; rac1 GTP-Binding Protein; Tumor Cells, Cultured | 2002 |
Involvement of tumor necrosis factor (TNF-alpha) in arsenic trioxide induced apoptotic cell death of murine myeloid leukemia cells.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Northern; Cell Division; Formazans; Interleukin-4; Leukemia, Myeloid; Mice; Oxides; Receptors, Interleukin-4; Receptors, Tumor Necrosis Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazolium Salts; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2002 |
Arsenic trioxide induces apoptosis in chronic myelogenous leukemia K562 cells: possible involvement of p38 MAP kinase.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Enzyme Activation; Enzyme Inhibitors; Humans; Imidazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microscopy, Electron; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinase 9; Mitogen-Activated Protein Kinases; Oxides; p38 Mitogen-Activated Protein Kinases; Pyridines | 2002 |
[Analysis with DNA chips of the changes of gene expressions in K562 cells in response to As2O3 treatment].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; K562 Cells; Oligonucleotide Array Sequence Analysis; Oxides | 2002 |
Real-time quantification of the multidrug resistance-1 gene expression in relapsed acute promyelocytic leukemia treated with arsenic trioxide.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dose-Response Relationship, Drug; Female; Genes, MDR; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Reverse Transcriptase Polymerase Chain Reaction | 2002 |
Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Base Sequence; Blotting, Western; Caspase 3; Caspases; Colonic Neoplasms; DNA Primers; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Indazoles; Models, Biological; Organoplatinum Compounds; Oxaliplatin; Oxides; Proto-Oncogene Proteins c-bcl-2 | 2002 |
Arsenic trioxide promotes histone H3 phosphoacetylation at the chromatin of CASPASE-10 in acute promyelocytic leukemia cells.
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Northern; Blotting, Western; Caspase 10; Caspases; Chromatin; DNA, Complementary; Dose-Response Relationship, Drug; Enzyme Activation; Histones; Humans; Leukemia, Promyelocytic, Acute; Oligonucleotide Array Sequence Analysis; Oligopeptides; Oxides; Phosphorylation; Polymerase Chain Reaction; Precipitin Tests; Protease Inhibitors; Protein Binding; Serine; Time Factors; Tumor Cells, Cultured | 2002 |
[Detection of cell apoptosis by MTT assay].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; DNA; Formazans; Humans; K562 Cells; Oxides; Tetrazolium Salts | 2002 |
The human herpes virus 8-encoded viral FLICE inhibitory protein protects against growth factor withdrawal-induced apoptosis via NF-kappa B activation.
Topics: Acetylcysteine; Acute Disease; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Cell Transformation, Viral; Enzyme Activation; Gene Expression Regulation, Viral; Granulocyte-Macrophage Colony-Stimulating Factor; Herpesvirus 8, Human; Humans; I-kappa B Proteins; Leukemia, Myeloid; Leupeptins; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; NF-kappa B; Oxides; Proto-Oncogene Proteins c-bcl-2; Recombinant Fusion Proteins; Recombinant Proteins; Rhadinovirus; Transcription, Genetic; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Viral Proteins | 2003 |
Arsenic trioxide in the mechanism of drug resistance reversal in MCF-7/ADM cell line of human breast cancer.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Isoenzymes; Oxides; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2002 |
Down-regulation of human papillomavirus E6/E7 oncogene by arsenic trioxide in cervical carcinoma cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA-Binding Proteins; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Neoplasm Invasiveness; Oncogene Proteins, Viral; Oxides; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proteins; Transcription Factor AP-1; Tumor Suppressor Protein p53; Uterine Cervical Neoplasms | 2002 |
Potassium antimonyl tartrate induces caspase- and reactive oxygen species-dependent apoptosis in lymphoid tumoral cells.
Topics: Amino Acid Chloromethyl Ketones; Antimony Potassium Tartrate; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Caspases; Cell Survival; Coumarins; Cysteine Proteinase Inhibitors; Fluorescent Dyes; Humans; Lymphoma; Oligopeptides; Oxides; Reactive Oxygen Species; Tumor Cells, Cultured | 2002 |
In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Division; Cyclic AMP; Leukemia, Promyelocytic, Acute; Mice; Mice, Transgenic; Oxides; Signal Transduction; Theophylline; Tretinoin; Tumor Cells, Cultured | 2002 |
Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Area Under Curve; Arsenic Trioxide; Arsenicals; Biological Availability; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Oxides; Time Factors | 2002 |
[Experimental study of low dose arsenic trioxide in treatment of patients with acute promyelocytic leukemia].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Isoquinolines; Leukemia, Promyelocytic, Acute; Oxides; Sulfonamides; Thionucleotides; Tumor Cells, Cultured | 2002 |
[Comparison of antitumor efficacy between arsacetyl and arsenic trioxide in vitro].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; DNA Fragmentation; Drug Screening Assays, Antitumor; Endothelium, Vascular; Flow Cytometry; G1 Phase; Humans; Inhibitory Concentration 50; Liver Neoplasms; Oxides; Resting Phase, Cell Cycle; Tumor Cells, Cultured | 2002 |
[Primary study of arsenic trioxide inhibits abdomino-metastatic tumor formation of human ovarian carcinoma in nude mice and its mechanisms].
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease Models, Animal; Fas Ligand Protein; fas Receptor; Female; Humans; Membrane Glycoproteins; Mice; Mice, Nude; Monomeric GTP-Binding Proteins; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms, Experimental; NM23 Nucleoside Diphosphate Kinases; Nucleoside-Diphosphate Kinase; Ovarian Neoplasms; Oxides; Transcription Factors; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Two cases of therapy-related acute promyelocytic leukemia (t-APL) after mantle cell lymphoma and gestational trophoblastic disease.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Arsenic Trioxide; Arsenicals; Etoposide; Female; Gestational Trophoblastic Disease; Humans; Leukemia, Promyelocytic, Acute; Lymphoma, Mantle-Cell; Male; Neoplasms, Second Primary; Oxides; Pregnancy; Tretinoin | 2002 |
Molecular remission and reconstitution of a full chimera with arsenic trioxide in a patient with acute promyelocytic leukemia relapsed after allogeneic bone marrow transplantation.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Molecular Diagnostic Techniques; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; RNA, Neoplasm; Salvage Therapy; Transplantation Chimera; Transplantation, Homologous | 2002 |
[Impact of arsenic trioxide on proliferation and metastasis of drug-resistant human ovarian carcinoma cell line].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Division; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; fas Receptor; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylases; Humans; Microscopy, Electron; Monomeric GTP-Binding Proteins; Neoplasm Metastasis; NM23 Nucleoside Diphosphate Kinases; Nucleoside-Diphosphate Kinase; Ovarian Neoplasms; Oxides; Proteins; Proto-Oncogene Proteins c-myc; Repressor Proteins; Time Factors; Trans-Activators; Transcription Factors; Tumor Cells, Cultured | 2002 |
Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Carcinoma, Renal Cell; Caspases; CDC2-CDC28 Kinases; Cell Cycle; Cell Division; Cyclin A; Cyclin D1; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; Humans; Kidney Neoplasms; Oxides; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; Retinoblastoma Protein; Tumor Cells, Cultured | 2003 |
[Arsenic trioxide induced apoptosis and expression of p53 and bcl-2 genes in human small cell lung cancer cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Small Cell; Gene Expression; Genes, bcl-2; Genes, p53; Humans; Lung Neoplasms; Oxides; Tumor Cells, Cultured | 2002 |
Blockage of multidrug resistance-associated proteins potentiates the inhibitory effects of arsenic trioxide on CYP1A1 induction by polycyclic aromatic hydrocarbons.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blotting, Western; Carcinogens; Carcinoma, Hepatocellular; Cell Survival; Cytochrome P-450 CYP1A1; Dioxins; Drug Synergism; Enzyme Induction; Genes, Reporter; Hepatocytes; Humans; Immunoblotting; In Vitro Techniques; Liver Neoplasms; Mitochondrial Proteins; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Oxides; Polycyclic Aromatic Hydrocarbons; Protein Processing, Post-Translational; Reactive Oxygen Species; Ribosomal Proteins; RNA, Messenger; Saccharomyces cerevisiae Proteins; Transcription, Genetic; Tumor Cells, Cultured | 2003 |
Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Caspase 9; Caspases; Cell Adhesion; Cell Division; Cell Nucleus; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance; Endothelial Growth Factors; Enzyme Activation; Flow Cytometry; Growth Inhibitors; Humans; Intercellular Signaling Peptides and Proteins; Interleukin-6; Lymphokines; Multiple Myeloma; Oxides; Signal Transduction; STAT3 Transcription Factor; Time Factors; Trans-Activators; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Synergistic effect of cell differential agent-II and arsenic trioxide on induction of cell cycle arrest and apoptosis in hepatoma cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Cycle; Cell Survival; Flow Cytometry; Growth Inhibitors; Humans; Liver Neoplasms; Oxides; Tumor Cells, Cultured | 2003 |
Effect of arsenic trioxide on different cell lines derived from chronic myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Cell Division; Dose-Response Relationship, Drug; Fusion Proteins, bcr-abl; Humans; In Situ Nick-End Labeling; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Tumor Cells, Cultured | 2002 |
[The comparison between the mechanisms of sodium selenite induced apoptosis and arsenic trioxide induced apoptosis in human acute promyelocytic leukemia cell line NB4 cells].
Topics: Acetylcysteine; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Division; DNA, Neoplasm; Flow Cytometry; Glutathione; Humans; Intracellular Membranes; Leukemia, Promyelocytic, Acute; Membrane Potentials; Mitochondria; Oxides; Reactive Oxygen Species; Sodium Selenite; Tumor Cells, Cultured | 2002 |
[The expression of Fas, FasL and Bcl-2 on RMA cells during the process of apoptosis induced by chemotherapeutic drugs].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Dexamethasone; Etoposide; Fas Ligand Protein; fas Receptor; Gene Expression; Membrane Glycoproteins; Mice; Oxides; Proto-Oncogene Proteins c-bcl-2; Tretinoin; Tumor Cells, Cultured | 2002 |
Clinical activity of arsenic trioxide in Burkitt-like lymphoma.
Topics: Acute Disease; Adult; Antigens, CD; Antineoplastic Agents; Antioxidants; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Burkitt Lymphoma; Drug Therapy, Combination; Female; Humans; L-Lactate Dehydrogenase; Leukemia, Lymphoid; Oxides; Salvage Therapy; Treatment Outcome | 2003 |
Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Caspase 8; Caspase 9; Caspases; Cell Cycle; Cysteine Proteinase Inhibitors; Enzyme Activation; Fluorescent Antibody Technique; G1 Phase; G2 Phase; Growth Inhibitors; Humans; Kinetics; Membrane Glycoproteins; Mitosis; Multiple Myeloma; Mutagenesis; Oxides; Poly(ADP-ribose) Polymerases; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53 | 2003 |
The cytotoxicity of arsenic trioxide to normal hematopoietic progenitors and leukemic cells is dependent on their cell-cycle status.
Topics: Antigens, CD34; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Division; Drug Resistance; Flow Cytometry; Hematopoietic Stem Cells; HL-60 Cells; Humans; Immunophenotyping; Interphase; Leukemia; Oxides | 2002 |
An exploratory investigation of the effect of arsenic trioxide on anti-Gal antibody production in baboons.
Topics: Animals; Antibodies, Monoclonal; Antibody Specificity; Antigens, CD20; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Disaccharides; In Vitro Techniques; Lymph Nodes; Oxides; Papio; Plasma Cells; Spleen; Transplantation, Heterologous; Whole-Body Irradiation | 2003 |
Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Survival; Cysteine Endopeptidases; Gene Expression Profiling; Gene Products, tax; Humans; Interferon-alpha; Leukemia-Lymphoma, Adult T-Cell; NF-kappa B; Oxides; Tumor Cells, Cultured | 2003 |
[Arsenic trioxide induces differentiation of human nasopharyngeal carcinoma in BALB/C nude mice xenograft model].
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Squamous Cell; Cell Differentiation; Cell Division; Female; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Neoplasms; Neoplasm Transplantation; Oxides; Proliferating Cell Nuclear Antigen; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |
[Experimental study on the apoptotic effect of arsenic trioxide on human osteosarcoma MG-63 cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Neoplasms; Humans; Osteosarcoma; Oxides; Tumor Cells, Cultured | 2002 |
As(2)O(3) enhances retroviral reverse transcription and counteracts Ref1 antiviral activity.
Topics: Animals; Arsenic Trioxide; Arsenicals; Carbon-Oxygen Lyases; Cell Line; DNA-(Apurinic or Apyrimidinic Site) Lyase; DNA, Complementary; HeLa Cells; HIV-1; Humans; Jurkat Cells; Leukemia Virus, Murine; Membrane Fusion; Mice; Oxides; Proteins; Transcription, Genetic; Transduction, Genetic; Virus Replication | 2003 |
[Effect of arsenic trioxide on apoptosis of pulmonary eosinophile in asthmatic guinea-pigs].
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Asthma; Eosinophils; Guinea Pigs; Image Processing, Computer-Assisted; Lung; Male; Ovalbumin; Oxides; Random Allocation | 2002 |
Arsenic species excretion after dimercaptopropanesulfonic acid (DMPS) treatment of an acute arsenic trioxide poisoning.
Topics: Adult; Antidotes; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Humans; Male; Oxides; Suicide, Attempted; Time Factors; Treatment Outcome; Unithiol | 2003 |
Promyelocytic leukemia protein (PML) functions as a glucocorticoid receptor co-activator by sequestering Daxx to the PML oncogenic domains (PODs) to enhance its transactivation potential.
Topics: Adaptor Proteins, Signal Transducing; Animals; Arsenic Trioxide; Arsenicals; Carrier Proteins; Co-Repressor Proteins; COS Cells; HeLa Cells; Humans; Intracellular Signaling Peptides and Proteins; Mammary Tumor Virus, Mouse; Molecular Chaperones; Neoplasm Proteins; Nuclear Proteins; Oxides; Promoter Regions, Genetic; Promyelocytic Leukemia Protein; Receptors, Glucocorticoid; Transcription Factors; Transcriptional Activation; Tumor Suppressor Proteins | 2003 |
Effect of arsenic trioxide on inhibition of restenosis after rabbit vascular injury and its mechanism.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; DNA; Female; Flow Cytometry; Male; Muscle, Smooth, Vascular; Oxides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Rabbits; Vascular Diseases | 2002 |
Docosahexaenoic acid enhances arsenic trioxide-mediated apoptosis in arsenic trioxide-resistant HL-60 cells.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Caspase 3; Caspases; Docosahexaenoic Acids; Drug Interactions; Drug Resistance, Neoplasm; HL-60 Cells; Humans; Leukemia; Lipid Peroxidation; Membrane Potentials; Mitochondria; Oleic Acid; Oxides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Tumor Cells, Cultured; Vitamin E | 2003 |
Reactive oxygen species and antioxidants in apoptosis of esophageal cancer cells induced by As2O3.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; DNA Fragmentation; Esophageal Neoplasms; Humans; Microscopy, Electron; Oxides; Reactive Oxygen Species | 2003 |
Reactive oxygen species are involved in arsenic trioxide inhibition of pyruvate dehydrogenase activity.
Topics: Animals; Antioxidants; Arsenic Trioxide; Arsenicals; Chelating Agents; Copper Sulfate; Enzyme Inhibitors; Ferrous Compounds; HL-60 Cells; Humans; Hydrogen Peroxide; Inhibitory Concentration 50; Mitochondria, Heart; Myocardium; NADPH Oxidases; Oxides; Pyruvate Dehydrogenase Complex; Reactive Oxygen Species; Sulfhydryl Compounds; Swine | 2003 |
[Hematology].
Topics: Arsenic Trioxide; Arsenicals; Biomedical Research; China; Hematologic Diseases; Hematology; Humans; Oxides | 2002 |
P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) are induced by arsenic trioxide (As(2)O(3)), but are not the main mechanism of As(2)O(3)-resistance in acute promyelocytic leukemia cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Resistance, Neoplasm; Gene Expression Regulation; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tumor Cells, Cultured | 2003 |
Arsenic trioxide induces apoptosis equally in T lymphoblastoid leukemia MOLT-4 cells and P-gp-expressing daunorubicin-resistant MOLT-4 cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Division; Cell Survival; Daunorubicin; Drug Resistance, Neoplasm; Humans; Oxides; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tumor Cells, Cultured | 2003 |
[Arsenic trioxide induced p15INK4B gene expression in myelodysplastic syndrome cell line MUTZ-1].
Topics: Arsenic Trioxide; Arsenicals; Cell Line; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p15; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Gene Expression Regulation; Humans; Myelodysplastic Syndromes; Oxides; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2002 |
Nuclear matrix associated protein PML: an arsenic trioxide apoptosis therapeutic target protein in HepG2 cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Neoplasm Proteins; Nuclear Matrix; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2003 |
[Successful treatment after acute promyelocytic leukemia (APL) syndrome of relapsed API with arsenic trioxide].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Administration Schedule; Female; Humans; Informed Consent; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Recurrence; Remission Induction | 2003 |
Bilateral oroantral fistulas following devitalization of teeth by arsenic trioxide: a case report.
Topics: Adult; Arsenic Trioxide; Arsenicals; Bone Transplantation; Female; Humans; Maxillary Sinus; Oroantral Fistula; Osteonecrosis; Oxides; Root Canal Filling Materials; Root Canal Therapy; Surgical Flaps; Tooth, Nonvital | 2003 |
Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis.
Topics: Animals; Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Arsenites; Down-Regulation; Gene Expression Profiling; Hodgkin Disease; Humans; I-kappa B Kinase; Mice; Mice, SCID; NF-kappa B; Oxides; Protein Serine-Threonine Kinases; Reed-Sternberg Cells; Sodium Compounds; Transplantation, Heterologous; Tumor Cells, Cultured | 2003 |
[In vitro study of the effects of arsenic trioxide combined with 8-CPT-cAMP on differentiation induction in retinoic acid resistant acute promyelocytic leukemia cells].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cyclic AMP; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Oxides; Thionucleotides; Tretinoin | 2003 |
[Clinical observation of the short-term efficacy of the treatment with combination of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in newly diagnosed acute promyelocytic leukemia (APL)].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Follow-Up Studies; Gene Expression; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Remission Induction; Time Factors; Treatment Outcome; Tretinoin | 2003 |
[Arsenic trioxide inhibits P-glycoprotein expression in multidrug-resistant human leukemia K562/ADM cell line that overexpresses mdr-1 gene and enhances their chemotherapeutic sensitivity].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Humans; K562 Cells; Oxides | 2003 |
[Preliminary observation of the combination of arsenic trioxide and all-trans retinoic acid for the treatment of acute promyelocytic leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Treatment Outcome; Tretinoin | 2003 |
Sustained molecular remission in advanced acute promyelocytic leukemia with combined pulsed retinoic acid and arsenic trioxide. Clinical evidence of synergistic effect and real-time quantification of minimal residual disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm, Residual; Oxides; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin | 2003 |
Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia.
Topics: Adolescent; Adult; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Child; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Retrospective Studies; Secondary Prevention; Survival Rate | 2003 |
Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Differentiation; Coculture Techniques; Glutathione Peroxidase; Hematopoietic Stem Cells; Humans; Hydrogen Peroxide; K562 Cells; Leukemia, Promyelocytic, Acute; Liver Neoplasms; Lymphoma; Methylation; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Tumor Cells, Cultured | 2003 |
Effect of arsenic trioxide on rat hepatocellular carcinoma and its renal cytotoxity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Division; Cisplatin; Female; Immunohistochemistry; Kidney; Liver Neoplasms, Experimental; Male; Oxides; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Wistar | 2003 |
[Toxic effect of fluoride-arsenic on the reproduction and development of rats].
Topics: Animals; Arsenic Trioxide; Arsenicals; Female; Male; Maternal Exposure; Oocytes; Oxides; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Wistar; Sodium Fluoride | 2000 |
Arsenic trioxide induces apoptosis of rat hepatocellular carcinoma cells in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Cycle; Female; Liver Neoplasms; Male; Microscopy, Electron; Oxides; Rats; Rats, Wistar; Tumor Cells, Cultured | 2003 |
Induction of autophagic cell death in malignant glioma cells by arsenic trioxide.
Topics: Amino Acid Chloromethyl Ketones; Anti-Bacterial Agents; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Caspase Inhibitors; Cell Division; Cytoplasm; Drug Interactions; Enzyme Inhibitors; G2 Phase; Glioma; Humans; Macrolides; Mitosis; Oxides; Tumor Cells, Cultured | 2003 |
Patterns of gene expressions induced by arsenic trioxide in cultured human fibroblasts.
Topics: Arsenic Trioxide; Arsenicals; Cell Division; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Fibroblasts; Gene Expression Regulation; Humans; Oxides; Time Factors | 2003 |
Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines.
Topics: Annexin A5; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Division; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Glutathione; Humans; In Situ Nick-End Labeling; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Reactive Oxygen Species; Tumor Cells, Cultured | 2003 |
Arsenic trioxide induces apoptosis in cells of MOLT-4 and its daunorubicin-resistant cell line via depletion of intracellular glutathione, disruption of mitochondrial membrane potential and activation of caspase-3.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Cell Survival; Daunorubicin; Drug Resistance; Enzyme Activation; Glutathione; Humans; Membrane Potentials; Mitochondria; Oxides; Tumor Cells, Cultured | 2003 |
Arsenic trioxide-induced apoptosis is independent of stress-responsive signaling pathways but sensitive to inhibition of inducible nitric oxide synthase in HepG2 cells.
Topics: Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Humans; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Oxidative Stress; Oxides; Signal Transduction | 2003 |
[Investigation of apoptosis mechanism of arsenic trioxide on oral squamous cell carcinoma].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Carcinoma, Squamous Cell; Caspase 3; Caspases; Cell Cycle; DNA, Neoplasm; Flow Cytometry; Humans; Intracellular Membranes; Membrane Potentials; Mitochondria; Mouth Neoplasms; Oxides; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2003 |
[Effect of arsenic trioxide on the expression of cyclins gene in HL60 cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cyclins; Down-Regulation; Gene Expression Profiling; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Oligonucleotide Array Sequence Analysis; Oxides; Up-Regulation | 2003 |
Direct cardiac effects of As2O3 in rabbits: evidence of reversible chronic toxicity and tissue accumulation of arsenicals after parenteral administration.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cardiovascular System; Drug Administration Schedule; In Vitro Techniques; Injections, Intravenous; Oxides; Rabbits; Tissue Distribution | 2003 |
[Mechanism of arsenic trioxide-induced apoptosis in hepatic blastoma cells HepG2].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Hep G2 Cells; Hepatoblastoma; Humans; Liver Neoplasms; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Transcription Factors; Tumor Suppressor Proteins | 2003 |
Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caffeine; Dithiothreitol; Drug Interactions; Humans; Leukemia, Promyelocytic, Acute; Membrane Potentials; Mitochondria; Mitosis; Oxides; Tumor Cells, Cultured | 2003 |
Radiation recall phenomenon associated with arsenic trioxide.
Topics: Arsenic Trioxide; Arsenicals; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Middle Aged; Oxides; Radiodermatitis; Radiotherapy; Radiotherapy, Adjuvant | 2003 |
[Down-regulation of expression of vascular endothelial growth factor induced by arsenic trioxide in bone marrow cells of chronic myeloid leukemia].
Topics: Adolescent; Adult; Aged; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Cells, Cultured; Child; Culture Media, Conditioned; Down-Regulation; Endothelial Growth Factors; Enzyme-Linked Immunosorbent Assay; Female; Humans; Intercellular Signaling Peptides and Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphokines; Male; Middle Aged; Oxides; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Preliminary study of the in vitro growth inhibition of human bladder cancer cell line BIU-87 by arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Division; Dose-Response Relationship, Drug; Down-Regulation; Humans; Oxides; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcr; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2000 |
Gene expression profile changes in NB4 cells induced by arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Oligonucleotide Array Sequence Analysis; Oncogenes; Oxides; Tumor Cells, Cultured | 2003 |
Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism.
Topics: 2-Methoxyestradiol; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cells, Cultured; Estradiol; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mitochondria; Oxides; Oxygen Consumption; Reactive Oxygen Species; Rotenone; Superoxides | 2003 |
[Effect of endogenous TGF-beta1 and TNF-alpha on the As(2)O(3) inducing apoptosis of HL-60 cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Down-Regulation; HL-60 Cells; Humans; Oxides; Proto-Oncogene Proteins c-bcl-2; Receptors, Tumor Necrosis Factor; RNA, Messenger; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha | 2003 |
[Effects of arsenic trioxide on cell cycle and expression of cyclin dependent kinase inhibitors of multiple myeloma cells].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Cycle; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Humans; Multiple Myeloma; Oxides; RNA, Messenger; Tumor Cells, Cultured | 2003 |
MDA-7 (interleukin-24) inhibits the proliferation of renal carcinoma cells and interacts with free radicals to promote cell death and loss of reproductive capacity.
Topics: Acetylcysteine; Adenoviridae; Adjuvants, Immunologic; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Brain Neoplasms; Carcinoma, Renal Cell; Caspases; Cell Division; Free Radical Scavengers; Free Radicals; Genes, Tumor Suppressor; Glioma; Glutathione Transferase; Humans; Interleukins; Kidney; Kidney Neoplasms; Oxides; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Receptors, Virus; Recombinant Fusion Proteins; Tumor Cells, Cultured | 2003 |
Arsenic trioxide induces apoptosis in pancreatic cancer cells via changes in cell cycle, caspase activation, and GADD expression.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Blotting, Western; Caspase 3; Caspase 7; Caspase 9; Caspases; CCAAT-Enhancer-Binding Proteins; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Enzyme Activation; GADD45 Proteins; Humans; Intracellular Signaling Peptides and Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Oxides; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Time Factors; Transcription Factor CHOP; Transcription Factors; Tumor Suppressor Proteins | 2003 |
Ezrin, actin and cytoskeleton in apoptosis of esophageal epithelial cells induced by arsenic trioxide.
Topics: Actins; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Division; Cytoskeletal Proteins; Cytoskeleton; Epithelium; Esophagus; Growth Inhibitors; Humans; Immunohistochemistry; Microscopy, Electron; Oxides; Phosphoproteins | 2003 |
[Effect of arsenic trioxide on rabbit vascular smooth muscle cells after balloon angioplasty].
Topics: Angioplasty, Balloon; Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Division; In Situ Nick-End Labeling; Muscle, Smooth, Vascular; Oxides; Rabbits | 2003 |
[Arsenic trioxide induced human esophageal cancer Ec109 cell apoptosis with downregulation of c-myc gene expression].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Down-Regulation; Esophageal Neoplasms; Gene Expression; Genes, myc; Humans; In Situ Nick-End Labeling; Oxides; Tumor Cells, Cultured | 2000 |
[Arsenic trioxide induces human tumor cell apoptosis and G2 + M arrest whereas causes HPV16 DNA immortalized cervical epithelial cells G1 block].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cervix Uteri; Epithelial Cells; Female; G1 Phase; G2 Phase; Gene Expression Regulation; Genes, myc; Humans; Male; Oxides; Tumor Cells, Cultured | 2000 |
Cellular stress and DNA damage invoke temporally distinct Mdm2, p53 and PML complexes and damage-specific nuclear relocalization.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cells, Cultured; Cyclin-Dependent Kinase Inhibitor p16; DNA Damage; Humans; Mice; Microscopy, Fluorescence; Nuclear Matrix; Nuclear Proteins; Oxides; Protein Binding; Protein Structure, Tertiary; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Tumor Suppressor Protein p14ARF; Tumor Suppressor Protein p53; Ultraviolet Rays | 2003 |
ZIP kinase triggers apoptosis from nuclear PML oncogenic domains.
Topics: Adaptor Proteins, Signal Transducing; Amino Acid Sequence; Animals; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Calcium-Calmodulin-Dependent Protein Kinases; Carrier Proteins; Caspases; Cell Nucleus Structures; Cells, Cultured; Co-Repressor Proteins; Death-Associated Protein Kinases; Enzyme Activation; Humans; Interferon-gamma; Intracellular Signaling Peptides and Proteins; Molecular Chaperones; Molecular Sequence Data; Mutation; Nuclear Proteins; Oxides; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; RNA, Small Interfering | 2003 |
Increasing sensitivity to arsenic trioxide-induced apoptosis by altered telomere state.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line; Dose-Response Relationship, Drug; Enzyme Inhibitors; Growth Inhibitors; Humans; Oxides; Telomerase; Telomere | 2003 |
Sustained activation of c-jun-terminal kinase (JNK) is closely related to arsenic trioxide-induced apoptosis in an acute myeloid leukemia (M2)-derived cell line, NKM-1.
Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Chronic Disease; Enzyme Activation; Humans; Hydrogen Peroxide; Intracellular Membranes; JNK Mitogen-Activated Protein Kinases; K562 Cells; Leukemia, Myeloid; Membrane Potentials; Mitochondria; Mitogen-Activated Protein Kinases; Oxides; Reactive Oxygen Species; Tumor Cells, Cultured | 2003 |
In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Azacitidine; Base Sequence; Benzamides; Cell Division; Cell Line, Tumor; Decitabine; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2004 |
Arsenic trioxide induces apoptosis in peripheral blood T lymphocyte subsets by inducing oxidative stress: a role of Bcl-2.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Glutathione; Humans; Mitochondria; Oxidative Stress; Oxides; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; T-Lymphocyte Subsets | 2003 |
[Inhibiting effect of arsenic trioxide on telomerase activity of NB4 and Jurkat cell lines].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Division; DNA-Binding Proteins; Enzyme Inhibitors; Humans; Jurkat Cells; Oxides; RNA, Messenger; Telomerase | 2003 |
Tetraarsenic oxide induces apoptosis in U937 leukemic cells through a reactive oxygen species-dependent pathway.
Topics: Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Catalase; Cytochromes c; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Hydrogen Peroxide; Leukemia; Membrane Potentials; Mitochondria; Oxides; Reactive Oxygen Species; Time Factors; U937 Cells | 2003 |
Prolonged molecular remission after arsenic trioxide and all-trans retinoic acid for acute promyelocytic leukemia relapsed after allogeneic stem cell transplantation.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Tretinoin | 2003 |
Effect of Ad-p16 combined with CDDP or As2O3 on human bladder cancer cells.
Topics: Adenoviridae; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cisplatin; Cyclin-Dependent Kinase Inhibitor p16; Genetic Vectors; Humans; Oxides; Transfection; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2003 |
The molecular mechanism of arsenic trioxide-induced apoptosis and oncosis in leukemia/lymphoma cell lines.
Topics: Acute Disease; Amino Acid Chloromethyl Ketones; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspase 8; Caspase 9; Caspases; Cell Division; Cysteine Proteinase Inhibitors; Down-Regulation; Fas Ligand Protein; fas Receptor; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid; Membrane Glycoproteins; Oxides; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Up-Regulation | 2003 |
Arsenic trioxide exposure in industry.
Topics: Arsenic; Arsenic Trioxide; Arsenicals; Humans; Oxides | 1953 |
Modulation of the arsenic effects on cytotoxicity, viability, and cell cycle in porcine endothelial cells by selenium.
Topics: Animals; Apoptosis; Arsenates; Arsenic; Arsenic Trioxide; Arsenicals; Arsenites; Caspase 3; Caspases; Cell Cycle; Cell Survival; Cells, Cultured; Cytotoxins; Dose-Response Relationship, Drug; Drug Interactions; Endothelial Cells; Glutathione Peroxidase; Interphase; Necrosis; Oxides; Selenium; Sodium Compounds; Sus scrofa; Tumor Suppressor Protein p53 | 2003 |
[Use of arsenic trioxide in dentistry].
Topics: Arsenic Trioxide; Arsenicals; Humans; Oxides; Root Canal Therapy | 1954 |
[Absorption of arsenic trioxide fumes by filter p. r].
Topics: Air Pollution; Arsenic; Arsenic Trioxide; Arsenicals; Filtration; Humans; Oxides | 1955 |
[Behavior of adenosinetriphosphatasic activity in acute experimental arsenious anhydride poisoning (As2O3)].
Topics: Anhydrides; Arsenic; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Oxides; Phosphoric Monoester Hydrolases; Poisoning | 1955 |
Acute oral toxicity and chemical and physical properties of arsenic trioxides.
Topics: Arsenic; Arsenic Trioxide; Arsenicals; Humans; Oxides; Physical Phenomena | 1958 |
[Clinical aspects & therapy of severe arsenic trioxide poisoning].
Topics: Arsenic; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Humans; Occupational Diseases; Oxides | 1958 |
[Experimental studies of the possibility of preventing the toxic effect of arsenous anhydride of inner ear structures by use of 2,3-dimercapropopanol (B.A.L.)].
Topics: Arsenic Trioxide; Arsenicals; Dimercaprol; Ear, Inner; Oxides | 1958 |
[Acute arsenic trioxide poisoning: report of 3 cases].
Topics: Arsenic; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Female; Humans; Oxides; Trichomonas; Trichomonas Vaginitis; Vaginitis | 1959 |
[Tissue histamine level under the influence of arsenous oxide].
Topics: Arsenic; Arsenic Trioxide; Arsenicals; Histamine; Humans; Oxides | 1962 |
EFFECT OF ARSENIC TRIOXIDE EXPOSURE ON MORTALITY.
Topics: Arsenic; Arsenic Trioxide; Arsenicals; Humans; Mortality; Occupational Diseases; Oxides | 1963 |
[EXPERIMENTAL STUDIES ON THE EFFECT OF ARSENIC TRIOXIDE ON PROTEIN CATABOLISM AND ON BACTERIA].
Topics: Animals; Anti-Infective Agents; Arsenic Trioxide; Arsenicals; Bacteria; Cattle; Dental Pulp Devitalization; Dental Pulp Necrosis; Mouth; Oxides; Pharmacology; Proteins; Research; Trypsin | 1965 |
[The toxicity of arsenic trioxide in the presence of phenol for mice].
Topics: Animals; Arsenic; Arsenic Trioxide; Arsenicals; Mice; Oxides; Phenol; Phenols | 1954 |
Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Clinical Trials as Topic; Electrocardiography; Female; Humans; Leukemia, Promyelocytic, Acute; Long QT Syndrome; Male; Middle Aged; Neoplasms; Oxides; Retrospective Studies; Torsades de Pointes | 2003 |
Arsenic trioxide-induced apoptosis of human malignant lymphoma cell lines and its mechanisms.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Burkitt Lymphoma; Caspase 3; Caspases; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Oxides; Proto-Oncogene Proteins c-bcl-2 | 2003 |
Effects of homeopathic arsenic on tobacco plant resistance to tobacco mosaic virus. Theoretical suggestions about system variability, based on a large experimental data set.
Topics: Antiviral Agents; Arsenic Trioxide; Arsenicals; Biological Assay; Homeopathy; Immunity, Innate; Nicotiana; Oxides; Plant Diseases; Plant Leaves; Research Design; Time Factors; Tobacco Mosaic Virus | 2003 |
12-O-tetradecanoylphorbol-13-acetate may both potentiate and decrease the generation of apoptosis by the antileukemic agent arsenic trioxide in human promonocytic cells. Regulation by extracellular signal-regulated protein kinases and glutathione.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cadmium Chloride; Caspase 3; Caspases; Dose-Response Relationship, Drug; Doxorubicin; Enzyme Activation; Enzyme Inhibitors; Glutathione; Humans; Immunoblotting; Mitogen-Activated Protein Kinases; Monocytes; Oxides; p38 Mitogen-Activated Protein Kinases; Protein Kinase C; Tetradecanoylphorbol Acetate; Time Factors; U937 Cells | 2004 |
Antitumor effect of arsenic trioxide in murine xenograft model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Brain; Carcinoma, Hepatocellular; Humans; In Situ Nick-End Labeling; Injections, Intravenous; Kidney; Liver; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Oxides; Spectrometry, X-Ray Emission; Transplantation, Heterologous; Tumor Cells, Cultured | 2003 |
Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells.
Topics: Acetylcysteine; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase Inhibitors; Caspases; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Oxides; Plasma Cells; Superoxides; Tumor Cells, Cultured | 2003 |
[Effects of As2O3 on tissue factor, plasminogen activator inhibitor-1 and -2 expression in NB4, HL-60 and THP-1 cells].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Oxides; Plasminogen Activator Inhibitor 1; Plasminogen Activator Inhibitor 2; Thromboplastin; Tumor Cells, Cultured | 2003 |
Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; 5' Untranslated Regions; Apoptosis; Arsenic Trioxide; Arsenicals; Down-Regulation; Eukaryotic Initiation Factor-4E; Fusion Proteins, bcr-abl; Genes, abl; HL-60 Cells; Humans; Jurkat Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Protein Biosynthesis; Protein Serine-Threonine Kinases; Ribosomal Protein S6 Kinases, 70-kDa; RNA, Messenger | 2003 |
[Study on cardiac toxicity in acute promyelocyte leukemia treatment of arsenic trioxide intravenous infusion in general dose].
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Calcium Channels; Electrocardiography; Female; Heart; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides | 2003 |
The revival of the ancient drug--arsenic.
Topics: Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Medicine, Chinese Traditional; Oxides | 2003 |
Effect of arsenic trioxide on cytokine expression by acute promyelocytic leukemia cells.
Topics: Arsenic Trioxide; Arsenicals; Cells, Cultured; Cytokines; Granulocyte Colony-Stimulating Factor; Humans; Interleukin-1; Interleukin-6; Interleukin-8; Leukemia, Promyelocytic, Acute; Oxides; Tumor Necrosis Factor-alpha | 2003 |
Arsenic trioxide inhibits p-glycoprotein expression in multidrug-resistant human leukemia cells that overexpress the MDR1 gene.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Resistance, Multiple; Gene Expression; Genes, MDR; Humans; Leukemia; Oxides | 2003 |
The effect of arsenic trioxide on QT interval prolongation during APL therapy.
Topics: Arsenic Trioxide; Arsenicals; Electrocardiography; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2003 |
Bcl-2 antisense oligodeoxynucleotide increases the sensitivity of leukemic cells to arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Division; Cell Line, Tumor; DNA; Dose-Response Relationship, Drug; Flow Cytometry; Genetic Therapy; Humans; K562 Cells; Leukemia; Oligonucleotides, Antisense; Oxides; Proto-Oncogene Proteins c-bcl-2; Time Factors | 2003 |
Essential role of the voltage-dependent anion channel (VDAC) in mitochondrial permeability transition pore opening and cytochrome c release induced by arsenic trioxide.
Topics: Animals; Annexin A5; Arsenic Trioxide; Arsenicals; Cytochromes c; Flow Cytometry; Humans; Intracellular Membranes; Ion Channel Gating; Membrane Potentials; Mice; Mice, Inbred BALB C; Mitochondria; Mitochondria, Liver; Multiple Myeloma; Oxides; Permeability; Porins; Proteolipids; Tumor Cells, Cultured; Voltage-Dependent Anion Channels | 2004 |
Intratumoral injection of arsenic to enhance antitumor efficacy in human esophageal carcinoma cell xenografts.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Division; Cell Line, Tumor; Esophageal Neoplasms; Humans; Injections, Intralesional; Mice; Mice, SCID; Microscopy, Electron; Oxides; Remission Induction; Tissue Distribution; Xenograft Model Antitumor Assays | 2004 |
Arsenic enhances the activation of Stat1 by interferon gamma leading to synergistic expression of IRF-1.
Topics: Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Cell Differentiation; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Interferon Regulatory Factor-1; Interferon-gamma; Leukemia, Promyelocytic, Acute; Oxides; Phosphoproteins; Promoter Regions, Genetic; Signal Transduction; STAT1 Transcription Factor; Superoxides; Trans-Activators; Tretinoin; Tumor Cells, Cultured | 2003 |
Impairment of heart rate variability control during arsenic trioxide treatment for acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Heart Rate; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2004 |
Arsenic trioxide-induced transcriptional activation of stress genes and expression of related proteins in human liver carcinoma cells (HepG2).
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Survival; Cloning, Molecular; Gene Expression Regulation, Neoplastic; Genes, Reporter; HSP70 Heat-Shock Proteins; Humans; Liver Neoplasms; Metallothionein; Oxides; Promoter Regions, Genetic; Proto-Oncogene Proteins c-fos; Transcriptional Activation; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2003 |
The role of mitochondrial targeting in arsenic trioxide-induced apoptosis in myeloid cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase Inhibitors; HL-60 Cells; Humans; Mitochondria; Myeloid Cells; Oxides; U937 Cells | 2004 |
Arsenic trioxide enhances radiation response of 9L glioma in the rat brain.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Combined Modality Therapy; Glioma; Magnetic Resonance Imaging; Male; Oxides; Rats; Rats, Inbred F344 | 2003 |
Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; CHO Cells; Cricetinae; Cricetulus; Glyburide; Heart; Long QT Syndrome; Myocardium; Oxides; Pinacidil; Potassium Channels; Potassium Channels, Inwardly Rectifying; Potassium Channels, Voltage-Gated | 2004 |
[Mechanism of arsenic trioxide-induced cytotoxicity on multiple myeloma cells].
Topics: Acetylcysteine; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Division; Cell Survival; Drug Interactions; Glutathione; Humans; Multiple Myeloma; Oxides; Tumor Cells, Cultured; Vitamin K 3 | 2003 |
JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cells, Cultured; Clone Cells; Drug Resistance, Neoplasm; Enzyme Activation; Glutathione; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Promyelocytic, Acute; Mice; Mice, Knockout; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinases; Oxides; Receptor, EphA4 | 2004 |
[Effect and mechanism of arsenic trioxide on chemosensitivity of human lung adenocarcinoma cells].
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Oxides; Proto-Oncogene Proteins c-bcl-2; Vault Ribonucleoprotein Particles | 2003 |
[Construction of subtracted cDNA library in human Jurkat T cell line induced by arsenic trioxide in vitro].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cloning, Molecular; DNA, Complementary; Gene Expression Regulation, Neoplastic; Gene Library; Humans; Jurkat Cells; Nucleic Acid Hybridization; Oxides; Sequence Analysis, DNA | 2003 |
[Application of arsenic trioxide in comprehensive therapy of liver carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Oxides | 2003 |
Arsenic trioxide-induced apoptosis is independent of CD95 in lymphatic cell lines.
Topics: Antibodies; Antigens, CD; Apoptosis; Arsenic Trioxide; Arsenicals; fas Receptor; Glutamic Acid; Growth Inhibitors; HL-60 Cells; Humans; Intracellular Membranes; Jurkat Cells; K562 Cells; Membrane Potentials; Mitochondria; Oxides | 2004 |
[Analysis of caspases activity of hematopoietic progenitor cells and its significance in myelodysplastic syndromes].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspase 9; Caspases; Hematopoietic Stem Cells; Humans; Myelodysplastic Syndromes; Oxides | 2003 |
[Emodin sensitizes HeLa cell to arsenic trioxide induced apoptosis via the reactive oxygen species-mediated signaling pathways].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Survival; Cells, Cultured; Child; Drug Synergism; Emodin; Fibroblasts; HeLa Cells; Humans; Membrane Potentials; Mitochondria; NF-kappa B; Oxides; Reactive Oxygen Species; Signal Transduction; U937 Cells | 2003 |
Arsenic trioxide and paclitaxel induce apoptosis by different mechanisms.
Topics: Apoptosis; Apoptosis Inducing Factor; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; BH3 Interacting Domain Death Agonist Protein; Carrier Proteins; Caspases; Cell Line; Cell Nucleus; Chromatin; Cytochromes c; Enzyme Activation; Flavoproteins; Flow Cytometry; Gene Expression Regulation; Humans; Intracellular Membranes; Membrane Glycoproteins; Membrane Proteins; Mitochondria; Oxides; Paclitaxel; Phosphoserine; Protein Transport; Proto-Oncogene Proteins c-bcl-2; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2004 |
Depolarization of mitochondria and activation of caspases are common features of arsenic(III)-induced apoptosis in myelogenic and lymphatic cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase Inhibitors; Caspases; Cell Line, Tumor; Enzyme Activation; Flow Cytometry; Fluorescent Dyes; HL-60 Cells; Humans; Jurkat Cells; Membrane Potentials; Mitochondria; Oxides | 2004 |
Emodin enhances arsenic trioxide-induced apoptosis via generation of reactive oxygen species and inhibition of survival signaling.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Emodin; Glutathione; Glutathione Disulfide; HeLa Cells; Humans; Oxides; Reactive Oxygen Species; Signal Transduction; U937 Cells | 2004 |
[Influence of some inhibitors (As2O3 and HCN) on the amino acid oxidase of the Staphylococcus albus].
Topics: Amino Acids; Arsenic Trioxide; Arsenicals; Oxides; Oxidoreductases; Staphylococcus; Staphylococcus epidermidis | 1951 |
Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Division; Humans; Immunoglobulin G; Melarsoprol; Mice; Mice, SCID; Multiple Myeloma; Neoplasm Transplantation; Neoplasms, Experimental; Oxides; Plasma Cells; Receptors, Interleukin-6; Survival Analysis; Tissue Distribution; Xenograft Model Antitumor Assays | 2004 |
Arsenic trioxide uptake by hexose permeases in Saccharomyces cerevisiae.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biological Transport; Carcinogens; Catalysis; DNA; Dose-Response Relationship, Drug; Escherichia coli; Glucose; Humans; Kinetics; Membrane Proteins; Models, Chemical; Monosaccharide Transport Proteins; Oxides; Plasmids; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Time Factors | 2004 |
[Inhibition effect of arsenic trioxide on the growth of human MDS cell line MUTZ-1 cells].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Cell Division; DNA; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Myelodysplastic Syndromes; Oxides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger | 2004 |
RWJ-241947 (MCC-555), a unique peroxisome proliferator-activated receptor-gamma ligand with antitumor activity against human prostate cancer in vitro and in beige/nude/ X-linked immunodeficient mice and enhancement of apoptosis in myeloma cells induced by
Topics: Agar; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Caspases; CD36 Antigens; Cell Cycle; Cell Differentiation; Cell Division; Cell Line, Tumor; Cell Survival; Genetic Linkage; Humans; Immunologic Deficiency Syndromes; Ligands; Luciferases; Male; Mice; Multiple Myeloma; Oxides; Prostatic Neoplasms; Receptors, Cytoplasmic and Nuclear; Tetrazolium Salts; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Transfection; U937 Cells; X Chromosome | 2004 |
[Clinical and experimental study of cardiac effects of conventional dosage arsenic trioxide in APL patients].
Topics: Adult; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Calcium; Calcium Channels, L-Type; Cricetinae; Electrocardiography; Female; Heart; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides | 2004 |
[Successful bone marrow transplantation with a matched unrelated donor in an acute promyelocytic leukemia patient after reinduction therapy with arsenic trioxide].
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Combined Modality Therapy; Histocompatibility Testing; Humans; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Male; Oxides; Remission Induction; Tissue Donors; Transplantation, Homologous; Treatment Outcome | 2004 |
Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Glutathione; HeLa Cells; Humans; Hydrogen Peroxide; Male; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms; Oxides; Prostatic Neoplasms; Reactive Oxygen Species; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2004 |
Dual effects of glutathione-S-transferase pi on As2O3 action in prostate cancer cells: enhancement of growth inhibition and inhibition of apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Isoenzymes; Male; Oxides; Prostatic Neoplasms | 2004 |
Radiofrequency ablation: Effect of pharmacologic modulation of hepatic and renal blood flow on coagulation diameter in a VX2 tumor model.
Topics: Adrenergic Agonists; Anesthetics, Inhalation; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma; Catheter Ablation; Disease Models, Animal; Epinephrine; Halothane; Kidney; Kidney Neoplasms; Laser-Doppler Flowmetry; Liver; Liver Neoplasms; Oxides; Rabbits; Regional Blood Flow | 2004 |
Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Benzamides; DNA-Binding Proteins; Enzyme Inhibitors; Flavonoids; Genes, Tumor Suppressor; Humans; In Vitro Techniques; K562 Cells; Leukemia, Erythroblastic, Acute; MAP Kinase Kinase 1; Mitogen-Activated Protein Kinase Kinases; Nuclear Proteins; Oxides; Proteins; Tumor Protein p73; Tumor Suppressor Proteins | 2004 |
Herpes zoster during treatment with arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Herpes Zoster; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2004 |
The cell cycle related apoptotic susceptibility to arsenic trioxide is associated with the level of reactive oxygen species.
Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Catalase; Cell Cycle; Cell Division; Cell Line, Tumor; Dactinomycin; Flow Cytometry; Fluoresceins; Humans; In Situ Nick-End Labeling; Interphase; Naphthoquinones; Oxides; Propidium; Reactive Oxygen Species | 2004 |
Arsenic trioxide uptake by human and rat aquaglyceroporins.
Topics: Amino Acid Sequence; Animals; Arsenic Trioxide; Arsenicals; Base Sequence; Cell Membrane Permeability; Cloning, Molecular; Humans; Mutagenesis, Site-Directed; Oocytes; Oxides; Porins; Rats; Recombinant Proteins; Species Specificity; Structure-Activity Relationship; Xenopus laevis | 2004 |
Resistance to oxidative stress in a freshwater fish Channa punctatus after exposure to inorganic arsenic.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cytosol; Fish Proteins; Fishes; Gills; Glutathione; Kidney; Lipid Peroxidation; Liver; Muscles; Oxidative Stress; Oxides; Time Factors | 2004 |
[Targeted in therapies multiple myeloma].
Topics: Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Multiple Myeloma; Oxides; Pyrazines; Thalidomide | 2004 |
Herpes zoster during treatment with arsenic trioxide.
Topics: 2-Aminopurine; Antineoplastic Agents; Antiviral Agents; Arsenic Trioxide; Arsenicals; Famciclovir; Female; Herpes Zoster; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Treatment Outcome | 2004 |
Biography of Zhu Chen.
Topics: Arsenic Trioxide; Arsenicals; China; Hematology; History, 20th Century; History, 21st Century; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2004 |
[Cytotoxic effects of arsenic trioxide in combination with chemotherapeutic drugs on acute non-promyelocytic leukemia cells].
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Leukemia; Male; Middle Aged; Oxides | 2004 |
45th Annual Meeting of the American Society of Hematology December 6-9, 2003.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Hematology; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multicenter Studies as Topic; Multiple Myeloma; Oxides; Prognosis; Protein-Tyrosine Kinases; Recurrence; Risk; Rituximab; Salvage Therapy; Thalidomide; Time Factors; ZAP-70 Protein-Tyrosine Kinase | 2004 |
Synthesis of [75Se]5-ethoxycarbonyl-4-methyl-1,2,3-selenadiazole.
Topics: Arsenic Trioxide; Arsenicals; Azoles; Chromatography, Thin Layer; Organoselenium Compounds; Oxidation-Reduction; Oxides; Protons; Radiochemistry; Radiopharmaceuticals; Selenium Radioisotopes; Temperature | 2004 |
[Effects of combination therapy with all-trans retinoic acid and arsenic trioxide on acute promyelocytic leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blood Coagulation; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Tretinoin | 2004 |
Bone marrow necrosis in a patient with acute promyelocytic leukemia during re-induction therapy with arsenic trioxide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow; Bone Marrow Diseases; Fever; Humans; Hydroxyurea; Leukemia, Promyelocytic, Acute; Male; Mercaptopurine; Middle Aged; Necrosis; Oxides; Pancytopenia; Remission Induction | 2004 |
[Hydrogen peroxide inhibits arsenic trioxide-induced apoptosis of Burkitt lymphoma cells].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Burkitt Lymphoma; Cell Line, Tumor; Humans; Hydrogen Peroxide; Microscopy, Electron, Scanning; Microscopy, Fluorescence; Oxides | 2004 |
Death by arsenic: implications of PML sumoylation.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; MAP Kinase Signaling System; Neoplasm Proteins; Nuclear Proteins; Oxides; Phosphorylation; Promyelocytic Leukemia Protein; Transcription Factors; Tumor Suppressor Proteins | 2004 |
Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cells, Cultured; CHO Cells; Cricetinae; Growth Inhibitors; HeLa Cells; Humans; Leukemia, Promyelocytic, Acute; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Phosphorylation; Promyelocytic Leukemia Protein; Signal Transduction; Small Ubiquitin-Related Modifier Proteins; Transcription Factors; Tumor Suppressor Proteins | 2004 |
The effect of dietary arsenic additions on the distribution of selenium and iodine in eggs and tissues of laying hens.
Topics: Animal Feed; Animals; Arsenic Trioxide; Arsenicals; Chickens; Eggs; Female; Iodine; Oxides; Selenium; Tissue Distribution | 2004 |
Acute promyelocytic leukemia cell line AP-1060 established as a cytokine-dependent culture from a patient clinically resistant to all-trans retinoic acid and arsenic trioxide.
Topics: Arsenic Trioxide; Arsenicals; Cell Culture Techniques; Cell Line, Tumor; Cytokines; Drug Resistance, Neoplasm; Humans; Karyotyping; Leukemia, Promyelocytic, Acute; Mutation, Missense; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Telomerase; Telomere; Tretinoin | 2004 |
Arsenic trioxide-induced death of neuroblastoma cells involves activation of Bax and does not require p53.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Blotting, Western; Calpain; Carboplatin; Caspase 3; Caspases; Cell Line, Tumor; Cytochromes c; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Mutation; Neuroblastoma; Oxides; Proto-Oncogene Proteins c-bcl-2; Time Factors; Tumor Suppressor Protein p53; Vincristine | 2004 |
Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Child, Preschool; Combined Modality Therapy; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Remission Induction | 2004 |
Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Carcinoma, Renal Cell; Caspases; Cell Division; Doxorubicin; Drug Synergism; Fluorouracil; Glutathione; Glutathione Transferase; Humans; Kidney Neoplasms; Oxidation-Reduction; Oxides; Tumor Cells, Cultured; Vinblastine | 2004 |
Hydrogen peroxide in the Burkitt's lymphoma cell line Raji provides protection against arsenic trioxide-induced apoptosis via the phosphoinositide-3 kinase signalling pathway.
Topics: Androstadienes; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Burkitt Lymphoma; Caspase 3; Caspases; Cell Death; Cell Line, Tumor; Enzyme Activation; Gene Expression; Genes, bcl-2; Humans; Hydrogen Peroxide; Oxides; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Wortmannin | 2004 |
Inorganic arsenic toxicosis in a beef herd.
Topics: Animal Feed; Animals; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Cattle; Cattle Diseases; Diagnosis, Differential; Fatal Outcome; Oxides | 2004 |
Topoisomerase I-DNA complexes contribute to arsenic trioxide-induced apoptosis.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Buthionine Sulfoximine; Caspase 3; Caspase Inhibitors; Caspases; DNA; DNA Fragmentation; DNA Topoisomerases, Type I; Enzyme Activation; Enzyme Inhibitors; Flow Cytometry; Gene Expression; Gene Silencing; Humans; Leukemia; Oxides; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Recombinant Proteins; Tumor Cells, Cultured | 2004 |
[Re-expression of p16 gene in myeloma cell line U266 by arsenic trioxide].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; DNA Methylation; DNA Methyltransferase 3A; DNA, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, p16; Humans; Multiple Myeloma; Oxides; RNA, Messenger | 2004 |
[Arsenic trioxide induced cell apoptosis by mitochondria dependent pathway in KB and KBv200 cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Division; Cell Membrane; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; KB Cells; Membrane Potentials; Mitochondria; Oxides | 2004 |
Dicoumarol alters cellular redox state and inhibits nuclear factor kappa B to enhance arsenic trioxide-induced apoptosis.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Dicumarol; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Emodin; Enzyme Inhibitors; HeLa Cells; Humans; NF-kappa B; Oxidation-Reduction; Oxides; Reactive Oxygen Species | 2004 |
Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression.
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Lineage; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Male; MDS1 and EVI1 Complex Locus Protein; Middle Aged; Myelodysplastic Syndromes; Oxides; Proto-Oncogenes; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; Spleen; Thalidomide; Transcription Factors; Zinc Fingers | 2004 |
Mechanisms of arsenic-induced prolongation of cardiac repolarization.
Topics: Animals; Arsenic Trioxide; Arsenicals; Calcium; Electrophysiology; Enzyme Inhibitors; Guinea Pigs; Heart; Heart Ventricles; Humans; Myocytes, Cardiac; Oxides; Potassium Channels | 2004 |
A P53 target gene, PIG11, contributes to chemosensitivity of cells to arsenic trioxide.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Base Sequence; Cell Line; Consensus Sequence; Gene Expression Regulation; Genes, p53; Humans; Kidney; Neoplasm Proteins; Oxides; Promoter Regions, Genetic; Proteins; Reactive Oxygen Species; Recombinant Proteins; Transfection | 2004 |
[Effects of arsenic trioxide, ginseng saponin and beta-elemene on telomere-telomerase system in K562 cell line].
Topics: Arsenic Trioxide; Arsenicals; Cell Survival; Humans; K562 Cells; Oxides; Panax; Saponins; Sesquiterpenes; Telomerase; Telomere | 2004 |
[Effect of arsenic trioxide on telomerase and telomerase reverse transcriptase in KM3 cell line].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Line, Tumor; DNA-Binding Proteins; Humans; Multiple Myeloma; Oxides; RNA, Messenger; Telomerase | 2004 |
Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Female; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Middle Aged; Oxides; Recurrence; Tretinoin | 2004 |
The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities.
Topics: Amino Acid Sequence; Animals; Antiviral Agents; Antiviral Restriction Factors; Arsenic Trioxide; Arsenicals; Carrier Proteins; Cats; Cell Line; Chlorocebus aethiops; Growth Inhibitors; Humans; Leukemia Virus, Murine; Mice; Molecular Sequence Data; Oxides; R Factors; Retroviridae; Retroviridae Infections; RNA, Small Interfering; Sequence Alignment; Sequence Homology, Amino Acid; Tripartite Motif Proteins; Ubiquitin-Protein Ligases | 2004 |
A case of M2a with complex chromosome aberrations obtained complete remission through modified As2O3 medication.
Topics: Adult; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Chromosome Aberrations; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Oxides; Remission Induction | 2004 |
Effect of arsenic (AsIII) on glutathione-dependent enzymes in liver and kidney of the freshwater fish Channa punctatus.
Topics: Animals; Arsenic Trioxide; Arsenicals; Catalase; Gills; Glutathione Peroxidase; Glutathione Reductase; Glutathione Transferase; Kidney; Liver; Muscles; Oxides; Perciformes; Water Pollutants, Chemical | 2004 |
Bibliography. Current world literature. Therapeutic modalities.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Dacarbazine; Genetic Therapy; Heat-Shock Proteins; Humans; Immunotherapy; Interferons; Oxides; Radiotherapy; Sirolimus; Temozolomide; Vitamin D | 2003 |
Arsenic trioxide: expanding roles for an ancient drug?
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Oxides; Salvage Therapy | 2004 |
A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients.
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Oxides; Salvage Therapy | 2004 |
Inhibition of hepatitis C virus replication by arsenic trioxide.
Topics: Antiviral Agents; Arsenic Trioxide; Arsenicals; Blotting, Northern; Blotting, Western; Cell Line; Drug Evaluation, Preclinical; Drug Synergism; Genes, Reporter; Hepacivirus; Humans; Interferon-alpha; Oxides; Replicon; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Virus Replication | 2004 |
Evaluation of DNA damage in patients with arsenic poisoning: urinary 8-hydroxydeoxyguanine.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adolescent; Adult; Aged; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; DNA Damage; Female; Growth Inhibitors; Guanine; Humans; Infant; Japan; Male; Middle Aged; Oxides | 2004 |
Suppression of cell proliferation and regulation of estrogen receptor alpha signaling pathway by arsenic trioxide on human breast cancer MCF-7 cells.
Topics: Arsenic Trioxide; Arsenicals; Breast Neoplasms; Cell Count; Cell Division; Cell Line, Tumor; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Humans; Oxides; Receptors, Estrogen; RNA, Messenger; Signal Transduction | 2004 |
Inhibition of apoptosis in acute promyelocytic leukemia cells leads to increases in levels of oxidized protein and LMP2 immunoproteasome.
Topics: Aging; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase Inhibitors; Cell Line, Tumor; Cysteine Endopeptidases; Enzyme Inhibitors; Humans; Hydrogen Peroxide; Iron; Leukemia, Promyelocytic, Acute; Oxidation-Reduction; Oxidative Stress; Oxides; Proteins | 2004 |
Channelling the Emperor: what really killed Napoleon?
Topics: Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Cause of Death; France; History, 19th Century; Humans; Oxides; Stomach Neoplasms; Torsades de Pointes | 2004 |
Comparison of effects of As2O3 and As4O6 on cell growth inhibition and gene expression profiles by cDNA microarray analysis in SiHa cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Northern; Cell Cycle; Cell Division; Cell Line, Tumor; DNA; DNA Fragmentation; DNA Repair; DNA, Complementary; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Humans; Nucleic Acid Hybridization; Oligonucleotide Array Sequence Analysis; Oxides; RNA; Time Factors; Up-Regulation; Uterine Cervical Neoplasms | 2004 |
Phenylarsine oxide (PAO) more intensely induces apoptosis in acute promyelocytic leukemia and As2O3-resistant APL cell lines than As2O3 by activating the mitochondrial pathway.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Membrane Potentials; Mitochondria; Oxides; Proto-Oncogene Proteins c-bcl-2 | 2004 |
Developmental arrest in Japanese medaka (Oryzias latipes) embryos exposed to sublethal concentrations of atrazine and arsenic trioxide.
Topics: Abnormalities, Drug-Induced; Animals; Arsenic Trioxide; Arsenicals; Atrazine; Cell Death; Embryo, Nonmammalian; Environmental Exposure; Female; Lethal Dose 50; Oryzias; Oxides; Time Factors; Water Pollutants, Chemical | 2004 |
Carbohydrate metabolism in growing rice seedlings under arsenic toxicity.
Topics: alpha-Amylases; Arsenic; Arsenic Trioxide; Arsenicals; beta-Amylase; beta-Fructofuranosidase; Carbohydrate Metabolism; Glucosyltransferases; Oryza; Oxides; Starch; Starch Phosphorylase; Sucrose | 2004 |
Arsenic trioxide poisoning: a description of two acute overdoses.
Topics: Acute Disease; Adult; Antidotes; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Drug Overdose; Feces; Humans; Male; Oxides; Powders; Succimer; Suicide, Attempted; Time Factors | 2004 |
Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells.
Topics: Androstadienes; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Line, Tumor; Chromones; Drug Resistance; Enzyme Activation; Enzyme Inhibitors; HL-60 Cells; Humans; Leukemia; Morpholines; Mutation; NF-kappa B; NF-kappa B p50 Subunit; Oxides; Peptides; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphoric Monoester Hydrolases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Transfection; Tumor Suppressor Proteins; Wortmannin | 2005 |
Tissue distribution of arsenic species in rabbits after single and multiple parenteral administration of arsenic trioxide: tissue accumulation and the reversibility after washout are tissue-selective.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Arsenites; Cacodylic Acid; Oxides; Rabbits; Tissue Distribution | 2005 |
Drug uptake and pharmacological modulation of drug sensitivity in leukemia by AQP9.
Topics: Aquaporins; Arsenic Trioxide; Arsenicals; Biological Transport; Cloning, Molecular; HL-60 Cells; Humans; Ion Channels; K562 Cells; Kinetics; Oxides; Recombinant Proteins; Transfection; Vitamin D | 2004 |
Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Glioblastoma; Humans; Mice; Mice, Nude; Oxides; Reactive Oxygen Species; Transplantation, Heterologous; Tumor Stem Cell Assay | 2004 |
Inhibition of cell proliferation and the action mechanisms of arsenic trioxide (As2O3) on human breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Breast Neoplasms; Cell Proliferation; DNA, Neoplasm; Down-Regulation; Female; Flow Cytometry; G1 Phase; Humans; Oxides; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Up-Regulation | 2004 |
Combined effect of arsenic trioxide and sulindac sulfide in A549 human lung cancer cells in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; In Vitro Techniques; Lung Neoplasms; Oxides; Sulindac; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2004 |
Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience.
Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Remission Induction; Survival Rate; Treatment Outcome | 2004 |
Treatment of acute promyelocytic leukemia in children: arsenic or ATRA.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Survival Rate; Treatment Outcome; Tretinoin | 2004 |
Simultaneously multi-parameter determination of hematonosis cell apoptosis by two-photon and confocal laser scanning microscopy.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Calcium; Cell Line, Tumor; Cell Nucleus; Dose-Response Relationship, Drug; Flow Cytometry; Hematologic Diseases; Humans; Leukemia; Membrane Potentials; Microscopy, Confocal; Mitochondria; Oxides; Photons | 2004 |
[Experimental research on the effect of arsenic trioxide on the growth of prostate cancer PC-3 cell lines].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Male; Oxides; Prostatic Neoplasms | 2004 |
L-ascorbic acid represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cyclooxygenase 2; DNA; Down-Regulation; Electrophoretic Mobility Shift Assay; Glutathione; HL-60 Cells; Humans; Hydrogen Peroxide; Isoenzymes; Leukemia, Myeloid, Acute; Membrane Proteins; NF-kappa B; Oxides; Prostaglandin-Endoperoxide Synthases; Protein Subunits; Superoxides; Tosylphenylalanyl Chloromethyl Ketone; Transcription Factor RelA | 2004 |
Arsenic trioxide sensitizes CD95/Fas-induced apoptosis through ROS-mediated upregulation of CD95/Fas by NF-kappaB activation.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; fas Receptor; Female; Gene Expression Regulation, Neoplastic; Humans; NF-kappa B; Oxides; Reactive Oxygen Species; Signal Transduction; Tumor Cells, Cultured; Up-Regulation; Uterine Cervical Neoplasms | 2004 |
Enhancement of arsenic trioxide-mediated apoptosis using docosahexaenoic acid in arsenic trioxide-resistant solid tumor cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Docosahexaenoic Acids; Drug Interactions; Drug Resistance, Neoplasm; Humans; Neoplasms; Oxides; Reactive Oxygen Species; Tumor Cells, Cultured | 2004 |
[Arsenic trioxide tablets, 1 mg].
Topics: Arsenic; Arsenic Trioxide; Arsenicals; Oxides; Tablets | 1950 |
Management of arsenic trioxide necrosis in the maxilla.
Topics: Adult; Alveolar Bone Loss; Arsenic Trioxide; Arsenicals; Dental Pulp Devitalization; Extravasation of Diagnostic and Therapeutic Materials; Female; Humans; Male; Maxillary Diseases; Oroantral Fistula; Osteonecrosis; Oxides | 2004 |
Arsenic trioxide liposomes: encapsulation efficiency and in vitro stability.
Topics: Arsenic Trioxide; Arsenicals; Capsules; Chemistry, Pharmaceutical; Drug Carriers; Drug Delivery Systems; Drug Stability; Kinetics; Lipids; Liposomes; Oxides; Sonication | 2004 |
Reverse effects of tetraarsenic oxide on the angiogenesis induced by nerve growth factor in the rat cornea.
Topics: Analysis of Variance; Angiogenesis Inhibitors; Animals; Arsenic Trioxide; Arsenicals; Corneal Neovascularization; Female; Male; Microscopy; Nerve Growth Factor; Oxides; Rats; Rats, Sprague-Dawley; Time Factors | 2004 |
[Relationship between drug resistance and the expression of NF-kappaB induced in leukemic cells].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; I-kappa B Proteins; K562 Cells; NF-kappa B; Oxides | 2004 |
Molecular remission with arsenic trioxide in patients with newly diagnosed acute promyelocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Child; Drug Evaluation; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Polymerase Chain Reaction; Proto-Oncogene Proteins c-bcr; Remission Induction; Retrospective Studies; Treatment Outcome | 2004 |
Nursing considerations for nontraditional treatment approaches to hematologic malignancies.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Nurse's Role; Oncology Nursing; Oxides; Treatment Outcome | 2004 |
Selection for loss of Ref1 activity in human cells releases human immunodeficiency virus type 1 from cyclophilin A dependence during infection.
Topics: Antiviral Restriction Factors; Arsenic Trioxide; Arsenicals; Carrier Proteins; Cell Line, Tumor; Cyclophilin A; DNA-(Apurinic or Apyrimidinic Site) Lyase; HIV-1; Humans; Oxides; Tripartite Motif Proteins; Ubiquitin-Protein Ligases | 2004 |
Sodium selenite induces apoptosis in acute promyelocytic leukemia-derived NB4 cells by a caspase-3-dependent mechanism and a redox pathway different from that of arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Humans; Leukemia, Promyelocytic, Acute; Mitochondria; Oxidation-Reduction; Oxides; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Signal Transduction; Sodium Selenite; Sulfhydryl Compounds; Tretinoin | 2004 |
Arsenic trioxide (As2O3) sensitivity of carcinoma cell lines and cancer cells from patients with carcinomatosis peritonei.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma; Cell Line, Tumor; Cell Survival; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Oxides; Peritoneal Neoplasms; Xenograft Model Antitumor Assays | 2004 |
Arsenic trioxide causes redistribution of cell cycle, caspase activation, and GADD expression in human colonic, breast, and pancreatic cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Breast Neoplasms; Caspase 3; Caspases; CCAAT-Enhancer-Binding Proteins; Cell Cycle; Cell Cycle Proteins; Cell Division; Colonic Neoplasms; DNA Fragmentation; Enzyme Activation; Gene Expression Regulation; Genes, bcl-2; Growth Inhibitors; Humans; In Situ Nick-End Labeling; Neoplasm Proteins; Nuclear Proteins; Oxides; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Transcription Factor CHOP; Transcription Factors; Tumor Cells, Cultured | 2004 |
Characterization of molecular events in a series of bladder urothelial carcinoma cell lines with progressive resistance to arsenic trioxide.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Forecasting; Glutathione; Humans; Inhibitory Concentration 50; MutS Homolog 2 Protein; NF-kappa B; Oxides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Superoxide Dismutase; Transcription Factor AP-1; Transcription Factors; Tumor Suppressor Protein p53; Up-Regulation; Urinary Bladder Neoplasms; Urothelium | 2004 |
Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma.
Topics: Aged; Antineoplastic Agents, Alkylating; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Oxides; Recurrence; Treatment Outcome | 2005 |
[The mechanism of arsenic trioxide-inducing apoptosis of K562 cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Caspase 3; Caspases; Cell Cycle; Cell Proliferation; Cytochromes c; Fusion Proteins, bcr-abl; Humans; K562 Cells; Oxides; Proto-Oncogene Proteins c-bcl-2 | 2004 |
Arsenic trioxide prevents radiation-enhanced tumor invasiveness and inhibits matrix metalloproteinase-9 through downregulation of nuclear factor kappaB.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Gamma Rays; Gene Expression Regulation, Neoplastic; Genes, Reporter; HeLa Cells; Humans; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mice; Neoplasm Invasiveness; NF-kappa B; Oxides; Reverse Transcriptase Polymerase Chain Reaction | 2005 |
Survival after a lethal dose of arsenic trioxide.
Topics: Adult; Antidotes; Arsenic Trioxide; Arsenicals; Charcoal; Chelating Agents; Electromyography; Female; Humans; Oxides; Radiography, Abdominal; Sodium Bicarbonate; Sodium Chloride; Suicide, Attempted; Therapeutic Irrigation | 2004 |
Effect of arsenic trioxide on human hepatocarcinoma in nude mice.
Topics: alpha-Fetoproteins; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blood Platelets; Carcinoma, Hepatocellular; Hemoglobins; Humans; Kidney; Leukocytes; Liver; Liver Neoplasms, Experimental; Male; Mice; Mice, Nude; Oxides | 2004 |
Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Flavonoids; Growth Inhibitors; Humans; Kinetics; Leukemia, Promyelocytic, Acute; MAP Kinase Kinase 1; Membrane Potentials; Mitochondria; Oxides; RNA, Small Interfering; Transfection | 2005 |
Anthraquinones sensitize tumor cells to arsenic cytotoxicity in vitro and in vivo via reactive oxygen species-mediated dual regulation of apoptosis.
Topics: Animals; Anthraquinones; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspase 9; Caspases; Cell Line, Tumor; Cytochromes c; Emodin; Enzyme Activation; Humans; Intracellular Membranes; Mice; Mitochondria; Neoplasm Transplantation; Neoplasms; NF-kappa B; Oxides; Phorbol Esters; Reactive Oxygen Species; Signal Transduction | 2004 |
Additional support for derivation of an acute/subchronic reference level for arsenic.
Topics: Arsenic; Arsenic Trioxide; Arsenicals; Diet; Glycine max; Humans; Oxides; Reference Values | 2004 |
Measurement trumps theory.
Topics: Arsenic; Arsenic Trioxide; Arsenicals; Diet; Glycine max; Humans; Oxides; Reference Values | 2004 |
Arsenic trioxide represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cyclooxygenase 2; DNA; Enzyme Activation; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutathione; HL-60 Cells; Humans; Hydrogen Peroxide; I-kappa B Kinase; Leukemia, Myeloid, Acute; Membrane Proteins; NF-kappa B; Oxides; Prostaglandin-Endoperoxide Synthases; Protein Binding; Protein Serine-Threonine Kinases; Protein Subunits; Protein Transport | 2005 |
[Study on effect of arsenic trioxide on adhesion and invasion of human hepatocarcinoma cells in vitro].
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Adhesion; Cell Line, Tumor; Cell Movement; Humans; Hyaluronan Receptors; Intercellular Adhesion Molecule-1; Liver Neoplasms; Matrix Metalloproteinase 2; Mice; Mice, Nude; Neoplasm Invasiveness; Oxides | 2004 |
[Synergistic inhibitory effect of STI571 in combination with arsenic trioxide on a multidrug-resistant leukemia cell line expressing bcr-abl].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Cell Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Genes, abl; Genes, MDR; Humans; Imatinib Mesylate; Inhibitory Concentration 50; K562 Cells; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Vincristine | 2004 |
Therapeutic spectrum in the treatment of myelodysplastic syndromes.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Erythropoietin; Forecasting; Granulocyte Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Myelodysplastic Syndromes; Oxides; Transplantation, Autologous; Transplantation, Homologous | 2004 |
Oral arsenic trioxide poisoning and secondary hazard from gastric content.
Topics: Arsenic Trioxide; Arsenicals; Emergency Service, Hospital; Fatal Outcome; Gases; Gastric Acid; Humans; Male; Middle Aged; Occupational Exposure; Oxides; Personnel, Hospital; Suicide, Attempted | 2004 |
Depolarisation of the plasma membrane in the arsenic trioxide (As2O3)-and anti-CD95-induced apoptosis in myeloid cells.
Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Membrane; Chloride Channels; Chlorides; fas Receptor; Humans; Membrane Potentials; Myeloid Cells; Nitrobenzoates; Oxides; Sodium; U937 Cells | 2004 |
Arsenic trioxide inhibits proliferation in K562 cells by changing cell cycle and survivin expression.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Division; Humans; Inhibitor of Apoptosis Proteins; K562 Cells; Microtubule-Associated Proteins; Neoplasm Proteins; Oxides; RNA, Messenger; Survivin | 2004 |
Effects of 1, 6-Bis[4-(4-amino-3-hydroxyphenoxy)phenyl]diamantane (DPD), a reactive oxygen species and apoptosis inducing agent, on human leukemia cells in vitro and in vivo.
Topics: Adamantane; Animals; Annexin A5; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Cell Cycle; Cell Division; HL-60 Cells; Humans; Membrane Potentials; Mice; Mice, SCID; Oxides; Reactive Oxygen Species; RNA, Messenger; Superoxide Dismutase | 2005 |
Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Blotting, Western; Brain Neoplasms; Gene Expression Profiling; Glioma; Humans; Membrane Proteins; Oligonucleotide Array Sequence Analysis; Oxides; Proto-Oncogene Proteins; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Up-Regulation | 2005 |
Hematological and molecular remission with combination chemotherapy in a patient with PLZF-RARalpha acute promyelocytic leukemia (APML).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Translocation, Genetic | 2005 |
[Toxicity of arsenic trioxide to human lung adenocarcinoma cell line SPCA1 and its mechanism].
Topics: Adenocarcinoma; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Calcium; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; fas Receptor; Humans; Inhibitory Concentration 50; Lung Neoplasms; Oxides; Proto-Oncogene Proteins c-bcl-2 | 2004 |
Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Bromodeoxyuridine; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Drug Interactions; Humans; Ki-67 Antigen; Kinetics; Leukemia, Myeloid, Acute; Oxides; S Phase; Tretinoin; Tumor Cells, Cultured | 2005 |
[Preliminary study on the arsenic trioxide-induced NB4 cell apoptosis and its molecular mechanisms].
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Oxides | 1997 |
[Effects of arsenic trioxide on the subcellular localization of PML/PML-RARalpha protein in leukemic cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; HL-60 Cells; Humans; Intracellular Space; Leukemia; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Protein Transport; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transcription Factors; Tretinoin; Tumor Suppressor Proteins | 1997 |
[In vitro study on arsenic trioxide-inducing apoptosis in primary acute promyelocytic leukemie cells].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Proliferation; Cells, Cultured; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides | 1997 |
[Effect of arsenic trioxide on drug transporting molecules in acute promyelocytic leukemia cell line].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Oxides; Tretinoin; Vault Ribonucleoprotein Particles | 2004 |
[Effects of protein tyrosine kinase, protein tyrosine phosphatase and protein kinase C on the apoptosis of arsenic trioxide treated NB4 cells and human cortex neurons].
Topics: Adult; Apoptosis; Arsenic Trioxide; Arsenicals; Calcium; Cell Line, Tumor; Cells, Cultured; Cerebral Cortex; Cytoplasm; Dose-Response Relationship, Drug; Humans; Leukemia, Promyelocytic, Acute; Male; Neurons; Oxides; Protein Kinase C; Protein Tyrosine Phosphatases; Protein-Tyrosine Kinases | 2004 |
[Biologic changes in MDS-L cell line induced by As2O3 and/or TRAIL].
Topics: Antigens, CD34; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line; Cyclin-Dependent Kinase Inhibitor p15; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Immunohistochemistry; Myelodysplastic Syndromes; Oxides; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; TNF-Related Apoptosis-Inducing Ligand | 2004 |
PRAM-1 potentiates arsenic trioxide-induced JNK activation.
Topics: Adaptor Proteins, Signal Transducing; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Enzyme Activation; Humans; JNK Mitogen-Activated Protein Kinases; Kinetics; Leukemia, Promyelocytic, Acute; Microfilament Proteins; Oligopeptides; Oxides; Proteins; src Homology Domains; Tretinoin | 2005 |
Preparation of arsenic trioxide-loaded albuminutes immuno-nanospheres and its specific killing effect on bladder cancer cell in vitro.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Fluorescent Antibody Technique; Mice; Mice, Inbred BALB C; Nanotubes; Oxides; Serum Albumin; Urinary Bladder Neoplasms | 2005 |
Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Enzyme Activation; Glutathione; Humans; Leukemia, Myeloid; Mitochondria; Oxides; Peroxides; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species | 2005 |
Proteomic analysis of nuclear matrix proteins during arsenic trioxide induced apoptosis in leukemia K562 cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Humans; K562 Cells; Nuclear Matrix-Associated Proteins; Oxides; Proteomics | 2005 |
Repeated arsenic trioxide intravenous infusion causes focal bone marrow necrosis in two acute promyelocytic leukemia patients.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Bone Marrow Diseases; Child; Female; Humans; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Male; Necrosis; Oxides | 2004 |
Arsenic trioxide triggers a regulated form of caspase-independent necrotic cell death via the mitochondrial death pathway.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Caspase 2; Caspase 9; Caspases; Cell Death; Cell Line, Tumor; Fibroblasts; Humans; Kinetics; Leukemia, Promyelocytic, Acute; Mitochondria; Necrosis; Oxides; Proto-Oncogene Proteins c-bcl-2 | 2005 |
Significance of intracellular arsenic trioxide for therapeutic response in acute promyelocytic leukemia.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Biological Transport; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis | 2005 |
Retinoic acid and arsenic trioxide cooperate for apoptosis through phosphorylated RXR alpha.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Base Sequence; Cell Line; Cell Line, Tumor; Dimerization; DNA Primers; Mice; Oxides; Phosphorylation; Plasmids; Retinoid X Receptor alpha; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin | 2005 |
Zinc protects against arsenic-induced apoptosis in a neuronal cell line, measured by DEVD-caspase activity.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Line; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Mice; Neurons; Oxides; Phenotype; Sodium Oxybate; Time Factors; Zinc; Zinc Sulfate | 2004 |
Simultaneous and ultrarapid determination of reactive oxygen species and reduced glutathione in apoptotic leukemia cells by microchip electrophoresis.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Electrophoresis, Microchip; Fluorescent Dyes; Glutathione; Humans; Lasers; Leukemia, Promyelocytic, Acute; Miniaturization; Oxides; Reactive Oxygen Species; Reproducibility of Results; Rhodamines; Signal Transduction; Spectrometry, Fluorescence; Tumor Cells, Cultured | 2005 |
Diarsenic and tetraarsenic oxide inhibit cell cycle progression and bFGF- and VEGF-induced proliferation of human endothelial cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Fibroblast Growth Factor 2; Humans; Neoplasms; Oxides; Vascular Endothelial Growth Factor A | 2005 |
Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; DNA Fingerprinting; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Multiple Myeloma; Oxides; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; Superoxides | 2005 |
Arsenic trioxide (As(2)O(3)) induces apoptosis through activation of Bax in hematopoietic cells.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Coloring Agents; Cytosol; Dose-Response Relationship, Drug; Enzyme Activation; Hematopoietic Stem Cells; Humans; Jurkat Cells; Mitochondria; Oxides; Peptides; Protein Conformation; Protein Transport; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Subcellular Fractions; Time Factors | 2005 |
Triterpenoid CDDO-Im downregulates PML/RARalpha expression in acute promyelocytic leukemia cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Leukemic; Humans; Imidazoles; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Nuclear Proteins; Oleanolic Acid; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Recombinant Fusion Proteins; Retinoic Acid Receptor alpha; Transcription Factors; Tretinoin; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2005 |
[Protein kinase C inhibitor Gö6976 sensitizes arsenic trioxide-induced cell apoptosis in chronic myeloid leukemic cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carbazoles; Cell Cycle; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Protein Kinase C; Time Factors | 2005 |
Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bryostatins; Cell Cycle; Cell Line, Tumor; Cell Transformation, Neoplastic; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Macrolides; Myelopoiesis; Oxides; Tretinoin | 2005 |
Elimination of the differential chemoresistance between the murine B-cell lymphoma LY-ar and LY-as cell lines after arsenic (As2O3) exposure via the overexpression of gsto1 (p28).
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Cell Survival; Cloning, Molecular; Drug Resistance, Neoplasm; Flow Cytometry; Glutathione; Glutathione Transferase; Humans; Lymphoma, B-Cell; Membrane Potentials; Mice; Mitochondria; Oxides | 2005 |
[Determination of arsenic in As2O3-treated esophagoscope-transplant mouse tissue by graphite furnace atomic absorption spectrometry].
Topics: Animal Feed; Animals; Arsenic; Arsenic Trioxide; Arsenicals; Graphite; Mice; Oxides; Peripheral Vascular Diseases; Spectrophotometry, Atomic | 2004 |
[The effect and mechanism of arsenic trioxide on hepatocellular carcinoma].
Topics: Adult; Aged; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Chemotherapy, Cancer, Regional Perfusion; Female; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Mice; Mice, Nude; Middle Aged; Oxides | 2005 |
19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Growth Processes; Cell Line, Tumor; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Screening Assays, Antitumor; Drug Synergism; Ergocalciferols; Gene Expression; HL-60 Cells; Humans; Leukemia, Myeloid; Mitochondria; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Steroid Hydroxylases; Vitamin D3 24-Hydroxylase | 2005 |
Preferential action of arsenic trioxide in solid-tumor microenvironment enhances radiation therapy.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carbon Dioxide; Endothelial Cells; Enzyme Activation; Female; Hydrogen-Ion Concentration; JNK Mitogen-Activated Protein Kinases; Mice; Mice, Inbred C3H; Neoplasms; Oxides; Oxygen; Oxygen Consumption; Partial Pressure; Radiation-Sensitizing Agents; Regional Blood Flow | 2005 |
[Proteome analysis of nuclear matrix proteins during arsenic trioxide induced apoptosis in K562 cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Humans; K562 Cells; Nuclear Matrix-Associated Proteins; Oxides; Proteomics | 2005 |
Effect of arsenic trioxide (ATO) on human lung carcinoma PG cell line: ATO induced apoptosis of PG cells and decreased expression of Bcl-2, Pgp.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Immunohistochemistry; In Vitro Techniques; Lung Neoplasms; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Microscopy, Phase-Contrast; Oxides; Proto-Oncogene Proteins c-bcl-2; Time Factors | 2004 |
Indirect effects of Bax and Bak initiate the mitochondrial alterations that lead to cytochrome c release during arsenic trioxide-induced apoptosis.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Caspase 3; Caspases; Cell Line, Transformed; Cell Transformation, Neoplastic; Cells, Cultured; Cytochrome c Group; Dose-Response Relationship, Drug; Embryo, Mammalian; Fibroblasts; Male; Mice; Mice, Inbred BALB C; Mice, Knockout; Mitochondria, Liver; Necrosis; Oxidative Stress; Oxides; Reactive Oxygen Species; Superoxides | 2005 |
[Effect of 2-methoxyestradiol on proliferation and apoptosis of myeloma cell lines].
Topics: 2-Methoxyestradiol; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Proliferation; Dexamethasone; Dose-Response Relationship, Drug; Drug Synergism; Estradiol; Humans; Multiple Myeloma; Oxides; Time Factors; Tumor Cells, Cultured | 2005 |
[Arsenic treatment for leukemia: new model of human cancer target treatment].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Promyelocytic, Acute; Oxides; Piperazines; Pyrimidines; Tretinoin | 2005 |
Chronic myelogenous leukemia in accelerated phase.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Fatal Outcome; Female; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myeloid, Accelerated Phase; Middle Aged; Oxides; Philadelphia Chromosome; Piperazines; Pyrimidines; Translocation, Genetic | 2005 |
Successful treatment of relapsed acute promyelocytic leukemia in a patient receiving continuous ambulatory peritoneal dialysis with oral arsenic trioxide.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Peritoneal Dialysis, Continuous Ambulatory; Recurrence; Treatment Outcome | 2005 |
Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Computational Biology; Drug Synergism; Electrophoresis, Gel, Two-Dimensional; Gene Expression Regulation, Neoplastic; Granulocytes; Humans; Leukemia, Promyelocytic, Acute; Mass Spectrometry; Oligonucleotide Array Sequence Analysis; Oxides; Proteomics; Reverse Transcriptase Polymerase Chain Reaction; Systems Biology; Tretinoin | 2005 |
Vascular targeting therapies for treatment of malignant disease.
Topics: Angiogenesis Inhibitors; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Neoplasms; Oxides | 2005 |
Up-regulation of telomere-binding TRF1, TRF2 related to reactive oxygen species induced by As(2)O(3) in MGC-803 cells.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Acetylcysteine; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Cycle; Cell Division; Cell Line, Tumor; Deoxyguanosine; Flow Cytometry; G2 Phase; Gene Expression Regulation, Neoplastic; Humans; Microscopy, Atomic Force; Oxides; Protein Binding; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Telomere; Telomeric Repeat Binding Protein 1; Telomeric Repeat Binding Protein 2; Tumor Suppressor Protein p53; Up-Regulation | 2005 |
The role of Akt on arsenic trioxide suppression of 3T3-L1 preadipocyte differentiation.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; CCAAT-Enhancer-Binding Protein-alpha; Cell Cycle; Cell Differentiation; Humans; Mice; Oxides; PPAR gamma; Proto-Oncogene Proteins c-akt; Retinoid X Receptor alpha | 2005 |
Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin; Tumor Cells, Cultured | 2005 |
Cell cycle arrest and apoptotic cell death in cultured human gastric carcinoma cells mediated by arsenic trioxide.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Line, Tumor; Humans; Oxides; Stomach Neoplasms | 2005 |
[Investigation of the effect of 2-methoxyestradiol and arsenic trioxide on the apoptosis-associated gene expression profile of myeloma cells].
Topics: 2-Methoxyestradiol; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Estradiol; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Oxides; Reverse Transcriptase Polymerase Chain Reaction; Tubulin Modulators | 2005 |
[Detection of gene expression alteration of myeloma cells treated with arsenic trioxide].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Library; Humans; Multiple Myeloma; Oxides; Plasmids; Transformation, Bacterial | 2005 |
[Effects of dexamethasone on arsenic trioxide induced apoptosis, NF-kappaB activation and gene expression in lymphoma cell line].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Dexamethasone; Drug Interactions; Glucocorticoids; Humans; Immunohistochemistry; Lymphoma, B-Cell; Matrix Metalloproteinase 9; NF-kappa B; Oxides; Vascular Endothelial Growth Factor A | 2005 |
As2O3-induced c-Src/EGFR/ERK signaling is via Sp1 binding sites to stimulate p21WAF1/CIP1 expression in human epidermoid carcinoma A431 cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Binding Sites; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase 8; Oxides; p38 Mitogen-Activated Protein Kinases; Promoter Regions, Genetic; Proto-Oncogene Proteins pp60(c-src); Sp1 Transcription Factor; Transcriptional Activation | 2006 |
Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Northern; Blotting, Western; Cell Adhesion; Cell Movement; Cell Proliferation; Electrophoretic Mobility Shift Assay; Fibrosarcoma; Humans; JNK Mitogen-Activated Protein Kinases; Luciferases; Matrix Metalloproteinase 2; Neoplasm Invasiveness; NF-kappa B; Oxides; p38 Mitogen-Activated Protein Kinases; Plasminogen Activator Inhibitor 1; Reactive Oxygen Species; Tissue Inhibitor of Metalloproteinases; Tumor Cells, Cultured; Urokinase-Type Plasminogen Activator | 2005 |
Arsenic trioxide induces Hsp70 expression via reactive oxygen species and JNK pathway in MDA231 cells.
Topics: Acetylcysteine; Anthracenes; Arsenic Trioxide; Arsenicals; Blotting, Western; Cells, Cultured; DNA Primers; DNA-Binding Proteins; Gene Expression Regulation; Heat Shock Transcription Factors; HSP70 Heat-Shock Proteins; Humans; Luciferases; MAP Kinase Kinase 4; Oxides; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Transcription Factors | 2005 |
Arsenic trioxide overcomes apoptosis inhibition in K562/ADM cells by regulating vital components in apoptotic pathway.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases; Cell Cycle; Cell Proliferation; DNA Fragmentation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Genes, MDR; Humans; K562 Cells; Oxides; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53 | 2005 |
Fluid retention during arsenic trioxide treatment in acute promyelocytic leukemia.
Topics: Aged; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Edema; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Male; Oxides | 2005 |
Effect of arsenic trioxide on multidrug resistant hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Oxides | 2006 |
[The association of HeLa cell apoptosis induced by arsenic trioxide with the down-regulation of HPV18 E6 oncogene and inhibition of telomerase activity].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; DNA-Binding Proteins; Down-Regulation; HeLa Cells; Humans; Oncogene Proteins, Viral; Oxides; Telomerase | 2005 |
Arsenic trioxide induces regulated, death receptor-independent cell death through a Bcl-2-controlled pathway.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 8; Caspase 9; Caspase Inhibitors; Caspases; Enzyme Inhibitors; fas Receptor; Fas-Associated Death Domain Protein; Humans; Jurkat Cells; Ligands; Mitochondria; Oxides; Proto-Oncogene Proteins c-bcl-2; Signal Transduction | 2005 |
[Hypermethylation of CpG island of p16 gene and arsenic trioxide induced p16 gene demethylation in multiple myeloma].
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; CpG Islands; Cyclin-Dependent Kinase Inhibitor p16; DNA Methylation; Female; Genes, p16; Humans; Male; Middle Aged; Multiple Myeloma; Oxides; RNA, Messenger | 2005 |
Arsenic trioxide mediates intrinsic and extrinsic pathways of apoptosis and cell cycle arrest in acute megakaryocytic leukemia.
Topics: Antigens, CD; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 8; Caspase 9; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; fas Receptor; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Intracellular Membranes; Leukemia, Megakaryoblastic, Acute; Membrane Potentials; Mitochondria; Oligonucleotide Array Sequence Analysis; Oxides; Proto-Oncogene Proteins c-bcl-2; Receptors, Cell Surface; Receptors, Nerve Growth Factor; Receptors, Tumor Necrosis Factor; RNA, Messenger; Signal Transduction; Time Factors; Tumor Necrosis Factor Receptor Superfamily, Member 9 | 2005 |
Acute lung injury induced by arsenic trioxide in a patient with refractory myelodysplastic syndrome.
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Male; Myelodysplastic Syndromes; Oxides; Respiratory Distress Syndrome | 2005 |
Multidrug-resistant neuroblastoma cells are responsive to arsenic trioxide at both normoxia and hypoxia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Caspase 3; Caspases; Cell Death; Cell Hypoxia; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Neuroblastoma; Oxides; Reference Values; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2005 |
[Therapeutic effects of combination of arsenic trioxide with low-dose all-trans retinoic acid on induction of remission acute promyeloeytic leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Administration Schedule; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Treatment Outcome; Tretinoin | 2005 |
[Primary research on arsenic trioxide inhibiting human breast cancer cells growth and its mechanisms].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Calcium; Cell Division; Cell Line, Tumor; fas Receptor; Female; Humans; Oxides; Proliferating Cell Nuclear Antigen | 2005 |
Gene expression alteration during redox-dependent enhancement of arsenic cytotoxicity by emodin in HeLa cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Survival; Dose-Response Relationship, Drug; Emodin; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Microarray Analysis; Oxidation-Reduction; Oxides; Reactive Oxygen Species; RNA, Messenger; Sensitivity and Specificity; Time Factors | 2005 |
As2O3 enhances the anion transport activity of band 3 and the action is related with the C-terminal 16 residues of the protein.
Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Adult; Anion Exchange Protein 1, Erythrocyte; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Erythrocytes; Female; Gene Deletion; HeLa Cells; Humans; In Vitro Techniques; Leukemia, Promyelocytic, Acute; Male; Oxides; Transfection; Yeasts | 2005 |
Comparison of the cytotoxicity of the MEIC reference chemicals measured in protein free and in complete culture medium.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Culture Media; Culture Media, Serum-Free; Mercuric Chloride; Oxides; Potassium Cyanide; Protein Binding; Rats; Reference Standards; Reproducibility of Results; Time Factors; Toxicity Tests | 2005 |
Absorption and metabolism of paracetamol in rats drinking high concentration of arsenic.
Topics: Acetaminophen; Animals; Arsenic Trioxide; Arsenicals; Chromatography, High Pressure Liquid; Gastric Lavage; Intestinal Absorption; Liver; Male; Oxides; Rats; Rats, Long-Evans | 2005 |
Clinical effects of arsenic trioxide by slowing-intravenous infusion on acute promyelocyte leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cerebral Hemorrhage; Humans; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides | 2005 |
[Clinical observation and follow-up study on acute promyelocytic leukemia in childhood treated mainly with arsenic trioxide].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Remission Induction; Survival Rate; Treatment Outcome | 2005 |
[Anti-hepatoma effect of arsenic trioxide on rat liver cancers induced by 2-acetamidofluorene].
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Fluoresceins; Liver Neoplasms, Experimental; Male; Oxides; Rats | 2005 |
[The effect of same devitalization agents on cells in tissue cultures. Study in phase contrast microscope].
Topics: Arsenic Trioxide; Arsenicals; Cell Nucleus; Cells, Cultured; Dental Pulp Devitalization; Dibucaine; Formaldehyde; HeLa Cells; Humans; Microscopy, Phase-Contrast; Oxides; Polymers | 1967 |
NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs).
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Blotting, Western; Bone Marrow Cells; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Dose-Response Relationship, Drug; Electrophoretic Mobility Shift Assay; Enzyme Activation; Etanercept; Flow Cytometry; Glutathione; Growth Inhibitors; Humans; Immunoglobulin G; Intracellular Signaling Peptides and Proteins; Membrane Glycoproteins; Myelodysplastic Syndromes; NF-kappa B; Oxides; Protein Transport; Receptors, Tumor Necrosis Factor; Reverse Transcriptase Polymerase Chain Reaction; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2005 |
Retinoid/arsenic combination therapy of promyelocytic leukemia: induction of telomerase-dependent cell death.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; DNA-Binding Proteins; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Remission Induction; Telomerase; Telomere; Tretinoin; Tumor Cells, Cultured | 2005 |
Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Flow Cytometry; Humans; In Situ Nick-End Labeling; Jurkat Cells; Leukemia; Leukemia, Promyelocytic, Acute; Leukemia, T-Cell; Oxides; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; RNA, Small Interfering; Signal Transduction; Transfection; Tumor Cells, Cultured | 2005 |
Green tea component, catechin, induces apoptosis of human malignant B cells via production of reactive oxygen species.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; B-Lymphocytes; bcl-2-Associated X Protein; Caspase 3; Caspases; Catechin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Intracellular Membranes; Membrane Potentials; Mitochondria; Multiple Myeloma; Oxides; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Signal Transduction; Tea; Time Factors | 2005 |
[Study on the mechanisms of telomerase regulations during apoptosis of the human MDS-RAEB cell line MUTZ-1 cells induced by arsenic trioxide].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Cell Line; Dose-Response Relationship, Drug; Flow Cytometry; Gene Expression; Humans; Myelodysplastic Syndromes; Oxides; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Telomerase; Telomeric Repeat Binding Protein 2 | 2005 |
mCICR is required for As2O3-induced permeability transition pore opening and cytochrome c release from mitochondria.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Calcium Signaling; Cytochromes c; Female; In Vitro Techniques; Ion Channels; Kinetics; Mitochondria, Liver; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Oxides; Rats; Rats, Wistar | 2005 |
Arsenic-induced histopathology and synthesis of stress proteins in liver and kidney of Channa punctatus.
Topics: Animals; Arsenic Trioxide; Arsenicals; Blotting, Western; Creatinine; Glutathione; Glutathione Transferase; Heat-Shock Proteins; Kidney; Kidney Function Tests; Liver; Liver Function Tests; Metallothionein; Oxides; Perciformes; Water Pollutants, Chemical | 2006 |
Arsenic trioxide in the treatment of relapsed and refractory acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Japan; Leukemia, Promyelocytic, Acute; Oxides; Recurrence | 2005 |
Delayed recovery of normal hematopoiesis in arsenic trioxide treatment of acute promyelocytic leukemia: a comparison to all-trans retinoic acid treatment.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation; Erythrocyte Count; Hematopoiesis; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Leukocytes; Oxides; Platelet Count; Time Factors; Tretinoin | 2005 |
Lung infiltration of adult T-cell leukemia cells following the administration of arsenic trioxide. Lung infiltration of ATL by AS(2)O(3).
Topics: Aged; Arsenic Trioxide; Arsenicals; Deltaretrovirus Antibodies; Fatal Outcome; Humans; Leukemia-Lymphoma, Adult T-Cell; Leukemic Infiltration; Lung; Male; Oxides | 2006 |
Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Agents; Arrhythmias, Cardiac; Arsenic Trioxide; Arsenicals; Black or African American; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Retrospective Studies | 2006 |
Arsenic trioxide induces apoptosis of human monocytes during macrophagic differentiation through nuclear factor-kappaB-related survival pathway down-regulation.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzimidazoles; Blotting, Western; Carcinogens; Caspases; Cell Differentiation; Cell Survival; DNA; Down-Regulation; Endocytosis; Flow Cytometry; Fluorescent Dyes; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Macrophages; Monocytes; NF-kappa B; Oncogene Protein p65(gag-jun); Oxides; Phagocytosis; Reverse Transcriptase Polymerase Chain Reaction; RNA; Signal Transduction; Tetradecanoylphorbol Acetate; U937 Cells; X-Linked Inhibitor of Apoptosis Protein | 2006 |
Arsenic trioxide inhibits nuclear receptor function via SEK1/JNK-mediated RXRalpha phosphorylation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinogens, Environmental; Chlorocebus aethiops; COS Cells; Environmental Exposure; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Promyelocytic, Acute; MAP Kinase Kinase 4; Oxides; Phosphorylation; Receptors, Estrogen; Receptors, Glucocorticoid; Retinoid X Receptor alpha; Serine; Signal Transduction; Transcription, Genetic; Transcriptional Activation | 2005 |
Arsenic trioxide-induced hela cell death is partially prevented by K+ channel blockers.
Topics: 4-Aminopyridine; Arsenic Trioxide; Arsenicals; Cell Death; HeLa Cells; Humans; Oxides; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Tetraethylammonium | 2005 |
Preparation of arsenic trioxide albumin microspheres and its release characteristics in vitro.
Topics: Arsenic Trioxide; Arsenicals; Cross-Linking Reagents; Delayed-Action Preparations; Drug Carriers; Drug Delivery Systems; Microspheres; Oxides; Serum Albumin, Bovine; Technology, Pharmaceutical | 2005 |
[The impact of arsenic trioxide or all-trans retinoic acid treatment on coagulopathy in acute promyelocytic leukemia].
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation Disorders; Down-Regulation; Female; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; RNA, Messenger; Thrombomodulin; Thromboplastin; Tretinoin | 2001 |
Cytogenetic evaluation of arsenic trioxide toxicity in Sprague-Dawley rats.
Topics: Animals; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Chromosome Aberrations; Growth Inhibitors; Male; Micronucleus Tests; Mitosis; Oxides; Rats; Rats, Sprague-Dawley | 2005 |
Arsenic trioxide synergizes with B7H3-mediated immunotherapy to eradicate hepatocellular carcinomas.
Topics: Animals; Antigens, CD; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; B7 Antigens; B7-1 Antigen; Carcinoma, Hepatocellular; Combined Modality Therapy; Gene Transfer Techniques; Humans; Immunotherapy; Interferon-gamma; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Oxides; Receptors, Immunologic; T-Lymphocytes, Cytotoxic | 2006 |
Interaction of arsenic trioxide As2O3 with DNA and RNA.
Topics: Animals; Arsenic Trioxide; Arsenicals; Binding Sites; Cattle; DNA; Oxides; RNA, Fungal; Saccharomyces cerevisiae; Spectroscopy, Fourier Transform Infrared | 2005 |
Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Prognosis; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Survival Rate; Treatment Outcome | 2006 |
Oxidative DNA damage in relation to neurotoxicity in the brain of mice exposed to arsenic at environmentally relevant levels.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Arsenic Trioxide; Arsenicals; Brain; Deoxyguanosine; DNA Damage; Mice; Neurotoxicity Syndromes; Oxides; Tissue Distribution | 2005 |
A biostatistical insight into the As(2)O(3) high dilution effects on the rate and variability of wheat seedling growth.
Topics: Arsenic Trioxide; Arsenicals; Germination; Growth Inhibitors; Homeopathy; Humans; Models, Biological; Oxides; Phytotherapy; Reproducibility of Results; Statistics as Topic; Triticum | 2005 |
The effects of a 45x potency of arsenicum album on wheat seedling growth -- a reproduction trial.
Topics: Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Evidence-Based Medicine; Germination; Growth Inhibitors; Homeopathy; Humans; Models, Biological; Oxides; Phytotherapy; Reproducibility of Results; Triticum | 2005 |
Synergistic effect of all-trans-retinoic acid and arsenic trioxide on growth inhibition and apoptosis in human hepatoma, breast cancer, and lung cancer cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Carcinoma, Hepatocellular; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Glutathione; Glutathione Transferase; Humans; Lung Neoplasms; Oxides; Tretinoin | 2005 |
Frequent varicella zoster reactivation associated with therapeutic use of arsenic trioxide: portents of an old scourge.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Chickenpox; Child; Female; Herpes Zoster; Humans; Male; Middle Aged; Oxides; Recurrence | 2005 |
Arsenic Trioxide inhibits the growth of human ovarian carcinoma cell line.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Humans; Ovarian Neoplasms; Oxides | 2005 |
Coordination of intrinsic, extrinsic, and endoplasmic reticulum-mediated apoptosis by imatinib mesylate combined with arsenic trioxide in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Endoplasmic Reticulum; Growth Inhibitors; Humans; Imatinib Mesylate; K562 Cells; Oxides; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2006 |
Current management and new approaches in the treatment of APL.
Topics: Aminoglycosides; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Drug Monitoring; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Stem Cell Transplantation; Tretinoin | 2003 |
Involvement of mitochondrial aggregation in arsenic trioxide (As2O3)-induced apoptosis in human glioblastoma cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Brain Neoplasms; Caspases; Enzyme Activation; Glioblastoma; Humans; Membrane Potentials; Mitochondria; Oxides; Reactive Oxygen Species; Tumor Cells, Cultured | 2005 |
[In vitro study on inhibition of human choroidal melanoma OCM-1 cell line by arsenic trioxide].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Choroid Neoplasms; Dose-Response Relationship, Drug; Glutathione Peroxidase; Humans; Melanoma; Oxides | 2005 |
Anti-hepatoma effect of arsenic trioxide on experimental liver cancer induced by 2-acetamidofluorene in rats.
Topics: 2-Acetylaminofluorene; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinogens; Cell Cycle; Liver Neoplasms, Experimental; Oxides; Rats; Rats, Sprague-Dawley; Vascular Endothelial Growth Factor A | 2005 |
[Arsenic trioxide induced leukemic cell apoptosis relative to NF-kappaB activation].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Flow Cytometry; Humans; Immunohistochemistry; K562 Cells; Matrix Metalloproteinase 9; NF-kappa B; Oxides; Vascular Endothelial Growth Factor A | 2005 |
Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cells, Cultured; Electrocardiography; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Haloperidol; Humans; Loratadine; Lovastatin; Methadone; Oxides; Pentamidine; Potassium Channel Blockers; Rabbits; Terfenadine; Torsades de Pointes | 2006 |
Opposite effect of ERK1/2 and JNK on p53-independent p21WAF1/CIP1 activation involved in the arsenic trioxide-induced human epidermoid carcinoma A431 cellular cytotoxicity.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Gene Expression Regulation; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase 1; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Oxides; raf Kinases; ras Proteins; RNA, Small Interfering; Signal Transduction | 2006 |
[Effects of arsenic trioxideon the cell apoptosis and hTERT mRNA of human tongue cancer cells].
Topics: Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Humans; Oxides; RNA, Messenger; Telomerase; Tongue Neoplasms | 2005 |
Mitogen-activated protein kinases mediate arsenic-induced down-regulation of survivin in human lung adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Down-Regulation; Drug Antagonism; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Microtubule-Associated Proteins; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Oxides; Poly(ADP-ribose) Polymerases; Survivin | 2006 |
Hypoxia-simulating agents selectively stimulate arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Division; Cell Hypoxia; Cobalt; Deferoxamine; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Tretinoin; U937 Cells | 2005 |
Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Cell Differentiation; Cell Division; Cell Hypoxia; Cell Line, Tumor; Cobalt; Deferoxamine; Drug Synergism; Gene Expression Regulation, Leukemic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Oxygen; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin; U937 Cells | 2005 |
Serial studies of methylation of CDKN2B and CDKN2A in relapsed acute promyelocytic leukaemia treated with arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Case-Control Studies; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; Humans; Leukemia, Promyelocytic, Acute; Methylation; Neoplasm, Residual; Oxides; Reverse Transcriptase Polymerase Chain Reaction | 2005 |
Arsonoliposomes: effect of lipid composition on their stability and morphology.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cattle; Cryoelectron Microscopy; Drug Compounding; Fluoresceins; Fluorescent Dyes; Lipids; Liposomes; Oxides | 2005 |
Increased cellular glutathione and protection by bone marrow stromal cells account for the resistance of non-acute promylocytic leukemia acute myeloid leukemia cells to arsenic trioxide in vivo.
Topics: Acute Disease; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Buthionine Sulfoximine; Cell Count; Cell Line, Tumor; Coculture Techniques; Disease Models, Animal; Drug Resistance, Neoplasm; Glutathione; Humans; Injections, Intraperitoneal; Leukemia, Myeloid; Mice; Mice, Inbred NOD; Mice, SCID; Oxides; Stromal Cells; Treatment Failure | 2006 |
Latent membrane protein-1 of Epstein - Barr virus increases sensitivity to arsenic trioxide-induced apoptosis in nasopharyngeal carcinoma cell.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Southern; Cell Line, Tumor; Cell Proliferation; Herpesvirus 4, Human; Humans; In Situ Nick-End Labeling; Nasopharyngeal Neoplasms; Oxides; Telomere; Viral Matrix Proteins | 2005 |
[Mechanism of opening of mitochondrial permeability transition pore induced by arsenic trioxide].
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Calcium; Cytochromes c; Female; In Vitro Techniques; Mitochondria, Liver; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Oxides; Rats; Rats, Wistar | 2006 |
PLC-beta2 monitors the drug-induced release of differentiation blockade in tumoral myeloid precursors.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Enzyme Induction; Growth Inhibitors; Humans; Myeloid Progenitor Cells; Oxides; Phospholipase C beta; Tretinoin | 2006 |
Arsenic trioxide (AT) is a novel human neutrophil pro-apoptotic agent: effects of catalase on AT-induced apoptosis, degradation of cytoskeletal proteins and de novo protein synthesis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Catalase; Cell Line, Tumor; Gelsolin; Humans; Lamin Type B; Microfilament Proteins; Neoplasm Proteins; Neutrophils; Oxides; Protein Denaturation; Reactive Oxygen Species; Tubulin | 2006 |
Induction of oxidative stress by arsenic in Clarias batrachus: involvement of peroxisomes.
Topics: Acyl-CoA Oxidase; Animals; Arsenic; Arsenic Trioxide; Arsenicals; Catalase; Catfishes; Glutathione; Glutathione Disulfide; Glutathione Peroxidase; Glutathione Reductase; Hydrogen Peroxide; Lethal Dose 50; Lipid Peroxidation; Liver; Male; Microsomes, Liver; Oxidative Stress; Oxides; Peroxisomes; Superoxide Dismutase | 2007 |
TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Caspase 8; Caspase Inhibitors; Caspases; Cell Line, Tumor; Humans; Leukemia; Membrane Glycoproteins; Oligopeptides; Oncogene Protein v-akt; Oxides; Phosphorylation; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2006 |
Arsenic counteracts human immunodeficiency virus type 1 restriction by various TRIM5 orthologues in a cell type-dependent manner.
Topics: Animals; Antiviral Restriction Factors; Aotus trivirgatus; Arsenic Trioxide; Arsenicals; Carrier Proteins; Cats; Cell Line; Chlorocebus aethiops; DNA, Complementary; Fibroblasts; Gene Silencing; HIV-1; Humans; Macaca mulatta; Oxides; RNA Interference; Transduction, Genetic; Tripartite Motif Proteins; Ubiquitin-Protein Ligases | 2006 |
[Oral administration of arsenic trioxide induced molecular remission in relapsed acute promyelocytic leukemia].
Topics: Administration, Oral; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Neoplasm Recurrence, Local; Oxides; Remission Induction | 2005 |
Inhibition of mitogen-activated protein kinase kinase enhances apoptosis induced by arsenic trioxide in human breast cancer MCF-7 cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Butadienes; Cell Survival; DNA; Enzyme Inhibitors; Flavonoids; Growth Inhibitors; Humans; Imidazoles; MAP Kinase Kinase 1; Nitriles; Oxides; p38 Mitogen-Activated Protein Kinases; Pyridines; Thymidine; Tissue Culture Techniques; Tumor Cells, Cultured | 2005 |
MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis.
Topics: Adult; Aged; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Female; Genes, Tumor Suppressor; Humans; Leukemia, Myeloid, Acute; Male; MAP Kinase Kinase 1; Middle Aged; Nuclear Proteins; Oxides; Tumor Cells, Cultured; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2006 |
[Role of arsenolite on 8-isoprostane of asthmatic mice plasm].
Topics: Animals; Anti-Asthmatic Agents; Arsenic Trioxide; Arsenicals; Asthma; Bronchoalveolar Lavage Fluid; Dinoprost; Leukocyte Count; Male; Materia Medica; Mice; Ovalbumin; Oxides; Random Allocation; Respiratory Function Tests | 2005 |
[Acute pancreatitis during the treatment of relapsed acute promyelocytic leukemia with As2O3].
Topics: Acute Disease; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Pancreatitis; Recurrence | 2006 |
Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C.
Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzoquinones; Cytarabine; DNA; Drug Administration Schedule; Drug Antagonism; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; G1 Phase; HeLa Cells; HSP90 Heat-Shock Proteins; Humans; Jurkat Cells; Lactams, Macrocyclic; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Oxides; Sensitivity and Specificity; Structure-Activity Relationship; Tumor Cells, Cultured | 2006 |
The incidence of recurrent herpes simplex and herpes zoster infection during treatment with arsenic trioxide.
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Colonic Neoplasms; Female; Herpes Simplex; Herpes Zoster; Humans; Male; Multiple Myeloma; Oxides; Recurrence | 2006 |
[Changes of gene expression profile of multiple myeloma cell line RPMI 8226 treated by arsenic trioxide].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Gene Expression Profiling; Humans; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Oxides; Tumor Cells, Cultured | 2006 |
The efficacy of combined therapy of arsenic trioxide and alpha interferon in human T-cell leukemia virus type-1-infected squirrel monkeys (Saimiri sciureus).
Topics: Animals; Antiviral Agents; Arsenic Trioxide; Arsenicals; Cell Line, Transformed; Drug Therapy, Combination; HTLV-I Infections; Human T-lymphotropic virus 1; Humans; Interferon-alpha; Male; Oxides; Saimiri; Treatment Outcome | 2006 |
Elemental arsenic entered the cerebrospinal fluid during oral arsenic trioxide treatment of meningeal relapse of acute promyelocytic leukemia.
Topics: Administration, Oral; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Meningeal Neoplasms; Middle Aged; Oxides; Recurrence | 2006 |
Optimization of combination therapy of arsenic trioxide and fractionated radiotherapy for malignant glioma.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Combined Modality Therapy; Dose Fractionation, Radiation; Glioma; Humans; Male; Mice; Mice, Nude; Oxides; Transplantation, Heterologous; Tumor Cells, Cultured | 2006 |
Effects of arsenic trioxide on the cellular proliferation, apoptosis and differentiation of human neuroblastoma cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Activation; Growth Inhibitors; Humans; Indoles; Neuroblastoma; Neurofilament Proteins; Neurons; Oxides; Protein Kinase C; Receptor, trkA; Receptor, trkB; Tyrosine 3-Monooxygenase; Up-Regulation | 2007 |
Spectroscopic study of the impact of arsenic speciation on arsenic/phosphorus uptake and plant growth in tumbleweed (Salsola kali).
Topics: Arsenic; Arsenic Trioxide; Arsenicals; Ligands; Oxides; Phosphorus; Plant Leaves; Plant Roots; Salsola; Spectrum Analysis; Sulfur | 2006 |
Upregulation of Bfl-1/A1 in leukemia cells undergoing differentiation by all-trans retinoic acid treatment attenuates chemotherapeutic agent-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Gene Silencing; HL-60 Cells; Humans; Leukemia; Minor Histocompatibility Antigens; Oxides; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Tretinoin; Up-Regulation | 2006 |
Mechanisms of apoptosis induction and cell cycle regulation in irradiated leukemia U937 cells and enhancement by arsenic trioxide.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Cycle Proteins; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Humans; Oxides; Radiation Dosage; Radiation Tolerance; U937 Cells | 2006 |
Cardiotoxic effects of arsenic trioxide/imatinib mesilate combination in rats.
Topics: Animals; Arsenic Trioxide; Arsenicals; Benzamides; Drug Combinations; Imatinib Mesylate; Liver; Male; Myocardium; Oxides; Piperazines; Pyrimidines; Rats; Rats, Wistar | 2006 |
Arsenic trioxide inhibits DNA methyltransferase and restores methylation-silenced genes in human liver cancer cells.
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cadherins; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Neoplasm; Genes, p16; Glutathione S-Transferase pi; Hepatocytes; Humans; Liver Neoplasms; Male; Middle Aged; Oxides; RNA, Messenger; Tumor Suppressor Proteins | 2006 |
Choline-modulated arsenic trioxide-induced prolongation of cardiac repolarization in Guinea pig.
Topics: Animals; Arsenic Trioxide; Arsenicals; Calcium; Choline; Electrocardiography; Female; Guinea Pigs; Heart; In Vitro Techniques; Long QT Syndrome; Male; Myocytes, Cardiac; Oxides; Patch-Clamp Techniques | 2006 |
[Experimental study of the anti-tumor effect of arsenic trioxide or thalidomide alone and combination of both for treatment of myelodysplastic syndrome model].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease Models, Animal; Immunohistochemistry; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Myelodysplastic Syndromes; Neoplasm Transplantation; Oxides; Random Allocation; Survival Rate; Thalidomide; Tumor Cells, Cultured | 2006 |
Arsenic trioxide (As(2)O(3)) inhibits peritoneal invasion of ovarian carcinoma cells in vitro and in vivo.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Adhesion; Cell Line, Tumor; Cell Movement; Dose-Response Relationship, Drug; Female; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Ovarian Neoplasms; Oxides; Peritoneal Neoplasms; RNA, Messenger; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2 | 2006 |
[Arsenic trioxide eluting stents to prevent restenosis of injured iliac arteries in rabbits].
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Coronary Restenosis; Drug-Eluting Stents; Iliac Artery; Male; Muscle, Smooth, Vascular; Oxides; Rabbits; Random Allocation | 2006 |
[Effect of arsenic trioxide on bone marrow stromal cells of patients with multiple myeloma].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Depression, Chemical; Humans; Interleukin-6; Multiple Myeloma; Oxides; Stromal Cells; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2006 |
[Alteration of expression of survivin in HL-60 cells treated with chemotherapeutic drugs].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Daunorubicin; Drug Resistance, Neoplasm; HL-60 Cells; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Mitoxantrone; Neoplasm Proteins; Oxides; RNA, Messenger; Survivin | 2006 |
Clinically tolerable concentrations of arsenic trioxide induce p53-independent cell death and repress NF-kappa B activation in Ewing sarcoma cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Line, Tumor; Enzyme Activation; Humans; JNK Mitogen-Activated Protein Kinases; Mitochondria; NF-kappa B; Oxides; Sarcoma, Ewing; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53 | 2006 |
Arsenic trioxide reduces the invasive and metastatic properties of nasopharyngeal carcinoma cells in vitro.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 9; Microscopy, Confocal; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; Neoplasm Metastasis; Oxides; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Viral Matrix Proteins | 2006 |
Is intravenous arsenic trioxide a useful therapy in myelodysplastic syndromes?
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Administration Schedule; Humans; Infusions, Intravenous; Myelodysplastic Syndromes; Oxides; Treatment Outcome | 2006 |
Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient: speciation of arsenic metabolites in serum and urine.
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Chromatography, High Pressure Liquid; Drug Resistance, Neoplasm; Humans; Injections, Intravenous; Leukemia, Promyelocytic, Acute; Male; Methylation; Oxides; Seafood; Tretinoin | 2006 |
Combination treatment with arsenic trioxide and sulindac augments their apoptotic potential in lung cancer cells through activation of caspase cascade and mitochondrial dysfunction.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Flow Cytometry; Growth Inhibitors; Humans; Hydrogen Peroxide; Lung Neoplasms; Oxides; Sulindac | 2006 |
Arsenic-induced genotoxic and cytotoxic effects in human keratinocytes, melanocytes and dendritic cells.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Death; Cell Line; Comet Assay; Dendritic Cells; Dose-Response Relationship, Drug; Drug Administration Schedule; Environmental Pollutants; Keratinocytes; Melanocytes; Oxides | 2004 |
Serum acetyl cholinesterase as a biomarker of arsenic induced neurotoxicity in sprague-dawley rats.
Topics: Acetylcholinesterase; Animals; Arsenic; Arsenic Trioxide; Arsenicals; Biomarkers; Brain; Dose-Response Relationship, Drug; Male; Oxides; Rats; Rats, Sprague-Dawley | 2005 |
Mechanism of arsenic trioxide inhibiting angiogenesis in multiple myeloma.
Topics: Angiogenesis Inhibitors; Arsenic Trioxide; Arsenicals; Brain-Derived Neurotrophic Factor; Cell Line, Tumor; Dose-Response Relationship, Drug; Endothelial Cells; Humans; Multiple Myeloma; Neovascularization, Pathologic; Oxides; Receptor, trkB | 2006 |
Influence of thyroxine and n-propylthiouracil on nephro-toxicity of inorganic arsenic in rat.
Topics: Animals; Antithyroid Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Creatinine; Glomerulonephritis; Glutathione; Glutathione Transferase; Hyperthyroidism; Hypothyroidism; Kidney; Male; Necrosis; Oxides; Propylthiouracil; Rats; Rats, Wistar; Thyroxine; Triiodothyronine | 2006 |
Improved tumor destruction with arsenic trioxide and radiofrequency ablation in three animal models.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation; Carcinoma, Renal Cell; Catheter Ablation; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Growth Inhibitors; Humans; Laser-Doppler Flowmetry; Mice; Mice, Nude; Neoplasms, Experimental; Oxides; Rabbits; Rats; Rats, Inbred F344; Regional Blood Flow; Sarcoma | 2006 |
Solid tumors subsequent to arsenic trioxide treatment for acute promyelocytic leukemia.
Topics: Adenocarcinoma; Adult; Aged; Arsenic Trioxide; Arsenicals; Colonic Neoplasms; Female; Growth Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Male; Nasopharyngeal Neoplasms; Neoplasms; Oxides | 2007 |
Role of GSTP1-1 in mediating the effect of As2O3 in the Acute Promyelocytic Leukemia cell line NB4.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activation; Glutathione S-Transferase pi; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oxidation-Reduction; Oxidative Stress; Oxides; Time Factors | 2006 |
Sustained activation of c-jun-N-terminal kinase plays a critical role in arsenic trioxide-induced cell apoptosis in multiple myeloma cell lines.
Topics: Anisomycin; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Enzyme Activation; Enzyme Inhibitors; Flow Cytometry; Humans; JNK Mitogen-Activated Protein Kinases; Membrane Potentials; Mitochondria; Multiple Myeloma; Oxides; Protein Synthesis Inhibitors | 2006 |
Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Evaluation; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Retrospective Studies; Salvage Therapy; Treatment Outcome; Tretinoin | 2006 |
Two cases of acute promyelocytic leukemia complicated by torsade de pointes during arsenic trioxide therapy.
Topics: Adult; Anthracyclines; Antifungal Agents; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cardiomyopathies; Female; Fluconazole; Humans; Hypokalemia; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Time Factors; Torsades de Pointes | 2006 |
Recurrent extramedullary relapse of acute promyelocytic leukemia after allogeneic stem cell transplantation: successful treatment by arsenic trioxide in combination with local radiotherapy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Combined Modality Therapy; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Radiography; Recurrence; Remission Induction; Sarcoma, Myeloid; Stem Cell Transplantation; Translocation, Genetic; Transplantation, Homologous; Tretinoin | 2006 |
Activation of the mitogen- and stress-activated kinase 1 by arsenic trioxide.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Enzyme Activation; Fibroblasts; Histones; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Knockout; Oxides; p38 Mitogen-Activated Protein Kinases; Ribosomal Protein S6 Kinases, 90-kDa; Stem Cells | 2006 |
Comparative investigations of sodium arsenite, arsenic trioxide and cadmium sulphate in combination with gamma-radiation on apoptosis, micronuclei induction and DNA damage in a human lymphoblastoid cell line.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Arsenites; Cadmium Compounds; Cell Line; Cell Nucleus; Comet Assay; DNA Damage; Dose-Response Relationship, Drug; Gamma Rays; Humans; Lymphocytes; Micronucleus Tests; Oxides; Sodium Compounds; Sulfates | 2006 |
Perturbations in the catfish immune responses by arsenic: organ and cell specific effects.
Topics: Aeromonas hydrophila; Animals; Arsenic Trioxide; Arsenicals; Catfishes; Disease Susceptibility; Head; Immunity, Innate; Immunoglobulin G; Kidney; Lethal Dose 50; Leukocyte Count; Oxides; Phagocytosis; Spleen; T-Lymphocytes | 2006 |
[Adverse effects of intravenous arsenic trioxide and their prevention].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Drug-Related Side Effects and Adverse Reactions; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides | 2006 |
[Further improving the standard of treatment for chronic myeloid leukemia].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Azacitidine; Benzamides; Cancer Vaccines; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines; Tumor Necrosis Factor-alpha | 2006 |
[The diagnosis and treatment of polycythemia rubra vera manifesting as acute cerebral stroke].
Topics: Adult; Aged; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Female; Harringtonines; Hematocrit; Humans; Hydroxyurea; Male; Middle Aged; Oxides; Polycythemia Vera; Prognosis; Stroke | 2006 |
Alteration of subcellular redox equilibrium and the consequent oxidative modification of nuclear factor kappaB are critical for anticancer cytotoxicity by emodin, a reactive oxygen species-producing agent.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Nucleus; DNA, Neoplasm; Emodin; HeLa Cells; Humans; I-kappa B Proteins; Neoplasms; NF-kappa B; NF-kappa B p50 Subunit; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Protein Transport; Reactive Oxygen Species; Transcription Factor RelA; Tumor Necrosis Factor-alpha | 2006 |
[Long-term survival analysis in 170 cases of acute promyelocytic leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Prognosis; Proportional Hazards Models; Remission Induction; Retrospective Studies; Survival Analysis; Survival Rate; Tretinoin | 2006 |
Use of Novoseven for arsenic trioxide-induced bleeding in PML.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Factor VII; Factor VIIa; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Lung Diseases; Oxides; Recombinant Proteins | 2006 |
Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; MAP Kinase Signaling System; Mice; Mice, Knockout; Oxides; p38 Mitogen-Activated Protein Kinases; Phosphorylation | 2006 |
Dose- and time-dependent response of human leukemia (HL-60) cells to arsenic trioxide treatment.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; HL-60 Cells; Humans; Leukemia; Oxides | 2006 |
Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice.
Topics: Animals; Antineoplastic Agents; Aorta; Apoptosis; Arsenic Trioxide; Arsenicals; Cattle; Cell Proliferation; Endothelial Cells; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Oxides; Vascular Endothelial Growth Factor A | 2006 |
Real-time PCR analysis of PML-RAR alpha in newly diagnosed acute promyelocytic leukaemia patients treated with arsenic trioxide as a front-line therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Child; Early Diagnosis; Female; Follow-Up Studies; Gene Expression; Glucosephosphate Dehydrogenase; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Oncogene Proteins, Fusion; Oxides; Protein Isoforms; Recombinant Fusion Proteins; Recurrence; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Arsenic and cigarette smoke synergistically increase DNA oxidation in the lung.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aerosols; Animals; Arsenates; Arsenic; Arsenic Trioxide; Arsenicals; Bronchoalveolar Lavage Fluid; Calcium Compounds; Cricetinae; Deoxyguanosine; DNA; Drug Synergism; Glutathione; Immunohistochemistry; Lung; Male; Mesocricetus; Nicotiana; Oxidation-Reduction; Oxidative Stress; Oxides; Smoke; Sulfides; Time Factors | 2006 |
[As2O3-induced permeability transition pore opening in mitochondria depends on Ca2+].
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Calcium; Dose-Response Relationship, Drug; Drug Synergism; Female; Mitochondria, Liver; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Oxides; Rats; Rats, Wistar | 2006 |
Role of oxidative stress in the apoptosis of hepatocellular carcinoma induced by combination of arsenic trioxide and ascorbic acid.
Topics: Acetylcysteine; Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Free Radical Scavengers; Humans; Liver Neoplasms; Oxidative Stress; Oxides; Proto-Oncogene Proteins c-bcl-2 | 2006 |
Arsenic-induced APL differentiation in cerebrospinal fluid.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Cell Differentiation; Cerebrospinal Fluid; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocytes; Oxides; Remission Induction; Treatment Outcome | 2007 |
Arsenic trioxide induces not only apoptosis but also autophagic cell death in leukemia cell lines via up-regulation of Beclin-1.
Topics: Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Beclin-1; Cell Death; Cell Line, Tumor; Cell Proliferation; Humans; Leukemia, T-Cell; Membrane Proteins; Myelodysplastic Syndromes; Oxides; Phosphorylation; Proto-Oncogene Proteins c-akt; Structure-Activity Relationship; Up-Regulation | 2007 |
[Preliminary report of combination chemotherapy including Arsenic trioxide for stage III osteosarcoma and Ewing sarcoma].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Neoplasms; Child; Etoposide; Female; Follow-Up Studies; Humans; Male; Osteosarcoma; Oxides; Paclitaxel; Sarcoma, Ewing; Treatment Outcome | 2006 |
ATR, PML, and CHK2 play a role in arsenic trioxide-induced apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line; Checkpoint Kinase 2; Enzyme Activation; Fibroblasts; Mice; Mice, SCID; Mice, Transgenic; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Protein Serine-Threonine Kinases; Transcription Factors; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2006 |
Iatrogenic arsenic induced Mees' lines.
Topics: Acute Disease; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Myeloid; Male; Nail Diseases; Oxides | 2006 |
Arsenic trioxide induces gallbladder carcinoma cell apoptosis via downregulation of Bcl-2.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma; Down-Regulation; Gallbladder Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Oxides; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2006 |
Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Blast Crisis; Cytarabine; Daunorubicin; Feasibility Studies; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; In Vitro Techniques; Interferons; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines; Vincristine | 2006 |
Arsenic trioxide-responsive leukemia cutis in a patient with acute promyelocytic leukemia after ATRA treatment.
Topics: Adolescent; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Female; Humans; Leukemia; Leukemia, Promyelocytic, Acute; Oxides; Risk; Skin; Tretinoin | 2006 |
Arsenic trioxide: A promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice.
Topics: Animals; Antibodies, Antinuclear; Antigen-Antibody Complex; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cytokines; Drug Evaluation, Preclinical; Enzyme Activation; fas Receptor; Glutathione; Humans; Lupus Erythematosus, Systemic; Lymphocyte Activation; Lymphoproliferative Disorders; Mice; Mice, Inbred MRL lpr; Nitric Oxide; Oxidation-Reduction; Oxides; Syndrome | 2006 |
[Inhibited proliferation of B-lymphoma Raji cells and down-regulated expression of VEGF by arsenic trioxide].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Proliferation; Down-Regulation; Humans; Lymphoma, B-Cell; Oxides; RNA, Messenger; Vascular Endothelial Growth Factor A | 2006 |
Arsenic trioxide concentration determines the fate of Ewing's sarcoma family tumors and neuroblastoma cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Enzyme Activation; Enzyme Inhibitors; Fibroblast Growth Factor 2; Flavonoids; Humans; In Vitro Techniques; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase 1; Mitogen-Activated Protein Kinase 1; Neuroblastoma; Neurons; Oxides; Phenotype; Sarcoma, Ewing | 2006 |
Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Arsenic; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prospective Studies | 2007 |
Cytotoxic effects of various stressors on PC12 cells: involvement of oxidative stress and effect of antioxidants.
Topics: Aldehydes; Animals; Annexin A5; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Survival; Free Radicals; Ketocholesterols; Kinetics; Oxidants; Oxidative Stress; Oxides; PC12 Cells; Propidium; Rats; Reactive Oxygen Species | 2007 |
Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Synergism; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Microtubule-Associated Proteins; Neoplasm Proteins; Oxides; Reactive Oxygen Species; Sulindac; Survivin | 2006 |
The effect of intracellular ascorbate on the susceptibility of HL60 and Jurkat cells to chemotherapy agents.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Caspases; Cell Count; Dehydroascorbic Acid; Drug Resistance, Neoplasm; Etoposide; HL-60 Cells; Humans; Jurkat Cells; Melphalan; Oxides | 2006 |
Down-regulation of wt1 expression in leukemia cell lines as part of apoptotic effect in arsenic treatment using two compounds.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Arsenites; Carrier Proteins; Co-Repressor Proteins; Cytoskeletal Proteins; Gene Expression Regulation; HL-60 Cells; Humans; K562 Cells; Leukemia; Oxides; Sodium Compounds; WT1 Proteins | 2006 |
Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells.
Topics: Acute Disease; Aquaporins; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Gene Expression Profiling; Humans; K562 Cells; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Oxides; Point Mutation; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Tretinoin; Up-Regulation | 2007 |
Pharmacologic inhibitors of extracellular signal-regulated kinase (ERKs) and c-Jun NH(2)-terminal kinase (JNK) decrease glutathione content and sensitize human promonocytic leukemia cells to arsenic trioxide-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Glutathione; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia; Leukemia, Promyelocytic, Acute; Oxides; Peroxides; Reactive Oxygen Species | 2006 |
Inhibitory effect of arsenic trioxide on angiogenesis and expression of vascular endothelial growth factor in gastric cancer.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Oxides; RNA, Messenger; Stomach Neoplasms; Time Factors; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2006 |
A survival study and prognostic factors analysis on acute promyelocytic leukemia at a single center.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Disease-Free Survival; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Survival Rate; Tretinoin | 2007 |
Anion exchanger 2 mediates the action of arsenic trioxide.
Topics: Anion Transport Proteins; Annexin A5; Antiporters; Apoptosis; Arsenic Trioxide; Arsenicals; Biomarkers; Blotting, Western; CD11b Antigen; CD11c Antigen; Cell Line, Tumor; Cell Survival; Flow Cytometry; Humans; Hydrogen-Ion Concentration; Leukemia, Promyelocytic, Acute; Oxides; Reverse Transcriptase Polymerase Chain Reaction; SLC4A Proteins | 2006 |
Arsenic trioxide eluting stent reduces neointima formation in a rabbit iliac artery injury model.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Arsenic Trioxide; Arsenicals; Blood Vessel Prosthesis Implantation; Cell Cycle; Cell Proliferation; Coated Materials, Biocompatible; Flow Cytometry; Growth Inhibitors; Hyperplasia; Iliac Artery; Male; Microscopy, Electron, Scanning; Models, Animal; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Oxides; Paclitaxel; Rabbits; Stents; Tunica Intima | 2006 |
ZNF198, a zinc finger protein rearranged in myeloproliferative disease, localizes to the PML nuclear bodies and interacts with SUMO-1 and PML.
Topics: Amino Acid Substitution; Apoptosis; Arsenic Trioxide; Arsenicals; Binding Sites; Carrier Proteins; Cell Line; Cell Nucleus Structures; Dimerization; DNA-Binding Proteins; Gene Fusion; Gene Rearrangement; Humans; In Vitro Techniques; Mutagenesis, Site-Directed; Mutant Chimeric Proteins; Myeloproliferative Disorders; Neoplasm Proteins; Nuclear Proteins; Oxides; Plasminogen Activator Inhibitor 2; Promyelocytic Leukemia Protein; Receptor, Fibroblast Growth Factor, Type 1; SUMO-1 Protein; Transcription Factors; Tumor Suppressor Proteins; Two-Hybrid System Techniques; Zinc Fingers | 2006 |
Lipid encapsulation of arsenic trioxide attenuates cytotoxicity and allows for controlled anticancer drug release.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Capsules; Chemistry, Pharmaceutical; Doxorubicin; Drug Delivery Systems; Humans; Hydrogen-Ion Concentration; Kinetics; Lipids; Liposomes; Lymphocytes; Microscopy, Electron, Transmission; Oxides; Temperature; Tumor Cells, Cultured | 2006 |
[Study of effects of HBV X gene and As2O3 on expression and activity of p53 in HepG2 cells with shRNA].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Gene Expression; Hep G2 Cells; Hepatitis B virus; Humans; Oxides; RNA, Small Interfering; Trans-Activators; Tumor Suppressor Protein p53; Viral Regulatory and Accessory Proteins | 2006 |
Mammalian glucose permease GLUT1 facilitates transport of arsenic trioxide and methylarsonous acid.
Topics: Animals; Arsenic Trioxide; Arsenicals; Biological Transport, Active; Cloning, Molecular; Colforsin; Cytochalasin B; Female; Glucose Transport Proteins, Facilitative; Glucose Transporter Type 1; Hexoses; Humans; In Vitro Techniques; Monosaccharide Transport Proteins; Oocytes; Oxides; Rats; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Xenopus laevis | 2006 |
Arsenic trioxide induced acute flare-up of rheumatoid arthritis in a patient with APL.
Topics: Aged; Arsenic Trioxide; Arsenicals; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides | 2007 |
Emodin and DHA potently increase arsenic trioxide interferon-alpha-induced cell death of HTLV-I-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1.
Topics: Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Death; Cell Line, Transformed; Docosahexaenoic Acids; Drug Synergism; Drug Therapy, Combination; Emodin; Human T-lymphotropic virus 1; Humans; Interferon-alpha; Leukemia-Lymphoma, Adult T-Cell; Oxides; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Transcription Factor AP-1 | 2007 |
Differentiation syndrome with lethal lung injury after arsenic trioxide treatment for myelodysplastic syndrome.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Oxides; Pulmonary Alveoli; Respiratory Distress Syndrome; Syndrome | 2007 |
Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors.
Topics: Adaptor Proteins, Signal Transducing; Amino Acid Motifs; Amino Acid Sequence; Animals; Arsenic Trioxide; Arsenicals; Carrier Proteins; Cell Nucleus; Chlorocebus aethiops; Co-Repressor Proteins; COS Cells; Dexamethasone; HeLa Cells; Humans; Intracellular Signaling Peptides and Proteins; Mice; Molecular Chaperones; Molecular Sequence Data; Neoplasm Proteins; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Protein Binding; Protein Structure, Tertiary; Protein Transport; Receptors, Glucocorticoid; Repressor Proteins; Small Ubiquitin-Related Modifier Proteins; Transcription Factors; Transcription, Genetic; Tumor Suppressor Proteins | 2006 |
Increased oxidative DNA products in patients with acute promyelocytic leukemia during arsenic therapy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Arsenic Trioxide; Arsenicals; Deoxyguanosine; DNA; Humans; Leukemia, Promyelocytic, Acute; Oxidation-Reduction; Oxides; Reactive Oxygen Species | 2006 |
Leukocytosis and retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Dyspnea; Female; Fever; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Leukocytosis; Male; Middle Aged; Oxides; Remission Induction; Syndrome | 2006 |
8-Oxoguanine DNA glycosylase and MutY homolog are involved in the incision of arsenite-induced DNA adducts.
Topics: Arsenic Trioxide; Arsenicals; Cell Line; Comet Assay; DNA Adducts; DNA Damage; DNA Glycosylases; DNA Repair; Environmental Pollutants; Ferrous Compounds; Humans; Hydrogen Peroxide; Oxidative Stress; Oxides | 2007 |
Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carrier Proteins; Cell Cycle; Cell Proliferation; DNA-Binding Proteins; Humans; Leukemia, Myeloid, Acute; Oxides; Phosphorylation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Signal Transduction; STAT Transcription Factors; STAT3 Transcription Factor; Transcription Factors; Transfection; Tumor Cells, Cultured | 2006 |
Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Fusion Proteins, bcr-abl; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Phosphorylation; Protein Kinases; Protein-Tyrosine Kinases; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2006 |
A patient with progressive multiple myeloma treated successfully with arsenic trioxide after allogeneic bone marrow transplantation.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Combined Modality Therapy; Graft vs Host Disease; Humans; Male; Middle Aged; Multiple Myeloma; Oxides | 2007 |
Prolonged molecular remission in a newly diagnosed acute promyelocytic leukaemia with a severe cardiomyopathy using low-dose gemtuzumab ozogamicin and all-trans retinoic acid.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cardiomyopathies; Drug Therapy, Combination; Echocardiography; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Tretinoin | 2007 |
Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Differentiation; Cell Line, Tumor; Core Binding Factor Alpha 2 Subunit; Dose-Response Relationship, Drug; Down-Regulation; Flow Cytometry; Gene Expression Regulation, Neoplastic; Growth Inhibitors; Humans; Leukemia, Experimental; Male; Mice; Mice, Inbred BALB C; NIH 3T3 Cells; Oncogene Proteins, Fusion; Oxides; Proteasome Endopeptidase Complex; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Survival Analysis; Transfection; Ubiquitin | 2006 |
Buthionine sulfoximine enhancement of arsenic trioxide-induced apoptosis in leukemia and lymphoma cells is mediated via activation of c-Jun NH2-terminal kinase and up-regulation of death receptors.
Topics: Amino Acid Chloromethyl Ketones; Anthracenes; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Buthionine Sulfoximine; Caspase 3; Caspase Inhibitors; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Glutathione; Humans; Hydrogen Peroxide; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; Leukemia; Lymphoma; Oxides; Receptors, TNF-Related Apoptosis-Inducing Ligand; Time Factors; U937 Cells | 2006 |
Arsenic trioxide, a potent inhibitor of NF-kappaB, abrogates allergen-induced airway hyperresponsiveness and inflammation.
Topics: Allergens; Animals; Arsenic Trioxide; Arsenicals; Asthma; Bronchitis; Female; Mice; Mice, Inbred BALB C; NF-kappa B; Ovalbumin; Oxides; Pulmonary Eosinophilia; Respiratory Hypersensitivity | 2006 |
Involvement of a Rho-ROCK-JNK pathway in arsenic trioxide-induced apoptosis in chronic myelogenous leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 9; Humans; Intracellular Signaling Peptides and Proteins; JNK Mitogen-Activated Protein Kinases; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Neoplasm Proteins; Oxides; Protein Serine-Threonine Kinases; rho GTP-Binding Proteins; rho-Associated Kinases | 2007 |
Phototactic behavior in Daphnia magna Straus as an indicator of toxicants in the aquatic environment.
Topics: 2-Methyl-4-chlorophenoxyacetic Acid; Analysis of Variance; Animals; Arsenic Trioxide; Arsenicals; Carbon Tetrachloride; Chlorophenols; Daphnia; Dimethoate; Fluorenes; Hexachlorocyclohexane; Light; Linuron; Mercuric Chloride; Oxides; Thiram; Toxicity Tests; Trialkyltin Compounds; Water Pollutants, Chemical | 2007 |
Arsenic trioxide induces apoptosis via the mitochondrial pathway by upregulating the expression of Bax and Bim in human B cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; B-Lymphocytes; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; Cytochromes c; Cytoplasm; Humans; Leukemia, Promyelocytic, Acute; Male; Membrane Potentials; Membrane Proteins; Mitochondria; Oxidative Stress; Oxides; Proto-Oncogene Proteins; Up-Regulation | 2007 |
Effect of ginseng saponin, arsenic trioxide, beta-elemene combined with CTX on telomere-telomerase system in K562 cell line.
Topics: Arsenic Trioxide; Arsenicals; Cyclophosphamide; Drug Synergism; Humans; K562 Cells; Oxides; Panax; Saponins; Sesquiterpenes; Telomerase; Telomere | 2006 |
In-vitro cytotoxic and genotoxic effects of arsenic trioxide on human leukemia (HL-60) cells using the MTT and alkaline single cell gel electrophoresis (Comet) assays.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Survival; Coloring Agents; Comet Assay; HL-60 Cells; Humans; Oxides; Silver Staining; Tetrazolium Salts; Thiazoles | 2007 |
[Mechanisms of arsenic trioxide induced tumor cell apoptosis in myelodysplastic syndrome mice model in vivo].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Blotting, Western; Caspases; Disease Models, Animal; Electrophoretic Mobility Shift Assay; Humans; I-kappa B Proteins; Immunohistochemistry; Mice; Mice, Nude; Mice, SCID; Mitochondria; Myelodysplastic Syndromes; NF-kappa B; NF-KappaB Inhibitor alpha; Oxides; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide | 2006 |
Combination treatment with arsenic trioxide and phytosphingosine enhances apoptotic cell death in arsenic trioxide-resistant cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Mitochondria; Models, Biological; Neoplasms; Oxides; p38 Mitogen-Activated Protein Kinases; Poly(ADP-ribose) Polymerases; Protein Transport; Reactive Oxygen Species; Sphingosine | 2007 |
An approach to elucidate potential mechanism of renal toxicity of arsenic trioxide.
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Arsenic Trioxide; Arsenicals; Catalase; Catecholamines; Cell Death; Cell Survival; Cells, Cultured; Cluster Analysis; Dose-Response Relationship, Drug; Gene Expression Profiling; Gene Expression Regulation; Heme Oxygenase-1; HL-60 Cells; Humans; Imidazolines; Kidney Cortex; Oligonucleotide Array Sequence Analysis; Oxides; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Superoxides; Thioctic Acid; Time Factors | 2007 |
Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells.
Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Granulocytes; HL-60 Cells; Humans; Leukemia, Myeloid; Macrophages; Monocytes; Oxides; Protein Transport; Proto-Oncogene Proteins c-akt; RNA-Binding Proteins; RNA, Small Interfering; Tretinoin | 2007 |
Establishment of an arsenic trioxide-resistant human leukemia cell line that shows multidrug resistance.
Topics: Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Clone Cells; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Leukemia; Multidrug Resistance-Associated Proteins; Oxides; Vincristine | 2007 |
Induction of apoptosis and inhibition of telomerase activity by arsenic trioxide (As2O3) in endometrial carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Endometrial Neoplasms; Female; Flow Cytometry; Humans; Oxides; RNA, Messenger; Telomerase | 2007 |
[Methylation of P15INK4B gene in patients with myelodysplastic syndromes and demethylating effects of drugs].
Topics: Arsenic Trioxide; Arsenicals; Azacitidine; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; Disease Progression; DNA Methylation; Genetic Predisposition to Disease; Humans; Leukemia; Myelodysplastic Syndromes; Oxides | 2007 |
Osteomyelitis due to arsenic trioxide use for tooth devitalization.
Topics: Adolescent; Arsenic Trioxide; Arsenicals; Dental Pulp Devitalization; Female; Humans; Mandible; Mandibular Diseases; Molar; Osteomyelitis; Osteonecrosis; Oxides; Root Canal Irrigants | 2007 |
Protection against arsenic trioxide-induced autophagic cell death in U118 human glioma cells by use of lipoic acid.
Topics: Acridine Orange; Antioxidants; Apoptosis Regulatory Proteins; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Autophagy; Blotting, Western; Cell Line, Tumor; Drug Interactions; Electrophoresis, Agar Gel; Flow Cytometry; Fluorescent Dyes; Glioma; Humans; Neuroglia; Oxides; Thioctic Acid | 2007 |
Various tolerances to arsenic trioxide between human cortical neurons and leukemic cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Calcium; Cell Line, Tumor; Cells, Cultured; Cerebral Cortex; Dose-Response Relationship, Drug; Drug Tolerance; Humans; Leukemia; Neurons; Oxides | 2006 |
Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.
Topics: Adult; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Neoplasm Recurrence, Local; Oxides; Remission Induction; Treatment Outcome; Tretinoin | 2007 |
ASK1 is activated by arsenic trioxide in leukemic cells through accumulation of reactive oxygen species and may play a negative role in induction of apoptosis.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line; Enzyme Activation; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia; MAP Kinase Kinase Kinase 5; Mice; Oxides; p38 Mitogen-Activated Protein Kinases; Reactive Oxygen Species; RNA, Small Interfering | 2007 |
Arsenic trioxide induces p53-dependent apoptotic signals in myeloma cells with SiRNA-silenced p53: MAP kinase pathway is preferentially activated in cells expressing inactivated p53.
Topics: Antineoplastic Agents; APOBEC Deaminases; Apoptosis; Arsenic Trioxide; Arsenicals; Cyclin-Dependent Kinase Inhibitor p21; Cytidine Deaminase; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Mitochondrial Membranes; Mitogen-Activated Protein Kinase Kinases; Muscle Proteins; Mutation; Oxides; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Tumor Suppressor Protein p53 | 2007 |
JWA as a functional molecule to regulate cancer cells migration via MAPK cascades and F-actin cytoskeleton.
Topics: Actins; Amino Acid Motifs; Amino Acid Sequence; Arsenic Trioxide; Arsenicals; Base Sequence; Cell Movement; Cyclooxygenase 2; Cytoskeleton; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Focal Adhesion Kinase 1; Heat-Shock Proteins; HeLa Cells; Humans; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase 1; MAP Kinase Signaling System; Membrane Transport Proteins; Mitogen-Activated Protein Kinases; Molecular Sequence Data; Neoplasms; Oxides; Phosphorylation; Protein Kinase C; Tetradecanoylphorbol Acetate | 2007 |
Current treatment of acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Clinical Trials as Topic; Computer Systems; Disease Management; Drug Monitoring; Hematopoietic Stem Cells; Humans; Leukemia, Promyelocytic, Acute; Leukocyte Count; Mice; Multicenter Studies as Topic; Oncogene Proteins, Fusion; Oxides; Polymerase Chain Reaction; Predictive Value of Tests; Recurrence; Sensitivity and Specificity; Transfection; Tretinoin | 2007 |
Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Ataxin-1; Ataxins; Biomarkers, Tumor; Cell Division; Cell Line, Tumor; Female; Growth Inhibitors; Hematopoietic Stem Cells; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, Inbred C57BL; Neoplastic Stem Cells; Nerve Tissue Proteins; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Recombinant Fusion Proteins; Transfection; Tretinoin; Tumor Stem Cell Assay | 2007 |
[Effects of arsenic trioxide on the autoimmunity and survival time in BXSB lupus mice].
Topics: Animals; Antibodies, Antinuclear; Arsenic Trioxide; Arsenicals; Autoimmunity; Enzyme-Linked Immunosorbent Assay; Immunoglobulin G; Injections, Intraperitoneal; Interferon-gamma; Kidney; Lupus Erythematosus, Systemic; Mice; Oxides; Random Allocation; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spleen; Survival Analysis | 2007 |
Therapeutic effect of arsenic trioxide (As2O3) on cervical cancer in vitro and in vivo through apoptosis induction.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Caspase 9; Cell Line, Tumor; Female; Humans; MAP Kinase Kinase 4; Mice; Mice, Inbred C57BL; Microtubules; Mitochondria; Oxides; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53; Uterine Cervical Neoplasms | 2007 |
Arsenic trioxide (As2O3) induced calcium signals and cytotoxicity in two human cell lines: SY-5Y neuroblastoma and 293 embryonic kidney (HEK).
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boron Compounds; Calcium; Calcium Signaling; Cell Line; Cell Line, Tumor; Cell Survival; Dantrolene; DNA Damage; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Inositol 1,4,5-Trisphosphate Receptors; Microscopy, Confocal; Mitosis; Oxides; Ryanodine Receptor Calcium Release Channel; Time Factors | 2007 |
Arsenic trioxide represses NF-kappaB activation and increases apoptosis in ATRA-treated APL cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Base Sequence; DNA Probes; Humans; Leukemia, Promyelocytic, Acute; NF-kappa B; Oxides; Tretinoin | 2006 |
Comparison of diarsenic oxide and tetraarsenic oxide on anticancer effects: relation to the apoptosis molecular pathway.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Separation; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; Neoplasms; Oxides; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins c-bcl-2 | 2007 |
Successful treatment of potentially fatal heavy metal poisonings.
Topics: Adult; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Chelation Therapy; Decontamination; Dimercaprol; Drug Therapy, Combination; Humans; Male; Mercuric Chloride; Mercury Poisoning; Oxides; Polyethylene Glycols; Solvents; Succimer; Suicide, Attempted; Therapeutic Irrigation | 2007 |
Synergism between arsenic trioxide and heat shock protein 90 inhibitors on signal transducer and activator of transcription protein 3 activity--pharmacodynamic drug-drug interaction modeling.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoquinones; Cell Line, Tumor; Cell Survival; Drug Synergism; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Models, Theoretical; Oxides; STAT3 Transcription Factor | 2007 |
Arsenic trioxide-induced neuroblastoma cell death is accompanied by proteolytic activation of nuclear Bax.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Cell Death; Cell Line, Tumor; Cell Nucleus; Enzyme Activation; Humans; Neuroblastoma; Oxides; Peptide Hydrolases | 2007 |
Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
Topics: Adult; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides | 2007 |
[Effects of arsenic trioxide on apoptosis of peripheral T-lymphocytes from asthmatic patients and normal subjects in vitro].
Topics: Adult; Anti-Asthmatic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Asthma; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Humans; Male; Microscopy, Fluorescence; Oxides; T-Lymphocytes | 2007 |
Synergistic therapeutic effect of arsenic trioxide and radiotherapy in BALB/C nude mice bearing nasopharyngeal carcinoma xenografts.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Combined Modality Therapy; Humans; Mice; Mice, Inbred BALB C; Mice, SCID; Nasopharyngeal Neoplasms; Oxides; Transplantation, Heterologous | 2007 |
[Effects of controlled-release arsenic-trioxide-eluting stents on in-stent neointimal hyperplasia in coronary artery: experiment with dog model].
Topics: Angioplasty, Balloon, Coronary; Animals; Arsenic Trioxide; Arsenicals; Dogs; Dose-Response Relationship, Drug; Drug-Eluting Stents; Hyperplasia; Oxides; Postoperative Period; Tunica Intima | 2007 |
Chinese folk treatment reveals power of arsenic to treat cancer, new studies under way.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; China; Clinical Trials, Phase III as Topic; Humans; Leukemia, Promyelocytic, Acute; National Institutes of Health (U.S.); Oxides; United States | 2007 |
One potential mechanism of cardiac toxicity induced by arsenic trioxide: apoptosis in coronary arterial and blood capillary endothelial cells.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Capillaries; Cattle; Endothelial Cells; Heart; Humans; Models, Biological; Models, Theoretical; Myocardium; Oxides; Signal Transduction; Umbilical Veins | 2007 |
In vitro cytogenetic effects of Andrographis paniculata (kalmegh) on arsenic.
Topics: Andrographis; Antimutagenic Agents; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Proliferation; Cells, Cultured; Ethyl Methanesulfonate; Humans; Lymphocytes; Mutagens; Oxides; Plant Extracts; Sister Chromatid Exchange | 2008 |
[n-MSP detection of p16 gene demethylation and transcription in human multiple myeloma U266 cell line induced by arsenic trioxide].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Base Sequence; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; DNA Methyltransferase 3B; Genes, p16; Humans; Molecular Sequence Data; Multiple Myeloma; Oxides; Polymerase Chain Reaction; Promoter Regions, Genetic; RNA, Messenger; Transcription, Genetic | 2007 |
[Effects of arsenic trioxide or retinoic acid on mRNA and protein expression of tissue factor and thrombomodulin and procoagulant activity in NB4 cells].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; RNA, Messenger; Thrombomodulin; Thromboplastin; Tretinoin; Tumor Cells, Cultured | 2007 |
Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta.
Topics: Adult; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Enzyme Activation; Humans; Leukemia; Middle Aged; Mitogen-Activated Protein Kinases; Oxides; Protease Inhibitors; Protein Kinase C-delta; Pyrazines; Tumor Cells, Cultured | 2007 |
Arsenic trioxide inhibits growth of As4.1 juxtaglomerular cells via cell cycle arrest and caspase-independent apoptosis.
Topics: Animals; Annexin A5; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Caspase 3; Caspase Inhibitors; Caspases; Cell Cycle; Cell Line; Enzyme Inhibitors; Flow Cytometry; G1 Phase; Glutathione; Hydrogen Peroxide; Indicators and Reagents; Indoles; Juxtaglomerular Apparatus; Membrane Potentials; Mice; Mice, Transgenic; Mitochondrial Membranes; Oxides; Oxygen Consumption | 2007 |
Arsenic trioxide (As2O3) reduces the invasive and metastatic properties of cervical cancer cells in vitro and in vivo.
Topics: Animals; Arsenic Trioxide; Arsenicals; beta Catenin; Cadherins; Caveolin 1; Cell Adhesion; Cell Line, Tumor; Cell Movement; Female; Growth Inhibitors; HeLa Cells; Humans; Lung Neoplasms; Mice; Mice, Inbred C57BL; Neoplasm Invasiveness; Neoplasm Metastasis; NF-kappa B; Oxides; Uterine Cervical Neoplasms | 2007 |
Regulating effects of arsenic trioxide on cell death pathways and inflammatory reactions of pancreatic acinar cells in rats.
Topics: Amylases; Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Flow Cytometry; In Situ Nick-End Labeling; Inflammation; L-Lactate Dehydrogenase; Male; NF-kappa B; Oxides; Pancreas; Pancreatitis; Peroxidase; Rats; Rats, Wistar; RNA, Messenger; Signal Transduction; Tumor Necrosis Factor-alpha | 2007 |
Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma; Humans; Oxides; RNA, Messenger; Tumor Suppressor Protein p53 | 2008 |
Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-Associated Death Protein; Blotting, Western; Caspases; Cell Line, Tumor; Cell Survival; Dexamethasone; Drug Resistance, Neoplasm; Drug Synergism; Glucocorticoids; Humans; Neoplasm, Residual; Oxides; Phosphorylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Remission Induction; RNA, Small Interfering; Signal Transduction; Sirolimus; Transfection; X-Linked Inhibitor of Apoptosis Protein | 2007 |
Cordycepin induced eryptosis in mouse erythrocytes through a Ca2+-dependent pathway without caspase-3 activation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Calcimycin; Calcium; Caspase 3; Cell Line, Tumor; Cell Survival; Deoxyadenosines; Dose-Response Relationship, Drug; Erythrocytes; Flow Cytometry; Hemolysis; HL-60 Cells; Humans; Indoles; Intracellular Fluid; Ionophores; Mice; Mice, Inbred BALB C; Oxides; Oximes | 2007 |
Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Ceramides; Glucosyltransferases; Humans; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Promyelocytic, Acute; Metabolic Networks and Pathways; Oxides | 2007 |
Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells.
Topics: Arsenic Trioxide; Arsenicals; Benzamides; Buthionine Sulfoximine; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Glutathione; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines | 2007 |
Endothelial gap junctions are down-regulated by arsenic trioxide.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line; Connexin 43; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Down-Regulation; Endothelium, Vascular; Gap Junctions; Humans; Immunohistochemistry; Leupeptins; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Oxides; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; von Willebrand Factor | 2007 |
Eosinophils derived from acute promyelocytic leukemia cells after arsenic trioxide treatment.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Lineage; Eosinophils; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides | 2007 |
PS-341 or a combination of arsenic trioxide and interferon-alpha inhibit growth and induce caspase-dependent apoptosis in KSHV/HHV-8-infected primary effusion lymphoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Boronic Acids; Bortezomib; Caspases; Cell Proliferation; Herpesvirus 8, Human; Humans; Interferon-alpha; Lymphoma; Membrane Potential, Mitochondrial; NF-kappa B; Oxides; Protease Inhibitors; Pyrazines | 2007 |
Oral arsenic trioxide therapy for acute promyelocytic leukemia before and after liver transplantation for hepatitis B virus-related liver failure.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Hepatitis B; Hepatitis B virus; Humans; Leukemia, Promyelocytic, Acute; Liver Failure; Liver Transplantation; Male; Oxides; RNA, Viral; Time Factors; Transplantation, Homologous; Virus Activation | 2007 |
Genotoxicity of arsenic evaluated by Allium-root micronucleus assay.
Topics: Allium; Arsenic Trioxide; Arsenicals; Arsenites; Micronucleus Tests; Mitotic Index; Mutagens; Oxides; Plant Root Cap; Sodium Compounds | 2007 |
Glycolytic metabolism confers resistance to combined all-trans retinoic acid and arsenic trioxide-induced apoptosis in HL60rho0 cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Drug Resistance, Neoplasm; Genes, Mitochondrial; Glycolysis; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2008 |
Aseptic necrosis of the maxilla after devitalisation of the teeth with arsenic trioxide.
Topics: Arsenic Trioxide; Arsenicals; Dental Pulp Devitalization; Extravasation of Diagnostic and Therapeutic Materials; Humans; Male; Maxillary Diseases; Middle Aged; Osteonecrosis; Oxides; Root Canal Irrigants | 2008 |
Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Humans; Immunoglobulin G; Melphalan; Mice; Mice, SCID; Multiple Myeloma; Oxides; Pyrazines; Xenograft Model Antitumor Assays | 2007 |
Potentiation of arsenic trioxide cytotoxicity by Parthenolide and buthionine sulfoximine in murine and human leukemic cells.
Topics: Adenosine Triphosphate; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Death; Cell Line, Tumor; DNA Fragmentation; Drug Synergism; Flow Cytometry; Glutamate-Cysteine Ligase; Glutathione; Humans; Leukemia; Mice; Microscopy, Fluorescence; NF-kappa B; Oxides; Reactive Oxygen Species; Sesquiterpenes | 2008 |
Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen.
Topics: Arsenic Trioxide; Arsenicals; Cytogenetics; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Promyelocytic, Acute; Mutation; Oxides; Prognosis; Retrospective Studies; Treatment Outcome | 2007 |
[Effect of Rhizoma Curcumae and arsenite trioxide on proliferation and signal transduction molecule of lens epithelial cell].
Topics: Animals; Arsenic Trioxide; Arsenicals; Calcium; Cattle; Cell Proliferation; Cells, Cultured; Curcuma; Cyclic AMP; Cyclic GMP; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Epithelial Cells; Fibroblast Growth Factor 2; Flow Cytometry; Growth Inhibitors; Lens, Crystalline; Oxides; Proliferating Cell Nuclear Antigen; Radioimmunoassay; Recombinant Proteins; Rhizome; Signal Transduction | 2007 |
Advances in management of acute promyelocytic leukemia with arsenic trioxide.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2007 |
Arsenic trioxide-mediated growth inhibition in gallbladder carcinoma cells via down-regulation of Cyclin D1 transcription mediated by Sp1 transcription factor.
Topics: Arsenic Trioxide; Arsenicals; Carcinoma; Cell Line, Tumor; Cyclin D1; Down-Regulation; Gallbladder Neoplasms; Humans; Oxides; Sp1 Transcription Factor; Transcription, Genetic; Transfection | 2007 |
Alternative pathways of programmed cell death are activated in cells with defective caspase-dependent apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Blotting, Western; Camptothecin; Caspases; Cell Line, Transformed; Cell Transformation, Neoplastic; Chickens; Cycloheximide; Genes, myb; Humans; Microscopy, Fluorescence; Necrosis; Oxides; Signal Transduction; U937 Cells | 2008 |
Arsenic metabolism in multiple myeloma and astrocytoma cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Astrocytoma; Biotransformation; Bone Marrow Cells; Cell Line, Tumor; Chromatography, Ion Exchange; Humans; Models, Chemical; Multiple Myeloma; Oxides; Reactive Oxygen Species; Time Factors | 2007 |
Acute intestinal pseudo-obstruction after induction treatment of relapsed acute promyelocytic leukemia with arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Digestive System Surgical Procedures; Female; Humans; Intestinal Pseudo-Obstruction; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Oxides | 2008 |
Melissoidesin G, a diterpenoid purified from Isodon melissoides, induces leukemic-cell apoptosis through induction of redox imbalance and exhibits synergy with other anticancer agents.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cytochromes c; Diterpenes; Glutathione; Humans; Isodon; Leukemia; Mitochondria; Molecular Structure; Oxidation-Reduction; Oxides; Phytotherapy; Tumor Cells, Cultured | 2007 |
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
Topics: Amino Acid Sequence; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Glutathione; Humans; Molecular Sequence Data; Neoplasms; Oxidation-Reduction; Oxides; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Thioredoxin-Disulfide Reductase | 2007 |
Refractory multiple myeloma treated with homoharringtonine: report of two cases.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carmustine; Cyclophosphamide; Dexamethasone; Doxorubicin; Harringtonines; Homoharringtonine; Humans; Male; Melphalan; Multiple Myeloma; Oxides; Prednisone; Remission Induction; Salvage Therapy; Thalidomide; Vincristine; Vindesine | 2007 |
Telomere attrition and chromosome instability via downregulation of TRF2 contributes to arsenic trioxide-induced apoptosis of human T-Cell leukemia cell line molt-4 cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Line, Tumor; Cell Proliferation; Chromosomal Instability; Humans; Leukemia-Lymphoma, Adult T-Cell; Oxides; Telomerase; Telomere; Telomeric Repeat Binding Protein 2 | 2007 |
[Effect of arsenic trioxide on VEGF/R and MMP-2, 9 expressed in K562 cells].
Topics: Arsenic Trioxide; Arsenicals; Cell Proliferation; Humans; K562 Cells; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Oxides; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2007 |
Cancer agents show first-line potential.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bevacizumab; Dasatinib; Humans; Kidney Neoplasms; Leukemia; Oxides; Pyrimidines; Thiazoles | 2007 |
Temporary effect of arsenic trioxide treatment of refractory extragonadal germ cell cancer.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Fatal Outcome; Humans; Male; Neoplasms, Germ Cell and Embryonal; Oxides; Prognosis; Time Factors; Treatment Failure | 2007 |
Entry of elemental arsenic into the central nervous system in patients with acute promyelocytic leukemia during arsenic trioxide treatment.
Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Central Nervous System; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2008 |
[HL-60 cell apoptosis induced by bortezomib alone or in combination with arsenic trioxide in vitro].
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Electrophoresis; Flow Cytometry; HL-60 Cells; Humans; Oxides; Pyrazines; Time Factors | 2007 |
Arsenic trioxide sensitizes promonocytic leukemia cells to TNFalpha-induced apoptosis via p38-MAPK-regulated activation of both receptor-mediated and mitochondrial pathways.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cytokines; Enzyme Activation; Enzyme Inhibitors; Glutathione; Humans; Leukemia; MAP Kinase Signaling System; Mitochondria; Myeloid Cells; NF-kappa B; Oxides; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Receptors, Cell Surface; Tumor Necrosis Factor-alpha | 2007 |
Trolox enhances the anti-lymphoma effects of arsenic trioxide, while protecting against liver toxicity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Chromans; Cytochromes c; Drug Synergism; Humans; Liver; Lymphoma; Membrane Potential, Mitochondrial; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Oxides | 2007 |
Effects of arsenic trioxide on voltage-dependent potassium channels and on cell proliferation of human multiple myeloma cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Multiple Myeloma; Oxides; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2007 |
Effect of n-propylthiouracil or thyroxine on arsenic trioxide toxicity in the liver of rat.
Topics: Animals; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Calcium; Hyperthyroidism; Hypothyroidism; Liver; Male; Oxides; Propylthiouracil; Rats; Rats, Wistar; Thyroid Gland; Thyroxine; Triiodothyronine | 2007 |
Role of Myc in differentiation and apoptosis in HL60 cells after exposure to arsenic trioxide or all-trans retinoic acid.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Differentiation; Enzyme-Linked Immunosorbent Assay; Gene Expression; Gene Expression Profiling; HL-60 Cells; Humans; Oxides; Proto-Oncogene Proteins c-myc; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Telomerase; Tretinoin | 2008 |
[Effect of early and non-early controlled-release of arsenic-trioxide eluting stents on restenosis inhibition in a canine model].
Topics: Angioplasty, Balloon, Coronary; Animals; Arsenic Trioxide; Arsenicals; Coronary Restenosis; Disease Models, Animal; Dogs; Drug-Eluting Stents; Oxides | 2007 |
The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Australia; Base Sequence; Bone Marrow; Chromosome Aberrations; Clinical Trials as Topic; Cyclic AMP-Dependent Protein Kinase RIalpha Subunit; DNA Mutational Analysis; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Mutant Chimeric Proteins; Neoplasm Proteins; Oxides; Receptors, Retinoic Acid; Registries; Remission Induction; Retinoic Acid Receptor alpha; RNA, Messenger; Sequence Deletion; Tretinoin | 2007 |
A potentized homeopathic drug, Arsenicum Album 200, can ameliorate genotoxicity induced by repeated injections of arsenic trioxide in mice.
Topics: Animals; Antidotes; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Disease Models, Animal; Dose-Response Relationship, Drug; Homeopathy; Mice; Oxides; Random Allocation; Treatment Outcome; Water Pollutants, Chemical | 2007 |
[Two different clinical cases of acute arsenic trioxide intoxication].
Topics: Adult; Alcoholic Intoxication; Antidotes; Arsenic; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Chelating Agents; Dehydration; Diarrhea; Dimercaprol; Fatal Outcome; Gastric Lavage; Gastritis; Heart Arrest; Humans; Infusions, Intravenous; Male; Middle Aged; Oxides; Renal Dialysis; Suicide, Attempted; Vomiting | 2007 |
Identification of an arsenic-sensitive block to primate lentiviral infection of human dendritic cells.
Topics: Antiviral Agents; Antiviral Restriction Factors; APOBEC-3G Deaminase; Arsenic; Arsenic Trioxide; Arsenicals; Carrier Proteins; CD4-Positive T-Lymphocytes; Cell Lineage; Cytidine Deaminase; Dendritic Cells; Gene Expression Regulation, Viral; HeLa Cells; HIV-1; Humans; Lentivirus; Lentivirus Infections; Oxides; Tripartite Motif Proteins; Ubiquitin-Protein Ligases; Zidovudine | 2007 |
Arsenic trioxide entered cerebrospinal fluid with the help of mannitol overwhelm the meningeal relapse of acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Female; Humans; Injections, Intravenous; Leukemia, Promyelocytic, Acute; Magnetic Resonance Imaging; Mannitol; Meningeal Neoplasms; Neoplasm Recurrence, Local; Oxides; Remission Induction | 2007 |
NADPH oxidase-derived reactive oxygen species are responsible for the high susceptibility to arsenic cytotoxicity in acute promyelocytic leukemia cells.
Topics: Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Humans; Leukemia, Promyelocytic, Acute; NADPH Oxidases; Oxides; Reactive Oxygen Species | 2008 |
[Effects of arsenic trioxide and ATRA on PLZF-RARalpha-positive U937 leukemic cells].
Topics: Antigens, CD; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Proliferation; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Transcription Factors; Leukemia; Nitroblue Tetrazolium; Oxidation-Reduction; Oxides; Promyelocytic Leukemia Zinc Finger Protein; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Tetracycline; Tretinoin; U937 Cells | 2007 |
Arsenic trioxide induced the apoptosis of laryngeal cancer via down-regulation of survivin mRNA.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Squamous Cell; Caspase 3; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Down-Regulation; Gene Expression; Humans; Inhibitor of Apoptosis Proteins; Laryngeal Neoplasms; Microscopy, Fluorescence; Microtubule-Associated Proteins; Neoplasm Proteins; Oxides; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survivin; Tumor Cells, Cultured | 2008 |
Sustained hematologic and central nervous system remission with single-agent denileukin diftitox in refractory adult T-cell leukemia/lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Central Nervous System Neoplasms; Diphtheria Toxin; Drug Resistance, Neoplasm; Hematologic Neoplasms; Humans; Interferons; Interleukin-2; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Oxides; Recombinant Fusion Proteins; Recurrence; Remission Induction; Transplantation, Homologous; Zidovudine | 2007 |
Prolonged oral arsenic trioxide therapy and nephrolithiasis [corrected].
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Case-Control Studies; Drug Administration Schedule; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Nephrolithiasis; Oxides; Time Factors | 2007 |
[Mechanisms underlying the effect of arsenic trioxide on proliferation inhibition and apoptosis induction in myeloma cell line u266].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Line, Tumor; Cell Proliferation; Humans; Multiple Myeloma; Oxides; RNA, Messenger; Telomerase | 2007 |
Effect of arsenic trioxide on uveal melanoma cell proliferation in vitro.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Flow Cytometry; Glutathione Peroxidase; Growth Inhibitors; Humans; Melanoma; Membrane Potentials; Microscopy, Electron; Mitochondria; Necrosis; Osmolar Concentration; Oxides | 2007 |
[A study on the apoptosis of gastric carcinoma cells induced by arsenic trioxide combined with Ad-IkappaBalphaM].
Topics: Adenoviridae; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Electrophoretic Mobility Shift Assay; Growth Inhibitors; Humans; I-kappa B Proteins; Immunohistochemistry; NF-kappa B; NF-KappaB Inhibitor alpha; Oxides; Protein Binding; Stomach Neoplasms; Transfection | 2007 |
[Effect of bortezomib used alone or in combination with arsenic trioxide on HL-60 cell xenograft in nude mice].
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Proliferation; Disease Models, Animal; HL-60 Cells; Humans; Leukemia; Male; Mice; Mice, Nude; Oxides; Pyrazines; Random Allocation; Xenograft Model Antitumor Assays | 2007 |
Arsenic trioxide initiates ER stress responses, perturbs calcium signalling and promotes apoptosis in human lens epithelial cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Calcium Signaling; Cell Line; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Endoplasmic Reticulum; Epithelial Cells; Growth Inhibitors; Humans; Lens Capsule, Crystalline; Lens, Crystalline; Oxidative Stress; Oxides; Polymerase Chain Reaction | 2007 |
The role of variability in evaluating ultra high dilution effects: considerations based on plant model experiments.
Topics: Arsenic Trioxide; Arsenicals; Germination; Models, Biological; Nicotiana; Oxides; Plant Diseases; Plant Leaves; Reproducibility of Results; Seeds; Tobacco Mosaic Virus; Triticum | 2007 |
[The effect of As2O3 on induction of apoptosis and inhibition of telomerase activity in colon cancer LS-174T cells].
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Inhibitory Concentration 50; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Electron; Microscopy, Fluorescence; Oxides; Polymerase Chain Reaction; Random Allocation; Telomerase; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2007 |
Reply to 'Arsenic patent keeps drug for rare cancer out of reach for many'.
Topics: Adult; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; China; Humans; Leukemia, Promyelocytic, Acute; Oxides; Patents as Topic; United States; United States Food and Drug Administration | 2007 |
Use of a fluorescently labeled poly-caspase inhibitor for in vivo detection of apoptosis related to vascular-targeting agent arsenic trioxide for cancer therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Enzyme Inhibitors; Female; Flow Cytometry; Fluorescent Dyes; Mice; Mice, Nude; Oxides | 2007 |
[Effects of arsenic trioxide on expressions of vascular endothelial growth factor and P-glycoprotein in multidrug resistant leukemia cell line K562/A02].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Proliferation; Down-Regulation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; K562 Cells; Oxides; Vascular Endothelial Growth Factor A | 2007 |
Dithiothreitol abrogates the effect of arsenic trioxide on normal rat liver mitochondria and human hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Dithiothreitol; Dose-Response Relationship, Drug; Electron Transport Chain Complex Proteins; Environmental Pollutants; Humans; Liver Neoplasms; Male; Membrane Potential, Mitochondrial; Mitochondria, Liver; Oxides; Oxygen Consumption; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species | 2008 |
[STI571 enhances the effect of arsenic trioxide and Velcade on bcr/abl+-CD34+ cell proliferation and apoptosis].
Topics: Adult; Aged; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Boronic Acids; Bortezomib; Cell Proliferation; Drug Synergism; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Oxides; Piperazines; Pyrazines; Pyrimidines; Tumor Cells, Cultured | 2007 |
Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responses.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Eukaryotic Initiation Factors; Gene Deletion; Humans; K562 Cells; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Oxides; Protein Kinases; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins; U937 Cells | 2008 |
[Reversal effect and mechanism of arsenic trioxide on multidrug resistance of gastric carcinoma cells SGC7901].
Topics: Adenocarcinoma; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epirubicin; Fluorouracil; Glutathione Transferase; Humans; Oxides; Stomach Neoplasms; Vincristine | 2007 |
Adhesion molecules and Differentiation Syndrome: phenotypic and functional analysis of the effect of ATRA, As2O3, phenylbutyrate, and G-CSF in acute promyelocytic leukemia.
Topics: Animals; Antigens, CD; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Adhesion; Cell Adhesion Molecules; Cell Differentiation; Gene Expression Regulation, Leukemic; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, Inbred BALB C; Mice, Knockout; Neoplasm Proteins; Oxides; Phenylbutyrates; Syndrome; Tretinoin; Tumor Cells, Cultured | 2007 |
[The effect of arsenic trioxide (As2O3) combined with BSO on K562/ADM cell and its mechanisms].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Buthionine Sulfoximine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Genes, MDR; Glutathione; Humans; K562 Cells; Oxides | 2007 |
[Inhibitory effect of arsenic trioxide on proliferation of human hepatocellular carcinoma cell line SMMC-7721 and the mechanism].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; COP9 Signalosome Complex; Cyclin-Dependent Kinase Inhibitor p27; Cytoplasm; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Oxides; Peptide Hydrolases | 2007 |
As2O3-induced oxidative stress and cycle progression in a human intestinal epithelial cell line (Caco-2).
Topics: Arsenic Trioxide; Arsenicals; Caco-2 Cells; Cell Cycle; Cell Survival; G1 Phase; G2 Phase; Humans; Membrane Potentials; Mitochondria; Mitochondrial Membranes; Oxidative Stress; Oxides; Reactive Oxygen Species; Tetrazolium Salts; Thiazoles | 2008 |
Arsenic trioxide induces de novo protein synthesis of annexin-1 in neutrophils: association with a heat shock-like response and not apoptosis.
Topics: Animals; Annexin A1; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cells, Cultured; Gene Expression Regulation; Heat-Shock Proteins; Heat-Shock Response; Humans; Mice; Mice, Knockout; Neutrophils; Oxides; RNA, Messenger | 2008 |
QT prolongation: a case of arsenical pericardial and pleural effusion.
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Long QT Syndrome; Male; Oxides; Pericardial Effusion; Pleural Effusion; Recovery of Function; Withholding Treatment | 2008 |
[Effect of arsenic trioxide on the expression of apoptosis-related genes in NB4 cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; CDC2 Protein Kinase; Cell Line, Tumor; Cyclin B; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Leukemia, Promyelocytic, Acute; Microtubule-Associated Proteins; Oxides; Survivin | 2007 |
[Effects of As2O3, dexamethasone and thalidomide on apoptosis and cytoplasmic [Ca2+] of myeloma cell line U266].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Calcium; Cell Line, Tumor; Cytoplasm; Dexamethasone; Humans; Multiple Myeloma; Oxides; Thalidomide | 2007 |
Arsenic contents of human organs after fatal poisoning with arsenic trioxide and other arsenical compounds, with some remarks on the manifestations of arsenic poisoning.
Topics: Antiprotozoal Agents; Antitrichomonal Agents; Arsenic; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Humans; Oxides | 1949 |
Analytical artefacts in the speciation of arsenic in clinical samples.
Topics: Arsenic Trioxide; Arsenicals; Artifacts; Chromatography, High Pressure Liquid; Humans; Leukemia, Promyelocytic, Acute; Mass Spectrometry; Multiple Myeloma; Oxides; Spectrometry, Fluorescence | 2008 |
Redox status of thioredoxin-1 (TRX1) determines the sensitivity of human liver carcinoma cells (HepG2) to arsenic trioxide-induced cell death.
Topics: Animals; Arsenic Trioxide; Arsenicals; Binding Sites; Carcinoma, Hepatocellular; Caspases; Cell Death; Cell Line, Tumor; Cytochromes c; Dinitrochlorobenzene; Drug Screening Assays, Antitumor; Enzyme Activation; Humans; Liver Neoplasms; Mice; Mitochondria; Mitochondrial Swelling; Mutant Proteins; NADP; Oxidation-Reduction; Oxides; Reactive Oxygen Species; Recombinant Proteins; RNA Interference; Thioredoxins | 2008 |
Using targeted magnetic arsenic trioxide nanoparticles for osteosarcoma treatment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Biological Availability; Cisplatin; Drug Delivery Systems; Ferric Compounds; Ferrous Compounds; Humans; Kidney; Lactic Acid; Magnetics; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Electron, Transmission; Nanoparticles; Osteosarcoma; Oxides; Particle Size; Polyesters; Polymers; Rabbits; Random Allocation; Xenograft Model Antitumor Assays | 2007 |
Dynamic effects of autophagy on arsenic trioxide-induced death of human leukemia cell line HL60 cells.
Topics: Adenine; Ammonium Chloride; Arsenic Trioxide; Arsenicals; Autophagy; Cadaverine; Cell Death; Fluorescent Antibody Technique; HL-60 Cells; Humans; Mitochondrial Membranes; Oxides; Subcellular Fractions | 2008 |
Insight into the selectivity of arsenic trioxide for acute promyelocytic leukemia cells by characterizing Saccharomyces cerevisiae deletion strains that are sensitive or resistant to the metalloid.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Biological Transport; Cell Line, Tumor; Cytoskeletal Proteins; DNA Repair; Gene Deletion; Glutathione; Humans; Leukemia, Promyelocytic, Acute; Membrane Proteins; Mitogen-Activated Protein Kinases; Osmotic Pressure; Oxidative Stress; Oxides; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Vacuoles | 2008 |
Effects of HBV X gene and arsenic trioxide on the expression of p53 in cultured HepG2 cells.
Topics: Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; Humans; Oxides; RNA Interference; Trans-Activators; Tumor Suppressor Protein p53; Viral Regulatory and Accessory Proteins | 2007 |
Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Astrocytes; Brain Neoplasms; Caspase 3; Glioma; Humans; Membrane Proteins; Oxides; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Transcription Factor CHOP; Tumor Cells, Cultured; Up-Regulation | 2008 |
P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Imidazoles; Molecular Chaperones; Multiple Myeloma; Neoplasm Proteins; Oxides; p38 Mitogen-Activated Protein Kinases; Pyridines; Signal Transduction; Tumor Cells, Cultured; Up-Regulation | 2008 |
Optical neuropathy possibly related to arsenic during acute promyelocytic leukemia treatment.
Topics: Adult; Arsenic; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Optic Neuropathy, Ischemic; Oxides | 2008 |
[Successful cyclosporine treatment for thrombocytopenia after salvage therapy with arsenic trioxide therapy followed by autologous hematopoietic stem cell transplantation in acute promyelocytic leukemia].
Topics: Arsenic Trioxide; Arsenicals; Autoimmune Diseases; Cyclosporine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Salvage Therapy; Thrombocytopenia; Transplantation, Autologous | 2007 |
Simultaneous appearance of central nervous system relapse and subarachnoid hemorrhage during the treatment for acute promyelocytic leukemia.
Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Combined Modality Therapy; Endothelium, Vascular; Gemtuzumab; Humans; Injections, Spinal; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Magnetic Resonance Imaging; Male; Meninges; Middle Aged; Oxides; Postoperative Complications; Recurrence; Subarachnoid Hemorrhage; Tomography, X-Ray Computed | 2008 |
Inhibitory role of TGIF in the As2O3-regulated p21 WAF1/CIP1 expression.
Topics: Arsenic Trioxide; Arsenicals; Base Sequence; Binding Sites; Blotting, Western; Cell Line, Tumor; Chromatin Immunoprecipitation; Cyclin-Dependent Kinase Inhibitor p21; DNA Primers; Electrophoretic Mobility Shift Assay; Gene Expression Regulation; Histone Deacetylases; Humans; Oxides; Phosphorylation; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Sp1 Transcription Factor | 2008 |
Inorganic arsenic induces necrosis of human CD34-positive haematopoietic stem cells.
Topics: Antigens, CD34; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Lineage; Cell Proliferation; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Environmental Pollutants; Hematopoietic Stem Cells; Humans; Membrane Potential, Mitochondrial; Necrosis; Oxides | 2008 |
Emodin-induced generation of reactive oxygen species inhibits RhoA activation to sensitize gastric carcinoma cells to anoikis.
Topics: Acetylcysteine; Actins; Anoikis; Arsenic Trioxide; Arsenicals; Carcinoma; Cell Line, Tumor; Emodin; Free Radical Scavengers; Humans; Oxidative Stress; Oxides; Protein Kinase Inhibitors; Reactive Oxygen Species; rhoA GTP-Binding Protein; Stomach Neoplasms; Transfection | 2008 |
Gene expression profile of multiple myeloma cell line treated by arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Gene Expression Profiling; Humans; Multiple Myeloma; Oxides; Tumor Cells, Cultured | 2007 |
PML enhances the regulation of p53 by CK1 in response to DNA damage.
Topics: Active Transport, Cell Nucleus; Arsenic Trioxide; Arsenicals; Casein Kinase I; Cell Line, Tumor; DNA Damage; Humans; Neoplasm Proteins; Nuclear Proteins; Oxides; Phosphorylation; Promyelocytic Leukemia Protein; Proto-Oncogene Proteins c-mdm2; Threonine; Transcription Factors; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2008 |
Intracellular GSH level is a factor in As4.1 juxtaglomerular cell death by arsenic trioxide.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Catalase; Cell Cycle; Cell Death; G1 Phase; Glutathione; MAP Kinase Kinase 4; Membrane Potential, Mitochondrial; Mice; Mice, Transgenic; Oxides; Oxygen; Reactive Oxygen Species; Superoxide Dismutase | 2008 |
Monitoring autophagy in glioblastoma with antibody against isoform B of human microtubule-associated protein 1 light chain 3.
Topics: Animals; Antibodies; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autophagy; Cell Line, Tumor; Ceramides; Dacarbazine; Female; Glioblastoma; Humans; Mice; Mice, Nude; Microtubule-Associated Proteins; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Oxides; Paclitaxel; Phagosomes; Survival Rate; Temozolomide; Transplantation, Heterologous; Tubulin Modulators | 2008 |
A combination of sulindac and arsenic trioxide synergistically induces apoptosis in human lung cancer H1299 cells via c-Jun NH2-terminal kinase-dependent Bcl-xL phosphorylation.
Topics: Acetylcysteine; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Drug Synergism; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Membrane Potential, Mitochondrial; Mitochondria; Oxides; Phosphorylation; Reactive Oxygen Species; Signal Transduction; Sulindac | 2008 |
Effect of the combination of ATRA, ATO and DNR on CD11b expression in NB4 cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; CD11b Antigen; Cell Line, Tumor; Daunorubicin; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2008 |
All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
Topics: Adolescent; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Dysplastic Nevus Syndrome; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Tretinoin | 2008 |
Berberine enhances inhibition of glioma tumor cell migration and invasiveness mediated by arsenic trioxide.
Topics: Actins; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Berberine; Cell Line, Tumor; Cell Movement; Cell Proliferation; Enzyme Activation; Glioma; Humans; Isoenzymes; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Oxides; Protein Kinase C-alpha; Protein Kinase C-epsilon; Rats; Transcription Factors; Translocation, Genetic | 2008 |
Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Chromosome Deletion; Chromosomes, Human, Pair 17; Drug Resistance, Neoplasm; Enzyme Activation; Female; Free Radical Scavengers; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Oxidative Stress; Oxides; Poly(ADP-ribose) Polymerases; Prognosis; Reactive Oxygen Species; Superoxide Dismutase; Vidarabine | 2008 |
Inhibition of mitochondrial protein translation sensitizes melanoma cells to arsenic trioxide cytotoxicity via a reactive oxygen species dependent mechanism.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Electron Transport Complex IV; Humans; Inhibitory Concentration 50; Melanoma; Mitochondrial Proteins; Oxides; Poly Adenosine Diphosphate Ribose; Protein Biosynthesis; Protein Synthesis Inhibitors; Reactive Oxygen Species; Tetracyclines; Thiostrepton | 2008 |
Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Blast Crisis; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Enzyme Activation; Enzyme Inhibitors; Eukaryotic Initiation Factor-4E; Fibroblasts; Gene Targeting; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Promyelocytic, Acute; Mice; Mitogen-Activated Protein Kinases; Oxides; Phosphorylation; Protein Serine-Threonine Kinases; Tumor Stem Cell Assay | 2008 |
Hyperleukocytosis from arsenic trioxide.
Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Oxides; Recurrence | 2008 |
[Effect of arsenic trioxide combined with bortezomib on proliferation, apoptosis and beta-catenin level in myeloma cell lines].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; beta Catenin; Boronic Acids; Bortezomib; Cell Proliferation; Drug Synergism; Humans; Multiple Myeloma; Oxides; Pyrazines; Tumor Cells, Cultured | 2008 |
Resveratrol protects against arsenic trioxide-induced cardiotoxicity in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Arsenic Trioxide; Arsenicals; Calcium; Caspase 3; Cell Survival; Cytoplasm; Electrocardiography; Female; Heart Diseases; In Situ Nick-End Labeling; In Vitro Techniques; L-Lactate Dehydrogenase; Male; Mice; Mice, Inbred BALB C; Microscopy, Fluorescence; Myocytes, Cardiac; Oxidative Stress; Oxides; Reactive Oxygen Species; Resveratrol; Stilbenes | 2008 |
[Effects of arsenic trioxide on apoptosis and proliferation of human lung cancer cells under hypoxia].
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Humans; Lung Neoplasms; Oxides | 2008 |
Arsenic trioxide-induced apoptosis in H9c2 cardiomyocytes: implications in cardiotoxicity.
Topics: Animals; Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Line; Cell Survival; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Enzyme Activation; Myocytes, Cardiac; Oligopeptides; Oxidative Stress; Oxides; Rats; Reactive Oxygen Species; Verapamil; Vitamin E | 2008 |
Arsenic trioxide down-regulates antiapoptotic genes and induces cell death in mycosis fungoides tumors in a mouse model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; bcl-X Protein; Cell Growth Processes; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Mice; Mice, Nude; Mycosis Fungoides; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; Oxides; Proto-Oncogene Proteins c-bcl-2; Skin Neoplasms; STAT5 Transcription Factor; T-Lymphocytes; Xenograft Model Antitumor Assays | 2008 |
BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Bcl-2-Like Protein 11; Cell Death; Cell Line, Tumor; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Multiple Myeloma; Oxides; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2 | 2008 |
Arsenic trioxide inhibits ATRA-induced prostaglandin E2 and cyclooxygenase-1 in NB4 cells, a model of acute promyelocytic leukemia.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; CD11c Antigen; Cell Differentiation; Cyclooxygenase 1; Dinoprostone; Drug Therapy, Combination; Humans; Indomethacin; Leukemia, Promyelocytic, Acute; Models, Biological; Oxides; Tretinoin; Tumor Cells, Cultured | 2008 |
In vitro arsenic trioxide induces apoptosis in T cells of asthmatic patients by a Bcl-2 related mechanism.
Topics: Adult; Anti-Asthmatic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Asthma; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gene Expression Regulation; Humans; Interleukin-4; Microscopy, Fluorescence; Middle Aged; Oxides; Proto-Oncogene Proteins c-bcl-2; T-Lymphocytes | 2008 |
Quercetin decreases intracellular GSH content and potentiates the apoptotic action of the antileukemic drug arsenic trioxide in human leukemia cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Cell Line, Tumor; Drug Synergism; Flavonoids; Glutathione; Humans; Leukemia; Membrane Potential, Mitochondrial; Oxides; Protein Kinases; Quercetin | 2008 |
Combination brings long-term remission in acute promyelocytic leukemia refractory for both all-trans retinoic acid and arsenic trioxide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Remission Induction; Salvage Therapy; Tretinoin | 2008 |
JWA is required for arsenic trioxide induced apoptosis in HeLa and MCF-7 cells via reactive oxygen species and mitochondria linked signal pathway.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Heat-Shock Proteins; HeLa Cells; Humans; In Situ Nick-End Labeling; Intracellular Signaling Peptides and Proteins; Membrane Potential, Mitochondrial; Membrane Transport Proteins; Mitochondria; Oxides; Phosphorylation; Reactive Oxygen Species; Signal Transduction | 2008 |
Apoptosis in arsenic trioxide-treated Calu-6 lung cells is correlated with the depletion of GSH levels rather than the changes of ROS levels.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Catalase; Cell Line, Tumor; DNA; Glutathione; Humans; Hydrogen Peroxide; Lung; Membrane Potentials; Mitochondria; Oxides; Oxygen; Reactive Oxygen Species; Superoxide Dismutase; Time Factors | 2008 |
The role of p38 MAPK and JNK in Arsenic trioxide-induced mitochondrial cell death in human cervical cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Blotting, Western; Enzyme Activation; Female; HeLa Cells; Humans; MAP Kinase Kinase 4; Membrane Potential, Mitochondrial; Mitochondria; Oxides; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Transport; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; RNA, Small Interfering; Signal Transduction; Transfection; Uterine Cervical Neoplasms | 2008 |
SUMOylation of HMGA2: selective destabilization of promyelocytic leukemia protein via proteasome.
Topics: Animals; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Nucleus; Chlorocebus aethiops; COS Cells; Down-Regulation; Epithelial Cells; Fluorescence; Fluorescent Antibody Technique; Green Fluorescent Proteins; HeLa Cells; HMGA2 Protein; Humans; Nuclear Proteins; Oxides; Parotid Gland; Promyelocytic Leukemia Protein; Proteasome Endopeptidase Complex; Protein Processing, Post-Translational; Rats; RNA, Small Interfering; SUMO-1 Protein; Transcription Factors; Transcription, Genetic; Tumor Suppressor Proteins; Ubiquitin; Ubiquitin-Conjugating Enzymes; Zinc Fingers | 2008 |
Inorganic arsenic activates reduced NADPH oxidase in human primary macrophages through a Rho kinase/p38 kinase pathway.
Topics: Arsenic Trioxide; Arsenicals; Cells, Cultured; Chemokines, CC; Environmental Exposure; Environmental Pollutants; Enzyme Activation; Enzyme Inhibitors; Humans; Macrophages; MAP Kinase Signaling System; NADPH Oxidases; Oxides; p38 Mitogen-Activated Protein Kinases; Phosphoproteins; Phosphorylation; rac1 GTP-Binding Protein; rho-Associated Kinases; Superoxides; Time Factors | 2008 |
Retrospective analysis of 65 Chinese children with acute promyelocytic leukemia: a single center experience.
Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Humans; Infant; Leukemia, Promyelocytic, Acute; Male; Oxides; Prognosis; Recurrence; Retrospective Studies; Treatment Outcome; Tretinoin | 2008 |
Down-regulation of beta1,4GalT V at protein level contributes to arsenic trioxide-induced glioma cell apoptosis.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; DNA, Antisense; Down-Regulation; Galactosyltransferases; Glioma; Humans; Optic Nerve Injuries; Oxides; Polysaccharides | 2008 |
Arsenic trioxide, arsenic pentoxide, and arsenic iodide inhibit human keratinocyte proliferation through the induction of apoptosis.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Caspase 3; Cell Cycle; Cell Line; Cell Proliferation; DNA Fragmentation; Fibroblasts; Humans; In Situ Nick-End Labeling; Iodine Compounds; Keratinocytes; Oxides | 2008 |
Mineral arsenicals in traditional medicines: orpiment, realgar, and arsenolite.
Topics: Animals; Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Humans; Lethal Dose 50; Medicine, Traditional; Models, Molecular; Molecular Structure; Oxides; Sulfides | 2008 |
Acute renal failure, gastrointestinal bleeding, and cardiac arrhythmia after administration of arsenic trioxide for acute promyelocytic leukemia.
Topics: Acute Kidney Injury; Aged, 80 and over; Antineoplastic Agents; Arrhythmias, Cardiac; Arsenic Trioxide; Arsenicals; Fatal Outcome; Female; Gastrointestinal Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2008 |
Induction of NKG2D ligands and subsequent enhancement of NK cell-mediated lysis of cancer cells by arsenic trioxide.
Topics: Arsenic Trioxide; Arsenicals; Cell Death; Cell Line, Tumor; Cell Membrane; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Killer Cells, Natural; Ligands; Neoplasms; NK Cell Lectin-Like Receptor Subfamily K; Oxides; Receptors, Immunologic; Receptors, Natural Killer Cell; Up-Regulation | 2008 |
Intravenous administration of arsenic trioxide encapsulated in liposomes inhibits the growth of C6 gliomas in rat brains.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Brain Neoplasms; Drug Stability; Glioma; Injections, Intravenous; Liposomes; Male; Microscopy, Electron; Neovascularization, Pathologic; Oxides; Rats; Rats, Wistar; Tissue Distribution | 2008 |
PML targeting eradicates quiescent leukaemia-initiating cells.
Topics: Adult; Animals; Arsenic Trioxide; Arsenicals; Cell Line; Coculture Techniques; Female; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Inbred C57BL; Neoplastic Stem Cells; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Recurrence; Regeneration; Transcription Factors; Tumor Suppressor Proteins | 2008 |
[Effects of vitamin C combined with arsenic trioxide on the apoptosis of Hep-2 cell].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cell Line, Tumor; Drug Synergism; Humans; Oxides | 2008 |
Mandibular bone necrosis caused by use of arsenic paste during endodontic treatment: two case reports.
Topics: Adult; Arsenic Trioxide; Arsenicals; Dental Pulp Devitalization; Extravasation of Diagnostic and Therapeutic Materials; Female; Humans; Mandibular Diseases; Middle Aged; Osteonecrosis; Oxides | 2008 |
Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Ataxia Telangiectasia Mutated Proteins; Cell Cycle; Cell Cycle Proteins; Checkpoint Kinase 1; Checkpoint Kinase 2; DNA Damage; DNA-Binding Proteins; Dose-Response Relationship, Drug; Enzyme Activation; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; MAP Kinase Signaling System; Oxides; p38 Mitogen-Activated Protein Kinases; Phosphoprotein Phosphatases; Phosphorylation; Protein Kinases; Protein Phosphatase 2C; Protein Serine-Threonine Kinases; RNA, Small Interfering; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2008 |
Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib.
Topics: 2-Methoxyestradiol; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; beta Catenin; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Estradiol; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Oxides; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured | 2008 |
Arsenic trioxide in environmentally and clinically relevant concentrations interacts with calcium homeostasis and induces cell type specific cell death in tumor and non-tumor cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Calcium; Calcium Signaling; Cell Line, Tumor; Cell Survival; DNA Damage; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Homeostasis; Humans; Kidney; Micronuclei, Chromosome-Defective; Microscopy, Confocal; Neuroblastoma; Oxides; Trypan Blue | 2008 |
Death-associated protein 5 (DAP5/p97/NAT1) contributes to retinoic acid-induced granulocytic differentiation and arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Base Sequence; Cell Differentiation; Cell Line, Tumor; Eukaryotic Initiation Factor-2; Eukaryotic Initiation Factor-4G; Granulocytes; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Models, Biological; Oxides; Phosphatidylinositol 3-Kinases; Protein Kinases; Proto-Oncogene Proteins c-akt; RNA-Binding Proteins; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Tretinoin; Up-Regulation | 2008 |
Second hematological malignancies during arsenic trioxide therapy of B-cell lymphomas.
Topics: Aged; Arsenic Trioxide; Arsenicals; Female; Hematologic Neoplasms; Humans; Lymphoma, B-Cell; Male; Neoplasms, Second Primary; Oxides | 2009 |
[Inhibitory effect of sorafenib combined with arsenic trioxide on hepatocellular carcinoma cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Humans; Liver Neoplasms; Membrane Potential, Mitochondrial; Niacinamide; Oxides; Phenylurea Compounds; Pyridines; Sorafenib | 2008 |
Suppression of arsenic trioxide-induced apoptosis in HeLa cells by N-acetylcysteine.
Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Catalase; Cell Cycle; Free Radical Scavengers; Glutathione; Growth Inhibitors; HeLa Cells; Humans; Membrane Potential, Mitochondrial; Oxides; Reactive Oxygen Species; Superoxide Dismutase; Superoxides | 2008 |
N-(beta-Elemene-13-yl)tryptophan methyl ester induces apoptosis in human leukemia cells and synergizes with arsenic trioxide through a hydrogen peroxide dependent pathway.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Catalase; Cell Proliferation; Cell Survival; Drug Synergism; HL-60 Cells; Humans; Hydrogen Peroxide; Leukemia; Oxides; Sesquiterpenes; Tryptophan | 2008 |
Arsenic trioxide inhibits the growth of Calu-6 cells via inducing a G2 arrest of the cell cycle and apoptosis accompanied with the depletion of GSH.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Line, Tumor; G2 Phase; Glutathione; Humans; Lung Neoplasms; Oxides; Reactive Oxygen Species; Superoxides | 2008 |
Genistein selectively potentiates arsenic trioxide-induced apoptosis in human leukemia cells via reactive oxygen species generation and activation of reactive oxygen species-inducible protein kinases (p38-MAPK, AMPK).
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Synergism; Electrophoretic Mobility Shift Assay; Enzyme Activation; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genistein; HL-60 Cells; Humans; Immunoblotting; Jurkat Cells; Leukemia; Multienzyme Complexes; Oxidative Stress; Oxides; p38 Mitogen-Activated Protein Kinases; Protein Serine-Threonine Kinases; Reactive Oxygen Species; U937 Cells | 2008 |
Comparative efficacy of two microdoses of a potentized homeopathic drug, arsenicum album, to ameliorate toxicity induced by repeated sublethal injections of arsenic trioxide in mice.
Topics: Acid Phosphatase; Alkaline Phosphatase; Animals; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Catalase; Chromosome Aberrations; Chronic Disease; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Glutathione; Lipid Metabolism; Male; Materia Medica; Mice; Mitotic Index; Oxides; Spermatozoa; Succinate Dehydrogenase; Transaminases; Treatment Outcome | 2008 |
Delayed hematological recovery following autologous transplantation utilizing peripheral blood stem cells harvested after treatment with arsenic trioxide.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Peripheral Blood Stem Cell Transplantation; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Autologous | 2008 |
Arsenic trioxide decreases AKT protein in a caspase-dependent manner.
Topics: Adaptor Proteins, Signal Transducing; Arsenic Trioxide; Arsenicals; Benzoquinones; Caspase 3; Caspases; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Humans; JNK Mitogen-Activated Protein Kinases; Lactams, Macrocyclic; Oxides; Proteasome Endopeptidase Complex; Protein Binding; Proto-Oncogene Proteins c-akt | 2008 |
Telomerase activity and telomere length in patients with acute promyelocytic leukemia: indicative of proliferative activity, disease progression, and overall survival.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Growth Processes; Disease Progression; Enzyme Activation; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Survival Rate; Telomerase; Telomere | 2008 |
Deletion of Glu155 causes a deficiency of glutathione transferase Omega 1-1 but does not alter sensitivity to arsenic trioxide and other cytotoxic drugs.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cytotoxins; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Genotype; Glutamic Acid; Glutathione Transferase; Humans; Oxides; Polymorphism, Genetic | 2008 |
Sulindac enhances arsenic trioxide-mediated apoptosis by inhibition of NF-kappaB in HCT116 colon cancer cells.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspase 8; Cell Proliferation; Drug Synergism; HCT116 Cells; Humans; I-kappa B Proteins; NF-kappa B; NF-KappaB Inhibitor alpha; Oxides; Phosphorylation; Sulindac | 2008 |
Enhancement of arsenic trioxide-induced apoptosis in HeLa cells by diethyldithiocarbamate or buthionine sulfoximine.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Survival; Ditiocarb; Glutathione; HeLa Cells; Humans; Membrane Potential, Mitochondrial; Oxides; Reactive Oxygen Species; Superoxides | 2008 |
Expression of Dlk1 gene in myelodysplastic syndrome determined by microarray, and its effects on leukemia cells.
Topics: Adult; Aged; Antigens, CD34; Apoptosis; Arsenic Trioxide; Arsenicals; Calcium-Binding Proteins; Cell Cycle; Cell Proliferation; Female; Gene Expression Profiling; Gene Expression Regulation; Humans; Intercellular Signaling Peptides and Proteins; K562 Cells; Leukemia; Leukocytes, Mononuclear; Male; Membrane Proteins; Middle Aged; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Oxides; Tetradecanoylphorbol Acetate; Up-Regulation | 2008 |
Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Diphenylamine; Humans; MAP Kinase Signaling System; Mice; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Multiple Myeloma; Oxides; Protein Kinase Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Arsenic trioxide and auranofin inhibit selenoprotein synthesis: implications for chemotherapy for acute promyelocytic leukaemia.
Topics: Adenocarcinoma; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Arsenites; Auranofin; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Oxides; Protein Biosynthesis; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Messenger; RNA, Small Interfering; Selenium Radioisotopes; Selenoproteins; Sodium Compounds; Sodium Selenite; Thioredoxin Reductase 1 | 2008 |
Induction of apoptosis in arsenic trioxide-treated lung cancer A549 cells by buthionine sulfoximine.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Cycle; Cell Membrane; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Glutathione; Humans; Lung Neoplasms; Membrane Potential, Mitochondrial; Oxides; Reactive Oxygen Species; Tumor Cells, Cultured | 2008 |
[Arsenic trioxide induced apoptosis in retinoblastoma cells in vitro and its possible mechanism].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Caspase 3; Humans; Oxides; Proto-Oncogene Proteins c-bcl-2; Retinal Neoplasms; Retinoblastoma; Tumor Cells, Cultured | 2008 |
Inhibition on LS-174T cell growth and activity of telomerase in vitro and in vivo by arsenic trioxide.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Nucleus; Cell Survival; Colorectal Neoplasms; Cytoplasmic Structures; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Formazans; Humans; Mice; Mice, Nude; Oxides; Polymerase Chain Reaction; Telomerase; Tetrazolium Salts; Xenograft Model Antitumor Assays | 2008 |
Arsenic trioxide and lead acetate induce apoptosis in adult rat hepatic stem cells.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cells, Cultured; Extracellular Signal-Regulated MAP Kinases; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Liver; Male; Organometallic Compounds; Oxides; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; Stem Cells | 2009 |
Evaluation of arsenic trioxide-loaded albumin nanoparticles as carriers: preparation and antitumor efficacy.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Survival; Chemistry, Pharmaceutical; Drug Carriers; Drug Evaluation; Liver Neoplasms, Experimental; Male; Mice; Nanoparticles; Oxides; Particle Size; Serum Albumin, Bovine | 2008 |
Arsenic trioxide impairs spermatogenesis via reducing gene expression levels in testosterone synthesis pathway.
Topics: Animals; Animals, Outbred Strains; Arsenic Trioxide; Arsenicals; Cell Survival; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Gene Expression; Gene Expression Regulation; Growth Inhibitors; Injections, Subcutaneous; Leydig Cells; Luteinizing Hormone; Male; Mice; Mice, Inbred ICR; Oxides; RNA, Messenger; Seminiferous Tubules; Sperm Motility; Spermatogenesis; Spermatozoa; Testis; Testosterone | 2008 |
A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines.
Topics: Animals; Anthracenes; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Resistance, Neoplasm; Glutathione; Hematologic Neoplasms; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase 4; Mice; Multidrug Resistance-Associated Proteins; Oncogene Proteins, Fusion; Oxidative Stress; Oxides | 2008 |
Combination treatment with arsenic trioxide and sulindac enhances apoptotic cell death in lung cancer cells via activation of oxidative stress and mitogen-activated protein kinases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; DNA Damage; Enzyme Inhibitors; Flow Cytometry; G1 Phase; Heme Oxygenase-1; Histones; Humans; Hydrogen Peroxide; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Oxidative Stress; Oxides; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Reactive Oxygen Species; Sulindac; Tumor Cells, Cultured | 2008 |
PML/RARalpha fusion protein mediates the unique sensitivity to arsenic cytotoxicity in acute promyelocytic leukemia cells: Mechanisms involve the impairment of cAMP signaling and the aberrant regulation of NADPH oxidase.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Survival; Cyclic AMP; Dose-Response Relationship, Drug; Humans; Leukemia, Promyelocytic, Acute; NADPH Oxidases; Oncogene Proteins, Fusion; Oxides; Reactive Oxygen Species; Signal Transduction; Time Factors; Transfection; U937 Cells | 2008 |
Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone.
Topics: Animals; Arsenic Trioxide; Arsenicals; Bone and Bones; Bone Resorption; Carcinoma, Squamous Cell; Cell Death; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dose-Response Relationship, Drug; Endothelial Cells; Humans; Mice; Mice, Inbred BALB C; Mice, SCID; Mouth Neoplasms; Neoplasm Metastasis; Neovascularization, Pathologic; Osteoblasts; Oxides; Radiation, Ionizing; Treatment Outcome; Tumor Stem Cell Assay; Vascular Endothelial Growth Factor A | 2008 |
[Arsenic trioxide resulting in alveolar bone chemical necrosis: report of 2 cases].
Topics: Arsenic Trioxide; Arsenicals; Dental Pulp; Dental Pulp Devitalization; Humans; Osteonecrosis; Oxides | 2008 |
The redox state of the lung cancer microenvironment depends on the levels of thioredoxin expressed by tumor cells and affects tumor progression and response to prooxidants.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Non-Small-Cell Lung; Cysteine; Disease Progression; Glutathione; HCT116 Cells; Humans; Intramolecular Oxidoreductases; Jurkat Cells; Lung Neoplasms; Macrophage Migration-Inhibitory Factors; Mice; Mice, SCID; Oxidation-Reduction; Oxides; Sulfhydryl Compounds; Thioredoxins | 2008 |
Requirement of a functional spindle checkpoint for arsenite-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Fibroblasts; HeLa Cells; Humans; Mitosis; Oxides; Paclitaxel; Spindle Apparatus; Tumor Suppressor Protein p53 | 2008 |
The minimal arsenic concentration required to inhibit the activity of thyroid peroxidase activity in vitro.
Topics: Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Humans; Iodide Peroxidase; Oxides | 2008 |
Sequential effects of daily arsenic trioxide treatment on essential and nonessential trace elements in tissues in mice.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Food Analysis; Mice; Mice, Inbred BALB C; Oxides; Tissue Distribution; Trace Elements; Water Supply | 2008 |
Acute promyelocytic leukemia: recent advances in diagnosis and management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Salvage Therapy; Treatment Outcome; Tretinoin | 2008 |
Role of p38 MAPK and JNK in enhanced cervical cancer cell killing by the combination of arsenic trioxide and ionizing radiation.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Caspases; Cell Nucleus; Combined Modality Therapy; Cytosol; Female; HeLa Cells; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase Kinases; Membrane Potential, Mitochondrial; Mitochondria; Oxides; Phosphorylation; Protein Transport; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Radiation, Ionizing; Reactive Oxygen Species; Signal Transduction; Uterine Cervical Neoplasms | 2008 |
Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Cytarabine; Female; Humans; Injections, Spinal; Leukemia, Promyelocytic, Acute; Male; Methotrexate; Middle Aged; Oxides; Recurrence | 2008 |
Arsenic trioxide stimulates SUMO-2/3 modification leading to RNF4-dependent proteolytic targeting of PML.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Down-Regulation; Humans; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oxides; Proteasome Endopeptidase Complex; Small Ubiquitin-Related Modifier Proteins; Transcription Factors; Ubiquitination; Ubiquitins | 2008 |
[Synergistic effects of arsenic trioxide and proteasome inhibitor bortezomib on apoptosis induction in Raji cell line].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Burkitt Lymphoma; Cell Line, Tumor; Drug Synergism; Humans; Oxides; Protease Inhibitors; Pyrazines | 2008 |
Novel human neutrophil agonistic properties of arsenic trioxide: involvement of p38 mitogen-activated protein kinase and/or c-jun NH2-terminal MAPK but not extracellular signal-regulated kinases-1/2.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Calcium; Cell Adhesion; Cell Movement; Cells, Cultured; Erythrocytes; Gelatinases; Humans; Hydrogen Peroxide; JNK Mitogen-Activated Protein Kinases; Lung; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neutrophils; Oxides; p38 Mitogen-Activated Protein Kinases; Phagocytosis; Phosphorylation; Reactive Oxygen Species; Sheep | 2008 |
[Arsenic trioxide combined with buthionine sulfoximine enhances apoptosis in multidrug-resistant human leukemia K562/ADM cells in vitro].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Glutathione; Humans; K562 Cells; Oxides | 2008 |
Acute arsenic trioxide ant bait ingestion by toddlers.
Topics: Administration, Oral; Arsenic Trioxide; Arsenicals; Chelating Agents; Child, Preschool; Female; Household Products; Humans; Infant; Insecticides; Male; Oxides; Poison Control Centers; Poisoning; Succimer; Vomiting | 2008 |
Tannic acid-induced apoptosis and -enhanced sensitivity to arsenic trioxide in human leukemia HL-60 cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Drug Synergism; HL-60 Cells; Humans; Kinetics; Leukemia, Myeloid, Acute; Mitochondria; Oxides; Superoxide Dismutase; Tannins | 2009 |
Glutathione regulation in arsenic-induced porcine aortic endothelial cells.
Topics: Animals; Aorta, Thoracic; Arsenates; Arsenic Trioxide; Arsenicals; Arsenites; Cells, Cultured; Endothelium, Vascular; gamma-Glutamyltransferase; Glutamate-Cysteine Ligase; Glutathione; Glutathione Disulfide; Oxides; RNA, Messenger; Sodium Compounds; Swine; Time Factors | 2008 |
Arsenic trioxide mutational spectrum analysis in the mouse lymphoma assay.
Topics: Animals; Arsenic Trioxide; Arsenicals; Biological Assay; Cell Line, Tumor; Leukemia L5178; Leukemia, Promyelocytic, Acute; Mice; Mutagenicity Tests; Oxides; Spectrum Analysis; Thymidine Kinase | 2008 |
Arsenic trioxide phosphorylates c-Fos to transactivate p21(WAF1/CIP1) expression.
Topics: Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; DNA-Binding Proteins; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutagenesis, Site-Directed; Oxides; Phosphorylation; Promoter Regions, Genetic; Proto-Oncogene Proteins c-fos; Transcriptional Activation | 2008 |
Folic acid or combination of folic acid and vitamin B(12) prevents short-term arsenic trioxide-induced systemic and mitochondrial dysfunction and DNA damage.
Topics: Animals; Antioxidants; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Biomarkers; Catalase; Chemoprevention; Dehydroascorbic Acid; DNA Damage; Drug Therapy, Combination; Folic Acid; Glutathione; Islets of Langerhans; Lymphocytes; Male; Mitochondria; Nitrites; Oxidative Stress; Oxides; Rats; Superoxide Dismutase; Vitamin B 12 | 2009 |
Oral arsenic treatment of leukemia and the risk of porphyria.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Oxides; Porphyrias; Porphyrins | 2009 |
The determination of arsenic pentoxide in white arsenic.
Topics: Arsenic; Arsenic Trioxide; Arsenicals; Humans; Oxides | 1948 |
The thioredoxin system mediates redox-induced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Aspirin; Gold Sodium Thiomalate; HT29 Cells; Humans; MAP Kinase Kinase Kinase 5; Mitogen-Activated Protein Kinases; NF-kappa B; Nitric Oxide Donors; Organophosphates; Oxidation-Reduction; Oxidative Stress; Oxides; Reactive Nitrogen Species; Reactive Oxygen Species; Thioredoxin-Disulfide Reductase; Thioredoxins | 2008 |
[Changes of activity and expression of protein phosphatase type 2A during the apoptosis of NB4 and MR2 cells induced by arsenic trioxide].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Humans; Oxides; Protein Phosphatase 2 | 2008 |
[Apoptosis of the adriamycin-resistant leukemia cell line induced by the recombinant mutant human TNF-related apoptosis-inducing ligand combined with arsenic trioxide].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Humans; K562 Cells; Oxides; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand | 2008 |
[Arsenic trioxide induces socs-1 gene demethylation in myeloma cell lines].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; CpG Islands; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Oxides; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling Proteins | 2008 |
Arsenic trioxide-induced growth arrest of human hepatocellular carcinoma cells involving FOXO3a expression and localization.
Topics: Androstadienes; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Forkhead Box Protein O3; Forkhead Transcription Factors; Humans; Liver Neoplasms; Metabolic Networks and Pathways; Oxides; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Wortmannin | 2009 |
Evaluation of the genotoxicity of treated urban sludge in the Tradescantia micronucleus assay.
Topics: Arsenic Trioxide; Arsenicals; Brazil; Dose-Response Relationship, Drug; Environmental Monitoring; Hydrogen-Ion Concentration; Micronucleus Tests; Oxides; Sewage; Time Factors; Tradescantia; Waste Disposal, Fluid; Water Purification | 2009 |
Catalase activity and arsenic sensitivity in acute leukemia.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Catalase; Cell Line, Tumor; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Oxides; Tumor Cells, Cultured | 2008 |
Detoxification system for inorganic arsenic: transformation of As2O3 into TMAO by vitamin B12 derivatives and conversion of TMAO into arsenobetaine.
Topics: Arsenic Trioxide; Arsenicals; Biomimetics; Glutathione; Iodoacetic Acid; Oxides; Vitamin B 12; Vitamin B Complex | 2008 |
Histopathological response of transitional cell carcinoma to arsenic trioxide during the treatment of concurrently diagnosed acute promyelocytic leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma, Transitional Cell; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Neoplasms, Multiple Primary; Oxides; Remission Induction; Tretinoin; Urinary Bladder Neoplasms | 2008 |
[Correlation of cell cycle alteration to SOCS-1 gene demethylation induced by arsenic trioxide in myeloma cell lines].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Methylation; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Multiple Myeloma; Oxides; RNA, Messenger; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling Proteins | 2008 |
Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia.
Topics: Arsenic Trioxide; Arsenicals; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Leukemia, Promyelocytic, Acute; Male; Mass Spectrometry; Middle Aged; Oxides; Recurrence; Remission Induction; Time Factors; Tretinoin | 2009 |
Apoptosis induction by (+)alpha-tocopheryl succinate in the absence or presence of all-trans retinoic acid and arsenic trioxide in NB4, NB4-R2 and primary APL cells.
Topics: alpha-Tocopherol; Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Growth Inhibitors; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Lipid Peroxidation; Oxides; Tretinoin | 2009 |
Antitumor effects of arsenic trioxide in transformed human thyroid cells.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Biological Transport, Active; Carcinoma, Papillary; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Glucose; Glutathione; Humans; Iodides; Iodine Radioisotopes; Oncogene Protein v-akt; Oxides; Phosphatidylinositol 3-Kinases; Radiation Tolerance; Reactive Oxygen Species; Thyroid Neoplasms | 2008 |
[Can As2O3 improve the prognosis of childhood acute promyelocytic leukemia?--A single center experience].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oncogene Proteins, Fusion; Oxides; Prognosis; Retrospective Studies; Treatment Outcome; Tretinoin | 2008 |
Evidence for basophilic differentiation of acute promyelocytic leukaemia cells during arsenic trioxide therapy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Basophils; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides | 2009 |
[New therapeutic perspectives for arsenic: from acute promyelocytic leukemia to autoimmune diseases].
Topics: Animals; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Autoimmune Diseases; Disease Models, Animal; Growth Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Lupus Erythematosus, Systemic; Lymphoproliferative Disorders; Mice; Oxides | 2008 |
Antitumor activity of arsenic trioxide on retinoblastoma: cell differentiation and apoptosis depending on arsenic trioxide concentration.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Caspase 3; Cell Cycle; Cell Differentiation; Cell Proliferation; Flow Cytometry; Humans; Hydrogen Peroxide; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Oxides; Phosphorylation; Retinal Neoplasms; Retinoblastoma; Tumor Cells, Cultured | 2009 |
[Study on inhibitory effect of arsenic trioxide on growth of rat C6 glioma cells].
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Glioma; Male; Oxides; Rats; Rats, Sprague-Dawley | 2008 |
Curative strategies in acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Cytarabine; Daunorubicin; Disease-Free Survival; Growth Inhibitors; History, 20th Century; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Neoplasm Recurrence, Local; Oxides; Tretinoin | 2008 |
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Administration Schedule; Female; Follow-Up Studies; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Polymerase Chain Reaction; Remission Induction; Survival Rate; Treatment Outcome; Tretinoin | 2009 |
Combination of DNA methylation inhibitor 5-azacytidine and arsenic trioxide has synergistic activity in myeloma.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Azacitidine; Base Sequence; Cell Line, Tumor; Disease Models, Animal; DNA Methylation; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Sequence Data; Neoplasm Proteins; Oxides; RNA, Messenger; Transcription, Genetic; Xenograft Model Antitumor Assays | 2009 |
Inhibition of interleukin-13 gene expression in T cells through GATA-3 pathway by arsenic trioxide.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Chromatin Immunoprecipitation; GATA3 Transcription Factor; Gene Expression; Humans; Immunoprecipitation; Interleukin-13; Mice; Oxides; Promoter Regions, Genetic; Protein Binding; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; T-Lymphocytes | 2008 |
Arsenic trioxide (As2O3) inhibits expression of estrogen receptor-alpha through regulation of the mitogen-activated protein kinase (MAPK) pathway in endometrial cancer cells.
Topics: Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Endometrial Neoplasms; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Oxides | 2008 |
[Effects of PML-RARalpha on cAMP-induced AML cell differentiation].
Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cyclic AMP; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Signal Transduction; Transfection | 2008 |
[Synergistic effects of VPA and As2O3 on Molt-4 cells in vitro and its possible mechanisms].
Topics: Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p15; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Oxides; Up-Regulation; Valproic Acid | 2008 |
[Effect of arsenic trioxide on vascular endothelial growth factor-C and its receptor (VEGFR-3) in nude mice with gastric cancer].
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Humans; Male; Mice; Mice, Nude; Oxides; Stomach Neoplasms; Vascular Endothelial Growth Factor C; Vascular Endothelial Growth Factor Receptor-3; Xenograft Model Antitumor Assays | 2008 |
[Apoptosis and cell cycle arrest in lymphoma Raji cells induced by arsenic trioxide].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Flow Cytometry; Humans; Lymphoma; Oxides | 2008 |
Increased aquaglyceroporin 9 expression disrupts arsenic resistance in human lung cancer cells.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Antineoplastic Agents; Aquaporins; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Deoxyguanosine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Glutathione; Humans; Lung Neoplasms; Oxides | 2009 |
Radiation-induced cathepsin S is involved in radioresistance.
Topics: Arsenic Trioxide; Arsenicals; Caspase 3; Cathepsins; Cell Line, Tumor; Cysteine Endopeptidases; Dose-Response Relationship, Radiation; Humans; Hydrogen Peroxide; Interferon Regulatory Factor-1; Interferon-gamma; Models, Biological; Oxides; Radiotherapy; Reactive Oxygen Species; Time Factors; Transfection | 2009 |
Induction of iodide uptake in transformed thyrocytes: a compound screening in cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Carcinoma; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Iodides; Lovastatin; Neoplasm Metastasis; Oxides; Pyrazines; Sirolimus; Thymus Gland; Thyroid Neoplasms; Tretinoin | 2009 |
Arsenic trioxide inhibits hepatitis C virus RNA replication through modulation of the glutathione redox system and oxidative stress.
Topics: Arsenic Trioxide; Arsenicals; Cell Line; Glutathione; Hepacivirus; Humans; Oxidation-Reduction; Oxidative Stress; Oxides; RNA, Viral; Superoxides; Virus Replication | 2009 |
Curing APL: differentiation or destruction?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Tretinoin | 2009 |
Co-application of arsenic trioxide (As2O3) and cisplatin (CDDP) on human SY-5Y neuroblastoma cells has differential effects on the intracellular calcium concentration ([Ca2+]i) and cytotoxicity.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Calcium; Cell Line, Tumor; Cisplatin; Cytotoxins; Drug Therapy, Combination; Humans; Intracellular Fluid; Neuroblastoma; Oxides | 2009 |
Global effects of inorganic arsenic on gene expression profile in human macrophages.
Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Down-Regulation; Gene Expression Profiling; Humans; Macrophages; Oxides; Up-Regulation | 2009 |
Inhibition of androgen receptor transcriptional activity as a novel mechanism of action of arsenic.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Nucleus; Cell Proliferation; Drug Evaluation, Preclinical; Drug Synergism; Humans; Male; Nitriles; Nuclear Receptor Coactivator 2; Oxides; Prostatic Neoplasms; Protein Binding; Protein Structure, Tertiary; Protein Transport; Receptors, Androgen; Response Elements; Tosyl Compounds; Transcriptional Activation; Tumor Cells, Cultured | 2009 |
Thermal behaviour of arsenic trioxide adsorbed on activated carbon.
Topics: Adsorption; Arsenates; Arsenic Trioxide; Arsenicals; Charcoal; Industrial Waste; Oxides; Temperature; Wood | 2009 |
Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Biomarkers; Caspase 3; Cell Death; Cell Differentiation; Cell Hypoxia; Cell Line, Tumor; Enzyme Activation; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Oxides; Small Cell Lung Carcinoma; Xenograft Model Antitumor Assays | 2009 |
As2O3 toxicity in rat hepatocytes: manifestation of caspase-mediated apoptosis.
Topics: Animals; Apoptosis; Apoptosis Inducing Factor; Arsenic Trioxide; Arsenicals; Blotting, Western; Caspase Inhibitors; Caspases; Cell Survival; Densitometry; Hepatocytes; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; JNK Mitogen-Activated Protein Kinases; Male; Models, Biological; Oxides; p38 Mitogen-Activated Protein Kinases; Polymerase Chain Reaction; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley | 2008 |
Hematopoietic stem cell differentiation affects expression and function of MRP4 (ABCC4), a transport protein for signaling molecules and drugs.
Topics: Antigens, CD34; Arsenic Trioxide; Arsenicals; Base Sequence; Blotting, Western; Cell Differentiation; Cholecalciferol; DNA Primers; Flow Cytometry; Hematopoietic Stem Cells; Humans; Microscopy, Fluorescence; Multidrug Resistance-Associated Proteins; Oxides; Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tetradecanoylphorbol Acetate | 2009 |
Tetra-arsenic oxide (Tetras) enhances radiation sensitivity of solid tumors by anti-vascular effect.
Topics: Angiogenesis Inhibitors; Animals; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Combined Modality Therapy; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Neoplasms; Neoplasm Transplantation; Neoplasms, Squamous Cell; Oxides; Radiation Tolerance; Transplantation, Heterologous | 2009 |
Combination treatment with arsenic trioxide and irradiation enhances apoptotic effects in U937 cells through increased mitotic arrest and ROS generation.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Cycle; Cell Division; Cyclin A; Cyclin B; Cytochromes c; Drug Screening Assays, Antitumor; G2 Phase; Humans; Mitochondrial Membranes; Mitosis; Oxides; Radiation, Ionizing; Reactive Oxygen Species; Tumor Cells, Cultured; Tumor Suppressor Protein p53; U937 Cells | 2009 |
[In vitro effect of bortezomib alone or in combination with harringtonine or arsenic trioxide on proliferation and apoptosis of multidrug resistant leukemia cells].
Topics: Adolescent; Adult; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Child; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Harringtonines; HL-60 Cells; Humans; Male; Oxides; Pyrazines; Young Adult | 2008 |
[Mechanism of arsenic trioxide induced apoptosis in cultured human lens epithelium cells].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cells, Cultured; Epithelial Cells; Humans; Lens, Crystalline; Oxides | 2008 |
Adsorption properties of As(III) and Cr(VI) in water environment by calcined gibbsite.
Topics: Adsorption; Aluminum Hydroxide; Arsenic Trioxide; Arsenicals; Chromates; Fresh Water; Hydrogen-Ion Concentration; Hydroxylation; Minerals; Oxides; Potassium Compounds; Thermodynamics; Water Supply; X-Ray Diffraction | 2009 |
Characterization of cytotoxicity induced by arsenic trioxide (a potent anti-APL drug) in rat cardiac myocytes.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Calcium; Cell Line, Tumor; Cell Survival; Leukemia, Promyelocytic, Acute; Myocytes, Cardiac; Oxides; Rats; Rats, Wistar; Reactive Oxygen Species | 2009 |
Arsenic-trioxide-induced apoptosis of chronic lymphocytic leukemia cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Oxides; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2010 |
Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.
Topics: Aquaporins; Arsenic Trioxide; Arsenicals; Gene Expression Regulation, Leukemic; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Prognosis; Survival Rate; Time Factors; Tretinoin | 2009 |
[Effect of As(2)O(3) on expressions of COX-2 and matrix metalloproteinases in SGC7901 and K562 cells].
Topics: Arsenic Trioxide; Arsenicals; Cyclooxygenase 2; Gene Expression Regulation, Leukemic; Humans; K562 Cells; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Oxides | 2009 |
[P27(Kip1), cyclin E and endogenous TGF-beta1 changes in apoptosis of NB4 cells induced by As(2)O(3) and/or TGF-beta1 and their significance].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cyclin E; Cyclin-Dependent Kinase Inhibitor p27; Humans; Oncogene Proteins; Oxides; Transforming Growth Factor beta1; Up-Regulation | 2009 |
Combination treatment with arsenic trioxide and irradiation enhances autophagic effects in U118-MG cells through increased mitotic arrest and regulation of PI3K/Akt and ERK1/2 signaling pathways.
Topics: Acridine Orange; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Cell Line, Tumor; Combined Modality Therapy; Cytoplasmic Vesicles; Dose-Response Relationship, Radiation; Extracellular Signal-Regulated MAP Kinases; Humans; MAP Kinase Signaling System; Membrane Potential, Mitochondrial; Microscopy, Fluorescence; Microtubule-Associated Proteins; Mitosis; Mitotic Index; Oxides; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Radiation, Ionizing; Time Factors | 2009 |
[Effects of As2O3 on apoptosis and Bcl-2/Bax expression of rat spermatogenic cells].
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Gene Expression; Male; Oxides; Proto-Oncogene Proteins c-bcl-2; Random Allocation; Rats; Rats, Sprague-Dawley; Spermatogonia | 2008 |
Reactive oxygen species are not required for an arsenic trioxide-induced antioxidant response or apoptosis.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Butylated Hydroxyanisole; Gene Expression Profiling; Growth Inhibitors; Heme Oxygenase-1; Humans; Multiple Myeloma; NF-E2-Related Factor 2; Oligonucleotide Array Sequence Analysis; Oxidative Stress; Oxides; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Subcellular Fractions | 2009 |
Survival after a massive overdose of arsenic trioxide.
Topics: Adolescent; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Chelating Agents; Critical Care; Hemofiltration; Humans; Male; Oxides; Parenteral Nutrition, Total; Suicide, Attempted | 2009 |
Gamma-glutamyltransferase-dependent resistance to arsenic trioxide in melanoma cells and cellular sensitization by ascorbic acid.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Catalase; Cell Line, Tumor; Cytoprotection; Drug Resistance, Neoplasm; Enzyme Activation; gamma-Glutamyltransferase; Gene Expression Regulation, Neoplastic; Growth Inhibitors; Humans; MAP Kinase Kinase Kinase 5; Melanoma; Oxidative Stress; Oxides | 2009 |
Antimony-trioxide- and arsenic-trioxide-induced apoptosis in myelogenic and lymphatic cell lines, recruitment of caspases, and loss of mitochondrial membrane potential are enhanced by modulators of the cellular glutathione redox system.
Topics: Antimony; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Caspase Inhibitors; Caspases; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Glutathione; HL-60 Cells; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, T-Cell; Membrane Potential, Mitochondrial; Neoplasm Proteins; Oxidation-Reduction; Oxides | 2009 |
Protein kinase C is involved in arsenic trioxide-induced apoptosis and inhibition of proliferation in human bladder cancer cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Activators; Humans; Oxides; Protein Kinase C; Protein Kinase Inhibitors; Signal Transduction; Tetradecanoylphorbol Acetate; Time Factors; Urinary Bladder Neoplasms | 2009 |
Arsenic trioxide affects the trace element balance in tissues in infected and healthy mice differently.
Topics: Animals; Arsenic Trioxide; Arsenicals; Brain; Female; Heart; Intestinal Mucosa; Intestines; Kidney; Liver; Lung; Mice; Mice, Inbred BALB C; Myocardium; Oxides; Pancreas; Trace Elements | 2009 |
Lung cancer mortality in arsenic-exposed workers from a cadmium recovery plant.
Topics: Aged, 80 and over; Arsenic Trioxide; Arsenicals; Cadmium; Cohort Studies; Colorado; Humans; Lung Neoplasms; Male; Occupational Diseases; Occupational Exposure; Oxides; Recycling; Time Factors | 2009 |
Possible roles of a tumor suppressor gene PIG11 in hepatocarcinogenesis and As2O3-induced apoptosis in liver cancer cells.
Topics: Adult; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Child; Cycloheximide; Dactinomycin; Down-Regulation; Female; Gene Expression; Gene Knockdown Techniques; Genes, Tumor Suppressor; Humans; Immunohistochemistry; Liver; Liver Neoplasms; Male; Middle Aged; Neoplasm Proteins; Nucleic Acid Synthesis Inhibitors; Oxides; Protein Synthesis Inhibitors | 2009 |
A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells.
Topics: Acetylcysteine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Growth Inhibitors; Humans; In Situ Nick-End Labeling; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Oxides; Pancreatic Neoplasms; Reactive Oxygen Species; Sesquiterpenes; Xenograft Model Antitumor Assays | 2009 |
Redox-sensitive regulation of gene expression in human primary macrophages exposed to inorganic arsenic.
Topics: Arsenic Trioxide; Arsenicals; Basic-Leucine Zipper Transcription Factors; Chemokine CXCL2; Gene Expression Regulation; Humans; Macrophages; NF-E2-Related Factor 2; Oxidation-Reduction; Oxides; Reactive Oxygen Species | 2009 |
Proteomic and functional analyses reveal a dual molecular mechanism underlying arsenic-induced apoptosis in human multiple myeloma cells.
Topics: 14-3-3 Proteins; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Electrophoresis, Gel, Two-Dimensional; Gene Knockdown Techniques; HSP90 Heat-Shock Proteins; Humans; Multiple Myeloma; Oxides; Protein Interaction Mapping; Proteome; Proteomics; RNA, Small Interfering; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Stress, Physiological; Ubiquitin-Protein Ligase Complexes | 2009 |
Effect of aqueous extracts of black and green teas in arsenic-induced toxicity in rabbits.
Topics: Animals; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Flavonoids; Glutathione; Nitrates; Nitrites; Oxidative Stress; Oxides; Phenols; Plant Extracts; Polyphenols; Rabbits; Tea; Thiobarbituric Acid Reactive Substances | 2009 |
Heat shock protein inhibitors, 17-DMAG and KNK437, enhance arsenic trioxide-induced mitotic apoptosis.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Benzhydryl Compounds; Benzoquinones; Dose-Response Relationship, Drug; Environmental Pollutants; Heat-Shock Proteins; HeLa Cells; Humans; Lactams, Macrocyclic; Mitosis; Oxides; Pyrrolidinones | 2009 |
[Role of P27(Kip1) and TGF-beta1 in APL cell apoptosis induced by As(2)O(3)].
Topics: Adolescent; Adult; Aged; Apoptosis; Arsenic Trioxide; Arsenicals; Cyclin-Dependent Kinase Inhibitor p27; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Transforming Growth Factor beta1; Tumor Cells, Cultured; Young Adult | 2009 |
Role of SUMO in RNF4-mediated promyelocytic leukemia protein (PML) degradation: sumoylation of PML and phospho-switch control of its SUMO binding domain dissected in living cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bacterial Proteins; Cell Line; Fluorescence Resonance Energy Transfer; Humans; In Vitro Techniques; Kidney; Leukemia, Promyelocytic, Acute; Luciferases, Renilla; Luminescent Measurements; Luminescent Proteins; Mutagenesis, Site-Directed; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Protein Binding; Protein Structure, Tertiary; SUMO-1 Protein; Transcription Factors; Transfection; Tumor Suppressor Proteins | 2009 |
[The significance of combined therapy of arsenic trioxide and all-trans retinoic acid in treating acute promyelocytic leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Retrospective Studies; Tretinoin; Young Adult | 2009 |
Direct toxicity assessment of toxic chemicals with electrochemical method.
Topics: Arsenic Trioxide; Arsenicals; Chlorophenols; Cyanates; Electrochemistry; Environmental Monitoring; Escherichia coli; Ferricyanides; Hydrogen-Ion Concentration; Metals, Heavy; Oxidation-Reduction; Oxides; Time Factors; Water Pollutants, Chemical | 2009 |
Arsenic trioxide suppresses paclitaxel-induced mitotic arrest.
Topics: Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line; Flow Cytometry; Humans; Microscopy, Fluorescence; Mitosis; Oxides; Paclitaxel | 2009 |
Downregulation of the c-MYC target gene, peroxiredoxin III, contributes to arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Base Sequence; Cell Line, Tumor; Chromatin Immunoprecipitation; DNA Primers; Down-Regulation; Genes, myc; Humans; Leukemia, Promyelocytic, Acute; Oxides; Peroxiredoxins; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering | 2009 |
Acute arsenic self-poisoning for suicidal purpose in a dentist: a case report.
Topics: Acute Disease; Aged; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Charcoal; Chelating Agents; Chelation Therapy; Dimercaprol; Gastric Lavage; Humans; Intubation, Gastrointestinal; Male; Oxides; Suicide, Attempted; Treatment Outcome | 2009 |
Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Line, Tumor; Cell Survival; Cysteine; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glutathione; Humans; Multiple Myeloma; Oxides | 2009 |
Subchronic exposure to arsenic decreased Sdha expression in the brain of mice.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antioxidants; Arsenic Trioxide; Arsenicals; Ascorbic Acid; ATP Synthetase Complexes; Brain; Computational Biology; Cytochromes c; Deoxyguanosine; Dose-Response Relationship, Drug; Electron Transport; Electron Transport Chain Complex Proteins; Electron Transport Complex III; Electron Transport Complex IV; Gene Expression Profiling; Gene Expression Regulation; Growth Inhibitors; Mice; Oligonucleotide Array Sequence Analysis; Oxides; Succinate Dehydrogenase; Taurine | 2009 |
Synergistic interaction between tetra-arsenic oxide and paclitaxel in human cancer cells in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Blotting, Western; Caspase 3; Cisplatin; Drug Interactions; Drug Synergism; Female; Fluorouracil; Head and Neck Neoplasms; Humans; In Vitro Techniques; Inhibitory Concentration 50; Oxides; Paclitaxel; Poly(ADP-ribose) Polymerases; Stomach Neoplasms; Tubulin; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Uterine Cervical Neoplasms | 2009 |
Enhancement of esculetin on arsenic trioxide-provoked apoptosis in human leukemia U937 cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Survival; Fluorescent Antibody Technique; Humans; Leukemia; Oxides; U937 Cells; Umbelliferones | 2009 |
Arsenic trioxide induces the apoptosis in vascular smooth muscle cells via increasing intracellular calcium and ROS formation.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Calcium; Dose-Response Relationship, Drug; Egtazic Acid; In Situ Nick-End Labeling; L-Lactate Dehydrogenase; Microscopy, Fluorescence; Muscle, Smooth, Vascular; Necrosis; Oxides; Rats; Reactive Oxygen Species | 2010 |
Modulation of p53, c-fos, RARE, cyclin A, and cyclin D1 expression in human leukemia (HL-60) cells exposed to arsenic trioxide.
Topics: Arsenic Trioxide; Arsenicals; Cyclin A1; Cyclin D1; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Neoplasm Proteins; Oxides; Proto-Oncogene Proteins c-fos; Response Elements; Tubulin; Tumor Suppressor Protein p53 | 2009 |
Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; G2 Phase; Gene Expression Regulation, Leukemic; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Metaphase; Neoplasm Proteins; Oxides; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-cbl; Signal Transduction; Stomach Neoplasms; Tumor Suppressor Protein p53; Ubiquitination; Up-Regulation | 2009 |
[Construction of subtractive cDNA library of apoptosis-related genes in NB4 cells treated by arsenic trioxide].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; DNA, Complementary; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Library; Humans; Leukemia, Promyelocytic, Acute; Nucleic Acid Hybridization; Oligonucleotide Array Sequence Analysis; Oxides; Sequence Analysis, DNA | 2009 |
MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Cycle; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Leukemia, Myeloid; Maximum Tolerated Dose; Membrane Potential, Mitochondrial; Mice; Oncogene Proteins, Fusion; Oxides; Reactive Oxygen Species; Succinates | 2010 |
Use of arsenic trioxide in secondary acute promyelocytic leukemia developing after treatment of multiple sclerosis with mitoxantrone.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Enzyme Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Male; Mitoxantrone; Multiple Sclerosis; Oxides; Remission Induction; Topoisomerase II Inhibitors; Treatment Outcome | 2009 |
[Immunofluorescence examination of CK-13 expression in cell line KB differentiated by all-trans retinoic acid or As2 O3].
Topics: Arsenic Trioxide; Arsenicals; Carcinoma, Squamous Cell; Cell Differentiation; Fluorescent Antibody Technique; Humans; KB Cells; Keratin-13; Mouth Neoplasms; Oxides; Tretinoin | 2009 |
[Effects of arsenic trioxide on human coronary smooth muscle cells: experiment in vitro].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cells, Cultured; Coronary Vessels; Humans; In Situ Nick-End Labeling; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Oxides | 2009 |
Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.
Topics: Adult; Aged; Arsenic Trioxide; Arsenicals; Blood Chemical Analysis; Bone Marrow; Cohort Studies; Confidence Intervals; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Monitoring, Physiologic; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Predictive Value of Tests; Probability; Prognosis; Proportional Hazards Models; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Severity of Illness Index; Survival Analysis; Treatment Outcome; Tretinoin | 2009 |
The overexpression of multidrug resistance-associated proteins and gankyrin contribute to arsenic trioxide resistance in liver and gastric cancer cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Oxides; Phosphorylation; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Retinoblastoma Protein; Stomach Neoplasms; Time Factors; Tumor Suppressor Protein p53; Up-Regulation; Verapamil | 2009 |
Arsenic trioxide associated toothache.
Topics: Arsenic Trioxide; Arsenicals; Humans; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Toothache; Tretinoin | 2010 |
Enhancement of arsenic trioxide cytotoxicity by dietary isothiocyanates in human leukemic cells via a reactive oxygen species-dependent mechanism.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Death; Drug Synergism; Humans; Isothiocyanates; Leukemia; Oxides; Reactive Oxygen Species; Sulfides; Sulfones; Sulfoxides; Thiocyanates; Tumor Cells, Cultured; Vegetables | 2010 |
Successful pregnancy after arsenic trioxide therapy for relapsed acute promyelocytic leukaemia.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Infant, Newborn; Leukemia, Promyelocytic, Acute; Male; Oxides; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Recurrence | 2009 |
Chromosomal aberrations in a fish, Channa punctata after in vivo exposure to three heavy metals.
Topics: Animals; Arsenic Trioxide; Arsenicals; Carcinogens; Chromosome Aberrations; Copper Sulfate; Fishes; Mercuric Chloride; Metals, Heavy; Mutagenicity Tests; Oxides; Water Pollutants, Chemical | 2009 |
Arsenic trioxide attenuated the rejection of major histocompatibility complex fully-mismatched cardiac allografts in mice.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cyclosporine; Graft Rejection; Graft Survival; Growth Inhibitors; Heart Transplantation; Histocompatibility Testing; Immunosuppressive Agents; Male; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Oxides; Transplantation, Homologous | 2009 |
[Influence of As(2)O(3) on proteasome beta(1)-subunit in NB4 cells].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Proteasome Endopeptidase Complex; Tumor Cells, Cultured | 2009 |
[Effect of arsenic trioxide on apoptosis in lymphoblastoid Raji cell line with relation to expression of mcl-1 gene].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Gene Expression; Humans; Membrane Potential, Mitochondrial; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Oxides; Proto-Oncogene Proteins c-bcl-2 | 2009 |
Effects of arsenic trioxide under different administration ways on T-cell lymphoma xenografts in nude mice: in vivo and in vitro experiments.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Female; Flow Cytometry; Inhibitory Concentration 50; Lymphoma, T-Cell; Male; Mice; Mice, Nude; Microscopy, Electron; Microscopy, Fluorescence; Neoplasms, Experimental; Oxides; Time Factors; Tumor Burden | 2009 |
Nanosized As2O3/Fe2O3 complexes combined with magnetic fluid hyperthermia selectively target liver cancer cells.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biocompatible Materials; Cell Line, Tumor; Female; Ferric Compounds; Humans; Hyperthermia, Induced; Liver Neoplasms; Magnetics; Male; Materials Testing; Medicine, Chinese Traditional; Mice; Mice, Nude; Nanospheres; Oxides; Random Allocation; Swine; Transplantation, Heterologous | 2009 |
Therapy-related acute promyelocytic leukemia: further insights into the molecular basis of the disease and showing the way forward in therapy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Medical Oncology; Neoplasms, Second Primary; Oxides; Translocation, Genetic; Treatment Outcome; Tretinoin | 2009 |
[Arsenic trioxide inhibits cell growth in imatinib-resistant bcr-abl mutant cell lines in vitro].
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Mutation; Nuclear Proteins; Oxides; Piperazines; Pyrimidines | 2009 |
Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Drug Carriers; Drug Delivery Systems; Female; Flow Cytometry; Folic Acid; Humans; Liposomes; Nanoparticles; Nasopharyngeal Neoplasms; Oxides; Tumor Cells, Cultured | 2009 |
Arsenic trioxide inhibits human t cell-lymphotropic virus-1-induced syncytiums by down-regulating gp46.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blotting, Western; Coculture Techniques; Down-Regulation; Gene Products, env; Giant Cells; HeLa Cells; Human T-lymphotropic virus 1; Humans; Oxides; Retroviridae Proteins, Oncogenic; T-Lymphocytes | 2009 |
Arsenic trioxide-induced apoptosis of Hep-2 cell line through modulating intracellular glutathione (GSH) level.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Squamous Cell; Cell Line, Tumor; Glutathione; Humans; Intracellular Space; Laryngeal Neoplasms; Membrane Potential, Mitochondrial; Oxides; Reactive Oxygen Species | 2010 |
[Effect of arsenic trioxide combined with adriamycin on the proliferation and apoptosis of human lymphoma cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Synergism; Humans; Lymphoma; Oxides | 2009 |
Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Drug Synergism; Enzyme Activation; HSP27 Heat-Shock Proteins; Humans; Multiple Myeloma; Oxides; p38 Mitogen-Activated Protein Kinases; Pyrazines; STAT3 Transcription Factor | 2010 |
[Effect of As2O3 on demethylation of SHP-1 gene in human lymphoma cell line T2].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; DNA Methylation; Dose-Response Relationship, Drug; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Lymphoma; Oxides; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Proto-Oncogene Proteins c-kit; RNA, Messenger; Signal Transduction | 2009 |
Size control of arsenic trioxide nanocrystals grown in nanowells.
Topics: Arsenic Trioxide; Arsenicals; Crystallization; Nanoparticles; Oxides; Particle Size; Pharmaceutical Preparations | 2009 |
[Clinical study on the fibrinolytic activity in patients with acute promyelocytic leukemia].
Topics: Adolescent; Adult; Aged; Annexin A2; Arsenic Trioxide; Arsenicals; Female; Fibrinolysis; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; RNA, Messenger; Tretinoin; Urokinase-Type Plasminogen Activator; Young Adult | 2009 |
Arsenic trioxide exerts synergistic effects with cisplatin on non-small cell lung cancer cells via apoptosis induction.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Synergism; Flow Cytometry; Humans; Lung Neoplasms; Oxides | 2009 |
[Effect of arsenic trioxide combined with aspirin on the growth of human gastric adenocarcinoma graft in nude mice].
Topics: Adenocarcinoma; Animals; Arsenic Trioxide; Arsenicals; Aspirin; bcl-2-Associated X Protein; Humans; Ki-67 Antigen; Mice; Mice, Nude; Neoplasm Transplantation; Oxides; Proto-Oncogene Proteins c-bcl-2; Stomach Neoplasms | 2009 |
Subchronic exposure to arsenic trioxide-induced oxidative DNA damage in kidney tissue of mice.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Arsenic Trioxide; Arsenicals; Deoxyguanosine; DNA Damage; Female; Immunohistochemistry; Kidney; Male; Mice; Mutagens; Oxides; Podocytes | 2010 |
Three epigenetic drugs up-regulate homeobox gene Rhox5 in cancer cells through overlapping and distinct molecular mechanisms.
Topics: Animals; Arsenic Trioxide; Arsenicals; Azacitidine; Benzamides; Cell Line, Tumor; Decitabine; DNA Modification Methylases; Epigenesis, Genetic; Genes, Homeobox; Growth Inhibitors; Histone Deacetylase Inhibitors; Homeodomain Proteins; Humans; Male; Mice; Oxides; Pyridines; Transcription Factors; Up-Regulation | 2009 |
Arsenic induces cell apoptosis in cultured osteoblasts through endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Calpain; Cells, Cultured; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Genes, bcl-2; Heat-Shock Proteins; Humans; Mice; Mitochondria; Osteoblasts; Oxides; Proto-Oncogene Proteins c-bcl-2 | 2009 |
Arsenic trioxide inhibits the growth of adriamycin resistant osteosarcoma cells through inducing apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Glutathione; Glutathione Transferase; Humans; Inhibitory Concentration 50; Intracellular Space; Multidrug Resistance-Associated Proteins; Osteosarcoma; Oxides | 2010 |
Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blindness; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Treatment Outcome | 2009 |
Modulation of arsenic trioxide-induced apoptosis by genistein and functionally related agents in U937 human leukaemia cells. Regulation by ROS and mitogen-activated protein kinases.
Topics: Adamantane; Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Catechin; Cell Cycle; Drug Synergism; Enzyme Activation; Estradiol; Etoposide; Genistein; HL-60 Cells; Humans; Hydroquinones; Immunoblotting; Microscopy, Fluorescence; Mitogen-Activated Protein Kinases; Oxides; Protein Kinase Inhibitors; Reactive Oxygen Species; RNA, Small Interfering; U937 Cells | 2009 |
Effects of arsenic trioxide on the cerulein-induced AR42J cells and its gene regulation.
Topics: Amylases; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Death; Cell Line, Tumor; Ceruletide; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; L-Lactate Dehydrogenase; Oligonucleotide Array Sequence Analysis; Oxides; Pancreatic Neoplasms | 2009 |
Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Chromatography, High Pressure Liquid; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides | 2010 |
Arsenic-induced pericardial and pleural effusion without acute promyelocytic leukemia differentiation syndrome.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Pericardial Effusion; Pleural Effusion | 2010 |
Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP,
Topics: Acute-Phase Proteins; Apoptosis; Arsenic Trioxide; Arsenicals; Ataxia Telangiectasia Mutated Proteins; Baculoviral IAP Repeat-Containing 3 Protein; bcl-X Protein; Carrier Proteins; Caspase 3; Cell Cycle Proteins; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Histone Acetyltransferases; Humans; I-kappa B Kinase; Inhibitor of Apoptosis Proteins; Lipocalin-2; Lipocalins; Lysine Acetyltransferase 5; Microtubule-Associated Proteins; Neoplasm Proteins; NF-kappa B; Nuclear Proteins; Oxides; Protein Serine-Threonine Kinases; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Proto-Oncogene Proteins; RNA, Messenger; RNA, Neoplasm; Sirtuin 1; Survivin; Transcription, Genetic; Tumor Protein p73; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases; X-Linked Inhibitor of Apoptosis Protein | 2010 |
Arsenic trioxide and cisplatin synergism increase cytotoxicity in human ovarian cancer cells: therapeutic potential for ovarian cancer.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cisplatin; Drug Synergism; Female; Gene Expression Profiling; Humans; Ovarian Neoplasms; Oxides | 2009 |
Arsenic trioxide modulates the central snail neuron action potential.
Topics: Action Potentials; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carbazoles; Estrenes; Neomycin; Neurons; Oxides; Pyrroles; Pyrrolidinones; Snails; Type C Phospholipases | 2009 |
Arsenic trioxide downregulates the expression of annexin II in bone marrow cells from patients with acute myelogenous leukemia.
Topics: Adult; Annexin A2; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Cell Survival; Cells, Cultured; Down-Regulation; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Reverse Transcriptase Polymerase Chain Reaction; Young Adult | 2009 |
Synergistic mitosis-arresting effects of arsenic trioxide and paclitaxel on human malignant lymphocytes.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; CDC2 Protein Kinase; Cells, Cultured; Drug Synergism; Humans; Jurkat Cells; Mitosis; Oxides; Paclitaxel; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tubulin Modulators | 2010 |
How I treat acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Examination; Dose-Response Relationship, Drug; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Outcome Assessment, Health Care; Oxides; Practice Guidelines as Topic; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin | 2009 |
Direct speciation analysis of arsenic in sub-cellular compartments using micro-X-ray absorption spectroscopy.
Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Hep G2 Cells; Humans; Intracellular Space; Organelles; Oxides; X-Ray Absorption Spectroscopy | 2010 |
Immunotoxicity and biodistribution analysis of arsenic trioxide in C57Bl/6 mice following a 2-week inhalation exposure.
Topics: Aerosols; Animals; Antibody Formation; Arsenic; Arsenic Trioxide; Arsenicals; Hemolytic Plaque Technique; Immunity, Cellular; Immunosuppressive Agents; Indicators and Reagents; Inhalation Exposure; Killer Cells, Natural; Lung; Lymphocyte Count; Lymphocyte Subsets; Male; Mice; Mice, Inbred C57BL; Mitogens; Mitosis; Oxides; Receptors, Cell Surface; Spleen; Tissue Distribution | 2009 |
Thermochemotherapy effect of nanosized As2O3/Fe3O4 complex on experimental mouse tumors and its influence on the expression of CD44v6, VEGF-C and MMP-9.
Topics: Animals; Arsenic Trioxide; Arsenicals; Female; Ferrosoferric Oxide; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Hyaluronan Receptors; Hyperthermia, Induced; Matrix Metalloproteinase 9; Metal Nanoparticles; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Oxides; Vascular Endothelial Growth Factor C; Xenograft Model Antitumor Assays | 2009 |
Arsthinol nanosuspensions: pharmacokinetics and anti-leukaemic activity on NB4 promyelocytic leukaemia cells.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Brain; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Female; Humans; Melarsoprol; Mice; Mice, Inbred Strains; Nanotechnology; Oxides; Suspensions | 2009 |
Mobilization of PML/RARalpha negative peripheral blood stem cells with a combination of G-CSF and CXCR4 blockade in relapsed acute promyelocytic leukemia pre-treated with arsenic trioxide.
Topics: Adult; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oxides; Peripheral Blood Stem Cell Transplantation; Promyelocytic Leukemia Protein; Receptors, CXCR4; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Secondary Prevention; Transcription Factors; Tumor Suppressor Proteins | 2010 |
Arsenic trioxide in a hemodialytic patient with acute promyelocytic leukemia.
Topics: Acute Kidney Injury; Aged; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Renal Dialysis | 2009 |
Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Child; Combined Modality Therapy; Female; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Myeloablative Agonists; Oncogene Proteins, Fusion; Oxides; Peripheral Blood Stem Cell Transplantation; Recurrence; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Tretinoin; Young Adult | 2009 |
Arsenic trioxide inhibits metastatic potential of mouse hepatoma H22 cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Liver Neoplasms; Lung Neoplasms; Male; Matrix Metalloproteinase 2; Mice; NM23 Nucleoside Diphosphate Kinases; Oxides; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2009 |
Arsenic trioxide inhibits the growth of human lung cancer cell lines via cell cycle arrest and induction of apoptosis at both normoxia and hypoxia.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; CDC2 Protein Kinase; Cell Cycle; Cell Hypoxia; Cell Line; Cyclin B; Cyclin B1; Cyclin-Dependent Kinases; Down-Regulation; Humans; Lung Neoplasms; Oxides; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 2009 |
Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome.
Topics: Anti-Inflammatory Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Chemokine CCL2; Chemokine CCL24; Chemokine CCL7; Chemokines; Dexamethasone; Enzyme-Linked Immunosorbent Assay; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Oligonucleotide Array Sequence Analysis; Oxides; Receptors, Retinoic Acid; Reverse Transcriptase Polymerase Chain Reaction; Syndrome; Tretinoin; Tumor Cells, Cultured | 2009 |
The effect of MAPK inhibitors on arsenic trioxide-treated Calu-6 lung cells in relation to cell death, ROS and GSH levels.
Topics: Adenocarcinoma; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Drug Synergism; Glutathione; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Membrane Potential, Mitochondrial; Mitogen-Activated Protein Kinases; Oxides; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Reactive Oxygen Species | 2009 |
Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2009 |
Evidence that endoplasmic reticulum (ER) stress and caspase-4 activation occur in human neutrophils.
Topics: Activating Transcription Factor 6; Arsenic Trioxide; Arsenicals; Caspases, Initiator; Cells, Cultured; DNA-Binding Proteins; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Enzyme Activation; Eukaryotic Initiation Factor-2; Heat-Shock Proteins; Humans; Neutrophils; Oxides; Protein Folding; Regulatory Factor X Transcription Factors; Stress, Physiological; Transcription Factor CHOP; Transcription Factors; X-Box Binding Protein 1 | 2010 |
Sublethal exposure of heavy metals induces micronuclei in fish, Channa punctata.
Topics: Animals; Arsenic Trioxide; Arsenicals; Copper Sulfate; Environmental Exposure; Mercuric Chloride; Metals, Heavy; Micronucleus Tests; Oxides; Perciformes; Water Pollutants, Chemical | 2009 |
TRIM5alpha and TRIMCyp form apparent hexamers and their multimeric state is not affected by exposure to restriction-sensitive viruses or by treatment with pharmacological inhibitors.
Topics: Animals; Aotidae; Arsenic Trioxide; Arsenicals; Cell Line; Cyclosporine; Enzyme Inhibitors; Leupeptins; Macaca mulatta; Mice; Oxides; Protein Multimerization; Proteins; Ubiquitin-Protein Ligases | 2009 |
Evaluation of adverse cardiac effects induced by arsenic trioxide, a potent anti-APL drug.
Topics: Action Potentials; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Dose-Response Relationship, Drug; Drug Antagonism; Edema, Cardiac; Guinea Pigs; Heart; Leukemia, Promyelocytic, Acute; Male; Membrane Transport Modulators; Myocardium; Oxidants; Oxides; Oxidoreductases; Vasodilator Agents | 2009 |
A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Arsenic Trioxide; Arsenicals; Biotransformation; Female; Humans; Karnofsky Performance Status; Kidney Diseases; Male; Methylation; Middle Aged; Neoplasms; Oxides | 2010 |
Syk is a novel target of arsenic trioxide (ATO) and is involved in the toxic effect of ATO in human neutrophils.
Topics: Antineoplastic Agents; Antisense Elements (Genetics); Apoptosis; Arsenic Trioxide; Arsenicals; Cell Adhesion; Cell Degranulation; Cell Separation; Enzyme Activation; Enzyme Inhibitors; Humans; In Vitro Techniques; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Neutrophils; Oxides; Phagocytosis; Phosphorylation; Protein-Tyrosine Kinases; Spleen; Stilbenes; Syk Kinase | 2010 |
Effect of colloidal gold nanoparticles on cell interface and their enhanced intracellular uptake of arsenic trioxide in leukemia cancer cells.
Topics: Arsenic Trioxide; Arsenicals; Colloids; Electrochemistry; Gold; Humans; K562 Cells; Leukemia; Metal Nanoparticles; Oxides | 2009 |
Isopathic treatment effects of Arsenicum album 45x on wheat seedling growth--further reproduction trials.
Topics: Arsenic Trioxide; Arsenicals; Culture Techniques; Germination; Oxides; Seedlings; Sulfhydryl Reagents; Triticum; Water | 2009 |
[As2O3 induces demethylation and up-regulates transcription of SHP-1 gene in human lymphoma cell line T2 cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; CpG Islands; DNA Methylation; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Oxides; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Proto-Oncogene Proteins c-kit; RNA, Messenger; Transcriptional Activation; Up-Regulation | 2009 |
[Apoptosis of MR2 cells induced by Tanshinone II A combined with arsenic trioxide].
Topics: Abietanes; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Oxides; Phenanthrenes; Tretinoin | 2009 |
[Study on the mechanism of arsenic trioxide inhibiting NB4 cells proliferation].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Proliferation; Humans; Janus Kinase 1; Oxides; Signal Transduction; Tumor Cells, Cultured | 2009 |
Effects of arsenic trioxide on cell death, reactive oxygen species and glutathione levels in different cell types.
Topics: Adenocarcinoma; Animals; Arsenic Trioxide; Arsenicals; Cattle; Cell Death; Cell Line; Cell Line, Tumor; Cell Proliferation; Endothelial Cells; Glutathione; Growth Inhibitors; HeLa Cells; Humans; Lung Neoplasms; Oxides; Reactive Oxygen Species | 2010 |
Berbamine, a novel nuclear factor kappaB inhibitor, inhibits growth and induces apoptosis in human myeloma cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzylisoquinolines; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Dexamethasone; DNA-Binding Proteins; Doxorubicin; G1 Phase; Humans; I-kappa B Kinase; Intracellular Signaling Peptides and Proteins; Multiple Myeloma; NF-kappa B; Nuclear Proteins; Oxides; Plasma Cells; Signal Transduction; Tumor Necrosis Factor alpha-Induced Protein 3 | 2009 |
Preparation, characterization, in vivo and in vitro studies of arsenic trioxide Mg-Fe ferrite magnetic nanoparticles.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Carriers; Ferric Compounds; Glycolates; Iron; Kidney; Lactic Acid; Liver; Magnesium; Magnetics; Metal Nanoparticles; Mice; Oxides; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2009 |
Arsenic trioxide-mediated Notch pathway inhibition depletes the cancer stem-like cell population in gliomas.
Topics: Animals; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Cell Line, Tumor; Down-Regulation; Glioblastoma; Humans; Intermediate Filament Proteins; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplastic Stem Cells; Nerve Tissue Proteins; Nestin; Oxides; Receptors, Notch; Signal Transduction | 2010 |
[Effect of arsenic pentaoxide on proliferation and apoptosis of human umbilical vein endothelial cell].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line; Cell Proliferation; Human Umbilical Vein Endothelial Cells; Humans; Oxides | 2009 |
[Comparison of efficacy and adverse effects between arsenic trioxide and all-trans retinoic acid in patients with acute promyelocytic leukemia].
Topics: Adolescent; Adult; Aged; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Retrospective Studies; Treatment Outcome; Tretinoin; Young Adult | 2009 |
Arsenic trioxide inhibits cholangiocarcinoma cell growth and induces apoptosis.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Separation; Cholangiocarcinoma; Flow Cytometry; Humans; Oxides; Signal Transduction | 2010 |
Arsenic trioxide and olanzapine co-administration: case analysis.
Topics: Adult; Antineoplastic Agents; Antipsychotic Agents; Arsenic Trioxide; Arsenicals; Benzodiazepines; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Electrocardiography; Humans; Leukemia, Promyelocytic, Acute; Long QT Syndrome; Male; Mental Disorders; Olanzapine; Oxides; Patient Safety; Risk Factors | 2011 |
Different pathways are involved in arsenic-trioxide-induced cell proliferation and growth inhibition in human keratinocytes.
Topics: Adolescent; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Squamous Cell; Caspase 3; Cell Cycle; Cell Enlargement; Cell Line; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Gene Expression Regulation; Humans; Keratinocytes; Male; Oxides; Skin Neoplasms | 2010 |
[Retrospective analysis of 76 children with acute promyelocytic leukemia].
Topics: Adolescent; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Retrospective Studies; Survival Rate; Treatment Outcome | 2009 |
Successful post-remission therapy with a combination of all-trans retinoic acid and arsenic trioxide in an elderly Japanese patient newly diagnosed with acute promyelocytic leukemia.
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Asian People; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Tretinoin | 2010 |
Down-regulation of heat shock protein 70 improves arsenic trioxide and 17-DMAG effects on constitutive signal transducer and activator of transcription 3 activity.
Topics: Algorithms; Apoptosis; Arsenic Trioxide; Arsenicals; Benzoquinones; Blotting, Western; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Electroporation; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Oxides; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; STAT3 Transcription Factor | 2010 |
Gangrenous cheilitis associated with all-trans retinoic acid therapy for acute promyelocytic leukemia.
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biopsy; Cheilitis; Female; Gangrene; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2010 |
Growth-inhibiting effects of arsenic trioxide plus epigenetic therapeutic agents on leukemia cell lines.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Azacitidine; Cell Proliferation; Cell Survival; Decitabine; DNA Methylation; DNA Modification Methylases; DNA, Neoplasm; Drug Antagonism; Drug Synergism; Electrophoresis, Capillary; Growth Inhibitors; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Hydroxamic Acids; K562 Cells; Leukemia; Oxides; U937 Cells; Valproic Acid | 2010 |
Potent reducing effects of vitamin D3 on the frequency of apoptosis induced by arsenic trioxide in NB4 cell line.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Cholecalciferol; Dose-Response Relationship, Drug; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2010 |
[Study on reproductive and immune toxicity of male rats exposed to As2O3].
Topics: Animals; Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Environmental Exposure; Epididymis; Immunity; Male; Mice; Oxides; Sperm Count; Spleen; Testis | 2009 |
Omega-3 and omega-6 polyunsaturated fatty acids enhance arsenic trioxide efficacy in arsenic trioxide-resistant leukemic and solid tumor cells.
Topics: Antineoplastic Agents; Apoptosis; Arachidonic Acid; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Fatty Acids, Omega-3; Fatty Acids, Omega-6; Humans; Leukemia; Lipid Peroxidation; Neoplasms; Oxides; Vitamin E | 2009 |
Blockage of JNK pathway enhances arsenic trioxide-induced apoptosis in human keratinocytes.
Topics: Anthracenes; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Humans; JNK Mitogen-Activated Protein Kinases; Keratinocytes; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 8; Oxides; Phosphorylation | 2010 |
[Induced RAS association domain family gene 1A gene expression by arsenic trioxide in nasopharyngeal carcinoma cell].
Topics: Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Line, Tumor; DNA Methylation; Gene Expression; Humans; Nasopharyngeal Neoplasms; Oxides; RNA, Messenger; Tumor Suppressor Proteins | 2009 |
Arsenic trioxide induces the apoptosis in bone marrow mesenchymal stem cells by intracellular calcium signal and caspase-3 pathways.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Marrow; Calcium; Calcium Signaling; Caspase 3; Cell Proliferation; Cell Survival; Male; Mesenchymal Stem Cells; Metabolic Networks and Pathways; Oxides; Rats; Rats, Sprague-Dawley | 2010 |
Phosphatidylserine exposure and procoagulant activity in acute promyelocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Coagulation; Blood Coagulation Tests; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Survival; Daunorubicin; Etoposide; Factor Xa; Female; Flow Cytometry; Humans; Leukemia, Promyelocytic, Acute; Male; Membrane Glycoproteins; Microscopy, Confocal; Milk Proteins; Oxides; Phosphatidylserines; Thrombin; Thromboplastin; Tretinoin; Young Adult | 2010 |
Autophagy modification augmented the treatment effects initiated by arsenic trioxide in NB4 cells.
Topics: Adenine; Antibiotics, Antineoplastic; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Cell Line, Tumor; Cell Survival; Flow Cytometry; Humans; Leukemia, Promyelocytic, Acute; Oxides; Sirolimus | 2011 |
Effect of arsenic trioxide on renal functions and its modulation by Curcuma aromatica leaf extract in albino rat.
Topics: Animals; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Creatinine; Curcuma; Kidney; Lethal Dose 50; Oxides; Phytotherapy; Plant Extracts; Plant Leaves; Protective Agents; Rats; Rats, Wistar; Urea; Uric Acid | 2009 |
Arsenic trioxide-mediated antiplatelet activity: pivotal role of the phospholipase C gamma 2-protein kinase C-p38 MAPK cascade.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Platelets; Cell Adhesion Molecules; Collagen; Enzyme Activation; Humans; Hydroxyl Radical; In Vitro Techniques; Leukemia, Promyelocytic, Acute; MAP Kinase Signaling System; Microfilament Proteins; Oxides; p38 Mitogen-Activated Protein Kinases; Phospholipase C gamma; Phosphoproteins; Phosphorylation; Platelet Activation; Platelet Aggregation Inhibitors; Protein Kinase C | 2010 |
Non-lethal bone marrow necrosis under first-line arsenic trioxide therapy in acute promyelocytic leukaemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Necrosis; Oxides; Treatment Outcome | 2010 |
[Correlation between mTOR signaling transduction pathway and arsenic trioxide response].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Humans; K562 Cells; Oxides; Signal Transduction; TOR Serine-Threonine Kinases | 2010 |
Arsenic trioxide induces endoplasmic reticulum stress-related events in neutrophils.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Calcineurin; Calcium; Caspase Inhibitors; Caspases; Caspases, Initiator; Cell Separation; Cells, Cultured; Endoplasmic Reticulum; Enzyme Activation; Humans; Neutrophils; Oxides; Reverse Transcriptase Polymerase Chain Reaction; Ubiquinone | 2010 |
miRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Cycle; Cell Proliferation; Flow Cytometry; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; MicroRNAs; Oxides; Reverse Transcriptase Polymerase Chain Reaction; RNA-Binding Proteins; RNA, Messenger; Tumor Cells, Cultured | 2011 |
Anti-miR-21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Cell Cycle; G1 Phase; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Oligonucleotides; Oxides; RNA-Binding Proteins; Up-Regulation | 2010 |
Arsenic trioxide-dependent activation of thousand-and-one amino acid kinase 2 and transforming growth factor-beta-activated kinase 1.
Topics: Acetylcysteine; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Dithiothreitol; Enzyme Activation; Genetic Variation; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Kinase Kinases; Oxides; Phosphorylation; Protein Kinases; Reactive Oxygen Species; RNA, Small Interfering; Tretinoin; U937 Cells | 2010 |
Effect of arsenic trioxide (Trisenox) on actin organization in K-562 erythroleukemia cells.
Topics: Actins; Apoptosis; Arsenic Trioxide; Arsenicals; Cytoplasm; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; Leukemia, Erythroblastic, Acute; Microscopy, Fluorescence; Oxides; Tumor Cells, Cultured | 2009 |
The expression of p38, ERK1 and Bax proteins has increased during the treatment of newly diagnosed acute promyelocytic leukemia with arsenic trioxide.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Blotting, Western; Bone Marrow; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitogen-Activated Protein Kinase 3; Neoplasm Staging; Oxides; p38 Mitogen-Activated Protein Kinases; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Curcumin supplementation protects from genotoxic effects of arsenic and fluoride.
Topics: Adult; Aneuploidy; Antimutagenic Agents; Antioxidants; Arsenic Trioxide; Arsenicals; Cells, Cultured; Chromosome Aberrations; Chromosome Breakage; Comet Assay; Curcumin; DNA Damage; Humans; Lymphocytes; Oxides; Phytohemagglutinins; Sodium Fluoride; Young Adult | 2010 |
Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro.
Topics: Amino Acid Chloromethyl Ketones; Amitrole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; Ascorbic Acid; B-Lymphocytes; Buthionine Sulfoximine; Catalase; Cell Line, Tumor; Cysteine Proteases; Cysteine Proteinase Inhibitors; Drug Evaluation, Preclinical; Drug Synergism; Enzyme Activation; Glutathione; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Oxidants; Oxidative Stress; Oxides; Reactive Oxygen Species | 2010 |
Awakening dormant haematopoietic stem cells.
Topics: Animals; Arsenic Trioxide; Arsenicals; Bone Marrow; Cell Growth Processes; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Activation; Mice; Oxides; Stem Cell Niche | 2010 |
External auditory canal and middle ear relapse of acute promyelocytic leukemia treated with arsenic trioxide: case report and review of the literature.
Topics: Arsenic Trioxide; Arsenicals; Child; Ear Canal; Ear Neoplasms; Ear, Middle; Female; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Oxides; Treatment Outcome | 2010 |
Keratin 6 expression correlates to areas of squamous differentiation in multiple independent isolates of As(+3)-induced bladder cancer.
Topics: Animals; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Carcinogens; Carcinoma, Transitional Cell; Cell Line, Transformed; Cell Line, Tumor; Cell Transformation, Neoplastic; Gene Expression Regulation, Neoplastic; Humans; Keratin-6; Mice; Mice, Nude; Neoplasm Transplantation; Oxides; Urinary Bladder Neoplasms; Urothelium | 2010 |
VDAC1 cysteine residues: topology and function in channel activity and apoptosis.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cattle; Cysteine; Electrophoresis, Polyacrylamide Gel; Ethylmaleimide; Fluoresceins; Humans; Hydrogen Peroxide; Immunoblotting; Lipid Bilayers; Mice; Mitochondrial Membranes; Oxides; Rabbits; Rats; RNA, Small Interfering; Sodium Selenite; Structure-Activity Relationship; Voltage-Dependent Anion Channel 1 | 2010 |
Combination treatment with arsenic trioxide and irradiation enhances cell-killing effects in human fibrosarcoma cells in vitro and in vivo through induction of both autophagy and apoptosis.
Topics: Adult; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Cell Cycle; Cell Line, Tumor; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Fibrosarcoma; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, SCID; Neoplasm Transplantation; Oxides | 2010 |
Genistein synergizes with arsenic trioxide to suppress human hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Caspase 9; Cell Line, Tumor; Cell Survival; Drug Synergism; Genistein; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Oxides; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2010 |
Gefitinib enhances arsenic trioxide (AS2O3)-induced differentiation of acute promyelocytic leukemia cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Leukemia, Promyelocytic, Acute; Oxides; Quinazolines | 2010 |
Sodium cacodylate and arsenic trioxide in anaplasmosis of cattle.
Topics: Anaplasmosis; Animals; Arsenic Trioxide; Arsenicals; Cacodylic Acid; Cattle; Oxides; Sodium | 1947 |
Successful imatinib and arsenic trioxide combination therapy for sudden onset promyelocytic crisis with t(15;17) in chronic myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Blast Crisis; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Prognosis; Pyrimidines; Translocation, Genetic | 2010 |
Arsenic inhibits myogenic differentiation and muscle regeneration.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Survival; Cells, Cultured; Creatine Kinase; Dose-Response Relationship, Drug; Growth Inhibitors; Humans; Immunoblotting; Immunohistochemistry; Mice; Muscle, Skeletal; Myoblasts; Oxides; Phosphorylation; Proto-Oncogene Proteins c-akt; Regeneration; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction | 2010 |
Differential role of cathepsins B and L in autophagy-associated cell death induced by arsenic trioxide in U87 human glioblastoma cells.
Topics: Adenine; Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Caspases; Cathepsin B; Cathepsin L; Cell Line, Tumor; Dipeptides; Down-Regulation; Epoxy Compounds; Glioblastoma; Humans; Macrolides; Oxides; Pyridines | 2010 |
Inhibition of liver x receptor/retinoid X receptor-mediated transcription contributes to the proatherogenic effects of arsenic in macrophages in vitro.
Topics: Animals; Apolipoprotein A-I; Arsenic Trioxide; Arsenicals; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Binding Sites; Biological Transport; Chlorocebus aethiops; Cholesterol; Chromatin Immunoprecipitation; Co-Repressor Proteins; COS Cells; Cyclic AMP; DNA-Binding Proteins; Dose-Response Relationship, Drug; Humans; Liver X Receptors; Macrophages; Mice; Orphan Nuclear Receptors; Oxides; Promoter Regions, Genetic; Protein Multimerization; Retinoid X Receptor alpha; Retinoid X Receptor beta; RNA Interference; RNA, Messenger; Signal Transduction; Sterol Regulatory Element Binding Protein 1; Transcriptional Activation; Transfection | 2010 |
Treatment of therapy related acute promyelocytic leukemia with the combination of all trans retinoic acid and arsenic trioxide without chemotherapy: a series of three patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Choriocarcinoma; Female; Humans; Kidney Neoplasms; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neuroectodermal Tumors; Ovarian Neoplasms; Oxides; Prognosis; Tretinoin | 2010 |
Ascorbic acid improves mitochondrial function in liver of arsenic-treated rat.
Topics: Adenosine Diphosphate; Adenosine Triphosphatases; Animals; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Caspase 3; Dose-Response Relationship, Drug; Histocytochemistry; Liver; Male; Mitochondria, Liver; Oxidative Phosphorylation; Oxides; Rats; Rats, Wistar; Succinate Dehydrogenase | 2010 |
Antitumor effect and mechanisms of arsenic trioxide on subcutaneously implanted human gastric cancer in nude mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma; Cell Proliferation; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Oxides; Stomach Neoplasms; Subcutaneous Tissue; Transplantation, Heterotopic; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
[Apoptosis of NB4 cells induced by Tanshinone II A combined with arsenic trioxide].
Topics: Abietanes; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2010 |
Arsenic trioxide and promyelocytic leukemia protein-adenovirus synergistically inhibit in vitro and in vivo growth of a hepatoma cell line.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Proliferation; Combined Modality Therapy; Drug Synergism; Flow Cytometry; Genetic Therapy; In Vitro Techniques; Liver Neoplasms, Experimental; Mice; Mice, Nude; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2010 |
Medicine. Poisonous contacts.
Topics: Arsenic; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Mutant Proteins; Mutation; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Protein Multimerization; Transcription Factors; Tumor Suppressor Proteins; Zinc Fingers | 2010 |
Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.
Topics: Arsenic; Arsenic Trioxide; Arsenicals; Cell Line; Humans; Leukemia, Promyelocytic, Acute; Mutant Proteins; Mutation; Nuclear Proteins; Oncogene Proteins, Fusion; Oxazines; Oxides; Promyelocytic Leukemia Protein; Protein Conformation; Protein Multimerization; Protein Structure, Secondary; Protein Structure, Tertiary; Receptors, Retinoic Acid; Recombinant Fusion Proteins; Retinoic Acid Receptor alpha; Small Ubiquitin-Related Modifier Proteins; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Transcription Factors; Tumor Suppressor Proteins; Ubiquitination; Zinc Fingers | 2010 |
Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxides; Radiotherapy Planning, Computer-Assisted; Temozolomide; Tomography, X-Ray Computed; Treatment Failure; Tumor Burden; Young Adult | 2011 |
The conformation change of Bcl-2 is involved in arsenic trioxide-induced apoptosis and inhibition of proliferation in SGC7901 human gastric cancer cells.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Blotting, Western; Cell Proliferation; Flow Cytometry; Fluorescent Antibody Technique; Humans; Oxides; Protein Conformation; Proto-Oncogene Proteins c-bcl-2; Stomach Neoplasms; Tumor Cells, Cultured | 2010 |
XPC silencing sensitizes glioma cells to arsenic trioxide via increased oxidative damage.
Topics: Arsenic Trioxide; Arsenicals; Autophagy; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cellular Senescence; DNA-Binding Proteins; Fluorescent Antibody Technique; Gene Silencing; Glioma; Humans; Oxidative Stress; Oxides; RNA, Small Interfering | 2010 |
Relapsed APL patient with variant NPM-RARalpha fusion responded to arsenic trioxide-based therapy and achieved long-term survival.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction | 2010 |
Glutathione depletion enhances arsenic trioxide-induced apoptosis in lymphoma cells through mitochondrial-independent mechanisms.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Glutathione; Humans; Lymphoma; Mitochondria; Oxides | 2010 |
[Arsenic trioxide reverses hypermethylation of p16 and activates its transcription in malignant lymphoma cell line CA46].
Topics: Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; DNA Methylation; Genes, p16; Humans; Lymphoma; Oxides; Transcriptional Activation | 2010 |
All-trans retinoic acid and arsenic rescue patients with acute promyelocytic leukemia from a potential 'perfect storm'.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Neoplasms; Oxides; Prognosis; Tretinoin | 2010 |
Antiangiogenic therapy in myelodysplastic syndromes: is there a role?
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; Bevacizumab; Clinical Trials as Topic; Drug Approval; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Lenalidomide; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Protein-Tyrosine Kinases; Thalidomide | 2008 |
Arsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growth.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Proliferation; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Oxides; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sp Transcription Factors; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2010 |
Combination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Carbamates; Cell Line, Tumor; Cell Proliferation; Cell Separation; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; Fluorescent Antibody Technique; Heterocyclic Compounds, 3-Ring; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Neoplasms, Experimental; Oxides; Signal Transduction; Xenograft Model Antitumor Assays | 2010 |
Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Transformation, Neoplastic; Gene Expression Regulation, Neoplastic; Granulocyte Precursor Cells; Humans; Leukemia, Promyelocytic, Acute; Mice; Oncogene Proteins, Fusion; Oncogenes; Oxides; Tretinoin | 2010 |
Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Separation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Female; Flow Cytometry; Gene Expression; Genes, cdc; Humans; In Situ Nick-End Labeling; Oligonucleotide Array Sequence Analysis; Oxides; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Transfection | 2011 |
Retrospective study of arsenic trioxide for childhood acute promyelocytic leukemia in China: a single-center experience.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow; Child; Child, Preschool; China; Disseminated Intravascular Coagulation; Female; Humans; Incidence; Leukemia, Promyelocytic, Acute; Male; Oxides; Retrospective Studies; Treatment Outcome; Tretinoin | 2010 |
[Study on the sensitivity of leukemic cells to arsenic trioxide enhanced by targeted suppression of mIRNA-21].
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Gene Expression Regulation, Leukemic; Humans; K562 Cells; MicroRNAs; Oligonucleotides, Antisense; Oxides; RNA-Binding Proteins; Transfection | 2010 |
Arsenic Trioxide overcomes cell adhesion-mediated drug resistance through down-regulating the expression of beta(1)-integrin in K562 chronic myelogenous leukemia cell line.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Bone Marrow Cells; Cell Adhesion; Cell Survival; Cells, Cultured; Coculture Techniques; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Humans; Inhibitory Concentration 50; Integrin beta1; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Stromal Cells | 2010 |
Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Blast Crisis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 8; Cell Cycle; Cell Proliferation; Drug Synergism; Gene Expression Profiling; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Myeloproliferative Disorders; NF-kappa B; Oligonucleotide Array Sequence Analysis; Oxides; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; Receptors, TNF-Related Apoptosis-Inducing Ligand; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand | 2010 |
Development and modeling of arsenic-trioxide-loaded thermosensitive liposomes for anticancer drug delivery.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Arsenic Trioxide; Arsenicals; Calorimetry, Differential Scanning; Gels; Humans; Lipid Bilayers; Liposomes; Molecular Dynamics Simulation; Neoplasms; Oxides; Permeability; Phase Transition; Phosphatidylcholines; Transition Temperature | 2011 |
Arsenic trioxide alleviates airway hyperresponsiveness and eosinophilia in a murine model of asthma.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Cells, Cultured; Disease Models, Animal; Eosinophils; Female; Immunoglobulin E; Interleukin-5; Mice; Mice, Inbred BALB C; Oxides | 2010 |
Interaction between arsenic trioxide (ATO) and human neutrophils.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cells, Cultured; Cytokines; Dinoprostone; Endoplasmic Reticulum; Enzyme-Linked Immunosorbent Assay; Humans; Neutrophils; NF-kappa B; Oxides; Protein Array Analysis; Transcription Factor CHOP | 2011 |
Arsenic trioxide induces a beclin-1-independent autophagic pathway via modulation of SnoN/SkiL expression in ovarian carcinoma cells.
Topics: Acetylcysteine; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Autophagy; Autophagy-Related Protein 5; Autophagy-Related Protein 7; Beclin-1; Carcinoma; Cell Line, Tumor; Female; Humans; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Microtubule-Associated Proteins; Multidrug Resistance-Associated Proteins; Ovarian Neoplasms; Oxides; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering; Signal Transduction; Transforming Growth Factor beta; Ubiquitin-Activating Enzymes | 2010 |
Sweet fruit from a poisonous kiss.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides | 2010 |
A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Cell Proliferation; Cell Survival; Disease Models, Animal; Female; Humans; Mammary Neoplasms, Experimental; Mice; Nanoparticles; Oxides; Rats; Rats, Sprague-Dawley; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
CNS relapse in acute promyeloctyic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Neoplasms; Brain Neoplasms; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cranial Irradiation; Cytarabine; Drug Administration Schedule; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Magnetic Resonance Imaging; Mercaptopurine; Methotrexate; Mutation; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Recurrence; Remission Induction; Retinoic Acid Receptor alpha; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factors; Translocation, Genetic; Transplantation, Autologous; Treatment Outcome; Tretinoin; Tumor Suppressor Proteins | 2010 |
Arsenic trioxide suppresses thymidylate synthase in 5-FU-resistant colorectal cancer cell line HT29 In Vitro re-sensitizing cells to 5-FU.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blotting, Western; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Fluorouracil; Gene Expression; HT29 Cells; Humans; Oxides; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thymidylate Synthase; Tumor Suppressor Protein p53 | 2010 |
Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Survival; Dose-Response Relationship, Drug; Enzyme Activation; Female; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Potential, Mitochondrial; Microscopy, Confocal; Middle Aged; Oxides; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; RNA Interference; Signal Transduction; Tumor Cells, Cultured; Up-Regulation | 2010 |
Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein.
Topics: Arsenic Trioxide; Arsenicals; Autophagy; Cell Differentiation; Cell Line, Tumor; HeLa Cells; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Protein Serine-Threonine Kinases; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; RNA, Small Interfering; Solubility; TOR Serine-Threonine Kinases; Transcription Factors; Tretinoin; Tumor Suppressor Proteins | 2010 |
Arsenic trioxide inhibits osteosarcoma cell invasiveness via MAPK signaling pathway.
Topics: Animals; Arsenic Trioxide; Arsenicals; Bone Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Humans; MAP Kinase Signaling System; Matrix Metalloproteinase 9; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Osteosarcoma; Oxides; Phosphorylation | 2010 |
Arsenic trioxide inhibits DNA methyltransferase and restores expression of methylation-silenced CDKN2B/CDKN2A genes in human hematologic malignant cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cyclin-Dependent Kinase Inhibitor p15; DNA Methylation; DNA Modification Methylases; Drug Evaluation, Preclinical; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, p16; Hematologic Neoplasms; Humans; Oxides; Promoter Regions, Genetic; Tumor Cells, Cultured; U937 Cells | 2010 |
Arsenic trioxide promotes mitochondrial DNA mutation and cell apoptosis in primary APL cells and NB4 cell line.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Base Sequence; Cell Line, Tumor; DNA Mutational Analysis; DNA, Mitochondrial; Humans; Leukemia, Promyelocytic, Acute; Molecular Sequence Data; Mutation; Oxides; Polymerase Chain Reaction; Tumor Cells, Cultured | 2010 |
[Arsenic trioxide treatment in a patient with recurrent acute promyelocytic leukemia (APL)].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Recurrence | 2010 |
Curcumin stimulates reactive oxygen species production and potentiates apoptosis induction by the antitumor drugs arsenic trioxide and lonidamine in human myeloid leukemia cell lines.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Survival; Curcumin; Electrophoretic Mobility Shift Assay; Flow Cytometry; Glutathione; HL-60 Cells; Humans; Indazoles; Membrane Potentials; Mitochondria; Oxidants; Oxides; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; U937 Cells | 2010 |
PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blotting, Western; Chlorocebus aethiops; CHO Cells; COS Cells; Cricetinae; Cricetulus; Disulfides; Embryo, Mammalian; Fibroblasts; Hematopoietic Stem Cells; Humans; Intranuclear Inclusion Bodies; Leukemia, Promyelocytic, Acute; Mice; Mice, Knockout; Mutation; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Processing, Post-Translational; Reactive Oxygen Species; Signal Transduction; Small Ubiquitin-Related Modifier Proteins; Transcription Factors; Tumor Suppressor Proteins | 2010 |
Arsenic trioxide cooperates with all trans retinoic acid to enhance mitogen-activated protein kinase activation and differentiation in PML-RARalpha negative human myeloblastic leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Cycle; Cell Differentiation; Cell Proliferation; Drug Synergism; Flow Cytometry; Humans; Leukemia, Promyelocytic, Acute; Mitogen-Activated Protein Kinases; Oncogene Proteins, Fusion; Oxides; Tretinoin; Tumor Cells, Cultured | 2010 |
Murine double minute 2 as a modulator of retroviral restrictions mediated by TRIM5alpha.
Topics: Animals; Antiviral Restriction Factors; Arsenic Trioxide; Arsenicals; Carrier Proteins; Cell Line; HIV-1; Humans; Infectious Anemia Virus, Equine; Leukemia Virus, Murine; Leupeptins; Mice; Oxides; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-mdm2; RNA Interference; Tripartite Motif Proteins; Ubiquitin-Protein Ligases | 2010 |
Arsenic trioxide and the phosphoinositide 3-kinase/akt pathway in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Survival; Enzyme Activation; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Lymphocytic, Chronic, B-Cell; Models, Biological; Oxides; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; Tumor Cells, Cultured; Up-Regulation | 2010 |
The effects of arsenic trioxide on DNA synthesis and genotoxicity in human colon cancer cells.
Topics: Arsenic Trioxide; Arsenicals; Colonic Neoplasms; Comet Assay; DNA Damage; DNA Replication; HT29 Cells; Humans; Mutagens; Oxides; Thymidine | 2010 |
Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector.
Topics: Animals; Arsenic Trioxide; Arsenicals; Arsenites; Cerebellar Neoplasms; Dose-Response Relationship, Drug; Hedgehog Proteins; Kruppel-Like Transcription Factors; Luciferases; Luminescent Proteins; Medulloblastoma; Mice; Mice, Knockout; Mice, Nude; Neoplasms, Experimental; NIH 3T3 Cells; Oxides; Protein Stability; Recombinant Fusion Proteins; Signal Transduction; Sodium Compounds; Transfection; Transplantation, Homologous; Tumor Suppressor Protein p53; Zinc Finger Protein Gli2 | 2010 |
Arsenic trioxide modulates DNA synthesis and apoptosis in lung carcinoma cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Cycle; Cell Line, Tumor; DNA Replication; Humans; Lung Neoplasms; Oxides; p38 Mitogen-Activated Protein Kinases; Thymidine | 2010 |
[Role of Survivin gene on the apoptosis of adenoid cystic carcinoma-2 cells induced by arsenic trioxide].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Adenoid Cystic; Humans; Inhibitor of Apoptosis Proteins; Oxides; Survivin | 2010 |
Arsenic trioxide influences viral replication in target organs of coxsackievirus B3-infected mice.
Topics: Animals; Antiviral Agents; Arsenic Trioxide; Arsenicals; Brain; Chlorocebus aethiops; Coxsackievirus Infections; Dose-Response Relationship, Drug; Enterovirus B, Human; Female; Mass Spectrometry; Mice; Mice, Inbred BALB C; Oxides; Pancreas; Plasma; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Time Factors; Vero Cells; Virus Replication | 2010 |
As2O3 may be a treatment option for adenoid cystic carcinoma of salivary gland.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Adenoid Cystic; Growth Inhibitors; Humans; Oxides; Salivary Gland Neoplasms | 2010 |
Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide.
Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Autophagy; Autophagy-Related Protein 7; Beclin-1; Humans; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Membrane Proteins; Mice; Mice, Knockout; Microtubule-Associated Proteins; Oxides; U937 Cells; Ubiquitin-Activating Enzymes | 2010 |
Stathmin is involved in arsenic trioxide-induced apoptosis in human cervical cancer cell lines via PI3K linked signal pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Female; HeLa Cells; Humans; In Situ Nick-End Labeling; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Mice, Nude; Oxides; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Stathmin; Survival Analysis; Tumor Burden; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2010 |
Trivalent arsenic inhibits the functions of chaperonin complex.
Topics: Actins; Arsenic Trioxide; Arsenicals; Blotting, Western; Chaperonin Containing TCP-1; Fluorescent Antibody Technique; Methanococcus; Microtubule Proteins; Microtubules; Molecular Chaperones; Mutation; Oxides; Protein Folding; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Tubulin | 2010 |
Toxoplasma gondii infection inhibits the mitochondrial apoptosis through induction of Bcl-2 and HSP70.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Caspase 3; Caspase 7; Cell Line; DNA Fragmentation; HSP70 Heat-Shock Proteins; Humans; Immunoprecipitation; Macrophages; Oxides; Proto-Oncogene Proteins c-bcl-2; Toxoplasma | 2010 |
Arsenic trioxide combined with co-stimulatory molecule blockade prolongs survival of cardiac allografts in alloantigen-primed mice.
Topics: Animals; Antibodies, Monoclonal; Arsenic Trioxide; Arsenicals; CD40 Ligand; Cells, Cultured; Graft Rejection; Graft Survival; Heart Transplantation; Immunization; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Oxides; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Transplantation, Homologous | 2010 |
Arsenic trioxide reduces 2,4,6-trinitrobenzene sulfonic acid-induced murine colitis via nuclear factor-κB down-regulation and caspase-3 activation.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Colitis; Colon; Crohn Disease; Cytokines; Disease Models, Animal; Humans; Male; Mice; Mice, Inbred BALB C; NF-kappa B; Nitric Oxide Synthase Type II; Oxides; Peroxidase; Trinitrobenzenesulfonic Acid | 2011 |
Application and assessment of Chinese arsenic drugs in treating malignant hematopathy in China.
Topics: Arsenic Trioxide; Arsenicals; China; Drugs, Chinese Herbal; Hematologic Neoplasms; Humans; Oxides | 2010 |
SnoN/SkiL, a TGFβ signaling mediator: a participant in autophagy induced by arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autophagy; Cell Line, Tumor; Female; Humans; Intracellular Signaling Peptides and Proteins; Ovarian Neoplasms; Oxides; Proto-Oncogene Proteins; Reactive Oxygen Species; Signal Transduction; Transforming Growth Factor beta | 2010 |
Arsenic eaters and altitude sickness: an epigenetic strategy for improving fitness in a hostile environment?
Topics: Altitude Sickness; Arsenic Trioxide; Arsenicals; Austria; DNA Methylation; Epigenesis, Genetic; Humans; Oxides | 2010 |
The NRF2-mediated oxidative stress response pathway is associated with tumor cell resistance to arsenic trioxide across the NCI-60 panel.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Cell Line, Tumor; Humans; Leukemia, Promyelocytic, Acute; National Cancer Institute (U.S.); NF-E2-Related Factor 2; Oxidative Stress; Oxides; RNA Interference; United States | 2010 |
Clinical efficacy of arsenic trioxide in a patient with acute promyelocytic leukemia with recurrent central nervous system involvement.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Central Nervous System; Central Nervous System Neoplasms; Female; Humans; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Meningeal Neoplasms; Oxides; Recurrence; Treatment Outcome | 2011 |
[Effects of STI571 combined with As₂O₃ on proliferation, apoptosis and caspase 3, Bcl-xL expression of K562 cells].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Benzamides; Caspase 3; Cell Proliferation; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Oxides; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines | 2010 |
[Levels of P27Kip1 expression and apoptosis in HL-60 cells after treatment with TGF-ß1 and/or arsenic trioxide].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cyclin E; Cyclin-Dependent Kinase Inhibitor p27; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Oxides; Proto-Oncogene Proteins c-bcl-2; Transforming Growth Factor beta1 | 2010 |
[Effect of arsenic trioxide on induction of apoptosis in MCL cell line and its possible mechanisms].
Topics: Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Membrane Potential, Mitochondrial; Mitochondria; Oxides | 2010 |
Abrogating HSP response augments cell death induced by As2O3 in glioma cell lines.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzhydryl Compounds; Caspase 3; Cell Death; Cell Line, Tumor; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Flow Cytometry; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Glioma; Heat Shock Transcription Factors; Heat-Shock Proteins; Heat-Shock Response; Humans; MAP Kinase Kinase 4; Membrane Potential, Mitochondrial; Oxides; Pyrrolidinones; RNA, Small Interfering; Time Factors; Transcription Factors; Trypan Blue | 2010 |
Autophagic degradation of an oncoprotein.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autophagy; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Proteasome Endopeptidase Complex; Tretinoin | 2010 |
Tumor growth inhibition of metastatic nasopharyngeal carcinoma cell lines by low dose of arsenic trioxide via alteration of cell cycle progression and induction of apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma; Caspase 3; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Female; Humans; Mice; Mice, Inbred BALB C; Nasopharyngeal Neoplasms; Oxides; Xenograft Model Antitumor Assays | 2011 |
Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Enzyme Activation; HL-60 Cells; Humans; Oxides; Phosphatidylserines | 2010 |
Arsenic trioxide induces apoptosis through JNK and ERK in human mesothelioma cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Line, Tumor; Drug Screening Assays, Antitumor; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; JNK Mitogen-Activated Protein Kinases; Mesothelioma; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinase 9; Oxides | 2011 |
Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Radiation-Induced; Oxides; Treatment Outcome; Tretinoin | 2011 |
Protection effect of taurine on nitrosative stress in the mice brain with chronic exposure to arsenic.
Topics: Animals; Arsenic Trioxide; Arsenicals; Brain; Female; Guanine; Humans; Male; Mice; Neuroprotective Agents; Oxides; Reactive Nitrogen Species; Taurine | 2010 |
Arsenic modulates APOBEC3G-mediated restriction to HIV-1 infection in myeloid dendritic cells.
Topics: Alu Elements; Antineoplastic Agents; APOBEC-3G Deaminase; Arsenic Trioxide; Arsenicals; Cytidine Deaminase; Dendritic Cells; HEK293 Cells; HIV-1; Humans; Interferon-alpha; Myeloid Cells; Oxides; Retroelements; Viral Tropism | 2010 |
Nuclear Factor-κB modulates cellular glutathione and prevents oxidative stress in cancer cells.
Topics: Animals; Arsenic Trioxide; Arsenicals; Glutathione; Humans; Leukemia; Male; Mice; NF-kappa B; Oxidative Stress; Oxides; Prostatic Neoplasms; Signal Transduction | 2010 |
[Preparation of As2O3 nanoparticles and its drug release characteristics in vitro].
Topics: Arsenic Trioxide; Arsenicals; Drug Carriers; Nanoparticles; Oxides; Particle Size; Polyglycolic Acid | 2010 |
[Effects of control-releasing arsenic trioxide-eluting stent on intimal smooth muscle cells and type III collagen in canine coronary artery post-stent model].
Topics: Animals; Arsenic Trioxide; Arsenicals; Collagen Type III; Coronary Restenosis; Coronary Vessels; Dogs; Drug-Eluting Stents; Female; Implants, Experimental; Male; Muscle, Smooth, Vascular; Oxides; Tunica Intima | 2010 |
A matter of balance between life and death: targeting reactive oxygen species (ROS)-induced autophagy for cancer therapy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autophagy; Cell Line, Tumor; Humans; Mercaptoethanol; Neoplasms; Oxidative Stress; Oxides; Reactive Oxygen Species | 2010 |
Arsenic trioxide up-regulates Fas expression in human osteosarcoma cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; fas Receptor; Flow Cytometry; Humans; Osteosarcoma; Oxides; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
MicroRNA-dependent regulation of PTEN after arsenic trioxide treatment in bladder cancer cell line T24.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Luciferases; MicroRNAs; Oligonucleotide Array Sequence Analysis; Oxides; PTEN Phosphohydrolase; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2011 |
Activation of the p38 MAPK/Akt/ERK1/2 signal pathways is required for the protein stabilization of CDC6 and cyclin D1 in low-dose arsenite-induced cell proliferation.
Topics: Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Flow Cytometry; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nuclear Proteins; Oxides; p38 Mitogen-Activated Protein Kinases; Protein Stability; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species | 2010 |
Arsenic trioxide (As₂O₃) inhibits murine WEHI-3 leukemia in BALB/c mice in vivo.
Topics: Animals; Antigens, Differentiation; Arsenic Trioxide; Arsenicals; B-Lymphocytes; Cell Differentiation; Cell Line, Tumor; Leukemia; Leukemia, Experimental; Macrophages; Male; Mice; Mice, Inbred BALB C; Oxides; Spleen; Tretinoin | 2012 |
Arsenic trioxide induces apoptosis of fibroblast-like synoviocytes and represents antiarthritis effect in experimental model of rheumatoid arthritis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Arthritis, Experimental; Arthritis, Rheumatoid; Caspase 8; Cells, Cultured; Disease Models, Animal; Fibroblasts; Humans; In Situ Nick-End Labeling; NF-kappa B; Oxides; Rats; Synovial Membrane | 2011 |
Modified native cellulose fibers--a novel efficient adsorbent for both fluoride and arsenic.
Topics: Adsorption; Algorithms; Arsenic; Arsenic Trioxide; Arsenicals; Cellulose; Electrochemistry; Fluorides; Hydrogen-Ion Concentration; Methacrylates; Microscopy, Electron, Scanning; Models, Chemical; Nylons; Oxides; Surface Properties; Thermodynamics | 2011 |
[Three different drug interaction mathematical models used to evaluate the cytotoxicity of SAHA and arsenic trioxide in combination].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Humans; Hydroxamic Acids; Models, Chemical; Oxides; Vorinostat | 2010 |
Synergistic cytotoxic effects of arsenic trioxide plus dithiothreitol on mice oral cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Dithiothreitol; Drug Synergism; Male; Mice; Mice, Inbred C57BL; Mouth Neoplasms; Oxides | 2010 |
5-Fluorouracil/Leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma: a clinical experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Treatment Outcome | 2011 |
Cytotoxicity of arsenic trioxide is enhanced by (-)-epigallocatechin-3-gallate via suppression of ferritin in cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caffeic Acids; Catechin; Cell Line, Tumor; Cytotoxins; Drug Synergism; Ferritins; Heme Oxygenase (Decyclizing); HL-60 Cells; Humans; Neoplasms; Oxides; Phenylethyl Alcohol | 2011 |
Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Growth Processes; Cell Survival; Down-Regulation; Humans; Interferon Regulatory Factor-1; Multiple Myeloma; Oxides; Receptors, TNF-Related Apoptosis-Inducing Ligand; Recombinant Proteins; RNA, Messenger; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand | 2010 |
The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.
Topics: Aged; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Oxides; Polymerase Chain Reaction; Pyrazines; Zoledronic Acid | 2011 |
Arsenic trioxide induces down-regulation of gp46 via protein oxidation: proteomics analysis of oxidative modified proteins in As2O3-treated HTLV-1-infected cells.
Topics: Arsenic Trioxide; Arsenicals; Cell Fusion; Down-Regulation; Electrophoresis, Gel, Two-Dimensional; Endoplasmic Reticulum Chaperone BiP; Gels; Gene Products, env; HeLa Cells; HTLV-I Infections; Humans; Hydrolysis; Immunoprecipitation; Oxidation-Reduction; Oxides; Proteomics; Retroviridae Proteins, Oncogenic; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Trypsin | 2010 |
NFκB inhibitors induce cell death in glioblastomas.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Astrocytes; Brain Neoplasms; Cell Cycle; Cell Death; Cell Line, Tumor; Cisplatin; Curcumin; Doxorubicin; Drug Synergism; Glioblastoma; Humans; Leupeptins; Molecular Targeted Therapy; NF-kappa B; Nitriles; Oxides; Rats; Sesquiterpenes; Signal Transduction; Sulfones | 2011 |
Synergistic apoptosis induction in leukemic cells by miR-15a/16-1 and arsenic trioxide.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Drug Synergism; Fusion Proteins, bcr-abl; Humans; K562 Cells; Leukemia, Promyelocytic, Acute; MicroRNAs; Mitochondria; Oxides | 2010 |
Arsenic trioxide induces apoptosis in uveal melanoma cells through the mitochondrial pathway.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Caspase 3; Caspase 9; Cell Line, Tumor; Cytochromes c; DNA Fragmentation; Dose-Response Relationship, Drug; Eye Neoplasms; Humans; Melanoma; Mitochondria; Oxides; Phytotherapy; Proto-Oncogene Proteins c-bcl-2; Signal Transduction | 2010 |
Long-term survey of outcome in acute promyelocytic leukemia: a single center experience in 340 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Survival Rate; Time Factors; Treatment Outcome; Tretinoin; Young Adult | 2011 |
[Acetyl-11-keto-beta-boswellic acid and arsenic trioxide regulate the productions and activities of matrix metalloproteinases in human skin fibroblasts and human leukemia cell line THP-1].
Topics: Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Fibroblasts; Humans; Matrix Metalloproteinases; Monocytes; Oxides; Triterpenes | 2010 |
Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: role of Akt and nuclear factor-κB.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Drug Synergism; Genistein; Hep G2 Cells; Humans; Liver Neoplasms; Mice; NF-kappa B; Oxides; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Xenograft Model Antitumor Assays | 2011 |
Hematological, biochemical and ionoregulatory responses of Indian major carp Catla catla during chronic sublethal exposure to inorganic arsenic.
Topics: Animals; Arsenic Trioxide; Arsenicals; Biochemical Phenomena; Biomarkers; Blood Chemical Analysis; Blood Glucose; Cyprinidae; Erythrocyte Count; Erythrocyte Indices; Gills; Hematocrit; Hematologic Tests; Hemoglobins; India; L-Lactate Dehydrogenase; Lethal Dose 50; Leukocyte Count; Oxides; Sodium-Potassium-Exchanging ATPase; Toxicity Tests, Acute; Water Pollutants, Chemical | 2011 |
Oxidative inactivation of the lipid phosphatase phosphatase and tensin homolog on chromosome ten (PTEN) as a novel mechanism of acquired long QT syndrome.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Calcium; Cells, Cultured; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Guinea Pigs; Heart Ventricles; Humans; Long QT Syndrome; Myocytes, Cardiac; Oxidation-Reduction; Oxides; Phosphatidylinositol 3-Kinases; Phosphatidylinositol Phosphates; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction | 2011 |
Treatment of patients with acute promyelocytic leukemia: a consensus statement on risk-adapted approaches to therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Risk Assessment; Treatment Outcome; Tretinoin | 2010 |
Utilization of molecular phenotypes to detect relapse and optimize the management of acute promyelocytic leukemia.
Topics: Adaptor Proteins, Signal Transducing; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Phenotype; Prognosis; Recurrence; Translocation, Genetic; Tretinoin | 2010 |
A serotype 5/3 adenovirus expressing MDA-7/IL-24 infects renal carcinoma cells and promotes toxicity of agents that increase ROS and ceramide levels.
Topics: Adenoviridae; Animals; Arsenic Trioxide; Arsenicals; Benzoquinones; Blotting, Western; Carcinoma, Renal Cell; Cell Line, Tumor; Ceramides; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Female; Flow Cytometry; Humans; Interleukins; Kidney Neoplasms; Lactams, Macrocyclic; Mice; Mice, Nude; Oxides; Reactive Oxygen Species; Transfection | 2011 |
Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Gene Products, tax; Human T-lymphotropic virus 1; Humans; In Situ Nick-End Labeling; Interferon-alpha; Leukemia-Lymphoma, Adult T-Cell; Mice; Mice, SCID; Mice, Transgenic; Organ Size; Oxides; Reverse Transcriptase Polymerase Chain Reaction; Spleen; Treatment Outcome | 2010 |
The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia.
Topics: Adolescent; Adult; Aged; Annexin A2; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blood Coagulation Tests; Blotting, Western; Cell Proliferation; Female; Fibrinolysin; Fibrinolysis; Flow Cytometry; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Plasminogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tissue Plasminogen Activator; Tretinoin; Young Adult | 2011 |
A review of three simple plant models and corresponding statistical tools for basic research in homeopathy.
Topics: Arsenic Trioxide; Arsenicals; Germination; Growth Inhibitors; Homeopathy; Humans; Models, Biological; Nicotiana; Oxides; Plant Development; Plants; Seedlings; Tobacco Mosaic Virus; Triticum | 2010 |
microRNA expression alteration after arsenic trioxide treatment in HepG-2 cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Reporter; Hep G2 Cells; Humans; Liver Neoplasms; MicroRNAs; Oligonucleotide Array Sequence Analysis; Oxides; Phosphoprotein Phosphatases; Protein Phosphatase 2C; Reverse Transcriptase Polymerase Chain Reaction; Transfection | 2011 |
[Mechanism of As(2)O(3) on hdpr1 gene demethylation in Jurkat cell line].
Topics: Adaptor Proteins, Signal Transducing; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Proliferation; DNA Methylation; Genes, Tumor Suppressor; Humans; Jurkat Cells; Nuclear Proteins; Oxides | 2010 |
E3 ubiquitin ligase Cbl-b potentiates the apoptotic action of arsenic trioxide by inhibiting the PI3K/Akt pathway.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Flow Cytometry; HL-60 Cells; Humans; Oxides; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-cbl; Rats; Signal Transduction; Ubiquitin-Protein Ligases; Up-Regulation | 2011 |
Normoxically overexpressed hypoxia inducible factor 1-alpha is involved in arsenic trioxide resistance acquisition in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Carcinoma, Hepatocellular; Caspase 3; Caspase 7; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Enzyme Activation; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Heat-Shock Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lipid Peroxidation; Liver Neoplasms; Membrane Potential, Mitochondrial; Nitric Oxide; Oxides; Oxygen; Reactive Oxygen Species; Tumor Cells, Cultured | 2011 |
Arsenic: a potentially useful poison for Hedgehog-driven cancers.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Hedgehog Proteins; Humans; Medulloblastoma; Mice; Models, Biological; Neoplasms; Oxides; Receptors, G-Protein-Coupled; Sarcoma, Ewing; Signal Transduction; Smoothened Receptor; Transcription Factors; Zinc Finger Protein GLI1 | 2011 |
Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Base Sequence; Cell Line, Tumor; DNA Primers; Gene Expression; Hedgehog Proteins; Hep G2 Cells; Humans; Medulloblastoma; Mice; Mice, SCID; Mice, Transgenic; Neoplasm Transplantation; Oncogene Proteins; Oxides; Receptors, G-Protein-Coupled; Recombinant Fusion Proteins; Sarcoma, Ewing; Signal Transduction; Smoothened Receptor; Trans-Activators; Transplantation, Heterologous; Zinc Finger Protein GLI1 | 2011 |
[Prevention of posterior capsule opacification by combination of arsenic trioxide and perfect capsule].
Topics: Arsenic Trioxide; Arsenicals; Calcium; Cataract; Cell Line; Epithelial Cells; Humans; Lens Capsule, Crystalline; Lenses, Intraocular; Oxides | 2010 |
Arsenic nanoparticle holds promise in blocking aggressive breast cancer.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Drug Delivery Systems; Female; Humans; Nanoparticles; Oxides | 2010 |
L-type calcium current (ICa,L) and inward rectifier potassium current (IK1) are involved in QT prolongation induced by arsenic trioxide in rat.
Topics: Action Potentials; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Caffeine; Calcium Channels, L-Type; Electrocardiography; Heart; Male; Microscopy, Confocal; Myocytes, Cardiac; Oxides; Patch-Clamp Techniques; Potassium Channels, Inwardly Rectifying; Potassium Chloride; Rats; Rats, Wistar | 2010 |
Don't just stand there, do something: strategies for the prevention of early death in acute promyelocytic leukemia: a commentary.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disseminated Intravascular Coagulation; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Secondary Prevention; Survival Rate; Time Factors; Treatment Failure; Tretinoin | 2011 |
Arsenic trioxide promotes senescence and regulates the balance of adipogenic and osteogenic differentiation in human mesenchymal stem cells.
Topics: Adipogenesis; Aging; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; CCAAT-Enhancer-Binding Protein-alpha; Cell Differentiation; Cells, Cultured; Cyclin-Dependent Kinase Inhibitor p21; Humans; Mesenchymal Stem Cells; Osteogenesis; Oxides; PPAR gamma | 2011 |
[A successful case of tanshinone II A treatment for relapsed acute promyelocytic leukemia after maintainance therapy of all-trans retinoic acid and arsenic trioxide].
Topics: Abietanes; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Mercaptopurine; Methotrexate; Neoplasm Recurrence, Local; Oxides; Tretinoin; Young Adult | 2010 |
miR-153 sensitized the K562 cells to As2O3-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Oxides; Real-Time Polymerase Chain Reaction | 2012 |
Arsenic trioxide induces procoagulant activity through phosphatidylserine exposure and microparticle generation in endothelial cells.
Topics: Arsenic Trioxide; Arsenicals; Blood Coagulation; Cell-Derived Microparticles; Cells, Cultured; Endothelial Cells; Humans; Microscopy, Confocal; Oxides; Phosphatidylserines | 2011 |
Involvement of glycogen synthase kinase-3β in arsenic trioxide-induced p21 expression.
Topics: Arsenic Trioxide; Arsenicals; Base Sequence; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; DNA Primers; Gene Expression Regulation; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Immunoprecipitation; Oxides; Phosphorylation; Promoter Regions, Genetic | 2011 |
Protective effect of α-lipoic acid against arsenic trioxide-induced acute cardiac toxicity in rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Alkaline Phosphatase; Animals; Antineoplastic Agents; Antioxidants; Arsenic Trioxide; Arsenicals; Creatinine; Death, Sudden, Cardiac; Deoxyguanosine; Dose-Response Relationship, Drug; Electrocardiography; Heart; Oxidative Stress; Oxides; Protective Agents; Rats; Rats, Wistar; Thioctic Acid; Time Factors; Transaminases | 2011 |
Arsenic trioxide induces apoptosis of p53 null osteosarcoma MG63 cells through the inhibition of catalase.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Bone Neoplasms; Catalase; Cell Line, Tumor; Flow Cytometry; Glutathione; Humans; Osteosarcoma; Oxides; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Suppressor Protein p53 | 2012 |
Lipoic acid ameliorates arsenic trioxide-induced HO-1 expression and oxidative stress in THP-1 monocytes and macrophages.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cells, Cultured; Cytoprotection; Heme Oxygenase-1; Humans; Macrophages; Monocytes; Oxidation-Reduction; Oxidative Stress; Oxides; Protoporphyrins; Signal Transduction; Superoxides; Thioctic Acid | 2011 |
Inhibition of heme oxygenase-1 enhances anti-cancer effects of arsenic trioxide on glioma cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Enzyme Inhibitors; Gene Knockdown Techniques; Glioma; Heme Oxygenase-1; Humans; NF-E2-Related Factor 2; Oxides; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
Development of chromanes as novel inhibitors of the uncoupling proteins.
Topics: Animals; Arsenic Trioxide; Arsenicals; Biological Transport; Cell Respiration; Cell Survival; Chromans; Drug Discovery; Drug Synergism; Fatty Acids; HT29 Cells; Humans; Ion Channels; Liver; Mice; Mitochondrial Proteins; Oxidative Phosphorylation; Oxidative Stress; Oxides; Protons; Rats; Saccharomyces cerevisiae; Superoxides; Uncoupling Protein 1; Uncoupling Protein 2 | 2011 |
Long-term remission after first-line single-agent treatment with arsenic trioxide of relapsed acute promyelocytic leukemia in an 8-year-old boy.
Topics: Arsenic Trioxide; Arsenicals; Child; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Recurrence; Remission Induction; Time Factors | 2011 |
Acute exposure of arsenic tri-oxide produces hyperglycemia in both sexes of an Indian teleost, Clarias batrachus (Linn.).
Topics: Animals; Arsenic Trioxide; Arsenicals; Blood Glucose; Catfishes; Environmental Monitoring; Female; Hyperglycemia; Male; Oxides; Water Pollutants, Chemical | 2011 |
Synergistic effects of arsenic trioxide and radiation in osteosarcoma cells through the induction of both autophagy and apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Catalase; Cell Line, Tumor; DNA Damage; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Humans; Osteosarcoma; Oxides; Polyethylene Glycols | 2011 |
Treatment of acute promyelocytic leukemia for older patients.
Topics: Age Factors; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Prognosis; Treatment Outcome; Tretinoin | 2011 |
Combination of Poly I:C and arsenic trioxide triggers apoptosis synergistically via activation of TLR3 and mitochondrial pathways in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; BH3 Interacting Domain Death Agonist Protein; Carcinoma, Hepatocellular; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; Humans; Inhibitor of Apoptosis Proteins; Interferon Inducers; Liver Neoplasms; Mitochondria; Oxides; Poly I-C; Polymerase Chain Reaction; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Survivin; Toll-Like Receptor 3 | 2011 |
Mediating effect of ROS on mtDNA damage and low ATP content induced by arsenic trioxide in mouse oocytes.
Topics: Acetylcysteine; Adenosine Triphosphate; Animals; Arsenic Trioxide; Arsenicals; DNA Damage; DNA, Mitochondrial; Female; Mice; Mitochondria; Oocytes; Oxidative Stress; Oxides; Reactive Oxygen Species | 2011 |
Arsenic trioxide may improve the prognosis of APL with ider(17)(q10): report of a rare adult case of acute promyelocytic leukemia with ider(17)(q10)t(15;17) showing poor response to all-trans retinoic acid.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Prognosis; Recombinant Fusion Proteins; Tretinoin | 2011 |
[Anti-angiogenesis effect of arsenic trioxide plus cinobufacin on human hepatocarcinoma transplantation model nude mice].
Topics: Amphibian Venoms; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Oxides; Phytotherapy; Xenograft Model Antitumor Assays | 2011 |
Arterial embolization hyperthermia using As2O3 nanoparticles in VX2 carcinoma-induced liver tumors.
Topics: Angiography; Animals; Arsenic Trioxide; Arsenicals; Embolization, Therapeutic; Hyperthermia, Induced; Immunohistochemistry; Liver; Liver Function Tests; Liver Neoplasms; Male; Microvessels; Nanoparticles; Necrosis; Oxides; Platelet Endothelial Cell Adhesion Molecule-1; Rabbits; Survival Analysis; Temperature; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
Mutant p53 protein is targeted by arsenic for degradation and plays a role in arsenic-mediated growth suppression.
Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Humans; Neoplasms; Nuclear Proteins; Oxidative Stress; Oxides; Promyelocytic Leukemia Protein; Proteasome Endopeptidase Complex; Transcription Factors; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2011 |
Therapy-related acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Neoplasms, Second Primary; Oxides; Radiotherapy, Computer-Assisted | 2011 |
Differential augmentative effects of buthionine sulfoximine and ascorbic acid in As2O3-induced ovarian cancer cell death: oxidative stress-independent and -dependent cytotoxic potentiation.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Buthionine Sulfoximine; Cell Death; Cell Line, Tumor; Drug Synergism; Female; Fibroblasts; Glutathione; Glutathione Peroxidase; Humans; Intracellular Space; Ovarian Neoplasms; Oxidative Stress; Oxides | 2011 |
Arsenic trioxide induces apoptosis of Burkitt lymphoma cell lines through multiple apoptotic pathways and triggers antiangiogenesis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Burkitt Lymphoma; Cell Proliferation; Flow Cytometry; Humans; Inhibitor of Apoptosis Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Neovascularization, Pathologic; Oxides; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survivin; Vascular Endothelial Growth Factor A | 2011 |
Successful treatment of relapsed and refractory extramedullary acute promyelocytic leukemia with tamibarotene.
Topics: Adult; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Bone Marrow; Bone Neoplasms; Combined Modality Therapy; Doxorubicin; Drug Resistance, Neoplasm; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Male; Mercaptopurine; Methotrexate; Oxides; Radionuclide Imaging; Remission Induction; Salvage Therapy; Sarcoma, Myeloid; Soft Tissue Neoplasms; Tetrahydronaphthalenes; Tretinoin | 2011 |
Synergic effect of 3'-azido-3'-deoxythymidine and arsenic trioxide in suppressing hepatoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antitubercular Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Caspase 3; Cell Growth Processes; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Oxides; Telomerase; Xenograft Model Antitumor Assays; Zidovudine | 2011 |
Sulindac and its metabolites: sulindac sulfide and sulindac sulfone enhance cytotoxic effects of arsenic trioxide on leukemic cell lines.
Topics: Animals; Annexin A5; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Drug Synergism; Flow Cytometry; HL-60 Cells; Humans; Jurkat Cells; K562 Cells; Lymphocytes; Membrane Potential, Mitochondrial; Mice; NF-kappa B; Oxides; Propidium; Staining and Labeling; Sulindac | 2011 |
Pharmacokinetics of arsenic trioxide (As₂O₃) in Chinese primary hepatocarcinoma patients.
Topics: Area Under Curve; Arsenic Trioxide; Arsenicals; Asian People; Carcinoma, Hepatocellular; Female; Half-Life; Humans; Injections, Intravenous; Liver Neoplasms; Male; Middle Aged; Oxides | 2011 |
[NB4 cell apoptosis induced by bortezomib combined with As(2)O(3) and its mechanism].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Caspase 3; Caspase 9; Cell Line, Tumor; Humans; Oxides; Proto-Oncogene Proteins c-bcl-2; Pyrazines; RNA, Small Interfering; Transfection | 2011 |
Assessment of the involvement of oxidative stress and Mitogen-Activated Protein Kinase signaling pathways in the cytotoxic effects of arsenic trioxide and its combination with sulindac or its metabolites: sulindac sulfide and sulindac sulfone on human leu
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Glutathione; Humans; Leukemia; Mitogen-Activated Protein Kinases; Oxidative Stress; Oxides; Reactive Oxygen Species; Signal Transduction; Sulindac | 2012 |
Treatment of relapsed acute promyelocytic leukemia by arsenic trioxide in Iran.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Cohort Studies; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Iran; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Remission Induction; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult | 2011 |
The cystine/cysteine cycle and GSH are independent and crucial antioxidant systems in malignant melanoma cells and represent druggable targets.
Topics: Antioxidants; Arsenic Trioxide; Arsenicals; Blotting, Western; Buthionine Sulfoximine; Cell Survival; Cysteine; Cystine; Glutathione; Glycine; HMGB1 Protein; Humans; Immunohistochemistry; Melanoma; Oxidation-Reduction; Oxides; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Tumor Cells, Cultured | 2011 |
Inorganic arsenic causes cell apoptosis in mouse cerebrum through an oxidative stress-regulated signaling pathway.
Topics: Acetylcysteine; Animals; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Cerebral Cortex; Dose-Response Relationship, Drug; Endoplasmic Reticulum Chaperone BiP; Environmental Pollutants; Gene Expression Regulation, Enzymologic; Glutathione; Glutathione Peroxidase; Lipid Peroxides; Male; MAP Kinase Signaling System; Mice; Mice, Inbred ICR; NAD(P)H Dehydrogenase (Quinone); Nerve Tissue Proteins; Neurons; Neuroprotective Agents; Oxidation-Reduction; Oxidative Stress; Oxides; Random Allocation; RNA, Messenger | 2011 |
Arsenic trioxide inhibits invasion/migration in SGC-7901 cells by activating the reactive oxygen species-dependent cyclooxygenase-2/matrix metalloproteinase-2 pathway.
Topics: Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Movement; Cyclooxygenase 2; Dinoprostone; Enzyme Activation; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Intracellular Space; Leukotriene B4; Matrix Metalloproteinase 2; Neoplasm Invasiveness; Oxides; Reactive Oxygen Species; Signal Transduction; Thromboxane B2 | 2011 |
Characterization of arsenic-induced cytogenetic alterations in acute promyelocytic leukemia cell line, NB4.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Survival; Chromosome Aberrations; Humans; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Oxides; Tumor Cells, Cultured | 2012 |
Arsenic trioxide-induced apoptosis in TM4 Sertoli cells: the potential involvement of p21 expression and p53 phosphorylation.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Caspases; Cell Cycle; Cell Line; Cytochromes c; Male; Membrane Potential, Mitochondrial; Mice; Mitochondria; Oncogene Protein p21(ras); Oxides; Phosphorylation; Reactive Oxygen Species; Sertoli Cells; Tumor Suppressor Protein p53 | 2011 |
[Mechanism of apoptosis induced by bortezomib and As2O3 in APL cell line NB4].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Line, Tumor; Humans; Leukemia, Promyelocytic, Acute; Oxides; Pyrazines | 2011 |
AID expression is correlated with Bcr-Abl expression in CML-LBC and can be down-regulated by As2O3 and/or imatinib.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Blast Crisis; Blotting, Western; Cells, Cultured; Cytidine Deaminase; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Female; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Male; Middle Aged; Mutation; Oxides; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
[Effects of As2O3 and all-trans retinoic acid on the growth of HeLa cell line and their relation with gene NDRG1].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Cycle Proteins; Cell Proliferation; Dose-Response Relationship, Drug; HeLa Cells; Humans; Intracellular Signaling Peptides and Proteins; Oxides; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tretinoin | 2011 |
Arsenic trioxide induces autophagy and apoptosis in human glioma cells in vitro and in vivo through downregulation of survivin.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Cell Cycle; Cell Survival; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glioma; Humans; Inhibitor of Apoptosis Proteins; Male; Mice; Mice, SCID; Mitogen-Activated Protein Kinases; Oxides; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Signal Transduction; Survivin; Tumor Burden | 2011 |
Arsenic mediated disruption of promyelocytic leukemia protein nuclear bodies induces ganciclovir susceptibility in Epstein-Barr positive epithelial cells.
Topics: Antiviral Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Resistance, Viral; Epithelial Cells; Ganciclovir; Gene Expression Regulation, Viral; Herpesvirus 4, Human; Humans; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Transcription Factors; Tumor Suppressor Proteins; Up-Regulation; Viral Matrix Proteins | 2011 |
Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Binding Sites; Cytoplasm; Drug Resistance, Neoplasm; Female; HeLa Cells; Humans; Immunoblotting; Leukemia, Promyelocytic, Acute; Male; Microscopy, Fluorescence; Middle Aged; Mutation, Missense; Neoplasm Recurrence, Local; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Reverse Transcriptase Polymerase Chain Reaction; Sumoylation; Transcription Factors; Transcription, Genetic; Tumor Suppressor Proteins; U937 Cells; Young Adult | 2011 |
Newly diagnosed acute promyelocytic leukemia: arsenic moves front and center.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Developing Countries; Humans; Leukemia, Promyelocytic, Acute; Oxides; Survival Analysis; Tretinoin | 2011 |
Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells.
Topics: 3' Untranslated Regions; Antigens, Surface; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; ELAV Proteins; ELAV-Like Protein 1; ErbB Receptors; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Homeodomain Proteins; Humans; Liver Neoplasms; Models, Biological; Oxides; Phosphatidylinositol 3-Kinases; Repressor Proteins; RNA Stability; RNA-Binding Proteins; RNA, Messenger; Signal Transduction; Transcription, Genetic; Transforming Growth Factor beta | 2011 |
BIM-mediated AKT phosphorylation is a key modulator of arsenic trioxide-induced apoptosis in cisplatin-sensitive and -resistant ovarian cancer cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Bcl-2-Like Protein 11; Cell Line, Tumor; Cell Survival; Cisplatin; Electrophoresis, Polyacrylamide Gel; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Silencing; Humans; Immunoblotting; Membrane Proteins; Ovarian Neoplasms; Oxides; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; RNA, Small Interfering | 2011 |
Arsenic trioxide for the treatment of a relapsed acute promyelocytic leukemia with acute renal failure.
Topics: Acute Kidney Injury; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Fatal Outcome; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Recurrence | 2011 |
Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Treatment Outcome; Tretinoin | 2011 |
How I treat adult T-cell leukemia/lymphoma.
Topics: Anti-Retroviral Agents; Antibodies, Monoclonal; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Hematopoietic Stem Cell Transplantation; HTLV-I Infections; Human T-lymphotropic virus 1; Humans; Leukemia-Lymphoma, Adult T-Cell; Oxides | 2011 |
Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia.
Topics: Adult; Anti-Arrhythmia Agents; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Electrocardiography; Female; Humans; Leukemia, Promyelocytic, Acute; Magnesium; Manitoba; Metoprolol; Oxides; Potassium; Tachycardia, Ventricular | 2011 |
Arsenic trioxide re-sensitizes ERα-negative breast cancer cells to endocrine therapy by restoring ERα expression in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Oxides; Tamoxifen; Transcription, Genetic; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Arsenic trioxide regulates the apoptosis of glioma cell and glioma stem cell via down-regulation of stem cell marker Sox2.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Biomarkers; Brain Neoplasms; Cell Line, Tumor; Down-Regulation; Glioblastoma; Humans; Neoplastic Stem Cells; Oxides; SOXB1 Transcription Factors; Transcription, Genetic | 2011 |
Integrated microfluidic array plate (iMAP) for cellular and molecular analysis.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Estrogen Receptor alpha; Fluorescent Antibody Technique; Gene Expression; HeLa Cells; Humans; Microfluidic Analytical Techniques; Oxides; Paclitaxel; Self-Sustained Sequence Replication; Structure-Activity Relationship | 2011 |
A study on the preparation and characterization of plasmid DNA and drug-containing magnetic nanoliposomes for the treatment of tumors.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; DNA; Drug Delivery Systems; Ferric Compounds; Gene Transfer Techniques; Hep G2 Cells; Humans; Hyperthermia, Induced; Imines; Liposomes; Magnesium Oxide; Magnetite Nanoparticles; Microscopy, Electron, Transmission; Oxides; Particle Size; Plasmids; Polyethylenes; Spectroscopy, Fourier Transform Infrared; Temperature; Zinc Oxide | 2011 |
Arsenic trioxide plus cisplatin/interferon α-2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Capecitabine; Carcinoma, Hepatocellular; Cell Line; Cisplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Fluorescent Dyes; Fluorouracil; Glycoproteins; Hep G2 Cells; Humans; Immunohistochemistry; Interferon-alpha; Liver Neoplasms; Oxides; Peptides; Rhodamine 123; Thy-1 Antigens | 2011 |
[Apoptosis of KBM5R cell line with T315I point mutation induced by arsenic trioxide].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tumor; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Imatinib Mesylate; Oxides; Piperazines; Point Mutation; Pyrimidines | 2011 |
[Mechanism of apoptosis of NB4 cells induced by arsenic trioxide and cyclooxygenase-2 expression].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cyclooxygenase 2; Humans; Leukemia, Promyelocytic, Acute; Membrane Potential, Mitochondrial; Oxides | 2011 |
A study on the thermochemotherapy effect of nanosized As2O3/MZF thermosensitive magnetoliposomes on experimental hepatoma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Calorimetry, Differential Scanning; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Humans; Hyperthermia, Induced; Liposomes; Liver; Liver Neoplasms, Experimental; Magnetics; Nanoparticles; Oxides; Rabbits | 2011 |
Applicability of a "Pick a Winner" trial design to acute myeloid leukemia.
Topics: Adenine Nucleotides; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Clinical Trials, Phase III as Topic; Clofarabine; Cost-Benefit Analysis; Cytarabine; Cytosine; Drug Discovery; Early Termination of Clinical Trials; Follow-Up Studies; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Middle Aged; Multicenter Studies as Topic; Oxides; Patient Selection; Quality-Adjusted Life Years; Quinolones; Randomized Controlled Trials as Topic; Research Design; Sample Size; Software Design; Treatment Outcome; United Kingdom | 2011 |
Arsenic trioxide and radiation enhance apoptotic effects in HL-60 cells through increased ROS generation and regulation of JNK and p38 MAPK signaling pathways.
Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Caspase 3; Cell Cycle; Cell Cycle Proteins; Cell Survival; Cyclins; DNA Fragmentation; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; F-Box Proteins; F-Box-WD Repeat-Containing Protein 7; HL-60 Cells; Humans; JNK Mitogen-Activated Protein Kinases; Membrane Potential, Mitochondrial; Models, Biological; Oxides; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Signal Transduction; Tumor Stem Cell Assay; Ubiquitin-Protein Ligases; X-Rays | 2011 |
miR-190-mediated downregulation of PHLPP contributes to arsenic-induced Akt activation and carcinogenesis.
Topics: Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Bronchi; Carcinogens, Environmental; Cell Line; Cell Proliferation; Cell Transformation, Neoplastic; Down-Regulation; Epithelial Cells; Gene Expression Regulation; Gene Silencing; Humans; MicroRNAs; Nuclear Proteins; Oxides; Phosphoprotein Phosphatases; RNA, Messenger; Talin | 2011 |
Arsenic trioxide inhibits HCCLM3 cells invasion through de novo ceramide synthesis and sphingomyelinase-induced ceramide production.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Ceramides; Humans; Liver Neoplasms; Matrix Metalloproteinase 9; Microscopy, Fluorescence; Neoplasm Invasiveness; Oxides; Sphingomyelin Phosphodiesterase | 2012 |
Arsenic trioxide reduces drug resistance to adriamycin in leukemic K562/A02 cells via multiple mechanisms.
Topics: Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; DNA Topoisomerases, Type II; Doxorubicin; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Genes, bcl-2; Glutathione S-Transferase pi; Humans; K562 Cells; Oxides; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger | 2011 |
Arsenic increases lipopolysaccharide-dependent expression of interleukin-8 gene by stimulating a redox-sensitive pathway that strengthens p38-kinase activation.
Topics: Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line; Cell Separation; Cell Survival; Enzyme Activation; Flow Cytometry; Gene Expression; Gene Expression Regulation; Humans; Interleukin-8; Lipopolysaccharides; Oxidation-Reduction; Oxides; p38 Mitogen-Activated Protein Kinases; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Toxins, Biological | 2011 |
Arsenic trioxide induces human pulmonary fibroblast cell death via the regulation of Bcl-2 family and caspase-8.
Topics: Arsenic Trioxide; Arsenicals; Caspase 8; Cell Death; Cell Proliferation; Fibroblasts; Humans; Lung; Membrane Potential, Mitochondrial; Oligopeptides; Oxides; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering | 2012 |
[The inhibition effect of DFO alone and in combination with ATO on xenograft tumor growth of HL-60 cells in nude mice and its possible mechanism].
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Deferoxamine; Female; HL-60 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Oxides; Transcription Factor RelA; Xenograft Model Antitumor Assays | 2011 |
Potentiation of arsenic trioxide-induced apoptosis by 8-bromo-7-methoxychrysin in human leukemia cells involves depletion of intracellular reduced glutathione.
Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; bcl-X Protein; Blotting, Western; Cell Survival; Cytochromes c; Dose-Response Relationship, Drug; Drug Synergism; Flavonoids; Glutathione; HL-60 Cells; Humans; Intracellular Space; Jurkat Cells; Leukemia; Mitochondria; Oxides; Phosphorylation; Proto-Oncogene Proteins c-akt; Time Factors; U937 Cells; X-Linked Inhibitor of Apoptosis Protein | 2011 |
Arsenic oxide targets stem cell marker CD133/prominin-1 in gallbladder carcinoma.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Gallbladder Neoplasms; Glycoproteins; Humans; Neoplastic Stem Cells; Oxides; Peptides; Plasmids; Proto-Oncogene Proteins c-akt; RNA, Messenger; Signal Transduction; Transfection | 2011 |
Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells.
Topics: Animals; Arsenic Trioxide; Arsenicals; Benzamides; Cell Death; Cell Line, Tumor; Cell Respiration; Drug Resistance, Neoplasm; Electron Transport; Energy Metabolism; Glucose; Imatinib Mesylate; Isothiocyanates; Leukemia; Mice; Mitochondria; Models, Biological; Oxidative Stress; Oxides; Piperazines; Pyrimidines; Reactive Oxygen Species | 2011 |
YY1 is a novel potential therapeutic target for the treatment of HPV infection-induced cervical cancer by arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; DNA Primers; Female; HeLa Cells; Human papillomavirus 16; Humans; Oxides; Papillomavirus Infections; Polymerase Chain Reaction; RNA, Messenger; Uterine Cervical Neoplasms; YY1 Transcription Factor | 2011 |
TCTP is a critical survival factor that protects cancer cells from oxidative stress-induced cell-death.
Topics: Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Cell Death; Dose-Response Relationship, Drug; Glutathione; Humans; Hydrogen Peroxide; Oxidative Stress; Oxides; Sensitivity and Specificity; Structure-Activity Relationship; Tumor Cells, Cultured; Tumor Protein, Translationally-Controlled 1 | 2011 |
As(2)O (3) oxidation by vitamin C: cell culture studies.
Topics: Animals; Antineoplastic Agents; Antioxidants; Arsenic Trioxide; Arsenicals; Arsenites; Ascorbic Acid; Cattle; Cell Culture Techniques; Cell Line, Tumor; Culture Media; Oxidation-Reduction; Oxides | 2012 |
Epoxyeicosatrienoic acids attenuate reactive oxygen species level, mitochondrial dysfunction, caspase activation, and apoptosis in carcinoma cells treated with arsenic trioxide.
Topics: 8,11,14-Eicosatrienoic Acid; Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase Inhibitors; Caspases; Cell Line, Tumor; Cell Transformation, Neoplastic; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; HEK293 Cells; Humans; Indazoles; Membrane Potential, Mitochondrial; Mitochondria; Nitrofurans; Oxides; Reactive Oxygen Species | 2011 |
JWA enhances As₂O₃-induced tubulin polymerization and apoptosis via p38 in HeLa and MCF-7 cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Cell Line, Tumor; Female; Flow Cytometry; Gene Silencing; Growth Inhibitors; Heat-Shock Proteins; Humans; Intracellular Signaling Peptides and Proteins; Membrane Transport Proteins; Microscopy, Fluorescence; Oxides; p38 Mitogen-Activated Protein Kinases; Plasmids; Polymerization; RNA, Small Interfering; Signal Transduction; Transfection; Tubulin; Tubulin Modulators; Up-Regulation; Uterine Cervical Neoplasms | 2011 |
Arsenic trioxide is a novel agent for combination therapy to prolong heart allograft survival in allo-primed T cells transferred mice.
Topics: Adoptive Transfer; Animals; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neutralizing; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Proliferation; Female; Graft Survival; Heart; Heart Transplantation; Interferon-gamma; Interleukin-2; Lymphocyte Transfusion; Mice; Mice, Inbred BALB C; Oxides; Spleen; T-Lymphocytes; Transplantation, Homologous | 2011 |
Simultaneous determination of arsenite and arsenate in arsenic trioxide injection by dual detection ion chromatography.
Topics: Antineoplastic Agents; Arsenates; Arsenic Trioxide; Arsenicals; Arsenites; Chromatography, Ion Exchange; Drug Contamination; Drug Stability; Electric Conductivity; Equipment Design; Oxides; Reproducibility of Results; Sensitivity and Specificity | 2011 |
[Effects of bortezomib alone or combined with arsenic trioxide on the apoptosis of Jurkat cells and expression of livin mRNA].
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Humans; Inhibitor of Apoptosis Proteins; Jurkat Cells; Neoplasm Proteins; Oxides; Pyrazines; RNA, Messenger | 2011 |
(+)α-Tocopheryl succinate inhibits the mitochondrial respiratory chain complex I and is as effective as arsenic trioxide or ATRA against acute promyelocytic leukemia in vivo.
Topics: alpha-Tocopherol; Animals; Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Line, Tumor; Cytochromes c; Disease Models, Animal; Electron Transport Complex I; Electron Transport Complex II; Humans; Leukemia, Promyelocytic, Acute; Membrane Potential, Mitochondrial; Mice; Mice, Transgenic; Mitochondria; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Oxides; Protein Stability; Rats; Reactive Oxygen Species; Transplantation, Isogeneic; Tretinoin | 2012 |
Arsenic trioxide versus tetraarsenic oxide in biomedical research: misunderstandings and misinterpretations.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biomedical Research; Humans; Oxidation-Reduction; Oxides; Tumor Cells, Cultured | 2012 |
Arsenic trioxide in the management of APL: proceed with caution.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2011 |
Proteomic identification of Hsp70 as a new Plk1 substrate in arsenic trioxide-induced mitotically arrested cells.
Topics: Arsenic Trioxide; Arsenicals; Cell Cycle Checkpoints; Cell Cycle Proteins; Electrophoresis, Gel, Two-Dimensional; HSP70 Heat-Shock Proteins; Humans; Immunohistochemistry; Mitosis; Oxides; Phosphoproteins; Phosphorylation; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proteome; Proto-Oncogene Proteins; Staurosporine | 2011 |
Increased apoptotic efficacy of lonidamine plus arsenic trioxide combination in human leukemia cells. Reactive oxygen species generation and defensive protein kinase (MEK/ERK, Akt/mTOR) modulation.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Indazoles; Leukemia; Membrane Potential, Mitochondrial; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Oxidative Stress; Oxides; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; TOR Serine-Threonine Kinases | 2011 |
Enhanced suppression of tumor growth by concomitant treatment of human lung cancer cells with suberoylanilide hydroxamic acid and arsenic trioxide.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Comet Assay; DNA Damage; Drug Synergism; Drug Therapy, Combination; Flow Cytometry; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Oxides; Vorinostat | 2011 |
Oral arsenic trioxide for relapsed acute promyelocytic leukemia in pediatric patients.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Recurrence; Time Factors | 2012 |
Arsenic trioxide inhibits Ewing's sarcoma cell invasiveness by targeting p38(MAPK) and c-Jun N-terminal kinase.
Topics: Anisomycin; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cytoskeleton; Humans; JNK Mitogen-Activated Protein Kinases; Matrix Metalloproteinase Inhibitors; Oxides; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Sarcoma, Ewing | 2012 |
Synergistic antitumor activity of oridonin and arsenic trioxide on hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Diterpenes, Kaurane; Drug Synergism; Female; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Membrane Potential, Mitochondrial; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; Neoplasm Transplantation; NF-kappa B; Oxides; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; X-Linked Inhibitor of Apoptosis Protein | 2012 |
Synergistic effects of arsenic trioxide and silibinin on apoptosis and invasion in human glioblastoma U87MG cell line.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Cell Line, Tumor; Drug Synergism; Glioblastoma; Humans; Neoplasm Invasiveness; Oxides; Silybin; Silymarin | 2012 |
S100A8-targeting siRNA enhances arsenic trioxide-induced myeloid leukemia cell death by down-regulating autophagy.
Topics: Active Transport, Cell Nucleus; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Autophagy; Beclin-1; Calgranulin A; Down-Regulation; Drug Synergism; Flow Cytometry; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid, Acute; Membrane Proteins; Oxides; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; RNA, Small Interfering; Transfection; Tumor Cells, Cultured | 2012 |
Epstein - Barr virus Latent Membrane Protein 1 suppresses reporter activity through modulation of promyelocytic leukemia protein-nuclear bodies.
Topics: Arsenic Trioxide; Arsenicals; beta-Galactosidase; Cell Line; Dose-Response Relationship, Drug; Epstein-Barr Virus Infections; Gene Expression Regulation, Leukemic; Gene Expression Regulation, Viral; Gene Silencing; Genes, Reporter; Herpesvirus 4, Human; Humans; Intranuclear Inclusion Bodies; Leukemia, Promyelocytic, Acute; Luciferases; Nuclear Proteins; Oxides; Plasmids; Promyelocytic Leukemia Protein; RNA, Small Interfering; Transcription Factors; Transcription, Genetic; Transfection; Tumor Suppressor Proteins; Viral Matrix Proteins | 2011 |
Lead acetate and arsenic trioxide induce instability of microsatellites at three different fragile sites (6q21, 9q32-9q33 and 15p14) within the genome of the rat.
Topics: Animals; Arsenic Trioxide; Arsenicals; Chromosome Fragile Sites; Male; Microsatellite Instability; Mutagens; Organometallic Compounds; Oxides; Rats | 2011 |
Combination of arsenic trioxide and BCNU synergistically triggers redox-mediated autophagic cell death in human solid tumors.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autophagy; Carmustine; Cell Death; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Glutathione; Glutathione Reductase; Humans; Oxidation-Reduction; Oxides; Reactive Oxygen Species; Structure-Activity Relationship; Tumor Cells, Cultured | 2011 |
Homeostatic regulation of elemental stoichiometry by Lemna gibba L. G3 when nutrient interact with toxic metals.
Topics: Araceae; Arsenic Trioxide; Arsenicals; Carbon; Homeostasis; Inactivation, Metabolic; Organic Chemicals; Oxides; Phosphates; Uranium Compounds; Water Pollutants, Chemical | 2012 |
Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Cell Line, Tumor; Coculture Techniques; Doxorubicin; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fibroblasts; Fulvestrant; Humans; Hypoglycemic Agents; Intracellular Signaling Peptides and Proteins; Ketone Bodies; Lactic Acid; Metformin; Mitochondria; Oxides; Phosphoric Monoester Hydrolases; Poly(ADP-ribose) Polymerase Inhibitors; Tamoxifen; Tumor Microenvironment | 2011 |
Alteration in miRNA gene expression pattern in acute promyelocytic leukemia cell induced by arsenic trioxide: a possible mechanism to explain arsenic multi-target action.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression; Humans; Leukemia, Promyelocytic, Acute; MicroRNAs; Oxides | 2012 |
Targeting metabolism with arsenic trioxide and dichloroacetate in breast cancer cells.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dichloroacetic Acid; Female; Humans; Membrane Potential, Mitochondrial; Mitochondria; Oxides; Reactive Oxygen Species | 2011 |
[Inhibitory effect of arsenic trioxide on the pulmonary metastasis of melanoma B16 cells].
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Oxides | 2011 |
Effects of Tat peptide on intracellular delivery of arsenic trioxide albumin microspheres.
Topics: Arsenic Trioxide; Arsenicals; Base Sequence; Cell Line, Tumor; Drug Carriers; Electrophoresis; Gene Products, tat; Green Fluorescent Proteins; Humans; Microspheres; Molecular Sequence Data; Oxides; Recombinant Fusion Proteins; Serum Albumin, Bovine; Urinary Bladder Neoplasms | 2012 |
Arsenic trioxide treatment decreases the oxygen consumption rate of tumor cells and radiosensitizes solid tumors.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Lewis Lung; Combined Modality Therapy; Disease Models, Animal; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred C57BL; Oxides; Oxygen Consumption; Radiation-Sensitizing Agents | 2012 |
Arsenic trioxide increases the sensitivity of 786-0 renal carcinoma cells to radiotherapy.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Renal Cell; Cell Line, Tumor; DNA Damage; G2 Phase Cell Cycle Checkpoints; Humans; Kidney Neoplasms; M Phase Cell Cycle Checkpoints; Membrane Potential, Mitochondrial; Oxides; Radiation-Sensitizing Agents; Reactive Oxygen Species | 2012 |
Opposite effects of arsenic trioxide on the Nrf2 pathway in oral squamous cell carcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Carcinoma, Squamous Cell; Cell Proliferation; Colony-Forming Units Assay; Endothelium, Vascular; Heme Oxygenase-1; Humans; Immunoenzyme Techniques; In Vitro Techniques; Mice; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; NAD(P)H Dehydrogenase (Quinone); NF-E2-Related Factor 2; Oxidative Stress; Oxides | 2012 |
Microarray analysis revealed dysregulation of multiple genes associated with chemoresistance to As(2)O(3) and increased tumor aggressiveness in a newly established arsenic-resistant ovarian cancer cell line, OVCAR-3/AsR.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gene Expression Profiling; Humans; Interleukin-1alpha; NF-E2-Related Factor 2; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Oxides; Paclitaxel | 2012 |
Effect of phosphatase and tensin homology deleted on chromosome 10 (PTEN) gene transfection on reversal of multidrug resistance in K562/ADM cells.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Survival; Cytarabine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Green Fluorescent Proteins; HEK293 Cells; Humans; Immunoblotting; K562 Cells; Leukemia, Erythroblastic, Acute; Oxides; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; PTEN Phosphohydrolase; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Transcription Factor RelA; Transfection | 2012 |
Promyelocytic leukemia nuclear bodies support a late step in DNA double-strand break repair by homologous recombination.
Topics: Arsenic Trioxide; Arsenicals; Cell Nucleus; DNA Breaks, Double-Stranded; DNA End-Joining Repair; DNA, Neoplasm; Genomic Instability; Histones; Humans; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Phosphorylation; Promyelocytic Leukemia Protein; Rad51 Recombinase; Recombinational DNA Repair; RNA Interference; Transcription Factors; Tretinoin; Tumor Suppressor Proteins | 2012 |
Arsenic trioxide induces cervical cancer apoptosis, but specifically targets human papillomavirus-infected cell populations.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; HeLa Cells; Humans; Oncogene Proteins, Viral; Oxides; Papillomavirus Infections; Repressor Proteins; Tumor Suppressor Protein p53; Uterine Cervical Neoplasms | 2012 |
Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Chromatography, High Pressure Liquid; Drug Monitoring; Female; Humans; Leukemia, Promyelocytic, Acute; Mass Spectrometry; Middle Aged; Neoplasm Recurrence, Local; Oxides; Prognosis; Remission Induction; Salvage Therapy; Tissue Distribution | 2012 |
Sustained molecular remission after arsenic trioxide and gemutuzumab ozogamicin in a pediatric patient with relapsed acute promyelocytic leukemia.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; Benzoates; Child; Drug Administration Schedule; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Recurrence; Remission Induction; Tetrahydronaphthalenes; Tretinoin | 2012 |
MAPK inhibitors and siRNAs differentially affect cell death and ROS levels in arsenic trioxide-treated human pulmonary fibroblast cells.
Topics: Arsenic Trioxide; Arsenicals; Cell Death; Cell Line; Cell Proliferation; Fibroblasts; Glutathione; Humans; Lung; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Oxides; Protein Kinase Inhibitors; Reactive Oxygen Species; RNA, Small Interfering | 2012 |
Effects of inorganic arsenic on bone marrow hematopoietic cells: an emphasis on apoptosis and Sca-1/c-Kit positive population.
Topics: Animals; Antigens, Ly; Apoptosis; Arsenic Trioxide; Arsenicals; Blood Cells; Blood Specimen Collection; Bone Marrow Cells; Cells, Cultured; Drug Evaluation, Preclinical; Flow Cytometry; Hematopoietic Stem Cells; Membrane Proteins; Mice; Oxides; Proto-Oncogene Proteins c-kit | 2010 |
Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma.
Topics: Animals; Arsenic Trioxide; Arsenicals; Bone Neoplasms; Cell Line, Tumor; Female; Growth Inhibitors; Mice; Mice, SCID; Oxides; Sarcoma, Ewing; Xenograft Model Antitumor Assays | 2012 |
[Mechanism of loss of human esophageal cancer-related gene 4 (ECRG4) gene expression in esophageal squamous cell carcinoma cell line EC9706].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Azacitidine; Carcinoma, Squamous Cell; Cell Line, Tumor; CpG Islands; Decitabine; DNA Methylation; Epigenesis, Genetic; Esophageal Neoplasms; Exons; Gene Expression Regulation, Neoplastic; Humans; Mutation; Neoplasm Proteins; Oxides; Promoter Regions, Genetic; RNA, Messenger; Tumor Suppressor Proteins | 2011 |
Are low-intensity induction strategies better for older patients with acute myeloid leukemia?
Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Daunorubicin; Etoposide; Female; Gemtuzumab; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Oxides; Quinolones; Remission Induction; Retrospective Studies; Treatment Outcome | 2012 |
Inhibition of small GTPase RalA regulates growth and arsenic-induced apoptosis in chronic myeloid leukemia (CML) cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; ral GTP-Binding Proteins; RNA Interference; RNA, Small Interfering | 2012 |
Tetramethylpyrazine potentiates arsenic trioxide activity against HL-60 cell lines.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Cycle; Cell Differentiation; Cell Proliferation; Drug Synergism; Flow Cytometry; HL-60 Cells; Humans; Oxides; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction | 2012 |
[Mechanism of arsenic trioxide-induced apoptosis on cell line KBM5R with T315I point mutation].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Oxides; Point Mutation | 2011 |
Molecular targeting therapy against promyelocytic leukemia protein using arsenic acids in experimental intracranial medulloblastoma.
Topics: Animals; Antineoplastic Agents; Arsenates; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cerebellar Neoplasms; Cytarabine; Humans; Medulloblastoma; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neoplasms, Experimental; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Transcription Factors; Tumor Suppressor Proteins | 2012 |
Arsenic trioxide enhances the radiation sensitivity of androgen-dependent and -independent human prostate cancer cells.
Topics: Androgens; Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Body Weight; Cell Line, Tumor; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Therapy, Combination; Humans; Male; Mice; Mice, Nude; Oxides; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Radiation Tolerance; Radiation, Ionizing; Signal Transduction; Time Factors; Tumor Burden | 2012 |
The influence of modified pluronic F127 copolymers with higher phase transition temperature on arsenic trioxide-releasing properties and toxicity in a subcutaneous model of rats.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biomarkers; Chemistry, Pharmaceutical; Drug Carriers; Heart; Hydrogels; Injections, Subcutaneous; Kidney; Liver; Male; Metal Nanoparticles; Myocardium; Oxidation-Reduction; Oxides; Poloxamer; Rats; Rats, Wistar; Rheology; Silver; Solubility; Technology, Pharmaceutical; Transition Temperature; Viscosity | 2012 |
Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Molecular Diagnostic Techniques; Monitoring, Physiologic; Neoadjuvant Therapy; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Predictive Value of Tests; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Young Adult | 2012 |
Arsenic trioxide exerts antimyeloma effects by inhibiting activity in the cytoplasmic substrates of histone deacetylase 6.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Cytoplasm; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; HSP90 Heat-Shock Proteins; Humans; I-kappa B Kinase; Immunoprecipitation; Multiple Myeloma; Oxides; Phosphorylation; Signal Transduction; Tubulin | 2012 |
Long-term remission in a case of acute promyelocytic leukemia patient with marked myelofibrosis treated with arsenic trioxide, all-trans retinoic acid and consolidation therapy with daunorubicin plus cytarabine.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Primary Myelofibrosis; Remission Induction; Survivors; Tretinoin | 2012 |
[Regulation of all-trans retinoic acid and arsenic trioxide on CD44v6 expression in NB4 cells].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Gene Expression Regulation, Leukemic; Humans; Hyaluronan Receptors; Leukemia, Promyelocytic, Acute; Oxides; Signal Transduction; Tretinoin | 2012 |
[Caspase-independent apoptosis induced by arsenic trioxide in human multiple myeloma cell RPMI8226].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Line, Tumor; Humans; Multiple Myeloma; Oxides; Proto-Oncogene Proteins c-bcl-2 | 2012 |
Effects of arsenic trioxide combined with bortezomib on apoptosis of multiple myeloma cell line KM3 and its mechanisms.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Bcl-2-Like Protein 11; bcl-X Protein; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Humans; Membrane Proteins; Multiple Myeloma; Oxides; Proto-Oncogene Proteins; Pyrazines | 2012 |
The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA.
Topics: Animals; Arsenic Trioxide; Arsenicals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Transformation, Neoplastic; HEK293 Cells; Humans; Lung Neoplasms; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Polymorphism, Single Nucleotide; Promyelocytic Leukemia Protein; Protein Inhibitors of Activated STAT; Rats; Small Ubiquitin-Related Modifier Proteins; Transcription Factors; Transfection; Tumor Suppressor Proteins; Ubiquitin | 2012 |
Quantification of PML/RARa transcript after induction predicts outcome in children with acute promyelocytic leukemia.
Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Multivariate Analysis; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Prognosis; Real-Time Polymerase Chain Reaction; Remission Induction; Transcription, Genetic; Treatment Outcome; Tretinoin | 2012 |
Preparation of a new nanosized As2O3/Mn0.5Zn0.5Fe2O4 thermosensitive magnetoliposome and its antitumor effect on MDA_MB_231 cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Ferric Compounds; Humans; Liposomes; Magnetics; Manganese; Microscopy, Electron, Transmission; Nanoparticles; Oxides; Zinc | 2011 |
Mitochondrial myopathy caused by arsenic trioxide therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; DNA Mutational Analysis; Female; Humans; Leukemia, Promyelocytic, Acute; Mitochondria, Muscle; Mitochondrial Myopathies; Oxides; Tretinoin | 2012 |
Direct effects of arsenic trioxide on action potentials in isolated cardiac tissues: importance of the choice of species, type of cardiac tissue and perfusion time.
Topics: Action Potentials; Animals; Animals, Laboratory; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Electrophysiologic Techniques, Cardiac; Female; Guinea Pigs; Heart; In Vitro Techniques; Male; Myocardial Reperfusion; Oxides; Perfusion; Purkinje Fibers; Rabbits; Species Specificity; Swine; Swine, Miniature; Time Factors; Toxicity Tests; Ventricular Premature Complexes | 2012 |
Parenthood in patients with acute promyelocytic leukemia after treatment with arsenic trioxide: a case series.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Fertility; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Pregnancy; Pregnancy Outcome | 2012 |
Arsenic trioxide affects bone remodeling by effects on osteoblast differentiation and function.
Topics: Alkaline Phosphatase; Animals; Arsenic Trioxide; Arsenicals; Base Sequence; Bone Density; Bone Remodeling; Cell Differentiation; Cells, Cultured; Collagen Type I; Core Binding Factor Alpha 1 Subunit; Interleukin-6; Male; Osteoblasts; Osteocalcin; Oxidative Stress; Oxides; Peptide Fragments; Peptides; Procollagen; Rats; Rats, Sprague-Dawley; RNA, Messenger; Transcription Factors; Vascular Cell Adhesion Molecule-1 | 2012 |
Therapeutic effect of Arsenicum album on leukocytes.
Topics: Arsenic Trioxide; Arsenicals; Cell Line, Transformed; Cell Survival; Dose-Response Relationship, Drug; Homeopathy; Humans; Leukocytes; Neoplasms; Oxides | 2012 |
Arsenic trioxide prevents murine sclerodermatous graft-versus-host disease.
Topics: Animals; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Chronic Disease; Disease Models, Animal; Female; Fibrosis; Graft vs Host Disease; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Oxides; Random Allocation; Scleroderma, Systemic; Spleen | 2012 |
Arsenic trioxide induces abnormal mitotic spindles through a PIP4KIIγ/Rho pathway.
Topics: Arsenic Trioxide; Arsenicals; Base Sequence; Cell Line; DNA Primers; Fluorescent Antibody Technique; GTP Phosphohydrolases; Humans; Oxides; Protein Kinases; Reverse Transcriptase Polymerase Chain Reaction; Spindle Apparatus | 2012 |
Inhibition of the heat shock response by PI103 enhances the cytotoxicity of arsenic trioxide.
Topics: Arsenic Trioxide; Arsenicals; Base Sequence; Blotting, Western; Cells, Cultured; DNA Primers; DNA-Binding Proteins; Electrophoretic Mobility Shift Assay; Furans; Heat Shock Transcription Factors; Heat-Shock Proteins; Heat-Shock Response; Humans; Oxides; Phosphorylation; Polymerase Chain Reaction; Pyridines; Pyrimidines; Transcription Factors; Transcriptional Activation | 2012 |
Antitumor effect of arsenic trioxide in human K562 and K562/ADM cells by autophagy.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Autophagy; Beclin-1; Blotting, Western; Cell Culture Techniques; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; Membrane Proteins; Microscopy, Electron, Transmission; Microscopy, Phase-Contrast; Microtubule-Associated Proteins; Oxides; Proto-Oncogene Proteins c-bcl-2; Real-Time Polymerase Chain Reaction; Vacuoles | 2012 |
Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Proliferation; Cell Transformation, Neoplastic; Cells, Cultured; Epithelial Cells; Female; Gene Regulatory Networks; Humans; Lung; Lung Neoplasms; Mice; Mitochondria; Neoplasm Invasiveness; Occupational Exposure; Oligonucleotide Array Sequence Analysis; Oxides; PPAR alpha; Signal Transduction | 2012 |
Does arsenic trioxide impact fertility?
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Fertility; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Pregnancy | 2012 |
NADPH oxidase-produced superoxide mediates EGFR transactivation by c-Src in arsenic trioxide-stimulated human keratinocytes.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line; Enzyme Inhibitors; Epidermal Growth Factor; Humans; Keratinocytes; NADPH Oxidases; Oxides; Phosphorylation; Protein Transport; Reactive Oxygen Species; src-Family Kinases; Superoxides | 2012 |
Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Staging; Oxides; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Treatment Outcome; Tretinoin; Young Adult | 2012 |
Darinaparsin: solid tumor hypoxic cytotoxin and radiosensitizer.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Marrow; Cell Hypoxia; Glutathione; Humans; Intestines; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Oxides; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins p21(ras); Radiation-Sensitizing Agents; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2012 |
[Expression of homeobox A9 in myeloid leukemia cell line HL-60 and effect of drugs on its expression].
Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; HL-60 Cells; Homeodomain Proteins; Humans; Leukemia, Myeloid; Oxides; RNA, Messenger; Tretinoin | 2012 |
Arsenic trioxide (ATO) influences the gene expression of metallothioneins in human glioblastoma cells.
Topics: Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Gene Expression; Glioblastoma; Humans; Metallothionein; Oxides | 2012 |
Arsenic induces functional re-expression of estrogen receptor α by demethylation of DNA in estrogen receptor-negative human breast cancer.
Topics: Animals; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Cell Line, Tumor; CpG Islands; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Neoplasm Proteins; Oxides; Polymerase Chain Reaction; Promoter Regions, Genetic; Protein Binding; RNA, Messenger; Sequence Analysis, DNA | 2012 |
Reactive oxygen species-mediated killing of activated fibroblasts by arsenic trioxide ameliorates fibrosis in a murine model of systemic sclerosis.
Topics: Animals; Arsenic Trioxide; Arsenicals; Autoantibodies; Collagen; Disease Models, Animal; Fibroblasts; Fibrosis; Glutathione; Interleukin-13; Interleukin-4; Mice; Oxides; Reactive Oxygen Species; Scleroderma, Systemic; Skin; Vascular Cell Adhesion Molecule-1 | 2012 |
Factors determining sensitivity and resistance of tumor cells to arsenic trioxide.
Topics: Actin Cytoskeleton; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cytotoxins; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Oxides; RNA, Messenger; RNA, Neoplasm; Signal Transduction | 2012 |
Arsenic induces apoptosis in myoblasts through a reactive oxygen species-induced endoplasmic reticulum stress and mitochondrial dysfunction pathway.
Topics: Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Cell Line; Cytotoxins; Endoplasmic Reticulum Stress; Humans; Mitochondria; Myoblasts; Oxides; Reactive Oxygen Species; Signal Transduction | 2012 |
Targeted inhibition of VEGF-modulated survival and arsenic sensitivity in acute myeloid leukemia (AML).
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Proliferation; Cell Survival; Drug Synergism; Gene Silencing; HL-60 Cells; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Oligonucleotides, Antisense; Oxides; Primary Cell Culture; Transfection; Trypan Blue; Vascular Endothelial Growth Factor A | 2012 |
Cardiac conduction block at multiple levels caused by arsenic trioxide therapy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Chelating Agents; Dimercaprol; Electrocardiography; Female; Follow-Up Studies; Growth Inhibitors; Heart Block; Heart Conduction System; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides | 2013 |
Regulatory role of KEAP1 and NRF2 in PPARγ expression and chemoresistance in human non-small-cell lung carcinoma cells.
Topics: Antineoplastic Agents; Antioxidant Response Elements; Arsenic Trioxide; Arsenicals; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation; Gene Knockdown Techniques; Glutamate-Cysteine Ligase; Heme Oxygenase-1; Humans; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Lung Neoplasms; Models, Biological; NAD(P)H Dehydrogenase (Quinone); Neoplastic Stem Cells; NF-E2-Related Factor 2; Oxides; PPAR gamma; Proto-Oncogene Mas; RNA Interference; Rosiglitazone; Thiazolidinediones | 2012 |
Arsenic trioxide induces human pulmonary fibroblast cell death via increasing ROS levels and GSH depletion.
Topics: Acetylcysteine; Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Buthionine Sulfoximine; Cell Death; Cell Line, Tumor; Fibroblasts; Glutathione; Humans; Lung; Oxides; Reactive Oxygen Species; Transfection | 2012 |
The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Nucleus; Cytoplasm; Fluorescent Antibody Technique; Humans; Leukemia, Promyelocytic, Acute; Mutation; Nuclear Pore Complex Proteins; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Recycling; Sumoylation; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2012 |
[Inhibitory mechanism on growth of MA-891 cells by arsenic trioxide].
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Dose-Response Relationship, Drug; Mammary Neoplasms, Experimental; Mice; Oxides; Telomerase | 2012 |
Altered arsenic disposition in experimental nonalcoholic fatty liver disease.
Topics: Animals; Arsenates; Arsenic Trioxide; Arsenicals; Biotransformation; Choline Deficiency; Diet, High-Fat; Disease Models, Animal; Environmental Pollutants; Fatty Liver; Kidney; Liver; Male; Methionine; Methyltransferases; Mice; Mice, Inbred C57BL; Multidrug Resistance-Associated Proteins; Non-alcoholic Fatty Liver Disease; Oxides | 2012 |
Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Female; Humans; Incidence; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; SEER Program; Time Factors; Tretinoin; United States | 2012 |
Synergistic anti-tumor effects of combination of photodynamic therapy and arsenic compound in cervical cancer cells: in vivo and in vitro studies.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Gene Expression Regulation, Neoplastic; Mice; Neoplasm Proteins; Neoplasms, Experimental; Oxides; Photochemotherapy; Uterine Cervical Neoplasms | 2012 |
Carbonyl reductase 1 offers a novel therapeutic target to enhance leukemia treatment by arsenic trioxide.
Topics: Alcohol Oxidoreductases; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Female; Gene Knockdown Techniques; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid; Mice; Mice, Inbred BALB C; NADPH Oxidases; Oxides; Promoter Regions, Genetic; Reactive Oxygen Species; Transcription Factor AP-1; U937 Cells; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
Arsenic trioxide induces G2/M arrest in hepatocellular carcinoma cells by increasing the tumor suppressor PTEN expression.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; CDC2 Protein Kinase; Cell Cycle Proteins; Cell Line, Tumor; Cyclin B; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Nuclear Proteins; Oxides; Phosphorylation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; RNA, Small Interfering; Signal Transduction | 2012 |
Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Down-Regulation; Enzyme Activation; Flow Cytometry; Glutathione; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Leukemia, Myeloid, Acute; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Oxides; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; RNA, Small Interfering; Tumor Cells, Cultured | 2013 |
The organic arsenic derivative GMZ27 induces PML-RARα-independent apoptosis in myeloid leukemia cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 9; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Activation; Female; HL-60 Cells; Humans; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Mice; Oncogene Proteins, Fusion; Oxides; Oxygen | 2012 |
Redox-related antimelanoma activity of ATN-224.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disulfiram; Drug Synergism; Enzyme Inhibitors; Glutathione; Humans; Melanins; Melanoma; Molybdenum; Oxidation-Reduction; Oxides; Reactive Oxygen Species; Superoxide Dismutase; Temozolomide | 2009 |
Effects and mechanism of arsenic trioxide on reversing the asthma pathologies including Th17-IL-17 axis in a mouse model.
Topics: Animals; Anti-Asthmatic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Asthma; Bronchial Hyperreactivity; Bronchial Provocation Tests; Calcium; Caspase 12; Cells, Cultured; Dexamethasone; Disease Models, Animal; Female; Interleukin-17; Lung; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Mucus; Ovalbumin; Oxides; Signal Transduction; Th17 Cells | 2012 |
[Effect of arsenic trioxide and daunorubicin on procoagulant activity of acute promyelocytic leukemia cells].
Topics: Adult; Arsenic Trioxide; Arsenicals; Blood Coagulation; Blood Coagulation Tests; Case-Control Studies; Daunorubicin; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Phosphatidylserines; Thromboplastin; Tumor Cells, Cultured; Young Adult | 2012 |
Kidney transplantation in a patient with end stage renal disease after complete remission of acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Humans; Kidney Failure, Chronic; Kidney Transplantation; Leukemia, Promyelocytic, Acute; Male; Oxides; Receptors, Retinoic Acid; Remission Induction; Retinoic Acid Receptor alpha; Ultrasonography | 2012 |
Radiosensitivity enhancement by arsenic trioxide in conjunction with hyperthermia in the EC-1 esophageal carcinoma cell line.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Esophageal Neoplasms; Humans; Hyperthermia, Induced; Inhibitory Concentration 50; Oxides; Radiation Tolerance; Radiotherapy Dosage | 2012 |
[Changes of cdk5, p35 and p53 gene expression levels in arsenic-induced neural cell apoptosis].
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cells, Cultured; Cyclin-Dependent Kinase 5; Neurons; Oxides; Phosphotransferases; Rats; Tumor Suppressor Protein p53 | 2012 |
Polycomb (PcG) proteins, BMI1 and SUZ12, regulate arsenic-induced cell transformation.
Topics: 3T3 Cells; Animals; Arsenic; Arsenic Trioxide; Arsenicals; Cell Transformation, Neoplastic; Cyclin-Dependent Kinase Inhibitor p16; Gene Expression Regulation, Neoplastic; Histones; Humans; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Oxides; Polycomb Repressive Complex 1; Polycomb Repressive Complex 2; Polycomb-Group Proteins; Proto-Oncogene Proteins; Signal Transduction | 2012 |
Arsenic-induced interstitial myocardial fibrosis reveals a new insight into drug-induced long QT syndrome.
Topics: Animals; Animals, Newborn; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Collagen; Down-Regulation; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fibroblasts; Fibrosis; Guinea Pigs; HEK293 Cells; Humans; Long QT Syndrome; Myocardium; Myocytes, Cardiac; Oxides; Potassium Channels, Inwardly Rectifying; Rats; Rats, Wistar; Signal Transduction; Transforming Growth Factor beta1 | 2012 |
Cbl-b-dependent degradation of FLIP(L) is involved in ATO-induced autophagy in leukemic K562 and gastric cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Arsenic Trioxide; Arsenicals; Autophagy; Base Sequence; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Cell Survival; Humans; Jurkat Cells; K562 Cells; Leukemia; Oxides; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-cbl; RNA, Small Interfering; Signal Transduction; Stomach Neoplasms; Ubiquitin | 2012 |
Upregulation of microRNA-1 and microRNA-133 contributes to arsenic-induced cardiac electrical remodeling.
Topics: Animals; Arsenic Trioxide; Arsenicals; Atrial Remodeling; Cells, Cultured; Guinea Pigs; Long QT Syndrome; Male; MicroRNAs; Myocytes, Cardiac; Oxides; Up-Regulation | 2013 |
Upfront maintenance therapy with arsenic trioxide in acute promyelocytic leukemia provides no benefit for non-t(15;17) subtype.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Humans; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Mercaptopurine; Middle Aged; Oxides; Retrospective Studies; Tretinoin | 2012 |
Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autophagy; Autophagy-Related Protein 7; Cathepsin B; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lysosomes; Oxides; Phosphorylation; Plasmids; Primary Cell Culture; Proteolysis; Sequestosome-1 Protein; Signal Transduction; Transfection; Ubiquitin-Activating Enzymes | 2012 |
Oral administration of arsenic trioxide in the treatment of acute promyelocytic leukaemia and accelerated phase chronic myeloid leukaemia: an Australian single-centre study.
Topics: Administration, Oral; Adult; Aged; Arsenic Trioxide; Arsenicals; Australia; Female; Growth Inhibitors; Humans; Leukemia, Myeloid, Accelerated Phase; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Treatment Outcome | 2012 |
ATRA plus arsenic gets another "A" in APL.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Oxides; Tretinoin | 2012 |
Arsenic trioxide synergizes with everolimus (Rad001) to induce cytotoxicity of ovarian cancer cells through increased autophagy and apoptosis.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Caspase 3; Caspase 7; Cell Cycle Proteins; Cell Line, Tumor; Drug Synergism; Everolimus; Female; Humans; Immunosuppressive Agents; Mice; Mice, SCID; Ovarian Neoplasms; Oxides; Phosphoproteins; Proto-Oncogene Proteins c-akt; Sirolimus; Xenograft Model Antitumor Assays | 2012 |
Sulforaphane synergistically enhances the cytotoxicity of arsenic trioxide in multiple myeloma cells via stress-mediated pathways.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspases, Initiator; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Drug Synergism; eIF-2 Kinase; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Eukaryotic Initiation Factor-2; Glutathione; HSP90 Heat-Shock Proteins; Humans; I-kappa B Kinase; Isothiocyanates; Multiple Myeloma; Oxides; Phosphorylation; Poly(ADP-ribose) Polymerases; Reactive Oxygen Species; Regulatory Factor X Transcription Factors; Signal Transduction; Sulfoxides; Thiocyanates; Transcription Factors; Tumor Necrosis Factor-alpha; Unfolded Protein Response; X-Box Binding Protein 1 | 2012 |
Radiosensitizing effects of arsenic trioxide on MCF-7 human breast cancer cells exposed to 89 strontium chloride.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2 Homologous Antagonist-Killer Protein; bcl-X Protein; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Oxides; Radiation-Sensitizing Agents; RNA, Messenger; Strontium | 2012 |
Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia.
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prognosis; Recurrence | 2013 |
Granulocyte colony-stimulating factor potentiates differentiation induction by all-trans retinoic acid and arsenic trioxide and enhances arsenic uptake in the acute promyelocytic leukemia cell line HT93A.
Topics: Antigens, CD34; Apoptosis; Aquaporins; Arsenic Trioxide; Arsenicals; Biological Transport; Biomarkers, Tumor; CD11b Antigen; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Promyelocytic, Acute; Lewis X Antigen; Oxides; Tretinoin; Up-Regulation | 2012 |
Cytotoxic effect of arsenic trioxide on acute promyelocytic leukemia cells through suppression of NFkβ-dependent induction of hTERT due to down-regulation of Pin1 transcription.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA-Binding Proteins; Down-Regulation; Gene Expression Regulation, Leukemic; Genes, myc; Humans; Inhibitor of Apoptosis Proteins; Leukemia, Promyelocytic, Acute; NF-kappa B; NIMA-Interacting Peptidylprolyl Isomerase; Nuclear Proteins; Oxides; Peptidylprolyl Isomerase; Phosphorylation; Survivin; Telomerase; Telomere Shortening; Transcription, Genetic; Tumor Protein p73; Tumor Suppressor Proteins | 2012 |
Arsenic trioxide inhibits cell growth and induces apoptosis through inactivation of notch signaling pathway in breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Breast Neoplasms; Cell Movement; Cell Proliferation; Female; Humans; NF-kappa B; Oxides; Real-Time Polymerase Chain Reaction; Receptors, Notch; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Tumor Cells, Cultured | 2012 |
Endoplasmic reticulum stress contributes to arsenic trioxide-induced apoptosis in drug-sensitive and -resistant leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caspase 12; DNA-Binding Proteins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Growth Inhibitors; Heat-Shock Proteins; Humans; K562 Cells; Oxides; Proto-Oncogene Proteins c-bcl-2; Regulatory Factor X Transcription Factors; Signal Transduction; Transcription Factor CHOP; Transcription Factors | 2012 |
Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines.
Topics: Adult; AMP-Activated Protein Kinases; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blotting, Western; Carcinoma, Hepatocellular; Cell Line; Cell Proliferation; Cell Survival; Drug Synergism; Enzyme Activation; Fluorouracil; Gene Expression Regulation, Enzymologic; Growth Inhibitors; Hep G2 Cells; Hepatic Stellate Cells; Humans; Inhibitory Concentration 50; Liver Neoplasms; Niacinamide; Oxides; Phenylurea Compounds; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Thymidylate Synthase; Time Factors | 2012 |
Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study.
Topics: Aged; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Female; Gene Expression; Genes, bcl-2; Humans; Male; Myelodysplastic Syndromes; Oxides; Real-Time Polymerase Chain Reaction | 2012 |
Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Drug Synergism; Humans; Lymphoma, Mantle-Cell; Oxides; Pyrazines | 2012 |
[microRNAs expression profile in acute promyelocytic leukemia cell differentiation induced by all-trans retinoic acid and arsenic trioxide].
Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; MicroRNAs; Oxides; RNA, Messenger; Tretinoin; Tumor Cells, Cultured | 2012 |
ABT-737 synergizes with arsenic trioxide to induce apoptosis of gastric carcinoma cells in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Biphenyl Compounds; Carcinoma; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nitrophenols; Oxides; Piperazines; Stomach Neoplasms; Sulfonamides; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
[Effects of arsenic trioxide on the proliferation of human breast cancer SKBR-3 cell and the expression of Notch1].
Topics: Arsenic Trioxide; Arsenicals; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Humans; Oxides; Receptor, Notch1; RNA, Messenger; Signal Transduction | 2012 |
Arsenic trioxide-induced growth arrest of breast cancer MCF-7 cells involving FOXO3a and IκB kinase β expression and localization.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Caspase 3; Cell Growth Processes; Female; Flow Cytometry; Forkhead Box Protein O3; Forkhead Transcription Factors; Growth Inhibitors; Humans; I-kappa B Kinase; Immunohistochemistry; MCF-7 Cells; Oxides; RNA, Messenger; Signal Transduction; Tumor Necrosis Factor-alpha | 2012 |
Linker for activation of T-cell family member2 (LAT2) a lipid raft adaptor protein for AKT signaling, is an early mediator of alkylphospholipid anti-leukemic activity.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Line; Cell Proliferation; Cholesterol; Enzyme Activation; Humans; Leukemia; Membrane Microdomains; Oxides; Phosphatidylinositol 3-Kinases; Phospholipids; Phosphorylcholine; Protein Structure, Tertiary; Proteome; Proto-Oncogene Proteins c-akt; RNA Interference; RNA, Small Interfering; Signal Transduction | 2012 |
High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Retrospective Studies; Tretinoin | 2013 |
Resveratrol attenuates hepatotoxicity of rats exposed to arsenic trioxide.
Topics: Animals; Antioxidants; Arsenic; Arsenic Trioxide; Arsenicals; Catalase; Glutathione; Glutathione Disulfide; Liver; Male; Oxidative Stress; Oxides; Rats; Rats, Wistar; Resveratrol; Stilbenes; Superoxide Dismutase | 2013 |
Protective and antioxidant role of selenium on arsenic trioxide-induced oxidative stress and genotoxicity in the fish hepatoma cell line PLHC-1.
Topics: Acetylcysteine; Animals; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Line, Tumor; DNA Damage; Fishes; Free Radical Scavengers; Hazardous Substances; Membrane Potential, Mitochondrial; Mutagens; Oxidative Stress; Oxides; Reactive Oxygen Species; Selenium | 2012 |
Requirement of PML SUMO interacting motif for RNF4- or arsenic trioxide-induced degradation of nuclear PML isoforms.
Topics: Amino Acid Motifs; Animals; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Nucleus; Cytoplasm; Humans; Mice; Mutation; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Proteasome Endopeptidase Complex; Protein Binding; Protein Isoforms; Proteolysis; SUMO-1 Protein; Sumoylation; Transcription Factors; Tumor Suppressor Proteins | 2012 |
Comparison of optical and power Doppler ultrasound imaging for non-invasive evaluation of arsenic trioxide as a vascular disrupting agent in tumors.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Vessels; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Optical Imaging; Oxides; Prostatic Neoplasms; Ultrasonography, Doppler | 2012 |
Near infrared imaging of EGFR of oral squamous cell carcinoma in mice administered arsenic trioxide.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Body Weight; Carbocyanines; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Gene Expression; Injections, Intraperitoneal; Injections, Intravenous; Magnetic Resonance Imaging; Mice; Mice, Nude; Mouth Neoplasms; Neoplasms, Experimental; Oxides; Recombinant Fusion Proteins; Spectroscopy, Near-Infrared; Tumor Burden; Tumor Cells, Cultured | 2012 |
2-Deoxy-D-glucose cooperates with arsenic trioxide to induce apoptosis in leukemia cells: involvement of IGF-1R-regulated Akt/mTOR, MEK/ERK and LKB-1/AMPK signaling pathways.
Topics: Adenosine Triphosphate; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Division; Cell Line, Tumor; Deoxyglucose; Humans; Leukemia; Mitochondria; Oxidative Stress; Oxides; Protein Kinase Inhibitors; Protein Kinases; Receptor, IGF Type 1; Signal Transduction; TOR Serine-Threonine Kinases | 2012 |
Arsenic trioxide improves hematopoiesis in refractory severe aplastic anemia.
Topics: Adult; Anemia, Aplastic; Anemia, Refractory; Arsenic Trioxide; Arsenicals; Female; Hematopoiesis; Humans; Male; Middle Aged; Oxides; Survival Rate; Treatment Outcome; Young Adult | 2012 |
BCR-ABL1-induced leukemogenesis and autophagic targeting by arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autophagy; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Neoplastic Stem Cells; Oxides; Translational Research, Biomedical | 2013 |
Feasibility of oral arsenic trioxide treatment for acute promyelocytic leukemia during hemodialysis.
Topics: Administration, Oral; Adult; Arsenic Trioxide; Arsenicals; Feasibility Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Renal Dialysis; Treatment Outcome | 2013 |
Arsenic trioxide for refractory aplastic anemia.
Topics: Anemia, Aplastic; Anemia, Refractory; Arsenic Trioxide; Arsenicals; Humans; Male; Oxides; Young Adult | 2013 |
Mitigation of hepatotoxic effects of arsenic trioxide through omega-3 fatty acid in rats.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Antioxidants; Arsenic Trioxide; Arsenicals; Aspartate Aminotransferases; Body Weight; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Fatty Acids, Omega-3; Glutathione; L-Lactate Dehydrogenase; Lipid Peroxidation; Liver; Male; Oxides; Rats; Rats, Wistar | 2014 |
Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide-treated myeloid leukemia and lymphoma cells: the role of glutathione S-transferase p1-1.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Catalase; Cell Line, Tumor; Drug Synergism; Enzyme Activation; Ethacrynic Acid; Glutathione; Glutathione S-Transferase pi; Humans; Leukemia, Myeloid; Lymphoma; MAP Kinase Kinase 4; Membrane Potential, Mitochondrial; Myeloid Cell Leukemia Sequence 1 Protein; Oxides; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Signal Transduction | 2012 |
Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Follow-Up Studies; Germany; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Leukocyte Count; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Oxides; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Risk; Thioguanine; Treatment Outcome; Tretinoin | 2013 |
Prognostic significance of CD44v6/v7 in acute promyelocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Female; Humans; Hyaluronan Receptors; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Tretinoin; Tumor Cells, Cultured; Young Adult | 2012 |
BCR-ABL/p62/SQSTM1: a cannibal embrace.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autophagy; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Signal Transduction | 2012 |
Arsenic trioxide-induced hERG K(+) channel deficiency can be rescued by matrine and oxymatrine through up-regulating transcription factor Sp1 expression.
Topics: Action Potentials; Alkaloids; Animals; Arsenic Trioxide; Arsenicals; Cardiovascular Agents; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Guinea Pigs; HEK293 Cells; Humans; In Vitro Techniques; Matrines; Myocytes, Cardiac; Oxides; Patch-Clamp Techniques; Promoter Regions, Genetic; Quinolizines; Sp1 Transcription Factor; Up-Regulation | 2013 |
Arsenic trioxide exerts antitumor activity through regulatory T cell depletion mediated by oxidative stress in a murine model of colon cancer.
Topics: Animals; Arsenic Trioxide; Arsenicals; CD8-Positive T-Lymphocytes; Colonic Neoplasms; Enzyme Inhibitors; Female; Fluorescein; Fluoresceins; Humans; Immunotherapy, Adoptive; Lymphocyte Activation; Lymphocyte Depletion; Metalloporphyrins; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Oxidative Stress; Oxides; Reactive Nitrogen Species; Reactive Oxygen Species; Superoxide Dismutase; T-Lymphocytes, Regulatory | 2012 |
Arsenic trioxide prevents nitric oxide production in lipopolysaccharide -stimulated RAW 264.7 by inhibiting a TRIF-dependent pathway.
Topics: Adaptor Proteins, Vesicular Transport; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Interferon Regulatory Factor-3; Interferon-beta; Lipopolysaccharide Receptors; Lipopolysaccharides; Macrophages; Mice; Mitogen-Activated Protein Kinase Kinases; Myeloid Differentiation Factor 88; NF-kappa B; Nitric Oxide; Nitric Oxide Synthase Type II; Oxides; Phosphorylation; RNA, Messenger; Signal Transduction; STAT1 Transcription Factor; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2013 |
Arsenic trioxide (As(2)O(3)) induces apoptosis and necrosis mediated cell death through mitochondrial membrane potential damage and elevated production of reactive oxygen species in PLHC-1 fish cell line.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line; Fishes; Membrane Potential, Mitochondrial; Mitochondria; Necrosis; Oxides; Reactive Oxygen Species; Water Pollutants, Chemical | 2013 |
[Management of relapsed acute promyelocytic leukemia].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoates; Brain; Humans; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Oxides; Recurrence; Tetrahydronaphthalenes | 2012 |
[Arsenic trioxide restores ERα expression in ERα-negative human breast cancer cells and its treatment efficacy in combination with tamoxifen in xenografts in nude mice].
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Dose-Response Relationship, Drug; Estrogen Receptor alpha; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Oxides; RNA, Messenger; Tamoxifen; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Arsenic trioxide toxicity in H9c2 myoblasts--damage to cell organelles and possible amelioration with Boerhavia diffusa.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Calcium Signaling; Cardiomyopathies; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Membrane Potential, Mitochondrial; Myoblasts, Cardiac; Nyctaginaceae; Organelles; Oxidative Stress; Oxides; Plant Extracts; Plants, Medicinal; Rats; Reactive Oxygen Species | 2013 |
Long term curative effects of sequential therapy with all-trans retinoic acid, arsenious oxide and chemotherapy on patients with acute promyelocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Treatment Outcome; Tretinoin; Young Adult | 2012 |
Influence of anticancer agents on cell survival, proliferation, and CD4+CD25+Foxp3+ regulatory T cell-frequency in human peripheral-blood mononuclear cells activated by T cell-mitogen.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Proliferation; Cell Survival; Concanavalin A; Cytokines; Dacarbazine; Female; Fluorouracil; Humans; Immunosuppressive Agents; Leukocytes, Mononuclear; Male; Methotrexate; Mitogens; Oxides; T-Lymphocytes, Regulatory; Young Adult | 2013 |
SnoN/SkiL expression is modulated via arsenic trioxide-induced activation of the PI3K/AKT pathway in ovarian cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Neoplasm Proteins; Ovarian Neoplasms; Oxides; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; RNA Interference; Shc Signaling Adaptor Proteins; Signal Transduction; Src Homology 2 Domain-Containing, Transforming Protein 1; src-Family Kinases | 2013 |
Cardioprotective effect of salvianolic acid B against arsenic trioxide-induced injury in cardiac H9c2 cells via the PI3K/Akt signal pathway.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; bcl-X Protein; Benzofurans; Blotting, Western; Cardiovascular Diseases; Caspase 3; Cell Line; Cell Survival; L-Lactate Dehydrogenase; Myocytes, Cardiac; Oxides; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Signal Transduction | 2013 |
The deubiquitinating enzyme USP37 regulates the oncogenic fusion protein PLZF/RARA stability.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Transformation, Neoplastic; Endopeptidases; Gene Expression Regulation, Leukemic; Humans; Leukemia, Promyelocytic, Acute; Mice; Oncogene Proteins, Fusion; Oxides; Protein Stability; Translocation, Genetic | 2013 |
Effects of arsenic trioxide (As(2)O(3)) on airway remodeling in a murine model of bronchial asthma.
Topics: Airway Remodeling; Animals; Arsenic Trioxide; Arsenicals; Asthma; Bronchi; Dexamethasone; Female; Lung; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Ovalbumin; Oxides; Random Allocation; Respiratory Function Tests; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A | 2012 |
Effect of subchronic exposure to arsenic on levels of essential trace elements in mice brain and its gender difference.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cerebellum; Cerebrum; Chromium; Copper; Environmental Pollutants; Female; Iron; Male; Mice; Oxides; Selenium; Sex Factors; Tissue Distribution; Trace Elements; Zinc | 2013 |
[Inhibitory effect of arsenic trioxide on invasion in human hepatocellular carcinoma SMMC-7721 cells and its mechanism].
Topics: Arsenic Trioxide; Arsenicals; Basigin; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Matrix Metalloproteinase 2; Neoplasm Invasiveness; Oxides | 2012 |
Potential role of sodium-proton exchangers in the low concentration arsenic trioxide-increased intracellular pH and cell proliferation.
Topics: Amiloride; Analysis of Variance; Animals; Arsenic Trioxide; Arsenicals; Blotting, Western; Carbazoles; Cell Count; Cell Fractionation; Cell Proliferation; Dogs; Flavonoids; Fluorometry; Hydrogen-Ion Concentration; Imidazoles; Macrolides; Madin Darby Canine Kidney Cells; Oxides; Sodium-Hydrogen Exchangers | 2012 |
Synergism between carnosic acid and arsenic trioxide on induction of acute myeloid leukemia cell apoptosis is associated with modulation of PTEN/Akt signaling pathway.
Topics: Abietanes; Apoptosis; Arsenic Trioxide; Arsenicals; Base Sequence; Blotting, Western; Cell Cycle; DNA Primers; Drug Synergism; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Oxides; Plant Extracts; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2012 |
Arsenic trioxide regulates the production and activities of matrix metalloproteinases-1, -2, and -9 in fibroblasts and THP-1.
Topics: Arsenic Trioxide; Arsenicals; Cell Line; Cells, Cultured; Electrophoresis, Polyacrylamide Gel; Fibroblasts; Humans; Interleukin-1; Matrix Metalloproteinase 1; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Monocytes; Oxides; Tumor Necrosis Factor-alpha | 2012 |
Aberrant overexpression of FOXM1 transcription factor plays a critical role in lung carcinogenesis induced by low doses of arsenic.
Topics: Adenocarcinoma; Adult; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Proliferation; Cell Transformation, Neoplastic; Cells, Cultured; Dose-Response Relationship, Drug; Forkhead Box Protein M1; Forkhead Transcription Factors; Gene Expression Regulation; Gene Knockdown Techniques; Humans; Lung; Lung Neoplasms; Mice; Mice, SCID; Oxides; Polymorphism, Single Nucleotide; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering | 2014 |
[Effects of cucurmosin combined with common chemotherapeutics on proliferation and apoptosis of NB4 cells].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Oxides; Plant Proteins; Tretinoin | 2012 |
[Effects of arsenic trioxide combined with bortezomib on proliferation and apoptosis of K562 cells and their mechanism].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Proliferation; Drug Synergism; Humans; K562 Cells; NF-kappa B; Oxides; Pyrazines | 2012 |
All-trans retinoic acid and arsenic trioxide resistance of acute promyelocytic leukemia with the variant STAT5B-RARA fusion gene.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; STAT5 Transcription Factor; Tretinoin | 2013 |
Arsenic suppresses cell survival via Pirh2-mediated proteasomal degradation of ΔNp63 protein.
Topics: Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Leupeptins; Oxides; Proteasome Endopeptidase Complex; Protein Stability; Proteolysis; RNA, Messenger; Signal Transduction; Time Factors; Transcription Factors; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases | 2013 |
Alterations in glutathione levels and apoptotic regulators are associated with acquisition of arsenic trioxide resistance in multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Glutathione; Humans; Melphalan; Minor Histocompatibility Antigens; Multiple Myeloma; Oxides; Phenotype; Proto-Oncogene Proteins c-bcl-2 | 2012 |
Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists.
Topics: Anilides; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Basal Cell; Drug Resistance, Neoplasm; Hedgehog Proteins; Itraconazole; Medulloblastoma; Mice; Oxides; Pyridines; Receptors, G-Protein-Coupled; Signal Transduction; Smoothened Receptor | 2013 |
BIBR 1532 increases arsenic trioxide-mediated apoptosis in acute promyelocytic leukemia cells: therapeutic potential for APL.
Topics: Aminobenzoates; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Naphthalenes; Oxides; Telomerase | 2013 |
A case report of acute myeloid leukemia after liver transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow; Cytarabine; Daunorubicin; Hepatitis B; Humans; Leukemia, Myeloid, Acute; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Mitoxantrone; Oxides; Tretinoin | 2013 |
Ultrastructural localization of F-actin using phalloidin and quantum dots in HL-60 promyelocytic leukemia cell line after cell death induction by arsenic trioxide.
Topics: Actins; Apoptosis; Arsenic Trioxide; Arsenicals; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Microscopy, Electron, Transmission; Oxides; Phalloidine; Quantum Dots | 2013 |
Arsenic speciation in saliva of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Topics: Adult; Antineoplastic Agents; Arsenates; Arsenic Trioxide; Arsenicals; Arsenites; Cacodylic Acid; Chromatography, High Pressure Liquid; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukemia, Promyelocytic, Acute; Male; Methylation; Middle Aged; Oxides; Saliva; Spectrophotometry, Atomic | 2013 |
Role of arsenic trioxide in acute promyelocytic leukemia.
Topics: Aminoglycosides; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials, Phase III as Topic; Gemtuzumab; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis; Randomized Controlled Trials as Topic; Tretinoin | 2013 |
Osteoblasts survive the arsenic trioxide treatment by activation of ATM-mediated pathway.
Topics: Animals; Arsenic Trioxide; Arsenicals; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Death; Cell Line; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Cyclin-Dependent Kinases; DNA Damage; DNA Repair; DNA-Binding Proteins; Enzyme Activation; G2 Phase Cell Cycle Checkpoints; Humans; M Phase Cell Cycle Checkpoints; Osteoblasts; Oxides; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases; Rats; Signal Transduction; Tumor Suppressor Proteins | 2013 |
Tetraarsenic oxide and cisplatin induce apoptotic synergism in cervical cancer.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Line, Tumor; Cisplatin; Drug Synergism; Female; Humans; Mice; Oxides; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Determination of arsenic metabolites in patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Chromatography, High Pressure Liquid; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Metabolomics; Middle Aged; Oxides; Young Adult | 2013 |
Inhibition of AKT enhances mitotic cell apoptosis induced by arsenic trioxide.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Growth Inhibitors; HeLa Cells; Humans; Mitosis; Oxides; Proto-Oncogene Proteins c-akt; Up-Regulation | 2013 |
Reversal effect of arsenic sensitivity in human leukemia cell line K562 and K562/ADM using realgar transforming solution.
Topics: Acidithiobacillus; Antineoplastic Agents; Apoptosis; Aquaporins; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; RNA, Messenger; Solutions; Sulfides | 2013 |
Genistein ameliorates adverse cardiac effects induced by arsenic trioxide through preventing cardiomyocytes apoptosis.
Topics: Animals; Anticarcinogenic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Calcium; Calcium Channels, L-Type; Caspase 3; Cells, Cultured; Down-Regulation; Electrocardiography; Genistein; Hemodynamics; JNK Mitogen-Activated Protein Kinases; Long QT Syndrome; Male; Membrane Potential, Mitochondrial; Myocytes, Cardiac; Oxides; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Rats; Rats, Wistar | 2013 |
Arsenic trioxide induced apoptosis in retinoblastoma cells by abnormal expression of microRNA-376a.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Blotting, Western; Caspase 3; Cell Proliferation; Humans; Luciferases; MicroRNAs; Oligonucleotide Array Sequence Analysis; Oxides; Real-Time Polymerase Chain Reaction; Retinoblastoma; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2013 |
Regulation of the kinase RSK1 by arsenic trioxide and generation of antileukemic responses.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Electrophoresis, Polyacrylamide Gel; Humans; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Oxides; Phosphorylation; Ribosomal Protein S6 Kinases, 90-kDa; U937 Cells | 2013 |
Expression of AFP and STAT3 is involved in arsenic trioxide-induced apoptosis and inhibition of proliferation in AFP-producing gastric cancer cells.
Topics: Adult; Aged; alpha-Fetoproteins; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Culture Media, Conditioned; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Staging; Oxides; Prognosis; Proto-Oncogene Proteins c-bcl-2; STAT3 Transcription Factor; Stomach Neoplasms | 2013 |
[Arsenic trioxide enhances TRAIL inducing human lung cancer cell line A549 cells apoptosis by down-regulate the expression of NF-kappaB].
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; NF-kappa B; Oxides; TNF-Related Apoptosis-Inducing Ligand | 2012 |
Arsenic trioxide stabilizes accumulations of adeno-associated virus virions at the perinuclear region, increasing transduction in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line; Dependovirus; Humans; Oxides; Transduction, Genetic; Virion; Virus Replication | 2013 |
Hepatotoxicity from arsenic trioxide for pediatric acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Hodgkin Disease; Humans; Leukemia, Promyelocytic, Acute; Liver; Male; Oxides | 2013 |
Microbial synthesis of poly-3-hydroxybutyrate and its application as targeted drug delivery vehicle.
Topics: Animals; Arsenic Trioxide; Arsenicals; Bacillus; Cell Line, Tumor; Drug Delivery Systems; Folate Receptor 1; Folic Acid; Hydroxybutyrates; Mice; Nanoparticles; Oxides; Particle Size; Polyesters; Polyvinyl Alcohol | 2013 |
Arsenic trioxide in treatment of de novo acute basophilic leukemia.
Topics: Aged; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Basophilic, Acute; Oxides | 2013 |
The novel arsenical Darinaparsin circumvents BRG1-dependent, HO-1-mediated cytoprotection in leukemic cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Blast Crisis; Blotting, Western; Cell Cycle; Cell Proliferation; Chromatin Immunoprecipitation; Cytoprotection; DNA Helicases; Flow Cytometry; Glutathione; Heme Oxygenase-1; Humans; Leukemia, Promyelocytic, Acute; NF-E2-Related Factor 2; Nuclear Proteins; Oxides; Phosphorylation; Promoter Regions, Genetic; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription Factors; Tumor Cells, Cultured | 2013 |
Selective inhibition of the NLRP3 inflammasome by targeting to promyelocytic leukemia protein in mouse and human.
Topics: Animals; Arsenic Trioxide; Arsenicals; Carrier Proteins; Caspase 1; Cell Line; Cells, Cultured; DNA, Mitochondrial; Down-Regulation; Gene Deletion; Growth Inhibitors; Humans; Inflammasomes; Interleukin-1beta; Macrophages; Mice; Mice, Knockout; NLR Family, Pyrin Domain-Containing 3 Protein; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Reactive Oxygen Species; Transcription Factors; Tumor Suppressor Proteins | 2013 |
Cyclooxygenase-2 positively regulates Akt signalling and enhances survival of erythroleukemia cells exposed to anticancer agents.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Casein Kinase II; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclooxygenase 2; Etoposide; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Erythroblastic, Acute; Oxides; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; RNA, Small Interfering; Signal Transduction; Staurosporine | 2013 |
Myocardial toxicity of acute promyelocytic leukaemia drug-arsenic trioxide.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Body Burden; Catalase; Glutathione; Glutathione Peroxidase; Glutathione Reductase; Glutathione Transferase; Heart Diseases; Leukemia, Promyelocytic, Acute; Lipid Peroxidation; Male; Myocytes, Cardiac; Oxides; Rats; Rats, Wistar; Superoxide Dismutase; Time Factors | 2013 |
Arsenic trioxide treatment of rabbit liver VX-2 carcinoma via hepatic arterial cannulation-induced apoptosis and decreased levels of survivin in the tumor tissue.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Catheterization; Chemoembolization, Therapeutic; Emulsions; Ethiodized Oil; Gene Expression Regulation; Hepatic Artery; In Situ Nick-End Labeling; Infusions, Intra-Arterial; Inhibitor of Apoptosis Proteins; Liver Neoplasms, Experimental; Male; Oxides; Rabbits; Reverse Transcriptase Polymerase Chain Reaction | 2013 |
Anticancer effect of arsenic trioxide on cholangiocarcinoma: in vitro experiments and in vivo xenograft mouse model.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Disease Models, Animal; Heterografts; Humans; Mice, Inbred BALB C; Mice, Nude; Oxides; Staining and Labeling; Tetrazolium Salts; Thiazoles; Treatment Outcome | 2014 |
Combination therapy with 5-amino-4-imidazolecarboxamide riboside and arsenic trioxide in acute myeloid leukemia cells involving AMPK/TSC2/mTOR pathway.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; HL-60 Cells; Humans; Hypoglycemic Agents; Leukemia, Myeloid, Acute; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Ribonucleotides; Signal Transduction; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins | 2013 |
Resveratrol protects against arsenic trioxide-induced nephrotoxicity by facilitating arsenic metabolism and decreasing oxidative stress.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antioxidants; Arsenic Trioxide; Arsenicals; Blood Urea Nitrogen; Catalase; Cats; Creatinine; Cytoprotection; Deoxyguanosine; Glutathione; Glutathione Peroxidase; Injections, Intravenous; Kidney; Kidney Diseases; Malondialdehyde; Oxidative Stress; Oxides; Resveratrol; Stilbenes; Superoxide Dismutase | 2013 |
Acute toxicity of arsenic under different temperatures and salinity conditions on the white shrimp Litopenaeus vannamei.
Topics: Adaptation, Physiological; Animals; Arsenic Trioxide; Arsenicals; Environmental Monitoring; Lethal Dose 50; Mexico; Oxides; Penaeidae; Salinity; Temperature; Toxicity Tests, Acute; Water Pollutants, Chemical | 2013 |
α-Lipoic acid protects against arsenic trioxide-induced acute QT prolongation in anesthetized guinea pigs.
Topics: Anesthesia; Animals; Arsenic Trioxide; Arsenicals; Cardiotonic Agents; Delayed Rectifier Potassium Channels; Guinea Pigs; Long QT Syndrome; Male; Myocytes, Cardiac; Oxides; Thioctic Acid | 2013 |
Arsenic trioxide alleviates airway hyperresponsiveness and promotes apoptosis of CD4+ T lymphocytes: evidence for involvement of the ER stress-CHOP pathway.
Topics: Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Bronchoconstriction; CD4-Positive T-Lymphocytes; Cells, Cultured; Disease Models, Animal; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Female; Heat-Shock Proteins; Lung; Mice; Mice, Inbred BALB C; Oxides; RNA Interference; Signal Transduction; Transcription Factor CHOP; Transfection | 2013 |
Anti-inflammatory effects of arsenic trioxide eluting stents in a porcine coronary model.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Coronary Vessels; Drug-Eluting Stents; Heart; Inflammation; Male; Myocardium; Oxides; Polymers; Swine; Tunica Intima | 2013 |
Nano-encapsulation of arsenic trioxide enhances efficacy against murine lymphoma model while minimizing its impact on ovarian reserve in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Female; Fertility; Humans; Lymphoma; Mice; Nanocapsules; Ovarian Follicle; Ovary; Oxides; Xenograft Model Antitumor Assays | 2013 |
Anticancer activity in human multiple myeloma U266 cells: synergy between cryptotanshinone and arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Drug Synergism; Humans; Multiple Myeloma; Oxides; Phenanthrenes | 2013 |
Rho-kinase inhibitor Y-27632 attenuates arsenic trioxide toxicity in H9c2 cardiomyoblastoma cells.
Topics: Amides; Animals; Animals, Newborn; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Blotting, Western; Cardiotonic Agents; Caspases; Cell Line, Tumor; Cell Survival; Enzyme Activation; Enzyme Inhibitors; Genetic Vectors; Oxides; Pyridines; Rats; Reactive Oxygen Species; rho-Associated Kinases; Transfection; Vimentin | 2013 |
Arsenic trioxide depletes cancer stem-like cells and inhibits repopulation of neurosphere derived from glioblastoma by downregulation of Notch pathway.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Basic Helix-Loop-Helix Transcription Factors; Brain Neoplasms; Cell Line; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glioblastoma; Homeodomain Proteins; Humans; Neoplastic Stem Cells; Oxides; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptors, Notch; Signal Transduction; STAT3 Transcription Factor; Transcription Factor HES-1 | 2013 |
Arsenic trioxide induces cardiac fibroblast apoptosis in vitro and in vivo by up-regulating TGF-β1 expression.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Caspase 3; Cells, Cultured; Fibroblasts; Gene Expression; Guinea Pigs; Heart; Male; Microscopy, Electron; Myocardium; Oxides; Rats; Transforming Growth Factor beta1; Up-Regulation | 2013 |
Attenuation of arsenic retention by resveratrol in lung of arsenic trioxide-exposed rats.
Topics: Animals; Antioxidants; Arsenic; Arsenic Trioxide; Arsenicals; Environmental Pollutants; Glutathione; Lung; Male; Oxidative Stress; Oxides; Rats; Rats, Wistar; Reactive Oxygen Species; Resveratrol; Stilbenes | 2013 |
Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair.
Topics: Acid Anhydride Hydrolases; Animals; Arsenic Trioxide; Arsenicals; BRCA1 Protein; DNA Breaks, Double-Stranded; DNA Repair; DNA Repair Enzymes; DNA-Binding Proteins; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasms; Oxides; Phosphorylation; Quinazolines; Rad51 Recombinase; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Arsenic: an old enemy now turned friend.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides | 2013 |
Aquaporin 9, a promising predictor for the cytocidal effects of arsenic trioxide in acute promyelocytic leukemia cell lines and primary blasts.
Topics: Antigens, CD; Antineoplastic Agents; Apoptosis; Aquaporins; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression; HL-60 Cells; Humans; Jurkat Cells; K562 Cells; Leukemia, Promyelocytic, Acute; Oxides | 2013 |
A variety of mild stresses upregulate stanniocalcin-1 (STC-1) and induce mitohormesis in neural crest-derived cells.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Calcium; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Flow Cytometry; Glycoproteins; Hormesis; Humans; Membrane Potential, Mitochondrial; Mitochondria; Neuroblastoma; Oxides; Phorbol Esters; Reactive Oxygen Species; Starvation; Stress, Physiological; Time Factors; Up-Regulation | 2013 |
Silibinin induced the apoptosis of Hep-2 cells via oxidative stress and down-regulating survivin expression.
Topics: Antineoplastic Agents, Phytogenic; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Squamous Cell; Caspase 3; Cell Line, Tumor; Down-Regulation; Gene Expression; Humans; Inhibitor of Apoptosis Proteins; Laryngeal Neoplasms; Membrane Potential, Mitochondrial; Neoplasm Proteins; Oxidative Stress; Oxides; Reactive Oxygen Species; RNA, Messenger; Silybin; Silymarin; Survivin | 2013 |
Arsenic methylation metabolism and liver injury of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Liver; Liver Function Tests; Male; Methylation; Middle Aged; Oxides; Sex Factors; Young Adult | 2013 |
[Abnormal methylation patterns of SFRP1 gene in cells of leukemia and inhibition of arsenic trioxide on the SFRP1 gene].
Topics: Arsenic Trioxide; Arsenicals; DNA Methylation; Humans; Intercellular Signaling Peptides and Proteins; K562 Cells; Membrane Proteins; Oxides | 2013 |
Mees lines and Beau lines.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Nail Diseases; Oxides; Remission Induction; Tretinoin | 2013 |
Phospholipid Scramblase 1, an interferon-regulated gene located at 3q23, is regulated by SnoN/SkiL in ovarian cancer cells.
Topics: Arsenic Trioxide; Arsenicals; Cell Death; Cell Line, Tumor; Chromosomes, Human, Pair 3; Female; Gene Dosage; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Ovarian Neoplasms; Oxides; Phospholipid Transfer Proteins; Proto-Oncogene Proteins; RNA Interference; RNA, Messenger | 2013 |
Arsenic reverses glioblastoma resistance to mTOR-targeted therapies.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Leukemia, Promyelocytic, Acute; Oxides; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Acute promyelocytic leukemia complicated by massive intracerebral hemorrhage: safety and efficacy of replacing conventional chemotherapy with arsenic trioxide in an adolescent.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cerebral Hemorrhage; Drug Administration Schedule; Drug Substitution; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Long-Term Care; Oxides; Remission Induction; Tomography, X-Ray Computed | 2013 |
Down-regulation of signal transducer and activator of transcription 3 improves human acute myeloid leukemia-derived dendritic cell function.
Topics: Aminosalicylic Acids; Antigen-Presenting Cells; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzenesulfonates; Blast Crisis; Blotting, Western; Dendritic Cells; Down-Regulation; Endocytosis; Enzyme-Linked Immunosorbent Assay; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Lymphocyte Activation; Oxides; RNA, Small Interfering; Signal Transduction; STAT3 Transcription Factor; T-Lymphocytes; Tumor Cells, Cultured | 2013 |
Azidothymidine hinders arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells by induction of p21 and attenuation of G2/M arrest.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; G2 Phase Cell Cycle Checkpoints; Humans; Leukemia, Promyelocytic, Acute; M Phase Cell Cycle Checkpoints; Oxides; Zidovudine | 2013 |
Reciprocal regulation of cyclooxygenase 2 and heme oxygenase 1 upon arsenic trioxide exposure in normal human lung fibroblast.
Topics: Arsenic Trioxide; Arsenicals; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytoprotection; Fibroblasts; Heme Oxygenase-1; Humans; Imidazoles; Lung; Nitrobenzenes; Oxides; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Protoporphyrins; Pyridines; Sulfonamides; Up-Regulation | 2013 |
Low-dose 1,25-dihydroxyvitamin D(3) combined with arsenic trioxide synergistically inhibits proliferation of acute myeloid leukemia cells by promoting apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Bone Density Conservation Agents; Calcitriol; Caspase 3; Cell Line, Tumor; Cell Survival; Glyceraldehyde 3-Phosphate Dehydrogenase (NADP+); HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid, Acute; Oxides; Proto-Oncogene Proteins c-bcl-2 | 2013 |
Metallothionein prevention of arsenic trioxide-induced cardiac cell death is associated with its inhibition of mitogen-activated protein kinases activation in vitro and in vivo.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Blotting, Western; Caspase 3; Cell Line; Cell Survival; In Situ Nick-End Labeling; Male; Metallothionein; Mice; Mice, Transgenic; Mitogen-Activated Protein Kinases; Myocytes, Cardiac; Oxidative Stress; Oxides; Random Allocation; Rats; Transcription Factor CHOP | 2013 |
SUMO regulates proteasome-dependent degradation of FLASH/Casp8AP2.
Topics: Animals; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Biological Transport; Calcium-Binding Proteins; Cell Line; Humans; Immunoblotting; Mice; Microscopy, Confocal; Oxides; Proteasome Endopeptidase Complex; SUMO-1 Protein | 2013 |
Co-treatment with arsenic trioxide and ganciclovir reduces tumor volume in a murine xenograft model of nasopharyngeal carcinoma.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Arsenic Trioxide; Arsenicals; Carcinoma; Disease Models, Animal; Drug Therapy, Combination; Ganciclovir; Heterografts; Humans; Mice; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Oxides; Treatment Outcome; Tumor Burden | 2013 |
[Effect of TAK1 gene silencing on the apoptosis of Kasumi-1 cells induced by arsenic trioxide].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Myeloid, Acute; MAP Kinase Kinase Kinases; Oxides; RNA Interference; RNA, Small Interfering; Signal Transduction | 2013 |
Arsenic trioxide-enhanced, matrine-induced apoptosis in multiple myeloma cell lines.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Bcl-2-Like Protein 11; Caspase 3; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Inhibitor of Apoptosis Proteins; Inhibitory Concentration 50; Matrines; Medicine, Chinese Traditional; Membrane Proteins; Multiple Myeloma; Oxides; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinolizines; Survivin | 2013 |
Complete remission of acute promyelocytic leukemia in a very elderly patient after treatment with low dose arsenic trioxide and sequential retinoic acid: a case report.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Remission Induction; Tretinoin | 2014 |
Evaluation of multiple myeloma cell apoptosis in primary bone marrow samples.
Topics: ADP-ribosyl Cyclase 1; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Marrow; Camptothecin; Female; Flow Cytometry; Humans; Immunophenotyping; Male; Multiple Myeloma; Oxides; Syndecan-1 | 2013 |
Growth and differentiation effects of Homer3 on a leukemia cell line.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Carrier Proteins; Cell Cycle; Cell Differentiation; Cell Proliferation; Flow Cytometry; Gene Expression Regulation, Neoplastic; Homer Scaffolding Proteins; Humans; Leukemia, Myeloid, Acute; Oxides; Proto-Oncogene Proteins c-bcl-2; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2013 |
Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with acute promyelocytic leukemia treated with arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; DNA, Viral; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Virus Activation | 2014 |
Urothelial cell intracytoplasmic inclusions after treatment of promyelocytic leukemia with arsenic trioxide.
Topics: Adult; Aged; Arsenic Trioxide; Arsenicals; Case-Control Studies; Female; Humans; Inclusion Bodies; Leukemia, Promyelocytic, Acute; Male; Microscopy, Electron, Transmission; Microscopy, Fluorescence; Middle Aged; Oxides; Urothelium | 2013 |
SUMO1 negatively regulates the transcriptional activity of EVI1 and significantly increases its co-localization with EVI1 after treatment with arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Blotting, Western; Chromatin Immunoprecipitation; DNA-Binding Proteins; Female; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Immunoprecipitation; MDS1 and EVI1 Complex Locus Protein; Mutagenesis, Site-Directed; Ovarian Neoplasms; Oxides; Proto-Oncogene Mas; Proto-Oncogenes; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; SUMO-1 Protein; Sumoylation; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Tumor Cells, Cultured | 2013 |
Coordinated regulation of the immunoproteasome subunits by PML/RARα and PU.1 in acute promyelocytic leukemia.
Topics: Antigen Presentation; Arsenic Trioxide; Arsenicals; Cysteine Endopeptidases; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Immunologic Factors; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oxides; Promoter Regions, Genetic; Promyelocytic Leukemia Protein; Proteasome Endopeptidase Complex; Protein Binding; Protein Subunits; Proto-Oncogene Proteins; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Trans-Activators; Transcription Factors; Transcriptional Activation; Transcriptome; Tretinoin; Tumor Escape; Tumor Suppressor Proteins | 2014 |
BCR/ABL fusion gene detected in acute promyelocytic leukemia: a case study of clinical and laboratory results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Piperazines; Pyrimidines; Translocation, Genetic; Treatment Outcome; Tretinoin | 2014 |
Inhibition of accelerated rejection mediated by alloreactive CD4⁺ memory T cells and prolonged allograft survival by arsenic trioxide.
Topics: Adoptive Transfer; Allografts; Animals; Arsenic Trioxide; Arsenicals; CD4-Positive T-Lymphocytes; Cell Proliferation; Cells, Cultured; Graft Rejection; Graft Survival; Heart Transplantation; Immunologic Memory; Immunosuppression Therapy; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Mice, Nude; Oxides; Postoperative Complications; T-Lymphocyte Subsets | 2013 |
[Demethylation effect of inhibitor As2O3 on expression of SHP-1 and C-kit genes in leukemia HL-60 cells].
Topics: Arsenic Trioxide; Arsenicals; DNA Methylation; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Oxides; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Proto-Oncogene Proteins c-kit | 2013 |
Acute promyelocytic leukemia with Flt3-TKD and WT1 mutations relapsing in a testicle and followed by systemic relapse.
Topics: Adult; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Daunorubicin; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Promyelocytic, Acute; Male; Neoplasm Recurrence, Local; Oxides; Salvage Therapy; Sarcoma, Myeloid; Testicular Neoplasms; Testis; Tretinoin; WT1 Proteins | 2013 |
The antitumor effects of an arsthinol-cyclodextrin complex in a heterotopic mouse model of glioma.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; beta-Cyclodextrins; Brain Neoplasms; Cell Line, Tumor; Excipients; Female; Glioma; Humans; Injections, Intraperitoneal; Magnetic Resonance Spectroscopy; Melarsoprol; Mice; Mice, Nude; Oxides; Xenograft Model Antitumor Assays | 2013 |
Enhanced cell growth and tumorigenicity of rat glioma cells by stable expression of human CD133 through multiple molecular actions.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Basic Helix-Loop-Helix Transcription Factors; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Cerebral Cortex; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Formazans; Gene Expression Regulation, Neoplastic; Glioma; Glycoproteins; GTPase-Activating Proteins; Homeodomain Proteins; Humans; Intercellular Signaling Peptides and Proteins; Lentivirus; Oncogene Protein v-akt; Oxides; Peptides; Rats; Rats, Sprague-Dawley; Receptor, Notch1; RNA, Messenger; RNA, Small Interfering; Tetrazolium Salts; Time Factors; Transcription Factor HES-1; Transfection; Tumor Stem Cell Assay | 2013 |
Effect of therapeutic arsenic exposure on pulmonary function.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Case-Control Studies; Cross-Sectional Studies; Dose-Response Relationship, Drug; Female; Forced Expiratory Volume; Humans; Leukemia, Promyelocytic, Acute; Lung Diseases; Male; Middle Aged; Oxides; Uteroglobin; Vital Capacity | 2013 |
Role of hematopoietic stem cell transplantation for relapsed acute promyelocytic leukemia: a retrospective analysis of JALSG-APL97.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoates; Combined Modality Therapy; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Japan; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Retrospective Studies; Salvage Therapy; Tetrahydronaphthalenes; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Tretinoin; Young Adult | 2013 |
Targeting agents alone to cure acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Tretinoin | 2013 |
Protective effect of edible marine algae, Laminaria japonica and Porphyra haitanensis, on subchronic toxicity in rats induced by inorganic arsenic.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Blood Urea Nitrogen; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creatinine; Female; Glutathione Peroxidase; Humans; Laminaria; Lipid Metabolism; Lipid Peroxidation; Male; Malondialdehyde; Oxides; Porphyra; Protective Agents; Rats; Rats, Wistar; Superoxide Dismutase; Treatment Outcome; Triglycerides | 2013 |
Autocrine human growth hormone increases sensitivity of mammary carcinoma cell to arsenic trioxide-induced apoptosis.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Autocrine Communication; Breast Neoplasms; Cell Line, Transformed; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Female; Gene Expression Regulation, Neoplastic; Human Growth Hormone; Humans; Matrix Metalloproteinases; MCF-7 Cells; Models, Biological; Neoplasm Metastasis; Oxides; Proteolysis; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; RNA, Messenger; Transcription, Genetic; Tumor Stem Cell Assay; Tumor Suppressor Protein p53 | 2013 |
Prevention of arsenic-mediated reproductive toxicity in adult female rats by high protein diet.
Topics: 17-Hydroxysteroid Dehydrogenases; 3-Hydroxysteroid Dehydrogenases; Animal Feed; Animals; Arsenic Trioxide; Arsenicals; Body Weight; Caseins; Cytoprotection; DNA Damage; Eating; Environmental Pollutants; Estradiol; Estrous Cycle; Female; Malondialdehyde; Organ Size; Ovary; Oxidative Stress; Oxides; Pisum sativum; Plant Proteins, Dietary; Rats; Rats, Wistar; Reproduction; Superoxide Dismutase; Uterus | 2013 |
Arsenic trioxide prevents osteosarcoma growth by inhibition of GLI transcription via DNA damage accumulation.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cisplatin; DNA Damage; Hedgehog Proteins; Humans; Mice; Osteosarcoma; Oxides; Signal Transduction; Transcription Factors; Transcription, Genetic; Zinc Finger Protein GLI1 | 2013 |
Arsenic trioxide inhibits the Hedgehog pathway which is aberrantly activated in acute promyelocytic leukemia.
Topics: Adolescent; Adult; Aged; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Female; Hedgehog Proteins; Humans; Kruppel-Like Transcription Factors; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Nuclear Proteins; Oxides; Patched Receptors; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Smoothened Receptor; Transcription Factors; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2 | 2013 |
A single course of all-trans retinoic acid plus arsenic trioxide reached a long-term survival in a patient with newly diagnosed acute promyelocytic leukemia: a suggestion for reduction of treatment courses?
Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Administration Schedule; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Treatment Outcome; Tretinoin | 2013 |
3Omics: a web-based systems biology tool for analysis, integration and visualization of human transcriptomic, proteomic and metabolomic data.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Gene Expression Profiling; Humans; Internet; Leukemia, Promyelocytic, Acute; Metabolomics; Oxides; Proteomics; Statistics as Topic; Systems Biology; Tretinoin; Urinalysis | 2013 |
Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib.
Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Nucleolus; Cell Proliferation; Cysteine; Cytosol; Drug Resistance, Neoplasm; Flow Cytometry; Free Radical Scavengers; Humans; Leukemia, Myeloid, Acute; Mutation; Nuclear Proteins; Nucleophosmin; Oxides; Pyrazines; Reactive Oxygen Species; Tryptophan; Tumor Cells, Cultured | 2013 |
Arsenic trioxide induced endoplasmic reticulum stress in laryngeal squamous cell line Hep-2 cells.
Topics: Activating Transcription Factor 4; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Squamous Cell; Cell Line, Tumor; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Eukaryotic Initiation Factor-2; Head and Neck Neoplasms; Heat-Shock Proteins; Humans; Laryngeal Neoplasms; Oxides; Squamous Cell Carcinoma of Head and Neck; Transcription Factor CHOP | 2014 |
Endoplasmic reticulum stress-mediated apoptosis in imatinib-resistant leukemic K562-r cells triggered by AMN107 combined with arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Endoplasmic Reticulum Stress; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Time Factors; Treatment Outcome | 2013 |
Arsenic trioxide induces unfolded protein response in vascular endothelial cells.
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Activating Transcription Factor 4; Activating Transcription Factor 6; Animals; Arsenic Trioxide; Arsenicals; Calcium; Caspase 3; Cell Death; Cell Line; Cinnamates; DNA-Binding Proteins; Dose-Response Relationship, Drug; eIF-2 Kinase; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Endothelial Cells; Gene Expression Regulation; Heat-Shock Proteins; Mice; Oxides; Reactive Oxygen Species; Regulatory Factor X Transcription Factors; Signal Transduction; Thioctic Acid; Thiourea; Transcription Factor CHOP; Transcription Factors; Unfolded Protein Response | 2014 |
Retinoic acid plus arsenic trioxide, the ultimate panacea for acute promyelocytic leukemia?
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2013 |
[Inhibitory effect of arsenic trioxide combined with cisplatin on human nasopharyngeal carcinoma xenograft and DAPK in nude mice].
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma; Cell Line, Tumor; Cisplatin; Death-Associated Protein Kinases; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Oxides; Xenograft Model Antitumor Assays | 2013 |
Artesunate possesses anti-leukemia properties that can be enhanced by arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Artemisinins; Artesunate; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Fas Ligand Protein; fas Receptor; Humans; K562 Cells; Leukemia; Oxides; Proto-Oncogene Proteins c-fos; U937 Cells | 2014 |
Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3.
Topics: Adolescent; Adult; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Female; Flow Cytometry; fms-Like Tyrosine Kinase 3; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Oxides; Prognosis; Proto-Oncogene Proteins c-bcl-2; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tandem Repeat Sequences; Tretinoin; Young Adult | 2013 |
Characterization of arsenic trioxide resistant clones derived from Jurkat leukemia T cell line: focus on PI3K/Akt signaling pathway.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Survival; Clone Cells; Flow Cytometry; Gene Expression Profiling; Humans; Jurkat Cells; Leukemia, T-Cell; Oxides; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Signal Transduction | 2013 |
Galectin-3 inhibition sensitizes human renal cell carcinoma cells to arsenic trioxide treatment.
Topics: Annexin A7; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Galectin 3; Gene Knockdown Techniques; Humans; Kidney Neoplasms; Membrane Potential, Mitochondrial; Oxides; Pectins; Protein Transport; RNA, Small Interfering | 2013 |
[Arsenic trioxide induces the apoptosis of prostate cancer PC-3 cells via the P38 signaling pathway].
Topics: Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Humans; Male; MAP Kinase Signaling System; Oxides; p38 Mitogen-Activated Protein Kinases; Prostatic Neoplasms; Signal Transduction | 2013 |
Overcoming treatment resistance in acute promyelocytic leukemia and beyond.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Tretinoin | 2013 |
Effective targeting of chronic myeloid leukemia initiating activity with the combination of arsenic trioxide and interferon alpha.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Bone Marrow Transplantation; Cell Transformation, Neoplastic; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Oxides; Piperazines; Prognosis; Pyrimidines; Real-Time Polymerase Chain Reaction; Survival Rate; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2014 |
The effect of coadministration of α-tocopherol and ascorbic acid on arsenic trioxide-induced testicular toxicity in adult rats.
Topics: alpha-Tocopherol; Animals; Antioxidants; Arsenic Trioxide; Arsenicals; Ascorbic Acid; DNA Damage; Drug Synergism; Drug Therapy, Combination; Endocrine Disruptors; Male; Oxidative Stress; Oxides; Rats; Rats, Wistar; Spermatogenesis; Testis; Testosterone | 2013 |
Unfolded protein response (UPR) signaling regulates arsenic trioxide-mediated macrophage innate immune function disruption.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Line; Endoplasmic Reticulum Chaperone BiP; Immunity, Innate; Macrophages; Mice; Oxides; Reactive Oxygen Species; Signal Transduction; Unfolded Protein Response | 2013 |
The combination of arsenic, interferon-alpha, and zidovudine restores an "immunocompetent-like" cytokine expression profile in patients with adult T-cell leukemia lymphoma.
Topics: Adult; Aged; Arsenic Trioxide; Arsenicals; Cytokines; Female; Gene Expression Profiling; HTLV-I Infections; Humans; Immunologic Factors; Interferon-alpha; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Oxides; Prospective Studies; Treatment Outcome; Zidovudine | 2013 |
Low-dose arsenic trioxide enhances 5-aminolevulinic acid-induced PpIX accumulation and efficacy of photodynamic therapy in human glioma.
Topics: Aminolevulinic Acid; Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Glioma; Heme; Humans; Intracellular Space; Oxides; Photochemotherapy; Photosensitizing Agents; Protoporphyrins; Rats; Rats, Wistar | 2013 |
Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; China; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Dexamethasone; Drug Evaluation; Female; Harringtonines; Homoharringtonine; Humans; Idarubicin; Infusions, Intravenous; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Oncogene Proteins, Fusion; Oxides; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult | 2014 |
Thyroid arsenic content and papillary thyroid carcinoma arising 10 years after oral arsenic trioxide therapy for refractory acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma; Carcinoma, Papillary; Female; Humans; Leukemia, Promyelocytic, Acute; Neoplasms, Second Primary; Oxides; Thyroid Cancer, Papillary; Thyroid Gland; Thyroid Neoplasms; Young Adult | 2014 |
2-methoxyestradiol induces mitotic arrest, apoptosis, and synergistic cytotoxicity with arsenic trioxide in human urothelial carcinoma cells.
Topics: 2-Methoxyestradiol; Aged; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-Associated Death Protein; Caspases; Cell Cycle Checkpoints; Cell Line, Transformed; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Estradiol; Female; Histones; Humans; Mitosis; Oxides; Phosphorylation; Poly(ADP-ribose) Polymerases; Urologic Neoplasms | 2013 |
Cathepsin L silencing enhances arsenic trioxide mediated in vitro cytotoxicity and apoptosis in glioblastoma U87MG spheroids.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Cathepsin L; Cell Line, Tumor; Cell Survival; Gene Silencing; Glioblastoma; Humans; Oxides; Spheroids, Cellular; Tumor Cells, Cultured | 2013 |
Icariin synergizes with arsenic trioxide to suppress human hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Flavonoids; Humans; Liver Neoplasms; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Oxides; Reactive Oxygen Species; Transplantation, Heterologous | 2014 |
[Homoharringtonine combined arsenic trioxide induced apoptosis in human multiple myeloma cell line RPMI 8226: an experimental research].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Caspase 3; Caspase 9; Cell Line, Tumor; Harringtonines; Homoharringtonine; Humans; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Oxides; Phosphorylation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2 | 2013 |
Risk communication and trust in decision-maker action: a case study of the Giant Mine Remediation Plan.
Topics: Arsenic Trioxide; Arsenicals; Communication; Decision Making, Organizational; Environmental Exposure; Environmental Restoration and Remediation; Gold; Humans; Indians, North American; Interviews as Topic; Mining; Northwest Territories; Oxides; Risk Management; Trust | 2013 |
Arsenic affects on cerebellar development of mice.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cerebellum; DNA Damage; Female; Immunohistochemistry; Lactation; Maternal Exposure; Mice; Mice, Inbred ICR; Mitosis; Oxides; Pregnancy; Prenatal Exposure Delayed Effects; Water Pollutants, Chemical | 2013 |
Importance of ERK activation in As2O3-induced differentiation and promyelocytic leukemia nuclear bodies formation in neuroblastoma cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Intranuclear Inclusion Bodies; Leukemia, Promyelocytic, Acute; MAP Kinase Signaling System; N-Myc Proto-Oncogene Protein; Neurites; Neuroblastoma; Nuclear Proteins; Oncogene Proteins; Oxides; Promyelocytic Leukemia Protein; Transcription Factors; Tumor Suppressor Proteins | 2013 |
Sodium arsenite and arsenic trioxide differently affect the oxidative stress, genotoxicity and apoptosis in A549 cells: an implication for the paradoxical mechanism.
Topics: Annexin A5; Apoptosis; Arsenic Trioxide; Arsenicals; Arsenites; Cell Cycle; Cell Line, Tumor; Coloring Agents; Comet Assay; Fluorescein-5-isothiocyanate; Fluorescent Dyes; Humans; In Situ Nick-End Labeling; Micronucleus Tests; Mutagens; Oxidative Stress; Oxides; Reactive Oxygen Species; Sodium Compounds; Superoxide Dismutase; Tetrazolium Salts; Thiazoles; Tumor Stem Cell Assay | 2013 |
Extremely low doses of arsenic affect in vitro pollen germination.
Topics: Actinidia; Arsenic Trioxide; Arsenicals; Germination; Oxides; Pharmaceutical Solutions; Pollen; Stress, Physiological; Water | 2013 |
Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
Topics: Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Consolidation Chemotherapy; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Male; Neoplasm, Residual; Oxides; Prognosis; Treatment Outcome; Tretinoin | 2013 |
Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cisplatin; Disease Models, Animal; DNA Damage; Drug Synergism; Etoposide; Female; Glutathione; Humans; Lung Neoplasms; Membrane Potential, Mitochondrial; Mice; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Oxides; Reactive Oxygen Species; Small Cell Lung Carcinoma; Xenograft Model Antitumor Assays | 2013 |
Arsenic trioxide combination improves survival in APL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Prognosis; Remission Induction; Survival Rate; Tretinoin | 2013 |
Arsenic trioxide co-exposure potentiates benzo(a)pyrene genotoxicity by enhancing the oxidative stress in human lung adenocarcinoma cell.
Topics: Adenocarcinoma; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzo(a)pyrene; Cell Line, Tumor; DNA Damage; Drug Synergism; Humans; Lung Neoplasms; Oxidative Stress; Oxides | 2013 |
High frequency of varicella zoster virus reactivation associated with the use of arsenic trioxide in patients with acute promyelocytic leukemia.
Topics: Acyclovir; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Incidence; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Retrospective Studies; Valacyclovir; Valine; Virus Activation | 2014 |
Analysis of the biological response of mouse liver (Mus musculus) exposed to As2O3 based on integrated -omics approaches.
Topics: Animals; Arsenic Trioxide; Arsenicals; Chromatography, Gel; Liver; Mass Spectrometry; Metabolomics; Mice; Mice, Inbred BALB C; Models, Molecular; Oxidation-Reduction; Oxides; Proteomics | 2013 |
Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
Topics: Anilides; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Itraconazole; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Molecular Targeted Therapy; Oxides; Pleural Neoplasms; Pyridines; Pyrimidines; Receptors, G-Protein-Coupled; RNA Interference; Signal Transduction; Smoothened Receptor; Time Factors; Transcription Factors; Transfection; Zinc Finger Protein GLI1 | 2014 |
[Mechanisms of arsenic trioxide induced apoptosis in Karpas299 cell].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Humans; Oxides | 2013 |
Neuroprotective effect of resveratrol on arsenic trioxide-induced oxidative stress in feline brain.
Topics: Animals; Antineoplastic Agents; Antioxidants; Arsenic Trioxide; Arsenicals; Cats; Cerebral Cortex; Cytoprotection; Environmental Pollutants; Female; Glutathione; Male; Malondialdehyde; Neuroprotective Agents; Oxidative Stress; Oxides; Reactive Oxygen Species; Resveratrol; Stilbenes | 2014 |
Redirecting apoptosis to aponecrosis induces selective cytotoxicity to pancreatic cancer cells through increased ROS, decline in ATP levels, and VDAC.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cell Line, Tumor; Disease Models, Animal; Disulfiram; Dose-Response Relationship, Drug; Heterografts; Humans; Male; Mice; Necrosis; Oxides; Pancreatic Neoplasms; Reactive Oxygen Species; Tumor Stem Cell Assay; Voltage-Dependent Anion Channels | 2013 |
VEGF depletion enhances bcr-abl-specific sensitivity of arsenic trioxide in chronic myelogenous leukemia.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oligodeoxyribonucleotides, Antisense; Oxides; Piperazines; Pyrimidines; Transfection; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2013 |
Carcinogenic risk of retained arsenic after successful treatment of acute promyelocytic leukemia with arsenic trioxide: a cause for concern?
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma; Carcinoma, Papillary; Female; Humans; Leukemia, Promyelocytic, Acute; Neoplasms, Second Primary; Oxides; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2014 |
Differential sensitivity of p44/p42-MAPK- and PI3K/Akt-targeted neuroblastoma subtypes to arsenic trioxide.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Base Sequence; Cell Line, Tumor; Cell Proliferation; DNA Primers; Enzyme Activation; Flow Cytometry; Humans; Neuroblastoma; Oxides; Protein Kinases; Real-Time Polymerase Chain Reaction | 2013 |
Selective apoptosis of multiple myeloma cells in primary samples induced by arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Marrow; Cells, Cultured; Female; Humans; Male; Multiple Myeloma; Oxides | 2014 |
Arsenic trioxide induces apoptosis in B-cell chronic lymphocytic leukemic cells through down-regulation of survivin via the p53-dependent signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Down-Regulation; Gene Expression Regulation, Leukemic; Humans; Inhibitor of Apoptosis Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Oxides; Signal Transduction; Survivin; Tumor Suppressor Protein p53; Up-Regulation | 2013 |
Toward a therapeutic reduction of imatinib refractory myeloproliferative neoplasm-initiating cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Blotting, Western; Bone Marrow Transplantation; Core Binding Factor Alpha 2 Subunit; Disease Models, Animal; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Mice, Inbred C57BL; Mice, Transgenic; Myeloproliferative Disorders; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Oxides; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2014 |
Identifying arsenic trioxide (ATO) functions in leukemia cells by using time series gene expression profiles.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cluster Analysis; Computational Biology; Databases, Nucleic Acid; Gene Expression Regulation, Leukemic; Humans; K562 Cells; Leukemia; Molecular Sequence Annotation; Oxides; Time Factors; Transcriptome | 2014 |
The synergistic antitumor activity of arsenic trioxide and vitamin K2 in HL-60 cells involves increased ROS generation and regulation of the ROS-dependent MAPK signaling pathway.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blotting, Western; Caspase 3; Caspase 9; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; HL-60 Cells; Humans; Indicators and Reagents; Mitogen-Activated Protein Kinases; Oxides; Reactive Oxygen Species; Signal Transduction; Vitamin K 2 | 2013 |
Both GLS silencing and GLS2 overexpression synergize with oxidative stress against proliferation of glioma cells.
Topics: Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; BH3 Interacting Domain Death Agonist Protein; Brain Neoplasms; Cell Movement; Cell Proliferation; Cell Survival; Flow Cytometry; Gene Silencing; Glioma; Glutaminase; Glutathione; Humans; Mitochondria; Oxidative Stress; Oxides; Proto-Oncogene Proteins c-myc; Reactive Oxygen Species; Staining and Labeling | 2014 |
Indomethacin-enhanced anticancer effect of arsenic trioxide in A549 cell line: involvement of apoptosis and phospho-ERK and p38 MAPK pathways.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Caspase 3; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Dexamethasone; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Humans; Indomethacin; Lung Neoplasms; MAP Kinase Signaling System; Oxides; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazoles; RNA, Messenger; Sulfonamides; Time Factors | 2013 |
Prognostic significance of additional cytogenetic abnormalities and FLT3 mutations in acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; fms-Like Tyrosine Kinase 3; Humans; Karyotype; Leukemia, Promyelocytic, Acute; Male; Mutation; Oxides | 2014 |
Investigation of the mechanism involved in the As2O3-regulated decrease in MDR1 expression in leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Binding Sites; Cell Line, Tumor; Drug Resistance, Neoplasm; HEK293 Cells; Humans; I-kappa B Kinase; K562 Cells; Leukemia; Molecular Sequence Data; Oxides; Phosphorylases; Phosphorylation; Promoter Regions, Genetic; Protein Binding; Sequence Analysis, DNA; Signal Transduction; Transcription Factor RelA; Tumor Necrosis Factor-alpha | 2014 |
Arsenic trioxide and other arsenical compounds inhibit the NLRP1, NLRP3, and NAIP5/NLRC4 inflammasomes.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antigens, Bacterial; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Arsenites; Bacterial Toxins; Calcium-Binding Proteins; Carrier Proteins; Caspase 1; Cell Death; Cell Line; Flagellin; Immunity, Innate; Inflammasomes; Interleukin-1beta; Macrophages; Mice; Mice, Inbred BALB C; Neuronal Apoptosis-Inhibitory Protein; Neutrophils; Nigericin; Nitrogen Oxides; NLR Family, Pyrin Domain-Containing 3 Protein; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Proteolysis; Reactive Oxygen Species; Signal Transduction; Sodium Compounds; Transcription Factors; Tumor Suppressor Proteins | 2014 |
Improved apoptotic cell death in drug-resistant non-small-cell lung cancer cells by tumor necrosis factor-related apoptosis-inducing ligand-based treatment.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzophenanthridines; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Humans; Isoquinolines; Lung Neoplasms; Oxides; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand | 2014 |
MicroRNAs contribute to promyelocyte apoptosis in As2O3-treated APL cells.
Topics: 3' Untranslated Regions; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Base Sequence; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cell Survival; DNA Fragmentation; Down-Regulation; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; MicroRNAs; Oxides; RNA, Messenger; Sequence Alignment; Up-Regulation | 2013 |
[Blocking effect of arsenic trioxide on the proliferation and cell cycle of human Burkitt lymphoma cells and its related mechanism].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Burkitt Lymphoma; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Humans; Oncogene Proteins; Oxides | 2013 |
Effects of arsenic trioxide alone and in combination with bortezomib in multiple myeloma RPMI 8266 cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; G2 Phase Cell Cycle Checkpoints; Humans; Multiple Myeloma; Oxides; Proto-Oncogene Proteins c-bcl-2; Pyrazines | 2013 |
Arsenic trioxide overcomes rapamycin-induced feedback activation of AKT and ERK signaling to enhance the anti-tumor effects in breast cancer.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Feedback, Physiological; Humans; Mice; Oxides; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; Xenograft Model Antitumor Assays | 2013 |
The impact of arsenic trioxide and all-trans retinoic acid on p53 R273H-codon mutant glioblastoma.
Topics: Amino Acid Sequence; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Codon; Extracellular Signal-Regulated MAP Kinases; Genes, p53; Glioblastoma; Humans; Molecular Sequence Data; Mutation; Neoplastic Stem Cells; Oxides; Tretinoin | 2014 |
Outcomes and prognostic factors of first relapsed acute promyelocytic leukemia patients undergoing salvage therapy with intravenous arsenic trioxide and chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Drug Evaluation; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prognosis; Proportional Hazards Models; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome; Young Adult | 2014 |
Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure.
Topics: Animals; Arsenic Trioxide; Arsenicals; Computational Biology; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Mice; Microarray Analysis; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Proteolysis; Receptors, Retinoic Acid; Recombinant Fusion Proteins; Retinoic Acid Receptor alpha; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Transcription Factors; Tretinoin; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2014 |
As2O3 synergistically reactivate latent HIV-1 by induction of NF-κB.
Topics: Arsenic Trioxide; Arsenicals; Aspirin; Cells, Cultured; Dose-Response Relationship, Drug; Genes, Reporter; HEK293 Cells; HIV Long Terminal Repeat; HIV-1; Humans; Jurkat Cells; Leukocytes, Mononuclear; Microscopy, Fluorescence; NF-kappa B; Oxides; Phorbol Esters; Signal Transduction; Transfection; Tumor Necrosis Factor-alpha; Valproic Acid; Virus Activation; Virus Latency | 2013 |
Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumors in vitro and in vivo by targeting overexpressed Gli1.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Proliferation; Computational Biology; Gene Expression Profiling; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Kruppel-Like Transcription Factors; Mice; Mice, SCID; Neoplasm Transplantation; Oxides; Prognosis; Rhabdoid Tumor; Signal Transduction; Transcription Factors; Zinc Finger Protein GLI1 | 2014 |
BIMEL is a key effector molecule in oxidative stress-mediated apoptosis in acute myeloid leukemia cells when combined with arsenic trioxide and buthionine sulfoximine.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Bcl-2-Like Protein 11; Buthionine Sulfoximine; Drug Combinations; Gene Knockdown Techniques; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Membrane Proteins; Oxidative Stress; Oxides; Phosphorylation; Proto-Oncogene Proteins | 2014 |
The novel arsenical darinaparsin is transported by cystine importing systems.
Topics: Amino Acid Transport System y+; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biological Transport; Cell Line, Tumor; Cysteine; gamma-Glutamyltransferase; Glutathione; Humans; Oxides; Sulfhydryl Compounds | 2014 |
Polyphenol-rich apple (Malus domestica L.) peel extract attenuates arsenic trioxide induced cardiotoxicity in H9c2 cells via its antioxidant activity.
Topics: Animals; Antioxidants; Arsenic Trioxide; Arsenicals; Cell Line; Fruit; Malus; Myoblasts; Oxidative Stress; Oxides; Polyphenols; Rats; Reactive Oxygen Species | 2014 |
Inorganic arsenic trioxide induces gap junction loss in association with the downregulation of connexin43 and E-cadherin in rat hepatic "stem-like" cells.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cadherins; Cell Line; Connexin 43; Gap Junctions; Liver; Neoplastic Stem Cells; Oxides; Rats | 2014 |
Metabolomic study in plasma, liver and kidney of mice exposed to inorganic arsenic based on mass spectrometry.
Topics: Administration, Oral; Amino Acids; Animals; Arsenic Trioxide; Arsenicals; Choline; Energy Metabolism; Kidney; Liver; Metabolomics; Methionine; Mice; Mice, Inbred BALB C; Oxides; Phospholipids; Spectrometry, Mass, Electrospray Ionization | 2014 |
Arsenic trioxide induces apoptosis in human platelets via C-Jun NH2-terminal kinase activation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; bcl-X Protein; Blood Platelets; Caspase 3; Dose-Response Relationship, Drug; Enzyme Activation; Female; Humans; JNK Mitogen-Activated Protein Kinases; Male; Membrane Potential, Mitochondrial; Mice; Oxides; Platelet Activation; Platelet Count; Proto-Oncogene Proteins c-bcl-2 | 2014 |
Arsenic trioxide targets miR-125b in glioma cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Proliferation; Drug Screening Assays, Antitumor; Glioma; Humans; MicroRNAs; Oxides; Structure-Activity Relationship; Tumor Cells, Cultured | 2014 |
Inactivation of Akt by arsenic trioxide induces cell death via mitochondrial-mediated apoptotic signaling in SGC-7901 human gastric cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Humans; Membrane Potential, Mitochondrial; Mitochondria; Oxides; Proto-Oncogene Proteins c-akt; Signal Transduction; Stomach Neoplasms | 2014 |
Resveratrol enhances the suppressive effects of arsenic trioxide on primitive leukemic progenitors.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Cell Line, Tumor; Drug Synergism; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Oxides; Resveratrol; Stilbenes | 2014 |
Treatment of an acute promyelocytic leukemia relapse using arsenic trioxide and all-trans-retinoic in a 6-year-old child.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Female; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin | 2014 |
Effects of arsenic on osteoblast differentiation in vitro and on bone mineral density and microstructure in rats.
Topics: Animals; Arsenic; Arsenic Trioxide; Arsenicals; Bone and Bones; Bone Density; Bone Morphogenetic Protein 2; Cell Differentiation; Core Binding Factor Alpha 1 Subunit; Drinking Water; Extracellular Signal-Regulated MAP Kinases; Hazardous Substances; Male; Osteoblasts; Osteogenesis; Oxides; Rats | 2014 |
[Anesthesia and arsenic trioxide in endodontia].
Topics: Anesthesia; Arsenic; Arsenic Trioxide; Arsenicals; Humans; Oxides; Root Canal Therapy | 1953 |
Tetrandrine enhances the anticancer effects of arsenic trioxide in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Benzylisoquinolines; Cell Cycle Checkpoints; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; HeLa Cells; Hep G2 Cells; Humans; Necrosis; Neoplasms; Oxides; Time Factors | 2014 |
Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Daunorubicin; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Retrospective Studies; Survival Analysis; Tretinoin | 2014 |
PML nuclear bodies mediate the therapeutic response of APL cells.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Cycle; Humans; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Signal Transduction; Tretinoin | 2014 |
Combined arsenic trioxide-cisplatin treatment enhances apoptosis in oral squamous cell carcinoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dose-Response Relationship, Drug; Drug Synergism; Humans; Membrane Potential, Mitochondrial; Mouth Neoplasms; Oxides; Reactive Oxygen Species | 2014 |
Differential binding of monomethylarsonous acid compared to arsenite and arsenic trioxide with zinc finger peptides and proteins.
Topics: Amino Acid Sequence; Arsenic Trioxide; Arsenicals; Arsenites; Cell Line; Humans; Mass Spectrometry; Molecular Sequence Data; Organometallic Compounds; Oxides; Peptides; Proteins; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Zinc Fingers | 2014 |
HSP70 colocalizes with PLK1 at the centrosome and disturbs spindle dynamics in cells arrested in mitosis by arsenic trioxide.
Topics: Amino Acid Substitution; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinogens, Environmental; Cell Cycle Proteins; Centrosome; Gene Silencing; HEK293 Cells; HeLa Cells; HSP70 Heat-Shock Proteins; Humans; Mitosis; Mitosis Modulators; Mutant Proteins; Oxides; Phosphorylation; Polo-Like Kinase 1; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins; Recombinant Proteins; Spindle Apparatus; Tubulin Modulators | 2014 |
Gingival and localized alveolar bone necrosis related to the use of arsenic trioxide paste--two case reports.
Topics: Adult; Alveolar Process; Arsenic Trioxide; Arsenicals; Dental Materials; Dental Pulp Devitalization; Female; Gingival Diseases; Humans; Mandibular Diseases; Middle Aged; Necrosis; Osteonecrosis; Oxides | 2014 |
Additivity, antagonism, and synergy in arsenic trioxide-induced growth inhibition of C6 glioma cells: effects of genistein, quercetin and buthionine-sulfoximine.
Topics: Animals; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Buthionine Sulfoximine; Cell Division; Cell Line, Tumor; Genistein; Glioma; Oxides; Quercetin; Rats | 2014 |
Arsenic trioxide induced indirect and direct inhibition of glutathione reductase leads to apoptosis in rat hepatocytes.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cells, Cultured; Environmental Pollutants; Free Radicals; Glutathione Disulfide; Glutathione Reductase; Hepatocytes; Kinetics; Male; Oxidation-Reduction; Oxides; Rats, Sprague-Dawley | 2014 |
The acute promyelocytic leukaemia success story: curing leukaemia through targeted therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Transformation, Neoplastic; Epigenesis, Genetic; Humans; Leukemia, Promyelocytic, Acute; Molecular Targeted Therapy; Oxides; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Retinoid X Receptor alpha; Signal Transduction; Tretinoin | 2014 |
[Effects of arsenic poisoning on neuronal cell apoptosis and mRNA and protein expression of calpain 1, calpain 2, and cdk5/p25].
Topics: Animals; Apoptosis; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Calpain; Cells, Cultured; Cyclin-Dependent Kinase 5; Neurons; Oxides; Rats | 2014 |
[Effects of arsenic trioxide on the methylation of TMS1 gene in K562 cells].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; CARD Signaling Adaptor Proteins; Cytoskeletal Proteins; DNA Methylation; Down-Regulation; Gene Expression Regulation, Leukemic; Humans; K562 Cells; Oxides; Proto-Oncogene Proteins c-bcl-2 | 2014 |
Heme oxygenase-1 silencing increases the sensitivity of human osteosarcoma MG63 cells to arsenic trioxide.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Base Sequence; Bone Neoplasms; Cell Line, Tumor; DNA Primers; Gene Silencing; Heme Oxygenase-1; Humans; Osteosarcoma; Oxides; Polymerase Chain Reaction; Reactive Oxygen Species | 2014 |
Arsenic trioxide induces differentiation of CD133+ hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse model.
Topics: AC133 Antigen; Animals; Antigens, CD; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Differentiation; Cell Line, Tumor; Disease Models, Animal; Down-Regulation; Glycoproteins; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Oxides; Peptides; Random Allocation; Signal Transduction; Survival Analysis; Transcription Factors; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1 | 2014 |
Arsenic trioxide attenuates the invasion potential of human liver cancer cells through the demethylation-activated microRNA-491.
Topics: Arsenic Trioxide; Arsenicals; Biomarkers; Carcinoma, Hepatocellular; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; Neoplasm Invasiveness; NF-kappa B; Oxides; Signal Transduction | 2014 |
Arsenic trioxide inhibits Hedgehog, Notch and stem cell properties in glioblastoma neurospheres.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cell Proliferation; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Flow Cytometry; Gene Expression Regulation, Neoplastic; Glial Fibrillary Acidic Protein; Glioblastoma; Hedgehog Proteins; Humans; Neoplastic Stem Cells; Oxides; Receptors, Notch; Signal Transduction | 2014 |
Downregulation of thymidylate synthase with arsenic trioxide in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Survival; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Liver Neoplasms, Experimental; Lung Neoplasms; Mice; Mice, Nude; Oxides; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2014 |
Oral arsenic trioxide-based regimen as salvage treatment for relapsed or refractory mantle cell lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Humans; Lymphoma, Mantle-Cell; Middle Aged; Oxides; Positron-Emission Tomography; Recurrence; Salvage Therapy; Survival Analysis | 2014 |
Induction of the mesenchymal to epithelial transition by demethylation- activated microRNA-200c is involved in the anti-migration/invasion effects of arsenic trioxide on human breast cancer cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; Methylation; MicroRNAs; Neoplasm Invasiveness; Oxides; Up-Regulation | 2015 |
Droplet evaporation method as a new potential approach for highlighting the effectiveness of ultra high dilutions.
Topics: Arsenic Trioxide; Arsenicals; Chemistry Techniques, Analytical; Crystallization; Germination; Microscopy; Oxides; Seeds; Triticum; Water | 2014 |
Normal CYP3A activity during arsenic trioxide therapy.
Topics: Arsenic Trioxide; Arsenicals; Cytochrome P-450 CYP3A; Enzyme Activation; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides | 2014 |
Antitumor efficacy of DMSA modified Fe3O4 magnetic nanoparticles combined with arsenic trioxide and adriamycin in Raji cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Shape; Doxorubicin; Ferric Compounds; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Intracellular Space; Magnetite Nanoparticles; Oxides; Proto-Oncogene Proteins c-bcl-2; Succimer; Survivin; Tumor Suppressor Protein p53 | 2014 |
Arsenic trioxide: marked suppression of tumor metastasis potential by inhibiting the transcription factor Twist in vivo and in vitro.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Embolization, Therapeutic; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Oxides; Rats; Rats, Inbred BUF; Twist-Related Protein 1 | 2014 |
Arsenic trioxide inhibits transforming growth factor-β1-induced fibroblast to myofibroblast differentiation in vitro and bleomycin induced lung fibrosis in vivo.
Topics: Animals; Arsenic Trioxide; Arsenicals; Bleomycin; Cell Transdifferentiation; Cells, Cultured; Fibroblasts; Humans; Lung; Mice; Mice, Inbred C57BL; Myofibroblasts; Oxides; Pulmonary Fibrosis; Transforming Growth Factor beta1 | 2014 |
[Effect of arsenic trioxide and 5-aza-2'-deoxycytidine on SHP-1, JAK3, TYK2 gene expression in K562 cells].
Topics: Arsenic Trioxide; Arsenicals; Azacitidine; Decitabine; DNA Methylation; Gene Expression Regulation, Leukemic; Humans; Janus Kinase 3; K562 Cells; Oxides; Protein Tyrosine Phosphatase, Non-Receptor Type 6; TYK2 Kinase | 2014 |
The effect to IL-3Ralpha, downstream PI3k/Akt signaling of all-trans retinoic acid and arsenic trioxide in NB4 cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Drug Resistance, Neoplasm; Humans; Interleukin-13 Receptor alpha1 Subunit; Leukemia, Myeloid; Neoplasm Proteins; Oncogene Protein v-akt; Oxides; Phosphatidylinositol 3-Kinases; RNA, Messenger; Signal Transduction; Tretinoin | 2014 |
Activation of the ubiquitin-proteasome system against arsenic trioxide cardiotoxicity involves ubiquitin ligase Parkin for mitochondrial homeostasis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Blotting, Western; Boronic Acids; Bortezomib; Heart Diseases; Homeostasis; Immunoprecipitation; Lysosomes; Membrane Potential, Mitochondrial; Mice; Microscopy, Fluorescence; Mitochondria, Heart; Myocytes, Cardiac; Oxides; Proteasome Endopeptidase Complex; Pyrazines; Ubiquitin; Ubiquitin-Protein Ligases; Voltage-Dependent Anion Channel 1 | 2014 |
Resistance to arsenic therapy in acute promyelocytic leukemia.
Topics: Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Mutation; Neoplasm Proteins; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha | 2014 |
cAMP protects acute promyelocytic leukemia cells from arsenic trioxide-induced caspase-3 activation and apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-Associated Death Protein; Caspase 3; Cell Line, Tumor; Cell Proliferation; Colforsin; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; DNA; G1 Phase Cell Cycle Checkpoints; Humans; Leukemia, Promyelocytic, Acute; Oxides; Proto-Oncogene Mas; Tumor Suppressor Protein p53 | 2014 |
Metabolism of arsenic trioxide in acute promyelocytic leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cacodylic Acid; Cell Line, Tumor; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; DNA Methyltransferase 3B; Glutathione; Humans; Leukemia, Promyelocytic, Acute; Methyltransferases; Oxides; S-Adenosylhomocysteine; S-Adenosylmethionine | 2014 |
Arsenic downregulates gene expression at the postsynaptic density in mouse cerebellum, including genes responsible for long-term potentiation and depression.
Topics: Animals; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Behavior, Animal; Blotting, Western; Cerebellum; Down-Regulation; Gene Expression Profiling; Gene Ontology; Gene Regulatory Networks; Learning; Long-Term Potentiation; Long-Term Synaptic Depression; Memory; Mice; Microscopy, Electron, Transmission; Oligonucleotide Array Sequence Analysis; Oxides; Post-Synaptic Density; RNA, Messenger; Synapses; Time Factors | 2014 |
Arsenic trioxide induces apoptosis of human gastrointestinal cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Drug Administration Schedule; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Oxides; Proto-Oncogene Proteins c-bcl-2; Time Factors; Treatment Outcome; Tumor Suppressor Protein p53 | 2014 |
Autophagy interplays with apoptosis and cell cycle regulation in the growth inhibiting effect of Trisenox in HEP-2, a laryngeal squamous cancer.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; Head and Neck Neoplasms; Humans; Laryngeal Neoplasms; Oxides; Reactive Oxygen Species; Squamous Cell Carcinoma of Head and Neck | 2015 |
Polymeric micelles for GSH-triggered delivery of arsenic species to cancer cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Caprolactam; Cell Line, Tumor; Drug Delivery Systems; Glutathione; Humans; Inhibitory Concentration 50; Micelles; Oxides; Polyethylene Glycols; Polymers | 2014 |
Knockdown of TWIST1 enhances arsenic trioxide- and ionizing radiation-induced cell death in lung cancer cells by promoting mitochondrial dysfunction.
Topics: Acetylcysteine; Arsenic Trioxide; Arsenicals; Carcinoma, Non-Small-Cell Lung; Cell Death; Gene Knockdown Techniques; Humans; Membrane Potential, Mitochondrial; Nuclear Proteins; Oxides; Radiation, Ionizing; Reactive Oxygen Species; RNA, Small Interfering; Twist-Related Protein 1 | 2014 |
Humanized anti-VEGFR-2 ScFv-As2O3-stealth nanoparticles, an antibody conjugate with potent and selective anti-hepatocellular carcinoma activity.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Immunohistochemistry; Leukocyte Count; Liver Neoplasms; Male; Mice, Nude; Microvessels; Nanoparticles; Oxides; Platelet Count; Single-Chain Antibodies; Tissue Distribution; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Identification of recurrent SMO and BRAF mutations in ameloblastomas.
Topics: Ameloblastoma; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Proliferation; High-Throughput Nucleotide Sequencing; Humans; Indoles; Jaw Neoplasms; Mutation; Oxides; Polymerase Chain Reaction; Proto-Oncogene Proteins B-raf; Receptors, G-Protein-Coupled; Smoothened Receptor; Sulfonamides; Tumor Cells, Cultured; Vemurafenib | 2014 |
[Research on the sodium arsenite and arsenic trioxide induced proliferation and apoptosis effects on human hepatocyte].
Topics: Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Arsenites; Cell Cycle; Cell Proliferation; Hepatocytes; Humans; Micronucleus Tests; Oxidative Stress; Oxides; Reactive Oxygen Species; Sodium Compounds | 2014 |
Trivalent methylated arsenic metabolites induce apoptosis in human myeloid leukemic HL-60 cells through generation of reactive oxygen species.
Topics: Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Arsenites; Cacodylic Acid; HL-60 Cells; Humans; Oxides; Reactive Oxygen Species | 2014 |
Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Liver Neoplasms; Lung Neoplasms; Mice; Mice, Nude; Mutation; Neoplasm Transplantation; Nuclear Proteins; Oxides; Piperazines; Signal Transduction; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2014 |
Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Caspase 3; Cytochromes c; DNA Damage; Drug Screening Assays, Antitumor; Glutathione; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Lipid Peroxidation; Membrane Potential, Mitochondrial; Mitochondria; Oxidative Stress; Oxides; Protein Transport; Single-Cell Analysis | 2014 |
Resveratrol and arsenic trioxide act synergistically to kill tumor cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Synergism; Humans; Male; Mice; Necrosis; Neovascularization, Pathologic; Oxides; Reactive Oxygen Species; Resveratrol; Stilbenes; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Low dose of arsenic trioxide triggers oxidative stress in zebrafish brain: expression of antioxidant genes.
Topics: Animals; Antioxidants; Arsenic Trioxide; Arsenicals; Bangladesh; Brain; Catalase; Female; Gene Expression; Glutathione Peroxidase; Hydrogen Peroxide; Male; Malondialdehyde; Mitochondrial Membranes; Oxidative Stress; Oxides; Reactive Oxygen Species; Superoxide Dismutase; Water Pollutants, Chemical; Zebrafish | 2014 |
The growth-inhibitory and apoptosis-inducing effect of deferoxamine combined with arsenic trioxide on HL-60 xenografts in nude mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Proliferation; Deferoxamine; Female; HL-60 Cells; Humans; Leukemia; Mice; Mice, Inbred BALB C; Mice, Nude; Oxides; Xenograft Model Antitumor Assays | 2014 |
Guest editorial: acute promyelocytic leukemia: change from "highly fatal to highly curable" leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Disseminated Intravascular Coagulation; Forkhead Box Protein O3; Forkhead Transcription Factors; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Tretinoin | 2014 |
Increased growth-inhibitory and cytotoxic activity of arsenic trioxide in head and neck carcinoma cells with functional p53 deficiency and resistance to EGFR blockade.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Breaks, Double-Stranded; Drug Resistance, Neoplasm; ErbB Receptors; Head and Neck Neoplasms; Humans; Oxides; Protein Kinase Inhibitors; Squamous Cell Carcinoma of Head and Neck; Tumor Suppressor Protein p53 | 2014 |
Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl‑dependent mechanisms.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Poly(ADP-ribose) Polymerases; Pyrazines; Pyrimidines; Reactive Oxygen Species; RNA, Messenger | 2014 |
Blood biochemistry, thyroid hormones, and oxidant/antioxidant status of guinea pigs challenged with sodium arsenite or arsenic trioxide.
Topics: Alanine Transaminase; Animals; Antioxidants; Arsenic Trioxide; Arsenicals; Arsenites; Aspartate Aminotransferases; Blood Glucose; Blood Proteins; Catalase; Cholesterol; Creatinine; Erythrocytes; Glutathione; Glutathione Reductase; Glutathione Transferase; Guinea Pigs; Hemoglobins; Lipid Peroxidation; Oxidants; Oxides; Random Allocation; Sodium Compounds; Superoxide Dismutase; Thyroid Hormones | 2014 |
Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; CD11b Antigen; Cell Differentiation; Cell Line, Tumor; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Oxides; Pyrimidines; Tretinoin; Up-Regulation | 2014 |
Matrix metalloproteinase-9 is involved in chronic lymphocytic leukemia cell response to fludarabine and arsenic trioxide.
Topics: Aged; Aged, 80 and over; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Membrane; Down-Regulation; Drug Resistance, Neoplasm; Female; HEK293 Cells; Humans; Hyaluronan Receptors; Integrin alpha4beta1; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Matrix Metalloproteinase 9; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Oxides; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Transcription, Genetic; Up-Regulation; Vidarabine | 2014 |
Pregnancy in acute promyelocytic leukaemia after front-line therapy with arsenic trioxide and all-trans retinoic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Fetus; Humans; Infant, Newborn; Leukemia, Promyelocytic, Acute; Oxides; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Tretinoin; Young Adult | 2014 |
Exposure of hepatocellular carcinoma cells to low-level As₂O₃ causes an extra toxicity pathway via L1 retrotransposition induction.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Coloring Agents; Deoxyribonuclease I; DNA; Flow Cytometry; Green Fluorescent Proteins; Humans; Indicators and Reagents; Liver Neoplasms; Liver Neoplasms, Experimental; Microscopy, Fluorescence; Oxides; Plasmids; Real-Time Polymerase Chain Reaction; Retroelements; Tetrazolium Salts; Thiazoles; Transfection | 2014 |
Anti-apoptotic and apoptotic pathway analysis of arsenic trioxide‑induced apoptosis in human gastric cancer SGC-7901 cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Oxides; Stomach Neoplasms | 2014 |
[The inhibitory effect of As₂O₃ combined with phorbol ester on the proliferation of Kasumi-1 cells and its mechanism].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Humans; Oxides; Phorbol Esters | 2014 |
Arsenic trioxide inhibits DNA methyltransferase and restores TMS1 gene expression in K562 cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; CARD Signaling Adaptor Proteins; Cytoskeletal Proteins; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Gene Expression Regulation, Leukemic; Humans; K562 Cells; Oxides; RNA, Messenger | 2015 |
Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells.
Topics: Arsenic Trioxide; Arsenicals; Cell Survival; Drug Synergism; Glutathione; Heme Oxygenase-1; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; NF-E2-Related Factor 2; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Tretinoin; Tumor Cells, Cultured | 2014 |
Arsenic trioxide inhibits CXCR4-mediated metastasis by interfering miR-520h/PP2A/NF-κB signaling in cervical cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Proliferation; Chemokine CXCL12; Down-Regulation; Female; HeLa Cells; Humans; Lung Neoplasms; Mice; MicroRNAs; Neoplasm Invasiveness; NF-kappa B; Oxides; Protein Phosphatase 2; Receptors, CXCR4; RNA, Messenger; Signal Transduction; Transcription, Genetic; Uterine Cervical Neoplasms | 2014 |
Enhancement of arsenic trioxide-mediated changes in human induced pluripotent stem cells (IPS).
Topics: Arsenic Trioxide; Arsenicals; Cell Line; Cell Survival; DNA Damage; Humans; Induced Pluripotent Stem Cells; Oxides | 2014 |
Inhibitory effect of humanized anti-VEGFR-2 ScFv-As2O3-stealth nanoparticles conjugate on growth of human hepatocellular carcinoma: in vitro and in vivo studies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Delivery Systems; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Microvessels; Nanoparticles; Neovascularization, Pathologic; Oxides; Single-Chain Antibodies; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Toward adjunctive therapy of acute myeloid leukemia: is it feasible?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Proliferation; Deferoxamine; Female; Humans; Leukemia; Oxides | 2014 |
All-trans retinoic acid and arsenic trioxide induce apoptosis and modulate intracellular concentrations of calcium in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Calcium; Carcinoma, Hepatocellular; Cell Proliferation; Hep G2 Cells; Humans; Liver Neoplasms; Oxides; Tretinoin | 2014 |
Torsade de Pointes during oral arsenic trioxide therapy for acute promyelocytic leukemia in a patient with heart failure.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Heart Failure; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Torsades de Pointes | 2015 |
Ebb-and-flow of macroautophagy and chaperone-mediated autophagy in Raji cells induced by starvation and arsenic trioxide.
Topics: Adenine; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autophagy; Burkitt Lymphoma; Cell Line, Tumor; Humans; Molecular Chaperones; Oxides; Starvation | 2014 |
GLI2 is a novel therapeutic target for metastasis of osteosarcoma.
Topics: Adolescent; Adult; Animals; Arsenic Trioxide; Arsenicals; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Child; Female; Hedgehog Proteins; Humans; Kruppel-Like Transcription Factors; Lung Neoplasms; Male; Mice; Neoplasm Invasiveness; Nuclear Proteins; Osteosarcoma; Oxides; Zinc Finger Protein Gli2 | 2015 |
Arsenic trioxide exerts anti-lung cancer activity by inhibiting angiogenesis.
Topics: Adaptor Proteins, Signal Transducing; Angiogenesis Inhibitors; Animals; Arsenic Trioxide; Arsenicals; Calcium-Binding Proteins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Oxides; Receptor, Notch1; Signal Transduction; Time Factors; Tumor Burden; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2014 |
Arsenic exposure disrupts the normal function of the FA/BRCA repair pathway.
Topics: Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Line; Cell Proliferation; Cell Survival; DNA Repair; Fanconi Anemia; Fanconi Anemia Complementation Group D2 Protein; Fibroblasts; Flow Cytometry; Genomic Instability; Humans; Micronucleus Tests; Oxides; Signal Transduction; Toxicity Tests, Acute | 2014 |
The rescuable function and mechanism of resveratrol on As₂O₃-induced hERG K⁺ channel deficiency.
Topics: Action Potentials; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blotting, Western; Cardiotonic Agents; Cardiotoxicity; Down-Regulation; Endoplasmic Reticulum Stress; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Guinea Pigs; Heart Ventricles; HEK293 Cells; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Myocytes, Cardiac; Oxides; Patch-Clamp Techniques; Resveratrol; Stilbenes | 2014 |
Arsenic trioxide induces autophagy and antitumor effects in Burkitt's lymphoma Raji cells.
Topics: Adenine; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Autophagy; Beclin-1; Burkitt Lymphoma; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Membrane Proteins; Oxides; Up-Regulation | 2014 |
Targeting catalase but not peroxiredoxins enhances arsenic trioxide-induced apoptosis in K562 cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Catalase; Cell Line, Tumor; Fusion Proteins, bcr-abl; Gene Knockdown Techniques; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Oxides; Peroxiredoxins; Reactive Oxygen Species | 2014 |
Arsenic trioxide reactivates proteasome-dependent degradation of mutant p53 protein in cancer cells in part via enhanced expression of Pirh2 E3 ligase.
Topics: Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Mutant Proteins; Oxides; Proteasome Endopeptidase Complex; Protein Binding; Proteolysis; Tumor Suppressor Protein p53; Ubiquitin-Protein Ligases; Ubiquitination | 2014 |
Arsenic trioxide inhibits cell proliferation and human papillomavirus oncogene expression in cervical cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Female; HeLa Cells; Human papillomavirus 16; Humans; Oncogene Proteins, Viral; Oxides; Papillomavirus E7 Proteins; Papillomavirus Infections; Repressor Proteins; Retinoblastoma Protein; Transcription Factor AP-1; Tumor Suppressor Protein p53; Uterine Cervical Neoplasms | 2014 |
Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Incidence; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Second Primary; Oxides; Tretinoin; Young Adult | 2015 |
ATO/ATRA/anthracycline-chemotherapy sequential consolidation achieves long-term efficacy in primary acute promyelocytic leukemia.
Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Consolidation Chemotherapy; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Remission Induction; Retrospective Studies; Treatment Outcome; Tretinoin; Young Adult | 2014 |
Arsenic trioxide prevents rat pulmonary fibrosis via miR-98 overexpression.
Topics: Actins; Animals; Arsenic Trioxide; Arsenicals; Bleomycin; Cadherins; Collagen Type I; Down-Regulation; Hydroxyproline; Male; MicroRNAs; Oxides; Pulmonary Fibrosis; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Signal Transduction; STAT3 Transcription Factor; Up-Regulation | 2014 |
Arsenic trioxide exerts a double effect on osteoblast growth in vitro.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line; Cell Proliferation; Cell Survival; Gene Expression Regulation; Humans; Osteoblasts; Oxides; Signal Transduction | 2014 |
[Effects of As2O3 in combination with TPA on K562 cells].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Drug Synergism; Humans; K562 Cells; Oxides; Tetradecanoylphorbol Acetate | 2014 |
[Apoptosis-inducing effect of valproic acid combined with arsenic trioxide on RPMI 8226 cells and its mechanism].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Multiple Myeloma; Oxides; Proto-Oncogene Proteins c-bcl-2; Valproic Acid | 2014 |
Arsenic trioxide and resveratrol show synergistic anti-leukemia activity and neutralized cardiotoxicity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Myocytes, Cardiac; Neoplasm Proteins; Oxides; Rats; Reactive Oxygen Species; Resveratrol; Stilbenes; Superoxide Dismutase | 2014 |
Resveratrol, a natural antioxidant, has a protective effect on liver injury induced by inorganic arsenic exposure.
Topics: Animals; Antioxidants; Arsenic; Arsenic Trioxide; Arsenicals; Cats; Environmental Exposure; Glutathione; Liver; Liver Diseases; Malondialdehyde; Oxidative Stress; Oxides; Reactive Oxygen Species; Resveratrol; Stilbenes | 2014 |
Realgar (As4S4) nanoparticles and arsenic trioxide (As2O3) induced autophagy and apoptosis in human melanoma cells in vitro.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Cell Line, Tumor; Cell Proliferation; Chloroquine; DNA Damage; Glutathione; Humans; Melanoma; Nanoparticles; Oxides; Phosphorylation; Sulfides | 2014 |
E2F1 downregulation by arsenic trioxide in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; E2F1 Transcription Factor; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Oxides; United States; United States Food and Drug Administration; Xenograft Model Antitumor Assays | 2014 |
Arsenic trioxide and microRNA-204 display contrary effects on regulating adipogenic and osteogenic differentiation of mesenchymal stem cells in aplastic anemia.
Topics: Adipose Tissue; Anemia, Aplastic; Arsenic Trioxide; Arsenicals; Base Sequence; Bone Marrow Cells; Cell Differentiation; Core Binding Factor Alpha 1 Subunit; DNA Primers; Humans; Immunophenotyping; Mesenchymal Stem Cells; MicroRNAs; Oxides | 2014 |
Inhibition of TGF-β/SMAD3/NF-κB signaling by microRNA-491 is involved in arsenic trioxide-induced anti-angiogenesis in hepatocellular carcinoma cells.
Topics: 3' Untranslated Regions; Angiogenesis Inhibitors; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA Methylation; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; Liver Neoplasms; MicroRNAs; Neovascularization, Pathologic; Neovascularization, Physiologic; NF-kappa B; Oxides; RNA Interference; Signal Transduction; Smad3 Protein; Time Factors; Transfection; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A | 2014 |
Thioredoxin-1 inhibitor PX-12 induces human acute myeloid leukemia cell apoptosis and enhances the sensitivity of cells to arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Cell Survival; Disulfides; Flow Cytometry; HL-60 Cells; Humans; Imidazoles; Leukemia, Myeloid, Acute; Oxides; Thioredoxins | 2014 |
A prospective, observational study of added medium-dose cytosine arabinoside versus As2O3 for elderly patients with acute promyelocytic leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Polymerase Chain Reaction; Prospective Studies; Survival Rate; Tretinoin | 2014 |
Acute promyelocytic leukaemia with a PML-RARA insertional translocation and a chromosome 21 abnormality in XYY syndrome: case report.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Chromosomes, Human, Pair 21; Humans; In Situ Hybridization, Fluorescence; Karyotype; Leukemia, Promyelocytic, Acute; Male; Mutagenesis, Insertional; Oncogene Proteins, Fusion; Oxides; Sex Chromosome Disorders; Translocation, Genetic; Treatment Outcome; Tretinoin; XYY Karyotype | 2014 |
Resistance to therapy in acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Mutation; Oncogene Proteins, Fusion; Oxides; Recurrence; Tretinoin | 2014 |
Sodium arsenite induces apoptosis and Epstein-Barr virus reactivation in lymphoblastoid cells.
Topics: Antigens, Nuclear; Apoptosis; Arsenic Trioxide; Arsenicals; Arsenites; Autoantigens; Autophagy; Burkitt Lymphoma; Cell Line, Tumor; Cell Proliferation; Herpesvirus 4, Human; Humans; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Sodium Compounds; Transcription Factors; Tumor Suppressor Proteins; Viral Matrix Proteins | 2014 |
Postremission therapy in acute promyelocytic leukemia: room for improvement?
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Electrocardiography; Female; Humans; Male; Oxides | 2014 |
Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide.
Topics: Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Electrocardiography; Female; Humans; Male; Middle Aged; Oxides; Prevalence | 2014 |
Galectin-3 as a marker and potential therapeutic target in breast cancer.
Topics: Adult; Apoptosis; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Galectin 3; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Molecular Targeted Therapy; Oxides; RNA, Small Interfering; Survival Analysis | 2014 |
The roles of mitoferrin-2 in the process of arsenic trioxide-induced cell damage in human gliomas.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cation Transport Proteins; Cell Line, Tumor; Glioma; Humans; Oxides; Reactive Oxygen Species | 2014 |
The influence of arsenic trioxide on the cell cycle, apoptosis and expression of cyclin D1 in the Jurkat cell line.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Death; Cell Line; Cyclin D1; Humans; Jurkat Cells; Microscopy, Electron, Transmission; Oxides | 2014 |
Endoplasmic reticulum stress contributes to arsenic trioxide-induced intrinsic apoptosis in human umbilical and bone marrow mesenchymal stem cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Caspase 3; Caspase 9; Cells, Cultured; Endoplasmic Reticulum Stress; Fetal Blood; Humans; Membrane Potential, Mitochondrial; Mesenchymal Stem Cells; Mitochondria; Oxides; Proteome; Signal Transduction | 2016 |
Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cell Transformation, Neoplastic; Cells, Cultured; Chlorocebus aethiops; COS Cells; Gene Expression Profiling; Humans; Leukemia, Promyelocytic, Acute; Mice, Inbred C57BL; Mice, Inbred Strains; Mice, Nude; Mice, Transgenic; Oncogene Proteins, Fusion; Oxides; Promoter Regions, Genetic; Protein Binding; Retinoid X Receptor alpha; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sumoylation; Transcriptional Activation; Tretinoin | 2014 |
Efficacy of intratumoral chemotherapy using arsenic trioxide (As2O3) sustained release tablets for the treatment of neurogliocytoma in nude mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Delayed-Action Preparations; Disease Models, Animal; Drug Carriers; Glioma; Injection, Intratympanic; Lactic Acid; Mice; Mice, Inbred BALB C; Mice, Nude; Oxides; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Random Allocation; Tablets | 2014 |
Naringenin, a citrus flavonoid, ameliorates arsenic-induced toxicity in Swiss albino mice.
Topics: Animals; Antioxidants; Arsenic Trioxide; Arsenicals; Blood Chemical Analysis; Body Weight; DNA Fragmentation; Dose-Response Relationship, Drug; Flavanones; Hematologic Tests; Male; Mice; Organ Size; Oxidative Stress; Oxides | 2014 |
Inhibition of transforming growth factor beta/SMAD signal by MiR-155 is involved in arsenic trioxide-induced anti-angiogenesis in prostate cancer.
Topics: Angiogenesis Inhibitors; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; Male; MicroRNAs; Oxides; Prostatic Neoplasms; Signal Transduction; Smad Proteins; Transforming Growth Factor beta | 2014 |
Tetraarsenic oxide-induced inhibition of malignant glioma cell invasion in vitro via a decrease in matrix metalloproteinase secretion and protein kinase B phosphorylation.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromones; Enzyme Activation; Enzyme Inhibitors; Glioblastoma; Humans; Matrix Metalloproteinase 14; Matrix Metalloproteinase 2; Morpholines; Neoplasm Invasiveness; Oxides; Phosphorylation; Proto-Oncogene Proteins c-akt | 2014 |
Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal.
Topics: 3' Untranslated Regions; AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Neoplastic Stem Cells; Oxides; Peptides; RNA Interference; Signal Transduction; Smad3 Protein; Time Factors; Transfection; Transforming Growth Factor beta; Xenograft Model Antitumor Assays | 2015 |
Stathmin is key in reversion of doxorubicin resistance by arsenic trioxide in osteosarcoma cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; G2 Phase Cell Cycle Checkpoints; Humans; Osteosarcoma; Oxides; RNA, Small Interfering; Stathmin | 2014 |
Silencing SATB1 inhibits the malignant phenotype and increases sensitivity of human osteosarcoma U2OS cells to arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Gene Expression; Gene Knockdown Techniques; Humans; Matrix Attachment Region Binding Proteins; Neoplasm Invasiveness; Osteosarcoma; Oxides; Phenotype; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering | 2014 |
[Effects of arsenic trioxide combined with cisplatin on the growth of human nasopharyngeal carcinoma cells and reversion of RASSF1A hympermethylation].
Topics: Animals; Arsenic Trioxide; Arsenicals; Carcinoma; Cell Line, Tumor; Cisplatin; DNA Methylation; Humans; Mice; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Transplantation; Oxides; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2014 |
Downregulation of thymidylate synthase and E2F1 by arsenic trioxide in mesothelioma.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Down-Regulation; E2F1 Transcription Factor; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Mice, Inbred BALB C; Mice, Nude; Oxides; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2015 |
[Synergistic killing effect of arsenic trioxide combined with curcumin on KG1a cells].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Cell Survival; Curcumin; Humans; Oxides | 2014 |
Resveratrol protects against arsenic trioxide-induced oxidative damage through maintenance of glutathione homeostasis and inhibition of apoptotic progression.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Bronchi; Cell Line; Cytotoxins; Epithelial Cells; Glutathione; Homeostasis; Humans; Lipid Peroxidation; Mutagens; Oxidative Stress; Oxides; Protective Agents; Reactive Oxygen Species; Resveratrol; Stilbenes | 2015 |
[The apoptotic mechanism of hepatocellular carcinoma cell line (HepG2) induced by arsenic trioxide].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Glutamate-Cysteine Ligase; Glutathione; Hep G2 Cells; Humans; Liver Neoplasms; Oxides; Reactive Oxygen Species | 2014 |
Critical role of cellular glutathione homeostasis for trivalent inorganic arsenite-induced oxidative damage in human bronchial epithelial cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Arsenites; Cell Line; Cell Proliferation; Cell Survival; DNA Damage; Epithelial Cells; Gene Expression Regulation; Glutathione; Homeostasis; Humans; Lung; NF-E2-Related Factor 2; Oxidative Stress; Oxides; Sodium Compounds | 2014 |
Direct binding of arsenic trioxide to AMPK and generation of inhibitory effects on acute myeloid leukemia precursors.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Humans; Leukemia, Myeloid, Acute; Mice; Oxides; Ribosomal Protein S6 Kinases, 90-kDa; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2015 |
Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Canada; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Leukemia, Promyelocytic, Acute; Male; Markov Chains; Middle Aged; Monte Carlo Method; Oxides; Quality-Adjusted Life Years; Recurrence; Treatment Failure; Treatment Outcome; Tretinoin | 2015 |
MiR-133b contributes to arsenic-induced apoptosis in U251 glioma cells by targeting the hERG channel.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cells, Cultured; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Glioma; Humans; MicroRNAs; Neurons; Oxides | 2015 |
Arsenic-rich acid mine water with extreme arsenic concentration: mineralogy, geochemistry, microbiology, and environmental implications.
Topics: Arsenic; Arsenic Trioxide; Arsenicals; Czech Republic; Environment; Ferric Compounds; Geology; Groundwater; Iron; Minerals; Mining; Oxidation-Reduction; Oxides; Water; Water Pollutants, Chemical; X-Ray Absorption Spectroscopy | 2014 |
Up-regulation of miR-21 and miR-23a Contributes to As2 O3 -induced hERG Channel Deficiency.
Topics: Animals; Animals, Newborn; Arsenic Trioxide; Arsenicals; Ether-A-Go-Go Potassium Channels; In Vitro Techniques; Kinetics; MicroRNAs; Myocytes, Cardiac; NF-kappa B; Oxides; Phosphorylation; Potassium Channel Blockers; Rats; Rats, Sprague-Dawley; Transfection; Up-Regulation | 2015 |
Cotylenin A and arsenic trioxide cooperatively suppress cell proliferation and cell invasion activity in human breast cancer cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Cell Cycle; Cell Differentiation; Cell Proliferation; Diterpenes; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Neoplasm Invasiveness; Oxides | 2015 |
Sensitivity of leukemic T-cell lines to arsenic trioxide cytotoxicity is dependent on the induction of phosphatase B220/CD45R expression at the cell surface.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Death; Cell Line, Tumor; Cell Membrane; HSP70 Heat-Shock Proteins; Humans; Jurkat Cells; Leukemia; Leukocyte Common Antigens; Mice; Mice, Inbred MRL lpr; NF-kappa B; Oxides; T-Lymphocytes | 2014 |
Efficacy of Arsenic Trioxide in the Treatment of Malignant Pleural Effusion Caused by Pleural Metastasis of Lung Cancer.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Microvessels; Neoplasm Metastasis; NF-kappa B; Oxides; Permeability; Pleural Effusion, Malignant; Tumor Burden; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2015 |
Downregulation of hTERT: an important As2O3 induced mechanism of apoptosis in myelodysplastic syndrome.
Topics: Aged; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Blotting, Western; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Proliferation; Child, Preschool; Down-Regulation; Female; Humans; Myelodysplastic Syndromes; NF-kappa B; Oxides; Poly(ADP-ribose) Polymerases; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; Sp1 Transcription Factor; Telomerase; Transcription Factor AP-1; X-Linked Inhibitor of Apoptosis Protein | 2014 |
Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Proliferation; Drug Synergism; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Neoplasm Proteins; Niacinamide; Oxides; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib | 2015 |
Economic evaluation of arsenic trioxide for treatment of newly diagnosed acute promyelocytic leukaemia in Canada.
Topics: Arsenic Trioxide; Arsenicals; Canada; Cost-Benefit Analysis; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides | 2015 |
Resveratrol synergistically triggers apoptotic cell death with arsenic trioxide via oxidative stress in human lung adenocarcinoma A549 cells.
Topics: Adenocarcinoma; Anticarcinogenic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Synergism; Humans; Lung Neoplasms; Oxidative Stress; Oxides; Resveratrol; Stilbenes | 2015 |
Arsenic trioxide suppresses transcription of hTERT through down-regulation of multiple transcription factors in HL-60 leukemia cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Proliferation; Down-Regulation; HL-60 Cells; Humans; Luciferases; Oxides; RNA, Small Interfering; Telomerase; Transcription Factors; Transfection | 2015 |
Arsenic trioxide amplifies cisplatin toxicity in human tubular cells transformed by HPV-16 E6/E7 for further therapeutic directions in renal cell carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Ataxia Telangiectasia Mutated Proteins; Blotting, Western; Carcinoma, Renal Cell; Cell Cycle; Cell Proliferation; Cell Transformation, Viral; Cisplatin; Comet Assay; DNA Breaks, Double-Stranded; Drug Synergism; Histones; Human papillomavirus 16; Humans; Kidney Neoplasms; Kidney Tubules; Oncogene Proteins, Viral; Oxides; Papillomavirus E7 Proteins; Papillomavirus Infections; Promoter Regions, Genetic; Repressor Proteins; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2015 |
Synergism of arsenic trioxide and MG132 in Raji cells attained by targeting BNIP3, autophagy, and mitochondria with low doses of valproic acid and vincristine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Autophagy; Cell Line, Tumor; Cell Survival; Drug Synergism; Enzyme Inhibitors; Humans; Leupeptins; Membrane Potential, Mitochondrial; Membrane Potentials; Membrane Proteins; Mitochondria; Oxides; Proto-Oncogene Proteins; U937 Cells; Up-Regulation; Valproic Acid; Vincristine | 2014 |
Lethal drug combination: arsenic loaded multiple drug mesoporous silica for theranostic applications.
Topics: Arsenic Trioxide; Arsenicals; Camptothecin; Contrast Media; Drug Delivery Systems; Oxides; Silicon Dioxide | 2014 |
Arsenic trioxide induces programmed cell death through stimulation of ER stress and inhibition of the ubiquitin-proteasome system in human sarcoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Blotting, Western; Cell Proliferation; Endoplasmic Reticulum Stress; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Oxides; Proteasome Endopeptidase Complex; Sarcoma; Signal Transduction; Tumor Cells, Cultured; Ubiquitin; Xenograft Model Antitumor Assays | 2015 |
Effects of arsenic trioxide on proliferation, paracrine and migration of cardiac progenitor cells.
Topics: Animals; Animals, Newborn; Arsenic Trioxide; Arsenicals; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Growth Inhibitors; Mice; Myocardium; Oxides; Paracrine Communication; Stem Cells | 2015 |
Proteasome inhibitors suppress the protein expression of mutant p53.
Topics: Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Humans; Oxides; Proteasome Inhibitors; Proto-Oncogene Proteins c-mdm2; RNA Interference; Tumor Suppressor Protein p53 | 2014 |
Metformin sensitizes hepatocellular carcinoma to arsenic trioxide-induced apoptosis by downregulating Bcl2 expression.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Proliferation; Drug Synergism; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Metformin; Oxides; Proto-Oncogene Proteins c-bcl-2 | 2015 |
Extramedullary relapse in RARA rearrangement-negative acute promyelocytic leukemia successfully treated in combination with chemotherapy, local radiotherapy, and cord blood transplantation.
Topics: Allografts; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Female; Gene Rearrangement; Humans; Infant; Leukemia, Promyelocytic, Acute; Oxides; Receptors, Retinoic Acid; Recurrence; Retinoic Acid Receptor alpha | 2015 |
PARP-1 inhibitor sensitizes arsenic trioxide in hepatocellular carcinoma cells via abrogation of G2/M checkpoint and suppression of DNA damage repair.
Topics: 1-Naphthylamine; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cyclin B1; DNA Damage; DNA Repair; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; G2 Phase Cell Cycle Checkpoints; Hep G2 Cells; Humans; Liver Neoplasms; M Phase Cell Cycle Checkpoints; Naphthalimides; Oxides; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Quinolones; Up-Regulation | 2015 |
Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; B7-H1 Antigen; Base Sequence; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Interferon-gamma; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Oligonucleotides, Antisense; Oxides; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Sequence Alignment; Up-Regulation | 2015 |
Real-life experience of a brief arsenic trioxide-based consolidation chemotherapy in the management of acute promyelocytic leukemia: favorable outcomes with limited anthracycline exposure and shorter consolidation therapy.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Consolidation Chemotherapy; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; Young Adult | 2015 |
Evaluation of arsenic trioxide genotoxicity in wheat seedlings using oxidative system and RAPD assays.
Topics: Antioxidants; Arsenic; Arsenic Trioxide; Arsenicals; Catalase; Gene Expression Regulation, Plant; Hydrogen Peroxide; Lipid Peroxidation; Oxides; Oxidoreductases; Peroxidase; Peroxidases; Random Amplified Polymorphic DNA Technique; Reactive Oxygen Species; Seedlings; Superoxides; Triticum | 2015 |
Apoptotic efficacy of etomoxir in human acute myeloid leukemia cells. Cooperation with arsenic trioxide and glycolytic inhibitors, and regulation by oxidative stress and protein kinase activities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Deoxyglucose; Epoxy Compounds; Glycolysis; Humans; Indazoles; Leukemia, Myeloid, Acute; Oxidative Stress; Oxides; Protein Kinases | 2014 |
[Hypermethylation of CpG island of DLC-1 gene and arsenic trioxide-induced DLC-1 gene demethylation in multiple myeloma].
Topics: Arsenic Trioxide; Arsenicals; Cell Line, Tumor; CpG Islands; DNA Methylation; GTPase-Activating Proteins; Humans; Multiple Myeloma; Oxides; RNA, Messenger; Tumor Suppressor Proteins | 2014 |
TG-interacting factor mediates arsenic-induced malignant transformation of keratinocytes via c-Src/EGFR/AKT/FOXO3A and redox signalings.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Line; Cell Transformation, Neoplastic; CSK Tyrosine-Protein Kinase; Dose-Response Relationship, Drug; ErbB Receptors; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Knockdown Techniques; Homeodomain Proteins; Humans; Keratinocytes; Mice; NIH 3T3 Cells; Oxidation-Reduction; Oxides; Proto-Oncogene Proteins c-akt; Repressor Proteins; Signal Transduction; src-Family Kinases | 2015 |
β-Carotene ameliorates arsenic-induced toxicity in albino mice.
Topics: Alanine Transaminase; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Aspartate Aminotransferases; beta Carotene; Blood Cell Count; Body Weight; Catalase; DNA Fragmentation; Glutathione; Glutathione Disulfide; Glutathione Peroxidase; Glutathione Reductase; Glutathione Transferase; Liver; Male; Mice; Organ Size; Oxides; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances; Time Factors; Vitamins | 2015 |
[Regulatory effect of As₂O₃on imbalance between adipogenic and osteogenic differentiation of BM-MSC from patients with aplastic anemia].
Topics: Adipocytes; Anemia, Aplastic; Arsenic Trioxide; Arsenicals; Bone Marrow; Cell Differentiation; Cells, Cultured; Humans; Mesenchymal Stem Cells; Osteoblasts; Osteogenesis; Oxides | 2014 |
Synergistic effects of arsenic trioxide combined with ascorbic acid in human osteosarcoma MG-63 cells: a systems biology analysis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Bone Neoplasms; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Humans; Osteosarcoma; Oxides; Systems Biology | 2014 |
Arsenic trioxide-induced cytotoxicity in small cell lung cancer via altered redox homeostasis and mitochondrial integrity.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Butylated Hydroxyanisole; Cell Death; Cell Line, Tumor; DNA Damage; Glutathione; Homeostasis; Humans; Lung Neoplasms; Mitochondria; Oxidation-Reduction; Oxides; Reactive Oxygen Species; Small Cell Lung Carcinoma; Thioredoxins | 2015 |
E2F1-mediated FOS induction in arsenic trioxide-induced cellular transformation: effects of global H3K9 hypoacetylation and promoter-specific hyperacetylation in vitro.
Topics: Acetylation; Arsenic Trioxide; Arsenicals; Cell Line; Chromatin Immunoprecipitation; Chromatography, Reverse-Phase; E2F1 Transcription Factor; HEK293 Cells; Histones; Humans; Immunoblotting; Oxides; Promoter Regions, Genetic | 2015 |
Arsenic trioxide inhibits growth of human chondrosarcoma cells through G2/M arrest and apoptosis as well as autophagy.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Bone Neoplasms; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Chondrosarcoma; G2 Phase Cell Cycle Checkpoints; Humans; Oxides; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases | 2015 |
Arsenic trioxide and reduced glutathione act synergistically to augment inhibition of thyroid peroxidase activity in vitro.
Topics: Arsenic Trioxide; Arsenicals; Drug Synergism; Enzyme Activation; Glutathione; Hydrogen-Ion Concentration; Iodide Peroxidase; Oxidation-Reduction; Oxides | 2015 |
Dose-adjusted arsenic trioxide for acute promyelocytic leukaemia in chronic renal failure.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Monitoring; Female; Humans; Kidney Failure, Chronic; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Pilot Projects; Treatment Outcome | 2015 |
Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Child; Child, Preschool; Disease-Free Survival; Europe; Female; Humans; International Cooperation; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prospective Studies; Recurrence; Registries; Treatment Outcome; Young Adult | 2015 |
[The diagnosis and treatment of arsenic trioxide induced necrosis of jaws: report of 10 consecutive cases].
Topics: Aged; Arsenic Trioxide; Arsenicals; Arsenites; Cone-Beam Computed Tomography; Humans; Jaw Diseases; Osteonecrosis; Oxides | 2014 |
Synchronization in the Heart Rate and the Vasomotion in Rat Aorta: Effect of Arsenic Trioxide.
Topics: Acetylcholine; Anesthesia; Animals; Antineoplastic Agents; Aorta; Arsenic Trioxide; Arsenicals; Electrocardiography; Female; Heart Rate; In Vitro Techniques; Isometric Contraction; Long QT Syndrome; Male; Nitric Oxide Donors; Nitroprusside; Oxides; Potassium Channels; Rats; Rats, Sprague-Dawley; Vasodilator Agents | 2016 |
[Effect of arsenic trioxide on differentiation induction of chronic myeloid leukemia k562 cells and its potential mechanism].
Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Megakaryocytes; Oxides; RNA, Messenger; Transcription Factors; Up-Regulation | 2015 |
Real-time monitoring of arsenic trioxide release and delivery by activatable T(1) imaging.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Carriers; Drug Liberation; Humans; Hydrogen-Ion Concentration; Magnetic Resonance Imaging; Manganese; Mice; Nanoparticles; Oxides; Silicon Dioxide; Solubility; Surface Properties; Theranostic Nanomedicine; Time Factors; Water | 2015 |
Impact of autophagy inhibition at different stages on cytotoxic effect of autophagy inducer in glioblastoma cells.
Topics: Adenine; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Autophagy; Beclin-1; Blotting, Western; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Chloroquine; Drug Synergism; Flow Cytometry; Glioblastoma; Humans; Membrane Proteins; Microscopy, Electron, Transmission; Oxides; rab GTP-Binding Proteins; rab7 GTP-Binding Proteins; RNA Interference; RNA, Small Interfering | 2015 |
Arsenic Trioxide and Icariin Show Synergistic Anti-leukemic Activity.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Flavonoids; Humans; Leukemia, Promyelocytic, Acute; Membrane Potential, Mitochondrial; Oxides; Reactive Oxygen Species | 2015 |
Environmentally relevant concentration of arsenic trioxide and humic acid promoted tumor progression of human cervical cancer cells: In vivo and in vitro studies.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Female; Glutathione; HeLa Cells; Humans; Humic Substances; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred NOD; Mice, SCID; Mitosis; Oxides; Reactive Oxygen Species; Transplantation, Heterologous; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A | 2016 |
Study of the effect of inorganic and organic complexes of arsenic metal on the status of GSH in T. cells and B. cells of blood.
Topics: Arsenates; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; B-Lymphocytes; Glutathione; Humans; Oxides; T-Lymphocytes | 2015 |
Low-dose arsenic trioxide combined with aclacinomycin A synergistically enhances the cytotoxic effect on human acute myelogenous leukemia cell lines by induction of apoptosis.
Topics: Aclarubicin; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Oxides | 2015 |
Phloretin ameliorates arsenic trioxide induced mitochondrial dysfunction in H9c2 cardiomyoblasts mediated via alterations in membrane permeability and ETC complexes.
Topics: Adenosine Triphosphate; Animals; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Calcium; Cell Membrane Permeability; Cells, Cultured; Electron Transport Chain Complex Proteins; Membrane Potential, Mitochondrial; Mitochondria; Myoblasts; Myocytes, Cardiac; Oxidative Stress; Oxides; Oxygen Consumption; Phloretin; Rats; Reactive Oxygen Species; Superoxides | 2015 |
The mechanism of synergistic effects of arsenic trioxide and rapamycin in acute myeloid leukemia cell lines lacking typical t(15;17) translocation.
Topics: Aged; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Line, Tumor; Cell Survival; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Drug Synergism; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitogen-Activated Protein Kinases; Oxides; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Translocation, Genetic | 2015 |
Inflammatory Factor Alterations in the Gastrointestinal Tract of Cocks Overexposed to Arsenic Trioxide.
Topics: Animals; Arsenic Trioxide; Arsenicals; Chickens; Gastrointestinal Tract; Gene Expression Regulation; Inflammation; Inflammation Mediators; Male; Oxides | 2015 |
TG-interacting factor transcriptionally induced by AKT/FOXO3A is a negative regulator that antagonizes arsenic trioxide-induced cancer cell apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Binding Sites; Cell Movement; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Homeodomain Proteins; Humans; JNK Mitogen-Activated Protein Kinases; MCF-7 Cells; Neoplasm Invasiveness; Neoplasms; Oxides; Phosphorylation; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; Repressor Proteins; Signal Transduction; Transcription, Genetic; Transfection | 2015 |
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Mutant Proteins; Mutation; Nuclear Proteins; Nucleophosmin; Oncogene Proteins; Oxides; Tretinoin; Tumor Cells, Cultured; U937 Cells; Xenograft Model Antitumor Assays | 2015 |
Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells.
Topics: Aged; Aged, 80 and over; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; Leukemia, Myeloid, Acute; Mutant Proteins; Mutation; Nuclear Proteins; Nucleophosmin; Oxides; Proteolysis; Tretinoin; Tumor Cells, Cultured | 2015 |
Lutein has a protective effect on hepatotoxicity induced by arsenic via Nrf2 signaling.
Topics: Animals; Antioxidants; Arsenic; Arsenic Trioxide; Arsenicals; Blotting, Western; Female; Gene Expression Regulation; Glutathione; Immunohistochemistry; Liver; Lutein; Male; Malondialdehyde; Mice; NF-E2-Related Factor 2; Oxidative Stress; Oxides; Protective Agents; Real-Time Polymerase Chain Reaction; Signal Transduction; Superoxide Dismutase | 2015 |
Synergistic effects of valproic acid and arsenic trioxide on RPMI8226 cells in vitro and the possible underlying mechanisms.
Topics: Acetylation; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Gene Expression Regulation, Neoplastic; Histone Deacetylase 1; Humans; Multiple Myeloma; Oxides; Proto-Oncogene Proteins c-bcl-2; Valproic Acid | 2015 |
Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Granulocyte Precursor Cells; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Prospective Studies; Recurrence; Transcription Factors; Tretinoin; Tumor Suppressor Proteins; Young Adult | 2015 |
Arsenic trioxide inhibits breast cancer cell growth via microRNA-328/hERG pathway in MCF-7 cells.
Topics: 3' Untranslated Regions; Adenocarcinoma; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Binding Sites; Breast Neoplasms; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Female; Gene Expression Regulation, Neoplastic; Genes, Reporter; HEK293 Cells; Humans; Luciferases; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Oxides; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
[Antileukemic].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzoates; Humans; Leukemia; Oxides; Remission Induction; Tetrahydronaphthalenes; Tretinoin | 2015 |
Tetraarsenic hexoxide demonstrates anticancer activity at least in part through suppression of NF-κB activity in SW620 human colon cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Kinase; Mice; NF-kappa B; Oxides; Phosphorylation; Tumor Necrosis Factor-alpha | 2015 |
ATRA and As₂O₃ regulate differentiation of human hematopoietic stem cells into granulocyte progenitor via alteration of HoxB8 expression.
Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Survival; Cells, Cultured; Female; Fetal Blood; Gene Expression Regulation; Granulocyte Precursor Cells; Hematopoietic Stem Cells; Homeodomain Proteins; Humans; Infant, Newborn; Oxides; Pregnancy; RNA, Messenger; Tretinoin | 2015 |
Arsenic trioxide binding to serum proteins.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cattle; Humans; Oxides; Protein Binding; Protein Structure, Secondary; Protein Structure, Tertiary; Serum Albumin; Serum Albumin, Bovine; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared | 2015 |
Arsenic trioxide synergistically potentiates the cytotoxic effect of fludarabine in chronic lymphocytic leukemia cells by further inactivating the Akt and ERK signaling pathways.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Drug Synergism; Enzyme Inhibitors; Female; Growth Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; MAP Kinase Signaling System; Middle Aged; Oxides; Proto-Oncogene Proteins c-akt; Signal Transduction; Tumor Cells, Cultured; Vidarabine | 2015 |
Evaluation of gene expression changes in human primary lung epithelial cells following 24-hr exposures to inorganic arsenic and its methylated metabolites and to arsenic trioxide.
Topics: Arsenic Trioxide; Arsenicals; Arsenites; Cells, Cultured; Culture Media; Dose-Response Relationship, Drug; Down-Regulation; Epithelial Cells; Glutathione; Humans; Interleukin-6; L-Lactate Dehydrogenase; Lung; Oxides; Primary Cell Culture; Time Factors; Transcription Factor AP-1; Transcriptome; Up-Regulation | 2015 |
Arsenic Trioxide-Induced Mandibular Osteomyelitis.
Topics: Arsenic Trioxide; Arsenicals; Humans; Male; Mandibular Diseases; Middle Aged; Osteomyelitis; Oxides; Radiography, Panoramic | 2015 |
Differential in vivo genotoxicity of arsenic trioxide in glutathione depleted mouse bone marrow cells: expressions of Nrf2/Keap1/P62.
Topics: Acetylcysteine; Adaptor Proteins, Signal Transducing; Animals; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Buthionine Sulfoximine; Chromatids; Chromosome Aberrations; Cytoskeletal Proteins; Dose-Response Relationship, Drug; Enzyme Inhibitors; Free Radical Scavengers; Gene Expression Regulation, Neoplastic; Glutamate-Cysteine Ligase; Glutathione; Kelch-Like ECH-Associated Protein 1; Male; Membrane Glycoproteins; Mice; Mutagens; Neoplasm Proteins; NF-E2-Related Factor 2; Nuclear Pore Complex Proteins; Oxides | 2015 |
Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bortezomib; Cell Cycle Checkpoints; Cell Line, Tumor; Disease Progression; Drug Synergism; Estradiol; Gene Expression Regulation, Leukemic; Gene Regulatory Networks; Humans; Leukemia, Myelomonocytic, Chronic; Neoplasm Proteins; NF-kappa B; Oxides; Proteasome Inhibitors; Signal Transduction | 2015 |
Construction of a BALB/c-Nu Mouse Model of Invasive Bladder Carcinoma and Preliminary Studies on the Treatment of Bladder Tumors through Internal Iliac Arterial Infusion of Albumin-Bound Arsenic Trioxide (As2O3).
Topics: Animals; Arsenic Trioxide; Arsenicals; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Humans; Infusions, Intra-Arterial; Mice; Mice, Inbred BALB C; Oxides; Serum Albumin, Bovine; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2015 |
MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzopyrans; Blotting, Western; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Melphalan; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Multiple Myeloma; Neoplastic Stem Cells; Oxides; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; Side-Population Cells; Signal Transduction; TOR Serine-Threonine Kinases; Transplantation, Heterologous; Tuberous Sclerosis | 2015 |
Arsenic Trioxide Induces T Cell Apoptosis and Prolongs Islet Allograft Survival in Mice.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Graft Rejection; Graft Survival; I-kappa B Proteins; Immunity, Cellular; Immunosuppressive Agents; Islets of Langerhans; Islets of Langerhans Transplantation; Lymphocyte Activation; Mice, Inbred BALB C; Mice, Inbred C57BL; NF-KappaB Inhibitor alpha; Oxides; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Signal Transduction; T-Lymphocytes; Time Factors | 2015 |
[4-amino-1,8-naphthalimide on the Sensitive effect of arsenic trioxide in hepatocellular carcinoma cells].
Topics: 1-Naphthylamine; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Survival; DNA Damage; DNA Repair; Hep G2 Cells; Humans; Liver Neoplasms; Naphthalimides; Oxides; Quinolones | 2015 |
Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
Topics: Animals; Arsenic Trioxide; Arsenicals; Camptothecin; Cell Differentiation; Cell Movement; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Leukemia, Promyelocytic, Acute; Mice; Mutation; Neoplasm Proteins; Oncogene Proteins, Fusion; Oxides; Polyethylene Glycols; Tretinoin | 2015 |
Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aquaporins; Arsenic Trioxide; Arsenicals; Azacitidine; Blotting, Western; Cell Line, Tumor; Cells, Cultured; Drug Synergism; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Oxides; Polymerase Chain Reaction; RNA, Small Interfering; Transfection; Up-Regulation | 2015 |
Convertible MRI contrast: Sensing the delivery and release of anti-glioma nano-drugs.
Topics: Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Contrast Media; Drug Delivery Systems; Drug Resistance, Neoplasm; Glioma; Humans; Magnetic Resonance Imaging; Manganese; Nanoparticles; Oxides; Radiography | 2015 |
The Role of Oxidative Stress in Gastrointestinal Tract Tissues Induced by Arsenic Toxicity in Cocks.
Topics: Animals; Antioxidants; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Catalase; Chickens; Free Radicals; Gastrointestinal Tract; Glutathione; Glutathione Peroxidase; Hydroxyl Radical; Male; Malondialdehyde; Oxidative Stress; Oxides; Trace Elements | 2015 |
The role of NF-κB in PARP-inhibitor-mediated sensitization and detoxification of arsenic trioxide in hepatocellular carcinoma cells.
Topics: 1-Naphthylamine; Acetylcysteine; Antineoplastic Agents; Antioxidants; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; DNA Damage; Hep G2 Cells; Humans; Inactivation, Metabolic; Liver Neoplasms; Naphthalimides; NF-kappa B; Oxidative Stress; Oxides; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinolones; Reactive Oxygen Species | 2015 |
Use of arsenic trioxide in a hemodialysis-dependent patient with relapsed acute promyelocytic leukemia.
Topics: Aged, 80 and over; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Monitoring; Humans; Kidney Failure, Chronic; Leukemia, Promyelocytic, Acute; Male; Oxides; Renal Dialysis | 2016 |
Perturbation of cellular oxidative state induced by dichloroacetate and arsenic trioxide for treatment of acute myeloid leukemia.
Topics: Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Dichloroacetic Acid; Humans; Leukemia, Myeloid, Acute; Oxidative Stress; Oxides | 2015 |
Arsenic Trioxide Inhibits Cell Growth and Invasion via Down- Regulation of Skp2 in Pancreatic Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Cycle; Cell Movement; Cell Proliferation; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Oxides; Pancreatic Neoplasms; S-Phase Kinase-Associated Proteins; Signal Transduction; Tumor Cells, Cultured; Wound Healing | 2015 |
[The clinical efficacy of all-trans retinoic acid plus arsenic trioxide in 177 newly diagnosed acute promyelocytic leukemia patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Tretinoin | 2015 |
Arsenic trioxide sensitizes glioblastoma to a myc inhibitor.
Topics: Aged; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Cell Differentiation; Cell Proliferation; Disease Progression; ErbB Receptors; Female; Glioblastoma; Hedgehog Proteins; Humans; Magnetic Resonance Imaging; Male; Mice, SCID; Middle Aged; Neoplastic Stem Cells; Oxides; Proto-Oncogene Proteins c-myc; Signal Transduction; Thiazoles; Xenograft Model Antitumor Assays | 2015 |
Arsenic trioxide inhibits accelerated allograft rejection mediated by alloreactive CD8(+) memory T cells and prolongs allograft survival time.
Topics: Allografts; Animals; Arsenic Trioxide; Arsenicals; CD8-Positive T-Lymphocytes; Cytokines; Female; Graft Rejection; Graft Survival; Heart Transplantation; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Oxides | 2015 |
Analysis of the transcriptional regulation of cancer-related genes by aberrant DNA methylation of the cis-regulation sites in the promoter region during hepatocyte carcinogenesis caused by arsenic.
Topics: Amino Acid Motifs; Arsenic Trioxide; Arsenicals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinogenesis; Cell Line; Cell Transformation, Neoplastic; Computational Biology; DNA Methylation; Gene Expression Regulation, Neoplastic; Hepatocytes; Humans; Liver; Liver Neoplasms; Oligonucleotide Array Sequence Analysis; Oxides; Promoter Regions, Genetic; RNA, Messenger; Signal Transduction; Transcription Factors; Transcriptional Activation; Wnt Proteins | 2015 |
Effects of Arsenic Trioxide Exposure on Heat Shock Protein Response in the Immune Organs of Chickens.
Topics: Animals; Arsenic Trioxide; Arsenicals; Chickens; Heat-Shock Response; HSP27 Heat-Shock Proteins; HSP40 Heat-Shock Proteins; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Male; Oxides | 2016 |
The influence of joint application of arsenic trioxide and daunorubicin on primary acute promyelocytic leukaemia cells and apoptosis and blood coagulation of cell strain.
Topics: Adult; Annexin A2; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Blood Coagulation; Cell Line, Tumor; Daunorubicin; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Thrombomodulin; Thromboplastin; Time Factors; Tumor Cells, Cultured; Young Adult | 2015 |
SUMO deconjugation is required for arsenic-triggered ubiquitylation of PML.
Topics: Amino Acid Sequence; Animals; Arsenic Trioxide; Arsenicals; Blotting, Western; Chlorocebus aethiops; CHO Cells; COS Cells; Cricetinae; Cricetulus; Cysteine Endopeptidases; Endopeptidases; HEK293 Cells; Humans; Lysine; Microscopy, Confocal; Molecular Sequence Data; Mutation; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; RNA Interference; Signal Transduction; Small Ubiquitin-Related Modifier Proteins; SUMO-1 Protein; Transcription Factors; Tumor Suppressor Proteins; Ubiquitination | 2015 |
The synergistic killing of AML cells co-cultured with HS-5 bone marrow stromal cells by As2O3 and the PI3K/Akt signaling pathway inhibitor LY294002.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Cell Adhesion; Cell Line, Tumor; Chromones; Coculture Techniques; Drug Synergism; Enzyme Inhibitors; HL-60 Cells; Humans; Morpholines; Oncogene Protein v-akt; Oxides; Phosphoinositide-3 Kinase Inhibitors; Signal Transduction; Stromal Cells; U937 Cells | 2015 |
[The expression of AQP9 in HepG2 cells affects cell biological behaviors and sensitivity to As2O3].
Topics: Antineoplastic Agents; Apoptosis; Aquaporins; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Metastasis; Oxides; Transfection | 2015 |
Detecting total toxicity in water using a mediated biosensor system with flow injection.
Topics: 2,4-Dinitrophenol; Arsenic Trioxide; Arsenicals; Biosensing Techniques; Environmental Monitoring; Equipment Design; Escherichia coli; Ferrocyanides; Flow Injection Analysis; Oxides; Potassium Cyanide; Pseudomonas putida; Salicylic Acid; Water; Water Pollutants, Chemical | 2015 |
Tetraarsenictetrasulfide and Arsenic Trioxide Exert Synergistic Effects on Induction of Apoptosis and Differentiation in Acute Promyelocytic Leukemia Cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Oxides; Reactive Oxygen Species; Sulfides | 2015 |
[Effects of As2O3 on the Proliferation, Differentiation and Apoptosis of HL-60 Cells and Its Related Mechanisms].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Proliferation; HL-60 Cells; Humans; Microtubule-Associated Proteins; Oxides | 2015 |
Arsenic trioxide Alters the MicroRNA Expression Profile of U87 glioblastoma.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gene Expression Profiling; Glioblastoma; Humans; MicroRNAs; Oxides; Real-Time Polymerase Chain Reaction; Structure-Activity Relationship | 2015 |
Promyelocytic leukemia protein induces arsenic trioxide resistance through regulation of aldehyde dehydrogenase 3 family member A1 in hepatocellular carcinoma.
Topics: Adult; Aged; Aldehyde Dehydrogenase; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Male; Middle Aged; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Transcription Factors; Tumor Suppressor Proteins | 2015 |
Evaluated the Twenty-Six Elements in the Pectoral Muscle of As-Treated Chicken by Inductively Coupled Plasma Mass Spectrometry.
Topics: Animals; Arsenic Trioxide; Arsenicals; Chickens; Environmental Pollutants; Mass Spectrometry; Oxides; Pectoralis Muscles; Sensitivity and Specificity; Trace Elements | 2016 |
Pure total flavonoids from Citrus paradisi Macfadyen act synergistically with arsenic trioxide in inducing apoptosis of Kasumi-1 leukemia cells in vitro.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Flavonoids; Humans; Leukemia, Myeloid, Acute; Oxides; Plant Extracts; Treatment Outcome | 2015 |
Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; CD56 Antigen; Chromosome Duplication; Female; fms-Like Tyrosine Kinase 3; Gene Expression; Humans; Injections, Intravenous; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Multivariate Analysis; Oncogene Proteins, Fusion; Oxides; Prognosis; Retrospective Studies; Risk Factors; Survival Analysis | 2015 |
Regeneration of Commercial SCR Catalysts: Probing the Existing Forms of Arsenic Oxide.
Topics: Acids; Arsenic; Arsenic Trioxide; Arsenicals; Catalysis; Models, Theoretical; Nitrogen Dioxide; Oxidation-Reduction; Oxides; Photoelectron Spectroscopy; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman; X-Ray Diffraction | 2015 |
Lutein alleviates arsenic-induced reproductive toxicity in male mice via Nrf2 signaling.
Topics: Administration, Oral; Animals; Antioxidants; Arsenic Trioxide; Arsenicals; Body Weight; Lipid Peroxidation; Lutein; Male; Mice, Inbred Strains; NF-E2-Related Factor 2; Organ Size; Oxides; Reproduction; Signal Transduction; Sperm Count; Spermatozoa; Testis; Water Pollutants, Chemical | 2016 |
Lessons taught by acute promyelocytic leukemia cure.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Mice; Oncogene Proteins, Fusion; Oxides; Tretinoin; Tumor Suppressor Protein p53 | 2015 |
Paper-based cell impedance sensor and its application for cytotoxic evaluation.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biocompatible Materials; Biosensing Techniques; Cell Survival; Cyclophosphamide; Dielectric Spectroscopy; Electric Impedance; Electrodes; Gold; Humans; K562 Cells; Metal Nanoparticles; Nanocomposites; Oxides; Paper; Tin Compounds | 2015 |
Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Biotransformation; Cacodylic Acid; Cell Differentiation; Cell Proliferation; Dose-Response Relationship, Drug; HEK293 Cells; HeLa Cells; Humans; Leukemia, Promyelocytic, Acute; Methylation; Nuclear Proteins; Oncogene Proteins, Fusion; Organometallic Compounds; Oxides; Promyelocytic Leukemia Protein; Proteasome Endopeptidase Complex; Protein Binding; Protein Interaction Domains and Motifs; Proteolysis; Sumoylation; Time Factors; Transcription Factors; Tumor Suppressor Proteins | 2015 |
Arsenic trioxide regulates adipogenic and osteogenic differentiation in bone marrow MSCs of aplastic anemia patients through BMP4 gene.
Topics: Adipogenesis; Adult; Anemia, Aplastic; Arsenic Trioxide; Arsenicals; Bone Morphogenetic Protein 4; Case-Control Studies; Cell Differentiation; Cellular Senescence; Humans; Mesenchymal Stem Cells; Osteogenesis; Oxides | 2015 |
Arsenic Trioxide Promotes Paclitaxel Cytotoxicity in Resistant Breast Cancer Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Oxides; Paclitaxel; Phosphoprotein Phosphatases; Protein Phosphatase 2C; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2015 |
Heat Shock Protein Alteration in the Gastrointestinal Tract Tissues of Chickens Exposed to Arsenic Trioxide.
Topics: Animals; Arsenic Trioxide; Arsenicals; Chickens; Gastrointestinal Tract; Heat-Shock Proteins; Male; Oxides | 2016 |
Budgetary impact of treating acute promyelocytic leukemia patients with first-line arsenic trioxide and retinoic acid from an Italian payer perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Italy; Leukemia, Promyelocytic, Acute; Male; Oxides; Tretinoin | 2015 |
VEGFA Expression Is Inhibited by Arsenic Trioxide in HUVECs through the Upregulation of Ets-2 and miRNA-126.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Movement; Cell Proliferation; Cell Survival; Down-Regulation; Human Umbilical Vein Endothelial Cells; Humans; MicroRNAs; Oxides; Proto-Oncogene Protein c-ets-2; Up-Regulation; Vascular Endothelial Growth Factor A | 2015 |
Arsenic Trioxide Attenuates NF-κB and Cytokine mRNA Levels in the Livers of Cocks.
Topics: Animals; Arsenic Trioxide; Arsenicals; Avian Proteins; Chickens; Cytokines; Liver; NF-kappa B; Oxides; RNA, Messenger | 2016 |
3D tumor tissue analogs and their orthotopic implants for understanding tumor-targeting of microenvironment-responsive nanosized chemotherapy and radiation.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Breast; Cisplatin; Coculture Techniques; Disease Models, Animal; Drug Delivery Systems; Endothelial Cells; Female; Fibroblasts; Galectin 1; Mice; Mice, Nude; Nanoparticles; Oxides; Spheroids, Cellular; Triple Negative Breast Neoplasms; Tumor Cells, Cultured; Tumor Microenvironment | 2015 |
Arsenic Trioxide Activate Transcription of Heme Oxygenase-1 by Promoting Nuclear Translocation of NFE2L2.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Nucleus; Gene Expression Regulation, Neoplastic; Heme Oxygenase-1; Humans; Immunohistochemistry; NF-E2-Related Factor 2; Osteosarcoma; Oxides; Transcription, Genetic | 2015 |
Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Disease-Free Survival; DNA Mutational Analysis; Epigenesis, Genetic; Female; Genes, Modifier; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mutation; Nucleophosmin; Oxides; Prognosis; Treatment Outcome; Tretinoin; Young Adult | 2015 |
Epigenetic Gene Mutations Impact on Outcome in Acute Myeloid Leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Tretinoin | 2015 |
Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Frequency; Humans; Leukemia, Promyelocytic, Acute; Longitudinal Studies; Male; Middle Aged; Mutation, Missense; Oncogene Proteins, Fusion; Oxides; Recurrence; Young Adult | 2015 |
[Effect of arsenic trioxide on proliferation and apoptosis of human leukemia cell line MV4-11 cells].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Humans; Leukemia; Oxides | 2015 |
Induction, consolidation, and maintenance therapies with arsenic as a single agent for acute promyelocytic leukaemia in a 11-year follow-up.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Neoplasm Recurrence, Local; Oxides; Remission Induction; Time Factors; Treatment Outcome; Young Adult | 2017 |
Arsenic trioxide rewires mantle cell lymphoma response to bortezomib.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Bortezomib; Caspases; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Synergism; Female; Humans; Lymphoma, Mantle-Cell; Membrane Potential, Mitochondrial; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Oxides; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Xenograft Model Antitumor Assays | 2015 |
[Effect of As₂O₃on Hedgehog Pathway in Chronic Myeloid Leukemia Cells].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Down-Regulation; Hedgehog Proteins; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Real-Time Polymerase Chain Reaction; RNA, Messenger; Signal Transduction | 2015 |
Arsenic trioxide negatively affects Echinococcus granulosus.
Topics: Animals; Arsenic Trioxide; Arsenicals; Echinococcus granulosus; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Oxides | 2015 |
Arsenic Trioxide Exposure Induces Heat Shock Protein Responses in Cock Livers.
Topics: Animals; Arsenic Trioxide; Arsenicals; Avian Proteins; Chickens; Heat-Shock Proteins; Liver; Oxides | 2016 |
Chemotherapy-free treatment of acute promyelocytic leukemia.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2015 |
Low-Concentration Arsenic Trioxide Inhibits Skeletal Myoblast Cell Proliferation via a Reactive Oxygen Species-Independent Pathway.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line; Cell Proliferation; Intracellular Space; Mice; Myoblasts, Skeletal; Oxides; Phosphorylation; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction | 2015 |
Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Case-Control Studies; Cost-Benefit Analysis; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Markov Chains; Models, Economic; Oxides; Treatment Outcome; Tretinoin; United States | 2015 |
Effects of As2O3 on DNA methylation, genomic instability, and LTR retrotransposon polymorphism in Zea mays.
Topics: Arsenic Trioxide; Arsenicals; DNA Methylation; Genomic Instability; Oxides; Polymorphism, Genetic; Retroelements; Seedlings; Terminal Repeat Sequences; Zea mays | 2015 |
Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; China; Cost Savings; Cost-Benefit Analysis; Direct Service Costs; Female; Health Care Costs; Hospitals, University; Humans; Length of Stay; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Middle Aged; Oxides; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Tretinoin; Young Adult | 2015 |
Inhibitory effect of arsenic trioxide on neuronal migration in vitro and its potential molecular mechanism.
Topics: Animals; Animals, Newborn; Arsenic Trioxide; Arsenicals; Cell Movement; Cells, Cultured; Dose-Response Relationship, Drug; Doublecortin Domain Proteins; Doublecortin Protein; Female; Gene Expression Regulation; In Vitro Techniques; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Microtubule-Associated Proteins; Neurons; Neuropeptides; Oxides; Rats | 2015 |
Endoplasmic reticulum stress mediates the arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; CCAAT-Enhancer-Binding Protein-beta; Cell Line, Tumor; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Hep G2 Cells; Humans; Oxides; Phenylbutyrates; RNA, Small Interfering; Signal Transduction; Transcription Factor CHOP | 2015 |
Arsenic trioxide alters the differentiation of mouse embryonic stem cell into cardiomyocytes.
Topics: Actinin; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biomechanical Phenomena; Blotting, Western; Cell Differentiation; Cell Line; Connexin 43; Fetal Proteins; Fluorescent Antibody Technique; GATA4 Transcription Factor; Gene Expression; Homeobox Protein Nkx-2.5; Homeodomain Proteins; Mice; Mouse Embryonic Stem Cells; Myocytes, Cardiac; Oxides; Reverse Transcriptase Polymerase Chain Reaction; Sarcomeres; Spheroids, Cellular; T-Box Domain Proteins; Time Factors; Transcription Factors; Troponin C; Troponin T | 2015 |
Time to improve health-related quality of life outcomes in patients with acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Quality of Life; Survival Rate; Tretinoin | 2015 |
Evaluation of the change in sphingolipids in the human multiple myeloma cell line U266 and gastric cancer cell line MGC-803 treated with arsenic trioxide.
Topics: Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Chromatography, High Pressure Liquid; Humans; Multiple Myeloma; Oxides; Spectrometry, Mass, Electrospray Ionization; Sphingolipids; Stomach Neoplasms; Tandem Mass Spectrometry | 2015 |
Downregulation of P-gp, Ras and p-ERK1/2 contributes to the arsenic trioxide-induced reduction in drug resistance towards doxorubicin in gastric cancer cell lines.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Down-Regulation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gastric Mucosa; Humans; MAP Kinase Signaling System; Oxides; ras Proteins; Stomach; Stomach Neoplasms | 2015 |
Arsenic Trioxide Inhibits Proliferation of Rabbit Tenon's Capsule Fibroblasts After Trabeculectomy by Downregulating Expression of Extracellular Matrix Proteins.
Topics: Animals; Antimetabolites; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Proliferation; Down-Regulation; Extracellular Matrix Proteins; Fibroblasts; Oxides; Proliferating Cell Nuclear Antigen; Rabbits; Tenon Capsule; Trabeculectomy | 2015 |
Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Chromosomes, Human, Pair 17; Female; Humans; Isochromosomes; Leukemia, Promyelocytic, Acute; Middle Aged; Oncogene Proteins, Fusion; Oxides; Remission Induction; Treatment Outcome; Tretinoin | 2015 |
Arsenic Trioxide Reduces Global Histone H4 Acetylation at Lysine 16 through Direct Binding to Histone Acetyltransferase hMOF in Human Cells.
Topics: Acetylation; Arsenic Trioxide; Arsenicals; Cell Death; Environmental Pollutants; HEK293 Cells; HeLa Cells; Histone Acetyltransferases; Histones; Humans; Lysine; Oxides; Protein Binding; Zinc Fingers | 2015 |
Dithiothreitol enhanced arsenic-trioxide-induced cell apoptosis in cultured oral cancer cells via mitochondrial dysfunction and endoplasmic reticulum stress.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Comet Assay; Dithiothreitol; DNA Damage; Drug Synergism; Endoplasmic Reticulum Stress; Humans; Membrane Potential, Mitochondrial; Mitochondrial Diseases; Mouth Neoplasms; Oxides; Sulfhydryl Reagents | 2017 |
Is There Still a Role for Low-Dose All-Transretinoic Acid in the Treatment of Acute Promyelocytic Leukemia in the Arsenic Trioxide Era?
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Idarubicin; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Oxides; Proportional Hazards Models; Treatment Outcome; Tretinoin; Young Adult | 2015 |
Effects and mechanism of arsenic trioxide in combination with rmhTRAIL in multiple myeloma.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Chromatography, High Pressure Liquid; Mass Spectrometry; Multiple Myeloma; Oxides; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand | 2016 |
Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Cell Proliferation; Female; Glioblastoma; Humans; Mice, Inbred C57BL; Mice, Nude; Neoplastic Stem Cells; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Proteolysis; Proto-Oncogene Proteins c-myc; RNA Interference; Signal Transduction; Spheroids, Cellular; Time Factors; Transcription Factors; Transfection; Tumor Burden; Tumor Cells, Cultured; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2015 |
Sumoylation of the Tumor Suppressor Promyelocytic Leukemia Protein Regulates Arsenic Trioxide-Induced Collagen Synthesis in Osteoblasts.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Line; Collagen; Femur; Humans; Male; Mice; Microscopy, Electron; Nuclear Proteins; Osteoblasts; Oxides; Promyelocytic Leukemia Protein; RNA Interference; RNA, Small Interfering; Small Ubiquitin-Related Modifier Proteins; SUMO-1 Protein; Sumoylation; Transcription Factors; Transforming Growth Factor beta1; Tumor Suppressor Proteins; Ubiquitin-Conjugating Enzymes | 2015 |
[Influence of Fe₃O₄Magnetic Nanoparticles Combined with As2O3 and Adriamycin on Raji Cell Apoptosis and Autophagy].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Ferric Compounds; Humans; Inhibitor of Apoptosis Proteins; Nanoparticles; Oncogene Proteins, Fusion; Oxides | 2015 |
Varying responses of PML-RARA with different genetic mutations to arsenic trioxide.
Topics: Active Transport, Cell Nucleus; Arsenic Trioxide; Arsenicals; Cell Nucleus; Cells, Cultured; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; HeLa Cells; Hematopoietic Stem Cells; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Point Mutation; Prognosis; Sumoylation; U937 Cells | 2016 |
Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Communication; Cell Line; Class I Phosphatidylinositol 3-Kinases; Coculture Techniques; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mesenchymal Stem Cells; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; Oxides; Phosphorylation; Protein Kinase C beta; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Purines; Quinazolinones; RNA Interference; Signal Transduction; STAT3 Transcription Factor; Staurosporine; Time Factors; Transfection; Tumor Cells, Cultured; Tumor Microenvironment; Up-Regulation | 2015 |
Combination of Hedgehog inhibitors and standard anticancer agents synergistically prevent osteosarcoma growth.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cisplatin; Doxorubicin; Drug Synergism; Hedgehog Proteins; Humans; Osteosarcoma; Oxides; Pyridines | 2016 |
Identification of Arsenic Direct-Binding Proteins in Acute Promyelocytic Leukaemia Cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biotin; Biotinylation; Carrier Proteins; Cell Line, Tumor; Chromatography, Liquid; Glutathione S-Transferase pi; HSP70 Heat-Shock Proteins; Humans; Leukemia, Promyelocytic, Acute; Membrane Proteins; Mitochondrial Proteins; Neoplasm Proteins; Oxides; Protein Binding; Streptavidin; Tandem Mass Spectrometry; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2015 |
Anti-tumoral effect of arsenic compound, sodium metaarsenite (KML001), in non-Hodgkin's lymphoma: an in vitro and in vivo study.
Topics: Aged; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Arsenites; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Female; Humans; Jurkat Cells; Lymphoma, Non-Hodgkin; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Oxides; Pilot Projects; Signal Transduction; Sodium Compounds; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
EZH2 mediates ATO-induced apoptosis in acute myeloid leukemia cell lines through the Wnt signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Gene Expression; Gene Knockdown Techniques; Glycogen Synthase Kinase 3 beta; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Oxides; Phosphorylation; Wnt Signaling Pathway | 2016 |
Arsenic trioxide suppresses cell growth and migration via inhibition of miR-27a in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Humans; MicroRNAs; Neoplasm Invasiveness; Oxides; Treatment Outcome | 2016 |
Systematic identification of arsenic-binding proteins reveals that hexokinase-2 is inhibited by arsenic.
Topics: Amino Acid Sequence; Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Carrier Proteins; Computational Biology; Glycolysis; Hexokinase; Humans; Metabolomics; Molecular Sequence Data; Oxides; Proteome | 2015 |
Melatonin enhances arsenic trioxide-induced cell death via sustained upregulation of Redd1 expression in breast cancer cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Survival; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Melatonin; Oxides; Transcription Factors; Up-Regulation | 2016 |
Ellagic acid protects against arsenic toxicity in isolated rat mitochondria possibly through the maintaining of complex II.
Topics: Animals; Antioxidants; Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Electron Transport Complex II; Ellagic Acid; Environmental Pollutants; In Vitro Techniques; Male; Membrane Potential, Mitochondrial; Mitochondria, Liver; Oxides; Rats, Wistar; Reactive Oxygen Species; Rotenone | 2016 |
pVAX14DNA-mediated add-on immunotherapy combined with arsenic trioxide and all-trans retinoic acid targeted therapy effectively increases the survival of acute promyelocytic leukemia mice.
Topics: Adjuvants, Immunologic; Animals; Arsenic Trioxide; Arsenicals; Disease Models, Animal; DNA; Immunotherapy; Leukemia, Promyelocytic, Acute; Mice; Oxides; Tretinoin | 2015 |
Exceptions in patterns of arsenic compounds in urine of acute promyelocytic leukaemia patients treated with As2O3.
Topics: Adult; Arsenic Trioxide; Arsenicals; Cacodylic Acid; Female; Humans; Inactivation, Metabolic; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides | 2016 |
Expression of cyclin A in A549 cell line after treatment with arsenic trioxide.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Line; Cyclin A; Epithelial Cells; Gene Expression; Humans; Image Cytometry; Microscopy, Electron; Oxides | 2015 |
Targeting hedgehog signalling by arsenic trioxide reduces cell growth and induces apoptosis in rhabdomyosarcoma.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Hedgehog Proteins; Humans; Itraconazole; Muscle Cells; Muscle, Skeletal; Neoplasm Recurrence, Local; Oxides; Rhabdomyosarcoma; Signal Transduction; Transcription Factors | 2016 |
[Influence of As2O3-lipiodol emulsion via transarterial embolization on a VX2 liver tumor model in rabbits].
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Embolization, Therapeutic; Emulsions; Ethiodized Oil; Liver Neoplasms, Experimental; Oxides; Rabbits; Tomography, Spiral Computed | 2015 |
Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia.
Topics: Adult; Aged; Alleles; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Gene Rearrangement; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mutation; Neoplasm Proteins; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Transcription Factors; Tumor Suppressor Proteins; Young Adult | 2016 |
[History of acute promyelocytic leukemia].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; History, 20th Century; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2015 |
Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma, Basal Cell; Drug Resistance, Neoplasm; Follow-Up Studies; Hedgehog Proteins; Humans; Itraconazole; Male; Middle Aged; Neoplasm Metastasis; Oxides; RNA, Messenger; Skin Neoplasms; Transcription Factors; Treatment Outcome; Zinc Finger Protein GLI1 | 2016 |
ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction underlie apoptosis induced by resveratrol and arsenic trioxide in A549 cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Synergism; Endoplasmic Reticulum Stress; Humans; Lung; Lung Neoplasms; Mitochondria; Oxides; Reactive Oxygen Species; Resveratrol; Stilbenes | 2016 |
Taurine protects against As2O3-induced autophagy in pancreas of rat offsprings through Nrf2/Trx pathway.
Topics: Animals; Arsenic Trioxide; Arsenicals; Autophagy; Gene Expression Regulation; Malondialdehyde; NF-E2-Related Factor 2; Oxides; Pancreas; Rats; Taurine; Thioredoxins | 2016 |
Downregulation of B7-H4 in the MHCC97-H hepatocellular carcinoma cell line by arsenic trioxide.
Topics: Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Janus Kinase 2; Liver Neoplasms; Matrix Metalloproteinase 2; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Oxides; RNA, Messenger; Signal Transduction; STAT3 Transcription Factor; V-Set Domain-Containing T-Cell Activation Inhibitor 1; Vascular Endothelial Growth Factor A | 2016 |
Genital vasculitis secondary to all-trans-retinoic-acid.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Genitalia; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Tretinoin; Vasculitis | 2016 |
Tamoxifen enhances the differentiation-inducing and growth-inhibitory effects of all-trans retinoic acid in acute promyelocytic leukemia cells.
Topics: Animals; Anthracyclines; Antineoplastic Agents, Hormonal; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; CD11b Antigen; Cell Differentiation; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell Survival; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Male; Mice; Mice, Inbred BALB C; Middle Aged; Oxides; Tamoxifen; Tretinoin | 2016 |
Microgranular acute promyelocytic leukemia presenting with leukopenia and an unusual immunophenotype.
Topics: Arsenic Trioxide; Arsenicals; Bone Marrow; Disseminated Intravascular Coagulation; Flow Cytometry; Humans; Immunophenotyping; Leukemia, Promyelocytic, Acute; Leukopenia; Male; Oxides; Treatment Outcome; Tretinoin; Young Adult | 2017 |
Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia.
Topics: Adolescent; Adult; Aged; Arsenic Trioxide; Arsenicals; Blood Coagulation; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Fibrinolysis; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Platelet Count; Prothrombin Time; Retrospective Studies; Tretinoin; Young Adult | 2016 |
Morphine Attenuated the Cytotoxicity Induced by Arsenic Trioxide in H9c2 Cardiomyocytes.
Topics: Arsenic Trioxide; Arsenicals; Cell Line; Cytotoxins; Humans; Morphine; Myocytes, Cardiac; Oxides; Reactive Oxygen Species | 2016 |
The Coadministration of N-Acetylcysteine Ameliorates the Effects of Arsenic Trioxide on the Male Mouse Genital System.
Topics: Acetylcysteine; Animals; Arsenic; Arsenic Trioxide; Arsenicals; Body Weight; Epididymis; Male; Mice; Organ Size; Oxides; Random Allocation; Reactive Oxygen Species; Sperm Motility; Spermatogenesis; Spermatozoa; Testis; Testosterone | 2016 |
A facile route to core-shell nanoparticulate formation of arsenic trioxide for effective solid tumor treatment.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Liberation; Female; Humans; Leukemia, Promyelocytic, Acute; Liver Neoplasms; Mice; Mice, Inbred ICR; Microscopy, Electron, Transmission; Nanoparticles; Oxides; Porosity; Silicon Dioxide; Surface Properties; Transplantation, Heterologous | 2016 |
Arsenic trioxide inhibits glioma cell growth through induction of telomerase displacement and telomere dysfunction.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; DNA Damage; Glioma; Humans; Oxides; Protein Transport; Telomerase; Telomere | 2016 |
Biocompatible arsenic trioxide nanoparticles induce cell cycle arrest by p21(WAF1/CIP1) expression via epigenetic remodeling in LNCaP and PC3 cell lines.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biocompatible Materials; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Epigenesis, Genetic; Humans; Male; Metal Nanoparticles; Oxides; Prostatic Neoplasms | 2016 |
[Treatment of refractory pulmonary metastases from hepatocellular carcinoma by transcatheter arterial chemoembolization using arsenic trioxide in combination with sorafinib].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Lung Neoplasms; Niacinamide; Oxides; Phenylurea Compounds; Sorafenib | 2015 |
Ultrasensitive and selective assay of glutathione species in arsenic trioxide-treated leukemia HL-60 cell line by molecularly imprinted polymer decorated electrochemical sensors.
Topics: Acetylcysteine; Arsenic Trioxide; Arsenicals; Biosensing Techniques; Dielectric Spectroscopy; Glutathione; Glutathione Disulfide; HL-60 Cells; Humans; Leukemia; Molecular Imprinting; Oxides; Polymers | 2016 |
Arsenic trioxide augments all-trans retinoic acid-induced differentiation of HL-60 cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; HL-60 Cells; Humans; Oxides; Tretinoin | 2016 |
Inorganic phosphate-triggered release of anti-cancer arsenic trioxide from a self-delivery system: an in vitro and in vivo study.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Movement; Dextrans; Drug Delivery Systems; Female; Hep G2 Cells; Humans; Kinetics; Liver Neoplasms; Mice; Microscopy, Electron, Transmission; Nanoparticles; Neoplasm Invasiveness; Neoplasm Transplantation; Oxides; Phosphates; Rats; Spectroscopy, Fourier Transform Infrared; Thermodynamics | 2016 |
TRIM21 Ubiquitylates SQSTM1/p62 and Suppresses Protein Sequestration to Regulate Redox Homeostasis.
Topics: Adaptor Proteins, Signal Transducing; Animals; Arsenic Trioxide; Arsenicals; Cell Death; Chemical and Drug Induced Liver Injury; Cytoskeletal Proteins; Disease Models, Animal; Heart Failure; Heat-Shock Proteins; HEK293 Cells; Homeostasis; Humans; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Liver; Lysine; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardium; Oxidation-Reduction; Oxidative Stress; Oxides; Protein Binding; Protein Interaction Domains and Motifs; Protein Multimerization; Ribonucleoproteins; RNA Interference; Sequestosome-1 Protein; Signal Transduction; Time Factors; Transfection; Ubiquitination | 2016 |
[Study on the resveratrol and arsenic trioxide combination induced apoptosis and its mechanism on lung adenocarcinoma cells].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Caspase 3; Drug Synergism; Glutathione; Humans; Lung Neoplasms; Membrane Potential, Mitochondrial; Mitochondria; Oxidation-Reduction; Oxides; Resveratrol; Stilbenes; Tumor Cells, Cultured | 2016 |
Carnosic Acid-combined Arsenic Trioxide Antileukaemia Cells in the Establishment of NB4/SCID Mouse Model.
Topics: Abietanes; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Mice; Mice, SCID; Oxides; PTEN Phosphohydrolase; RNA, Messenger | 2016 |
The Effects of Arsenic Trioxide in Combination with Retinoic Acids on Cutaneous T-Cell Lymphoma Cell Lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Humans; Lymphoma, T-Cell, Cutaneous; Oxides; Tretinoin | 2016 |
Targeted Therapy Alone for Acute Promyelocytic Leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Disease-Free Survival; Follow-Up Studies; Humans; Intention to Treat Analysis; Leukemia, Promyelocytic, Acute; Oxides; Randomized Controlled Trials as Topic; Tretinoin | 2016 |
Role of Signal Regulatory Protein α in Arsenic Trioxide-induced Promyelocytic Leukemia Cell Apoptosis.
Topics: Antigens, Differentiation; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Humans; Leukemia, Promyelocytic, Acute; MicroRNAs; Oxides; Receptors, Immunologic | 2016 |
[Relapse of acute promyelocytic leukemia in the central nervous system revealed by isolated dementia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Dementia; Female; Humans; Leukemia, Promyelocytic, Acute; Meningeal Neoplasms; Neoplasm Recurrence, Local; Oxides; Recurrence; Remission Induction | 2016 |
Lacustrine Arcellinina (Testate Amoebae) as Bioindicators of Arsenic Contamination.
Topics: Amoeba; Arsenic; Arsenic Trioxide; Arsenicals; Canada; Cluster Analysis; Environmental Monitoring; Geologic Sediments; Gold; Lakes; Mining; Oxides | 2016 |
PCGF2 negatively regulates arsenic trioxide-induced PML-RARA protein degradation via UBE2I inhibition in NB4 cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Fluorescent Antibody Technique; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Immunoprecipitation; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Polycomb Repressive Complex 1; Protein Binding; Proteolysis; RNA Interference; Signal Transduction; Sumoylation; Time Factors; Transfection; Ubiquitin-Conjugating Enzymes; Ubiquitination | 2016 |
Chronic arsenic trioxide exposure leads to enhanced aggressiveness via Met oncogene addiction in cancer cells.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Crizotinib; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Mice, SCID; Neoplasms; Oxides; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; RNA Interference; Xenograft Model Antitumor Assays | 2016 |
Arsenic Trioxide Induces Apoptosis and Incapacitates Proliferation and Invasive Properties of U87MG Glioblastoma Cells through a Possible NF-κB-Mediated Mechanism.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Adhesion; Cell Movement; Cell Proliferation; Glioblastoma; Humans; Neoplasm Invasiveness; NF-kappa B; Oxides; Phosphorylation; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Telomerase; Tumor Cells, Cultured | 2016 |
Construction of a metabolomics profile of arsenic trioxide effect in gastric carcinoma cell line SGC7901.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biogenic Polyamines; Cell Line, Tumor; Cytokines; Fatty Acids; Gas Chromatography-Mass Spectrometry; Glutathione; Glycerophospholipids; Humans; Inflammation Mediators; Metabolome; Metabolomics; NAD; Oxides; Stomach Neoplasms; Tandem Mass Spectrometry | 2016 |
pH-triggered sustained release of arsenic trioxide by polyacrylic acid capped mesoporous silica nanoparticles for solid tumor treatment in vitro and in vivo.
Topics: Absorption, Physicochemical; Acrylic Resins; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Coated Materials, Biocompatible; Delayed-Action Preparations; Drug Delivery Systems; Drug Synergism; Female; Humans; Hydrogen-Ion Concentration; Male; Nanocapsules; Nanopores; Neoplasms, Experimental; Oxides; Rats; Rats, Sprague-Dawley; Silicon Dioxide; Treatment Outcome | 2016 |
Autologous transplant remains the preferred therapy for relapsed APL in CR2.
Topics: Adolescent; Adult; Aged; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Infant; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Young Adult | 2016 |
Role of berberine against arsenic induced oxidative damage in isolated rat liver mitochondria.
Topics: Animals; Arsenic Trioxide; Arsenicals; Berberine; Male; Membrane Potential, Mitochondrial; Mitochondria, Liver; Oxidative Stress; Oxides; Rats; Rats, Wistar; Reactive Oxygen Species | 2016 |
[Antiapoptotic Effect of the Leukemia Associated Gene MLAA-34 in HeLa Cells].
Topics: Antigens, Neoplasm; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Proliferation; HeLa Cells; Humans; Lentivirus; Oxides; Transfection | 2016 |
[As2O3 Up-regulates the Autophagy of RPMI 8226 Cells Induced by Beclin-1].
Topics: Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Autophagy; Beclin-1; Cell Line, Tumor; Cell Proliferation; Humans; Membrane Proteins; Oxides; Up-Regulation | 2016 |
Arsenic trioxide mediates HAPI microglia inflammatory response and subsequent neuron apoptosis through p38/JNK MAPK/STAT3 pathway.
Topics: Animals; Anthracenes; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line; Cell Line, Tumor; Humans; Imidazoles; Inflammation; Interleukin-1beta; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Microglia; Neurons; Oxides; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Pyridines; Rats; Signal Transduction; STAT3 Transcription Factor | 2016 |
As2 O3 combined with leflunomide prolongs heart xenograft survival via suppressing the response of Th1, Th2, and B cells in a rat model.
Topics: Animals; Arsenic Trioxide; Arsenicals; B-Lymphocytes; Graft Rejection; Graft Survival; Heart Transplantation; Heterografts; Immunoglobulin G; Immunosuppressive Agents; Isoxazoles; Leflunomide; Male; Oxides; Rats, Inbred Lew; Th1 Cells; Th2 Cells; Transplantation, Heterologous | 2016 |
Chemosensitivity enhancement toward arsenic trioxide by inhibition of histone deacetylase in NB4 cell line.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Oxides; Vorinostat | 2016 |
Arsenic trioxide plus PX-478 achieves effective treatment in pancreatic ductal adenocarcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Binding Sites; Carcinoma, Pancreatic Ductal; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Forkhead Box Protein O1; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice, Nude; Mustard Compounds; Oxidative Stress; Oxides; Pancreatic Neoplasms; Phenylpropionates; Promoter Regions, Genetic; Reactive Oxygen Species; RNA Interference; Signal Transduction; Time Factors; Transcriptional Activation; Transfection; Xenograft Model Antitumor Assays | 2016 |
PHA-Induced Peripheral Blood Cytogenetics and Molecular Analysis: a Valid Diagnostic and Follow-up Modality for Acute Promyelocytic Leukemia Patients Treated with ATRA and/or Arsenic Tri-oxide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Blood Cells; Child; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cytogenetic Analysis; Female; Follow-Up Studies; Gene Rearrangement; Humans; In Situ Hybridization, Fluorescence; India; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oncogene Proteins, Fusion; Oxides; Phytohemagglutinins; Prognosis; Translocation, Genetic; Tretinoin | 2016 |
Radiation-enhanced therapeutic targeting of galectin-1 enriched malignant stroma in triple negative breast cancer.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cells, Cultured; Chemoradiotherapy; Cisplatin; Female; Galectin 1; Human Umbilical Vein Endothelial Cells; Humans; Mesenchymal Stem Cells; Mice; Mice, Nude; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Oxides; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays; Young Adult | 2016 |
[The Experiment Study and Mechanism of Aspirin Enhances Cellular Sensitivity of Hepatocellular Carcinoma Cell Line to Arsenic Trioxide].
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Flow Cytometry; Heme Oxygenase-1; Humans; Liver Neoplasms; NF-E2-Related Factor 2; Oxides; Reactive Oxygen Species | 2016 |
Taurine protects against As2O3-induced autophagy in livers of rat offsprings through PPARγ pathway.
Topics: Animals; Arsenic Trioxide; Arsenicals; Autophagy; Cell Proliferation; Down-Regulation; Gene Expression Regulation; Hep G2 Cells; Humans; Liver; Oxides; PPAR gamma; Rats; Reactive Oxygen Species; Rosiglitazone; Signal Transduction; Taurine; Thiazolidinediones | 2016 |
Nrf2 activation ameliorates cytotoxic effects of arsenic trioxide in acute promyelocytic leukemia cells through increased glutathione levels and arsenic efflux from cells.
Topics: Abietanes; Arsenic; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cytotoxins; Glutathione; Humans; Leukemia, Promyelocytic, Acute; NF-E2-Related Factor 2; Oxides; RNA, Small Interfering | 2016 |
Mitophagy inhibits proliferation by decreasing cyclooxygenase-2 (COX-2) in arsenic trioxide-treated HepG2 cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Proliferation; Cell Survival; Cyclooxygenase 2; Cytoplasm; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Microscopy, Confocal; Mitochondria; Mitophagy; Oxides; Time Factors | 2016 |
Fucoidan enhances the therapeutic potential of arsenic trioxide and all-trans retinoic acid in acute promyelocytic leukemia, in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Mice; Mice, Inbred BALB C; Mice, Nude; Oxides; Polysaccharides; Tretinoin; Xenograft Model Antitumor Assays | 2016 |
Inhibitory effects of CaO/Fe2O3 on arsenic emission during sewage sludge pyrolysis.
Topics: Arsenic; Arsenic Trioxide; Arsenicals; Calcium Compounds; China; Ferric Compounds; Hot Temperature; Oxides; Sewage; Spectrometry, X-Ray Emission; Thermogravimetry; Waste Disposal, Fluid | 2016 |
The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Case-Control Studies; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Quality of Life; Survival Analysis | 2016 |
Melatonin promotes ATO-induced apoptosis in MCF-7 cells: Proposing novel therapeutic potential for breast cancer.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Cell Cycle; Cell Proliferation; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; MCF-7 Cells; Melatonin; Oxides; Proto-Oncogene Proteins c-myc; Real-Time Polymerase Chain Reaction; Survivin; Telomerase; Transcription, Genetic; Tumor Suppressor Protein p53 | 2016 |
Curcumin reduces the expression of survivin, leading to enhancement of arsenic trioxide-induced apoptosis in myelodysplastic syndrome and leukemia stem-like cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Line, Tumor; Curcumin; Down-Regulation; Drug Synergism; Humans; Inhibitor of Apoptosis Proteins; Leukemia; Myelodysplastic Syndromes; Oxides; Poly(ADP-ribose) Polymerases; RNA, Small Interfering; Stem Cells; Survivin | 2016 |
Oxidative stress-mediated intrinsic apoptosis in human promyelocytic leukemia HL-60 cells induced by organic arsenicals.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Proliferation; Cytochromes c; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; MCF-7 Cells; Membrane Potential, Mitochondrial; Oxidative Stress; Oxides; Reactive Oxygen Species; Signal Transduction | 2016 |
Activating transcription factor 4 underlies the pathogenesis of arsenic trioxide-mediated impairment of macrophage innate immune functions.
Topics: Activating Transcription Factor 4; Animals; Arsenic Trioxide; Arsenicals; Calcium; Cell Line; Cytokines; Homeostasis; Immunity, Innate; Macrophages, Alveolar; Mice; Mice, Inbred C57BL; Mice, Transgenic; Oxides | 2016 |
Successful treatment of acute promyelocytic leukemia with arsenic trioxide and all-trans retinoic acid in a double lung and kidney transplanted patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma, Squamous Cell; Humans; Immunocompromised Host; Kidney Transplantation; Leukemia, Promyelocytic, Acute; Lung Transplantation; Male; Middle Aged; Neoplasms, Second Primary; Oxides; Postoperative Complications; Skin Neoplasms; Tretinoin | 2016 |
RUNX3 plays an important role in As2O3‑induced apoptosis and allows cells to overcome MSC‑mediated drug resistance.
Topics: Adult; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Core Binding Factor Alpha 3 Subunit; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mesenchymal Stem Cells; Microscopy, Fluorescence; Middle Aged; Oxides; Polymerase Chain Reaction; Young Adult | 2016 |
Arsenic trioxide induces Noxa-dependent apoptosis in rhabdomyosarcoma cells and synergizes with antimicrotubule drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase Inhibitors; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Furans; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Ketones; Mitochondria; Oxides; Proto-Oncogene Proteins c-bcl-2; Rhabdomyosarcoma; RNA Interference; Signal Transduction; Time Factors; Transfection; Tubulin Modulators; Up-Regulation; Vinblastine; Vincristine; Zinc Finger Protein GLI1 | 2016 |
PML at Mitochondria-Associated Membranes Is Critical for the Repression of Autophagy and Cancer Development.
Topics: Adenine; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autophagy; Calcium; Cell Line, Tumor; Disease Progression; Fibroblasts; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Membrane Potential, Mitochondrial; Mice; Mice, Knockout; Mitochondria; Mitochondrial Membranes; Oncogene Proteins, Fusion; Oxides; Promyelocytic Leukemia Protein; Signal Transduction; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2016 |
Stratification and therapeutic potential of PML in metastatic breast cancer.
Topics: Animals; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Cell Line, Tumor; Female; Gene Knockdown Techniques; Humans; MCF-7 Cells; Mice; Neoplasm Invasiveness; Oxides; Promoter Regions, Genetic; Promyelocytic Leukemia Protein; SOX9 Transcription Factor; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2016 |
Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Autophagy; Bortezomib; Cell Line, Tumor; Cell Transplantation; Drug Synergism; Humans; Leukemia, Promyelocytic, Acute; Mice; NF-kappa B; Oxides; Proteasome Inhibitors; Reactive Oxygen Species; Transplantation, Heterologous; Tumor Cells, Cultured; Unfolded Protein Response | 2016 |
Induction of the mesenchymal to epithelial transition by demethylation-activated microRNA-125b is involved in the anti-migration/invasion effects of arsenic trioxide on human chondrosarcoma.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Chondrosarcoma; DNA Demethylation; Down-Regulation; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; MicroRNAs; Neoplasm Invasiveness; Neoplasm Metastasis; Oxides; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2016 |
Osteoblasts activate the Nrf2 signalling pathway in response to arsenic trioxide treatment.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; DNA Damage; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; NF-E2-Related Factor 2; Osteoblasts; Oxidative Stress; Oxides; Signal Transduction | 2016 |
Arsenic trioxide suppresses liver X receptor β and enhances cholesteryl ester transfer protein expression without affecting the liver X receptor α in HepG2 cells.
Topics: Arsenic Trioxide; Arsenicals; Biological Transport; Cholesterol; Cholesterol Ester Transfer Proteins; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver X Receptors; Oxides; Protein Binding; Sterol Regulatory Element Binding Protein 1; Time Factors | 2016 |
Shikonin potentiates the effect of arsenic trioxide against human hepatocellular carcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; DNA Damage; Drug Synergism; Endoplasmic Reticulum Stress; Hep G2 Cells; Humans; Liver Neoplasms; Mice, Nude; Naphthoquinones; Oxides; Xenograft Model Antitumor Assays | 2016 |
Arsenic trioxide and triptolide synergistically induce apoptosis in the SKM‑1 human myelodysplastic syndrome cell line.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diterpenes; Drug Synergism; Epoxy Compounds; Gene Expression Regulation, Neoplastic; Humans; Myelodysplastic Syndromes; Oxides; Phenanthrenes; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species | 2016 |
Arsenic trioxide potentiates the effectiveness of etoposide in Ewing sarcomas.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Bone Neoplasms; Drug Synergism; Etoposide; Flow Cytometry; Humans; Oxides; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Sarcoma, Ewing; Tumor Cells, Cultured | 2016 |
Arsenic prepared by Chinese alchemist-pharmacists.
Topics: Alchemy; Antimalarials; Arsenic; Arsenic Trioxide; Arsenicals; Artemisinins; History, Ancient; Medicine, Chinese Traditional; Oxides; Pharmacists | 2016 |
Neurotoxicity induced by arsenic in Gallus Gallus: Regulation of oxidative stress and heat shock protein response.
Topics: Animals; Antioxidants; Arsenic; Arsenic Trioxide; Arsenicals; Brain; Catalase; Chickens; Glutathione Peroxidase; Heat-Shock Proteins; Heat-Shock Response; HSP70 Heat-Shock Proteins; Male; Malondialdehyde; Neurotoxins; Oxidative Stress; Oxides; RNA, Messenger | 2017 |
Autologous hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission: outcomes before and after the introduction of arsenic trioxide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Japan; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Recurrence; Remission Induction; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2017 |
Annexin A6 regulates adipocyte lipid storage and adiponectin release.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Adiponectin; Animals; Annexin A6; Arsenic Trioxide; Arsenicals; Chemokines; Fatty Acids; Gene Knockdown Techniques; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Intercellular Signaling Peptides and Proteins; Intra-Abdominal Fat; Lipid Droplets; Lipid Metabolism; Lipolysis; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Obesity; Oxides; Signal Transduction; Triglycerides | 2017 |
Induction treatments for acute promyelocytic leukemia: a network meta-analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Humans; Induction Chemotherapy; Infant; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Network Meta-Analysis; Oxides; Randomized Controlled Trials as Topic; Tretinoin; Young Adult | 2016 |
Protective effects of oxymatrine against arsenic trioxide-induced liver injury.
Topics: Alkaloids; Animals; Antioxidants; Arsenic Trioxide; Arsenicals; Blotting, Western; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Heme Oxygenase-1; Male; NF-E2-Related Factor 2; Oxidative Stress; Oxides; Quinolizines; Rats; Rats, Wistar; Signal Transduction | 2017 |
microRNA-539 suppresses tumor growth and tumorigenesis and overcomes arsenic trioxide resistance in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Hep G2 Cells; Humans; Liver; Liver Neoplasms; Male; Mice, Nude; MicroRNAs; Oxides | 2016 |
Differential expression and response to arsenic stress of MRPs and ASAN1 determine sensitivity of classical multidrug-resistant leukemia cells to arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Arsenite Transporting ATPases; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression; HL-60 Cells; Humans; K562 Cells; Leukemia; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Oxides | 2016 |
SurvivinT34A increases the therapeutic efficacy of arsenic trioxide in mouse hepatocellular carcinoma models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Inhibitor of Apoptosis Proteins; Liposomes; Liver Neoplasms, Experimental; Membrane Potential, Mitochondrial; Mice, Inbred C57BL; Mutation, Missense; Neoplasm Transplantation; Oxides; Reactive Oxygen Species; Repressor Proteins; Survivin | 2016 |
Arsenic and fluoride induce apoptosis, inflammation and oxidative stress in cultured human umbilical vein endothelial cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cells, Cultured; Endothelium, Vascular; Fluorides; Human Umbilical Vein Endothelial Cells; Humans; Inflammation; Lipid Peroxidation; NADPH Oxidases; Nitric Oxide; Oxidation-Reduction; Oxidative Stress; Oxides; Reactive Oxygen Species; Up-Regulation | 2017 |
Arsenic trioxide induces cell cycle arrest and alters DNA methylation patterns of cell cycle regulatory genes in colorectal cancer cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Cycle Checkpoints; Cell Line, Tumor; Colon; Colorectal Neoplasms; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Oxides; Rectum; Retinoblastoma-Like Protein p107 | 2016 |
Survivin isoform expression in arsenic trioxide-treated acute promyelocytic leukemia cell line and patients: The odd expression pattern of survivin-2α.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Marrow; Case-Control Studies; Caspase 3; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Humans; Inhibitor of Apoptosis Proteins; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Protein Isoforms; Survivin | 2017 |
[Synergistic Inhibitory Effect of Arsenic Trioxide Combined with Itraconazole on Hedgehog Pathway of Multiple Myeloma NCI-H929 Cells].
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Hedgehog Proteins; Humans; Itraconazole; Mice; Multiple Myeloma; Oxides; Signal Transduction | 2016 |
Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Binding Sites; Cell Line, Tumor; Cell Survival; Cilia; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Interstitial Cells of Cajal; Mutation; Nerve Tissue Proteins; Nuclear Proteins; Oxides; Promoter Regions, Genetic; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; RNA Interference; RNA, Messenger; Signal Transduction; Transfection; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2; Zinc Finger Protein Gli3 | 2016 |
Combination effects of arsenic trioxide and fibroblast growth factor receptor inhibitor in squamous cell lung carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cysteine Proteinase Inhibitors; Drug Therapy, Combination; Female; Leupeptins; Lung Neoplasms; Mice; Mice, Nude; Oxides; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 1; Xenograft Model Antitumor Assays | 2016 |
Arsenic trioxide degrades NPM-ALK fusion protein and inhibits growth of ALK-positive anaplastic large cell lymphoma.
Topics: Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Humans; Lymphoma, Large-Cell, Anaplastic; Oxides; Protein-Tyrosine Kinases | 2017 |
[Influence of HMGB1/MAPK/m-TOR signaling pathway on cell autophagy and chemotherapy resistance in K562 cells].
Topics: AMP-Activated Protein Kinases; Arsenic Trioxide; Arsenicals; Autophagy; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; HMGB1 Protein; Humans; K562 Cells; Microtubule-Associated Proteins; Oxides; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Vincristine | 2016 |
Antagonistic effect of N-ethylmaleimide on arsenic-mediated oxidative stress-induced poly(ADP-ribosyl)ation and cytotoxicity.
Topics: Antidotes; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Line, Tumor; Cell Survival; Colony-Forming Units Assay; Comet Assay; DNA Damage; DNA Repair; Ethylmaleimide; Humans; Oxidative Stress; Oxides; Poly ADP Ribosylation | 2017 |
Activation of the basal cell carcinoma pathway in a patient with CNS HGNET-BCOR diagnosis: consequences for personalized targeted therapy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Axin Protein; Biomarkers, Tumor; Biopsy; Brain Neoplasms; Carcinoma, Basal Cell; Cell Survival; Child; DNA Mutational Analysis; Dose-Response Relationship, Drug; Genetic Predisposition to Disease; Hedgehog Proteins; Humans; Inhibitory Concentration 50; Magnetic Resonance Imaging; Male; Mutation; Neoplasms, Neuroepithelial; Oxides; Patched-1 Receptor; Phenotype; Polymorphism, Single Nucleotide; Precision Medicine; Predictive Value of Tests; Proto-Oncogene Proteins; Repressor Proteins; Smoothened Receptor; Tumor Cells, Cultured; Up-Regulation; Wnt Signaling Pathway; Zinc Finger Protein GLI1 | 2016 |
Gene expression profile induced by arsenic trioxide in chronic lymphocytic leukemia cells reveals a central role for heme oxygenase-1 in apoptosis and regulation of matrix metalloproteinase-9.
Topics: Aged; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Heme Oxygenase-1; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Matrix Metalloproteinase 9; Middle Aged; Oxides; p38 Mitogen-Activated Protein Kinases; RNA Interference; Signal Transduction; Time Factors; Transcription Factor AP-1; Transcriptome; Transfection | 2016 |
Low dose of arsenic trioxide inhibits multidrug resistant-related P-glycoprotein expression in human neuroblastoma cell line.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; G2 Phase Cell Cycle Checkpoints; Humans; Neuroblastoma; Oxides | 2016 |
Recurrent acute myopericarditis without effusion during ATRA induction and ATO salvage of APL: a variant form of the differentiation syndrome?
Topics: Acute Disease; Adolescent; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Electrocardiography; Humans; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Oxides; Pericarditis; Remission Induction; Tretinoin | 2017 |
Arsenic trioxide is an immune adjuvant in liver cancer treatment.
Topics: Adjuvants, Immunologic; Animals; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cytokine-Induced Killer Cells; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Fluorescent Antibody Technique; Humans; Liver Neoplasms; Lymphocytes, Tumor-Infiltrating; Male; Mice; Oxides; Real-Time Polymerase Chain Reaction; T-Lymphocytes; Xenograft Model Antitumor Assays | 2017 |
The optimal dose of arsenic trioxide induced opposite efficacy in autophagy between K562 cells and their initiating cells to eradicate human myelogenous leukemia.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Cell Differentiation; Cell Proliferation; Cellular Senescence; Female; Humans; K562 Cells; Leukemia, Myeloid; Mice; Mice, Inbred BALB C; Mice, Nude; Oxides; Reactive Oxygen Species; Tumor Burden | 2017 |
Melatonin protects against arsenic trioxide-induced liver injury by the upregulation of Nrf2 expression through the activation of PI3K/AKT pathway.
Topics: Animals; Arsenic Trioxide; Arsenicals; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Gene Expression Regulation; Injections, Intraperitoneal; Liver; Male; Melatonin; NF-E2-Related Factor 2; Oxidative Stress; Oxides; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Signal Transduction; Up-Regulation | 2017 |
[Effects of Arsenic Trioxide on K562 Cell Proliferation and Its Mechanisms].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Humans; K562 Cells; Oxides | 2016 |
Combination of Arsenic trioxide and Everolimus (Rad001) synergistically induces both autophagy and apoptosis in prostate cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Beclin-1; Cell Line, Tumor; Drug Synergism; Everolimus; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Male; Mice, SCID; Microscopy, Fluorescence; Microtubule-Associated Proteins; Oxides; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Xenograft Model Antitumor Assays | 2017 |
Effect and mechanism of Sorbus pohuashanensis (Hante) Hedl. flavonoids protect against arsenic trioxide-induced cardiotoxicity.
Topics: Animals; Antioxidants; Arsenic Trioxide; Arsenicals; Cardiotonic Agents; Cardiotoxicity; Caspases; Cell Death; Cell Survival; Flavonoids; L-Lactate Dehydrogenase; Male; Mice, Inbred BALB C; Myocardium; Oxidative Stress; Oxides; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Signal Transduction; Sorbus; Spectrometry, Mass, Electrospray Ionization | 2017 |
Chronic drug-induced effects on contractile motion properties and cardiac biomarkers in human induced pluripotent stem cell-derived cardiomyocytes.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biomarkers; Cardiotoxicity; Cells, Cultured; Doxorubicin; Drug Evaluation, Preclinical; Humans; Hydroxamic Acids; Indoles; Induced Pluripotent Stem Cells; Microscopy, Video; Muscle Contraction; Myocytes, Cardiac; Oxides; Panobinostat | 2017 |
RGD conjugated liposome-hollow silica hybrid nanovehicles for targeted and controlled delivery of arsenic trioxide against hepatic carcinoma.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Delayed-Action Preparations; Drug Carriers; Drug Delivery Systems; Hep G2 Cells; Humans; Hydrogen-Ion Concentration; Liposomes; Liver Neoplasms; MCF-7 Cells; Mice; Nanoparticles; Oligopeptides; Oxides; Silicon Dioxide | 2017 |
First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Female; Humans; Infant; Leukemia, Promyelocytic, Acute; Male; Oxides; Retrospective Studies; Treatment Outcome; Tretinoin | 2017 |
[Very Severe Differentiation Syndrome in Low Risk Acute Promyelocytic Leukemia - A Peril of Differentiating Therapy].
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Diagnosis, Differential; Dyspnea; Female; Fever; Humans; Hypotension; Leukemia, Promyelocytic, Acute; Leukocytosis; Lung Diseases; Oxides; Risk Factors; Severity of Illness Index; Syndrome; Treatment Outcome; Tretinoin | 2017 |
Periostin contributes to arsenic trioxide resistance in hepatocellular carcinoma cells under hypoxia.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Caspase 3; Cell Adhesion Molecules; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Oxides; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2017 |
RXRα ligand Z-10 induces PML-RARα cleavage and APL cell apoptosis through disrupting PML-RARα/RXRα complex in a cAMP-independent manner.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Caspases; Cell Line, Tumor; Chlorocebus aethiops; COS Cells; Cyclic AMP; Flow Cytometry; HEK293 Cells; Humans; Leukemia, Promyelocytic, Acute; Ligands; Naphthalenes; Nitro Compounds; Oncogene Proteins, Fusion; Oxides; Protein Binding; Proteolysis; Retinoid X Receptor alpha; Styrenes; Tretinoin | 2017 |
Manipulating PML SUMOylation via Silencing UBC9 and RNF4 Regulates Cardiac Fibrosis.
Topics: Angiotensin II; Animals; Arsenic Trioxide; Arsenicals; Collagen; Fibrosis; Gene Silencing; Mice; Myocardium; Myofibroblasts; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Protein Binding; Sumoylation; Transcription Factors; Transforming Growth Factor beta1; Ubiquitin-Conjugating Enzymes; Ubiquitin-Protein Ligases | 2017 |
Resistance to arsenic trioxide and retinoic acid therapy in acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Leukemia, Promyelocytic, Acute; Male; Mutation, Missense; Oncogene Proteins, Fusion; Oxides; Tretinoin | 2017 |
Poisoning the Devil.
Topics: Arsenic Trioxide; Arsenicals; China; France; History, 20th Century; History, 21st Century; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2017 |
Cryptotanshinone enhances the effect of Arsenic trioxide in treating liver cancer cell by inducing apoptosis through downregulating phosphorylated- STAT3 in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Down-Regulation; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Oxides; Phenanthrenes; Phosphorylation; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2017 |
Cytotoxicity of arsenic trioxide in single leukemia cells by time-resolved ICP-MS together with lanthanide tags.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Death; Cell Differentiation; Cell Line, Tumor; Cisplatin; HL-60 Cells; Humans; Lanthanoid Series Elements; Leukemia; Mass Spectrometry; Oxides; Single-Cell Analysis; Time Factors | 2017 |
Clinical impact of galectin-3 in newly diagnosed t (15;17)(q22;q21)/PML-RARa acute promyelocytic leukemia treated with all-trans retinoic acid and arsenic trioxide-based regimens.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Case-Control Studies; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Female; Galectin 3; Humans; Immunophenotyping; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Proportional Hazards Models; Retrospective Studies; Risk Factors; Survival Analysis; Translocation, Genetic; Treatment Outcome; Tretinoin; Young Adult | 2017 |
Arsenic trioxide regulates gastric cancer cell apoptosis by mediating cAMP.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Line, Tumor; Cyclic AMP; Humans; Oxides; Protein Kinase C; Stomach Neoplasms | 2017 |
Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1.
Topics: AMP-Activated Protein Kinases; Animals; Arsenic Trioxide; Arsenicals; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Drug Synergism; Heterografts; Humans; Mechanistic Target of Rapamycin Complex 1; Metformin; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 6; Oxides; p38 Mitogen-Activated Protein Kinases; Signal Transduction | 2017 |
Anti-tumor activity of PI3K-δ inhibitor in hematologic malignant cells: Shedding new light on resistance to Idelalisib.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation; Humans; Inhibitor of Apoptosis Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Oxides; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Purines; Quinazolinones; Survivin | 2017 |
Dihydroartemisinin Sensitizes Human Lung Adenocarcinoma A549 Cells to Arsenic Trioxide via Apoptosis.
Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Artemisinins; Bronchi; Cell Cycle Checkpoints; Cell Survival; DNA Damage; Epithelial Cells; Humans; Lung Neoplasms; Oxides; Reactive Oxygen Species | 2017 |
Cytotoxicity and genotoxicity effects of arsenic trioxide on SQ20B human laryngeal carcinoma cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Squamous Cell; Cell Line, Tumor; Comet Assay; DNA Damage; Head and Neck Neoplasms; Humans; Laryngeal Neoplasms; Oxides; Squamous Cell Carcinoma of Head and Neck | 2017 |
Arsenic trioxide targets MTHFD1 and SUMO-dependent nuclear de novo thymidylate biosynthesis.
Topics: Aminohydrolases; Animals; Arsenic Trioxide; Arsenicals; Cell Line; Cell Nucleus; Fibroblasts; Formate-Tetrahydrofolate Ligase; Genomic Instability; Glycine Hydroxymethyltransferase; Humans; Methylenetetrahydrofolate Dehydrogenase (NADP); Mice; Mice, Knockout; Multienzyme Complexes; Oxides; Proteolysis; Small Ubiquitin-Related Modifier Proteins; Sumoylation; Thymidine Monophosphate; Thymidylate Synthase; Uracil | 2017 |
Targeted therapy for a subset of acute myeloid leukemias that lack expression of aldehyde dehydrogenase 1A1.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Arsenic Trioxide; Arsenicals; Cells, Cultured; Cyclophosphamide; Drug Therapy, Combination; Heterografts; Humans; Leukemia, Myeloid, Acute; Mice; Molecular Targeted Therapy; Oxides; Retinal Dehydrogenase | 2017 |
Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Second Primary; Oxides; Remission Induction; Survival Analysis; Treatment Outcome; Young Adult | 2017 |
Number of succussion strokes affects effectiveness of ultra-high-diluted arsenic on in vitro wheat germination and polycrystalline structures obtained by droplet evaporation method.
Topics: Arsenic Trioxide; Arsenicals; Chemistry Techniques, Analytical; Crystallization; Drug Compounding; Germination; Homeopathy; Humans; Oxides; Triticum | 2017 |
Bruising and abnormal leucocytes on a blood film--a haematological emergency.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Contusions; Gingival Hemorrhage; Humans; Lethargy; Leukemia, Promyelocytic, Acute; Leukocytes; Male; Oxides; Tretinoin; Young Adult | 2017 |
Effect of ATRA and ATO on the expression of tissue factor in NB4 acute promyelocytic leukemia cells and regulatory function of the inflammatory cytokines TNF and IL-1β.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; CD11c Antigen; Cell Line, Tumor; Enzyme Inhibitors; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Imidazoles; Interleukin-1beta; JNK Mitogen-Activated Protein Kinases; Leukemia, Promyelocytic, Acute; NF-kappa B; Oxides; p38 Mitogen-Activated Protein Kinases; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thromboplastin; Time Factors; Tretinoin; Tumor Necrosis Factor-alpha; U937 Cells | 2017 |
Tetraarsenic hexoxide induces G2/M arrest, apoptosis, and autophagy via PI3K/Akt suppression and p38 MAPK activation in SW620 human colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Blotting, Western; CDC2 Protein Kinase; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Enzyme Activation; G2 Phase Cell Cycle Checkpoints; Humans; Membrane Potential, Mitochondrial; Oxides; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptors, TNF-Related Apoptosis-Inducing Ligand; Time Factors | 2017 |
Salvianolic Acid A Protects H9c2 Cells from Arsenic Trioxide-Induced Injury via Inhibition of the MAPK Signaling Pathway.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Caffeic Acids; Cardiotonic Agents; Cell Line; Cell Survival; Extracellular Signal-Regulated MAP Kinases; Lactates; MAP Kinase Signaling System; Necrosis; Oxides; Proto-Oncogene Proteins c-bcl-2; Rats; Up-Regulation | 2017 |
Arsenic trioxide induced rhabdomyolysis, a rare but severe side effect, in an APL patient: a case report.
Topics: Acute Kidney Injury; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Creatinine; Dyspnea; Female; Humans; Leukemia, Promyelocytic, Acute; Medicine, Chinese Traditional; Oxides; Rhabdomyolysis | 2017 |
High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Oxides; Reactive Oxygen Species; Survival Analysis; Tumor Cells, Cultured | 2017 |
Subchronic arsenism-induced oxidative stress and inflammation contribute to apoptosis through mitochondrial and death receptor dependent pathways in chicken immune organs.
Topics: Animals; Apoptosis; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Bursa of Fabricius; Caspase 3; Caspase 8; Caspase 9; Chickens; In Situ Nick-End Labeling; Inflammation; Male; Mitochondria; Oxidative Stress; Oxides; Proto-Oncogene Proteins c-bcl-2; Receptors, Death Domain; Spleen; Thymus Gland | 2017 |
Chrysin and silibinin sensitize human glioblastoma cells for arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; ATP-Binding Cassette Transporters; Cell Line, Tumor; Flavonoids; Glioblastoma; Humans; Oxides; Silybin; Silymarin | 2017 |
A proteomics research of apoptosis of leukemia cells induced by arsenic trioxide.
Topics: Amino Acid Sequence; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Shape; HL-60 Cells; Humans; Leukemia; Mass Spectrometry; Neoplasm Proteins; Oxides; Proteomics | 2017 |
Extracellular signal-regulated kinase 8-mediated NF-κB activation increases sensitivity of human lung cancer cells to arsenic trioxide.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Humans; Lung Neoplasms; NF-kappa B; Oxides; Phosphorylation; Protein Binding; Proteolysis; Substrate Specificity | 2017 |
All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells.
Topics: Arsenic Trioxide; Arsenicals; Cell Differentiation; Female; Humans; Interferon Regulatory Factors; Leukemia, Promyelocytic, Acute; Male; Monocytes; Neoplasm Proteins; Oxides; Tretinoin | 2017 |
Inhibition of nicotinamide phosphoribosyltransferase and depletion of nicotinamide adenine dinucleotide contribute to arsenic trioxide suppression of oral squamous cell carcinoma.
Topics: Adult; Arsenic Trioxide; Arsenicals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cytokines; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Mouth Neoplasms; NAD; Nicotinamide Phosphoribosyltransferase; Oxides | 2017 |
Mechanism of As2O3-Induced Action Potential Prolongation and Using hiPS-CMs to Evaluate the Rescue Efficacy of Drugs With Different Rescue Mechanism.
Topics: Action Potentials; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; ERG1 Potassium Channel; HEK293 Cells; Humans; Induced Pluripotent Stem Cells; Leukemia, Promyelocytic, Acute; Long QT Syndrome; Lysosomes; Myocytes, Cardiac; Oxides; Patch-Clamp Techniques; Proteolysis; Resveratrol; Stilbenes; Terfenadine | 2017 |
Arsenic trioxide and angiotensin II have inhibitory effects on HERG protein expression: Evidence for the role of PML SUMOylation.
Topics: Angiotensin II; Animals; Arsenic Trioxide; Arsenicals; Cyclic AMP-Dependent Protein Kinases; ERG1 Potassium Channel; Gene Expression Regulation; Gene Knockdown Techniques; Humans; Intranuclear Inclusion Bodies; Mice; Models, Biological; Myocytes, Cardiac; NIMA-Interacting Peptidylprolyl Isomerase; Oxides; Promyelocytic Leukemia Protein; Sumoylation; Transforming Growth Factor beta1; Ubiquitin-Conjugating Enzymes | 2017 |
Survival without peripheral neuropathy after massive acute arsenic poisoning: Treated by 2,3-dimercaptopropane-1-sulphonate.
Topics: Adult; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Chelating Agents; Female; Humans; Oxides; Peripheral Nervous System Diseases; Suicide, Attempted; Treatment Outcome; Unithiol | 2017 |
Combined application of arsenic trioxide and lithium chloride augments viability reduction and apoptosis induction in human rhabdomyosarcoma cell lines.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; Humans; Lithium Chloride; Oxides; Rhabdomyosarcoma | 2017 |
[Effect of Cell Autophagy on the Apoptosis of Hepatocellular Carcinoma Cells Induced by Arsenic Trioxide].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Beclin-1; Carcinoma, Hepatocellular; Hep G2 Cells; Humans; Liver Neoplasms; Microtubule-Associated Proteins | 2017 |
Arsenic trioxide inhibits EBV reactivation and promotes cell death in EBV-positive lymphoma cells.
Topics: Arsenic Trioxide; Arsenicals; Cell Death; Cell Line, Tumor; Cell Survival; Herpesvirus 4, Human; Humans; Lymphocytes; Oxides; Virus Activation | 2017 |
Infections caused by resistant organisms: Could organic arsenic compounds be an effective treatment?
Topics: Animals; Arsenic; Arsenic Trioxide; Arsenicals; Arsphenamine; Drug Resistance, Bacterial; Haptens; Humans; Inhibitory Concentration 50; Leukemia, Promyelocytic, Acute; Lyme Disease; Methicillin-Resistant Staphylococcus aureus; Models, Theoretical; Molecular Weight; Oxides; Staphylococcal Infections; Syphilis; Treatment Outcome | 2017 |
(-)-Epicatechin rescues the As
Topics: Action Potentials; Animals; Arsenic Trioxide; Arsenicals; Catechin; Cells, Cultured; ERG1 Potassium Channel; HEK293 Cells; Humans; Kinetics; Myocytes, Cardiac; Oxides; Patch-Clamp Techniques; Rats, Sprague-Dawley; Sp1 Transcription Factor | 2017 |
Long-term exposure of immortalized keratinocytes to arsenic induces EMT, impairs differentiation in organotypic skin models and mimics aspects of human skin derangements.
Topics: Animals; Arsenic; Arsenic Trioxide; Cell Culture Techniques; Cell Differentiation; Cell Transformation, Neoplastic; Epithelial-Mesenchymal Transition; Female; Humans; Keratinocytes; Mice, Inbred Strains; Organ Culture Techniques; Skin; Toxicity Tests, Chronic; Xenograft Model Antitumor Assays | 2018 |
Role of AQP9 in transport of monomethyselenic acid and selenite.
Topics: Animals; Aquaporins; Arsenic Trioxide; Arsenicals; Biological Transport; Cacodylic Acid; Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone; Gene Expression; Humans; Hydrogen-Ion Concentration; Kinetics; Lactic Acid; Nigericin; Oocytes; Organometallic Compounds; Organoselenium Compounds; Oxides; Phloretin; Selenious Acid; Substrate Specificity; Transgenes; Valinomycin; Xenopus laevis | 2017 |
Arsenic trioxide consolidation in APL.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials, Phase III as Topic; Consolidation Chemotherapy; Disease-Free Survival; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome | 2017 |
A mouse model for embryonal tumors with multilayered rosettes uncovers the therapeutic potential of Sonic-hedgehog inhibitors.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Disease Models, Animal; Down-Regulation; Gene Expression Profiling; Hedgehog Proteins; Humans; Immunohistochemistry; Mice; Mice, Transgenic; MicroRNAs; Neoplasms, Germ Cell and Embryonal; Oxides; Reverse Transcriptase Polymerase Chain Reaction; RNA-Binding Proteins; Signal Transduction; Wnt Signaling Pathway; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1 | 2017 |
The antitumor effects of arsenic trioxide in mantle cell lymphoma via targeting Wnt/β‑catenin pathway and DNA methyltransferase-1.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Azacitidine; Cell Line, Tumor; Cell Survival; DNA (Cytosine-5-)-Methyltransferase 1; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Oxides; Wnt Signaling Pathway | 2017 |
HOXA9 is critical in the proliferation, differentiation, and malignancy of leukaemia cells both in vitro and in vivo.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Down-Regulation; HL-60 Cells; Homeodomain Proteins; Humans; Leukemia; Male; Mice; Mice, Nude; MicroRNAs; Oxides; RNA Interference; RNA, Messenger; Transplantation, Heterologous; Tretinoin | 2017 |
Analysis of 28 trace elements in the blood and serum antioxidant status in chickens under arsenic and/or copper exposure.
Topics: Animals; Antioxidants; Arsenic; Arsenic Trioxide; Arsenicals; Chickens; Copper; Copper Sulfate; Diet; Male; Oxides; Random Allocation; Trace Elements | 2017 |
Distinct TP73-DAPK2-ATG5 pathway involvement in ATO-mediated cell death versus ATRA-mediated autophagy responses in APL.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Autophagy-Related Protein 12; Autophagy-Related Protein 5; Cell Line, Tumor; Cell Nucleus; Death-Associated Protein Kinases; Gene Knockdown Techniques; HEK293 Cells; Humans; Leukemia, Promyelocytic, Acute; Models, Biological; Oxides; Promoter Regions, Genetic; Protein Binding; Protein Isoforms; Protein Stability; Signal Transduction; Transcription, Genetic; Tretinoin; Tumor Protein p73 | 2017 |
Regulation of autophagy factors by oxidative stress and cardiac enzymes imbalance during arsenic or/and copper induced cardiotoxicity in Gallus gallus.
Topics: Animals; Antioxidants; Arsenic Trioxide; Arsenicals; Autophagy; Cardiotoxicity; Chickens; Copper; Drug Synergism; Male; Myocardium; Oxidative Stress; Oxides | 2018 |
Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity.
Topics: Alendronate; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Bone and Bones; Bone Marrow Cells; Cell Survival; Cells, Cultured; Decitabine; Mice, Transgenic; Myelodysplastic Syndromes; Nanoparticles; Oxides; Phosphatidylethanolamines; Polyethylene Glycols; Tissue Distribution | 2017 |
Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Death; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Delivery Systems; Humans; Mice, SCID; Molecular Targeted Therapy; Multiple Myeloma; Nanoparticles; Neoplastic Stem Cells; Oxides; Prohibitins; Sulfides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
Inhibition of early T cell cytokine production by arsenic trioxide occurs independently of Nrf2.
Topics: Animals; Antigens, CD; Arsenic Trioxide; Arsenicals; Cytokines; Mice; Mice, Inbred C57BL; NF-E2-Related Factor 2; Oxides; Spleen; T-Lymphocytes | 2017 |
Leukemia-associated gene MLAA-34 reduces arsenic trioxide-induced apoptosis in HeLa cells via activation of the Wnt/β-catenin signaling pathway.
Topics: Antigens, Neoplasm; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; beta Catenin; Blotting, Western; HeLa Cells; Humans; Oxides; Signal Transduction; Wnt Proteins | 2017 |
Arsenic biotransformation potential of microbial arsH responses in the biogeochemical cycling of arsenic-contaminated groundwater.
Topics: Arsenates; Arsenic; Arsenic Trioxide; Arsenicals; Arsenites; Biodegradation, Environmental; Biotransformation; Groundwater; Operon; Oxidation-Reduction; Oxides; Oxidoreductases; Pseudomonas putida; Vietnam; Water Pollutants, Chemical | 2018 |
Metformin ameliorates arsenic trioxide hepatotoxicity via inhibiting mitochondrial complex I.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line; Chemical and Drug Induced Liver Injury; Electron Transport Complex I; Glucose; Glycolysis; Humans; Leukemia, Myeloid; Male; Metformin; Mice; NAD; Oxidative Phosphorylation; Oxides; Reactive Oxygen Species; Rotenone | 2017 |
Pancreatic islet-autonomous effect of arsenic on insulin secretion through endoplasmic reticulum stress-autophagy pathway.
Topics: Adenine; Animals; Arsenic Trioxide; Arsenicals; Autophagy; Biomarkers; eIF-2 Kinase; Endoplasmic Reticulum Stress; Indoles; Insulin; Insulin Secretion; Islets of Langerhans; Mice; Mice, Inbred C57BL; Oxides; Specific Pathogen-Free Organisms; Tissue Culture Techniques | 2018 |
A new ETV6-NTRK3 cell line model reveals MALAT1 as a novel therapeutic target - a short report.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line; Cell Proliferation; Humans; Leukemia, Promyelocytic, Acute; Mitogen-Activated Protein Kinase 1; Models, Biological; Oncogene Proteins, Fusion; Oxides; Pyrimidines; RNA, Long Noncoding | 2018 |
Low dosage of arsenic trioxide inhibits vasculogenic mimicry in hepatoblastoma without cell apoptosis.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Survival; Dose-Response Relationship, Drug; Hep G2 Cells; Hepatoblastoma; Humans; Liver Neoplasms; Male; Mice, Nude; Neovascularization, Pathologic; Oxides; Xenograft Model Antitumor Assays | 2018 |
Redistribution of cell cycle by arsenic trioxide is associated with demethylation and expression changes of cell cycle related genes in acute promyelocytic leukemia cell line (NB4).
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Division; Cell Line, Tumor; Demethylation; DNA Methylation; Gene Expression Regulation, Leukemic; Genes, cdc; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2018 |
Effects of Arsenic Trioxide on INF-gamma Gene Expression in MRL/lpr Mice and Human Lupus.
Topics: Adult; Animals; Arsenic Trioxide; Arsenicals; Cells, Cultured; Female; Gene Expression; Humans; Interferon-gamma; Leukocytes, Mononuclear; Lupus Erythematosus, Systemic; Male; Mice, Inbred C57BL; Mice, Inbred MRL lpr; Oxides; Spleen; Young Adult | 2018 |
Mechanism of As2O3 induces apoptosis of glioma U87 cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Caspase 3; Caspase 9; Cell Count; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Glioma; Humans; Oxides; Tumor Suppressor Protein p53 | 2017 |
Cortex and hippocampus DNA epigenetic response to a long-term arsenic exposure via drinking water.
Topics: 5-Methylcytosine; Animals; Arsenic; Arsenic Trioxide; Arsenicals; Cerebral Cortex; DNA Methylation; DNA Modification Methylases; Drinking Water; Epigenesis, Genetic; Hippocampus; Learning; Male; Oxidative Stress; Oxides; Rats, Sprague-Dawley; Water Pollutants, Chemical | 2018 |
Arsenic mobility and characterization in lakes impacted by gold ore roasting, Yellowknife, NWT, Canada.
Topics: Arsenic; Arsenic Trioxide; Arsenicals; Canada; Environmental Monitoring; Geologic Sediments; Gold; Lakes; Mining; Oxides; Water Pollutants, Chemical | 2018 |
[miR-155/BACH1 Signaling Pathway in Human Lung Adenocarcinoma Cell Death Induced by Arsenic Trioxide].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Apoptosis; Arsenic Trioxide; Arsenicals; Basic-Leucine Zipper Transcription Factors; Cell Death; Cell Line, Tumor; Heme Oxygenase-1; Humans; Lung Neoplasms; MicroRNAs; NAD(P)H Dehydrogenase (Quinone); Oxides; Signal Transduction | 2017 |
[Comparison of Curative Effect between Fu Fang Huang Dai Pian and Arsenic Trioxide in Treatment of 45 Patients with Acute Promyelocytic Leukaemia].
Topics: Arsenic Trioxide; Arsenicals; Child; Humans; Leukemia, Promyelocytic, Acute; Medicine, Chinese Traditional; Oxides; Remission Induction; Retrospective Studies; Treatment Outcome; Tretinoin | 2017 |
Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the first-line treatment of adult acute promyelocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blood Coagulation; Female; Hemorrhage; Humans; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Male; Middle Aged; Oxides; Platelet Adhesiveness; Platelet Aggregation; Platelet Function Tests; Remission Induction; Treatment Outcome; Young Adult | 2018 |
Targeting of EGFR increase anti-cancer effects of arsenic trioxide: Promising treatment for glioblastoma multiform.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; M Phase Cell Cycle Checkpoints; Molecular Targeted Therapy; Oxides; Reactive Oxygen Species | 2018 |
L-ascorbic acid and α-tocopherol attenuate arsenic trioxide-induced toxicity in H9c2 cardiomyocytes by the activation of Nrf2 and Bcl2 transcription factors.
Topics: alpha-Tocopherol; Animals; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cardiotoxicity; Cell Line; Cytoprotection; Heart Diseases; Membrane Potential, Mitochondrial; Mitochondria, Heart; Myocytes, Cardiac; NF-E2-Related Factor 2; Oxidative Stress; Oxides; Proto-Oncogene Proteins c-bcl-2; Rats; Signal Transduction | 2018 |
Arsenic trioxide induces autophagic cell death in osteosarcoma cells via the ROS-TFEB signaling pathway.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autophagy; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Metabolic Networks and Pathways; Osteosarcoma; Oxides; Reactive Oxygen Species | 2018 |
Antileukemic effect of paclitaxel in combination with metformin in HL-60 cell line.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Drug Therapy, Combination; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Metformin; NF-kappa B; Oxides; Paclitaxel; Signal Transduction | 2018 |
Ellagic acid mitigates arsenic-trioxide-induced mitochondrial dysfunction and cytotoxicity in SH-SY5Y cells.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Comet Assay; Cytochromes c; DNA Fragmentation; Ellagic Acid; Humans; Membrane Potential, Mitochondrial; Mitochondria; Mitochondrial Dynamics; Nerve Tissue Proteins; Neurons; Neuroprotective Agents; Osmolar Concentration; Oxidative Stress; Oxides; Reactive Oxygen Species | 2018 |
Ameliorative role of genistein against age-dependent chronic arsenic toxicity in murine brains via the regulation of oxidative stress and inflammatory signaling cascades.
Topics: Age Factors; Animals; Antioxidants; Arsenic; Arsenic Poisoning; Arsenic Trioxide; Behavior, Animal; Biogenic Amines; Blood-Brain Barrier; Brain; Encephalitis; Genistein; L-Lactate Dehydrogenase; Male; Rats, Wistar; Signal Transduction; Toxicity Tests, Chronic | 2018 |
Downregulation of Long Non-Coding RNA Kcnq1ot1: An Important Mechanism of Arsenic Trioxide-Induced Long QT Syndrome.
Topics: Action Potentials; Animals; Arsenic Trioxide; Arsenicals; Cells, Cultured; Down-Regulation; KCNQ1 Potassium Channel; Lentivirus; Long QT Syndrome; Mice; Myocytes, Cardiac; Oxides; Patch-Clamp Techniques; Phenotype; RNA Interference; RNA, Long Noncoding; RNA, Small Interfering | 2018 |
Effect of subchronic exposure to inorganic arsenic on the structure and function of the intestinal epithelium.
Topics: Arsenic Trioxide; Arsenicals; Caco-2 Cells; Cell Differentiation; Cell Movement; Cell Proliferation; Digestion; Dose-Response Relationship, Drug; Epithelial Cells; Gene Expression Regulation; Humans; Inflammation Mediators; Interleukin-8; Intestinal Absorption; Intestinal Mucosa; Microvilli; Oxides; Permeability; Risk Assessment; Time Factors; Toxicity Tests, Subchronic; Up-Regulation; Wound Healing | 2018 |
Eugenol, a plant-derived phenolic nutraceutical, protects thiol (SH) group in myocardium from ROS-mediated oxidation under chemotherapeutic stress induced by arsenic trioxide - a in vivo model study.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Eugenol; Male; Myocardium; Oxidation-Reduction; Oxides; Protective Agents; Rats; Rats, Wistar; Reactive Oxygen Species; Sulfhydryl Compounds | 2018 |
Relapse of acute promyelocytic leukemia in the external auditory canal confirmed by PML/RARA dual-fusion and RARA break-apart fluorescence in situ hybridization.
Topics: Abnormal Karyotype; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; DNA Probes; Ear Canal; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Male; Middle Aged; Oncogene Proteins, Fusion; Oxides; Positron-Emission Tomography; Recurrence; RNA, Messenger; RNA, Neoplasm; Tomography, X-Ray Computed; WT1 Proteins | 2018 |
[Acute Promyelocytic Leukemia - A Rare, Life-Threatening Disease with High Healing Chance].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Rare Diseases; Tretinoin | 2018 |
Arsenic trioxide attenuates STAT-3 activity and epithelial-mesenchymal transition through induction of SHP-1 in gastric cancer cells.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cadherins; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; Humans; Mice, Nude; Oxides; Protein Tyrosine Phosphatase, Non-Receptor Type 6; RNA Interference; Snail Family Transcription Factors; STAT3 Transcription Factor; Stomach Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Transcriptomic analysis of the PI3K/Akt signaling pathway reveals the dual role of the c-Jun oncogene in cytotoxicity and the development of resistance in HL-60 leukemia cells in response to arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cyclin D1; Drug Resistance, Neoplasm; Forkhead Box Protein O1; Gene Expression Profiling; Genes, jun; HL-60 Cells; Humans; Oxides; Phosphatidylinositol 3-Kinases; Protein Kinase C beta; Proto-Oncogene Proteins c-akt; Signal Transduction | 2017 |
Case report: Purulent transformation of granulocytic sarcoma: An unusual pattern of differentiation in acute promyelocytic leukemia.
Topics: Abdomen; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Differentiation; Female; Humans; Induction Chemotherapy; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Sarcoma, Myeloid; Suppuration; Tretinoin | 2018 |
γ-Glutamylcysteine synthetase (γ-GCS) as a target for overcoming chemo- and radio-resistance of human hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Catalysis; Chromatography, High Pressure Liquid; Drug Resistance, Neoplasm; Glutamate-Cysteine Ligase; Hep G2 Cells; Humans; Liver Neoplasms; Membrane Potential, Mitochondrial; Oxides; Radiation Tolerance; Reactive Oxygen Species | 2018 |
Inorganic arsenic causes apoptosis cell death and immunotoxicity on European sea bass (Dicentrarchus labrax).
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Bass; Gene Expression; Gills; Immunity, Cellular; Immunoglobulin M; Liver; Oxides; Phagocytosis; Water Pollutants, Chemical | 2018 |
VS-5584 as a PI3K/mTOR inhibitor enhances apoptotic effects of subtoxic dose arsenic trioxide via inhibition of NF-κB activity in B cell precursor-acute lymphoblastic leukemia.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; Morpholines; NF-kappa B; Oxides; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Purines; TOR Serine-Threonine Kinases | 2018 |
Influence of acute promyelocytic leukemia therapeutic drugs on nuclear pore complex density and integrity.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line; Cell Nucleus; Humans; Kinetics; Leukemia, Promyelocytic, Acute; Mitosis; Nuclear Envelope; Nuclear Pore; Oxides; Permeability; Tretinoin | 2018 |
Effective Delivery of Arsenic Trioxide to HPV-Positive Cervical Cancer Cells Using Optimised Liposomes: A Size and Charge Study.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Drug Compounding; Drug Delivery Systems; Female; Humans; Liposomes; Oxides; Papillomavirus Infections; Particle Size; Static Electricity; Uterine Cervical Neoplasms | 2018 |
Arsenic speciation in hair and nails of acute promyelocytic leukemia (APL) patients undergoing arsenic trioxide treatment.
Topics: Adult; Arsenic; Arsenic Trioxide; Arsenicals; Chromatography, High Pressure Liquid; Female; Hair; Humans; Leukemia, Promyelocytic, Acute; Male; Mass Spectrometry; Middle Aged; Nails; Oxides; Young Adult | 2018 |
Guo-Qiang Chen: haematologist who risked all for research success.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biomedical Research; China; Hematology; History, 20th Century; History, 21st Century; Humans; Leukemia; Oxides; Portraits as Topic | 2018 |
Toxic effects of arsenic trioxide on Echinococcus granulosus protoscoleces through ROS production, and Ca2+-ER stress-dependent apoptosis.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Calcium; Caspase 12; Caspase 3; Echinococcosis; Echinococcus granulosus; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Heat-Shock Proteins; Helminth Proteins; Oxides; Reactive Oxygen Species; Sheep; Sheep Diseases; Superoxide Dismutase | 2018 |
Inhibitory Effects of Arsenic Trioxide and Thalidomide on Angiogenesis and Vascular Endothelial Growth Factor Expression in Leukemia Cells
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; Leukemia, Myeloid, Acute; Neovascularization, Pathologic; Oxides; Thalidomide; U937 Cells; Vascular Endothelial Growth Factors | 2018 |
Copper and arsenic-induced oxidative stress and immune imbalance are associated with activation of heat shock proteins in chicken intestines.
Topics: Animals; Arsenic Trioxide; Arsenicals; Chickens; Copper Sulfate; Cytokines; Heat-Shock Proteins; Intestinal Mucosa; Intestines; Male; Oxidative Stress; Oxides | 2018 |
Cutaneous herald: leukaemia cutis as presenting manifestation of relapse in acute promyelocytic leukaemia.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Biopsy; Consolidation Chemotherapy; Daunorubicin; Female; Humans; Leukemia, Promyelocytic, Acute; Leukemic Infiltration; Oxides; Skin; Tretinoin | 2018 |
Arsenic trioxide induces apoptosis and inhibits the growth of human liver cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Humans; Liver Neoplasms; Oxides; Receptors, Notch | 2018 |
The apoptosis in arsenic-induced oxidative stress is associated with autophagy in the testis tissues of chicken.
Topics: Animals; Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Autophagy; Chickens; Dose-Response Relationship, Drug; Environmental Pollutants; Male; Oxidative Stress; Oxides; Random Allocation; Testis | 2018 |
Role of arsenic (+3 oxidation state) methyltransferase in arsenic mediated APL treatment: an in vitro investigation.
Topics: Antineoplastic Agents; Apoptosis; Arsenic; Arsenic Trioxide; Cell Differentiation; Cell Proliferation; Hep G2 Cells; Humans; In Vitro Techniques; Leukemia, Promyelocytic, Acute; Methyltransferases; Oncogene Proteins, Fusion; Tumor Cells, Cultured | 2018 |
DNA methylation of a non-CpG island promoter represses NQO1 expression in rat arsenic-transformed lung epithelial cells.
Topics: Animals; Arsenic Trioxide; Arsenicals; Azacitidine; Cell Line, Transformed; Cell Transformation, Neoplastic; CpG Islands; Decitabine; DNA Methylation; Enzyme Inhibitors; Epithelial Cells; Gene Expression Regulation; Lung; NAD(P)H Dehydrogenase (Quinone); Oxides; Promoter Regions, Genetic; Rats | 2018 |
Molecular mechanism of the increased tissue uptake of trivalent inorganic arsenic in mice with type 1 diabetes mellitus.
Topics: Animals; Aquaporins; Arsenic; Arsenic Trioxide; Arsenites; Biological Transport; Blood Glucose; Body Weight; Diabetes Mellitus, Type 1; Glucose Transporter Type 1; Inorganic Chemicals; Kidney; Liver; Male; Mice; Mice, Inbred ICR; RNA, Messenger; Tissue Distribution | 2018 |
[Relationship between the Therapeutic Dose of Arsenic Trioxide and Relapse in Acute Promyelocytic Leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Retrospective Studies; Tretinoin | 2018 |
[Effects of Arsenic Trioxide on Cdc20 and Mad2 in Acute Myeloid Leukemia HL-60 Cell Line].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cdc20 Proteins; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Oxides | 2018 |
[As
Topics: Anemia, Aplastic; Arsenic Trioxide; Arsenicals; Forkhead Transcription Factors; Humans; Oxides; RNA, Messenger; T-Lymphocytes, Regulatory | 2018 |
Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Drug Evaluation; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Proportional Hazards Models; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Tretinoin; Young Adult | 2018 |
Salinomycin induces apoptosis and differentiation in human acute promyelocytic leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imides; Leukemia, Promyelocytic, Acute; Oxides; Pyrans; Quinolines; Tretinoin; Wnt Signaling Pathway | 2018 |
A novel RGDyC/PEG co-modified PAMAM dendrimer-loaded arsenic trioxide of glioma targeting delivery system.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Blood-Brain Barrier; Cell Cycle; Cell Line, Tumor; Dendrimers; Drug Carriers; Drug Delivery Systems; Drug Liberation; Endocytosis; Glioma; Humans; Male; Mice; Oligopeptides; Oxides; Polyethylene Glycols; Rabbits; Rats; Static Electricity; Treatment Outcome | 2018 |
Arsenic-induced cardiotoxicity correlates with mitochondrial damage and trace elements imbalance in broiler chickens.
Topics: Animals; Apoptosis; Arsenic; Arsenic Trioxide; Cardiotoxicity; Chickens; Male; Mitochondria; Random Allocation; Trace Elements | 2019 |
Pharmacokinetic Properties of Arsenic Species after Intravenous and Intragastrical Administration of Arsenic Trioxide Solution in Cynomolgus Macaques Using HPLC-ICP-MS.
Topics: Administration, Intravenous; Animals; Arsenates; Arsenic; Arsenic Trioxide; Arsenicals; Arsenites; Biological Availability; Cacodylic Acid; Chromatography, High Pressure Liquid; Macaca fascicularis; Mass Spectrometry | 2019 |
A Fatal Case of Acute Arsenic Poisoning.
Topics: Arsenic Poisoning; Arsenic Trioxide; Arsenicals; China; Fatal Outcome; Fatty Liver; Female; Humans; Liver; Quackery; Schizophrenia; Stomach; Sulfides; Young Adult | 2019 |
Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide.
Topics: Adult; Aged; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Cacodylic Acid; Child; Chromatography, High Pressure Liquid; Erythrocytes; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Mass Spectrometry; Middle Aged; Time Factors; Young Adult | 2019 |
Characterization of arsenic oxidation and uranium bioremediation potential of arsenic resistant bacteria isolated from uranium ore.
Topics: Arsenic; Arsenic Trioxide; Bacillus; Bacteria; Biodegradation, Environmental; Oxidation-Reduction; Phylogeny; RNA, Ribosomal, 16S; Uranium | 2019 |
Effects of As2O3 and Resveratrol on the Proliferation and Apoptosis of Colon Cancer Cells and the hERG-mediated Potential Mechanisms.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Humans; Oxides; Resveratrol; Signal Transduction; Transcriptional Regulator ERG | 2019 |
Use of a Mouse Model and Human Umbilical Vein Endothelial Cells to Investigate the Effect of Arsenic Exposure on Vascular Endothelial Function and the Associated Role of Calpains.
Topics: Animals; Arsenic; Arsenic Trioxide; Calpain; Capillary Permeability; Endothelium, Vascular; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Inbred C57BL | 2019 |
Effects of Proanthocyanidins on Arsenic Methylation Metabolism and Efflux in Human Hepatocytes L-02.
Topics: Arsenic; Arsenic Trioxide; Biological Transport; Gene Expression Regulation; Glutathione; Hepatocytes; Humans; Methylation; Methyltransferases; Multidrug Resistance-Associated Proteins; Oxidation-Reduction; Proanthocyanidins | 2019 |
Replacing chemotherapy with arsenic trioxide for the treatment of acute promyelocytic leukemia in the frontline setting: Is it cost-effective?
Topics: Arsenic Trioxide; Arsenicals; China; Cost-Benefit Analysis; Humans; Leukemia, Promyelocytic, Acute; Tretinoin | 2020 |
Ventricular repolarization dynamics in arsenic trioxide treatment of acute promyelocytic leukemia.
Topics: Arsenic Trioxide; Arsenicals; Electrocardiography; Heart Rate; Humans; Leukemia, Promyelocytic, Acute; Long QT Syndrome; Oxides | 2020 |
[Efficacy of Arsenic Trioxide Combined with ATRA and Chemotherapy for Relapsed Acute Promyelocytic Leukemia Patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Treatment Outcome; Tretinoin | 2020 |
Comparative study of arsenic toxicosis and ocular pathology in wild muskrats (Ondatra zibethicus) and red squirrels (Tamiasciurus hudsonicus) breeding in arsenic contaminated areas of Yellowknife, Northwest Territories (Canada).
Topics: Animals; Arsenic; Arsenic Poisoning; Arsenic Trioxide; Arvicolinae; Breeding; Canada; Environmental Exposure; Environmental Pollutants; Gold; Northwest Territories; Sciuridae; Soil | 2020 |
Interplay of Ubiquitin-Like Modifiers Following Arsenic Trioxide Treatment.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; HEK293 Cells; Humans; Nuclear Proteins; Oncogene Proteins, Fusion; Oxides; Ubiquitin; Ubiquitin-Specific Proteases | 2020 |
[Preliminary study of Realgar and arsenic trioxide on gut microbiota of mice].
Topics: Animals; Arsenic Trioxide; Arsenicals; Bacteria; Gastrointestinal Microbiome; Mice; Sulfides | 2020 |
Complex effects of pH and organic shocks on arsenic oxidation and removal by manganese-oxidizing aerobic granular sludge in sequencing batch reactors.
Topics: Arsenic; Arsenic Trioxide; Bioreactors; Hydrogen-Ion Concentration; Manganese; Oxidation-Reduction; Sewage; Waste Disposal, Fluid; Wastewater | 2020 |
Severe Wernicke encephalopathy and acute pancreatitis due to all-trans-retinoic acid and arsenic trioxide during treatment of acute promyelocytic leukaemia: a case report.
Topics: Acute Disease; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Pancreatitis; Tretinoin; Wernicke Encephalopathy | 2020 |
Herpes zoster during arsenic trioxide therapy for acute promyelocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Herpes Zoster; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2021 |
Autologous stem cell transplantation finds a place in acute promyelocytic leukaemia.
Topics: Arsenic Trioxide; Arsenicals; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Recurrence, Local; Transplantation, Autologous; Tretinoin | 2021 |
[Clinical features analysis of 10 cases of acute arsenic trioxide poisoning].
Topics: Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Humans; Liver; Oxides | 2020 |
Arsenic trioxide and all-trans retinoic acid in the treatment of children with newly diagnosed acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Child; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2021 |
Arsenic and an Old Place: Rescuing p53 Mutants in Cancer.
Topics: Arsenic; Arsenic Trioxide; Humans; Mutation; Neoplasms; Tumor Suppressor Protein p53 | 2021 |
Arsenic hexoxide has differential effects on cell proliferation and genome-wide gene expression in human primary mammary epithelial and MCF7 cells.
Topics: Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Breast Neoplasms; Cell Cycle; Cell Cycle Checkpoints; Cell Differentiation; Cell Proliferation; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Mammary Glands, Human; MCF-7 Cells; Primary Cell Culture; Tumor Cells, Cultured | 2021 |
Characteristics of arsenic species in cerebrospinal fluid (CSF) of acute promyelocytic leukaemia (APL) patients treated with arsenic trioxide plus mannitol.
Topics: Arsenic; Arsenic Trioxide; Chromatography, High Pressure Liquid; Humans; Leukemia, Promyelocytic, Acute; Mannitol; Neoplasm Recurrence, Local | 2021 |
Monomethylated arsenic was the Major methylated arsenic in Red blood cells of acute promyelocytic leukemia patients treated with arsenic trioxide.
Topics: Adolescent; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Biotransformation; Cacodylic Acid; Child; Child, Preschool; Chromatography, High Pressure Liquid; Erythrocytes; Female; Hemoglobins; Humans; Infant; Infant, Newborn; Leukemia, Promyelocytic, Acute; Male; Methylation; Middle Aged; Protein Binding; Spectrometry, Fluorescence; Spectrophotometry, Atomic; Young Adult | 2021 |
A call to action for the treatment of acute promyelocytic leukemia in the modern era: It is no longer just about the ATRA and arsenic.
Topics: Arsenic; Arsenic Trioxide; Humans; Leukemia, Promyelocytic, Acute; Tretinoin | 2021 |
Arsenic trioxide reduces the expression of E2F1, cyclin E, and phosphorylation of PI3K signaling molecules in acute leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cyclin E; E2F1 Transcription Factor; Humans; Leukemia, Promyelocytic, Acute; Oxides; Phosphatidylinositol 3-Kinases; Phosphorylation | 2021 |
Arsenic and all-
Topics: Arsenic; Arsenic Trioxide; Humans; Leukemia, Promyelocytic, Acute; Tretinoin | 2021 |
Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Retrospective Studies; Treatment Outcome; Tretinoin | 2022 |
PML/RARA destabilization by hyperthermia: a new model for oncogenic fusion protein degradation?
Topics: Arsenic Trioxide; Arsenicals; Humans; Hyperthermia, Induced; Leukemia, Promyelocytic, Acute; Oxides; Proteolysis | 2021 |
Effects of co-administration of arsenic trioxide and Schiff base oxovanadium complex on the induction of apoptosis in acute promyelocytic leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Schiff Bases | 2021 |
Arsenic trioxide induces expression of BCL-2 expression via NF-κB and p38 MAPK signaling pathways in BEAS-2B cells during apoptosis.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; NF-kappa B; Oxides; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-bcl-2 | 2021 |
Impact of sociodemographic factors on early mortality in acute promyelocytic leukemia in the United States: A time-trend analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Sociodemographic Factors; Treatment Outcome; Tretinoin; United States | 2022 |
Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia.
Topics: Animals; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Leukemia, Promyelocytic, Acute; Mice; Oxides; Tretinoin | 2022 |
Resveratrol protects against inorganic arsenic-induced oxidative damage and cytoarchitectural alterations in female mouse hippocampus.
Topics: Animals; Arsenic; Arsenic Trioxide; Brain Injuries; Female; Hippocampus; Mice; Pyramidal Cells; Resveratrol | 2021 |
The pharmacokinetics of therapeutic arsenic trioxide in acute promyelocytic leukemia patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2022 |
Polymorphisms of the AS3MT gene are associated with arsenic methylation capacity and damage to the P21 gene in arsenic trioxide plant workers.
Topics: Adult; Alleles; Arsenic; Arsenic Trioxide; China; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; Female; Humans; Male; Methyltransferases; Middle Aged; Occupational Exposure; Polymerase Chain Reaction; Polymorphism, Single Nucleotide | 2021 |
Bone marrow necrosis as complication of treatment with all-trans retinoic acid and arsenic trioxide: case report and implications for treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow; Humans; Leukemia, Promyelocytic, Acute; Necrosis; Tretinoin | 2022 |
Bcl-2 hijacks the arsenic trioxide resistance in SH-SY5Y cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Humans; Mice; Mice, Nude; Oxides | 2022 |
In vitro toxic interaction of arsenic and hyperglycemia in mitochondria: an important implication of increased vulnerability in pre-diabetics.
Topics: Animals; Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Diabetes Mellitus, Type 2; Glucose; Glutathione; Hyperglycemia; Mitochondria; Oxides; Prediabetic State; Rats; Reactive Oxygen Species | 2022 |
Notch pathway inhibition mediated by arsenic trioxide depletes tumor initiating cells in small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplastic Stem Cells; Small Cell Lung Carcinoma | 2022 |
TP53 inhibitor PFTα increases the sensitivity of arsenic trioxide in TP53 wildtype tumor cells.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Synergism; Humans; Mice; Oxides; Tumor Suppressor Protein p53 | 2022 |
Gemtuzumab Ozogamicin Followed by Unrelated Cord Blood Transplantation With Reduced-intensity Conditioning for a Child With Refractory Acute Promyelocytic Leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cord Blood Stem Cell Transplantation; Female; Gemtuzumab; Humans; Infant; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2022 |
Venetoclax for arsenic-resistant acute promyelocytic leukaemia.
Topics: Arsenic; Arsenic Trioxide; Arsenicals; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Promyelocytic, Acute; Oxides; Sulfonamides; Tretinoin | 2022 |
F-box protein FBXO41 plays vital role in arsenic trioxide-mediated autophagic death of cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagic Cell Death; Cell Line, Tumor; F-Box Proteins; Humans; Neoplasms; Oxides | 2022 |
Arsenic Trioxide Triggers Mitochondrial Dysfunction, Oxidative Stress, and Apoptosis via Nrf 2/Caspase 3 Signaling Pathway in Heart of Ducks.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Ducks; Humans; Mitochondria; Oxidative Stress; Oxides; RNA, Messenger; Signal Transduction | 2023 |
Protective effects and possible mechanism of 6-gingerol against arsenic trioxide-induced nephrotoxicity based on network pharmacological analysis and experimental validation.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Arsenic Trioxide; Arsenicals; Catechols; Fatty Alcohols; Mice; Oxides | 2022 |
Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 Activation.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; NF-E2-Related Factor 2; Oxides; Reactive Oxygen Species; Recurrence; Sulfonamides | 2022 |
Mitochondrial Toxicity of Organic Arsenicals.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Membrane Potential, Mitochondrial; Mitochondria; Oxides; Reactive Oxygen Species | 2022 |
Galbanic Acid Improves Accumulation and Toxicity of Arsenic Trioxide in MT-2 Cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Coumarins; Humans; Mitoxantrone; Oxides; Tumor Suppressor Protein p53 | 2023 |
Glucogallin Attenuates RAW 264.7 Cells from Arsenic Trioxide Induced Toxicity via the NF-ҡB/NLRP3 Pathway.
Topics: Animals; Apoptosis; Arsenic; Arsenic Poisoning; Arsenic Trioxide; Hydrolyzable Tannins; Mice; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Oxidative Stress; Oxides; RAW 264.7 Cells; Reactive Oxygen Species | 2022 |
Self-activated arsenic manganite nanohybrids for visible and synergistic thermo/immuno-arsenotherapy.
Topics: Albumins; Antineoplastic Agents; Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Glutathione; Humans; Immune Checkpoint Inhibitors; Manganese; Manganese Compounds; Neoplasms; Oxides; Protons; Tumor Microenvironment | 2022 |
Arsenic trioxide and Erlotinib loaded in RGD-modified nanoliposomes for targeted combination delivery to PC3 and PANC-1 cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Erlotinib Hydrochloride; Humans; Oligopeptides; Oxides; PC-3 Cells | 2023 |
2-Aminoethoxydiphenyl-borate reduces arsenic-induced cardiotoxicity in rats.
Topics: Animals; Arsenic; Arsenic Trioxide; Arsenicals; Borates; Cardiotoxicity; Rats | 2022 |
Subcellular Partitioning of Arsenic Trioxide Revealed by Label-Free Imaging.
Topics: Antineoplastic Agents; Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Protein Aggregates; Sulfur; Tretinoin | 2022 |
Combinatorial Effect of Arsenic and Herbal Compounds in Telomerase-Mediated Apoptosis Induction in Liver Cancer.
Topics: Antineoplastic Agents; Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Emodin; Humans; Liver Neoplasms; Oxides; Quercetin; Telomerase | 2023 |
Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Treatment Outcome; Tretinoin | 2022 |
Higher than normal mitochondrial DNA content associated with better outcome in acute promyelocytic leukaemia? Maybe.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; DNA, Mitochondrial; Humans; Leukemia, Promyelocytic, Acute; Oxides; Tretinoin | 2023 |
Synergy of directional oxidation and vacuum gasification for green recovery of As
Topics: Arsenic; Arsenic Trioxide; Arsenicals; Humans; Oxidation-Reduction; Oxides | 2023 |
Selenium Supplementation Protects Against Arsenic-Trioxide-Induced Cardiotoxicity Via Reducing Oxidative Stress and Inflammation Through Increasing NAD
Topics: Animals; Apoptosis; Arsenic; Arsenic Trioxide; Cardiotoxicity; Dietary Supplements; Inflammation; Mice; NAD; Oxidative Stress; Selenium | 2023 |
Arsenic trioxide elicits prophylactic and therapeutic immune responses against solid tumors by inducing necroptosis and ferroptosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Ferroptosis; Humans; Immunity; Necroptosis; Neoplasms; Oxides | 2023 |
Long-term real-world outcomes of patients with acute promyelocytic leukaemia treated with arsenic trioxide and all-trans retinoic acid without chemotherapy-a retrospective, single-centre study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Retrospective Studies; Treatment Outcome; Tretinoin | 2023 |
Long-term retrospective study of retinoic acid combined with arsenic and chemotherapy for acute promyelocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Retrospective Studies; Treatment Outcome; Tretinoin | 2023 |
Immunological consequences of arsenic trioxide-induced necrosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Necrosis | 2023 |
Arsenic-Loaded Biomimetic Iron Oxide Nanoparticles for Enhanced Ferroptosis-Inducing Therapy of Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Biomimetics; Carcinoma, Hepatocellular; Cell Line, Tumor; Ferroptosis; Liver Neoplasms; Magnetic Iron Oxide Nanoparticles; Mice | 2023 |
Arsenic trioxide as an inducer of immunogenic cell death.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Immunogenic Cell Death | 2023 |
Induction of filamin-C and its involvement in the regulation of cellular senescence and apoptosis in Huh-7 hepatoma cells during arsenic trioxide exposure.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cellular Senescence; Filamins; Humans; Liver Neoplasms; Oxides | 2023 |
Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RARα.
Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Nuclear Proteins; Oxides; Transcription Factors; Tretinoin; Ubiquitination | 2023 |
Transglutaminase 2 associated with PI3K and PTEN in a membrane-bound signalosome platform blunts cell death.
Topics: Arsenic Trioxide; Arsenicals; Cell Death; Humans; Integrins; Leukemia, Promyelocytic, Acute; Mechanistic Target of Rapamycin Complex 2; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Protein Glutamine gamma Glutamyltransferase 2; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; TOR Serine-Threonine Kinases; Tretinoin | 2023 |
Monomethylarsonous acid binds to Cys-104α and Cys-112β of hemoglobin in acute promyelocytic leukemia patients treated with arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Hemoglobins; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2023 |
Type 2 diabetes affects arsenic metabolism via transporters in arsenic trioxide treated acute promyelocytic leukemia patients.
Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Diabetes Mellitus, Type 2; Glucose; HEK293 Cells; Humans; Leukemia, Promyelocytic, Acute; Oxides | 2023 |
Torsemide increases arsenic concentrations by inhibition of multidrug resistance protein 4 in arsenic trioxide treated acute promyelocytic leukemia patients.
Topics: Animals; Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Drug Resistance, Multiple; HEK293 Cells; Humans; Leukemia, Promyelocytic, Acute; Multidrug Resistance-Associated Proteins; Oxides; Rats; Torsemide | 2023 |
Arsenic trioxide-induced cytotoxicity in A549 cells: The role of necroptosis.
Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Humans; Necroptosis; Oxides; Reactive Oxygen Species | 2023 |
Involvement of Mitochondrial Damage and Oxidative Stress in Apoptosis Induced by Betulin Plus Arsenic Trioxide in Neuroblastoma Cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Humans; Oxidative Stress; Oxides; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species | 2023 |
MDM2-mediated Inhibitory Effect of Arsenic Trioxide on Small Cell Lung Cancer Cell Line by Degrading Mutant p53.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Humans; Lung Neoplasms; Mice; Oxides; Proto-Oncogene Proteins c-mdm2; Small Cell Lung Carcinoma; Tumor Suppressor Protein p53 | 2023 |
Variant acute promyelocytic leukaemia with novel NAB2::RARA fusion shows clinical all-trans retinoic acid and arsenic trioxide sensitivity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Oxides; Repressor Proteins; Retinoic Acid Receptor alpha; Tretinoin | 2023 |
[Arsenic speciation and valence].
Topics: Arsenic; Arsenic Trioxide; Arsenicals; Biological Products; Drugs, Chinese Herbal; Medicine, Chinese Traditional; Sulfides | 2023 |
Intracranial bleeding in acute promyelocytic leukemia treated with arsenic trioxide based regimens is associated with induction mortality but not with relapse.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Tretinoin | 2023 |
ATO Increases ROS Production and Apoptosis of Cells by Enhancing Calpain-Mediated Degradation of the Cancer Survival Protein TG2.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Calpain; Humans; Leukemia, Promyelocytic, Acute; Leukocytes, Mononuclear; Oxides; Protein Glutamine gamma Glutamyltransferase 2; Reactive Oxygen Species; Tretinoin | 2023 |
Utility of end of induction bone marrow biopsy and survival outcomes in acute promyelocytic leukemia treated with fixed-dose induction regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow; Humans; Leukemia, Promyelocytic, Acute; Oxides; Remission Induction; Retrospective Studies; Treatment Outcome; Tretinoin | 2023 |
miR-603 promotes cell proliferation and differentiation by targeting TrkB in acute promyelocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Proliferation; Humans; Leukemia, Promyelocytic, Acute; MicroRNAs; Oxides | 2023 |